0001437749-23-006751.txt : 20230316 0001437749-23-006751.hdr.sgml : 20230316 20230315185336 ACCESSION NUMBER: 0001437749-23-006751 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 82 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230316 DATE AS OF CHANGE: 20230315 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Avinger Inc CENTRAL INDEX KEY: 0001506928 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 208873453 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36817 FILM NUMBER: 23736647 BUSINESS ADDRESS: STREET 1: 400 CHESAPEAKE DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 650-363-2400 MAIL ADDRESS: STREET 1: 400 CHESAPEAKE DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 10-K 1 avgr20221231_10k.htm FORM 10-K avgr20221231_10k.htm
0001506928 false --12-31 2022 FY 2 0 0 0 0 0 0 0 0 3 0 0 0 0 0 0 0 9.99 5 2 5.5 5 5 0 314,000 314,000 0 0 0 0 0 0 0 0 1 0 0 0 0 1 5 3 1 1 1 0 0 0 5 2 5.5 5 5 00015069282022-01-012022-12-31 thunderdome:item iso4217:USDxbrli:shares 0001506928us-gaap:SubsequentEventMember2023-01-18 utr:Y 0001506928us-gaap:RestrictedStockMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:SubsequentEventMember2023-01-182023-01-18 xbrli:shares 0001506928avgr:PrivatePrefundedWarrantsMemberus-gaap:SubsequentEventMember2023-02-14 0001506928avgr:PrivatePrefundedWarrantsMemberus-gaap:SubsequentEventMember2023-02-142023-02-14 iso4217:USD 0001506928avgr:The401kPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-01-012022-12-31 xbrli:pure 00015069282021-12-31 00015069282022-12-31 00015069282021-01-012021-12-31 00015069282020-12-31 0001506928us-gaap:DomesticCountryMemberus-gaap:ResearchMember2021-12-31 0001506928us-gaap:DomesticCountryMemberus-gaap:ResearchMember2022-12-31 0001506928us-gaap:DomesticCountryMember2022-12-31 0001506928us-gaap:StateAndLocalJurisdictionMember2022-12-31 0001506928us-gaap:StateAndLocalJurisdictionMember2021-01-012021-12-31 0001506928us-gaap:StateAndLocalJurisdictionMember2022-01-012022-12-31 0001506928us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-12-31 0001506928us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-12-31 0001506928us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-12-31 0001506928us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-12-31 0001506928us-gaap:CostOfSalesMember2021-01-012021-12-31 0001506928us-gaap:CostOfSalesMember2022-01-012022-12-31 0001506928avgr:OfficerAndDirectorSharePurchasePlanMember2022-12-31 0001506928avgr:OfficerAndDirectorSharePurchasePlanMember2021-12-31 0001506928us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-31 0001506928us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-31 0001506928us-gaap:RestrictedStockUnitsRSUMember2022-12-31 0001506928us-gaap:RestrictedStockUnitsRSUMember2021-12-31 0001506928us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-12-31 0001506928us-gaap:RestrictedStockUnitsRSUMember2020-12-31 0001506928us-gaap:RestrictedStockUnitsRSUMembersrt:MinimumMember2022-01-012022-12-31 0001506928us-gaap:EmployeeStockOptionMember2021-01-012021-12-31 0001506928us-gaap:EmployeeStockOptionMember2022-01-012022-12-31 0001506928us-gaap:EmployeeStockOptionMember2022-12-31 0001506928avgr:ExercisePriceRange4Member2022-12-31 0001506928avgr:ExercisePriceRange4Member2022-01-012022-12-31 0001506928avgr:ExercisePriceRange3Member2022-12-31 0001506928avgr:ExercisePriceRange3Member2022-01-012022-12-31 0001506928avgr:ExercisePriceRange2Member2022-12-31 0001506928avgr:ExercisePriceRange2Member2022-01-012022-12-31 0001506928avgr:ExercisePriceRange1Member2022-12-31 0001506928avgr:ExercisePriceRange1Member2022-01-012022-12-31 00015069282002-01-012020-12-31 0001506928avgr:CommonStockOptionsMembersrt:MinimumMember2022-01-012022-12-31 0001506928avgr:The2015EmployeeStockPurchasePlanMember2022-12-31 0001506928avgr:The2015EmployeeStockPurchasePlanMember2022-10-142022-10-14 0001506928avgr:CommonWarrantsMemberus-gaap:SeriesDPreferredStockMemberavgr:January2022OfferingMember2022-01-14 0001506928avgr:PlacementAgentPreferredInvestmentOptionsMember2022-08-31 0001506928avgr:SeriesBFinancingWarrantsMember2022-08-31 0001506928avgr:SeriesAPreferredInvestmentOptionsMember2022-08-31 0001506928avgr:PrefundedWarrantsIssuedInAugust2022FinancingMember2022-12-31 0001506928avgr:RegisteredDirectPrefundedWarrantsMember2022-01-012022-12-31 0001506928avgr:PrefundedWarrantsIssuedInAugust2022FinancingMember2022-08-04 0001506928avgr:PrivatePrefundedWarrantsMember2022-08-04 0001506928avgr:RegisteredDirectPrefundedWarrantsMember2022-08-04 0001506928avgr:PlacementAgentWarrantsIssuedInTheJanuary2022FinancingMember2022-01-14 0001506928avgr:CommonWarrantsMember2022-01-14 0001506928avgr:November2018WarrantsMember2021-12-31 0001506928avgr:Series2February2018WarrantsMember2021-12-31 0001506928avgr:Series1February2018WarrantsMember2021-12-31 0001506928avgr:PlacementAgentPrivateInvestmentOptionsIssuedInAugust2022FinancingMember2022-12-31 0001506928avgr:SeriesBPrivateInvestmentOptionsIssuedInAugust2022FinancingMember2022-12-31 0001506928avgr:SeriesAPrivateInvestmentOptionsIssuedInAugust2022FinancingMember2022-12-31 0001506928avgr:WarrantsIssuedInTheJanuary2022FinancingMember2022-12-31 0001506928avgr:PlacementAgentWarrantsIssuedInTheJanuary2022FinancingMember2022-12-31 0001506928avgr:November2018WarrantsMember2022-12-31 0001506928avgr:Series2February2018WarrantsMember2022-12-31 0001506928avgr:Series1February2018WarrantsMember2022-12-31 0001506928us-gaap:MeasurementInputExpectedDividendRateMember2022-01-14 0001506928us-gaap:MeasurementInputDiscountRateMember2022-01-14 0001506928us-gaap:MeasurementInputPriceVolatilityMember2022-01-14 0001506928us-gaap:MeasurementInputExpectedTermMember2022-01-14 0001506928avgr:CommonStockWarrantsIssuedWithSeriesDConvertiblePreferredStockMember2022-01-142022-01-14 0001506928avgr:January2022PublicOfferingMember2022-01-142022-01-14 0001506928us-gaap:SeriesDPreferredStockMember2022-12-31 0001506928avgr:ConversionOfSeriesDPreferredStockIntoCommonStockMember2022-01-012022-12-31 0001506928us-gaap:SeriesDPreferredStockMemberavgr:January2022OfferingMember2022-01-14 0001506928us-gaap:SeriesDPreferredStockMemberavgr:January2022OfferingMember2022-01-142022-01-14 0001506928us-gaap:SeriesBPreferredStockMember2021-12-31 0001506928us-gaap:SeriesBPreferredStockMember2022-12-31 0001506928avgr:ConversionOfSeriesBPreferredStockIntoCommonStockMember2021-01-012021-12-31 0001506928us-gaap:SeriesBPreferredStockMember2018-02-16 0001506928us-gaap:SeriesAPreferredStockMember2021-01-012021-12-31 0001506928us-gaap:SeriesAPreferredStockMember2022-01-012022-12-31 0001506928us-gaap:SeriesAPreferredStockMember2022-12-31 0001506928us-gaap:SeriesAPreferredStockMember2021-12-31 0001506928avgr:CRGMemberus-gaap:SeriesAPreferredStockMember2021-01-012021-12-31 0001506928avgr:CRGMemberus-gaap:SeriesAPreferredStockMember2022-01-012022-12-31 0001506928avgr:ConversionOfPrincipalAmountOfSeniorSecuredLoanToNewlyAuthorizedSeriesAPreferredStockMemberus-gaap:SeriesAPreferredStockMember2018-02-142018-02-14 0001506928us-gaap:PurchaseCommitmentMember2022-12-31 00015069282019-04-01 0001506928avgr:PaycheckProtectionProgramCARESActMember2022-01-012022-12-31 0001506928avgr:PaycheckProtectionProgramCARESActMember2021-04-012021-04-30 0001506928avgr:PaycheckProtectionProgramCARESActMemberus-gaap:OtherNonoperatingIncomeExpenseMember2021-04-012021-04-30 0001506928avgr:PaycheckProtectionProgramCARESActMember2020-04-232020-04-23 0001506928avgr:CRGMemberavgr:LoanAgreementMember2021-01-012021-12-31 0001506928avgr:CRGMemberavgr:LoanAgreementMember2022-01-012022-12-31 0001506928avgr:CRGMemberavgr:LoanAgreementMember2021-12-31 0001506928avgr:CRGMemberavgr:LoanAgreementMember2022-12-31 0001506928avgr:CRGMemberavgr:LoanAgreementMember2015-09-22 0001506928avgr:LoanAgreementMemberavgr:CRGMember2022-12-31 0001506928avgr:CRGMemberavgr:LoanAgreementMember2022-08-10 0001506928avgr:CRGMemberavgr:LoanAgreementMember2022-08-102022-08-10 0001506928avgr:CRGMemberavgr:LoanAgreementMember2018-02-14 0001506928avgr:SeriesAPreferredStockPurchaseAgreementWithCRGMemberavgr:CRGMemberavgr:LoanAgreementMember2018-02-142018-02-14 0001506928avgr:SecondTrancheBorrowedOnJune152016Memberavgr:CRGMemberavgr:LoanAgreementMember2016-06-15 0001506928avgr:FirstTrancheBorrowedOnSeptember222015Memberavgr:CRGMemberavgr:LoanAgreementMember2015-09-22 0001506928avgr:LeasedEquipmentMember2021-01-012021-12-31 0001506928avgr:LeasedEquipmentMember2022-01-012022-12-31 0001506928us-gaap:LeaseholdImprovementsMember2021-12-31 0001506928us-gaap:LeaseholdImprovementsMember2022-12-31 0001506928us-gaap:FurnitureAndFixturesMember2021-12-31 0001506928us-gaap:FurnitureAndFixturesMember2022-12-31 0001506928us-gaap:ComputerEquipmentMember2021-12-31 0001506928us-gaap:ComputerEquipmentMember2022-12-31 0001506928us-gaap:SoftwareDevelopmentMember2021-12-31 0001506928us-gaap:SoftwareDevelopmentMember2022-12-31 0001506928us-gaap:MachineryAndEquipmentMember2021-12-31 0001506928us-gaap:MachineryAndEquipmentMember2022-12-31 0001506928avgr:EquipmentHeldByCustomersMember2021-12-31 0001506928avgr:EquipmentHeldByCustomersMember2022-12-31 0001506928us-gaap:FairValueInputsLevel3Member2021-12-31 0001506928us-gaap:FairValueInputsLevel2Member2021-12-31 0001506928us-gaap:FairValueInputsLevel3Member2022-12-31 0001506928us-gaap:FairValueInputsLevel2Member2022-12-31 0001506928us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMembercountry:US2021-01-012021-12-31 0001506928us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMembercountry:US2022-01-012022-12-31 0001506928us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-31 0001506928us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-31 0001506928us-gaap:PreferredStockMember2021-01-012021-12-31 0001506928us-gaap:PreferredStockMember2022-01-012022-12-31 0001506928avgr:CommonStockOptionsMember2021-01-012021-12-31 0001506928avgr:CommonStockOptionsMember2022-01-012022-12-31 0001506928avgr:CommonStockWarrantsMember2021-01-012021-12-31 0001506928avgr:CommonStockWarrantsMember2022-01-012022-12-31 00015069282022-01-012022-01-31 0001506928srt:MaximumMember2022-01-012022-12-31 0001506928srt:MinimumMember2022-01-012022-12-31 0001506928us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberavgr:OneCustomerMember2021-01-012021-12-31 0001506928us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberavgr:OneCustomerMember2022-01-012022-03-31 0001506928us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-31 0001506928us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-31 0001506928us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberavgr:OneCustomerMember2021-01-012021-12-31 0001506928us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-31 0001506928us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-31 0001506928avgr:ReverseStockSplitMember2022-03-112022-03-11 0001506928avgr:CommonStockInJune2022Member2022-01-012022-12-31 0001506928avgr:CommonStockInJune2022Member2022-12-31 0001506928avgr:CommonStockInJune2022Member2022-05-20 0001506928avgr:SeriesBPreferredInvestmentOptionsMember2022-08-31 0001506928avgr:PrefundedWarrantsMember2022-12-31 0001506928avgr:RegisteredDirectPrefundedWarrantsMemberus-gaap:PrivatePlacementMember2022-08-04 0001506928avgr:August2022PurchaseAgreementMember2022-08-042022-08-04 0001506928us-gaap:PrivatePlacementMember2022-08-042022-08-04 0001506928us-gaap:PrivatePlacementMember2022-08-04 0001506928avgr:August2022PurchaseAgreementMember2022-08-04 0001506928avgr:PlacementAgentWarrantsIssuedInTheJanuary2022FinancingMemberus-gaap:SeriesDPreferredStockMember2022-01-14 0001506928avgr:CommonWarrantsMemberus-gaap:SeriesDPreferredStockMember2022-01-14 0001506928us-gaap:SeriesDPreferredStockMemberavgr:January2022PublicOfferingMember2022-01-14 0001506928us-gaap:SeriesDPreferredStockMember2022-01-14 0001506928us-gaap:SeriesDPreferredStockMemberavgr:January2022PublicOfferingMember2022-01-142022-01-14 0001506928avgr:February2021PulicOfferingMember2021-02-022021-02-02 0001506928avgr:February2021PulicOfferingMember2021-02-02 0001506928avgr:February2021PulicOfferingMember2021-02-012021-02-28 0001506928avgr:January2022PublicOfferingMember2022-01-012022-12-31 0001506928avgr:TheMarketOfferingAgreementTheAtmAgreementMember2022-01-012022-12-31 0001506928avgr:August2022PublicOfferingMember2022-08-012022-08-31 0001506928us-gaap:PreferredStockMember2021-01-012021-12-31 0001506928us-gaap:PreferredStockMember2022-01-012022-12-31 0001506928us-gaap:CommonStockMember2021-01-012021-12-31 0001506928us-gaap:CommonStockMember2022-01-012022-12-31 0001506928us-gaap:RetainedEarningsMember2022-12-31 0001506928us-gaap:AdditionalPaidInCapitalMember2022-12-31 0001506928us-gaap:CommonStockMember2022-12-31 0001506928us-gaap:PreferredStockMember2022-12-31 0001506928us-gaap:RetainedEarningsMember2022-01-012022-12-31 0001506928us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-31 0001506928us-gaap:CommonStockMember2022-01-012022-12-31 0001506928us-gaap:PreferredStockMember2022-01-012022-12-31 0001506928us-gaap:SeriesDPreferredStockMember2022-01-012022-12-31 0001506928us-gaap:RetainedEarningsMemberus-gaap:SeriesDPreferredStockMember2022-01-012022-12-31 0001506928us-gaap:AdditionalPaidInCapitalMemberus-gaap:SeriesDPreferredStockMember2022-01-012022-12-31 0001506928us-gaap:CommonStockMemberus-gaap:SeriesDPreferredStockMember2022-01-012022-12-31 0001506928us-gaap:PreferredStockMemberus-gaap:SeriesDPreferredStockMember2022-01-012022-12-31 0001506928us-gaap:RetainedEarningsMemberavgr:January2022PublicOfferingMember2022-01-012022-12-31 0001506928us-gaap:AdditionalPaidInCapitalMemberavgr:January2022PublicOfferingMember2022-01-012022-12-31 0001506928us-gaap:CommonStockMemberavgr:January2022PublicOfferingMember2022-01-012022-12-31 0001506928us-gaap:PreferredStockMemberavgr:January2022PublicOfferingMember2022-01-012022-12-31 0001506928us-gaap:RetainedEarningsMember2021-12-31 0001506928us-gaap:AdditionalPaidInCapitalMember2021-12-31 0001506928us-gaap:CommonStockMember2021-12-31 0001506928us-gaap:PreferredStockMember2021-12-31 0001506928us-gaap:RetainedEarningsMember2021-01-012021-12-31 0001506928us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-31 0001506928us-gaap:CommonStockMember2021-01-012021-12-31 0001506928us-gaap:PreferredStockMember2021-01-012021-12-31 0001506928us-gaap:RetainedEarningsMember2020-12-31 0001506928us-gaap:AdditionalPaidInCapitalMember2020-12-31 0001506928us-gaap:CommonStockMember2020-12-31 0001506928us-gaap:PreferredStockMember2020-12-31 0001506928avgr:SecSchedule1209AllowanceSalesReturnsMember2022-12-31 0001506928avgr:SecSchedule1209AllowanceSalesReturnsMember2022-01-012022-12-31 0001506928avgr:SecSchedule1209AllowanceSalesReturnsMember2021-12-31 0001506928avgr:SecSchedule1209AllowanceSalesReturnsMember2021-01-012021-12-31 0001506928avgr:SecSchedule1209AllowanceSalesReturnsMember2020-12-31 0001506928us-gaap:AllowanceForCreditLossMember2022-12-31 0001506928us-gaap:AllowanceForCreditLossMember2022-01-012022-12-31 0001506928us-gaap:AllowanceForCreditLossMember2021-12-31 0001506928us-gaap:AllowanceForCreditLossMember2021-01-012021-12-31 0001506928us-gaap:AllowanceForCreditLossMember2020-12-31 00015069282023-03-10 00015069282022-06-30
 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 10-K

 

(Mark One)

☒

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Fiscal Year Ended December 31, 2022

or

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission File Number: 001-36817

 

 

AVINGER, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

20-8873453

(State or other jurisdiction of

(I.R.S. Employer

incorporation or organization)

Identification Number)

 

400 Chesapeake Drive

Redwood City, California 94063

(Address of principal executive offices and zip code)

(650) 241-7900

(Telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class:

Trading Symbol(s):

Name of each exchange on which registered

Common Stock, par value $0.001 per share

AVGR

The Nasdaq Capital Market

 

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

 
 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐

Accelerated filer ☐

Non-accelerated filer ☒

Smaller reporting company ☒

Emerging growth company  ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  ☐

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to § 240.10D-1(b). ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

 

The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant, based on the closing price of a share of the registrant’s common stock on June 30, 2022, the last business day of the registrant’s most recently completed second fiscal quarter, as reported by the Nasdaq Capital Market on such date, was approximately $8.8 million. This calculation does not reflect a determination that certain persons are affiliates of the registrant for any other purpose.

 

As of March 10, 2023, the number of outstanding shares of the registrant’s common stock, par value $0.001 per share, was 8,614,508.

 

DOCUMENTS INCORPORATED BY REFERENCE

None.

 

 

 
 

 

 

AVINGER, INC.

ANNUAL REPORT ON FORM 10-K

FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022

TABLE OF CONTENTS

 

   

Page

Part I

3

Item 1.

Business

3

Item 1A.

Risk Factors

20

Item 1B.

Unresolved Staff Comments

50

Item 2.

Properties

50

Item 3.

Legal Proceedings

50

Item 4.

Mine Safety Disclosures

50
     

Part II

51

Item 5.

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

51

Item 6.

[RESERVED]

51

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

52

Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

 64

Item 8.

Financial Statements and Supplementary Data

 64

Item 9.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

 64

Item 9A.

Controls and Procedures

 64

Item 9B.

Other Information

 65

Item 9C.

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

 65
     

Part III

 66

Item 10.

Directors, Executive Officers and Corporate Governance

 66

Item 11.

Executive Compensation

 71

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 78

Item 13.

Certain Relationships and Related Transactions, and Director Independence

 80

Item 14.

Principal Accountant Fees and Services

 81
     

Part IV

 82

Item 15.

Exhibits and Financial Statement Schedules

 82

Item 16.

Form 10-K Summary

 86

Signatures

 F-30

 

“Avinger,” “Pantheris,” “Lumivascular,” and “Tigereye” are trademarks of our company. Our logo and our other trade names, trademarks and service marks appearing in this Annual Report on Form 10-K are our property. Other trade names, trademarks and service marks appearing in this Annual Report on Form 10-K are the property of their respective owners. Solely for convenience, our trademarks and trade names referred to in this Annual Report on Form 10-K appear without the ™ symbol, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the right of the applicable licensor to these trademarks and trade names.

 

 
 

 

 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This Annual Report on Form 10-K contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:

 

 

●

the outcome of and expectations regarding our current clinical studies, and any additional clinical studies we initiate;

 

 

●

our plans to modify our current products, or develop new products, to address additional indications;

 

 

●

our ability to obtain additional financing through future equity or debt financings;

 

 

●

the expected timing of 510(k) clearances by the FDA for additional versions of Pantheris, Ocelot, Tigereye and Lightbox;

 

 

●

the expected timing of 510(k) submission to the FDA, and associated marketing clearances by the FDA, for additional versions of Pantheris, Ocelot, Tigereye and Lightbox;

 

 

●

the expected growth in our business and our organization;

 

 

●

our expectations regarding government and third-party payor coverage and reimbursement, including the ability of Pantheris to qualify for reimbursement codes used by other atherectomy products;
     
 

●

our ability to continue as a going concern;

 

 

●

our ability to remain in compliance with the listing requirements of the Nasdaq Capital Market;
     
 

●

our ability to retain and recruit key personnel, including the continued development of our sales and marketing infrastructure;

 

 

●

our ability to obtain and maintain intellectual property protection for our products;

 

 

●

our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for, or ability to obtain, additional financing;

 

 

●

our expectations regarding revenue, cost of revenue, gross margins, and expenses, including research and development and selling, general and administrative expenses;

 

 

●

our expectations of qualitative and quantitative effects of COVID-19 to the extent discussed, as well as any expectations of recovery from or forward looking short-term or long-term implications thereof;
   

 
 

●

the effects of the COVID-19 pandemic on our business and results of operations;

 

 

●

our ability to identify and develop new and planned products and acquire new products, including those for the coronary market;

 

 

●

our financial performance;

 

 

●

our ability to remain in compliance with laws and regulations that currently apply or become applicable to our business, both in the United States and internationally; and

 

 

●

developments and projections relating to our competitors or our industry.

 

1
 

 

We believe that it is important to communicate our future expectations to our investors. However, there may be events in the future that we are not able to accurately predict or control and that may cause our actual results to differ materially from the expectations we describe in our forward-looking statements. These forward-looking statements are based on management’s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and management’s beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this Annual Report on Form 10-K may turn out to be inaccurate. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed in Part I, Item 1A under the “Risk Factors” section and elsewhere in this Annual Report on Form 10-K. We urge you to consider these factors carefully in evaluating the forward-looking statements. These forward-looking statements speak only as of the date of this Annual Report on Form 10-K. We assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

 

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Annual Report on Form 10-K to conform these statements to actual results or to changes in our expectations.

 

You should read this Annual Report on Form 10-K and the documents that we reference in this Annual Report on Form 10-K and have filed with the United States Securities and Exchange Commission (“SEC”) as exhibits to the Annual Report on Form 10-K with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.

 

2
 

 

PART I

 

ITEM 1.     BUSINESS

 

Overview

 

We are a commercial-stage medical device company that designs, manufactures, and sells real-time high-definition image-guided, minimally invasive catheter-based systems that are used by physicians to treat patients with peripheral artery disease (“PAD”). Patients with PAD have a build-up of plaque in the arteries that supply blood to areas away from the heart, particularly the pelvis and legs. Our mission is to significantly improve the treatment of vascular disease through the introduction of products based on our Lumivascular platform, the only intravascular real-time high-definition image-guided system available in this market.

 

We design, manufacture, and sell a suite of products in the United States and select international markets. We are located in Redwood City, California. Our current Lumivascular platform consists of products including our Lightbox imaging console, the Ocelot and Tigereye family of devices, which are image-guided devices designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (“CTO”), and the Pantheris family of catheters, our image-guided atherectomy catheters which are designed to allow physicians to precisely remove arterial plaque in PAD patients.

 

We are in the process of developing CTO crossing devices to target the coronary CTO market. However, the market for medical devices in the coronary artery disease (“CAD”) space is highly competitive, dynamic, and marked by rapid and substantial technological development and product innovation and there is no guarantee that we will be successful in developing and commercializing any new CAD product. At this stage, we are working on understanding market requirements, and initiated the development process for the new CAD product, which we anticipate will require additional expenses. We currently anticipate assessing our prototype CAD products in animal studies in the second quarter of 2023, with the goal of filing of an investigational device exemption submission with the FDA within the next 12 months to allow for initiation of a clinical study in 2024.

 

We received CE Marking for our original Ocelot product in September 2011 and received from the U.S. Food and Drug Administration, or FDA, 510(k) clearance in November 2012. We received 510(k) clearance from the FDA for commercialization of Pantheris in October 2015. We received an additional 510(k) clearance for an enhanced version of Pantheris in March 2016 and commenced sales of Pantheris in the United States and select European countries promptly thereafter. In May 2018, we received 510(k) clearance from the FDA for our current next-generation version of Pantheris. In April 2019, we received 510(k) clearance from the FDA for our Pantheris Small Vessel (“SV”), a version of Pantheris targeting smaller vessels, and commenced sales in July 2019. In September 2020, we received 510(k) clearance of Tigereye, a next-generation CTO crossing system utilizing Avinger’s proprietary image-guided technology platform. Tigereye is a product line extension of Avinger’s Ocelot family of image-guided CTO crossing catheters. In January 2022, we received 510(k) clearance from the FDA for our Lightbox 3 imaging console, an advanced version of our Lightbox that allows for easy portability and offers significant reductions in size, weight, and production cost in comparison to the incumbent version.

 

In July 2022, we submitted a 510(k) application to the FDA for the Tigereye Spinning Tip (“ST”) device, a next generation CTO crossing system. Tigereye ST is a line extension of our Ocelot and Tigereye family of CTO crossing catheters. This new image-guided catheter has an integrated outer spinning tip that pairs with the rotation of the inner tip to penetrate challenging blockages and CTO caps. Tigereye ST incorporates an advanced shaft design for pushability and torque response and a three-marker system, similar to Ocelot's, to facilitate consistent image interpretation across the platform. Tigereye ST continues to provide the high definition, real-time intravascular imaging, user-controlled deflectable tip, and faster rotational speeds introduced to Avinger's CTO portfolio with the commercial launch of Tigereye in early 2021. The low-profile Tigereye ST has a working length of 140 cm and 5 French sheath.

 

In January 2023, we submitted a 510(k) application to the FDA for the Pantheris LV device, a next generation image guided atherectomy system for the treatment of larger vessels, such as the superficial femoral artery (“SFA”) and popliteal arteries. Pantheris LV is a line extension of our Pantheris and Pantheris SV family of atherectomy products. This catheter offers higher speed plaque excision for efficient removal of challenging occlusive tissue and multiple features to streamline and simplify user-operation, including enhanced tissue packing and removal, a radiopaque gauge to measure volume of plaque excised during the procedure, and enhanced guidewire management.

 

3
 

 

Current treatments for PAD, including bypass surgery, can be costly and may result in complications, high levels of post-surgery pain, and lengthy hospital stays and recovery times. Minimally invasive, or endovascular, treatments for PAD include stenting, angioplasty, and atherectomy, which is the use of a catheter-based device for the removal of plaque. These treatments all have limitations in their safety or efficacy profiles and frequently result in recurrence of the disease, also known as restenosis. We believe one of the main contributing factors to high restenosis rates for PAD patients treated with endovascular technologies is the amount of vascular injury that occurs during an intervention. Specifically, these treatments often disrupt the membrane between the outermost layers of the artery, which is referred to as the external elastic lamina (“EEL”).

 

We believe our Lumivascular platform is the only technology that offers radiation free, high-definition real-time visualization of the inside of the artery during PAD treatment through the use of optical coherence tomography, or OCT, a high resolution, light-based, radiation-free imaging technology. Our Lumivascular platform provides physicians with high-definition real-time OCT images from the inside of an artery, and we believe Ocelot and Pantheris are the first products to offer intravascular visualization during CTO crossing and atherectomy, respectively. We believe this approach will significantly improve patient outcomes by providing physicians with a clearer picture of the artery using radiation-free image guidance during treatment, enabling them to better differentiate between plaque and healthy arterial structures. Our Lumivascular platform is designed to improve patient safety by enabling physicians to direct treatment towards the plaque, while avoiding damage to healthy portions of the artery.

 

During the first quarter of 2015, we completed enrollment of patients in VISION, a clinical trial designed to support our August 2015 510(k) submission to the FDA for our Pantheris atherectomy device. VISION was designed to evaluate the safety and efficacy of Pantheris to perform atherectomy using intravascular imaging and successfully achieved all primary and secondary safety and efficacy endpoints. We believe the data from VISION allows us to demonstrate that avoiding damage to healthy arterial structures, and in particular disruption of the external elastic lamina, which is the membrane between the outermost layers of the artery, reduces the likelihood of restenosis, or re-narrowing, of the diseased artery. Although the original VISION study protocol was not designed to follow patients beyond six months, we worked with 18 of the VISION sites to re-solicit consent from previous clinical trial patients in order for them to evaluate patient outcomes through 12 and 24 months following initial treatment. Data collection for the remaining patients from participating sites was completed in May 2017, and we released the final 12- and 24-month results for a total of 89 patients in July 2017.

 

During the fourth quarter of 2017, we began enrolling patients in INSIGHT, a clinical trial designed to support a submission to the FDA to expand the indication for our Pantheris atherectomy device to include the treatment of in-stent restenosis. Patient enrollment began in October 2017 and was completed in July 2021. Patient outcomes were evaluated at thirty days, six months and one year following treatment. In November 2021, we received 510(k) clearance from the FDA for this new clinical indication for treating in-stent restenosis with Pantheris using the data collected and analyzed from INSIGHT. We expect this will expand our addressable market for Pantheris to include a high-incidence disease state for which there are few available indicated or effective treatment options.

 

We are pursuing additional clinical data programs including a post-market study, IMAGE-BTK, that is designed to evaluate the safety and efficacy of Pantheris SV in the treatment of PAD lesions below-the-knee. We are currently enrolling patients, and we expect to complete enrollment in 2023.

 

We focus our direct sales force, marketing efforts and promotional activities on interventional cardiologists, vascular surgeons and interventional radiologists. We also work on developing strong relationships with physicians and hospitals that we have identified as key opinion leaders. Although our sales and marketing efforts are directed at these physicians because they are the primary users of our technology, we consider the hospitals and medical centers where the procedure is performed to be our customers, as they typically are responsible for purchasing our products. We are designing additional future products to be compatible with our Lumivascular platform, which we expect to enhance the value proposition for hospitals to invest in our technology. Pantheris qualifies for existing reimbursement codes currently utilized by other atherectomy products, further facilitating adoption of our products.

 

We have assembled a team with extensive medical device development and commercialization experience in both start-up and large, multi-national medical device companies. We assemble all of our catheter products at our manufacturing facility but certain critical processes, such as coating and sterilization, are performed by outside vendors. Our Lightbox 3 imaging console is assembled through a qualified contract manufacturer. We expect our current manufacturing facility in California, will be sufficient through at least 2023. We generated revenues of $8.8 million in 2020, $10.1 million in 2021 and $8.3 million in 2022. Revenue in 2020 was adversely affected by COVID-19 as hospitals deferred elective procedures, which among other things, created unpredictability in case volume. This unpredictability created more volatility in our revenues which continued to adversely affect our business in 2021 and 2022. The decline in revenue in 2022 was also attributable to the adverse effects of staffing shortages, resource constraints on our customers as hospitals deferred elective procedures, and the impact of a very competitive market for talent on the retention of our commercial team.

 

4
 

 

Our Products

 

Our current products include our Lightbox imaging consoles and our various catheter-based devices used in PAD treatment. All our revenues are currently derived from sales of our various PAD catheters and Lightbox imaging consoles and related services in the United States and select international markets. Each of our current products is, and our future products will be, designed to address significant unmet clinical needs in the treatment of vascular disease.

 

LUMIVASCULAR PRODUCTS

 

Name

Clinical
Indication

  

Size
(Length,

Diameter)

  

Regulatory
Status

  

Original
Clearance Date

PRODUCTS

              

Lightbox (1)

OCT Imaging

  

N/A

  

FDA Cleared
CE Marking

  

November 2012
September 2011

Lightbox 3 (2)

OCT Imaging

  

N/A

  

FDA Cleared

  

January 2022
               

Pantheris SV (Small Vessel) (3)

Atherectomy

  

140cm, 6F

  

FDA Cleared

CE Marking

  

April 2019

October 2018

Pantheris (Next-Generation) (4)

Atherectomy

  

110cm, 7F

  

FDA Cleared
CE Marking

  

May 2018
December 2017

Ocelot (5)

CTO Crossing

  

110cm, 6F

  

FDA Cleared
CE Marking

  

November 2012
September 2011

Ocelot MVRX (5)

CTO Crossing

  

110cm, 6F

  

FDA Cleared

  

December 2012

Ocelot PIXL (5)

CTO Crossing

  

135cm, 5F

  

FDA Cleared
CE Marking

  

December 2012
October 2012

Tigereye (5)

CTO Crossing

  

140cm, 5F

  

FDA Cleared

CE Marking

  

September 2020

December 2019

 

PIPELINE PRODUCTS

              
             

Submission

Date

 

Tigereye ST (Spinning Tip)

CTO Crossing

  

140cm, 5F

  

FDA Submitted

  

July 2022

Pantheris LV (Large Vessel)

Atherectomy

  

110cm, 7F

  

FDA Submitted

  

January 2023

 

 

 

(1)

Lightbox is cleared for use with compatible Avinger products.

 

(2)

The Lightbox 3, intended to deliver advancements in imaging and portability, incorporates advanced features, including an advanced solid-state laser for enhanced high-definition OCT imaging, a more powerful computing platform, and a redesigned software system with a highly intuitive user interface that emphasizes efficiency and ease-of-use. We initiated a limited launch of Lightbox 3 in the United States in the first quarter of 2022 and expanded to a full commercial launch in the second quarter of 2022.
 

 

(3)

The Pantheris SV system is intended to remove plaque (atherectomy) from partially stenosed or occluded vessels in the peripheral vasculature with a reference diameter of 2.0 mm to 4.0 mm, under direct real-time imaging using OCT. The system is an adjunct to fluoroscopy by providing images of vessel lumen, wall structures and vessel morphologies. The Pantheris SV system is contraindicated for use in the iliac, coronary, cerebral, renal or carotid vasculature.

 

(4)

The Pantheris system is intended to remove plaque (atherectomy) from partially stenosed or occluded vessels in the peripheral vasculature with a reference diameter of 3.0 mm to 7.0 mm, under direct real-time imaging using OCT. The system is an adjunct to fluoroscopy by providing images of vessel lumen, wall structures and vessel morphologies. The Pantheris system is contraindicated for use in the iliac, coronary, cerebral, renal or carotid vasculature.

 

(5)

The Ocelot system is intended to facilitate the intra-luminal placement of conventional guidewires beyond stenotic lesions including subtotal and chronic total occlusions in the peripheral vasculature prior to further percutaneous interventions using OCT-assisted orientation and imaging. The system is an adjunct to fluoroscopy and provides images of vessel lumen, plaques and wall structures. The Ocelot system is contraindicated for use in the iliac, coronary, cerebral, renal and carotid vasculature.

 

5
 

 

Lumivascular Platform Overview

 

Our Lumivascular platform integrates OCT (optical coherence tomography) visualization with interventional devices and is the industry’s only system that provides radiation free, high definition real-time intravascular imaging simultaneously with treatment in PAD procedures. Our Lumivascular platform consists of a capital component, Lightbox, and a variety of disposable catheter products, including the Ocelot, Tigereye and Pantheris family of catheters.

 

Lightbox

 

Lightbox is our proprietary video imaging console, which enables the use of Lumivascular devices during PAD procedures. The console contains an optical transceiver that transmits light into the artery through an optical fiber and displays a cross-sectional image of the vessel to the physician on a high-definition monitor during the procedure.

 

Lightbox displays a cross-sectional view of the vessel, which provides physicians with detailed information about the orientation of the catheter and the surrounding artery and plaque. Layered structures represent relatively healthy portions of the artery and non-layered structures represent the plaque that is blocking blood flow in the artery. Navigational markers allow the physician to orient the catheter toward the treatment area, helping to avoid damage to the healthy arterial structures during a procedure. Lightbox received FDA 510(k) clearance in November 2012 and CE Marking in Europe in September 2011.

 

In January 2022, we received 510(k) clearance from the FDA for our next generation Lightbox 3 imaging console, the Lightbox 3, a version of our Lightbox that delivers important advancements in imaging, portability and capability in comparison to the incumbent version. Lightbox 3 incorporates advanced features, including an advanced solid-state laser for enhanced high-definition OCT imaging, a more powerful computing platform, and a redesigned software system with a highly intuitive user interface that emphasizes efficiency and ease-of-use into a significantly smaller size and weight console. We initiated a limited launch of Lightbox 3 in the United States in the first quarter of 2022 and expanded to full commercial availability in the subsequent quarter.

 

Pantheris

 

We believe Pantheris is the first atherectomy device to incorporate radiation free high-definition real-time OCT intravascular imaging to guide the procedure. Pantheris may be used alone or following a CTO crossing procedure using Ocelot or other products. Pantheris is a single-use product and provides physicians with the ability to see a cross-sectional view of the peripheral artery to guide the removal of blockages throughout the procedure. The Pantheris device restores blood flow by shaving strips of plaque using a high-speed directional cutting mechanism that enables physicians to specifically target the portion of the artery where the plaque resides while minimizing disruption to healthy arterial structures. The excised plaque is deposited, collected and contained into the nosecone of the Pantheris device and removed from the artery within the device.

 

In October 2015, we received 510(k) clearance from the FDA for commercialization of Pantheris. We made modifications to Pantheris after the completion of the VISION trial and commenced sales in the United States and select international markets following receipt of FDA approval for this initial version of Pantheris in March 2016. We first received CE Marking for Pantheris in June 2015. We received CE Marking in December 2017 and 510(k) clearance in May 2018 for a next-generation version of Pantheris, which includes new features and design improvements to the handle, shaft, balloon and nosecone of the device. The next-generation Pantheris atherectomy device is currently available for commercial sale in the United States and select international markets. All previous versions of Pantheris have been discontinued.

 

We also offer a line extension of our Pantheris image-guided atherectomy platform, Pantheris SV, a lower profile version of Pantheris. The Pantheris SV has a smaller diameter and longer length and is designed for use in smaller vessels 2.0 to 4.0 millimeters in diameter. We received CE Marking in October 2018 and 510(k) clearance in April 2019 for this product and commenced sales in the United States in July 2019.

 

We recently developed another line extension of our Pantheris platform, Pantheris LV. The Pantheris LV has a larger diameter and shorter length than the Pantheris SV and is designed for use in larger vessels 3.0 to 7.0 millimeters in diameter. We submitted a 510(k) application for Pantheris LV to the FDA in January 2023.

 

6
 

 

Ocelot and Tigereye

 

Ocelot is the first CTO crossing catheter to incorporate radiation free high-definition real-time OCT intravascular imaging, which allows physicians to see the inside of a peripheral artery during a CTO crossing procedure. Physicians have traditionally relied solely on fluoroscopy and tactile feedback to guide interventional catheters through complicated blockages. Ocelot allows physicians to accurately navigate through CTOs by utilizing the OCT images to precisely guide the device through the arterial blockage, while minimizing disruption to the healthy arterial structures. A successful CTO crossing and placement of a guidewire allows the physician to subsequently treat the vessel with a minimally invasive therapeutic device. We received CE Marking for Ocelot in September 2011 and received FDA 510(k) clearance in November 2012.

 

We also offer Ocelot PIXL, a lower profile CTO crossing device for below-the-knee arteries and Ocelot MVRX, which offers a different tip design for peripheral arteries above-the-knee. We received CE Marking for Ocelot PIXL in October 2012 and received FDA 510(k) clearance in December 2012. We received FDA 510(k) clearance for Ocelot MVRX in December 2012.

 

Tigereye is a product line extension of our Ocelot family of image-guided CTO crossing devices. Its design elements include an upgrade of the image capture rate to provide high definition, real-time intravascular video imaging similar to the Pantheris image-guided atherectomy system and a user-controlled deflectable tip designed to assist in steerability across the blockage. We received CE Marking for Tigereye in December 2019 and received FDA 510(k) clearance in September 2020.

 

We recently developed another line extension of our Ocelot family of catheters, Tigereye ST. The Tigereye ST has a comparable diameter and length to the Tigereye catheter. This new image-guided catheter has an integrated outer spinning tip that pairs with the rotation of the inner tip to penetrate challenging blockages and CTO caps. Tigereye ST incorporates an advanced shaft design for pushability and torque response and a three-marker system, similar to Ocelot's, to facilitate consistent image interpretation across the platform. We submitted a 510(k) application for Tigereye ST to the FDA in July 2022.

 

Other Products

 

Our first-generation CTO crossing catheters, Wildcat and Kittycat 2, employ a proprietary design that uses a rotational spinning technique, allowing the physician to switch between passive and active modes when navigating across a CTO. Once across the CTO, Wildcat and Kittycat 2 allow for placement of a guidewire and removal of the catheter while leaving the wire in place for additional therapies. Both products require the use of fluoroscopy solely rather than our Lumivascular (OCT-guided) platform for imaging. Wildcat was our first commercial product and has both FDA 510(k) clearance in the United States and CE Marking in Europe for crossing peripheral artery CTOs. Kittycat 2 has FDA 510(k) clearance in the United States and CE Marking in Europe for the treatment of peripheral artery CTOs. We discontinued selling these products as we are focusing on the promotion of our Lumivascular platform products.         

 

Clinical Development

 

We have conducted several clinical trials to evaluate the safety and efficacy of our products in both pre-market and post-market assessments. We received FDA clearance for the Ocelot CTO crossing device in 2012, for the Pantheris device for atherectomy in peripheral arteries in October 2015 and then in November 2021 for the indication for use of the Pantheris device to include treatment of in-stent restenosis following completion of clinical trials of these devices.

 

CONNECT II (Ocelot)

 

Our clinical trial for Ocelot, known as CONNECT II, was a prospective, multi-center, non-randomized trial that evaluated the safety and efficacy of Ocelot in crossing CTOs in arteries of the upper leg using OCT intravascular imaging. The CONNECT II trial enrolled 100 patients with CTOs at 13 centers in the United States and 2 centers in Europe. Patients were followed for 30 days post-procedure and an independent group of physicians verified the results to confirm the primary efficacy and safety endpoints. Results from the CONNECT II trial demonstrated that Ocelot surpassed its primary efficacy endpoint by successfully crossing the CTO in 97% of the cases following unsuccessful attempts to cross with standard guidewire techniques. Ocelot achieved these rates with 98% freedom from MAEs.

 

7
 

 

VISION (Pantheris)

 

VISION was our pivotal, non-randomized, prospective, single-arm trial to evaluate the safety and effectiveness of Pantheris across 20 sites within the United States and Europe. The objective of the clinical trial was to demonstrate that Pantheris can be used to effectively remove plaque from diseased lower extremity arteries while using on-board visualization as an adjunct to fluoroscopy. Two groups of patients were treated in VISION: (1) optional roll-ins, which are typically the first two procedures at a site, and (2) the primary cohort, which are the analyzable group of patients. The data for these two groups were reported separately in our 510(k) submission to the FDA. Based on final enrollment, the primary cohort included 130 patients. In March 2015, we completed enrollment of patients in the VISION clinical trial and we submitted for 510(k) clearance from the FDA in August 2015. In October 2015, we received 510(k) clearance from the FDA for commercialization of Pantheris. We made modifications to Pantheris subsequent to the completion of VISION and received 510(k) clearance an enhanced version of Pantheris in March 2016, and received 510(k) clearance in May 2018 for a next-generation version of Pantheris, which included new features and design improvements to the handle, shaft, balloon, and nose cone of the device as well as 510(k) clearance in April 2019 for Pantheris SV, a lower profile Pantheris.

 

VISION’s primary efficacy endpoint required that at least 87% of lesions treated by physicians using Pantheris have a residual stenosis of less than 50%, as verified by an independent core laboratory. The primary safety endpoint required that less than 43% of patients experience an MAE through six-month follow-up as adjudicated by an independent Clinical Events Committee, or CEC. MAEs as defined in VISION included cardiovascular-related death, unplanned major index limb amputation, clinically driven target lesion revascularization, or TLR, heart attack, clinically significant perforation, dissection, embolus, and pseudoaneurysm. Results from the VISION trial demonstrated that Pantheris surpassed its primary efficacy and safety endpoints; residual restenosis of less than 50% was achieved in 96.3% of lesions treated in the primary cohort, while MAEs were experienced in 16.6% of patients.

 

Final VISION trial data are summarized in the table below.

 

   

Roll-In
Cohort

    

Primary
Cohort

    

Total

  

Patients Treated

     28       130       158  
                         

Lesions treated

     34       164       198  

Primary Efficacy Endpoint

                        

Lesions analyzed by core lab

     34       164       198  

Lesions meeting primary efficacy endpoint criterion of residual restenosis of less than 50% by core lab

     100

%

     96.3

%

     97

%
      (34/34

)

     (158/164

)

     (192/198

)

Primary Safety Endpoint (MAEs through 6 months)

                        

Total MAEs Reported

     3       22       25  

Reported MAEs as a percentage of patients enrolled

     11.5

%

     17.6

%

     16.6

%
      (3/26

)

     (22/125

)

     (25/151

)

Histopathology Results (Non-Endpoint Data)

                        

Lesions with histopathology results

     34       162       196  

Average percent area of adventitia in all lesions with histopathology results

     0.56

%

     1.02

%

     0.94

%

 

Although not mandated by the FDA to support the market clearance of Pantheris, the protocol for the VISION trial allowed for routine histopathological analysis of the tissue extracted by Pantheris to be conducted. This process allowed us to determine the amount of adventitia present in the tissue, which in turn indicated the extent to which the external elastic lamina had been disrupted during Pantheris procedures. We completed histopathological analysis on tissue from 129 patients in the primary cohort, representing 162 lesions, and determined that the average percent area of adventitia in the total excised tissue was only 1.0%. Research shows that a low level of arterial wall disruption correlates to lower restenosis rates and improved long-term outcomes for patients treated with Pantheris. The results of this histopathological analysis in conjunction with the primary safety and efficacy endpoint data from the VISION trial were published in the Journal of Endovascular Therapy in 2017.

 

Although the original VISION study protocol was not designed to follow patients beyond six months, in 2016 we began working with 18 of the VISION sites to re-consent patients in order for them to be evaluated for patient outcomes through 12 and 24 months following initial treatment. Data collection for patients from participating sites was completed in May 2017, and we released the final 12- and 24-month results for a total of 73 patients and 89 lesions in July 2017. The key metrics reported for this group were freedom from target lesion revascularization, or TLR, at 12 months and 24 months, which were 82% and 74% by patient and 83% and 76% by lesion, respectively, based on Kaplan-Meier curve assessments.

 

8
 

 

INSIGHT (Pantheris)

 

The INSIGHT Trial was a prospective, global, single-arm, multi-center trial to evaluate the safety and effectiveness of Pantheris for treating in-stent restenosis (“ISR”) in lower extremity arteries. ISR occurs when a blocked artery previously treated with a stent becomes narrowed again, thereby reducing blood flow. Physicians often face challenges when treating ISR both in terms of safety and efficacy. From a safety standpoint, limitations in imaging techniques, such X-ray fluoroscopy, and the inability to control the directionality of other atherectomy devices create concerns about impacting the integrity of the stent during the procedure. In terms of efficacy, current therapies for in-stent restenosis, such as balloon angioplasty, have high rates of recurrent narrowing within stents.

 

The INSIGHT trial enrolled 97 patients at sites in the United States and Europe. Patient enrollment began in October 2017 and concluded in July 2021. Patients were evaluated at thirty days, six months and one year following treatment.

 

The primary safety endpoint was defined as freedom from a composite of major adverse events (MAEs) through 30 days after the procedure, as adjudicated by an independent Clinical Events Committee (CEC). The primary effectiveness endpoint was technical success, defined as the percent of target lesions that have a residual diameter stenosis ≤ 50% after use of the Pantheris device alone, as assessed by an independent angiographic core laboratory. The secondary safety endpoint was absence of new or worsening stent fracture following use of the Pantheris catheter. A secondary powered effectiveness endpoint was freedom from target lesion revascularization (TLR) at 6 months following the index procedure. Additional secondary effectiveness included procedural success, defined as the percent of target lesions that have residual diameter stenosis ≤ 30% post-Pantheris and any other adjunctive therapy, as determined by an independent core lab, and changes in Ankle- Brachial Index (ABI), and Rutherford Classes at 30 days and 6 months after the procedure in relation to the measurements prior to the procedure.

 

The subjects enrolled in the INSIGHT trial presented with documented symptomatic in-stent restenosis (stenosis >70% by visual estimation) and met all eligibility criteria. The target in-stent restenotic lesion had to be located in vessels with diameters of > 3 mm and < 7 mm and were not to exceed 30 cm in length. Subjects were followed through 30 days and six months post-procedure for purposes of the FDA submission to expand the indication for use statement. The clinical data for 97 subjects enrolled that reported for clinic visits 30 days and 85 subjects who reported for clinic visits 6 months after the index procedure were analyzed.

 

The primary safety endpoint was defined as freedom from a composite of major adverse events (MAEs) through 30 days after the procedure, as adjudicated by an independent Clinical Events Committee (CEC). Only 3 subjects (3%) experienced a MAE, with 97% of subjects free from MAEs within 30 days. With only 3% subjects reporting an MAE and a 95% one-sided upper confidence bound of 6.5%, the primary safety performance goal of MAEs occurring in < 20% of subjects was met.

 

The secondary safety endpoint was absence of new or worsening stent fracture following use of the Pantheris catheter. Only one (1) catheter inadvertently made contact with a stent during the 97 procedures, a rate of 1%. This endpoint was not established with a sample size requirement, so this performance goal was met not only due to its extremely low incidence rate but also by the experience that after re-training the one physician who had this event on the use of real-time optical coherence tomography imaging during the procedure the physician completed 12 subsequent cases with no further events.

 

The primary effectiveness endpoint of this study was technical success, defined as the percent of target lesions that have a residual diameter stenosis ≤ 50% after use of the Pantheris device alone, as assessed by an independent angiographic core laboratory. In this analysis, 86 out of 97 (89%) subjects had <50% residual stenosis following use of the Pantheris catheter alone, with a 95% one-sided upper confidence bound of 95% and a lower confidence bound of 82%, which met the adjusted performance goal of > 79%.

 

A secondary powered effectiveness endpoint was freedom from target lesion revascularization (TLR) at 6 months following the index procedure. The freedom from TLR of the 85 subjects that have completed their 6-month follow-up visits after the index procedure was 93% (79/85), with a 95% one-sided upper confidence bound of 98% and a lower bound of 87%, which met the performance goal of > 61%.

 

Additional secondary effectiveness included procedural success, defined as the percent of target lesions that have residual diameter stenosis ≤ 30% post-Pantheris and any other adjunctive therapy, as determined by an independent core lab, and changes in Ankle- Brachial Index (ABI), and Rutherford Classes at 30 days and 6 months after the procedure in relation to the measurements prior to the procedure.

 

Procedural success was determined if the residual diameter stenosis was < 30% following adjunctive treatment. In this cohort 78 of the 97 subjects (80%) were determined to have a residual stenosis < 30% following review of angiograms by the core lab, with a mean stenosis of 15% ±10.1%.

 

9
 

 

The ABI measures improved 39% from baseline by the time of the 6-month visit and the Rutherford Classification measures improved by 71% at the same time.

 

Adjunctive devices used in the procedure were primarily balloons (83%), with balloon angioplasty followed by placement of a stent occurring in 13% of the cases, and no adjunctive treatment provided in 4% of the procedures.

 

The results from the INSIGHT trial demonstrated that the Pantheris catheter is safe and effective when used to address in-stent restenosis. The study endpoints achieved the effectiveness performance goals while demonstrating a strong safety profile indicating that the Pantheris catheter can be used to safely excise tissue from occluded vascular stents with precision. The study results also demonstrate extremely low, acute device-related adverse events.

 

A 510(k) application to the FDA was submitted in June 2021 and the we received clearance to add ISR treatment to the indication for use for the Pantheris catheter in November 2021.

 

Other Studies

 

We are pursuing additional clinical data programs, including a post-market study, IMAGE-BTK, that is designed to evaluate the safety and efficacy of Pantheris SV in the treatment of PAD lesions below-the-knee. We are currently enrolling subjects and expect to complete enrollment by the end of 2023.

 

Sales and Marketing

 

We focus our sales and marketing efforts primarily on the approximately 10,000 interventional cardiologists, vascular surgeons and interventional radiologists in the United States that are potential users of our Lumivascular platform products. Our marketing efforts are focused on developing strong relationships with physicians and hospitals that we have identified as key opinion leaders based on their knowledge of our products, clinical expertise and reputation. We also use continuing medical education programs and other opportunities to train interventional cardiologists, vascular surgeons, and interventional radiologists in the use of our Lumivascular platform products and educate them as to the benefits of our products as compared to alternative procedures such as angioplasty, stenting, bypass surgery or other atherectomy procedures. In addition, we work with physicians to help them develop their practices and with hospitals to market themselves as centers of excellence in PAD treatment by making our products available to physicians for treating patients.

 

Our sales team currently consists of a Vice President, Regional Director, Territory Sales Managers, Clinical Specialists, and one Vice President of International Sales. Territory Sales managers are responsible for all product sales, which include disposable devices and sale and service of our Lightbox console, while Clinical Specialists are primarily responsible for case coverage and account support. We have an extensive hands-on sales training program, focused on our technologies, Lumivascular image interpretation, case management, sales processes, sales tools and implementing our sales and marketing programs and compliance with applicable federal and state laws and regulations. Our sales team is supported by our marketing team, which focuses primarily on clinical training and education, marketing communications and product management. We have partnered with a third-party field service firm for the installation, service and maintenance of our Lightbox consoles.

 

For the year ended December 31, 2022, we had one customer that represented approximately 14% of revenues. For the year ended December 31, 2021, we had one customer that represented approximately 10% of revenues.

 

Competition

 

The medical device industry is highly competitive, subject to rapid change and significantly affected by new product introductions, results of clinical research, reimbursement dynamics, corporate combinations and other factors relating to our industry. Because of the market opportunity and the high growth potential of the PAD treatment market, competitors and potential competitors have historically dedicated, and will continue to dedicate, significant resources to aggressively develop and commercialize their products.

 

10
 

 

Our products compete with a variety of products or devices for the treatment of PAD, including other CTO crossing devices, stents, balloons and atherectomy catheters, as well as products used in vascular surgery. Large competitors in the CTO crossing, stent and balloon market segments include Abbott Laboratories, AngioDynamics, Becton Dickinson, Boston Scientific, Cardinal Health, Cook Medical, Medtronic and Philips. Competitors in the atherectomy market include AngioDynamics, Boston Scientific, Cardiovascular Systems, Medtronic and Philips. Some competitors have attempted to combine intravascular imaging with atherectomy and although we are not aware of any active initiatives in this area, these and other companies may attempt to incorporate on-board visualization into their products in the future or may have ongoing programs of which we are not aware. Other competitors include pharmaceutical companies that manufacture drugs for the treatment of symptoms associated with mild to moderate PAD and companies that provide products used by surgeons in peripheral and coronary bypass procedures. These competitors and other companies may introduce new products that compete with our solution.

 

Many of our competitors have substantially greater financial, manufacturing, marketing and technical resources than we do. Furthermore, many of our competitors have well-established brands, widespread distribution channels and broader product offerings, and have established stronger and deeper relationships with target customers.

 

To compete effectively, we have to demonstrate that our products are attractive alternatives to other devices and treatments on the basis of:

 

 

●

procedural safety and efficacy;

 

 

●

acute and long-term outcomes;

 

 

●

ease of use and procedure time;

 

 

●

third-party reimbursement;

 

 

●

size, effectiveness, and productivity of sales force;

 

 

●

radiation exposure for physicians, hospital staff and patients; and

 

 

●

price.

 

Intellectual property

 

In order to remain competitive, we must develop and maintain protection of the proprietary aspects of our technologies. We rely on a combination of patents, copyrights, trademarks, trade secret laws and confidentiality and invention assignment agreements to protect our intellectual property rights.

 

It is our policy to require our employees, consultants, contractors, outside scientific collaborators and other advisors to execute non-disclosure and assignment of invention agreements on commencement of their employment or engagement. Agreements with our employees also forbid them from using the proprietary rights of third parties in their work for us. We also require confidentiality or material transfer agreements from third parties that receive our confidential data or materials.

 

As of December 31, 2022, we held 54 issued and allowed U.S. patents, 1 U.S. pending provisional application, 22 U.S. utility patent applications and 4 PCT applications pending. As of December 31, 2022, we also had 84 issued and allowed patents from outside of the United States. As of December 31, 2022, we had 35 pending patent applications outside of the United States, including in Australia, Canada, China, Europe, India, Japan and Mexico. As we continue to research and develop our products and technology, we intend to file additional U.S. and foreign patent applications related to the design, manufacture and therapeutic uses of our devices. Our issued patents expire between the years 2028 and 2037.

 

Our patent applications may not result in issued patents and our patents may not be sufficiently broad to protect our technology. Any patents issued to us may be challenged by third parties as being invalid, or third parties may independently develop similar or competing technology that avoids our patents. The laws of certain foreign countries do not protect our intellectual property rights to the same extent as do the laws of the United States.

 

As of December 31, 2022, we held six registered U.S. trademarks. In Europe, we hold three registered trademarks. In the United Kingdom, we hold three registered trademarks. In addition, we held one International Registration under the Madrid Protocol with granted extensions to China, Europe, Japan, and Korea (reflected in the three European registrations noted above).

 

11
 

 

Research and Development

 

Our ongoing research and development activities are primarily focused on improving and enhancing our Lumivascular platform, specifically our core competency of integrating OCT intravascular imaging onto therapeutic catheters. Our research objectives target areas of unmet clinical need, increase the utility of the Lumivascular platform and adoption of our products by healthcare providers.

 

 

●

Product line improvements and extensions. We are developing improvements to our Lumivascular platform, including additional catheters for use in different clinical applications. For example, we are developing next-generation CTO crossing devices to target both the peripheral and coronary CTO markets.

 

 

●

Additional treatment indications. We intend to seek additional regulatory clearances from FDA to expand the indications for which our products can be marketed. This includes both expanding the marketed indications for our current products, as well as development of new products.

 

 

●

Improved software and user interface. We intend to further develop our software to provide more information and control to our end users during a procedure. We use physician and staff feedback to improve the features and user functionality of our Lumivascular platform

 

In addition to our internal team, we retain third-party contractors from time to time to provide us with assistance on specialized projects. We also work closely with experts in the medical community to supplement our internal research and development resources.

 

Manufacturing

 

All of our products are manufactured in-house using components and sub-assemblies fabricated both at our facility in Redwood City, California and by key qualified outside vendors. We assemble all of our finished catheter products at our manufacturing facility but certain critical processes such as coating and sterilization are done by specialized outside vendors. We expect our current manufacturing facility will be sufficient through at least 2023.

 

Order quantities and lead times for components purchased from outside suppliers are based on our forecasts derived from historical demand and anticipated future demand. Lead times for components may vary significantly depending on the size of the order, time required to fabricate and test the components, specific supplier requirements and current market demand for the components and subassemblies. To date, we have experienced some delays in obtaining some of our components and subassemblies. Any significant delay or interruption in our supply chain could impair our ability to meet the demands of our customers and could harm our business.

 

We rely on single and limited source suppliers for several of our components and sub-assemblies. For example, we rely on single vendors for our optical fiber, coating and drive cables that are key components of our catheters, and we rely on single vendors for our laser and data acquisition card that are key components of our Lightbox, as well as assembly of our Lightbox 3. These components are critical to our products and there are relatively few alternative sources of supply for them. Identifying and qualifying additional or replacement suppliers for any of the components used in our products could involve significant time and cost. Any supply or service interruption from our vendors or failure to obtain additional vendors for any of the components or services used to manufacture our products would limit our ability to manufacture our products and could therefore harm our business, financial condition and results of operations.

 

Our manufacturing operations are subject to regulatory requirements of 21 CFR part 820 of the Federal Food, Drug and Cosmetic Act, or FFDCA; the Quality System Regulation, or QSR, for medical devices sold in the United States, which is enforced by FDA; the Medical Devices Directive 93/42/EEC, which is required for doing business in the European Union; and applicable requirements relating to the environment, waste management and health and safety matters, including measures relating to the release, use, storage, treatment, transportation, discharge, disposal and remediation of hazardous substances, and the sale, labeling, collection, recycling, treatment and disposal of products containing hazardous substances. We cannot ensure that we will not incur material costs or liability in connection with our operations, or that our past or future operations will not result in claims by or injury to employees or the public.

 

12
 

 

We have registered with FDA as a medical device manufacturer and have obtained a manufacturing license from the California Department of Public Health, or CDPH. We and our component suppliers are required to manufacture our products in compliance with FDA’s QSR in 21 CFR part 820 of the FFDCA. The QSR regulates extensively the methods and documentation of the design, testing, control, manufacturing, labeling, quality assurance, packaging, storage and shipping of our products. FDA enforces the QSR through periodic unannounced inspections that may include the manufacturing facilities of our subcontractors. In 2019, 2020 and 2021, BSI conducted multiple routine audits including surveillance audit, Microbiology audit, a MDSAP re-certification audit and an unannounced audit in September 2019. Our Quality System has undergone more than 20 external audits by third-parties and regulatory authorities since 2009. Most recently, we were audited in March 2022 as part of ISO 13485:2016 & MDSAP re-certification. The audit was conducted by BSI at the behest of US-FDA. No major non-conformances were identified. Minor non-conformances identified in the audits have been either successfully resolved or are being actively addressed via Avinger’s CAPA system.

 

Our failure or the failure of our component suppliers to maintain compliance with the QSR requirements could result in the shutdown of our manufacturing operations or the recall of our products, which would harm our business. In the event that one of our suppliers fails to maintain compliance with our or governmental quality requirements, we may have to qualify a new supplier and could experience manufacturing delays as a result. We have opted to maintain quality assurance and quality management certifications to enable us to market our products in the member states of the European Union, the European Free Trade Association and countries which have entered into Mutual Recognition Agreements with the European Union. Our Redwood City facilities meet the requirements set forth by ISO 13485:2016 Medical devices—Quality management systems—Requirements for regulatory purposes and MDD 93/42/EEC European Union Council Medical Device Directive.

 

Government Regulation

 

In general, medical device companies must navigate a challenging regulatory environment. In the United States the FDA regulates the medical device market to ensure the safety and efficacy of these products. The FDA allows two primary pathways for a medical device to gain approval for commercialization: (i) a pre-market notification or 510(k) submission based upon being equivalent to a device already in commercial distribution (a predicate device) or (ii) a PMA (pre-market approval). A completely novel product must go through the more rigorous PMA process if it cannot receive authorization through a 510(k) submission. The FDA has established three different classes of medical devices that indicate the level of risk associated with using a device and consequent degree of regulatory controls needed to govern its safety and efficacy. Class I and Class II devices are considered to have minimal risk to the user. Some Class I and almost all Class II devices gain clearance for commercial distribution following review of an application to the FDA, generally known as the 510(k) process. The devices regarded as the highest risk by the FDA are designated Class III and generally require the submission of a PMA application for approval prior to commercialization. Class III devices generally include life-sustaining, life-supporting, or implantable devices or devices without a known predicate technology already approved by the FDA.

 

The 510(k) clearance path can be significantly less time-consuming and less arduous than the PMA path, making this route generally preferable for a medical device company. A 510(k) application must include documentation that its device is substantially equivalent to a technology already cleared through a 510(k) or in distribution before May 28, 1976, and for which the FDA has not required a PMA submission. The FDA has 90 days from the date of the pre-market equivalence acceptance to authorize or decline commercial distribution of the device. However, similar to the PMA process, clearance may take longer than this three-month window, as the FDA can request additional data to support the submission. If the FDA resolves that the product is not substantially equivalent to a predicate device, then the device acquires a Class III designation, and a PMA must be approved before the device can be commercialized. All of our currently marketed products have received commercial clearance and associated indications for use through the 510(k) regulatory pathway, some with the support of clinical data.

 

After a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a change in its intended use, requires an additional 510(k) submission and clearance before the modified device can be commercialized. The FDA allows each manufacturer to make this determination initially, but the FDA can review any such decision and can disagree with the manufacturer’s determination. If the FDA disagrees with the determination not to seek a new 510(k) clearance or PMA the FDA may retroactively require a new 510(k) clearance or pre-market approval for the modified device. The FDA could also require a manufacturer to cease marketing and distribution of the modified device and/or recall the modified device until 510(k) clearance or PMA approval is obtained. Also, in these circumstances, a manufacturer may be subject to significant regulatory fines, penalties, and enforcement actions.

 

13
 

 

A PMA application must include reasonable scientific and clinical data that demonstrates the device is safe and effective for the intended uses and indications being sought. The application must also include preclinical testing, technical, manufacturing, and labeling information. If the FDA determines the application can undergo substantive review, it has 180 days to review the submission, but it can typically take longer (up to several years) as this regulatory body can request additional information or clarifications. The FDA may also impose additional regulatory hurdles for a PMA, including the institution of an advisory panel of experts to assess the application or provide recommendations as to whether to approve the device. Although the FDA in the end approves or disapproves the device, in nearly all cases the FDA follows the recommendation from the advisory panel. As part of this process, the FDA will usually inspect the manufacturing facilities and operations prior to approval to verify compliance with quality control regulations. Significant changes in the manufacturing of a device, or changes in the intended use, indications and labeling or design of a product require new PMA applications or PMA supplements for a product originally approved under a PMA. This creates substantial regulatory risk for devices undergoing the PMA route.

 

Pervasive and Continuing Regulation

 

After a device is placed on the market, numerous regulatory requirements continue to apply. These include:

 

 

●

the FDA’s QSR (quality system regulation) that requires manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation, and other quality assurance procedures during all aspects of the manufacturing process;

 

 

●

labeling regulations and FDA prohibitions against the promotion of products for uncleared, unapproved or off-label uses;

 

 

●

clearance or approval of product modifications that could significantly affect safety or efficacy or that would constitute a major change in intended use;

 

 

●

medical device reporting, or MDR, regulations, that require manufacturers report to the FDA if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction were to recur; and

 

 

●

post-market surveillance regulations, which apply when necessary to protect the public health or to provide additional safety and effectiveness data for the device.

 

We are registered with the FDA as a medical device manufacturer and have obtained a manufacturing license from the CDPH. The FDA has broad post-market and regulatory enforcement powers. We are subject to unannounced inspections by the FDA and the Food and Drug Branch of CDPH to determine our compliance with the QSR and other regulations, and these inspections may include the manufacturing facilities of our suppliers. Our current facility has been inspected by the FDA in 2009, 2011 and 2013, and two, three and zero observations, respectively, were noted during those inspections. In the latest FDA audit in 2013, there were no observations that involved a material violation of regulatory requirements, and no non-conformances were noted. Our responses to the observations noted in 2009 and 2011 were accepted by the FDA, and we believe that we are in substantial compliance with the QSR. BSI, our European Notified Body, inspected our facility several times between 2010 and 2015 and found zero non-conformances. BSI conducted four external audits in 2016 and zero non-conformances were found in all except for one audit, for which four minor non-conformances were found. In 2016, we joined the medical device-single audit program, or MDSAP that permits audits by our Notified Body to substitute for routine FDA inspections. Our Notified Body audit performed in January 2017 resulted in zero non-conformances and an unannounced audit in September 2019, noted only two minor non-conformances, that were addressed promptly and resolved. In 2019, 2020 and 2021, BSI conducted multiple routine audits including surveillance audit, a Microbiology audit, a MDSAP re-certification audit and an unannounced audit in September 2019. Our quality system has undergone more than 20 external audits by third-party and regulatory authorities since 2009. Most recently, we were audited in March 2022 as part of ISO 13485:2016 & MDSAP re-certification. The audit was conducted by BSI at the behest of the FDA. No major non-conformances were identified. Minor non-conformances identified in the audits have been either successfully resolved or are being actively addressed via our corrective action system. As of the date of this filing, we have no outstanding unresolved major non-conformances or findings pending with any regulatory body.

 

14
 

 

Failure to comply with applicable regulatory requirements can result in enforcement action by FDA, which may include any of the following sanctions:

 

 

●

warning letters, adverse publicity, fines, injunctions, consent decrees and civil penalties;

 

 

●

repair, replacement, refunds, recall or seizure of our products;

 

 

●

operating restrictions, partial suspension or total shutdown of production;

 

 

●

refusing our requests for 510(k) clearance or pre-market approval of new products, new intended uses or modifications to existing products;

 

 

●

withdrawing 510(k) clearance or pre-market approvals that have already been granted; and

 

 

●

criminal prosecution.

 

Regulatory System for Medical Devices in Europe

 

The system of regulating medical devices operates by way of a certification for each medical device. Each certificated device is given CE marking that shows the device has a Certificat de Conformité. There are national bodies known as Competent Authorities in each member state in the EU that oversee the implementation of the EU’s medical device directive, or MDD, within its jurisdiction. The means of achieving the requirements for CE marking varies according to the nature of the device. Devices are classified in accordance with their perceived risks, similarly to the U.S. system. The class of a product determines the requirements to be fulfilled before CE marking can be placed on a product, known as a conformity assessment. Currently conformity assessments for our products are carried out as required by the MDD. Each member state can appoint Notified Bodies within its jurisdiction. If a Notified Body of one member state has issued a Certificat de Conformité, the device can be distributed throughout the European Union without further conformance tests being required by other member states.

 

In March 2019, we successfully transferred all current product certificates from BSI-UK to BSI-Netherlands in anticipation of the UK leaving the European Union. Our products currently with CE marking are distributed in the EU, subject to the EU’s medical devices directive, or MDD with certification renewed in May 2021. In May 2021, we successfully extended the validity of the MDD certificates by 3-years, which will provide certification until we fully certify to the new EU-MDR, expected to become effective after calendar year 2027. We have made significant progress towards achieving MDR certification, however, the certification process is ongoing and we expect to obtain certification in the near term. Until such time as we are fully certified to EU MDR, we will be highly limited in our ability to make significant product changes to existing design and intended purposes of products (for distribution in the EU only) and/or will be unable to launch new products in the EU. Such limitations could harm our business, financial condition, and operating results.

 

Federal, State and Foreign Fraud and Abuse Laws

 

Because of the significant federal funding involved in Medicare and Medicaid, Congress and the states have enacted, and actively enforce, a number of laws to eliminate fraud and abuse in federal healthcare programs. Our business is subject to compliance with these laws. In March 2010, the Patient Protection and Affordable Care Act, as amended by the Healthcare and Education Affordability Reconciliation Act, which we refer to collectively as the Affordable Care Act, was enacted in the United States. The provisions of the Affordable Care Act are effective on various dates. The Affordable Care Act expands the government’s investigative and enforcement authority and increases the penalties for fraud and abuse, including amendments to both the Anti-Kickback Statute and the False Claims Act, to make it easier to bring suit under these statutes. The Affordable Care Act also allocates additional resources and tools for the government to police healthcare fraud, with expanded subpoena power for HHS, additional funding to investigate fraud and abuse across the healthcare system and expanded use of recovery audit contractors for enforcement.

 

Anti-Kickback Statutes.    The federal Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing or arranging for a good or service, for which payment may be made under a federal healthcare program such as Medicare or Medicaid. Violation of the Anti-Kickback Statue is a criminal felony, and can result in criminal sanctions, civil penalties, enforcement under the False Claims Act, and exclusion from federal healthcare programs.

 

15
 

 

The definition of “remuneration” has been broadly interpreted to include anything of value, including, for example, gifts, certain discounts, the furnishing of free supplies, equipment or services, credit arrangements, payment of cash and waivers of payments. Several courts have interpreted the statute’s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered businesses, the statute has been violated. Penalties for violations include criminal penalties and civil sanctions such as fines, imprisonment and possible exclusion from Medicare, Medicaid and other federal healthcare programs. In addition, some kickback allegations have been claimed to violate the Federal False Claims Act, discussed in more detail below.

 

The Anti-Kickback Statute is broad and prohibits many arrangements and practices that are otherwise lawful in businesses outside of the healthcare industry. Recognizing that the Anti-Kickback Statute is broad and may technically prohibit many innocuous or beneficial arrangements, Congress authorized the Office of Inspector General, or OIG, of HHS to issue a series of regulations known as “safe harbors.” These safe harbors set forth provisions that, if all their applicable requirements are met, will assure healthcare providers and other parties that they will not be prosecuted under the Anti-Kickback Statute. The failure of a transaction or arrangement to fit precisely within one or more safe harbors does not necessarily mean that it is illegal or that prosecution will be pursued. However, conduct and business arrangements that do not fully satisfy an applicable safe harbor may result in increased scrutiny by government enforcement authorities such as OIG.

 

Many states have adopted laws similar to the Anti-Kickback Statute. Some of these state prohibitions apply to referral of recipients for healthcare items or services reimbursed by any source, not only the Medicare and Medicaid programs.

 

Government officials have focused their enforcement efforts on the marketing of healthcare services and products, among other activities, and recently have brought cases against companies, and certain individual sales, marketing and executive personnel, for allegedly offering unlawful inducements to potential or existing customers in an attempt to procure their business.

 

Federal False Claims Act.    Another development affecting the healthcare industry is the increased use of the federal False Claims Act by federal prosecutors, and in particular, action brought pursuant to the False Claims Act’s “whistleblower” or “qui tam” provisions. The False Claims Act imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal healthcare program. The qui tam provisions of the False Claims Act allow a private individual to bring actions on behalf of the federal government alleging that the defendant has violated the False Claims Act and to share in any monetary recovery. In recent years, the number of suits brought against healthcare providers by private individuals has increased substantially. In addition, various states have enacted false claims laws analogous to the False Claims Act, and many of these state laws apply where a claim is submitted to any third-party payor and not just a federal healthcare program.

 

When an entity is determined to have violated the False Claims Act, it may be required to pay up to three times the actual damages sustained by the government, plus civil penalties of between $11,665-$23,331 for each separate instance of false claim. As part of any settlement, the government may ask the entity to enter into a corporate integrity agreement, which imposes certain compliance, certification, and reporting obligations. There are many potential bases for liability under the False Claims Act. Liability arises, primarily, when an entity knowingly submits, or causes another to submit, a false claim for reimbursement to the federal government. The federal government has used the False Claims Act to assert liability on the basis of inadequate care, kickbacks and other improper referrals, and improper use of Medicare numbers when detailing the provider of services, in addition to the more predictable allegations as to misrepresentations with respect to the services rendered. In addition, the federal government has prosecuted companies under the False Claims Act in connection with off-label promotion of products. Our future activities relating to the reporting of wholesale or estimated retail prices of our products, the reporting of discount and rebate information and other information affecting federal, state, and third-party reimbursement of our products and the sale and marketing of our products may be subject to scrutiny under these laws.

 

While we are unaware of any current matters, we are unable to predict whether we will be subject to actions under the False Claims Act or a similar state law, or the impact of such actions. However, the costs of defending such claims, as well as any sanctions imposed, could significantly affect our financial performance.

 

16
 

 

The Sunshine Act.    The Physician Payment Sunshine Act, or the Sunshine Act, which was enacted as part of the Affordable Care Act, requires all United States manufacturers of a prescription drug, device, biologic or other medical supply that has been approved or cleared by the FDA, and is available for coverage by Medicare, Medicaid or the Children’s Health Insurance Program to report annually to the Secretary of HHS: (i) payments or other transfers of value made by that entity, or by a third-party as directed by that entity, to physicians and teaching hospitals or to third parties on behalf of physicians or teaching hospitals; and (ii) physician ownership and investment interests in the drug and device manufacturing entity. The payments required to be reported include the cost of meals provided to a physician, travel reimbursements and other transfers of value, including those provided as part of contracted services such as speaker programs, advisory boards, consultation services and clinical trial services. Failure to comply with the reporting requirements can result in significant civil monetary penalties ranging from $1,000 to $10,000 for each payment or other transfer of value that is not reported (up to a maximum per annual report of $150,000) and from $10,000 to $100,000 for each knowing failure to report (up to a maximum per annual report of $1,150,000). Additionally, there are criminal penalties if an entity intentionally makes false statements in such reports. We are subject to the Sunshine Act and the information we disclose may lead to greater scrutiny, which may result in modifications to established practices and additional costs. Additionally, similar reporting requirements have also been enacted on the state level domestically, and an increasing number of countries worldwide either have adopted or are considering similar laws requiring transparency of interactions with healthcare professionals.

 

Foreign Corrupt Practices Act.    The Foreign Corrupt Practices Act, or FCPA, prohibits any United States individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party, or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring us to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, if any, and to devise and maintain an adequate system of internal accounting controls for international operations.

 

International Laws.    In Europe, various countries have adopted anti-bribery laws providing for severe consequences, in the form of criminal penalties and/or significant fines, for individuals and/or companies committing a bribery offense. Violations of these anti-bribery laws, or allegations of such violations, could have a negative impact on our business, results of operations and reputation. For instance, in the United Kingdom, under the Bribery Act 2010, which went into effect in July 2011, a bribery occurs when a person offers, gives, or promises to give a financial or other advantage to induce or reward another individual to improperly perform certain functions or activities, including any function of a public nature. Bribery of foreign public officials also falls within the scope of the Bribery Act 2010. Under the new regime, an individual found in violation of the Bribery Act of 2010, faces imprisonment of up to 10 years. In addition, the individual can be subject to an unlimited fine, as can commercial organizations for failure to prevent bribery.

 

There are also international privacy laws that impose restrictions on the access, use, and disclosure of health information. All of these laws may impact our business. Our failure to comply with these privacy laws or significant changes in the laws restricting our ability to obtain required patient information could significantly impact our business and our future business plans.

 

U.S. Healthcare Reform

 

Changes in healthcare policy could increase our costs and subject us to additional regulatory requirements that may interrupt commercialization of our current and future solutions. Changes in healthcare policy could increase our costs, decrease our revenues, and impact sales of and reimbursement for our current and future solutions. The Affordable Care Act substantially changes the way healthcare is financed by both governmental and private insurers, and significantly impacts our industry principally by moving healthcare reimbursement towards more value-based and quality-based payment methodologies. The Act contains a number of provisions that impact our business and operations, some of which in ways we cannot currently predict, including those governing enrollment in federal healthcare programs and reimbursement changes.

 

There will continue to be proposals by legislators at both the federal and state levels, regulators and third-party payors to reduce costs while expanding individual healthcare benefits. Certain of these changes could impose additional limitations on the prices we will be able to charge for our current and future solutions or the amounts of reimbursement available for our current and future solutions from governmental agencies or third-party payors. Furthermore, the current presidential administration and Congress may again attempt broad sweeping changes to the current healthcare laws. We face uncertainties that might result from modification or repeal of any of the provisions of the Affordable Care Act, including as a result of current and future executive orders and legislative actions. The impact of those changes on us and potential effect on the medical device industry as a whole is currently unknown. But any changes to the Affordable Care Act are likely to have an impact on our results of operations, and may have a material adverse effect on our results of operations. We cannot predict what other healthcare programs and regulations will ultimately be implemented at the federal or state level or the effect any future legislation or regulation in the United States may have on our business.

 

17
 

 

Third-Party Reimbursement

 

Payment for patient care in the United States is generally made by third-party payors, including private insurers and government insurance programs, such as Medicare and Medicaid. The Medicare program, the largest single payor in the United States, is a federal governmental health insurance program administered by the Centers for Medicare and Medicaid Services, or CMS, and covers certain medical care expenses for eligible elderly and disabled individuals. Because a large percentage of the population with PAD includes Medicare beneficiaries, and private insurers may follow the coverage and payment policies of Medicare, Medicare’s coverage and payment policies are significant to our operations.

 

Medicare pays PAD treatment facilities, including hospitals and physician office-based labs, pre-determined amounts for each procedure performed. These payment amounts differ based on a variety of factors, including:

 

 

•

Type of procedure performed—angioplasty, stent or atherectomy;

 

 

•

Patient-specific complexities and comorbidities;

 

 

•

Type of facility—hospital, teaching hospital or office-based lab;

 

 

•

Inpatient or outpatient status; and

 

 

•

Geographic region.

 

We receive payment from the treatment facility for our products, and the Medicare reimbursement to the facility is intended to cover the overall cost of treatment, including the cost of products used during the procedure as well as the overhead cost associated with the facility where the procedure is performed. For procedures performed in hospitals, the physician who performs the procedure is reimbursed separately under the Medicare physician fee schedule. Claims for PAD procedures are typically submitted by the treatment facility and physician to Medicare or other health insurers using established billing codes. These codes identify the procedures performed and are relied upon to determine third-party payor reimbursement amounts.

 

Medicare reimbursement for hospital outpatient PAD procedures that include atherectomy for 2022 ranged between approximately $10,000 to greater than $16,000. These amounts include the cost of disposable devices such as Ocelot and Pantheris. While reimbursement varies based on the type of procedure performed (e.g., angioplasty, stent or atherectomy), additional device-specific reimbursement is not available. The amount of reimbursement can vary substantially by geographical region and by facility. Payment rates of other third-party payors may follow Medicare rates, or they may be higher or lower, depending on their particular reimbursement methodology. Because of the wide variability, it is not possible to identify an average rate for third-party payors other than Medicare.

 

Human Capital

 

As of December 31, 2022, we had 71 employees, including 23 in manufacturing and operations, 25 in sales and marketing, 7 in research and development and clinical and regulatory affairs, 6 in quality assurance and 10 in finance, general administrative and executive administration. Of these 71 employees, 4 are part time employees.

 

None of our employees are represented by a labor union or covered by a collective bargaining agreement. We have never experienced any employment-related work stoppages and we consider our employee relations to be good.

 

Although the COVID-19 pandemic has disrupted business and operations for companies around the globe, the resilience of our employees has enabled us to minimize disruption to our sales, research, clinical studies and operations. Our onsite employees, particularly in manufacturing and operations, have rapidly adjusted to numerous stringent safety protocols.

 

We are optimistic about the potential to expand our workforce and create a more inclusive environment for all of our employees.

 

Diversity, Equity and Inclusion

 

We understand the importance of diversity in our workforce. We will continue to focus on building a pipeline of opportunities for both the hiring and advancement of qualified individuals, including for women, persons with disabilities, and minority groups that are underrepresented in science and engineering industries. We believe that diverse perspectives will help empower our employees, patients and industry.

 

18
 

 

Communications and Engagement

 

Our success depends on employees understanding our strategic vision as well as our day-to-day objectives. To that end, we employ a mix of communication and engagement channels, including all-hands meetings, regular leadership meetings, and quarterly updates on our progress against our strategic goals. We have also created a cross-functional team focused on improving the employee experience and driving engagement.

 

A central part of our communications and engagement efforts are connecting people to purpose. To this end, we regularly share stories of physicians and patients that have been treated with our devices with our employees. Their experiences reinforce our commitment to expand our reach into new patient populations, geographies and markets.

 

Health, Safety and Wellness

 

We are deeply committed to the safety, health and wellness of our employees. The Avinger Environmental, Health & Safety team develops safety practices and procedures, trains employees, and monitors compliance. Through these efforts, along with leadership commitment and investment of resources in support of workplace safety initiatives, our total US injury rate has consistently tracked below industry averages.

 

Compensation

 

We recognize that our employees are our most valuable asset. Our total rewards package includes market competitive pay, comprehensive and competitive benefits and retirement offerings and paid time off and family leave, among other benefits. To foster a stronger sense of ownership and align the interests of employees with shareholders, we have offered restricted stock units and awards to eligible employees under our broad-based stock incentive programs.

 

Corporate and other Information

 

We were incorporated in Delaware on March 8, 2007. Our principal executive offices are located at 400 Chesapeake Drive, Redwood City, California 94063, and our telephone number is (650) 241-7900. Our website address is www.avinger.com. References to our website address do not constitute incorporation by reference of the information contained on the website, and the information contained on the website is not part of this document.

 

We make available, free of charge on our corporate website, copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, Proxy Statements, and all amendments to these reports, as soon as reasonably practicable after such material is electronically filed with or furnished to the Securities and Exchange Commission, or the SEC, pursuant to Section 13(a) or 15(d) of the Securities Exchange Act. We also show detail about stock trading by corporate insiders by providing access to SEC Forms 3, 4 and 5. This information may also be obtained from the SEC’s on-line database, which is located at www.sec.gov. Our common stock is traded on the Nasdaq Capital Market under the symbol “AVGR”.

 

19
 

 

Item 1A.    Risk Factors

 

Investing in our common stock involves a high degree of risk. We have identified the following risks and uncertainties that may have a material adverse effect on our business, financial condition, results of operations and future growth prospects. Our business could be harmed by any of these risks. The risks and uncertainties described below are not the only ones we face. If any of the risks actually occur, our business, financial condition, results of operations, cash flows and prospects could be materially and adversely affected. The trading price of our common stock could decline due to any of these risks, and you may lose all or part of your investment. In assessing these risks, you should also refer to the other information contained in this Annual Report on Form 10-K, including our financial statements and related notes. Please also see “Cautionary Notes Regarding Forward-Looking Statements.”

 

Risk Factor Summary         

 

The risk factors summarized and detailed below could materially harm our business, operating results and/or financial condition, impair our future prospects and/or cause the price of our common stock to decline. These are not all of the risks we face and other factors not presently known to us or that we currently believe are immaterial may also affect our business if they occur. Material risks that may affect our business, operating results and financial condition include, but are not necessarily limited to, those relating to:

 

Risks Related to Our Business

 

 

●

significant fluctuations in our operating results, our history of net losses and ability to achieve profitability;

 

 

●

our ability to continue as a going concern;

 

 

●

our ability to obtain additional capital on acceptable terms or at all and our significant levels of debt;

 

 

●

our covenants and restrictions under and our ability to service our Loan Agreement with CRG;

 

 

●

the liquidation preference of our Series A preferred stock;

 

 

●

rights of warrant and preferred option holders in the event of a fundamental transaction,

 

 

●

our reliance on a limited number of products with a limited commercial history;

 

 

●

our reliance on sales professionals to market and sell our products;

 

 

●

our dependence on our senior management team and key employees;

 

 

●

our ability to demonstrate the benefits of our Lumivascular platform to physicians, hospitals, and patients and our ability to innovate successfully;

 

 

●

our competition, which includes companies that have longer operating histories, more established products, and greater resources;

 

 

●

the potential for disruptions at our manufacturing facility;

 

 

●

our dependence on third-party vendors, including some single-source suppliers, to manufacture some of our components, coating, and sub-assemblies;

 

 

●

our intention not to devote significant resources in the near-term to market our Lumivascular platform internationally;

 

 

●

our ability to use our net operating loss carryforwards;

 

 

●

the possibility that we may acquire other companies or technologies, or be the target of strategic transactions;

 

 

●

Outbreaks of contagious diseases, such as the novel coronavirus, COVID-19, and other public health crises may materially impact our business and operations;

 

20
 

 

 

●

Disruptions of our supply chain could have a material adverse effect on our operating and financial results;

 

 

●

 New product development for the coronary artery disease market carries great risk;
     
  ● Adverse developments affecting the financial services industry, including events or concerns involving liquidity, defaults or non-performance by financial institutions, could adversely affect our business, financial condition or results of operations;

 

Risks Related to Our Use of Technology and Intellectual Property

 

 

●

our technology infrastructure and the potential of a cybersecurity incident or data breach;

 

 

●

any future intellectual property litigation or administrative proceedings;

 

 

●

any failure to adequately protect our intellection property rights and the assertion of patents held by third parties against us;

 

Regulatory and Litigation Risks

 

 

●

compliance with applicable laws and regulations and our ability to obtain necessary regulatory clearances and approvals;

 

 

●

any material modifications to our Lumivascular platform products, which may require new clearances or approvals;

 

 

●

certain limitations on our ability to market our current products in the United States;

 

 

●

the success and timing of our clinical trials;

 

 

●

the performance of the outside parties that we engage to perform services related to certain of our clinical studies;

 

 

●

our limited long-term data regarding the safety and efficacy of our Lumivascular platform products;

 

 

●

our suppliers’ compliance with the FDA’s QSR;

 

 

●

any product recalls on our Lumivascular products;

 

 

●

any changes in coverage and reimbursement for procedures using our Lumivascular products and any healthcare reform measures;

 

 

●

compliance with healthcare regulations, environmental laws and regulations;

 

 

●

regulations related to “conflict minerals” and any use, misuse, or off-label use of our products;

 

 

●

the expense and availability of insurance coverage for liabilities resulting from our products;

 

 

●

related composition requirements;

 

21
 

 

Risks Related to Our Organizational Structure

 

 

●

the volatility of our stock price;

 

 

●

our ability to meet guidance or expectations and receive coverage of our business by securities or industry analysts;

 

 

●

any sales of substantial numbers of shares of our common stock in the public market;

 

 

●

the requirements and expense of being a public company;

 

 

●

the possibility that Nasdaq may delist our securities from its exchange;

 

 

●

anti-takeover provisions in our amended and restated certificate of incorporation, bylaws, and Delaware law;

 

 

●

the forum selection clause in our amended and restated certificate of incorporation;

 

 

●

our anticipation that we will not pay cash dividends in the foreseeable future;

 

 

●

CRG’s ability to exert significant control over certain matters pursuant to our Loan Agreement;

 

 

●

the current number of authorized shares available for issuance, and;

 

 

●

 our dependence on our board of directors.

 

22
 

 

Risks Related to Our Business

 

Our quarterly and annual results may fluctuate significantly, may not fully reflect the underlying performance of our business and may result in decreases in the price of our common stock.

 

Our quarterly and annual results of operations, including our revenues, profitability and cash flow, may vary significantly in the future and period-to-period comparisons of our operating results may not be meaningful. Accordingly, the results of any one quarter or period should not be relied upon as an indication of future performance. Our quarterly and annual financial results may fluctuate as a result of a variety of factors, many of which are outside our control and, as a result, may not fully reflect the underlying performance of our business. Fluctuation in quarterly and annual results may decrease the value of our common stock. Factors that may cause fluctuations in our quarterly and annual results include, without limitation:

 

 

●

our ability to obtain and maintain FDA clearance and approval from foreign regulatory authorities for our products, and the timing of such clearances and approvals, particularly with respect to current and future generations of Pantheris, Tigereye and Ocelot product families;

 

 

●

market acceptance of our Lumivascular platform and products, including Pantheris, Ocelot, Tigereye and Lightbox;

 

 

●

the availability of reimbursement for our Lumivascular platform products;

 

 

●

our ability to attract new customers and increase the amount of business we generate from existing customers;

 

 

●

results of our clinical trials;

 

 

●

the timing and success of new product and feature introductions by us or our competitors or any other change in the competitive dynamics of our industry, including consolidation among competitors, customers or strategic partners;

 

 

●

the amount and timing of costs and expenses related to the maintenance and expansion of our business and operations;

 

 

●

changes in our pricing policies or those of our competitors;

 

 

●

general economic, political, industry and market conditions;

 

 

●

the regulatory environment;

 

 

●

the hiring, training and retention of key employees, including our sales team;

 

 

●

the cost and potential outcomes of any litigation;

 

 

●

our ability to obtain additional financing; and

 

 

●

advances and trends in new technologies and industry standards.

 

In addition, we rely on estimates and forecasts of our expenses and revenues to provide guidance and inform our business strategies, and some of our past estimates and forecasts have not been accurate. The evolving nature of our business makes forecasting operating results difficult. If we fail to accurately forecast our expenses and revenues, our business, prospects, financial condition and results of operations may suffer, and the value of our business may decline. If our estimates and forecasts prove incorrect, we may not be able to adjust our operations quickly enough to respond to lower-than-expected sales which, for example, could result in higher than anticipated inventory levels, or higher-than-expected expenses which, for example, could be the result of building excess capacity.

 

Based upon the factors above and others beyond our control, we have a limited ability to forecast our future revenue, costs and expenses. If we fail to meet or exceed the operating results expectations of analysts and investors or if analysts and investors have estimates and forecasts of our future performance that are unrealistic or that we do not meet, the market price of our common stock could decline. In addition, if one or more of the analysts who cover us adversely change their recommendation regarding our stock, the market price of our common stock could decline. In the past, companies that have experienced volatility in the market price of their stock have been subject to securities litigation. We may be the target of this type of litigation in the future, which could result in substantial costs and divert our management’s attention from other business concerns.

 

23
 

 

You should consider our business in light of the risks and difficulties we may encounter, as described above and elsewhere in this “Risk Factors” section. If we fail to address the risks and difficulties that we face, our business and operating results will be adversely affected.

 

We have a history of net losses and we may not be able to achieve or sustain profitability.

 

We have incurred significant losses in each period since our inception in 2007. We incurred net losses of $17.6 million in 2022 and $17.4 million in 2021. As of December 31, 2022, we had an accumulated deficit of approximately $402.4 million. These losses and our accumulated deficit reflect the substantial investments we have made to develop our Lumivascular platform and acquire customers.

 

We expect our losses to continue for the foreseeable future as we continue to make significant future expenditures to develop and expand our business. In addition, as a public company, we will continue to incur significant legal, accounting and other expenses. Accordingly, we cannot assure you that we will achieve profitability in the future or that, if we do become profitable, we will sustain profitability. Our failure to achieve and sustain profitability would negatively impact the market price of our common stock.

 

Our 2022 financial statements contain disclosure that there is substantial doubt about our ability to continue as a going concern, and we will need additional financing to execute our business plan, to fund our operations and to continue as a going concern.

 

Since inception, we have experienced recurring operating losses and negative cash flows and we expect to continue to generate operating losses and consume significant cash resources for the foreseeable future. There is substantial doubt regarding our ability to continue as a going concern. Our independent registered public accounting firm has expressed in its auditors’ report on our 2022 financial statements, included in this Annual Report on Form 10-K, an emphasis of matter paragraph relating to our ability to continue as a “going concern,” meaning that our recurring losses from operations and negative cash flows from operations raise substantial doubt regarding our ability to continue as a going concern. We have prepared our financial statements on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. Our 2022 financial statements do not include any adjustment to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty, with the exception that all borrowings are classified as current on the balance sheets.

 

Under our Term Loan Agreement (the “Loan Agreement”) with CRG Partners III L.P. and certain of its affiliated funds (collectively “CRG”), a “Material Adverse Change” or “Material Adverse Effect” (each as defined in the Loan Agreement) is an “Event of Default” thereunder, which gives Majority Lenders (as defined in the Loan Agreement) the right to declare amounts outstanding under the Loan Agreement immediately due and payable. Due to the substantial doubt about our ability to continue operating as a going concern and the Event of Default that could result due to a Material Adverse Change under the Loan Agreement, the entire amount of borrowings at December 31, 2022 and 2021 is classified as current. Majority Lenders have not purported that an Event of Default has occurred as a result of a Material Adverse Change However, there can be no guarantee that Majority Lenders will not invoke such Event of Default in the future, or that we will not experience other Material Adverse Changes or other Material Adverse Effect that could give rise to an Event of Default under the Loan Agreement.

 

We may not be able to secure additional financing on favorable terms, or at all, to meet our future capital needs and our failure to obtain additional financing when needed could force us to delay, reduce or eliminate our product development programs and commercialization efforts or cause us to become insolvent.

 

We believe that our cash and cash equivalents at December 31, 2022, together with debt and financing activities and expected revenues from operations, will be sufficient to satisfy our capital requirements and fund our operations through at least the third quarter of 2023. Even though we received net proceeds of approximately $13.0 million from the sale of our common stock in February 2021, $6.7 million from the sale of our Series D Convertible Preferred Stock in January 2022, $4.4 million from the sale of our common stock in August 2022, and $0.8 million from the sale of our common stock under our at-the-market program that we entered into on May 20, 2022, we may need to raise additional funds through future equity or debt financings in the near future to meet our operational needs and capital requirements for product development, clinical trials and commercialization. We can provide no assurance that we will be successful in raising funds pursuant to additional equity or debt financings or that such funds will be raised at prices that do not create substantial dilution for our existing stockholders. Given the volatility of our stock price, any financing that we undertake could cause substantial dilution to our existing stockholders.

 

24
 

 

To date, we have financed our operations primarily through sales of our products and net proceeds from the issuance of our preferred stock and debt financings, our initial public offering (“IPO”), and our follow-on public offerings. We do not know when or if our operations will generate sufficient cash to fund our ongoing operations. We cannot be certain that additional capital will be available as needed on acceptable terms, or at all. In the future, we may require additional capital in order to (i) continue to conduct research and development activities, (ii) conduct post-market clinical studies, as well as clinical trials to obtain regulatory clearances and approvals necessary to commercialize our Lumivascular platform products, (iii) expand our sales and marketing infrastructure, (iv) acquire complementary businesses technologies or products; or (v) respond to business opportunities, challenges, a decline in sales, increased regulatory obligations or unforeseen circumstances. Our future capital requirements will depend on many factors, including:

 

 

●

the degree of success we experience in commercializing our Lumivascular platform products, particularly Pantheris, and any future versions of such products;

 

 

●

the costs, timing and outcomes of clinical trials and regulatory reviews associated with our future products;

 

 

●

the costs and expenses of maintaining or expanding our sales and marketing infrastructure and our manufacturing operations;

 

 

●

the costs and timing of developing variations of our Lumivascular platform products and, if necessary, obtaining FDA clearance of such variations;

 

 

●

the extent to which our Lumivascular platform is adopted by hospitals for use by interventional cardiologists, vascular surgeons and interventional radiologists in the treatment of PAD;

 

 

●

the number and types of future products we develop and commercialize;

 

 

●

the costs of defending ourselves against future litigation;

 

 

●

the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property-related claims; and

 

 

●

the extent and scope of our general and administrative expenses.

 

We may raise additional funds in equity or debt financings or enter into credit facilities in order to access funds for our capital needs. Any debt financing obtained by us in the future would cause us to incur additional debt service expenses and could include restrictive covenants relating to our capital raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and pursue business opportunities. In addition, due to our current level of debt, future equity investors may require that we convert all or a portion of our debt to equity, and our debtholders may not agree to such terms. If we raise additional funds through further issuances of equity or convertible debt securities, and/or if we convert all or a portion of our existing debt to equity, our existing stockholders could suffer significant dilution in their percentage ownership of our company, and any new equity securities we issue could have rights, preferences and privileges senior to those of holders of our common stock. If we are unable to obtain adequate financing or financing on terms satisfactory to us when we require it, we may terminate or delay the development of one or more of our products, delay clinical trials necessary to market our products, delay establishment of sales and marketing capabilities or other activities necessary to commercialize our products, and significantly scale back our operations, or we may become insolvent. If this were to occur, our ability to continue to grow and support our business and to respond to business challenges could be significantly limited.

 

25
 

 

We have a significant amount of debt, which may adversely affect our ability to operate our business and our financial position and our ability to secure additional financing in the future.

 

As of December 31, 2022, we had $14.2 million in principal, back-end fees and interest outstanding under the Loan Agreement, with CRG. Our significant amount of debt may:

 

 

●

increase our vulnerability to adverse changes in general economic, industry and competitive conditions;

 

 

●

require us to dedicate a substantial portion of our cash flow from operations to make payments on our debt, thereby reducing the availability of our cash flow to fund working capital, capital expenditures and other general corporate purposes;

 

 

●

limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate;

 

 

●

restrict us from exploiting business opportunities;

 

 

●

make it more difficult to satisfy our financial obligations, including payments on the Loan Agreement;

 

 

●

place us at a competitive disadvantage compared to our competitors that have less debt obligations; and

 

 

●

limit our ability to borrow additional funds for working capital, capital expenditures, acquisitions, debt service requirements, execution of our business strategy or other general corporate purposes on satisfactory terms or at all.

 

The existence of a substantial amount of debt may make it difficult for us to run our business effectively or raise the capital we need to continue our operations.

 

Covenants under the Loan Agreement will restrict our business in many ways.

 

The Loan Agreement contains various covenants that limit, subject to certain exceptions, our ability to, among other things:

 

 

●

incur or assume liens;

 

 

●

incur additional debt or provide guarantees in respect of obligations of other persons;

 

 

●

issue redeemable stock and preferred stock;

 

 

●

pay dividends or make distributions on capital stock, repurchase, redeem or make payments on capital stock or repay, repurchase, redeem, retire, defease, acquire or cancel debt prior to the stated maturity thereof;

 

 

●

make loans, investments or acquisitions;
     
 

●

create or permit restrictions on the ability of our subsidiaries to pay dividends or make other distributions to us or to guarantee our debt, limit our or any of our subsidiaries ability to create liens, or make or pay intercompany loans or advances;

 

 

●

enter into certain transactions with affiliates;

 

 

●

sell, transfer, license, lease or dispose of our or our subsidiaries’ assets, including the capital stock of our subsidiaries; and

 

 

●

dissolve, liquidate, consolidate or merge with or into, or sell substantially all of our assets to another person.

 

In particular, the Loan Agreement, as most recently amended in August 2022, includes a covenant that we maintain a minimum of $3.5 million of cash and certain cash equivalents, and we will have to achieve minimum revenues of $8.0 million in 2022, $10.0 million in 2023, $14.5 million in 2024 and $17.0 million in 2025. If we fail to meet the applicable minimum revenue target in any calendar year, the Loan Agreement provides a cure right if we prepay a portion of the outstanding principal equal to 2.0 times the revenue shortfall. Such prepayment would use capital resources that are otherwise required for us to operate our business and, therefore, if we are required to pay such amounts our liquidity and operations could be adversely affected. In addition, if we are unable to make such required prepayment and, as a result, default on our obligations under the Loan Agreement, our business will be adversely affected. There can be no assurance as to our future compliance with the covenants under the Loan Agreement, as amended.

 

26
 

 

The covenants contained in the Loan Agreement could adversely affect our ability to execute our business strategies by restricting our ability to make capital expenditures, engage in strategic acquisitions, refinance our outstanding indebtedness, or obtain additional financing. Such restrictions may make it difficult to plan for or react to changes in market conditions, such as future downturns in our business or the economy in general.

 

In addition, potential sources of equity financing may decline to invest in our company given the amount of debt and the rights that debt holders have to get paid before equity holders. In order to facilitate equity investments, future equity investors may require that we convert all or a portion of our debt to equity, and our debtholders may not agree to such terms. The amount of debt could therefore affect our ability to finance our company and prevent us from obtaining necessary operating capital as a result.

 

We may not be able to generate sufficient cash to service our obligations under the Loan Agreement. If we default on payments or otherwise fail to comply with our obligations under our Loan Agreement, the lenders thereunder may be able to accelerate amounts owed under the loan facility and may foreclose upon the assets securing our obligations.

 

Borrowings under our Loan Agreement are secured by substantially all of our personal property, including our intellectual property. The existing collateral pledged under the Loan Agreement may prevent us from being able to secure additional debt or equity financing on favorable terms, or at all, or to pursue business opportunities, including potential acquisitions. Our ability to make scheduled payments, comply with our debt covenants, or to refinance our debt obligations depends on numerous factors, including the amount of our cash reserves and our actual and projected financial and operating performance. These amounts and our performance are subject to numerous risks, including the risks in this section, some of which may be beyond our control. We cannot assure you that we will maintain a level of cash reserves or cash flows from operating activities sufficient to permit us to pay the principal, premium, if any, and interest on our existing or future indebtedness. If our cash flows and capital resources are insufficient to fund our debt service obligations, we may be forced to reduce or delay capital expenditures, sell assets or operations, seek additional capital or restructure or refinance our indebtedness. We cannot assure you that we would be able to take any of these actions, or that these actions would permit us to meet our scheduled debt service obligations. In addition, in the event of our breach of the Loan Agreement, we may be required to repay any outstanding amounts earlier than anticipated. If we fail to comply with our obligations under the Loan Agreement, the lender would be able to accelerate the required repayment of amounts due and, if they are not repaid, could foreclose upon our assets securing our obligations under the Loan Agreement.

 

The Series A preferred stock have a liquidation preference senior to our common stock and Series B preferred stock.

 

Our outstanding shares of Series A preferred stock have a liquidation preference that gets paid prior to any payment on our common stock (including shares issuable upon the exercise of our outstanding warrants) and Series B preferred stock. As a result, if we were to dissolve, liquidate, merge with another company or sell our assets, the holders of our Series A preferred stock would have the right to receive up to approximately $60.9 million as of December 31, 2022, plus any unpaid dividends, and, after the payment of the liquidation preference to the holders of the Series A preferred stock before any amount is paid to the holders of our Series B preferred stock or common stock or pursuant to the redemption rights in the warrants for fundamental transactions. The payment of the liquidation preferences could result in common stockholders, Series B preferred stockholders and warrant holders not receiving any consideration if we were to liquidate, dissolve or wind up, either voluntarily or involuntarily. In January 2019, December 2019, December 2020, December 2021, and December 2022, 2,945, 3,580, 3,866, 4,175 and 4,510 additional shares of Series A preferred stock, respectively, were issued to CRG as payment of dividends accrued through December 31, 2022.

 

The existence of the liquidation preferences may reduce the value of our common stock, make it harder for us to sell shares of common stock in offerings in the future, or prevent or delay a change of control.

 

We have outstanding shares of convertible preferred stock, some of which contain “full-ratchet” anti-dilution protection, which may cause significant dilution to our stockholders.

 

As of December 31, 2022, we had outstanding 7,832,644 shares of common stock. As of that date we had outstanding 85 shares of Series B convertible preferred stock convertible into an aggregate of 56,591 shares of common stock and 60,876 shares of Series A convertible preferred stock convertible, subject to certain conditions, into an aggregate of 152,190 shares of common stock. The issuance of shares of common stock upon the conversion of such shares of preferred stock would dilute the percentage ownership interest of all stockholders, might dilute the book value per share of our common stock and would increase the number of our publicly traded shares, which could depress the market price of our common stock. The shares of Series B preferred stock contain a “full-ratchet” anti-dilution provision which, subject to limited exceptions, would reduce the conversion price of the Series B preferred stock (and increase the number of shares issuable) in the event that we in the future issue common stock, or securities convertible into or exercisable to purchase common stock, at price per share lower than the conversion price then in effect. Our outstanding 85 shares of Series B preferred stock are convertible into 56,591 shares of common stock at a conversion price of $1.502 per share.

 

27
 

 

The certificate of designation for our Series A preferred stock, as amended, currently provides that shares of such Series A preferred stock will not be convertible into shares of our common stock until our stockholders have approved an amendment to our Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000 to at least 125,000,000 shares. Our Board of Directors may determine to remove this requirement. If our stockholders approve such amendment to our Amended and Restated Certificate of Incorporation, shares of Series A preferred stock may be converted into shares of our common stock, which will result in dilution to our stockholders.

 

Certain of our outstanding warrants and preferred investment options include put rights upon the occurrence of a fundamental transaction, which could make it difficult for us to complete a fundamental transaction that would otherwise be beneficial to our stockholders.

 

Certain of our outstanding warrants, including the warrants issued in February 2018, November 2018, and January 2022 and the preferred investment options issued in August 2022, include provisions that, in the event of certain fundamental transactions defined in the relevant agreements, provide the holders of such warrants and preferred investment options with the right to require us, or the successor company in such transaction, to repurchase any unexercised portion of such warrants or preferred investment options from the holder at their Black-Scholes value. In some circumstance this repurchase must be made in cash. Such Black-Scholes value may be significant and the requirement to pay such amount could prevent us from completing a transaction which would otherwise be accretive to shareholders or make such transaction more costly and reduce the value of such transaction to holders of our common stock.

 

Our success depends in large part on a limited number of products, particularly the Pantheris product family, all of which have a limited commercial history. If these products fail to gain, or lose, market acceptance, our business will suffer.

 

Ocelot, Ocelot PIXL, Ocelot MVRX, Tigereye, Lightbox 3, Pantheris and Pantheris SV are our only products currently cleared for sale, and our current revenues are wholly dependent on them. In addition, the long-term viability of our company is largely dependent on the successful commercialization and continued development of the Pantheris product family and we expect that sales of our other current and future Lumivascular platform products in the United States will account for substantially all of our revenues for the foreseeable future. Accordingly, our success depends on the continued and growing acceptance and use of Lumivascular platform products by the medical community.

 

All of our products have a limited commercial history. For example, we received 510(k) clearance from the FDA to commercialize Pantheris in October 2015 as well as a separate FDA clearance to market enhanced versions of Pantheris in March 2016 and May 2018 and those versions of Pantheris became commercially available in the United States and select international markets promptly thereafter. Pantheris SV launched in July 2019 after having received FDA clearance in April 2019. Tigereye launched in October 2020 after having received FDA clearance in September 2020. Our limited commercialization experience and number of approved products make it difficult to evaluate our current business and predict our future prospects. We have encountered and will continue to encounter risks and difficulties frequently experienced by companies in rapidly changing industries.

 

Our ability to successfully market Lumivascular platform products will also be limited due to a number of factors including regulatory restrictions in our labeling. We cannot assure demand for Lumivascular platform products will continue to grow or that our products will significantly penetrate current or new markets. Market demand for our Lumivascular platform products and physician adoption of these products also may be negatively impacted by product performance issues and the need to replace certain products in accordance with our warranty policy. Utilization of our products has been less than we anticipated historically. If demand for our Lumivascular platform products does not increase and we cannot sell our products as planned, our financial results will be harmed. In addition, market acceptance may be hindered if physicians are not presented with compelling data from long-term studies of the safety and efficacy of our Lumivascular platform products compared to alternative procedures, such as angioplasty, stenting, bypass surgery or other atherectomy procedures. For example, if patients undergoing treatment with our Lumivascular platform products have retreatment rates higher than or comparable with the retreatment rates of alternative procedures, it will be difficult to demonstrate the value of our Lumivascular platform products. Any studies we may conduct comparing our Lumivascular platform with alternative procedures will be expensive, time consuming and may not yield positive results. Physicians will also need to appreciate the value of real-time imaging in improving patient outcomes in order to change current methods for treating PAD patients. In addition, demand for our Lumivascular platform products may decline or may not increase as quickly as we expect. Failure of our Lumivascular platform products to significantly penetrate current or new markets, or our failure to successfully commercialize our products, would harm our business, financial condition and results of operations.

 

28
 

 

We are also aware of certain characteristics and features of our Lumivascular platform that may prevent widespread market adoption. For example, in procedures using the current model of Pantheris, some physicians may prefer to have a technician or second physician assisting with the operation of the catheter as well as a separate technician to operate the Lightbox, potentially making it less financially attractive for physicians and their hospitals and medical facilities. It may take significant time and expense to modify our products to allow a single physician to operate the entire system and we can provide no guarantee that we will be able to make such modifications or obtain any additional and necessary regulatory clearances for such modifications. Although the OCT images created by our Lightbox may make it possible for physicians to reduce the degree to which fluoroscopy and contrast dye are used when using our Lumivascular platform products compared to competing endovascular products, physicians are still using both fluoroscopy and contrast dye in these procedures. As a result, risks of complications from radiation and contrast dye are still present and may limit the commercial success of our products. Finally, it requires training of technicians and physicians to effectively operate our Lumivascular platform products, including interpreting the OCT images created by our Lightbox, which may affect adoption of our products by physicians.

 

Our Lumivascular products are highly complex, and the failure of relatively minor components could result in product failure or other significant performance issues that may not be discovered until after delivery to customers, which could give rise to claims from our customers or their patients. We have in the past, and may in the future, become aware of performance issues with our products. For example, prior to becoming commercially available on March 1, 2016, Pantheris had been used in clinical trials mainly in controlled situations. Since its commercialization and as more physicians have used Pantheris, we have received additional feedback on its performance, both positive and negative. We have attempted to address certain of these concerns with our current version of Pantheris. However, there can be no assurance that the changes and improvements will fully address the performance issues that have been raised by earlier versions of Pantheris. Our revenue has been adversely impacted by these product performance issues. We also had to incur additional expenses to make product changes and improvements, and to replace products in accordance with our warranty policy. If future product performance issues are not resolved and physician concerns not addressed, our reputation could suffer, which could lead to decreased sales of our products.

 

We rely heavily on our sales professionals to market and sell our products. If we are unable to hire, effectively train, manage, improve the productivity of, and retain our sales professionals, our business will be harmed, which would impair our future revenue and profitability.

 

Our success largely depends on our ability to hire, train, manage and improve the productivity levels of our sales professionals. Competition for sales professionals who are familiar with and trained to sell our products continues to be strong and our larger competitors are able to offer compensation and benefits that we are not able to. We have experienced and continue to experience significant turnover of our sales professionals. Significant turnover of our sales professionals makes it difficult for us to maintain an adequate presence in some markets and to preserve institutional expertise among our sales teams. While we train our new sales professionals to better understand our existing and new product technologies and how they can be positioned against our competitors’ products, it takes time for the sales professionals to become productive following their hiring and training and there can be no assurance that newly hired sales professionals will reach adequate levels of productivity, or that we will not continue to experience significant levels of attrition in the future. Measures we implement to improve the productivity of our sales professionals may not be successful and may instead cause additional departures from our sales organization. Such attrition could further reduce our revenue, profitability, and harm our business and our stock price may be adversely impacted as a result. 

 

In addition, the loss of any member of our sales team’s senior management could weaken our sales expertise and harm our business, and we may not be able to find adequate replacements on a timely basis, or at all. Attrition in our senior management team over sales that have occurred over the past several years have created and likely will continue to create instability in our sales force, which could lead to further attrition in our team of sales professionals. If we are unable to retain experienced sales professionals, our ability to market and sell our products in our target markets will be adversely affected, which will adversely affect our sales and results of operations.

 

We depend on our senior management team and the loss of one or more key employees or an inability to attract and retain highly skilled employees could harm our business.

 

Our success largely depends upon the continued services of our executive management team and key employees and the loss of one or more of our executive officers or key employees could harm us and directly impact our financial results. Our employees may terminate their employment with us at any time. Changes in our executive management team resulting from the hiring or departure of executives could disrupt our business. For example, our Chief Financial Officer resigned from the Company effective May 12, 2022. Nabeel Subainati, our Vice President of Finance, has been designated as Principal Financial Officer and Principal Accounting Officer effective as of July 21, 2022. If we are unable to hire one or more replacement employees for officers who have departed or may depart, or otherwise fill their responsibilities, our ability to effectively manage our business could be adversely affected.

 

29
 

 

We must attract and retain highly qualified personnel. Competition for skilled personnel is intense, especially for engineers with high levels of experience in designing and developing medical devices and for sales professionals. We have, from time to time, experienced, and we expect to continue to experience, difficulty in hiring and retaining employees with appropriate qualifications. Many of the companies with which we compete for experienced personnel have greater resources than we have. If we hire employees from competitors or other companies, their former employers may attempt to assert that these employees or we have breached legal obligations, resulting in a diversion of our time and resources and, potentially, damages. In addition, job candidates and existing employees, particularly in the San Francisco Bay Area, often consider the value of the stock awards they receive in connection with their employment. If the perceived value of our stock awards declines or if we do not make grants of stock-based incentive awards, it may harm our ability to recruit and retain highly skilled employees. In addition, we invest significant time and expense in training our employees, which increases their value to competitors who may seek to recruit them. If we fail to attract new personnel or fail to retain and motivate our current personnel, our business would be harmed.

 

Our ability to compete is highly dependent on demonstrating the benefits of our Lumivascular platform to physicians, hospitals and patients and our ability to innovate new and improved products.

 

In order to generate sales, we must be able to clearly demonstrate that our Lumivascular platform is a more effective treatment system than the alternatives offered by our competitors. If we are unable to convince physicians that our Lumivascular platform leads to significantly lower rates of restenosis, or narrowing of the artery, and leads to fewer adverse events during treatment than those using competing technologies, our business will suffer. We must convince hospitals and physicians that our Lumivascular platform results in significantly better patient outcomes at a competitive overall cost. For example, we may need to demonstrate that the investment hospitals must make of purchasing our Lightbox and the incremental costs of having a technician or a second individual operate Pantheris can be justified based on the benefits to patients, physicians and hospitals. If we are unable to develop robust clinical data to support these claims, we will be unable to convince hospitals and third-party payors of these benefits and our business will suffer. In addition, attrition among our sales professionals may make it difficult to maintain relationships with physicians and hospitals, which could adversely affect our sales and results of operations.

 

Our value proposition to physicians and hospitals is largely dependent upon our contention that the rate of arterial damage when physicians are using our imaging products is lower than with non-imaging competing products. If minimizing arterial damage does not significantly impact patient outcomes, meaning either (i) that restenosis is often triggered without disrupting healthy arterial structures or (ii) arteries can be damaged during treatment without triggering restenosis, then we may be unable to demonstrate our Lumivascular platform’s benefits are any different than competing technologies. Furthermore, physicians may find our imaging system difficult to use, and we may not be able to provide physicians with adequate training to be able to realize the benefits of our Lumivascular platform. If physicians do not value the benefits of on-board imaging and the enhanced visualization enabled by our products during an endovascular intervention as compared to our competitors’ products, or do not believe that such benefits improve clinical outcomes, our Lumivascular platform products may not be widely adopted.

 

In order to remain competitive, we must also continue to develop new product offerings and enhancements to our existing Lumivascular platform products. The market for medical devices in general, and in the PAD market in particular, is highly competitive, dynamic, and marked by rapid and substantial technological development and product innovation. If we are unable to innovate successfully, our Lumivascular platform products could become obsolete, and our revenues would decline as our customers purchase our competitors’ products. In addition, our innovation efforts may not result in new products that generate additional revenue. For example, we believe that our next-generation Pantheris, Pantheris SV and any future iterations of these products are important to our future revenues, and we are devoting a significant portion of our resources to their continued development. However, we do not yet know whether these or any other new offerings will be well received and broadly accepted by physicians, and if so, whether sales will be sufficient for us to offset costs of development, implementation, support, operation, sales and marketing. Additionally, new products may subject us to additional risks of product performance, market adoption, customer complaints and litigation. If sales of our new product offerings are lower than we expect, fail to gain anticipated market acceptance or cause us to expend additional resources to fix unforeseen problems and develop modifications, our revenues and results of operations may not improve, and our business will be adversely affected.

 

30
 

 

Our ability to develop, market, and sell our products depends in part upon our working relationships with physicians, and any events that damage those relationships, or make it more difficult to build and maintain those relationships, could harm our business.

 

The development, marketing, and sale of our products depends upon our ability to maintain strong working relationships with physicians. We rely on these professionals to provide us with considerable knowledge and experience regarding the development, marketing and sale of our products. Physicians assist us in clinical trials and as researchers, marketing and product consultants and public speakers. If we cannot maintain our strong working relationships with these professionals and continue to receive their advice and input, the development and marketing of our products could suffer, which could harm our business, financial condition and results of operations. The medical device industry’s relationship with physicians is under increasing scrutiny by the Office of Inspector General, or OIG, the Department of Justice, or DOJ, state attorneys general, and other foreign and domestic government agencies. Changes to or our failure to comply with laws, rules and regulations governing our relationships with physicians, or an investigation into our compliance by the OIG, DOJ, state attorneys general and other government agencies, could significantly harm our business by damaging our reputation among, or restricting our ability to work with, physicians.

 

In addition, we target our sales efforts to interventional cardiologists, vascular surgeons and interventional radiologists because they are often the physicians diagnosing and treating both coronary artery disease and PAD. If these physicians are not made aware of our Lumivascular platform products, those patients may instead be surgically treated or treated with an alternative interventional procedure. In addition, there is a significant correlation between PAD and coronary artery disease, and many physicians do not routinely screen for PAD while screening for coronary artery disease. If we are not successful in educating physicians about screening for PAD and about the capabilities of our Lumivascular platform products, our ability to increase our revenues may be impaired.

 

We compete against companies that have longer operating histories, more established products and greater resources, which may prevent us from achieving significant market penetration, increasing our revenues or becoming profitable.

 

Our products compete with a variety of products and devices for the treatment of PAD, including other CTO crossing devices, stents, balloons and atherectomy catheters, as well as products used in vascular surgery. Large competitors in the CTO crossing, stent and balloon markets include Abbott Laboratories, AngioDyamics, Boston Scientific, Cardinal Health, Cook Medical, Becton Dickinson and Medtronic. Competitors in the atherectomy market include AngioDyamics, Boston Scientific, Cardiovascular Systems, Medtronic and Philips. Some competitors have previously attempted to combine intravascular imaging with atherectomy and may have current programs underway to do so. These and other companies may attempt to incorporate on-board visualization into their products in the future and may remain competitive with us in marketing traditional technologies. Other competitors include pharmaceutical companies that manufacture drugs for the treatment of symptoms associated with mild to moderate PAD and companies that provide products used by surgeons in peripheral and coronary bypass procedures. These competitors and other companies may introduce new products that compete with our products. Many of our competitors have significantly greater financial and other resources than we do and have well-established reputations, as well as broader product offerings and worldwide distribution channels that are significantly larger and more effective than ours. In addition, competitors with greater financial resources than ours could acquire other companies to gain enhanced name recognition and market share, as well as new technologies or products that could effectively compete with our existing products, which may cause our revenues to decline and would harm our business. Competition with these companies could result in price-cutting, reduced profit margins and loss of market share, any of which would harm our business, financial condition and results of operations.

 

If we are unable to effectively differentiate our products or company from those of our competitors and our business may be adversely affected.

 

If our manufacturing facility becomes damaged or inoperable, or we are required to vacate the facility, or our electronic systems are compromised, our ability to manufacture and sell our Lumivascular platform products and to pursue our research and development efforts may be jeopardized.

 

We currently manufacture and assemble our Lumivascular platform products in-house. Our products are comprised of components sourced from a variety of contract manufacturers, with final assembly completed at our facility in Redwood City, California. Our facility and equipment, or those of our suppliers, could be harmed or rendered inoperable by natural or man-made disasters, including fire, earthquake, terrorism, flooding and power outages. Further, our electronic systems may experience service interruptions, denial-of-service and other cyber-attacks, computer viruses or other events. Any of these may render it difficult or impossible for us to manufacture products, pursue our research and development efforts or otherwise run our business for some period of time. If our facility is inoperable for even a short period of time, the inability to manufacture our current products, and the interruption in research and development of any future products, may result in harm to our reputation, increased costs, lower revenues and the loss of customers. Furthermore, it could be costly and time-consuming to repair or replace our facilities and the equipment we use to perform our research and development work and manufacture our products. 

 

31
 

 

We depend on third-party vendors to manufacture some of our components, coating and sub-assemblies, including some single source suppliers, which could make us vulnerable to supply shortages and price fluctuations that could harm our business.

 

We currently manufacture some of our components and sub-assemblies at our Redwood City facility and rely on third-party vendors for other components and sub-assemblies used in our Lumivascular platform. For several of our components and sub-assemblies we rely on single and limited source suppliers. For example, we rely on single vendors for our optical fiber, coatings and drive cables that are key components of our catheters, and we rely on single vendors for our laser and data acquisition card that are key components of our Lightbox. These components are critical to our products and there are relatively few alternative sources of supply. Further, we do not carry a significant inventory of these components. If our suppliers of these materials cease doing business, reduce their production capacity, or otherwise limit the amount of materials we can purchase, we may be unable to acquire necessary materials on favorable terms, or at all. If we are unable to purchase required inputs for our production, our business will be adversely affected.

 

Our reliance on third-party vendors subjects us to a number of risks that could impact our ability to manufacture our products and harm our business.

 

We rely on third-party vendors to supply us with raw materials, as well as certain components and sub-assemblies used in the manufacture of our products. Our reliance on such third parties subjects us to a number of risks that could adversely affect our operations, including:

 

 

●

interruption of supply resulting from modifications to, or discontinuation of, a supplier’s operations;
 

●

delays in shipments resulting from slowdowns in manufacturing due to the COVID-19 pandemic or other causes, such as government restrictions on the movement of people and goods;
 

●

delays in product shipments resulting from uncorrected defects, reliability issues or a supplier’s failure to consistently produce quality components;
 

●

price fluctuations due to a lack of long-term supply arrangements with our suppliers for key components;
 

●

inability to obtain adequate supply in a timely manner or on commercially reasonable terms;
 

●

difficulty identifying and qualifying alternative or additional suppliers for components in a timely manner;
 

●

inability of the manufacturer or supplier to comply with QSR as enforced by the FDA and state regulatory authorities;
 

●

inability to control the quality of products manufactured by third parties;
 

●

production delays related to the evaluation and testing of products from alternative suppliers and corresponding regulatory qualifications; and
 

●

delays in delivery by our suppliers due to changes in demand from us or their other customers.

 

The indirect and direct effects of the COVID-19 pandemic, including subsequent variants, and measures taken in response by governments and businesses worldwide to contain its spread, including quarantines, facility closures, travel and logistics restrictions, border controls, and shelter in place or stay at home and social distancing orders, have adversely impacted and are expected to continue to adversely impact global supply chain, manufacturing, and logistics operations. Shipping and freight delays have also been increasing in response to port closures, port congestion, shipping container and ship shortages, and global conflicts. To the extent the COVID-19 pandemic and other events result in continuation or worsening of manufacturing and shipping delays and constraints, our suppliers of raw materials and other components may have difficulty obtaining and providing the materials we require to manufacture our products, which could adversely affect our ability to acquire and maintain adequate inventory and meet demand for our products.

 

Some of our suppliers have begun requiring us to provide longer-term forecasts of our supply requirements. If our assumptions about customer demand are incorrect, the forecasts we provide to our suppliers may result in excess inventory due to reduced demand or insufficient inventory to meet demand, which would adversely affect our business and results of operations. We also compete with other manufacturers who require the same components as us, or inputs used in producing the components that we purchase. Other purchasers may be able to leverage stronger relationships or greater purchasing power than we have to gain advantages over us in the supply chain.

 

32
 

 

We do not currently intend to devote significant additional resources in the near-term to market our Lumivascular platform internationally, which will limit our potential revenues from our Lumivascular platform products.

 

Marketing our Lumivascular platform outside of the United States would require substantial additional sales and marketing, regulatory and personnel expenses. As part of our product development and regulatory strategy, we plan to expand into select international markets, but we do not currently intend to devote significant additional resources to market our Lumivascular platform internationally in order to focus our resources and efforts on the U.S. market. Our decision to market our products primarily in the United States in the near-term will limit our ability to reach all of our potential markets and will limit our potential sources of revenue. In addition, our competitors will have an opportunity to further penetrate and achieve market share outside of the United States until such time, if ever, that we devote significant additional resources to market our Lumivascular platform products or other products internationally.

 

Our ability to utilize our net operating loss carryforwards may be limited.

 

As of December 31, 2022, we had federal and state net operating loss carryforwards, or NOLs, due to prior period losses of $346.0 million and $209.8 million, respectively, which if not utilized will begin to expire in 2027 for federal purposes and 2023 for state purposes. Out of the total Federal net operating loss carryforwards, $88.5 million were generated in years after December 31, 2017 and have no expiration. Subject to certain limitations, NOLs can be used to offset taxable income for U.S. federal income tax purposes. However, Section 382 of the Internal Revenue Code of 1986, as amended, may limit the NOLs we may use in any year for U.S. federal income tax purposes in the event of certain changes in ownership of our company. A Section 382 “ownership change” generally occurs if one or more stockholders or groups of stockholders who own at least 5% of our stock increase their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period. Similar rules may apply under state tax laws. It is possible that prior transactions with respect to our stock may have caused, and that future issuances or sales of our stock (including certain transactions involving our stock that are outside of our control) could cause, an “ownership change.” A number of our common and preferred stock financings over the past year may affect our ability to use NOLs. If an “ownership change” occurs, Section 382 would impose an annual limit on the amount of pre-ownership change NOLs and other tax attributes we can use to reduce our taxable income, potentially increasing and accelerating our liability for income taxes, and also potentially causing those tax attributes to expire unused. Any limitation on using NOLs could (depending on the extent of such limitation and the NOLs previously used) result in our retaining less cash after payment of U.S. federal income taxes during any year in which we have taxable income (rather than losses) than we would be entitled to retain if such NOLs were available as an offset against such income for U.S. federal income tax reporting purposes, which could harm our profitability.

 

On December 22, 2017, the Tax Cuts and Jobs Act, or Tax Act, was enacted into law with many significant changes to the U.S. tax laws. The Tax Act limits the utilization of NOLs arising in tax years beginning after December 31, 2017 to 80% of taxable income per year. However, existing NOLs that arose in years prior to December 31, 2017 are not affected by these provisions. Our ability to utilize NOLs arising in future tax periods may be limited by the Tax Act.

 

Outbreaks of contagious diseases, such as the novel coronavirus, COVID-19, and other public health crises may impact our business and operations, which could materially adversely affect our financial condition and results of operations.

 

We have experienced a disruption in procedures using our products and in our operations as a result of the COVID-19 outbreak. Public health crises, including an outbreak of a contagious disease, such as COVID-19, particularly to the extent it becomes a pandemic like COVID-19, could significantly disrupt our business. The effects of such a public health crisis are difficult to predict, but may include a decrease in procedure volumes due to restrictions and guidelines implemented by facilities and governmental entities; reduced availability of physicians or lab space to treat patients using our products and/or different treatment prioritizations of those physicians; increased cost pressures and burdens on the overall healthcare infrastructure that result in reallocation of resources; changed treatment decisions by patients who may elect to defer or avoid treatment for procedures that use our products due to concerns about the potential spread of diseases in facilities; the suspension of clinical trial activity; restrictions on the ability of our personnel and personnel of our distribution partners and sales agents to travel and to access customers and medical facilities for sales activities, training and case support; delays in approvals by regulatory bodies; delays in product development efforts, which will also disrupt or delay our ability to launch affected products; reallocation of company resources from our strategic priorities; supply chain disruptions that limit, delay or prevent us from acquiring the components used to manufacture our products or ship those products once manufactured; disruptions in our relationships with our distributors and sales agents due to the impact of the outbreak on their operations; temporary closures of our facilities; loss of employee productivity; government requirements to “shelter at home” or other incremental mitigation efforts that may further impact our capacity to manufacture, sell and support the use of our products; legal actions threatened or commenced against us by employees, customers or others who allege that our actions or inactions relating to safety measures led to their exposure to COVID-19 or other personal injury; and adverse impacts on the national and global economies.

 

33
 

 

The extent of the COVID-19 pandemic may be further aggravated by the spread of new, more viral or deadly variants. Public health crises and pandemics, such as the outbreak of COVID-19, also affect the economy generally, which may affect our stock price, our ability to borrow or raise additional capital, and the funding of health systems that purchase our products, among other potential effects. The United States and world economies could enter into periods of sustained recession or depression, which could materially adversely affect our business. The total impact of these disruptions could have a material adverse impact on our financial condition and results of operations, and, we cannot predict the specific extent, or duration, of the impact of the COVID-19 outbreak or any other outbreak of a contagious disease or other public health crisis on our financial condition and results. Furthermore, the global COVID-19 pandemic continues to evolve and we do not yet know the full extent and duration of its impact. The full extent to which a public health crisis will directly or indirectly impact our business and results will depend on future developments that are highly uncertain and difficult to predict. Finally, to the extent a public health crisis adversely affects our business, results and prospects, it may also have the effect of heightening many of the other risks described in this section.

 

Disruptions of supply chains could have a material adverse effect on our operating and financial results

 

Disruption of supply chains due to trade restrictions, political instability, severe weather, natural disasters, public health crises such as the COVID-19 pandemic, terrorism, product recalls, port closures, labor supply or stoppages, the financial or operational instability of key suppliers and carriers, government restrictions or measures, or other reasons could impair our ability to distribute our products, or cause the demand for our products to decrease. Many industries, including our own, face supply chain challenges as a result of COVID-19 and other macroeconomic issues, including reduced freight availability and increased costs, port disruption, manufacturing facility closures, labor shortages and other supply chain disruptions. For example, hospitals reported a shortage of an iodinated contract medium used in X-rays, radiography and CT scans due to Shanghai’s lockdowns during the COVID-19 pandemic. A shortage of such products could lead to a reduced number of surgeries and decrease the demand for our products.

 

In addition, we have and continue to experience supply chain challenges related to extended lead times from certain key suppliers. Should these challenges persist or worsen, we may be unable to manufacture enough inventory to meet the current demand for our Lumivascular products and consequently incur significant adverse effects on our operating and financial results. To the extent we are unable to mitigate the likelihood or potential impact of such events, there could be a material adverse effect on our operating and financial results.

 

We may acquire other companies or technologies or be the target of strategic transactions, which could divert our management’s attention, result in additional dilution to our stockholders and otherwise disrupt our operations and harm our operating results.

 

We may in the future seek to acquire or invest in businesses, applications or technologies that we believe could complement or expand our Lumivascular platform, enhance our technical capabilities or otherwise offer growth opportunities. The pursuit of potential acquisitions may divert the attention of management and cause us to incur various costs and expenses in identifying, investigating and pursuing suitable acquisitions, whether or not they are consummated. We may not be able to identify desirable acquisition targets or be successful in entering into an agreement with any particular target or obtain the expected benefits of any acquisition or investment.

 

To date, our technology and product development efforts have been organic, and we have no experience in acquiring other businesses. In any acquisition, we may not be able to successfully integrate acquired personnel, operations and technologies, or effectively manage the combined business following the acquisition. Acquisitions could also result in dilutive issuances of equity securities, the use of our available cash, or the incurrence of debt, which could harm our operating results. In addition, if an acquired business fails to meet our expectations, our operating results, business and financial condition may suffer.

 

In addition, we sometimes receive inquiries relating to potential strategic transactions, including from third parties who may seek to acquire us. We will continue to consider and discuss such transactions as we deem appropriate. Such potential transactions may divert the attention of management, and cause us to incur various costs and expenses in investigating and evaluating such transactions, whether or not they are consummated.

 

34
 

 

New product development for the coronary artery disease market may be challenging, expensive and carries no guarantee of an approved commercial product.

 

In order to create more opportunities to grow our revenue base, we must continue to develop new product offerings and enhancements to our existing Lumivascular platform products. The market for medical devices in general, and in the CAD market, is highly competitive, dynamic, and marked by rapid and substantial technological development and product innovation. We believe that a Lumivascular product developed for the CAD market is important to our future revenues, and we are beginning to devote a significant portion of our resources to its development. Consequently, we anticipate we will need additional capital to finance this endeavor encompassing the research and development, clinical trials and eventual promotion of any new CAD product. Even if we are able to obtain additional capital, we may not be successful in the development any new CAD product.

 

Our team may not have all the necessary qualifications and experience for the development of such a product. Therefore, we may need to attract and retain highly qualified personnel with specific experience in the coronary industry. Competition for skilled personnel is intense, especially for engineers with high levels of experience in designing and developing these types of medical devices, and we may not be successful in hiring and retaining employees with appropriate qualifications. Many of the companies with which we compete for experienced personnel have greater resources than we have. We may also may not be able to complete development of such products or choose to allocate our financial and other resources elsewhere due to unforeseen circumstances.

 

Should we develop a CAD product, we will need to conduct a clinical trial. Clinical development is a long, expensive, and uncertain process and is subject to delays and the risk that this product may ultimately prove unsafe or ineffective in treating the indications for which they it will be designed. Completion of clinical trials may take several years or more and failure of the trial can occur at any time. We cannot provide any assurance that our clinical trials will meet their primary endpoints or that such trials or their results will be accepted by the FDA or foreign regulatory authorities. Even if we achieve positive early or preliminary results in clinical trials, these results do not necessarily predict final results, and positive results in early trials may not indicate success in later trials. Many companies in the medical device industry have suffered significant setbacks in late-stage clinical trials, even after receiving promising results in earlier trials or in the preliminary results from these late-stage clinical trials.

 

Furthermore, we do not yet know whether any new CAD product, if developed and approved, will be well received and broadly accepted by physicians, and if so, whether sales will be sufficient for us to offset costs of development, implementation, support, operation, sales and marketing. Additionally, such products may subject us to additional risks of product performance, market adoption, customer complaints and litigation. If sales of this coronary device are lower than we expect, fail to gain anticipated market acceptance or cause us to expend additional resources to fix unforeseen problems and develop modifications, our revenues and results of operations may not improve and our business will be adversely affected.

 

Adverse developments affecting the financial services industry, including events or concerns involving liquidity, defaults or non-performance by financial institutions, could adversely affect our business, financial condition or results of operations.

 

Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future adversely affect our liquidity. For example, on March 10, 2023, the Federal Deposit Insurance Corporation (“FDIC”) announced that Silicon Valley Bank had been closed by the California Department of Financial Protection and Innovation. At that time, all of our cash and cash equivalents were held at Silicon Valley Bank and our access to such funds was limited until the United States Department of the Treasury announced in a joint statement with the Federal Reserve and FDIC that depositors of Silicon Valley Bank will have access to all of their money starting March 13, 2023. While we have regained access to our funds at Silicon Valley Bank and are evaluating our banking relationships, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by events such as liquidity constraints or failures, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry. These factors may also adversely affect our ability to access our cash and cash equivalents at affected financial institutions.

 

In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on terms favorable to us, or at all.  Any decline in available funding or access to our cash and liquidity resources could, among other things, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other obligations, result in breaches of our contractual obligations or result in violations of federal or state wage and hour laws. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our liquidity and our business, financial condition or results of operations.

 

35
 

 

Risks Related to Our Use of Technology and Intellectual Property

 

If our technology infrastructure is compromised, damaged or interrupted by a cybersecurity incident, data security breach or other security problems, our operating results and financial condition could be adversely affected.

 

We use technology in substantially all aspects of our business operations, and our ability to serve customers most effectively depends on the reliability of our technology systems. Cybersecurity incidents can include computer viruses, computer denial-of-service attacks, worms, and other malicious software programs or other attacks, covert introduction of malware to computers and networks, impersonation of authorized users, and efforts to discover and exploit any design flaws, bugs, security vulnerabilities or security weaknesses, as well as intentional or unintentional acts by employees or other insiders with access privileges, intentional acts of vandalism by third parties and sabotage.

 

In addition, our technology infrastructure and systems are vulnerable to damage or interruption from natural disasters, power loss and telecommunications failures. Any such disruption to our systems, or the technology systems of third parties on which we rely, the failure of these systems to otherwise perform as anticipated, or the theft, destruction, loss, misappropriation, or release of sensitive and/or confidential information or intellectual property, could require us to notify affected individuals, federal or state agencies or media outlets of the incident and could result in business disruption, negative publicity, loss of customers, potential liability, including litigation or other legal actions against us or the imposition of penalties, fines, fees or liabilities, which may not be covered by our insurance policies, and competitive disadvantage, any or all of which would potentially adversely affect our customer service, decrease the volume of our business and result in increased costs and lower profits. Moreover, a cybersecurity breach could require us to devote significant management resources to address the problems associated with the breach and to expend significant additional resources to upgrade further the security measures we employ to protect information against cyber-attacks and other wrongful attempts to access such information, which could result in a disruption of our operations.

 

While we have invested, and continue to invest, in technology security initiatives and other measures to prevent security breaches and cyber incidents, as well as disaster recovery plans, these initiatives and measures may not be entirely effective to insulate us from technology disruption that could result in adverse effects on our results of operations.

 

We may in the future be a party to intellectual property litigation or administrative proceedings that could be costly and could interfere with our ability to sell our Lumivascular platform products.

 

The medical device industry has been characterized by extensive litigation regarding patents, trademarks, trade secrets, and other intellectual property rights, and companies in the industry have used intellectual property litigation to gain a competitive advantage. It is possible that U.S. and foreign patents and pending patent applications or trademarks controlled by third parties may be alleged to cover our products, or that we may be accused of misappropriating third parties’ trade secrets. Additionally, our products include hardware and software components that we purchase from vendors, and may include design components that are outside of our direct control. Our competitors, many of which have substantially greater resources and have made substantial investments in patent portfolios, trade secrets, trademarks, and competing technologies, may have applied for or obtained or may in the future apply for or obtain, patents or trademarks that will prevent, limit or otherwise interfere with our ability to make, use, sell and/or export our products or to use product names. They may devote substantial resources towards obtaining claims that cover the design of our atherectomy products to prevent the marketing and selling of competitive products. We may become a party to patent or trademark infringement or trade secret claims and litigation as a result of these and other third-party intellectual property rights being asserted against us. The defense and prosecution of these matters are both costly and time consuming. Vendors from whom we purchase hardware or software may not indemnify us in the event that such hardware or software is accused of infringing a third-party’s patent or trademark or of misappropriating a third-party’s trade secret.

 

Further, if such patents, trademarks, or trade secrets are successfully asserted against us, this may harm our business and result in injunctions preventing us from selling our products, license fees, damages and the payment of attorney fees and court costs. In addition, if we are found to willfully infringe third-party patents or trademarks or to have misappropriated trade secrets, we could be required to pay treble damages in addition to other penalties. Although patent, trademark, trade secret, and other intellectual property disputes in the medical device area have often been settled through licensing or similar arrangements, costs associated with such arrangements may be substantial and could include ongoing royalties. We may be unable to obtain necessary licenses on satisfactory terms, if at all. If we do not obtain necessary licenses, we may not be able to redesign our Lumivascular platform products to avoid infringement.

 

36
 

 

Similarly, interference or derivation proceedings provoked by third parties or brought by the U.S. Patent and Trademark Office, or USPTO, may be necessary to determine the priority of inventions or other matters of inventorship with respect to our patents or patent applications. We may also become involved in other proceedings, such as re-examination, inter partes review, or opposition proceedings, before the USPTO or other jurisdictional body relating to our intellectual property rights or the intellectual property rights of others. Adverse determinations in a judicial or administrative proceeding or failure to obtain necessary licenses could prevent us from manufacturing and selling our Lumivascular platform products or using product names, which would have a significant adverse impact on our business.

 

Additionally, we may need to commence proceedings against others to enforce our patents or trademarks, to protect our trade secrets or know-how, or to determine the enforceability, scope and validity of the proprietary rights of others. These proceedings would result in substantial expense to us and significant diversion of effort by our technical and management personnel. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. We may not be able to stop a competitor from marketing and selling products that are the same or similar to our products or from using product names that are the same or similar to our product names, and our business may be harmed as a result.

 

We are aware of patents held by third parties that may be asserted against us in litigation that could be costly and could limit our ability to sell our Lumivascular platform products.

 

We are aware of patent families related to catheter positioning, optical coherence tomography, occlusion cutting and atherectomy owned by third parties. With regard to atherectomy patents, one of our founders, Dr. John Simpson, founded FoxHollow Technologies prior to founding our company. FoxHollow Technologies developed an atherectomy device that is currently sold by Medtronic, and Dr. Simpson and our Chief Technology Officer, Himanshu Patel, are listed as inventors on patents covering that device that are now held by Medtronic. We are not currently aware of any claims Medtronic has made or intends to make against us with respect to Pantheris or any other product or product under development. Because of a doctrine known as “assignor estoppel,” if any of Dr. Simpson’s earlier patents are asserted against us by Medtronic, we may be prevented from asserting an invalidity defense regarding those patents, and our defense may be compromised. Medtronic has significantly greater financial resources than we do to pursue patent litigation and could assert these patent families against us at any time. Adverse determinations in any such litigation could prevent us from manufacturing or selling Pantheris or other products or products under development, which would significantly harm our business.

 

Intellectual property rights may not provide adequate protection, which may permit third parties to compete against us more effectively.

 

In order to remain competitive, we must develop and maintain protection of the proprietary aspects of our technologies. We rely on a combination of patents, copyrights, trademarks, trade secret laws and confidentiality and invention assignment agreements to protect our intellectual property rights. As of December 31, 2022, we held 54 issued and allowed U.S. patents, 1 U.S. pending provisional application, 22 U.S. utility patent applications and 4 PCT applications pending. As of December 31, 2022, we also had 84 issued and allowed patents from outside of the United States. As of December 31, 2022, we had 35 pending patent applications outside of the United States, including in Australia, Canada, China, Europe, India, Japan and Mexico. Our patents and patent applications include claims covering key aspects of the design, manufacture and therapeutic use of OCT imaging catheters, occlusion-crossing catheters, atherectomy devices and our imaging console. Our patent applications may not result in issued patents and our patents may not be sufficiently broad to protect our technology. Any patents issued to us may be challenged by third parties as being invalid, or third parties may independently develop similar or competing technology that avoids our patents. Should such challenges be successful, competitors might be able to market products and use manufacturing processes that are substantially similar to ours. We may not be able to prevent the unauthorized disclosure or use of our technical knowledge or other trade secrets by consultants, vendors or former or current employees, despite the existence generally of confidentiality agreements and other contractual restrictions. Monitoring unauthorized use and disclosure of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property will be adequate. In addition, the laws of many foreign countries will not protect our intellectual property rights to the same extent as the laws of the United States. Consequently, we may be unable to prevent our proprietary technology from being exploited abroad, which could affect our ability to expand to international markets or require costly efforts to protect our technology. To the extent our intellectual property protection is incomplete, we are exposed to a greater risk of direct competition. In addition, competitors could purchase our products and attempt to replicate some or all of the competitive advantages we derive from our development efforts or design around our protected technology. Our failure to secure, protect and enforce our intellectual property rights could substantially harm the value of our Lumivascular platform, brand and business.

 

37
 

 

We use certain open source software in all versions of our Lightbox. We may face claims from companies that incorporate open source software into their products or from open source licensors, claiming ownership of, or demanding release of, the source code, the open source software or derivative works that were developed using such software, or otherwise seeking to enforce the terms of the applicable open source license. These claims could result in litigation and could require us to cease offering Lightbox unless and until we can re-engineer it to avoid infringement. This re-engineering process could require significant additional research and development resources, and we may not be able to complete it successfully. These risks could be difficult to eliminate or manage, and, if not addressed, could harm our business, financial condition and operating results.

 

Regulatory and Litigation Risks

 

If we fail to obtain and maintain necessary regulatory clearances or approvals for our Lumivascular platform products, or if clearances or approvals for future products and indications are delayed or not issued, our commercial operations would be harmed.

 

Our Lumivascular platform products are medical devices that are subject to extensive regulation by FDA in the United States and by regulatory agencies in other countries where we do business. Government regulations specific to medical devices are wide-ranging and govern, among other things:

 

 

●

product design, development and manufacture;

 

 

●

laboratory, preclinical and clinical testing, labeling, packaging, storage and distribution;

 

 

●

pre-marketing clearance or approval;

 

 

●

record keeping;

 

 

●

product marketing, promotion and advertising, sales and distribution; and

 

 

●

post-marketing surveillance, including reporting of deaths or serious injuries and recalls and correction and removals.

 

Before a new medical device, or a new intended use for, an existing product can be marketed in the United States, a company must first submit and receive either 510(k) clearance or pre-marketing approval from FDA, unless an exemption applies. Either process can be expensive, lengthy and unpredictable. We may not be able to obtain the necessary clearances or approvals or may be unduly delayed in doing so, which could harm our business. Furthermore, even if we are granted regulatory clearances or approvals, they may include significant limitations on the indicated uses for the product, which may limit the market for the product. Although we have obtained 510(k) clearance to market our Pantheris family of catheters for atherectomy, and our Ocelot and Tigereye family of catheters for crossing sub and total occlusions in the peripheral vasculature, our clearance can be revoked if safety or efficacy problems develop. Delays in obtaining clearance or approval could increase our costs and harm our revenues and growth.

 

In addition, we are required to timely file various reports with the FDA, including medical device reports, or MDRs, if our devices may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction were to recur. If these MDRs are not filed timely, regulators may impose sanctions and sales of our products may suffer, and we may be subject to product liability or regulatory enforcement actions, all of which could harm our business.

 

If we initiate a correction or removal for one of our devices to reduce a risk to health posed by the device, we would be required to submit a publicly available Correction and Removal report to the FDA and in many cases, similar reports to other regulatory agencies. This report could be classified by the FDA as a device recall that could lead to increased scrutiny by the FDA, other international regulatory agencies and our customers regarding the quality and safety of our devices. Furthermore, the submission of these reports has been and could be used by competitors against us in competitive situations and cause customers to delay purchase decisions or cancel orders and would harm our reputation.

 

The FDA and the Federal Trade Commission, or FTC, also regulate the advertising and promotion of our products to ensure that the claims we make are consistent with our regulatory clearances, that there are adequate and reasonable scientific data to substantiate the claims and that our promotional labeling and advertising is neither false nor misleading in any respect. If the FDA or FTC determines that any of our advertising or promotional claims are misleading, not substantiated or not permissible, we may be subject to enforcement actions, including Warning Letters, adverse publicity, and we may be required to revise our promotional claims and make other corrections or restitutions.

 

38
 

 

The FDA and state authorities have broad enforcement powers. Our failure to comply with applicable regulatory requirements could result in enforcement action by the FDA or state agencies, which may include, among other things, harm to our reputation; fines, injunctions, civil penalties, or criminal prosecution; product replacements or recalls; or rejecting our requests for future 510(k) clearance or pre-market approval or withdrawal of a previously granted 510(k) clearance. If any of these events were to occur, our business and financial condition would be harmed.

 

Material modifications to our Lumivascular platform products may require new 510(k) clearances or pre-market approvals or may require us to recall or cease marketing our Lumivascular platform products until clearances or approvals are obtained.

 

Material modifications to the intended use or technological characteristics of our Lumivascular platform products will require new 510(k) clearances or pre-market approvals or require us to recall or cease marketing the modified devices until these clearances or approvals are obtained if such changes were made via the “Letter-to-File” process of internal documentation. Based on published FDA guidelines, the FDA requires device manufacturers to initially make and document a determination of whether or not a modification requires a new approval, supplement or clearance; however, the FDA can review a manufacturer’s decision. Any modification to an FDA-cleared device that would significantly affect its safety or efficacy or that would constitute a major change in its intended use would require a new 510(k) clearance or possibly a pre-market approval. We may not be able to obtain additional 510(k) clearances or pre-market approvals for new products or for modifications to, or additional indications for, our Lumivascular platform products in a timely fashion, or at all. Delays in obtaining required future clearances would harm our ability to introduce new or enhanced products in a timely manner, which in turn would harm our future growth. We have made modifications to our Lumivascular platform products in the past and will make additional modifications in the future that we believe do not or will not require additional clearances or approvals. If the FDA disagrees and requires new clearances or approvals for the modifications, we may be required to recall and to stop selling or marketing our Lumivascular platform products as modified, which could harm our operating results and require us to redesign our Lumivascular platform products. In these circumstances, we may be subject to significant enforcement actions. Future versions of are Lumivascular platform incorporating enhancements may require additional regulatory clearances or approvals.

 

Our ability to market our current products in the United States is limited to use in peripheral vessels, and if we want to market our products for other uses, we will need to file for FDA clearances or approvals and may need to conduct trials to support expanded use, which would be expensive, time-consuming and may not be successful.

 

Our current products are cleared in the United States only for crossing sub-total and chronic total occlusions and for performing atherectomy in the peripheral vasculature. These FFDCA clearances prohibits us from marketing or advertising our products for any other indication within the peripheral vasculature, which restricts our ability to sell these products and could affect our growth. Additionally, our products are contraindicated for use in the cerebral, carotid, coronary, iliac, and renal arteries. While off-label use of medical devices is common and the FDA does not regulate physicians’ choice of treatments, the FDA does restrict a manufacturer’s communications regarding such off-label use. We are not allowed to actively promote or advertise our products for off-label use. In addition, we cannot make comparative claims regarding the use of our products against any alternative treatments without conducting head-to-head comparative clinical studies, which would be expensive and time consuming. If our promotional activities fail to comply with the FDA’s regulations or guidelines, we may be subject to warnings or enforcement action by the FDA and other government agencies. In the future, if we want to market a variation of Ocelot, Tigereye or Pantheris product families in the United States for use in other applications for which we do not currently have clearance, such as the coronary arteries, we will need to make modifications to these products, conduct further clinical trials and obtain new clearances or approvals from the FDA. There can be no assurance that we will successfully develop these modifications, that future clinical studies will be successful or that the expense of these activities will be offset by additional revenues.

 

If our clinical trials are unsuccessful or significantly delayed, or if we do not complete our clinical trials, our business may be harmed.

 

Clinical development is a long, expensive, and uncertain process and is subject to delays and the risk that products may ultimately prove unsafe or ineffective in treating the indications for which they are designed. Completion of clinical trials may take several years or more and failure of the trial can occur at any time. We cannot provide any assurance that our clinical trials will meet their primary endpoints or that such trials or their results will be accepted by the FDA or foreign regulatory authorities. Even if we achieve positive early or preliminary results in clinical trials, these results do not necessarily predict final results, and positive results in early trials may not indicate success in later trials. Many companies in the medical device industry have suffered significant setbacks in late-stage clinical trials, even after receiving promising results in earlier trials or in the preliminary results from these late-stage clinical trials.

 

39
 

 

We may experience numerous unforeseen events during, or because of, the clinical trial process that could delay or prevent us from receiving regulatory clearance or approval for new products or modifications of existing products, including new indications for existing products, including:

 

 

●

negative or inconclusive results that may cause us to decide, or regulators may require us, to conduct additional clinical and/or preclinical testing which may be expensive and time consuming;

 

 

●

trial results that do not meet the level of statistical significance required by the FDA or other regulatory authorities;

 

 

●

findings by the FDA or similar foreign regulatory authorities that the product is not sufficiently safe for investigational use in humans;

 

 

●

interpretations of data from preclinical testing and clinical testing by the FDA or similar foreign regulatory authorities that may be different from our own;

 

 

●

delays or failure to obtain approval of our clinical trial protocols from the FDA or other regulatory authorities;

 

 

●

delays in obtaining institutional review board approvals or government approvals to conduct clinical trials at prospective sites;

 

 

●

findings by the FDA or similar foreign regulatory authorities that our or our suppliers’ manufacturing processes or facilities are unsatisfactory;

 

 

●

changes in the review policies of the FDA or similar foreign regulatory authorities or the adoption of new regulations that may negatively affect or delay our ability to bring a product to market or receive approvals or clearances to treat new indications;

 

 

●

trouble in managing multiple clinical sites;

 

 

●

delays in agreeing on acceptable terms with third-party research organizations and trial sites that may help us conduct the clinical trials; and

 

 

●

the suspension or termination by us, or regulators, of our clinical trials because the participating patients are being exposed to unacceptable health risks.

 

Failures or perceived failures in our clinical trials will delay and may prevent our product development and regulatory approval process, damage our business prospects and negatively affect our reputation and competitive position.

 

From time to time, we engage outside parties to perform services related to certain of our clinical studies and trials, and any failure of those parties to fulfill their obligations could increase costs and cause delays.

 

From time to time, we engage consultants to help design, monitor, and analyze the results of certain of our clinical studies and trials. The consultants we engage interact with clinical investigators to enroll patients in our clinical trials. We depend on these consultants and clinical investigators to help facilitate the clinical studies and trials and monitor and analyze data from these studies and trials under the investigational plan and protocol for the study or trial and in compliance with applicable regulations and standards, commonly referred to as good clinical practices. We may face delays in our regulatory approval process if these parties do not perform their obligations in a timely, compliant or competent manner. If these third parties do not successfully carry out their duties or meet expected deadlines, or if the quality, completeness or accuracy of the data they obtain is compromised due to the failure to adhere to our clinical trial protocols or for other reasons, our clinical studies or trials may be extended, delayed or terminated or may otherwise prove to be unsuccessful, and we may have to conduct additional studies, which would significantly increase our costs, in order to obtain the regulatory clearances that we need to commercialize our products.

 

40
 

 

We have limited long-term data regarding the safety and efficacy of our Lumivascular platform products, including Pantheris. Any long-term data that is generated by clinical trials involving our Lumivascular platform may not be positive or consistent with our short-term data, which would harm our ability to obtain clearance to market and sell our products.

 

Our Lumivascular platform is a novel system, and our success depends on its acceptance by the medical community as being safe and effective, and improving clinical outcomes. Important factors upon which the efficacy of our Lumivascular platform products, including Pantheris, will be measured are long-term data on the rate of restenosis following our procedure, and the corresponding duration of patency, or openness of the artery, and publication of that data in peer-reviewed journals. Another important factor that physicians will consider is the rate of reintervention, or retreatment, following the use of our Lumivascular platform products. The long-term clinical benefits of procedures that use our Lumivascular platform products are not known.

 

The results of short-term clinical experience of our Lumivascular platform products do not necessarily predict long-term clinical benefit. Restenosis rates typically increase over time. We believe that physicians will compare the rates of long-term restenosis and reintervention for procedures using our Lumivascular platform products against alternative procedures, such as angioplasty, stenting, bypass surgery and other atherectomy procedures. If the long-term rates of restenosis and reintervention do not meet physicians’ expectations, our Lumivascular platform products may not become widely adopted and physicians may consider alternative treatments for their patients. Another significant factor that physicians will consider is acute safety data on complications that occur during the use of our Lumivascular platform products. If the results obtained from any post-market studies that we conduct or post-clearance surveillance indicate that the use of our Lumivascular platform products are not as safe or effective as other treatment options or as current short-term data would suggest, adoption of our product may suffer and our business would be harmed. In addition, we are responsible for the costs associated with conducting studies to obtain safety and efficacy data. If we are unable to obtain sufficient financing, whether through our operations or from third parties, we will not be able to conduct the studies necessary to obtain long-term data regarding the safety and efficacy of our products.

 

Even if we believe the data collected from clinical studies or clinical experience indicate positive results, each physician’s actual experience with our products will vary. Physicians who are technically proficient participate in our clinical trials and are high-volume users of our Lumivascular platform products. Consequently, the results of our clinical trials and their experiences using our products may lead to better patient outcomes than those of physicians that are less proficient, perform fewer procedures or who use our products infrequently.

 

If we or our suppliers fail to comply with the FDA’s QSR, our manufacturing operations could be delayed or shut down and Lumivascular platform sales could suffer.

 

Our manufacturing processes and those of our third-party suppliers are required to comply with the FDA’s QSR, which covers the procedures and documentation of the design, testing, production, control, quality assurance, labeling, packaging, storage and shipping of our Lumivascular platform products. We are also subject to similar state requirements and licenses. In addition, we must engage in extensive recordkeeping and reporting and must make available our manufacturing facilities and records for periodic unannounced inspections by governmental agencies, including the FDA, state authorities and comparable agencies in other countries. If we fail a QSR inspection, our operations could be disrupted and our manufacturing interrupted. Failure to take adequate corrective action in response to an adverse QSR inspection could result in, among other things, a shut-down of our manufacturing operations, significant fines, suspension of marketing clearances and approvals, seizures or recalls of our device, operating restrictions and criminal prosecutions, any of which would cause our business to suffer. Furthermore, our key component suppliers may not currently be or may not continue to be in compliance with applicable regulatory requirements, which may result in manufacturing delays for our products and cause our revenues to decline.

 

We have registered with the FDA as a medical device manufacturer and have obtained a manufacturing license from the CDPH. The FDA has broad post-market and regulatory enforcement powers. We are subject to unannounced inspections by the FDA and the Food and Drug Branch of CDPH to determine our compliance with the QSR and other regulations, and these inspections may include the manufacturing facilities of our suppliers. We have undergone numerous audits, inspections, and reviews by the FDA, CDPH, and BSI, our European Notified Body, in the past, some of which resulted in the identification of instances of non-compliance which we were required to correct. We expect that we will undergo additional audits, inspections, and reviews in the future, which could result in further corrective actions.

 

We can provide no assurance that we will continue to remain in substantial compliance with the QSR. If the FDA, CDPH or BSI inspect our facility and discover major compliance problems, we may have to shut down our facility and cease manufacturing until we can take the appropriate remedial steps to correct the audit findings. Taking corrective action may be expensive, time consuming and a distraction for management and if we experience a shutdown or delay at our manufacturing facility, we may be unable to produce our Lumivascular platform products, which would harm our business.

 

41
 

 

Our Lumivascular platform products may in the future be subject to product recalls that could harm our reputation.

 

FDA and similar governmental authorities in other countries have the authority to require the recall of commercialized products in the event of material regulatory deficiencies or defects in design or manufacture. A government mandated or voluntary recall by us could occur as a result of component failures, manufacturing errors or design or labeling defects. Recalls of our Lumivascular platform products or products we commercialize in the future would divert managerial attention, be expensive, harm our reputation with customers and harm our financial condition and results of operations. A recall announcement would negatively affect our stock price.

 

Changes in coverage and reimbursement for procedures using our Lumivascular platform products could affect the adoption of our Lumivascular platform and our future revenues.

 

Currently, our Lumivascular platform procedure is typically reimbursed by third-party payors, including Medicare and private healthcare insurance companies, under existing reimbursement codes. These payors may change their coverage and reimbursement policies, as well as payment amounts, in a way that would prevent or limit reimbursement for our products, which would significantly harm our business. Also, healthcare reform legislation or regulation may be proposed or enacted in the future, which may adversely affect such policies and amounts. We cannot predict whether and to what extent existing coverage and reimbursement will continue to be available. If physicians, hospitals and other providers are unable to obtain adequate coverage and reimbursement for procedures performed using our Lumivascular platform products, they are significantly less likely to use our Lumivascular platform products and our business would be harmed.

 

Healthcare reform measures could hinder or prevent our planned products’ commercial success.

 

In the United States, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system in ways that could harm our future revenues and profitability and the future revenues and profitability of our potential customers. Federal and state lawmakers regularly propose and, at times, enact legislation that would result in significant changes to the healthcare system, some of which are intended to contain or reduce the costs of medical products and services. The current presidential administration and Congress may continue to attempt broad sweeping changes to the current healthcare laws. We face uncertainties that might result from modifications or repeal of any of the provisions of the Affordable Care Act, including as a result of current and future executive orders and legislative actions. The impact of those changes on us and potential effect on the medical device industry as a whole is currently unknown. Any changes to the Affordable Care Act are likely to have an impact on our results of operations and may have a material adverse effect on our results of operations. We cannot predict what other healthcare programs and regulations will ultimately be implemented at the federal or state level or the effect of any future legislation or regulation in the United States may have on our business.

 

The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare may harm:

 

 

●

our ability to set a price that we believe is fair for our products;

 

 

●

our ability to generate revenues and achieve or maintain profitability; and

 

 

●

the availability of capital.

 

If we fail to comply with healthcare regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected.

 

Even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, certain federal and state healthcare laws and regulations pertaining to fraud and abuse and patients’ rights are and will be applicable to our business. We are subject to many healthcare fraud and abuse and patient privacy regulations by both the federal government and the states in which we conduct our business. The regulations that affect how we operate include:

 

 

●

the federal healthcare program Anti-Kickback Statute, which prohibits, among other things, any person from knowingly and willfully offering, soliciting, receiving or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs, such as the Medicare and Medicaid programs;

 

 

●

the federal False Claims Act, which prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, false claims, or knowingly using false statements, to obtain payment from the federal government;

 

42
 

 

 

●

federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;

 

 

●

the Sunshine Act, created under the Affordable Care Act, and its implementing regulations, which require manufacturers of drugs, medical devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid, or the Children’s Health Insurance Program to report annually to the HHS information related to payments or other transfers of value made to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;

 

 

●

HIPAA, as amended by the HITECH Act, which protects the security and privacy of protected health information; and

 

 

●

state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers.

 

The Affordable Care Act, among other things, amends the intent requirement of the Federal Anti-Kickback Statute and criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it. In addition, the Affordable Care Act provides that the government may assert that a claim including items or services resulting from a violation of the Federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act.

 

Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could harm our ability to operate our business and our results of operations. In addition, the clearance or approval and commercialization of any of our products outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.

 

Compliance with environmental laws and regulations could be expensive. Failure to comply with environmental laws and regulations could subject us to significant liability.

 

Our research and development and manufacturing operations involve the use of hazardous substances and are subject to a variety of federal, state, local and foreign environmental laws and regulations relating to the safe storage, use, discharge, disposal, remediation of, and human exposure to, hazardous substances and the sale, labeling, collection, recycling, treatment and disposal of products containing hazardous substances, such as isopropyl alcohol and other solvents. In addition, our research and development may acquire biological waste materials, such as human and animal tissue, for the sole use of product design testing. Upon completion of the product testing, these biological wastes are safely disposed of following all federal, state, local and foreign environmental laws and regulations. These operations are permitted by regulatory authorities, and the resultant waste materials are disposed of in material compliance with environmental laws and regulations. Liability under environmental laws and regulations can be joint and several and without regard to fault or negligence. Compliance with environmental laws and regulations may be expensive and non-compliance could result in substantial liabilities, fines and penalties, personal injury and third-party property damage claims and substantial investigation and remediation costs. Environmental laws and regulations could become more stringent over time, imposing greater compliance costs and increasing risks and penalties associated with violations. We cannot assure you that violations of these laws and regulations will not occur in the future or have not occurred in the past as a result of human error, accidents, equipment failure or other causes. The expense associated with environmental regulation and remediation could harm our financial condition and operating results.

 

43
 

 

The use, misuse or off-label use of the products in our Lumivascular platform may result in injuries that lead to product liability suits, which could be costly to our business.

 

We require limited training in the use of our Lumivascular platform products because we market primarily to physicians who are experienced in the interventional techniques required to use our device. If demand for our Lumivascular platform continues to grow, less experienced physicians will likely use the devices, potentially leading to more injury and an increased risk of product liability claims. The use or misuse of our Lumivascular platform products has in the past resulted, and may in the future result, in complications, including damage to the treated artery, infection, internal bleeding, and limb loss, potentially leading to product liability claims. Our Lumivascular platform products are contraindicated for use in the carotid, cerebral, iliac, or renal arteries. Our sales force does not promote the use of our products for off-label indications, and our U.S. instructions for use specify that our Lumivascular platform products are not intended for use in the carotid, cerebral, coronary, iliac or renal arteries. However, we cannot prevent a physician from using our Lumivascular platform products for these off-label applications. The application of our Lumivascular platform products to coronary arteries, as opposed to peripheral arteries, is more likely to result in complications that have serious consequences. For example, if excised plaque were not captured properly in our device, it could be carried by the bloodstream to a narrower location, blocking a coronary artery, leading to a heart attack, or blocking an artery to the brain, leading to a stroke. If our Lumivascular platform products are defectively designed, manufactured or labeled, contain defective components or are misused, we may become subject to costly litigation initiated by our customers or their patients. Product liability claims are especially prevalent in the medical device industry and could harm our reputation, divert management’s attention from our core business, be expensive to defend and may result in sizable damage awards against us. Although we maintain product liability insurance, the amount or breadth of our coverage may not be adequate for the claims that are made against us.

 

The expense and potential unavailability of insurance coverage for liabilities resulting from our products could harm us and our ability to sell our Lumivascular platform products.

 

We may not have sufficient insurance coverage for future product liability claims. We may not be able to obtain insurance in amounts or scope sufficient to provide us with adequate coverage against all potential liabilities. Any product liability claims brought against us, with or without merit, could increase our product liability insurance rates or prevent us from securing continuing coverage, harm our reputation in the industry, significantly increase our expenses, and reduce product sales. Product liability claims in excess of our insurance coverage would be paid out of cash reserves, harming our financial condition and operating results.

 

Some of our customers and prospective customers may have difficulty in procuring or maintaining liability insurance to cover their operations and use of our Lumivascular platform products. Medical malpractice carriers are also withdrawing coverage in certain states or substantially increasing premiums. If this trend continues or worsens, our customers may discontinue using our Lumivascular platform products and potential customers may opt against purchasing our Lumivascular platform products due to the cost or inability to procure insurance coverage.

 

44
 

 

Risks Related to Our Organizational Structure

 

Our stock price may be volatile, and purchasers of our common stock could incur substantial losses.

 

Our stock price has fluctuated significantly since our IPO and is likely to continue to fluctuate substantially. As a result of this price fluctuation, investors may experience losses on their investments in our stock. In addition, the development stage of our operations may make it difficult for investors to evaluate the success of our business to date and to assess our future viability. The market price for our common stock may be influenced by many factors, including:

 

 

●

sales of stock by our existing stockholders, including our affiliates;

 

 

●

market acceptance of our Lumivascular platform and products;

 

 

●

the results of our clinical trials;

 

 

●

changes in analysts’ estimates, investors’ perceptions, recommendations by securities analysts or our failure to achieve analysts’ and our own estimates;

 

 

●

the financial projections we may provide to the public, any changes in these projections or our failure to meet these projections;

 

 

●

actual or anticipated fluctuations in our financial condition and operating results;

 

 

●

quarterly variations in our or our competitors’ results of operations;

 

 

●

general market conditions and other factors unrelated to our operating performance or the operating performance of our competitors;

 

 

●

changes in operating performance and stock market valuations of other technology companies generally, or those in the medical device industry in particular;

 

 

●

the loss of key personnel, including changes in our board of directors and management;

 

 

●

legislation or regulation of our business;

 

 

●

lawsuits threatened or filed against us;

 

 

●

the announcement or approvals of new products or product enhancements by us or our competitors;

 

 

●

announcements related to patents issued to us or our competitors and to litigation; and

 

 

●

developments in our industry.

 

From time to time, our affiliates may sell stock for reasons due to their personal financial circumstances. These sales may be interpreted by other stockholders as an indication of our performance and result in subsequent sales of our stock that have the effect of creating downward pressure on the market price of our common stock. In addition, the stock prices of many companies in the medical device industry have experienced wide fluctuations that have often been unrelated to the operating performance of those companies.

 

The market price and trading volume of our common stock has been volatile over the past year, and it may continue to be volatile. During the year ended December 31, 2022, our common stock has closed as low as $0.96 and as high as $10.20 per share. We cannot predict the price at which our common stock will trade in the future and it may decline. The price at which our common stock trades may fluctuate significantly and may be influenced by many factors, including our financial results; developments generally affecting our industry; general economic, industry and market conditions; the depth and liquidity of the market for our common stock; investor perceptions of our business; reports by industry analysts; announcements by other market participants, including, among others, investors, our competitors, and our customers; regulatory action affecting our business; and the impact of other “Risk Factors” discussed in this Annual Report. In addition, changes in the trading price of our common stock may be inconsistent with our operating results and outlook. The volatility of the market price of our common stock may adversely affect investors’ ability to purchase or sell shares of our common stock.

 

45
 

 

We may fail to meet our publicly announced guidance or other expectations about our business and future operating results, which would cause our stock price to decline.

 

We have provided in the past and may provide guidance in the future about our business and future operating results. In developing this guidance, our management must make certain assumptions and judgments about our future performance, including projected revenues and the timing of regulatory approvals. Furthermore, analysts and investors may develop and publish their own projections of our business, which may form a consensus about our future performance. Our business results may vary significantly from such guidance or that consensus due to a number of factors, many of which are outside of our control, and which could adversely affect our operations and operating results. Furthermore, if we make downward revisions of our previously announced guidance, or if our publicly announced guidance of future operating results fails to meet expectations of securities analysts, investors or other interested parties, the price of our common stock would decline. 

 

If securities or industry analysts do not publish research or reports about our business, or publish negative reports about our business, our share price and trading volume could decline.

 

The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business, our market and our competitors. We do not have any control over these analysts. The analysts who previously published research reports on our stock following our IPO have discontinued coverage. We do not currently have analyst coverage. If analysts do not begin regularly publishing reports on us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline.

 

Sales of a substantial number of shares of our common stock in the public market, including by our existing stockholders, could cause our stock price to fall.

 

Sales of a substantial number of shares of our common stock in the public market, or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that these sales and others may have on the prevailing market price of our common stock.

 

We will need to raise additional funds through future equity or debt financings to meet our operational needs and capital requirements for product development, clinical trials and commercialization. We can provide no assurance that we will be successful in raising funds pursuant to additional equity or debt financings or that such funds will be raised at prices that do not create substantial dilution for our existing stockholders. Given our stock price, any financing that we undertake in the future could cause substantial dilution to our existing stockholders.

 

On March 28, 2022, we filed a universal shelf registration statement (the “Shelf Registration Statement”) to offer up to $50.0 million of our securities, which expires on March 29, 2025. On May 20, 2022, we entered into an “at-the-market” agreement pursuant to which we may offer and sell shares of our common stock pursuant to the Shelf Registration Statement. On August 3, 2022, we suspended the offer and sale of our common stock under our at-the-market program but may engage in such activity in the future. Due to the SEC’s “baby shelf rules,” which prohibit companies with a public float of less than $75 million from issuing securities under a shelf registration statement in excess of one-third of such company’s public float in a twelve-month period, we are limited in our ability to use the Shelf Registration Statement.

 

Our directors and employees may sell our stock through 10b5-1 trading plans or in the market during open windows under our insider trading policy without such plans in place. Sales of our common stock by our directors and employees could be perceived negatively by investors or cause downward pressure on our common stock and cause a reduction in the price of our common stock as a result. We have also registered shares of our common stock that we may issue under our employee equity incentive plans. These shares will be able to be sold freely in the public market upon issuance.

 

46
 

 

The requirements of being a public company may strain our resources, divert management’s attention and affect our ability to attract and retain executive management and qualified board members.

 

As a public company, we are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Act, the listing requirements of Nasdaq and other applicable securities laws, rules and regulations. Compliance with these laws, rules and regulations have increased our legal and financial compliance costs and will make some activities more difficult, time-consuming or costly and increase demand on our systems and resources, particularly after we are no longer an “emerging growth company.” The Exchange Act requires, among other things, that we file annual, quarterly and current reports with respect to our business and operating results. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. In order to maintain and, if required, improve our disclosure controls and procedures and internal control over financial reporting to meet this standard, significant resources and management oversight may be required. Our management and other personnel now need to devote a substantial amount of time to these compliance initiatives. As a result, management’s attention may be diverted from other business concerns and our costs and expenses will increase, which could harm our business and operating results. We may need to hire more employees in the future or engage outside consultants to comply with these requirements, which will increase our costs and expenses.

 

In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time consuming. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management’s time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and our business may be harmed.

 

We will incur additional compensation costs in the event that we decide to pay our executive officers cash compensation closer to that of executive officers of other public medical device companies, which would increase our general and administrative expense and could harm our profitability. Any future equity awards will also increase our compensation expense. We also expect that being a public company and compliance with applicable rules and regulations will make it more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified executive officers and members of our board of directors, particularly to serve on our audit committee and compensation committee.

 

As a result of disclosure of information in this Annual Report on Form 10-K and in other filings required of a public company, our business and financial condition will become more visible, which could be advantageous to our competitors and clients and could result in threatened or actual litigation, including by competitors and other third parties. If such claims are successful, our business and operating results could be harmed, and even if the claims are resolved in our favor, these claims, and the time and resources necessary to resolve them, could divert the resources of our management and harm our business and operating results.

 

Nasdaq may delist our securities from its exchange, which could harm our business and limit our stockholders’ liquidity.

 

Our common stock is currently listed on the Nasdaq Capital Market (“Nasdaq”), which has qualitative and quantitative listing criteria. However, we cannot assure you that our common stock will continue to be listed on Nasdaq in the future. In order to continue listing our common stock on Nasdaq, we must maintain certain financial, distribution and stock price levels. Generally, we must maintain a minimum amount in stockholders’ equity, a minimum number of holders of our common stock and a minimum bid price.

 

In particular, Nasdaq Listing Rule 5550(a) and 5550(b)(1) require us to maintain a minimum stockholders’ equity of $2.5 million. While we are currently in compliance with this rule, we may not be able to maintain compliance in the future. We have, since our inception, incurred net losses and expect we will continue to incur net losses. The decline in our equity is a direct result of our net loss. As we continue to incur losses, our accumulated deficit will continue to increase, which will have a negative impact on our equity balance. Therefore, if we do not continually raise funds through various equity offerings that have an accretive value to our equity, our equity balances will continue to decline. If we are unable to raise capital in a manner that provides accretive value to our equity, our stockholders’ equity may decrease below the minimum required by Nasdaq, which could result in Nasdaq delisting our common stock.

 

47
 

 

If Nasdaq delists our common stock from trading on its exchange and we are not able to list our securities on another national securities exchange, we expect our securities could be quoted on an over-the-counter market. If this were to occur, we could face significant material adverse consequences, including:

 

 

●

a limited availability of market quotations for our securities;

 

 

●

reduced liquidity for our securities;

 

 

●

a determination that our common stock is a “penny stock” which will require brokers trading in our common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities;

 

 

●

a limited amount of news and analyst coverage; and

 

 

●

a decreased ability to issue additional securities or obtain additional financing in the future.

 

The National Securities Markets Improvement Act of 1996, which is a federal statute, prevents or preempts the states from regulating the sale of certain securities, which are referred to as “covered securities.” If our common stock continues to be listed on NASDAQ, our common stock will be a covered security. Although the states are preempted from regulating the sale of our securities, the federal statute does allow the states to investigate companies if there is a suspicion of fraud, and, if there is a finding of fraudulent activity, then the states can regulate or bar the sale of covered securities in a particular case.

 

Anti-takeover provisions in our amended and restated certificate of incorporation and bylaws and Delaware law could discourage a takeover.

 

Our amended and restated certificate of incorporation and bylaws contain provisions that might enable our management to resist a takeover. These provisions include:

 

 

●

a classified board of directors;

 

 

●

advance notice requirements applicable to stockholders for matters to be brought before a meeting of stockholders and requirements as to the form and content of a stockholder’s notice;

 

 

●

a supermajority stockholder vote requirement for amending certain provisions of our amended and restated certificate of incorporation and bylaws;

 

 

●

the right to issue preferred stock without stockholder approval, which could be used to dilute the stock ownership of a potential hostile acquirer;

 

 

●

allowing stockholders to remove directors only for cause;

 

 

●

a requirement that the authorized number of directors may be changed only by resolution of the board of directors;

 

 

●

allowing all vacancies, including newly created directorships, to be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum, except as otherwise required by law;

 

 

●

a requirement that our stockholders may only take action at annual or special meetings of our stockholders and not by written consent;

 

 

●

limiting the forum for certain litigation against us to Delaware; and

 

 

●

limiting the persons that can call special meetings of our stockholders to our board of directors, the chairperson of our board of directors, the chief executive officer or the president (in the absence of a chief executive officer).

 

These provisions might discourage, delay or prevent a change in control of our company or a change in our management. The existence of these provisions could adversely affect the voting power of holders of common stock and limit the price that investors might be willing to pay in the future for shares of our common stock. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with any “interested” stockholder for a period of three years following the date on which the stockholder became an “interested” stockholder.

 

48
 

 

Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.

 

Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of fiduciary duty owed by any of our directors, officers or other employees to us or to our stockholders, (iii) any action asserting a claim arising pursuant to the Delaware General Corporation Law or our certificate of incorporation or bylaws (iv) any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws, or (v) any action asserting a claim governed by the internal affairs doctrine. This exclusive forum provision would not apply to suits brought to enforce any liability or duty created by the Securities Act or the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. To the extent that any such claims may be based upon federal law claims, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder.

 

This choice of forum provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers or employees. If a court were to find the choice of forum provision contained in our certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could have a material adverse effect on our business, financial condition, results of operations and prospects.

 

We have not paid cash dividends in the past and do not expect to pay cash dividends in the future, and any return on investment may be limited to the value of our stock.

 

We have never paid cash dividends and do not anticipate paying cash dividends in the foreseeable future. The payment of dividends will depend on our earnings, capital requirements, financial condition, prospects and other factors our board of directors may deem relevant. In addition, our Loan Agreement with CRG prohibits us from, among other things, paying any dividends or making any other distribution or payment on account of our common stock. The terms of our Series A preferred stock, Series B preferred stock and Series D preferred stock provide that we may not pay dividends on our common stock without concurrently declaring dividends on each. If we do not pay dividends, our stock may be less valuable because a return on your investment will only occur if you sell our common stock after our stock price appreciates. For more information on restrictions governing our ability to pay dividends, see the section titled “Dividend Policy” below.

 

CRG has the ability to exert significant control over matters pursuant to the protective provisions therein as well as the covenants and other restrictions in the Loan Agreement.

 

Even though Series A preferred stock is non-voting stock, our governing documents, as amended, have protective provisions that will require CRG to consent to certain significant Company events. For example, CRG’s consent would be necessary to create additional shares of Series A preferred stock, amend our organizational documents, or approve any merger, sale of assets, or other major corporate transaction. This consent requirement could delay or prevent any acquisition of our company on terms that other stockholders may desire, and may adversely affect the market price of our common stock.

 

We depend on our board of directors and the loss of one or more or our board members or an inability to attract and retain highly qualified members could harm our business.

 

Our success largely depends upon the continued services and involvement of the members of our board of directors and the loss of one or more of our directors could adversely affect us. Additionally, changes in the composition of our board resulting from the addition or departure of members could disrupt our business.

 

We must attract and retain highly qualified board members. Competition for these individuals can be intense. We have, from time to time, experienced, and we may experience in the future, difficulty in adding and retaining members of our board with appropriate qualifications. In addition, some states and other regulatory authorities, including Nasdaq, have adopted board diversity requirements, which mandate that companies have a minimum number of directors who meet specified diversity criteria, or otherwise require that companies disclose board diversity information. If we are unable to attract and retain qualified board members who meet such diversity criteria, we will be unable to comply with such requirements and could face enforcement or other regulatory actions.

 

49
 

 

ITEM 1B.    UNRESOLVED STAFF COMMENTS

 

None.

 

ITEM 2.    PROPERTIES

 

The Company’s operating lease obligations primarily consist of leased office, laboratory, and manufacturing space under a non-cancelable operating lease located in Redwood City, California. In addition to the minimum future lease commitments presented below, the lease requires the Company to pay property taxes, insurance, maintenance, and repair costs. The lease includes a rent holiday concession and escalation clauses for increased rent over the lease term. Rent expense is recognized in accordance with the Financial Accounting Standards Board (“FASB”), Accounting Standards Codification (“ASC”), 842, Leases, using the straight-line method over the term of the lease.

 

The lease will expire on November 30, 2024. The Company is obligated to pay approximately $5.8 million in base rent payments through November 2024, beginning on December 1, 2019. The weighted average remaining lease term as of December 31, 2022 is 1.9 years.

 

We believe that our current facilities are adequate for our current and anticipated future needs through at least 2023.

 

ITEM 3.    LEGAL PROCEEDINGS

 

We are not involved in any pending legal proceedings that we believe could have a material adverse effect on our financial condition, results of operations or cash flows. From time to time we may be involved in legal proceedings or investigations, which could harm our reputation, business and financial condition and divert the attention of our management from the operation of our business.

 

ITEM 4.    MINE SAFETY DISCLOSURES

 

Not applicable.

 

50
 

 

PART II

 

ITEM 5.    MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 

Our common stock began trading on the Nasdaq Global Market on January 30, 2015 and was transferred to the Nasdaq Capital Market on January 19, 2018, where it trades under the symbol “AVGR”.

 

HOLDERS OF RECORD

 

As of March 10, 2022, there were 8,614,508 shares of our common stock held by 123 holders of record of our common stock. The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.

 

DIVIDEND POLICY

 

Our Series A preferred stock carries an 8% cumulative dividend, which accumulates and is compounded annually. This cumulative dividend is payable in arrears on December 31 of each year, commencing with December 31, 2018, and at our option is payable in additional shares of Series A preferred stock. Additionally, the terms of our Series A preferred stock and Series B preferred stock provide that we may not declare dividends on the common stock without concurrently declaring dividends on such series of preferred stock in an amount equal to that payable had they been converted to common stock prior to the dividend. We have issued a total of 19,076 shares of Series A preferred stock to pay the preferred dividend to the holder of Series A preferred stock through December 31, 2022. Other than the preferred dividend on Series A preferred stock, we have never declared or paid any cash dividends on any of our capital stock. Except with respect to the Series A preferred stock’s cumulative dividend, we do not anticipate paying any dividends in the foreseeable future and currently intend to retain all available funds and any future earnings for use in the operation of our business and to finance the growth and development of our business.

 

Future determination as to the declaration and payment of dividends, if any, will be at the discretion of our board of directors and will depend on then existing conditions, including our operating results, financial condition, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant. In addition, our Loan Agreement with CRG prohibits us from paying any dividends or making any other distribution or payment on account of our common stock.

 

RECENT SALES OF UNREGISTERED SECURITIES

 

There were no sales of unregistered securities during fiscal 2022 other than those transactions previously reported to the SEC on a Quarterly Report on Form 10-Q or Current Report on Form 8-K.

 

PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS

 

None.

 

ITEM 6.    [RESERVED]

 

51
 

 

ITEM 7.    MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes included elsewhere in this Annual Report on Form 10-K. This discussion and other parts of this Annual Report on Form 10-K contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions, that are based on the beliefs of our management, as well as assumptions made by, and information currently available to, our management. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section of this Annual Report on Form 10-K entitled “Risk factors.”

 

Overview

 

We are a commercial-stage medical device company that designs, manufactures, and sells real-time high-definition image-guided, minimally invasive catheter-based systems that are used by physicians to treat patients with peripheral artery disease (“PAD”). Patients with PAD have a build-up of plaque in the arteries that supply blood to areas away from the heart, particularly the pelvis and legs. Our mission is to significantly improve the treatment of vascular disease through the introduction of products based on our Lumivascular platform, the only intravascular real-time high-definition image-guided system available in this market.

 

We design, manufacture, and sell a suite of products in the United States and select international markets. We are located in Redwood City, California. Our current Lumivascular platform consists of products including our Lightbox imaging console, the Ocelot and Tigereye family of devices, which are image-guided devices designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (“CTO”), and the Pantheris family of catheters, our image-guided atherectomy catheters which are designed to allow physicians to precisely remove arterial plaque in PAD patients.

 

We are in the process of developing CTO crossing devices to target the coronary CTO market. However, the market for medical devices in the coronary artery disease (“CAD”) space is highly competitive, dynamic, and marked by rapid and substantial technological development and product innovation and there is no guarantee that we will be successful in developing and commercializing any new CAD product. At this stage, we are working on understanding market requirements, and initiated the development process for the new CAD product, which we anticipate will require additional expenses.

 

We received CE Marking for our original Ocelot product in September 2011 and received from the U.S. Food and Drug Administration, or FDA, 510(k) clearance in November 2012. We received 510(k) clearance from the FDA for commercialization of Pantheris in October 2015. We received an additional 510(k) clearance for an enhanced version of Pantheris in March 2016 and commenced sales of Pantheris in the United States and select European countries promptly thereafter. In May 2018, we received 510(k) clearance from the FDA for our current next-generation version of Pantheris. In April 2019, we received 510(k) clearance from the FDA for our Pantheris Small Vessel (“SV”), a version of Pantheris targeting smaller vessels, and commenced sales in July 2019. In September 2020, we received 510(k) clearance of Tigereye, a next-generation CTO crossing system utilizing Avinger’s proprietary image-guided technology platform. Tigereye is a product line extension of Avinger’s Ocelot family of image-guided CTO crossing catheters. In January 2022, we received 510(k) clearance from the FDA for our Lightbox 3 imaging console, an advanced version of our Lightbox that allows for easy portability and offers significant reductions in size, weight, and production cost in comparison to the incumbent version.

 

In July 2022, we submitted a 510(k) application to the FDA for the Tigereye Spinning Tip (“ST”) device, a next generation CTO crossing system. Tigereye ST is a line extension of our Ocelot and Tigereye family of CTO crossing catheters. This new image-guided catheter has an integrated outer spinning tip that pairs with the rotation of the inner tip to penetrate challenging blockages and CTO caps. Tigereye ST incorporates an advanced shaft design for pushability and torque response and a three-marker system, similar to Ocelot's, to facilitate consistent image interpretation across the platform. Tigereye ST continues to provide the high definition, real-time intravascular imaging, user-controlled deflectable tip, and faster rotational speeds introduced to Avinger's CTO portfolio with the commercial launch of Tigereye in early 2021. The low-profile Tigereye ST has a working length of 140 cm and 5 French sheath.

 

In January 2023, we submitted a 510(k) application to the FDA for the Pantheris LV device, a next generation image guided atherectomy system for the treatment of larger vessels, such as the superficial femoral artery (“SFA”) and popliteal arteries. Pantheris LV is a line extension of our Pantheris and Pantheris SV family of atherectomy products. This catheter offers higher speed plaque excision for efficient removal of challenging occlusive tissue and multiple features to streamline and simplify user-operation, including enhanced tissue packing and removal, a radiopaque gauge to measure volume of plaque excised during the procedure, and enhanced guidewire management.

 

52
 

 

Current treatments for PAD, including bypass surgery, can be costly and may result in complications, high levels of post-surgery pain, and lengthy hospital stays and recovery times. Minimally invasive, or endovascular, treatments for PAD include stenting, angioplasty, and atherectomy, which is the use of a catheter-based device for the removal of plaque. These treatments all have limitations in their safety or efficacy profiles and frequently result in recurrence of the disease, also known as restenosis. We believe one of the main contributing factors to high restenosis rates for PAD patients treated with endovascular technologies is the amount of vascular injury that occurs during an intervention. Specifically, these treatments often disrupt the membrane between the outermost layers of the artery, which is referred to as the external elastic lamina (“EEL”).

 

We believe our Lumivascular platform is the only technology that offers radiation free, high-definition real-time visualization of the inside of the artery during PAD treatment through the use of optical coherence tomography (“OCT”), a high resolution, light-based, radiation-free imaging technology. Our Lumivascular platform provides physicians with high-definition real-time OCT images from the inside of an artery, and we believe Ocelot and Pantheris are the first products to offer intravascular visualization during CTO crossing and atherectomy, respectively. We believe this approach will significantly improve patient outcomes by providing physicians with a clearer picture of the artery using radiation-free image guidance during treatment, enabling them to better differentiate between plaque and healthy arterial structures. Our Lumivascular platform is designed to improve patient safety by enabling physicians to direct treatment towards the plaque, while avoiding damage to healthy portions of the artery.

 

During the first quarter of 2015, we completed enrollment of patients in VISION, a clinical trial designed to support our August 2015 510(k) submission to the FDA for our Pantheris atherectomy device. VISION was designed to evaluate the safety and efficacy of Pantheris to perform atherectomy using intravascular imaging and successfully achieved all primary and secondary safety and efficacy endpoints. We believe the data from VISION allows us to demonstrate that avoiding damage to healthy arterial structures, and in particular disruption of the external elastic lamina, which is the membrane between the outermost layers of the artery, reduces the likelihood of restenosis, or re-narrowing, of the diseased artery. Although the original VISION study protocol was not designed to follow patients beyond six months, we worked with 18 of the VISION sites to re-solicit consent from previous clinical trial patients in order for them to evaluate patient outcomes through 12 and 24 months following initial treatment. Data collection for the remaining patients from participating sites was completed in May 2017, and we released the final 12- and 24-month results for a total of 89 patients in July 2017.

 

During the fourth quarter of 2017, we began enrolling patients in INSIGHT, a clinical trial designed to support a submission to the FDA to expand the indication for our Pantheris atherectomy device to include the treatment of in-stent restenosis. Patient enrollment began in October 2017 and was completed in July 2021. Patient outcomes were evaluated at thirty days, six months and one year following treatment. In November 2021, we received 510(k) clearance from the FDA for this new clinical indication for treating in-stent restenosis with Pantheris using the data collected and analyzed from INSIGHT. We expect this will expand our addressable market for Pantheris to include a high-incidence disease state for which there are few available indicated or effective treatment options.

 

We are pursuing additional clinical data programs including a post-market study, IMAGE-BTK, that is designed to evaluate the safety and efficacy of Pantheris SV in the treatment of PAD lesions below-the-knee. We are currently enrolling patients, and we expect to complete enrollment in 2023.

 

We focus our direct sales force, marketing efforts and promotional activities on interventional cardiologists, vascular surgeons and interventional radiologists. We also work on developing strong relationships with physicians and hospitals that we have identified as key opinion leaders. Although our sales and marketing efforts are directed at these physicians because they are the primary users of our technology, we consider the hospitals and medical centers where the procedure is performed to be our customers, as they typically are responsible for purchasing our products. We are designing additional future products to be compatible with our Lumivascular platform, which we expect to enhance the value proposition for hospitals to invest in our technology. Pantheris qualifies for existing reimbursement codes currently utilized by other atherectomy products, further facilitating adoption of our products.

 

We have assembled a team with extensive medical device development and commercialization experience in both start-up and large, multi-national medical device companies. We assemble all of our catheter products at our manufacturing facility but certain critical processes, such as coating and sterilization, are performed by outside vendors. Our Lightbox 3 imaging console is assembled through a qualified contract manufacturer. We expect our current manufacturing facility in California, will be sufficient through at least 2023. We generated revenues of $8.8 million in 2020, $10.1 million in 2021 and $8.3 million in 2022. Revenue in 2020 was adversely affected by COVID-19 as hospitals deferred elective procedures, which among other things, created unpredictability in case volume. This unpredictability created more volatility in our revenues which continued to adversely affect our business in 2021 and 2022. The decline in revenue in 2022 was also attributable to the adverse effects of staffing shortages, resource constraints on our customers as hospitals deferred elective procedures, and the impact of a very competitive market for talent on the retention of our commercial team.

 

53
 

 

Recent Developments

 

COVID-19 and Hospital Capacity Update

 

As a result of the effects of the COVID-19 pandemic and hospital staffing shortages, we experienced a significant decline in sales, particularly as individuals, as well as hospitals and other medical providers, deferred elective procedures in response to COVID-19. We have continued to experience fluctuating sales as practitioners in certain jurisdictions were able to perform elective procedures while other jurisdictions were continuing to experience capacity issues. While at present, a majority of jurisdictions have eased restrictions on performing elective procedures, we cannot be certain that such restrictions will not be adopted again in the future. Some jurisdictions have experienced and continue to experience a resurgence in COVID-19 cases, which could prompt certain hospitals and other medical providers in such areas to again defer elective procedures or further prolong or reinstate existing restrictions on such procedures. If other jurisdictions experience a resurgence in COVID-19 cases, these jurisdictions may also prolong restrictions on elective procedures. Further, hospital staffing shortages, including issues independent of COVID-19-related capacity issues, have had and are likely to continue to have adverse impacts on our business and results of operations. This situation has created a significant amount of volatility in the medical industry which makes future developments and results difficult to predict.

 

We believe COVID-19 and the related burdens on the hospital systems have had and may continue to have an adverse effect on our ability to generate sales due to the fluctuating and unpredictable levels of capacity medical providers have to perform procedures that require the use of our products, as was the case since the onset of the pandemic in 2020. Consequently, it is unclear whether any reduction in sales from levels experienced during COVID-19 are temporary and whether such sales may be recoverable in the future. In addition, we have experienced disruptions in our manufacturing and supply chain, as well as delays in site initiation and patient enrollment for our clinical studies. If we are unable to successfully complete these or other clinical studies, our business and results of operations could be harmed.

 

The COVID-19 pandemic, staffing and capacity challenges at hospitals, and responses thereto have resulted in reduced consumer and investor confidence, instability in the credit and financial markets, volatile corporate profits, and reduced business and consumer spending, which could increase the cost of capital and/or limit the availability of capital to us in the future. These and other factors could adversely affect our ability to effectively manage our available cash and other resources.

 

Global Supply Chain

 

We are closely monitoring the impacts of the COVID-19 pandemic and general economic conditions on global supply chain, manufacturing, and logistics operations. As inflationary pressures increase, we anticipate that our production and operating costs may similarly increase, including costs and availability of materials and labor. In addition, COVID-19 and other events, including port closures or labor shortages, have resulted in manufacturing and shipping constraints generally. While we have had sufficient inventory on-hand to meet our current production requirements and customer demand, we have experienced some constraints with respect to the availability of certain materials and extended lead times from certain key suppliers. We have also experienced some delays in shipping products to our customers. Any significant delay or interruption in our supply chain could impair our ability to meet the demands of our customers in the future and could harm our business.

 

We may need to identify and qualify new suppliers in response to disruptions and difficulties experienced by some of our current suppliers. The process of identifying and qualifying suppliers is lengthy with no guarantee of ultimately mitigating the current issues experience by the Company. This process can include but is not limited to delays in qualification, quality issues on components, and higher costs to source these components. All of these issues may impair our ability to meet the demands of our customers in the future.

 

Reverse Stock Split

 

On March 11, 2022, our board of directors approved an amendment to our amended and restated certificate of incorporation to effect a 1-for-20 reverse stock split of our issued and outstanding common stock. The reverse stock split became effective on March 14, 2022. The par value of the common stock and preferred stock was not adjusted as a result of the reverse stock split. All common stock, stock options, and restricted stock units, and per share amounts in the financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock splits.

 

Principal Financial and Accounting Officer

 

As previously disclosed, our prior Chief Financial Officer left the Company on May 12, 2022. On July 21, 2022, our board of directors appointed Nabeel Subainati, who currently serves as our Vice President, Finance, as our Principal Financial Officer and Principal Accounting Officer.

 

54
 

 

Financing

 

During the years ended December 31, 2022 and 2021, our net loss and comprehensive loss was $17.6 million and $17.4 million, respectively. We have not been profitable since inception, and as of December 31, 2022, our accumulated deficit was $402.4 million. Since inception, we have financed our operations primarily through private and public placements of our preferred and common securities and, to a lesser extent, debt financing arrangements.

 

In September 2015, we entered into a Term Loan Agreement (the “Loan Agreement”) with CRG Partners III L.P. and certain of its affiliated funds (collectively, “CRG”), under which we were able to borrow up to $50.0 million on or before the end of the twenty-fourth (24th) month period commencing on the first Borrowing Date (as defined in the Loan Agreement), subject to certain terms and conditions. Under the Loan Agreement we borrowed $30.0 million on September 22, 2015 and an additional $10.0 million on June 15, 2016. Contemporaneously with the execution of the Loan Agreement, we entered into a Securities Purchase Agreement with CRG (the “Securities Purchase Agreement”), pursuant to which CRG purchased 44 shares of our common stock on September 22, 2015 at a price of $111,928 per share, which represents the 10-day average of closing prices of our common stock ending on September 21, 2015. Pursuant to the Securities Purchase Agreement, we filed a registration statement covering the resale of the shares sold to CRG and must comply with certain affirmative covenants during the time that such registration statement remains in effect.

 

On February 14, 2018, we entered into a Series A preferred stock Purchase Agreement (the “Series A Purchase Agreement”) with CRG, pursuant to which it agreed to convert $38.0 million of the outstanding principal amount of its senior secured term loan (plus the back-end fee and prepayment premium applicable thereto) under the Loan Agreement into a newly authorized Series A preferred stock. As discussed in the section of this report titled “Dividend Policy,” the holders of Series A preferred stock are entitled to receive annual accruing dividends at a rate of 8%, payable in additional shares of Series A preferred stock or cash, at our option. The shares of Series A preferred stock have no voting rights and rank senior to all other classes and series of the Company’s equity in terms of repayment and certain other rights.

 

We have entered into several amendments (collectively, the “Amendments”) to the Loan Agreement with CRG since September 2015, the most recent of which, was entered into on August 10, 2022. The Amendments, among other things: (1) extended the interest-only period through December 31, 2023; (2) extended the period during which we may elect to pay a portion of interest in payment-in-kind, or PIK, interest payments through December 31, 2023 so long as no Default (as defined in the Loan Agreement) has occurred and is continuing; (3) permitted us to make our entire interest payments in PIK interest payments through December 31, 2023 so long as no Default has occurred and is continuing; (4) extended the Stated Maturity Date (as defined in the Loan Agreement) to December 31, 2025; (5) reduced the minimum liquidity covenant to $3.5 million at all times; (6) eliminated the minimum revenue covenant for 2018, 2019 and 2020; (7) reduced the minimum revenue covenant to $8 million for 2021 and 2022; (8) added minimum revenue covenants of $10 million for 2023, $14.5 million for 2024 and $17 million for 2025; (9) changed the date under the on-going stand-alone representation regarding no “Material Adverse Change” to December 31, 2020; (10) amended the on-going stand-alone representation and stand-alone Event of Default (as defined in the Loan Agreement) regarding Material Adverse Change such that any adverse change in or effect upon the revenue of us and our subsidiaries due to the outbreak of COVID-19 will not constitute a Material Adverse Change; and (11) provided CRG with board observer rights.

 

Components of our Results of Operations

 

Revenues

 

All of our revenues are currently derived from sales of our various PAD catheters in the United States and select international markets, Lightbox consoles, and related services. We expect our revenues to increase in 2023 due to the introduction of our Tigereye ST and Pantheris LV products (provided that they receive 510(k) clearance), investments in sales personnel and easing conditions involving hospital staffing and capacity issues. For the year ended December 31, 2022, there was one customer that represented approximately 14% of revenues. For the year ended December 31, 2021, there was one customer that represented approximately 10% of revenues.

 

Revenues may fluctuate from quarter to quarter due to a variety of factors including capital equipment purchasing patterns that are typically increased towards the end of the calendar year and decreased in the first quarter and our ability to have product available in light of supply chain challenges. In addition, during the first quarter, our results can be harmed by adverse weather and by resetting of annual patient healthcare insurance plan deductibles, both of which may cause patients to delay elective procedures. In the third quarter, the number of elective procedures nationwide is historically lower than other quarters throughout the year, which we believe is primarily attributable to the summer vacations of physicians and their patients. Additionally, we believe COVID-19 and hospital capacity and staffing issues have had and will continue to have an adverse effect on our ability to generate sales due to the fluctuating and unpredictable levels of capacity medical providers have to perform procedures that require the use of our products.

 

55
 

 

Cost of Revenues and Gross Margin

 

Cost of revenues consists primarily of costs related to manufacturing overhead, materials and direct labor. We expense all warranty costs and inventory provisions as cost of revenues. We periodically write-down inventory for estimated excess, obsolete and non-sellable inventories based on assumptions about future demand, past usage, changes to manufacturing processes and overall market conditions. A significant portion of our cost of revenues currently consists of manufacturing overhead costs. These overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management. We expect overhead costs as a percentage of revenues to become less significant as our production volume increases. Cost of revenues also includes depreciation expense for production equipment, depreciation and related maintenance expense for placed Lightboxes held by customers and certain direct costs such as those incurred for shipping our products.

 

We calculate gross margin as gross profit divided by revenues. Our gross margin has been and will continue to be affected by a variety of factors, primarily production volumes, manufacturing costs, product yields, headcount, charges for excess and obsolete inventories and cost-reduction strategies. We intend to use our design, engineering and manufacturing capabilities to further advance and improve the efficiency of our manufacturing processes, which we believe will reduce costs and increase our gross margin. In the future, we may seek to manufacture certain of our products outside the United States to further reduce costs. Our gross margin will likely fluctuate from quarter to quarter as we continue to introduce new products and sales channels, and as we adopt new manufacturing processes and technologies.

 

Research and Development Expenses

 

Research and development (“R&D”), expenses consist primarily of engineering, product development, clinical and regulatory affairs, consulting services, materials, depreciation and other costs associated with products and technologies in development. These expenses include employee compensation, including stock-based compensation, supplies, materials, quality assurance expenses allocated to R&D programs, consulting, related travel expenses and facilities expenses. Clinical expenses include clinical trial design, clinical site reimbursement, data management, travel expenses and the cost of manufacturing products for clinical trials. We expect R&D expenses to vary over time depending on the level and timing of our new product development efforts, as well as our clinical development, clinical trial and other related activities.

 

Selling, General and Administrative Expenses

 

Selling, general and administrative (“SG&A”), expenses consist primarily of compensation for personnel, including stock-based compensation, selling and marketing functions, physician education programs, business development, finance, information technology and human resource functions. Other SG&A expenses include commissions, training, travel expenses, educational and promotional activities, marketing initiatives, market research and analysis, conferences and trade shows, professional services fees, including legal, audit and tax fees, insurance costs and general corporate expenses. We expect SG&A expenses to increase as we expand our commercial efforts and additional costs related to corporate matters.

 

Interest Expense, Net

 

Interest expense, net consists primarily of interest incurred on our outstanding indebtedness and non-cash interest related to the amortization of debt discount and issuance costs associated with our debt agreement.

 

Other (Expense) Income, Net

 

Other (expense) income, net primarily consists of gains and losses resulting from the remeasurement of foreign exchange transactions and other miscellaneous income and expenses.

 

56
 

 

Results of Operations:

 

   

Year Ended December 31,

  
   

2022

    

2021

  

(in thousands)

                

Revenues

   $ 8,273     $ 10,130  

Cost of revenues

     5,619       6,706  

Gross profit

     2,654       3,424  

Gross margin

     32

%

     34

%
                 

Operating expenses:

                

Research and development

     4,390       5,900  

Selling, general and administrative

     14,221       15,625  

Total operating expenses

     18,611       21,525  

Loss from operations

     (15,957

)

     (18,101

)

Interest expense, net

     (1,665

)

     (1,648

)

Other (expense) income, net

     (1

)

     2,337  

Net loss and comprehensive loss

   $ (17,623

)

   $ (17,412

)

 

Comparison of Years Ended December 31, 2022 and 2021

 

Revenues.

 

Revenues decreased $1.9 million, or 18%, to $8.3 million during the year ended December 31, 2022. The decrease in revenues reflects the fluctuating demand partially due to the adverse impacts of COVID-19 and hospital staffing shortages as capacity limitations in hospitals have limited the ability of practitioners to perform elective surgical procedures using our products in certain jurisdictions. In addition, we have experienced attrition and turnover of our sales professionals which has resulted in a less experienced sales team and limited our ability to maintain an adequate presence in some markets. The attrition and turnover are largely attributable to the increasingly competitive labor market landscape, which has had an adverse effect on our ability to generate revenues for the year ended December 31, 2022.

 

During the year ended December 31, 2021, we experienced increases in revenue largely due to easing restrictions from COVID-19 prompting the performance of a backlog of elective procedures that were previously deferred during 2020. We anticipate that COVID-19, hospital staffing and hospital capacity challenges, and the attrition and turnover of sales professionals could continue to impact demand for our products, for the foreseeable future.

 

Cost of Revenues and Gross Margin.

 

Cost of revenues decreased $1.1 million, or 16%, to $5.6 million during the year ended December 31, 2022. This decrease was primarily attributable to the decrease in revenues. Stock-based compensation expense within cost of revenues totaled $18,000 and $101,000 for the years ended December 31, 2022 and 2021, respectively.

 

Gross margin for the year ended December 31, 2022 decreased to 32% compared to 34% in the prior year. The decrease in gross margin was primarily due to the decrease in revenues and consequently a decrease in economies of scale relating to the decreased levels of production, partially offset by favorable changes in product mix.

 

Research and Development Expenses.

 

R&D expenses decreased $1.5 million or 26%, to $4.4 million during the year ended December 31, 2022. The decrease is primarily due to the completion of our development efforts on the Lightbox 3 last fiscal year. Stock-based compensation expense within R&D totaled $37,000 and $287,000 for the years ended December 31, 2022 and 2021, respectively. We expect R&D expense to fluctuate based on the ongoing product development of our coronary device and future iterations of existing product lines.

 

Selling, General and Administrative Expenses.

 

SG&A expenses decreased $1.4 million, or 9%, to $14.2 million during the year ended December 31, 2022. This decrease was primarily due to decreased variable compensation which include retention bonuses and decreased selling and marketing ancillary costs resulting from the decline in revenues. Stock-based compensation expense within SG&A totaled $72,000 and $627,000 for the years ended December 31, 2022 and 2021, respectively. We expect SG&A expense to fluctuate during 2023 largely due to variable compensation related to fluctuations in revenues.

 

57
 

 

Interest Expense, Net.

 

Interest expense, net is comprised of interest expense net of interest income. Interest expense remained flat compared to the prior year primarily due to the higher CRG loan balance from PIK interest being compounded, partially offset by increases in interest income due to the recent rising money market interest rates.

 

Other (Expense) Income, Net.

 

Other (expense) income, net primarily consists of gains and losses resulting from the remeasurement of foreign exchange transactions, which are typically a small percentage of transaction volume, and other miscellaneous income and expenses. Other income, net for the year ended December 31, 2022 decreased approximately $2.3 million or 100%, in comparison to the prior year as the loan pursuant to the Paycheck Protection Program under the CARES Act (the “PPP Loan”) was fully forgiven resulting in a gain on extinguishment of that debt, a one-time occurrence during the prior year period. Both periods also included remeasurement gains and losses from foreign exchange transactions resulting in nominal changes between periods.

 

Liquidity and Capital Resources

 

As of December 31, 2022, we had cash and cash equivalents of $14.6 million and an accumulated deficit of $402.4 million, compared to cash and cash equivalents of $19.5 million and an accumulated deficit of $384.8 million as of December 31, 2021. We expect to incur losses for the foreseeable future. We believe that our cash and cash equivalents of $14.6 million at December 31, 2022 and expected revenues, debt and financing activities and funds from operations will be sufficient to allow us to fund our current operations through the third quarter of 2023.

 

To date, we have financed our operations primarily through net proceeds from the issuance of our preferred stock, common stock and debt financings, our at the market program, our initial public offering (“IPO”), our follow-on public offerings and warrant issuances. We do not know when or if our operations will generate sufficient cash to fund our ongoing operations. Additional debt financing, if available, may involve covenants restricting our operations or our ability to incur additional debt. Any additional debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders and require significant debt service payments, which divert resources from other activities. Additional financing may not be available at all, or if available, may not be in amounts or on terms acceptable to us. If we are unable to obtain additional financing, we may be required to delay the development, commercialization and marketing of our products and we may be required to significantly scale back our business and operations.

 

In addition, the COVID-19 pandemic and responses thereto have resulted in reduced consumer and investor confidence, instability in the credit and financial markets, volatile corporate profits, restrictions on elective medical procedures, and reduced business and consumer spending, which could increase the cost of capital and/or limit the availability of capital to us. While we have taken certain actions to manage our available cash and other resources to mitigate the effects of COVID-19 and hospital staffing shortages, and related hospital capacity issues, on our business, there can be no assurance that such strategies will be successful in mitigating the negative impacts resulting from the COVID-19 pandemic on our liquidity and capital resources.

 

Currently all of our cash and cash equivalents are held at a single financial institution, Silicon Valley Bank. On March 10, 2023, the Federal Deposit Insurance Corporation announced that Silicon Valley Bank had been closed by the California Department of Financial Protection and Innovation. While we have regained access to our accounts at Silicon Valley Bank and are evaluating our banking relationships, future disruptions of financial institutions where we bank or have credit arrangements, or disruptions of the financial services industry in general, could adversely affect our ability to access our cash and cash equivalents. If we are unable to access our cash and cash equivalents as needed, our financial position and ability to operate our business will be adversely affected.

 

Equity Financings

 

On February 2, 2021, under our shelf registration statement, we completed a bought deal offering of 500,000 shares of common stock at an offering price of $28.80 per share. As a result, we received aggregate net proceeds of approximately $13.0 million after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses.

 

58
 

 

January 2022 Offering

 

On January 14, 2022, we entered into a securities purchase agreement with several institutional investors pursuant to which we agreed to sell and issue, in a registered direct offering (“January 2022 Offering”), an aggregate of 7,600 shares of our Series D Convertible Preferred Stock, par value of $0.001 per share, at an offering price of $1,000 per share which was convertible into common stock at a conversion price of $8.00 per share. Concurrently, we agreed to issue to these investors warrants to purchase up to an aggregate of 807,500 shares of our common stock (the “Common Warrants”). As a result, we received aggregate net proceeds of approximately $6.7 million after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses. During the year ended December 31, 2022, all 7,600 shares issued of Series D preferred stock were converted into a total of 950,000 shares of common stock. Consequently, there were no shares of Series D preferred stock outstanding as of December 31, 2022.

 

The 807,500 Common Warrants have an exercise price of $9.60 per share and became exercisable beginning July 14, 2022. The Common Warrants will expire five years following the time they become exercisable, or July 14, 2027. We also issued to the Placement Agent or its designees warrants to purchase up to an aggregate of 66,500 shares of common stock (the “Placement Agent Warrants”). The Placement Agent Warrants are subject to the same terms as the Common Warrants, except that the Placement Agent Warrants have an exercise price of $10.00 per share and a term of five years from the commencement of the sales pursuant to the January 2022 Offering, or January 12, 2027.

 

At The Market Offering Agreement

 

On May 20, 2022, we entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (the “Agent”), as sales agent, pursuant to which we may offer and sell shares of common stock, par value $0.001 per share (the “Shares”) up to an aggregate offering price of $7,000,000 from time to time, in an at the market public offering. Sales of the Shares are to be made at prevailing market prices at the time of sale, or as otherwise agreed with the Agent. The Agent will receive a commission from us of 3.0% of the gross proceeds of any Shares sold under the ATM Agreement. The Shares sold under the ATM Agreement are offered and sold pursuant to our shelf registration statement on Form S-3, which was initially filed with the SEC on March 29, 2022 and declared effective on April 7, 2022, and a prospectus supplement and the accompanying prospectus relating to the at the market program filed with the SEC on May 20, 2022. During the year ended December 31, 2022, we sold 585,603 shares of common stock pursuant to the ATM Agreement at an average price of $1.67 per share for aggregate proceeds of $1.0 million, of which approximately $29,000 was paid in the form of commissions to the Agent. Other than the ATM Agreement, we currently do not have any commitments to obtain additional funds. On August 3, 2022, we suspended sales under the ATM Agreement. We plan to reactivate the ATM Agreement in March 2023 and may resume sales in the future. However, there can be no assurance that we will be successful in acquiring additional funding through these means.

 

August 2022 Offering

 

On August 4, 2022, we entered into a securities purchase agreement with a single institutional investor for the issuance and sale of 1,484,019 shares of its common stock in a registered direct offering (“RD” or “Registered Direct”) at a purchase price of $1.752 per share, or pre-funded warrants in lieu thereof. In a concurrent private placement, we also agreed to issue and sell to the investor 1,369,864 shares of common stock at the same purchase price as in the registered direct offering, or pre-funded warrants in lieu thereof (“Private Placement” and together with the Registered Direct offering the “August 2022 Offering”). As a result, we received aggregate net proceeds of approximately $4.4 million after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses.

 

On August 4, 2022, we entered into a securities purchase agreement with a single institutional investor, pursuant to which we issued (i) 700,000 shares of common stock, and (ii) pre-funded warrants in lieu of common stock to purchase up to an aggregate of 784,019 shares of common stock in a registered direct offering ( the “Registered Direct Offering”) at a purchase price of $1.752 per share. In a concurrent private placement, we also issued and sold to the investor pre-funded warrants to purchase up to an aggregate of 1,369,864 shares of common stock at the same purchase price as in the Registered Direct Offering (the “Private Placement” and together with the Registered Direct Offering, the “August 2022 Offering”). As a result, we received aggregate net proceeds of approximately $4.4 million after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses.

 

59
 

 

In addition, we issued to the investor in the August 2022 Offering Series A preferred investment options to purchase up to 2,853,883 additional shares of our common stock and Series B preferred investment options to purchase up to 2,853,883 additional shares of our common stock (the “Preferred Investment Options”). The Series A preferred investment options have an exercise price of $1.502 per share, are immediately exercisable, and will expire five and one-half years from the date of issuance, or February 8, 2028, and the Series B preferred investment options have an exercise price of $1.502 per share, are immediately exercisable, and will expire two years from the date of issuance, or August 8, 2024. We also issued to the Placement Agent or its designees preferred investment options to purchase up to an aggregate of 171,233 shares of common stock (the “Placement Agent Preferred Investment Options”). The Placement Agent Preferred Investment Options are subject to the same terms as the Preferred Investment Options, except that the Placement Agent Preferred Investment Options have an exercise price of $2.19 per share and a term of five years from the commencement of the sales pursuant to the August 2022 Offering, or August 3, 2027.

 

PPP Loan

 

On April 23, 2020, we received PPP loan proceeds of $2.3 million. The PPP Loan, which was in the form of a promissory note, dated April 20, 2020 (the “Promissory Note”), between us and Silicon Valley Bank (“SVB”) as the lender, was set to mature on April 20, 2022 and bore interest at a fixed rate of 1% per annum.

 

As previously disclosed, the PPP was administered by the U.S. Small Business Administration (the “SBA”). The SBA was given the authority under the PPP to forgive loans if all employees were kept on the payroll for a required period and the loan proceeds were used for payroll, rent and utilities. We applied for debt forgiveness in December 2020. On April 17, 2021, we were notified by SVB that its PPP Loan had been fully forgiven by the SBA and that there was no remaining balance on the PPP Loan. We recorded the forgiveness as other income in April 2021 in the amount of $2.4 million, of which approximately $23,000 was accrued interest.

 

Contractual Obligations

 

Our principal obligations consist of the operating lease for our facility, our Loan Agreement with CRG and non-cancelable purchase commitments. The following table sets out, as of December 31, 2022, our contractual obligations due by period (in thousands):

 

   

Payments Due by Period

  
   

Less Than
1 Year

    

2 - 3
Years

    

4-5 Years

    

More
Than 5
Years

    

Total

  

Operating lease obligations (1)

   $ 1,203     $ 1,138     $ —     $ —     $ 2,341  

CRG Loan (2)

     —       19,384       —       —       19,384  

Noncancelable purchase commitments (3)

     1,079       34       —       —       1,113  
    $ 2,282     $ 20,556     $ —     $ —     $ 22,838  

 

(1)

Operating lease obligations primarily consist of leased office, laboratory, and manufacturing space under a non-cancelable operating lease. In addition to the minimum future lease commitments presented above, the lease requires the Company to pay property taxes, insurance, maintenance, and repair costs. The lease will expire on November 30, 2024.

(2)

The total CRG Loan amount, shown as borrowings on the balance sheet as of December 31, 2022, is $14.2 million. The contractual obligation in the table above of $19.4 million under the CRG Loan includes future interest to be accrued but not paid in cash as well as a $2.2 million back-end fee to be paid in December 2025 upon maturity of the CRG Loan which is being accreted. Refer to Item 8, Financial Statements and Supplementary Data, Footnote 7 for additional details.

(3)

Noncancelable purchase commitments consist of agreements to purchase goods and services entered into in the ordinary course of business.

 

60
 

 

CRG Loan

 

We have entered into several amendments to the Loan Agreement (the “Amendments”) with CRG since September 2015, the most recent of which was entered into on August 10, 2022. The Amendments, among other things: (1) extended the interest-only period through December 31, 2023; (2) extended the period during which we may elect to pay a portion of interest in payment-in-kind, or PIK, interest payments through December 31, 2023 so long as no Default (as defined in the Loan Agreement) has occurred and is continuing; (3) permitted us to make the entire interest payments in PIK interest payments for through December 31, 2023 so long as no Default has occurred and is continuing; (4) extended the Stated Maturity Date (as defined in the Loan Agreement) to December 31, 2025; (5) reduced the minimum liquidity covenant to $3.5 million at all times; (6) eliminated the minimum revenue covenant for 2018, 2019 and 2020; (7) reduced the minimum revenue covenant to $8 million for 2021 and 2022; (8) added minimum revenue covenants of $10 million for 2023, $14.5 million for 2024 and $17 million for 2025; (9) changed the date under the on-going stand-alone representation regarding no “Material Adverse Change” to December 31, 2020; (10) amended the on-going stand-alone representation and stand-alone Event of Default (as defined in the Loan Agreement) regarding Material Adverse Change such that any adverse change in or effect upon our revenue and our subsidiaries due to the outbreak of COVID-19 will not constitute a Material Adverse Change; and (11) provided CRG with board observer rights. The total Loan amount under the Loan Agreement (the “CRG Loan”), shown as short-term borrowings on the balance sheet as of December 31, 2022, is $14.2 million. However, upon maturity of the obligations under the Loan Agreement in December 2025, we will be obligated to pay $19.4 million under the Loan Agreement, which includes future interest to be accrued but not paid in cash as well as a $2.2 million back-end fee to be paid in December 2025 upon maturity of the CRG Loan which is being accreted to the maturity date. Due to the substantial doubt about our ability to continue operating as a going concern and the “Material Adverse Change” clause under the Loan Agreement, the entire amount of outstanding borrowings at December 31, 2022 and 2021 is classified as current. CRG has not purported that any Event of Default (as defined in the Loan Agreement) has occurred as a result a “Material Adverse Change” under the Loan Agreement. Refer to Item 8, Financial Statements and Supplementary Data, Footnote 7 for additional details.

 

Lease Agreements

 

Our operating lease obligations primarily consist of leased office, laboratory, and manufacturing space under a non-cancelable operating lease. In addition to the minimum future lease commitments presented below, the lease requires us to pay property taxes, insurance, maintenance, and repair costs. The lease includes a rent holiday concession and escalation clauses for increased rent over the lease term. Rent expense is recognized using the straight-line method over the term of the lease.

 

The lease will expire on November 30, 2024. We are obligated to pay a total approximately $5.8 million in base rent payments through November 2024, which began on December 1, 2019. The weighted average remaining lease term as of December 31, 2022 is 1.9 years.

 

Cash Flows:

 

   

Year Ended December 31,

  
   

2022

    

2021

  

 (in thousands)

                

Net cash (used in) provided by:

                

Operating activities

   $ (16,760

)

   $ (15,697

)

Investing activities

     (51

)

     (34

)

Financing activities

     11,917       13,043  

Net change in cash and cash equivalents

   $ (4,894

)

   $ (2,688

)

 

Net Cash Used in Operating Activities

 

Net cash used in operating activities for the year ended December 31, 2022 was $16.8 million, consisting primarily of a net loss of $17.6 million and an increase in net operating assets of $1.7 million, partially offset by non-cash charges of $2.6 million. Non-cash charges largely related to non-cash interest expense of $1.9 million. The increase in net operating assets was primarily due to the increase in inventory of $1.4 million due to purchases of inventory components in anticipation of forecasted demand in light of extended lead times and a decrease in accounts payable due to timing of payments and overall, less expenditures. These increases were partially offset by the increase in other long-term liabilities as certain variable compensation continues to accrue.

 

61
 

 

Net cash used in operating activities for the year ended December 31, 2021 was $15.7 million, consisting primarily of a net loss of $17.4 million and a decrease in net operating assets of approximately $0.4 million, partially offset by net non-cash charges of $1.3 million. We recognized a non-cash gain on extinguishment of debt due to the forgiveness of the PPP Loan of $2.4 million. This gain was partially offset by non-cash charges related to stock-based compensation of $1.0 million, non-cash interest expense of $1.6 million, and depreciation of $0.7 million. The decrease in net operating assets was primarily due to an increase in accounts payable and other long-term liabilities; partially offset by the increase in inventory and a decrease in accrued compensation.

 

Net Cash Used in Investing Activities

 

Net cash used in investing activities during both the years ended December 31, 2022 and 2021 consisted of purchases of property and equipment.

 

Net Cash Provided by Financing Activities

 

Net cash provided by financing activities for the year ended December 31, 2022 of $11.9 million primarily relates to proceeds of $6.7 million from the issuance of preferred stock and warrants in the January 2022 Offering, net of commissions and various issuance costs, and proceeds of $4.4 million from the issuance of common stock and preferred investment options in the August 2022 Offering. We also received approximately $0.8 million, net of commissions and various issuance costs, from the sale of common stock pursuant to the ATM Agreement.

 

Net cash provided by financing activities for the year ended December 31, 2021 of $13.0 million relates to proceeds from the issuance of common stock in our February 2021 public offering, net of various issuance costs.

 

Critical Accounting Policies and Estimates

 

Management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions for the reported amounts of assets, liabilities, revenues, expenses and related disclosures of contingent assets and liabilities. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material.

 

While our significant accounting policies are more fully described in Note 2 of our financial statements included in this Annual Report on Form 10-K, we believe the following discussion addresses our most critical accounting policies, which are those that are most important to our financial condition and results of operations and require our most difficult, subjective and complex judgments.

 

Revenue Recognition

 

The Company’s revenues are derived from (1) sale of Lightbox consoles, (2) sale of disposables, which consist of catheters and accessories, and (3) sale of customer service contracts and maintenance. The Company sells its products directly to hospitals and medical centers as well as through distributors. The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. The Company’s revenues are measured based on consideration specified in the contract with each customer, net of any sales incentives and taxes collected from customers that are remitted to government authorities. For all sales, the Company uses either a signed agreement or a binding purchase order as evidence of an arrangement. The Company’s revenue recognition policies generally result in revenue recognition at the following points:

 

 

1.

Lightbox console sales: Provided all other criteria for revenue recognition have been met, the Company recognizes revenue for Lightbox console sales directly to end customers when delivery and acceptance occurs, which is defined as receipt by the Company of an executed form that the installation process is complete.

 

 

2.

Sales of disposables: Disposable revenues consist of sales of the Company’s catheters and accessories and are recognized when the product has shipped, risk of loss and title has passed to the customer and collectability is reasonably assured.
   

 
 

3.

Service revenue: Service contract revenue consists of preventative maintenance, upgrades, and service contracts. Service contracts are recognized ratably over the term of the service period and maintenance contract revenue is recognized when work is completed. To date, service revenue has been insignificant.

 

62
 

 

The Company offers its customers the ability to purchase or lease the Lightbox console. In addition, the Company provides a Lightbox under a limited commercial evaluation program to allow accounts to install and utilize the Lightbox for a limited trial period. When a Lightbox is placed under a lease agreement or under a commercial evaluation program, the Company retains title to the equipment and it remains capitalized on its balance sheet under property and equipment. Depreciation expense on these placed Lightboxes is recorded to cost of revenues on a straight-line basis. The costs to maintain these placed Lightboxes are charged to cost of revenues as incurred.

 

The Company evaluates its lease and commercial evaluation program agreements and accounts for these contracts under the guidance in Accounting Standards Codification (“ASC”) 842, Leases and ASU No. 2014 09, Revenue from Contracts with Customers (Topic 606). The guidance requires arrangement consideration to be allocated between a lease deliverable and a non-lease deliverable based upon the relative selling-price of the deliverables.

 

The Company assessed whether the embedded lease is an operating lease or sales-type lease. Based on the Company’s assessment of the guidance and given that any payments under the lease agreements are dependent upon contingent future sales, it was determined that collectability of the minimum lease payments is not reasonably predictable. Accordingly, the Company concluded the embedded lease did not meet the criteria of a sales-type lease and accounts for it as an operating lease. The Company recognizes revenue allocated to the lease as the contingent disposable product purchases are delivered and are included in revenues within the statement of operations and comprehensive loss.

 

For sales through distributors, the Company recognizes revenue when control of the product transfers from the Company to the distributor. The distributors are responsible for all marketing, sales, training and warranty in their respective territories. The standard terms and conditions contained in the Company’s distribution agreements do not provide price protection or stock rotation rights to any of its distributors. In addition, its distributor agreements do not allow the distributor to return or exchange products, and the distributor is obligated to pay the Company upon invoice regardless of its ability to resell the product.

 

Inventories

 

Inventories are valued at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method for all inventories. The Company’s policy is to write down inventory that has expired or become obsolete, inventory that has a cost basis in excess of its expected net realizable value, and inventory in excess of expected requirements. At each balance sheet date, management evaluates inventories for excess quantities, and obsolescence. This evaluation by management includes analysis of historical sales levels by product, projections of future demand, the risk of technological or competitive obsolescence for products, general market conditions, as well as the feasibility of reworking or using excess or obsolete products or components in the production or assembly of other products that are not obsolete or for which there are not excess quantities in inventory. To the extent that management determines there are excess or obsolete inventory, management adjusts the carrying value to estimated net realizable value. When quantities on hand exceed sales forecasts, a write-down is recorded for such excess inventories along with a corresponding charge to cost of revenues. The estimate of excess quantities is subjective and primarily dependent on the estimates of future demand for a particular product. Specifically, the future demand is derived based on our historical experience, from discussion with users of our products and general market conditions. Changes in assumptions of product demand could have a significant impact on the amount of write-down recorded. Inventory used in clinical trials is expensed at the time of production and recorded as research and development expense if the inventory is contractually being provided at no cost to the clinical site. The cost of inventories are regularly reviewed against estimated market value and record a lower of cost or market reserve for inventories that have a cost in excess of estimated market value, which could have a material impact on our gross margin and inventory balances based on additional write-downs to net realizable value or a benefit from inventories previously written down.

 

63
 

 

ITEM 7A.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Interest Rate Risk

 

The risk associated with fluctuating interest rates is primarily limited to our cash equivalents, which are carried at quoted market prices. Due to the short-term maturities and low risk profile of our cash equivalents, an immediate 100 basis point change in interest rates would not have a material effect on the fair value of our cash equivalents. We do not currently use or plan to use financial derivatives in our investment portfolio.

 

Credit Risk

 

As of December 31, 2022, our cash and cash equivalents were maintained with one financial institution in the United States, and our current deposits are in excess of insured limits. We have reviewed the financial statements of this institution and believe it has sufficient assets and liquidity to conduct its operations in the ordinary course of business with little or no credit risk to us.

 

Our accounts receivable primarily relate to revenues from the sale of our Lumivascular platform products to hospitals and medical centers in the United States. At December 31, 2022, there was no customer that represented 10% or more of the Company’s accounts receivable, whereas at December 31 2021, there was one customer that represented 21% of accounts receivable. For the years ended December 31, 2022 and 2021, there was one customer that represented approximately 14% and 10% of revenues, respectively.

 

Foreign Currency Risk

 

Our business is primarily conducted in U.S. dollars. Any transactions that may be conducted in foreign currencies are not expected to have a material effect on our results of operations, financial position or cash flows.

 

ITEM 8.    FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 

The information required by this item appears in a separate section of this Annual Report on Form 10-K beginning on page F-1 and is incorporated herein by reference.

 

ITEM 9.    CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 

None.

 

ITEM 9A.    CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Securities Exchange Act of 1934, as amended, or the Exchange Act, and the rules and regulations thereunder, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

 

As required by Rule 13a-15(b) under the Exchange Act, our management, under the supervision and with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of December 31, 2022. Based on such evaluation, our principal executive officer and principal financial officer have concluded that, as of December 31, 2022, our disclosure controls and procedures were effective.

 

64
 

 

Management’s Annual Report on Internal Control Over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule 13a-15(f) of the Exchange Act. Our management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, management concluded that our internal control over financial reporting was effective as of December 31, 2022.

 

This Annual Report on Form 10-K does not include an attestation report of our registered public accounting firm on our internal control over financial reporting We are currently a non-accelerated filer and are therefore not required to provide an attestation report on our internal control over financial reporting until such time as we are an accelerated filer or large accelerated filer.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal controls over financial reporting identified in management’s evaluation pursuant to Rules 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended December 31, 2022 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Inherent Limitations on Effectiveness of Controls

 

Our management, including our chief executive officer and chief financial officer, believes that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However, our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

 

ITEM 9B.    OTHER INFORMATION

 

On March 14, 2023, the Company and Nabeel Subainati entered into an amendment (the “CIC Amendment”) to Mr. Subainati’s Change in Control and Severance Agreement, dated May 16, 2022, to (i) provide that, in order to be eligible to receive the severance benefits in the event of a termination in connection with a change of control, the termination of Mr. Subainati’s employment must occur upon or within twelve months of such change of control, (ii) revise the amount of severance pay to equal Mr. Subainati’s monthly base salary and prorated target bonus, as then in effect, for a period of six months plus one month for every year of service completed, not to exceed an aggregate of twelve months, and (iii) provide that if Mr. Subainati continues to be employed by the Company (or any successor) on the date that is twelve months following a change of control, he will be entitled to receive, in a lump sum bonus payment, an amount equal to the severance pay he would have received if his employment had been terminated within twelve months following a change of control. The foregoing description of the CIC Amendment does not purport to be complete and is qualified in its entirety by reference to the text of the CIC Amendment, which is filed as Exhibit 10.58 to this Annual Report on Form 10-K and incorporated herein by reference.

 

ITEM 9C.    DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

 

Not applicable.

 

65
 

 

PART III

 

ITEM 10.    DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

 

Directors

 

Our business affairs are managed under the direction of our board of directors, which is currently composed of four members.  Three of our directors are independent within the meaning of the listing standards of The Nasdaq Stock Market, or Nasdaq.  Our board of directors is divided into three staggered classes of directors.  At each annual meeting of stockholders, a class of directors will be elected for a three-year term to succeed the same class whose term is then expiring.

 

The following table sets forth the names, ages as of March 1, 2023 and certain other information for each of the directors with terms expiring at the 2023 annual meeting of stockholders (the “Annual Meeting”) (who are also nominees for election as a director at the Annual Meeting) and for each of the continuing members of our board of directors:

 

 

Class

  

Age

  

Position

  

Director

Since

  

Current

Term

Expires

  

Directors

                   

James G. Cullen(1)(2)(3)

III

  

80

  

Director and Chairman of the Board of Directors

  

2014

  

2024

  

Jeffrey M. Soinski

I

  

61

  

President, Chief Executive Officer and Director

  

2014

  

2025

  

James B. McElwee(1)(2)(3)

II

  

70

  

Director

  

2011

  

2023

  

Tamara N. Elias(1)(2)(3)

III

  

51

  

Director

  

2019

  

2024

  

 

 

(1)

Member of our audit committee

(2)

Member of our compensation committee

(3)

Member of our nominating and corporate governance committee

 

Jeffrey M. Soinski has served as our President, Chief Executive Officer and a member of our Board of Directors since December 2014. From its formation in September 2009 until the acquisition of its Unisyn business by GE Healthcare in May 2013, Mr. Soinski served as Chief Executive Officer of Medical Imaging Holdings and its primary operating company Unisyn Medical Technologies, a national provider of technology-enabled products and services to the medical imaging industry. Mr. Soinski was a Director of Medical Imaging Holdings and its remaining operating company Consensys Imaging Service from September 2009 until its sale in October 2017. Mr. Soinski served periodically as a Special Venture Partner from July 2008 to June 2013 and as a Special Investment Partner since October 2016 for Galen Partners, a leading healthcare-focused private equity firm, which included Medical Imaging Holdings as one of its portfolio companies. From 2001 until its acquisition by C.R. Bard in 2008, Mr. Soinski was President and CEO of Specialized Health Products International, a publicly-traded manufacturer and marketer of proprietary safety medical products. He served on the board of directors of Merriman Holdings, parent of Merriman Capital, a San Francisco-based investment banking and brokerage firm, from 2008 until March 2016. Mr. Soinski holds a B.A. degree from Dartmouth College.

 

We believe Mr. Soinski is qualified to serve as a member of our board of directors because of his extensive corporate finance and business strategy experience as well as his experience with public companies.

 

James G. Cullen has served as a member of our board of directors since December 2014, as our Lead Independent Director since January 2015 and as our Non-Executive Chairman since December 2017. During the last five years, Mr. Cullen has held board and committee positions with various companies. Mr. Cullen is currently a director of Keysight Technologies, which was spun out of Agilent Technologies, where he was previously a director. Mr. Cullen previously served as a director and chairman of the audit committee of Johnson & Johnson and as a director and member of the investment and finance committees of Prudential Financial. From 1993 to 2000, Mr. Cullen was President, Vice Chairman and Chief Operating Officer of Bell Atlantic Corporation (now Verizon). From 1989 to 1993, he was President and Chief Executive Officer of Bell Atlantic-New Jersey. Mr. Cullen holds a B.A. in Economics from Rutgers University and an M.S. in Management Science from the Massachusetts Institute of Technology.

 

We believe Mr. Cullen is qualified to serve as a member of our board of directors because of his extensive experience serving on the boards of public companies as well as his financial and business expertise.

 

66
 

 

James B. McElwee has served as a member of our board of directors since March 2011. Mr. McElwee has served as an independent venture capital investor since 2010. Mr. McElwee served as general partner of Weston Presidio, a private equity and venture capital firm, from 1992 to 2010. During his tenure as a general partner and member of the investment committee, Weston Presidio led the start up financing of JetBlue Airways and made investments in Fender Musical Instruments, The Coffee Connection, Guitar Center, Mapquest, Party City, Petzazz, RE/MAX, and others.

 

We believe Mr. McElwee is qualified to serve as a member of our board of directors because of his substantial corporate development and business strategy expertise gained in the venture capital industry.

 

Tamara N. Elias, M.D., was appointed to our board of directors in December 2019. Dr. Elias currently serves as SVP, Strategy and Business Incubation at Nuance Communications, a Microsoft Company. Previously she served as VP, Head of Global Partnerships at Merck. From 2020 to 2022. Dr. Elias was VP, Clinical Product Development at Aetna from 2018 to 2020. From 2015 to 2017, Dr. Elias was Vice President of Corporate Strategy and Business Development for the $8 billion medical segment at Becton Dickinson. From 2007 to 2015, Dr. Elias was a Partner with Essex Woodlands Healthcare Partners, a healthcare only growth equity firm founded in 1985. Earlier in her career, Dr. Elias was a management consultant at McKinsey, advising pharmaceutical, diagnostic and device companies in R&D, product commercialization and M&A. She currently serves on the board of REVA Medical BehaVR. Dr. Elias has previously served on the boards of several private companies, including Millennium Pharmacy Systems (sold to PharMerica), BreatheAmerica and Influence Health (sold to Healthgrades) as well as on the public company board of ATS Medical (sold to Medtronic). Dr. Elias holds degrees in Biology and Anthropology from Yale University, and an M.D. from The Johns Hopkins School of Medicine. She trained as a general surgeon at Massachusetts General Hospital.

 

We believe Dr. Elias is qualified to serve as a member of our board of directors because of her substantial corporate development and business strategy expertise and her experience in the healthcare industry.

 

Executive Officers

 

The following table identifies certain information about our executive officers as of March 1, 2023.  Our executive officers are appointed by, and serve at the discretion of, our board of directors.  Each of our executive officers serves at the discretion of our board of directors and holds office until his successor is duly elected and qualified or until his earlier resignation or removal.  There are no family relationships among any of our directors or executive officers.

 

Name

  

Age

  

Title

Jeffrey M. Soinski

  

61

  

President, Chief Executive Officer and Director

Himanshu N. Patel

  

63

  

Chief Technology Officer

Nabeel Subainati

  

39

  

Vice President, Finance, Principal Financial Officer and Principal Accounting Officer

 

 

For a brief biography of Mr. Soinski, please see the section of this Annual Report on Form 10-K titled “Directors.”

 

Himanshu N. Patel. co-founded Avinger in 2007 and has served as our Chief Technology Officer from January 2011 to November 2011 and then since October 2013. From September 1999 to February 2007, Mr. Patel held various research and development positions, including Director of Advanced Technologies, at FoxHollow Technologies. Mr. Patel previously held research and development positions at EndoTex Interventional Systems, General Surgical Innovations and Ethicon, a Johnson and Johnson company. Mr. Patel holds a B.S. in Mechanical Engineering from M.S. University of Baroda, India, and an M.S. in Mechanical Engineering from the University of Florida.

 

Nabeel Subainati has served in multiple capacities since January 2020. Currently Mr. Subainati is serving as the Company’s Vice President, Finance, formerly Mr. Subainati held the position of Vice President, Corporate Controller. He was appointed to serve as our Principal Financial Officer and Principal Accounting Officer effective as of July 21, 2022. Prior to joining the Company, Mr. Subainati served as Controller at Crossbar, Inc., a semiconductor memory technology provider from July 2018 until January 2020. Mr. Subainati previously served as Corporate Controller of Sigma Designs, Inc. a Nasdaq-listed integrated system-on-chip solutions provider for home and industrial applications, from May 2014 until its acquisition by Silicon Labs, Inc. in June 2018. Earlier in his career Mr. Subainati worked at Ernst & Young and Deloitte. He received a B.S. in business administration with an accounting major from Santa Clara University. He earned and currently holds an active CPA designation.

 

67
 

 

Code of Business Conduct

 

We have adopted a code of business conduct that applies to all of our employees, officers and directors, including those officers responsible for financial reporting. The code of business conduct is available on our website at www. investors.avinger.com/governance. Updates to or waivers of the code will be disclosed on the same website. We intend to satisfy the disclosure requirement under Item 5.05 of Form 8-K regarding any amendment to, or waiver of, any provision of the code in the future by disclosing such information on our website.

 

Board Leadership Structure

 

We believe that the structure of our board of directors and its committees provides strong overall management of our company.  Our board of directors does not have a formal policy on whether the roles of Chief Executive Officer and Chairman of our board of directors should be separate.  However, Messrs. Soinski and Cullen, respectively, hold these positions at present.

 

Our Chief Executive Officer, Mr. Soinski, is responsible for setting the strategic direction of our company, the general management and operation of the business and the guidance and oversight of senior management.  In his capacity as Chairman of our board of directors, Mr. Cullen is also responsible for the guidance and oversight of senior management, monitoring the content, quality and timeliness of information sent to our board of directors, consultation with our board of directors regarding the oversight of our business affairs, presiding over meetings of our board of directors and performing such additional duties as our Board may otherwise determine and delegate.  At the end of each board meeting, the independent directors are expected to meet in executive session, without Mr. Soinski present.  Following each meeting, Mr. Cullen is expected to provide feedback to Mr. Soinski on his performance and the performance of our employees during the meeting and to recommend new agenda items for the next meeting.

 

Director Independence

 

Our common stock is listed on The Nasdaq Capital Market.  Under the Nasdaq listing standards, independent directors must comprise a majority of a listed company’s board of directors.  In addition, the Nasdaq listing standards require that, subject to specified exceptions, each member of a listed company’s audit, compensation, and nominating and corporate governance committees be independent.  Under the Nasdaq listing standards, a director will only qualify as an “independent director” if, in the opinion of that listed company’s board of directors, that director does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.

 

Audit committee members must also satisfy the additional independence criteria set forth in Rule 10A-3 under the Securities Exchange Act of 1934, as amended, or the “Exchange Act, and the Nasdaq listing standards.  Compensation committee members must also satisfy the additional independence criteria set forth in Rule 10C-1 under the Exchange Act and the Nasdaq listing standards. 

 

Our board of directors has undertaken a review of the independence of each of our directors.  Based on information provided by each director concerning his background, employment and affiliations, our board of directors has determined that Messrs. Cullen, McElwee and Dr. Elias do not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is “independent” as that term is defined under the Nasdaq listing standards.  In making these determinations, our board of directors considered the current and prior relationships that each non-employee director has with our company and all other facts and circumstances our board of directors deemed relevant in determining their independence, including the beneficial ownership of our capital stock by each non-employee director, and the transactions involving them described below under the heading “Related Person Transactions.”

 

Board Meetings and Committees

 

During our fiscal year ended December 31, 2022, our board of directors held 9 meetings (including regularly scheduled and special meetings), and each director attended at least 75% of the aggregate of (i) the total number of meetings of our board of directors held during the period for which he or she has been a director and (ii) the total number of meetings held by all committees of our board of directors on which he or she served during the periods that he or she served.  All of our directors who were directors at the time attended our 2022 annual meeting of stockholders telephonically.

 

Although we do not have a formal policy regarding attendance by members of our board of directors at annual meetings of stockholders, we strongly encourage our directors to attend.

 

Our board of directors has established an audit committee, a compensation committee and a nominating and corporate governance committee.  The composition and responsibilities of each of the committees of our board of directors are described below.  Members will serve on these committees until their resignation or until as otherwise determined by our board of directors.

 

68
 

 

Audit Committee

 

Messrs. McElwee, Cullen and Dr. Elias serve on our audit committee.  Mr. Cullen serves as the chair of the audit committee.  Our board of directors has assessed whether all members of the audit committee meet the composition requirements of Nasdaq, including the requirements regarding financial literacy and financial sophistication.  Our board of directors found that Messrs. McElwee, Cullen and Dr. Elias have met the financial literacy and financial sophistication requirements and that Messrs. McElwee, Cullen and Dr. Elias are independent under SEC and Nasdaq rules.  In addition, our board of directors has determined that Mr. Cullen is an audit committee financial expert within the meaning of Item 407(d) of Regulation S-K under the Securities Act of 1933, as amended, or the Securities Act.  The audit committee’s primary responsibilities include:

 

 

●

appointing, approving the compensation of, and assessing the qualifications and independence of our independent registered public accounting firm, which currently is Moss Adams LLP;

 

 

●

reviewing and discussing with management and our independent registered public accounting firm our annual and quarterly financial statements and related disclosures;

 

 

●

preparing the audit committee report required by SEC rules to be included in our annual proxy statements;

 

 

●

monitoring our internal control over financial reporting, disclosure controls and procedures;

 

 

●

reviewing our risk management status;

 

 

●

establishing policies regarding hiring employees from our independent registered public accounting firm and procedures for the receipt and retention of accounting related complaints and concerns;

 

 

●

meeting independently with our independent registered public accounting firm and management; and

 

 

●

monitoring compliance with the code of business conduct and ethics for financial management.

 

All audit and non-audit services must be approved in advance by the audit committee.  Our audit committee operates under a written charter that satisfies the applicable rules and regulations of the SEC and Nasdaq listing standards.  A copy of the charter of our audit committee is available on our website at www.avinger.com under “Investors–Governance.” During our fiscal year ended December 31, 2022, our audit committee held four meetings.

 

Compensation Committee

 

Messrs. Cullen, McElwee and Dr. Elias serve on our compensation committee.  Mr. McElwee serves as the chair of the compensation committee.  Each member of our compensation committee meets the requirements for independence for compensation committee members under the Nasdaq listing standards and SEC rules and regulations, including Rule 10C-1 under the Exchange Act.  Each member of our compensation committee is also a non-employee director, as defined pursuant to Rule 16b-3 promulgated under the Exchange Act, and an outside director, as defined pursuant to Section 162(m) of the Internal Revenue Code.  Our compensation committee is responsible for, among other things:

 

 

●

annually reviewing and approving corporate goals and objectives relevant to compensation of our chief executive officer and our other executive officers;

 

 

●

determining the compensation of our chief executive officer and our other executive officers;

 

 

●

reviewing and making recommendations to our board of directors with respect to director compensation; and

 

 

●

overseeing and administering our equity incentive plans.

 

69
 

 

Our Chief Executive Officer and Principal Financial Officer make compensation recommendations for our other executive officers and initially propose the corporate and departmental performance objectives under our Executive Incentive Compensation Plan to the compensation committee.  From time to time, the compensation committee may use outside compensation consultants to assist it in analyzing our compensation programs and in determining appropriate levels of compensation and benefits.  For example, we have periodically engaged Radford, a business unit of Aon Hewitt, to help develop our compensation philosophy, select a group of peer companies to use for compensation benchmarking purposes and advise on cash and equity compensation levels for our directors, executives and other employees based on current market practices.  We did not use any compensation consultants during our year ended December 31, 2022. Our compensation committee operates under a written charter that satisfies the applicable rules and regulations of the SEC and Nasdaq listing standards.  A copy of the charter of our compensation committee is available on our website at www.avinger.com under “Investors–Governance.” During our fiscal year ended December 31, 2022, our compensation committee held four meetings.

 

Nominating and Corporate Governance Committee

 

Messrs. Cullen, McElwee and Dr. Elias serve on our nominating and corporate governance committee.  Dr. Elias serves as the chair of the nominating and corporate governance committee.  Each member of our nominating and corporate governance committee meets the requirements for independence under the Nasdaq listing standards and SEC rules and regulations.  Our nominating and corporate governance committee is responsible for, among other things:

 

 

●

identifying individuals qualified to become members of our board of directors;

 

 

●

recommending to our board of directors the persons to be nominated for election as directors and to each of our board’s committees;

 

 

●

reviewing and making recommendations to our board of directors with respect to management succession planning;

 

 

●

developing, updating and recommending to our board of directors corporate governance principles and policies; and

 

 

●

overseeing the evaluation of our board of directors and committees.

 

Our nominating and corporate governance committee operates under a written charter that satisfies the applicable Nasdaq listing standards.  A copy of the charter of our nominating and corporate governance committee is available on our website at www.avinger.com under “Investors–Governance.” During our fiscal year ended December 31, 2022, our nominating and corporate governance committee held two meetings.

 

Considerations in Evaluating Director Nominees

 

Our nominating and corporate governance committee uses a variety of methods for identifying and evaluating director nominees. In its evaluation of director candidates, our nominating and corporate governance committee will consider the current size and composition of our board of directors and the needs of our board of directors and the respective committees of our board of directors. Some of the qualifications that our nominating and corporate governance committee considers include, without limitation, issues of character, integrity, judgment, diversity of experience, independence, area of expertise, corporate experience, length of service, potential conflicts of interest and other commitments. We also look for nominees who have skills and experience that would support the short and long-term goals and strategy of the Company. Our nominating and corporate governance committee seeks to maintain an appropriate balance of backgrounds, skills, knowledge, and experience to support current and future needs. Nominees must also have the ability to offer advice and guidance to our Chief Executive Officer based on past experience in positions with a high degree of responsibility and be leaders in the companies or institutions with which they are affiliated.

 

In the case of incumbent directors whose terms of office are set to expire, our nominating and corporate governance committee reviews these directors’ overall service to the Company during their terms, including the number of meetings attended, level of participation, quality of performance and any other relationships and transactions that might impair the directors’ independence.

 

Director candidates, including incumbent directors, must have sufficient time available in the judgment of our nominating and corporate governance committee to perform all board of director and committee responsibilities. Members of our board of directors are expected to prepare for, attend and participate in all board of director and applicable committee meetings. Other than the foregoing, there are no stated minimum criteria for director nominees, although our nominating and corporate governance committee may also consider such other factors as it may deem, from time to time, are in our and our stockholders’ best interests.

 

70
 

 

Although our board of directors does not maintain a specific policy with respect to board diversity, our board of directors believes that our board of directors should be a diverse body, and our nominating and corporate governance committee considers a broad range of backgrounds and experiences. In making determinations regarding nominations of directors, our nominating and corporate governance committee may take into account the benefits of diverse viewpoints, backgrounds, and experiences. Our nominating and corporate governance committee also considers these and other factors as it oversees the annual board of director and committee evaluations. After completing its review and evaluation of director candidates, our nominating and corporate governance committee recommends to our full board of directors the director nominees for selection.

 

In addition to utilizing personal networks and relationships to identify potential candidates, our nominating and corporate governance committee may also engage, if it deems appropriate, a professional search firm. The nominating and corporate governance committee conducts any appropriate and necessary inquiries into the backgrounds and qualifications of possible candidates after considering the function and needs of the board. The nominating and corporate governance committee meets to discuss and consider the candidates’ qualifications and then selects a nominee for recommendation to the board.

 

Stockholder Recommendations for Nominations to the Board of Directors

 

Our nominating and corporate governance committee will consider candidates for director recommended by stockholders, so long as such recommendations comply with our amended and restated certificate of incorporation, amended and restated bylaws and applicable laws, rules and regulations, including those promulgated by the SEC. Our nominating and corporate governance committee will evaluate such recommendations in accordance with its charter, our amended and restated bylaws, our policies and procedures for director candidates, as well as the regular director nominee criteria described above. This process is designed to ensure that our board of directors includes members with diverse backgrounds, skills and experience, including appropriate financial and other expertise relevant to our business. Eligible stockholders wishing to recommend a candidate for nomination should contact our Secretary in writing. Such recommendations must include information about the candidate, a statement of support by the recommending stockholder, evidence of the recommending stockholder’s ownership of our common stock and a signed letter from the candidate confirming willingness to serve on our board of directors. Our nominating and corporate governance committee has discretion to decide which individuals to recommend for nomination as directors.

 

Under our amended and restated bylaws, stockholders may also nominate candidates for our board of directors. Any nomination must comply with the requirements set forth in our amended and restated bylaws and should be sent in writing to our Secretary at 400 Chesapeake Drive, Redwood City, California 94063. To be timely for our 2023 annual meeting of stockholders, our Secretary must receive the nomination no earlier than June 18, 2023 and no later than July 18, 2023.

 

ITEM 11.    EXECUTIVE COMPENSATION

 

Processes and Procedures for Compensation Decisions

 

Our compensation committee is responsible for the executive compensation programs for our executive officers and reports to our board of directors on its discussions, decisions and other actions.  Our compensation committee reviews and approves corporate goals and objectives relating to the compensation of our Chief Executive Officer, evaluates the performance of our Chief Executive Officer in light of those goals and objectives and determines and approves the compensation of our Chief Executive Officer based on such evaluation.  Our compensation committee has the sole authority to determine our Chief Executive Officer’s compensation.  In addition, our compensation committee, in consultation with our Chief Executive Officer, reviews and approves all compensation for other officers. Our Chief Executive Officer and Chief Financial Officer also make compensation recommendations for our other executive officers and initially propose the corporate and departmental performance objectives under our Executive Incentive Compensation Plan to the compensation committee.

 

The compensation committee is authorized to retain the services of one or more executive compensation and benefits consultants or other outside experts or advisors as it sees fit, in connection with the establishment of our compensation programs and related policies. 

 

71
 

 

Summary Compensation Table

 

The following table presents summary information regarding the total compensation for services rendered in all capacities that was earned by our Chief Executive Officer and our two other most highly compensated executive officers in our fiscal years ended December 31, 2022 and 2021.  The individuals listed in the table below are our named executive officers for our fiscal year ended December 31, 2022.

 

Name and Principal Position

  

Year

  

Salary ($)

    

Bonus ($)

    

Stock

Awards

($)

    

Option

Awards

($)

    

Non-Equity

Incentive Plan

Compensation

($)(1)

    

All Other

Compensation

($)

    

Total ($)

  

Jeffrey M. Soinski

  

2022

     400,000       -       -       -       205,155       -       605,155  

President and Chief Executive Officer

 

2021

     400,000       -       -       -       194,824       -       594,824  

Himanshu Patel

  

2022

     300,000       -       -       -       123,093       -       423,093  

Chief Technology Officer

  

2021

     300,000       -       -       -       116,047       -       416,047  

Nabeel P. Subainati

  

2022

     247,500       -       -       -       48,349       -       295,849  

Principal Financial and Accounting Officer

 

2021

     197,500       -       -       -       25,253       -       222,753  

 

 

(1)

Non-equity incentive plan compensation includes cash awards granted at the discretion of the Compensation Committee under our Executive Incentive Compensation Plan for achieving certain performance-based criteria.

 

Executive Employment Letters

 

Jeffrey M. Soinski

 

Pursuant to the employment letter, as revised on September 9, 2020, between the Company and Jeffrey M. Soinski, our President and Chief Executive Officer, Mr. Soinski is entitled to receive as compensation (i) a base salary of $400,000, (ii) a discretionary bonus targeted at 75% of his base salary, subject to the achievement of certain goals mutually agreed upon by him and our board of directors and payable semi-annually; and (iii) other standard benefits provided to each of the Company’s executive officers. The letter has no specific term and provides for at-will employment.

 

Pursuant to Mr. Soinski’s employment offer letter, if, within the 12-month period following a “change in control,” we terminate Mr. Soinski’s employment without “cause,” or Mr. Soinski resigns for “good reason” (as such terms are defined in Mr. Soinski’s employment offer letter), Mr. Soinski will receive accelerated vesting as to 100% of his outstanding unvested stock options.  If we experience a change in control, and Mr. Soinski remains our employee through such date, Mr. Soinski will receive accelerated vesting as to 50% of his outstanding unvested stock options and/or restricted stock.

 

If we terminate Mr. Soinski without cause at any time, he will be entitled to receive 12 months of base salary and COBRA medical and dental insurance coverage, in each case payable in substantially equal installments in accordance with our payroll practices, as severance, in exchange for signing and not revoking a severance agreement and general release against us and our affiliates within 60 days following his termination of employment. 

 

401(k) Plan

 

We maintain a tax-qualified retirement plan that provides eligible employees with an opportunity to save for retirement on a tax advantaged basis.  We may make a discretionary matching contribution to the 401(k) plan, and may make a discretionary employer contribution to each eligible employee each year.  To date, we have not made any matching or profits sharing contributions into the 401(k) plan.  All participants’ interests in our matching and profit sharing contributions, if any, vest pursuant to a four-year graded vesting schedule from the time of contribution.  Pre-tax contributions are allocated to each participant’s individual account and are then invested in selected investment alternatives according to the participants’ directions.  The 401(k) plan is intended to qualify under Sections 401(a) and 501(a) of the Code.  As a tax-qualified retirement plan, contributions to the 401(k) plan and earnings on those contributions are not taxable to the employees until distributed from the 401(k) plan, and all contributions are deductible by us when made.

 

Pension Benefits and Nonqualified Deferred Compensation

 

We do not provide a pension plan for our employees, and none of our named executive officers participated in a nonqualified deferred compensation plan in 2022.

 

72
 

 

Outstanding Equity Awards at Fiscal Year-End

 

The following table provides information regarding equity awards held by our named executive officers at December 31, 2022.

 

       

Option Awards

    

Stock Awards

  
       

Number of

Securities

Underlying

Unexercised

Options (#)

    

Number of

Securities

Underlying

Unexercised

Options (#)

    

Option

Exercise

Price

($)(4)

   

Option

Expiration

Date

    

Number of

Shares or

Units of

Stock That

Have Not

Vested (#)

    

Market

Value of

Shares or

Units of

Stock That

Have Not

Vested

($)(5)

 

Name

  

Grant Date

  

Exercisable (3)

    

Unexercisable

                                  

Jeffrey M. Soinski

  

12/31/2014(1)(7)

     76       —       36,000    

12/31/2024

       —       —  
   

3/7/2016 (2)(7)

     7       —       103,680    

3/7/2026

       —       —  
   

3/13/2017 (2) (7)

     7       —       16,400    

3/13/2027

       —       —  
   

9/18/2019(2) (8)

     —       —       —       —       —       —  
                                                     

Himanshu Patel

  

11/5/2013 (1) (6)

     2       —       162,000    

11/5/2023

       —       —  
   

12/31/2014(1)(7)

     20       —       36,000    

12/31/2024

       —       —  
   

3/3/2016(2) (7)

     2       —       103,920    

3/3/2026

       —       —  
   

3/13/2017 (2) (7)

     3       —       16,400    

3/13/2027

       —       —  
   

9/18/2019(2) (8)

     —       —       —       —       —       —  
                                                     

Nabeel Subainati (10)

  

1/6/2020(2) (8)

     —       —       —       —       417       452  

 

 

(1)

Each of the outstanding equity awards was granted pursuant to our 2009 Stock Plan.  No additional awards may be granted under the 2009 Stock Plan, and all awards granted under the 2009 Stock Plan that are repurchased, forfeited, expired, are cancelled or otherwise not issued become available for grant under the 2015 Plan in accordance with its terms.

(2)

Each of the outstanding equity awards was granted pursuant to our 2015 Equity Incentive Plan.

(3)

All of our options granted pursuant to our 2009 Stock Plan are early exercisable subject to the Company’s right to repurchase any unvested shares.

(4)

This column represents the fair value of a share of our common stock on the date of grant, as determined by our board of directors.

(5)

This column represents the market value of the unvested shares of our common stock underlying the RSUs as of December 31, 2022, based on the closing price of our common stock, as reported on the Nasdaq Global Select Market, of $1.09 per share.

(6)

25% of the shares of our common stock subject to this option vested on October 11, 2014, and the balance vested in 36 successive equal monthly installments, subject to continued service through each such vesting date.

(7)

25% of the shares of our common stock subject to this option vested on the one year anniversary of the grant date, and the balance vests in 36 successive equal monthly installments, subject to continued service through each such vesting date.

(8)

33.3% of the shares of our common stock subject to this stock award vests on the one year anniversary of the grant date, and the balance vests in 2 successive equal annual installments, subject to continued service through each such vesting date.

(9)

Mr. Subainati has been designated as Principal Financial Officer and Principal Accounting Officer effective as of July 21, 2022.

 

73
 

 

Potential Payments upon Termination or Change of Control

 

Jeffrey M. Soinski

 

In March 2018, we entered into a change of control and severance agreement with Jeffrey M. Soinski, which was subsequently amended in March 2020. Under this agreement, as amended, if, within the 18 month period following a “change of control,” we terminate Mr. Soinski’s employment other than for “cause,” death or disability, or the employee resigns for “good reason” (as such terms are defined in the employee’s employment agreement) and, within 60 days following the employee’s termination, the employee executes an irrevocable separation agreement and release of claims, the employee is entitled to receive (i) continuing payments of severance pay at a rate equal to the employee’s monthly base salary and pro-rated target bonus, as then in effect, for a period of 12 months plus one month for every year of service completed for the Company (provided that such severance shall not exceed 18 months), (ii) reimbursement of premiums to maintain group health insurance continuation benefits pursuant to “COBRA” for employee and employee’s dependents for up to 12 months, (iii) accelerated vesting as to 100% of the employee’s outstanding unvested stock options and/or restricted stock, and (iv) the extension of the post-termination exercise period of any options held by the employee for a period of 1 year.  Additionally, if we experience a change in control, 50% of Mr. Soinski’s outstanding unvested stock options and/or restricted stock will vest. In the event of any conflict between Mr. Soinski’s change of control and severance agreement and his offer letter, described above under “Executive Employment Letters,” he will be entitled to the greater of the benefits provided by either. The agreement also provides that if the employee is employed by the Company or the Company’s successor on the date that is 12 months following a change of control, then the employee will be entitled to a lump sum bonus payment in an amount equal to what the employee would have received as a severance payment if the employee had been terminated other than for cause, death or disability.

 

Himanshu Patel

 

We previously entered into a change of control and severance agreement with Himanshu Patel, which was subsequently amended in March 2020. Under this agreement, as amended, if, within the 18 month period following a “change of control,” we terminate Mr. Patel’s employment other than for “cause,” death or disability, or the employee resigns for “good reason” (as such terms are defined in the employee’s employment agreement) and, within 60 days following the employee’s termination, the employee executes an irrevocable separation agreement and release of claims, the employee is entitled to receive (i) continuing payments of severance pay at a rate equal to the employee’s monthly base salary and pro-rated target bonus, as then in effect, for a period of 12 months plus one month for every year of service completed for the Company (provided that such severance shall not exceed 18 months), (ii) reimbursement of premiums to maintain group health insurance continuation benefits pursuant to “COBRA” for employee and employee’s dependents for up to 12 months, (iii) accelerated vesting as to 100% of the employee’s outstanding unvested stock options and/or restricted stock, and (iv) the extension of the post-termination exercise period of any options held by the employee for a period of 1 year. The agreement also provides that if the employee is employed by the Company or the Company’s successor on the date that is 12 months following a change of control, then the employee will be entitled to a lump sum bonus payment in an amount equal to what the employee would have received as a severance payment if the employee had been terminated other than for cause, death or disability.

 

Nabeel Subainati

 

We previously entered into a change in control agreement with Mr. Subainati, which we subsequently amended in March 2023. Under the agreement, as amended, we agreed that if, within the 18 month period following a “change of control,” we terminate Mr. Subainati’s employment other than for “cause” or death or disability, or if the employee resigns for “good reason” (as such terms are defined in the employee’s employment agreement) and, within 60 days following the employee’s termination, the employee executes an irrevocable separation agreement and release of claims, the employee is entitled to receive (i) continuing payments of severance pay at a rate equal to the employee’s base salary and target bonus, as then in effect, for six months plus one month for every year of service completed for the Company (provided that such severance shall not exceed 12 months), (ii) reimbursement of premiums to maintain group health insurance continuation benefits pursuant to “COBRA” for the employee and the employee’s dependents for up to six months, (iii) accelerated vesting as to 100% of the employee’s outstanding unvested stock options and/or restricted stock, and (iv) the extension of the post-termination exercise period of any options held by the employee for a period of 1 year. Additionally, if we experience a change in control, 50% of Mr. Subainati’s outstanding unvested stock options and/or restricted stock will vest. The agreement, as amended, also provides that if the employee is employed by us or our successor on the date that is 12 months following a change of control, then the employee will be entitled to a lump sum bonus payment in an amount equal to what the employee would have received as a severance payment if the employee had been terminated other than for cause, death or disability.

 

74
 

 

Executive Incentive Compensation Plan

 

Our board of directors has adopted an Executive Incentive Compensation Plan, or the Bonus Plan, which is administered by our compensation committee.  The Bonus Plan allows our compensation committee to provide cash incentive awards to selected employees, including our named executive officers, based upon performance goals established by our compensation committee.

 

Under the Bonus Plan, our compensation committee determines the performance goals applicable to any award, which goals may include, without limitation: attainment of research and development milestones, sales bookings, business divestitures and acquisitions, cash flow, cash position, earnings (which may include any calculation of earnings, including but not limited to earnings before interest and taxes, earnings before taxes, earnings before interest, taxes, depreciation and amortization and net earnings), earnings per share, net income, net profit, net sales, operating cash flow, operating expenses, operating income, operating margin, overhead or other expense reduction, product defect measures, product release timelines, productivity, profit, return on assets, return on capital, return on equity, return on investment, return on sales, revenue, revenue growth, sales results, sales growth, stock price, time to market, total stockholder return, working capital, and individual objectives such as peer reviews or other subjective or objective criteria.  Performance goals that include our financial results may be determined in accordance with GAAP or such financial results may consist of non-GAAP financial measures and any actual results may be adjusted by the compensation committee for one-time items or unbudgeted or unexpected items when performance goals that include our financial results may be determined in accordance with GAAP, or such financial results may consist of non-GAAP financial measures, and any actual results may be adjusted by the compensation committee for one-time items or unbudgeted or unexpected items when determining whether the performance goals have been met.  The goals may be on the basis of any factors the compensation committee determines relevant, and may be adjusted on an individual, divisional, business unit or company-wide basis.  The performance goals may differ from participant to participant and from award to award.

 

Our compensation committee may, in its sole discretion and at any time, increase, reduce or eliminate a participant’s actual award, and/or increase, reduce or eliminate the amount allocated to the bonus pool for a particular performance period.  The actual award may be below, at or above a participant’s target award, in the compensation committee’s discretion.  Our compensation committee may determine the amount of any reduction on the basis of such factors as it deems relevant, and it is not required to establish any allocation or weighting with respect to the factors it considers.

 

Actual awards are paid in cash only after they are earned, which usually requires continued employment through the date a bonus is paid.  Our compensation committee has the authority to amend, alter, suspend or terminate the Bonus Plan provided such action does not impair the existing rights of any participant with respect to any earned bonus.

 

Retention Bonuses

 

On March 9, 2021, the Compensation Committee (the “Committee”) of the Board of Directors of the Company determined to provide certain incentive payments (the “Retention Bonuses”) to certain full-time executive officers and vice presidents of the Company, including Jeffrey M. Soinski, and Himanshu Patel, who serve as the Company’s Chief Executive Officer and Chief Technology Officer, respectively (the “Bonus Officers”), based on certain performance goals. The Retention Bonus consists of incentive payments in an amount equal to 100% of such Bonus Officer’s annual salary as of December 31, 2023, 50% of which will be paid if such Bonus Officer is in good standing in their service at the Company on December 31, 2023, and 50% to be paid if such Bonus Officer is in good standing in their service at the Company on December 31, 2024 (each, a “Retention Bonus Payment”). The Retention Bonus Payments may be paid in cash or equity, or a combination of both, as determined by the Committee. In addition, the Retention Bonus Payments shall accelerate in the event of a Change in Control, as defined in the Company’s Amended and Restated 2015 Equity Incentive Plan, provided that the Bonus Officer remains in his or her respective position through such Change in Control. Each Retention Bonus Payment shall be increased in the event that the price of the common stock of the Company is above $60.00 (subject to adjustment for any stock splits, reverse stock splits, or similar transactions) as of the date of such Retention Bonus Payment, according to the schedule below:

 

 

●

If the stock price is between $60.00 and $79.99 (subject to adjustment for any stock splits, reverse stock splits, or similar transactions) as of the date of the Retention Bonus Payment, such Retention Bonus Payment shall be increased by 25%;

 

 

●

If the stock price is between $80.00 and $99.99 (subject to adjustment for any stock splits, reverse stock splits, or similar transactions) as of the date of the Retention Bonus Payment, such Retention Bonus Payment shall be increased by 50%; and

 

 

●

 If the stock price is $100.00 or above (subject to adjustment for any stock splits, reverse stock splits, or similar transactions) as of the date of the Retention Bonus Payment, such Retention Bonus Payment shall be increased by 100%.

 

The Retention Bonuses are in addition to any other bonus to which the Bonus Officers may be entitled under the Company’s Bonus Plan.

 

75
 

 

Director Compensation

 

Our board of directors approved our Outside Director Compensation Policy in January 2015 to compensate each non-employee director for his or her service and amended certain aspects of this policy in August 2018.  Our board of directors will have the discretion to revise non-employee director compensation as it deems necessary or appropriate.  Under our Outside Director Compensation Policy, non-employee directors will receive compensation in the form of equity and cash, as described below:

 

Cash Compensation.  All non-employee directors will be entitled to receive the following cash compensation for their services:

 

 

●

$35,000 per year for service as a board member;

 

 

●

$25,000 per year additionally for service as chairman of the board;

 

 

●

$20,000 per year additionally for service as chairman of the audit committee;

 

 

●

$10,000 per year additionally for service as an audit committee member;

 

 

●

$15,000 per year additionally for service as chairman of the compensation committee;

 

 

●

$7,500 per year additionally for service as a compensation committee member;

 

 

●

$10,000 per year additionally for service as chairman of the nominating and corporate governance committee; and

 

 

●

$5,000 per year additionally for service as a nominating and corporate governance committee member.

 

All cash payments to non-employee directors, or the Retainer Cash Payments, will be paid semiannually with the first semiannual installment payable on the date of our annual meeting of stockholders or, if no annual meeting occurs in a given year, May 1, and the second semiannual installment payable on November 1 of each year.

 

Election to Receive RSUs in Lieu of Cash Payments.  All non-employee directors may elect to convert a Retainer Cash Payment into RSUs, or Retainer RSUs, with a grant date fair value equal to the applicable Retainer Cash Payment.  Each Retainer RSU will be granted on the date that the applicable Retainer Cash Payment was scheduled to be paid, and all of the shares underlying the Retainer RSUs will vest and become exercisable six months from the date of grant, subject to continued service as a director through the applicable vesting date.  The Retainer RSUs will be subject to certain terms and conditions as described below under the section titled “Director Compensation—Equity Compensation.”

 

Elections to convert a Retainer Cash Payment into a Retainer RSU must generally be made on or prior to December 31 of the year prior to the year in which the Retainer Cash Payment is scheduled to be paid, or such earlier deadline as is established by our board of directors or compensation committee.  A newly appointed non-employee director will be permitted to elect to convert Retainer Cash Payments payable in the same calendar year into Retainer RSUs, provided that such election is made prior to the date the individual becomes a non-employee director.

 

Equity Compensation.  Nondiscretionary, automatic grants of RSUs will be made to our non-employee directors.

 

 

●

Initial Grant.  Generally, each person who first becomes a non-employee director will be granted RSUs having a grant date fair value equal to $115,000, or the Initial Grant.  The Initial Grant will typically be granted on the date of the first meeting of our board of directors or compensation committee occurring on or after the date on which the individual first became a non-employee director.  The Initial Grant will vest and become exercisable as to one thirty-sixth (1/36th) of the shares subject to such Initial Grant on each monthly anniversary of the commencement of the non-employee director’s service as a director, subject to the continued service as a director through the applicable vesting date.

 

 

●

Annual Grant.  Once each calendar year, on the same date that our board of directors grants annual equity awards to our senior executives, each non-employee director will be granted RSUs having a grant date fair value equal to $75,000, or the Annual Grant.  All of the shares underlying the Annual Grant will vest and become exercisable one year from the date of grant, subject to continued service as a director through the applicable vesting date.

 

The grant date fair value is the closing sales price for the Company’s common stock (or the closing bid, if no sales were reported) as quoted on such exchange or system on the date such award is granted.

 

76
 

 

Any RSUs granted under our outside director compensation policy will fully vest and become exercisable in the event of a change in control, as defined in our 2015 Plan, provided that the holder remains a director through such change in control.  Further, our 2015 Plan provides that in the event of a merger or change in control, as defined in our 2015 Plan, each outstanding equity award granted under our 2015 Plan that is held by a non-employee director will fully vest, all restrictions on the shares subject to such award will lapse and, with respect to awards with performance-based vesting, all performance goals or other vesting criteria will be deemed achieved at 100% of target levels, and all of the shares subject to such award will become fully exercisable, if applicable, provided such optionee remains a director through such merger or change in control.

 

2021 Changes to Director Compensation

 

Notwithstanding the above, pursuant to the authority of our board of directors to revise non-employee director compensation, our board of directors has deemed it appropriate and necessary to pay the Annual Grant for the year 2021 in the amount of $75,000 in cash, in lieu of making the 2021 Annual Grant in the form of RSUs.

 

Compensation for Fiscal Year 2022

 

The following table sets forth a summary of the compensation received by our non-employee directors who received compensation during our fiscal year ended December 31, 2022:

 

Name

  

Fees earned or

   

Option awards(1)

   

Stock

    

Total

  
   

paid in cash

            

awards(2)

          

James G. Cullen

   $ 92,500     $ -     $ 75,000     $ 167,500  

James B. McElwee

     65,000       -       75,000       140,000  

Tamara Elias

     62,500       -       75,000       137,500  

 

 

(1)

As of December 31, 2022, Messrs. Cullen and McElwee had outstanding options to purchase a total of 169 and 12 shares of our common stock, respectively.

(2)

All non-employee directors that were directors at the time of grant received an Annual RSU grant on January 18, 2023 for the prior fiscal year ended December 31, 2022.

 

Directors who are also our employees receive no additional compensation for their service as directors.  During 2022, Jeffrey M. Soinski, our President, Chief Executive Officer and a director, was also our employee.  See the section titled “Summary Compensation Table” below for additional information about the compensation for Mr. Soinski.

 

Officer and Director Share Purchase Plan

 

On August 22, 2018, the Board of Directors of the Company approved the adoption of an Officer and Director Share Purchase Plan (“ODPP”), which allowed executive officers and directors to purchase shares of our common stock at fair market value in lieu of salary or, in the case of directors, director fees. Eligible individuals were allowed voluntarily participate in the ODPP by authorizing payroll deductions or, in the case of directors, deductions from director fees for the purpose of purchasing common stock. Elections to participate in the ODPP may only be made during open trading windows under our insider trading policy when the participant does not otherwise possess material non-public information concerning the Company. There was no common stock issued under the ODPP during either the year ended December 31, 2022 or 2021. On May 16, 2022, the Board of Directors of the Company terminated the Amended and Restated Officer and Director Share Purchase Plan due to the administrative costs of maintaining such plan and the limited amount of remaining shares. Consequently, there are no longer any shares reserved for issuance under this plan.

 

77
 

 

ITEM 12.    SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 

Equity Compensation Plan Information

 

All of our equity compensation plans have been approved by our stockholders.  The following table provides information as of December 31, 2022, with respect to the shares of our common stock that may be issued under our existing equity compensation plans.

 

Plan Category

  

(a) Number of

Securities to be

Issued Upon

Exercise of

Outstanding

Options,

Restricted

Stock Units and

Rights

    

(b) Weighted

Average Exercise

Price of

Outstanding

Options,

Restricted

Stock Units and

Rights (2)

    

(c) Number of

Securities

Remaining

Available for

Future Issuance

Under Equity

Compensation

Plans (Excluding

Securities

Reflected in

Column (a))

  

Equity compensation plans approved by stockholders (1)

     720     $ 19,360.30       1,759,566  

 

 

(1)

Includes the following plans: our 2009 Stock Plan and our 2015 Plan.  Our 2015 Plan provides that on the first day of each fiscal year commencing in fiscal year 2016, the number of shares authorized for issuance under the 2015 Plan is periodically increased by such number of shares that may be determined by our board of directors and approved by our stockholders.  

(2)

The weighted average exercise price does not take into account outstanding restricted stock, restricted stock awards, or RSUs, which have no exercise price.

 

Security Ownership of Certain Beneficial Owners and Management

 

The following table sets forth certain information with respect to the beneficial ownership of our capital stock as of March 1, 2023 for:

 

 

●

each person or group of affiliated persons known by us to be the beneficial owner of more than 5% of our common stock;

 

 

●

each of our named executive officers;

 

 

●

each of our directors and nominees for director; and

 

 

●

all of our current executive officers and directors as a group.

 

We have determined beneficial ownership in accordance with the rules and regulations of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose.  Except as indicated by the footnotes below, we believe, based on information furnished to us, that the persons and entities named in the table below have sole voting and sole investment power with respect to all shares of our capital stock that they beneficially own, subject to applicable community property laws.

 

Applicable percentage ownership is based on 8,580,508 shares of our common stock outstanding as of March 1, 2023. In computing the number of shares of capital stock beneficially owned by a person and the percentage ownership of such person, we deemed to be outstanding all shares of our capital stock subject to options, restricted stock awards (“RSAs”) or RSUs held by the person that are currently exercisable, exercisable or vests within 60 days of March 1, 2023.  However, we did not deem such shares of our capital stock outstanding for the purpose of computing the percentage ownership of any other person.

 

78
 

 

Unless otherwise indicated, the address of each beneficial owner listed in the table below is c/o Avinger, Inc., 400 Chesapeake Drive, Redwood City, California 94063. The information provided in the table is based on our records, information filed with the SEC and information provided to us, except where otherwise noted.

 

   

Shares Beneficially Owned

  

Name of Beneficial Owner

  

Number of

Shares

    

Percentage

  

Named Executive Officers and Directors (8):

                
                 

Jeffrey M. Soinski(1)

     257,160       2.9 %

Himanshu Patel(2)

     188,654       2.2 %

Nabeel Subainati(3)

     85,895       1.0 %

James G. Cullen(4)

     64,636       *  

James B. McElwee(5)

     64,481       *  

Tamara N. Elias(6)

     65,476       *  

All executive officers, directors and director nominees as a group (6 individuals)(7)

     726,302       *  

 

 

*

Represents ownership of less than 1%

(1)

Consists of (i) 7,070 shares of common stock held of record by Mr. Soinski, (ii) 90 shares of common stock issuable upon exercise of options exercisable within 60 days of March 1, 2023, and (iii) 250,000 shares of common stock underlying RSAs, none of which vests within 60 days of March 1, 2023, but currently include voting rights equivalent to common stock.

(2)

Consists of (i) 5,088 shares of common stock held of record by Mr. Patel, (ii) warrants to purchase 250 shares of common stock, (iii) 27 shares of common stock issuable upon exercise of options exercisable within 60 days of March 1, 2023, (iv) 33,289 shares of common stock that are issuable upon the conversion of shares of Series B preferred stock that are immediately convertible to common stock and (v) 150,000 shares of common stock underlying RSAs, none of which vest within 60 days of March 1, 2023, but that currently include voting rights equivalent to common stock.

(3)

Consists of (i) 478 shares of common stock held of record by Mr. Subainati, (ii) 417 shares of common stock issuable upon vesting of RSUs within 60 days of March 1, 2023, and (iii) 85,000 shares of common stock underlying RSAs, none of which vest within 60 days of March 1, 2023, but that currently include voting rights equivalent to common stock.

(4)

Consists of (i) 3,491 shares of common stock held of record by 2000 James Cullen Generation Skipping Family Trust, and (ii) 169 shares of common stock issuable upon exercise of options exercisable within 60 days of March 1, 2023, and (iii) 60,976 shares of common stock underlying RSAs, none of which vest within 60 days of March 1, 2023, but that currently include voting rights equivalent to common stock. Mr. Cullen has sole voting and dispositive power with respect to shares held by James Cullen Generation Skipping Family Trust.  Mr. Cullen does not have a pecuniary interest in the James Cullen Generation Skipping Family Trust.

(5)

Consists of (i) 3,493 shares of common stock held of record by Mr. McElwee, and (ii) 12 shares of common stock issuable upon exercise of options exercisable within 60 days of March 1, 2023, and (iii) 60,976 shares of common stock underlying RSAs, none of which vest within 60 days of March 1, 2023, but that currently include voting rights equivalent to common stock.

(6)

Consists of (i) 4,500 shares of common stock held of record by Mrs. Elias, and (ii) 60,976 shares of common stock underlying RSAs, none of which vest within 60 days of March 1, 2023, but that currently include voting rights equivalent to common stock.

(7)

Consists of (i) 24,120 shares of common stock, (ii) warrants to purchase 250 shares of common stock, (iii) 715 shares of common stock issuable upon exercise of options exercisable or vesting of RSUs within 60 days of March 1, 2023, (iv) 33,289 shares of common stock that are issuable upon the conversion of shares of Series B preferred stock that are immediately convertible to common stock and (v) 667,928 shares of common stock underlying RSAs, none of which vest within 60 days of March 1, 2023, but that currently include voting rights equivalent to common stock.

 

79
 

 

ITEM 13.    CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

 

Related Person Transactions

 

We describe below transactions and series of similar transactions, since January 1, 2021, to which we were a party or will be a party, in which:

 

 

●

the amounts involved exceeded or will exceed the lesser of $120,000 or 1% of the average of our total assets at year-end for the last two completed fiscal years; and

 

 

●

any of our directors, nominees for director, executive officers or beneficial holders of more than 5% of our outstanding common stock, or any immediate family member of, or person sharing the household with, any of these individuals or entities (each, a related person), had or will have a direct or indirect material interest.

 

We have entered into employment and separation arrangements with certain current and former executive officers.  For more information on these employment and separation agreements, see the section titled “Executive Compensation - Executive Employment Letters” and “Executive Compensation – Potential Payments upon Termination or Change of Control” in Item 11 above.

 

We have entered into indemnification agreements with our directors and executive officers.  The indemnification agreements, as well as our certificate of incorporation and bylaws, require us to indemnify our directors and executive officers to the fullest extent permitted by Delaware law.

 

Policies and Procedures for Related Party Transactions

 

Our board of directors has adopted a written policy that our executive officers, directors, nominees for election as a director, beneficial owners of more than 5% of any class of our common stock and any members of the immediate family of any of the foregoing persons are not permitted to enter into a related person transaction with us without the prior consent of our audit committee.  Any request for us to enter into a transaction with an executive officer, director, nominee for election as a director, beneficial owner of more than 5% of any class of our common stock or any member of the immediate family of any of the foregoing persons in which the amount involved exceeds the lesser of $120,000 or 1% of the average of our total assets at year-end for the last two completed fiscal years and such person would have a direct or indirect interest must first be presented to our audit committee for review, consideration and approval.  In approving or rejecting any such proposal, our audit committee is to consider the material facts of the transaction, including, but not limited to, whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third-party under the same or similar circumstances and the extent of the related person’s interest in the transaction.

 

Director Independence

 

Information regarding the independence of directors is disclosed above under Item 10 under the heading “Director Independence” and incorporated herein by reference.

 

80
 

 

ITEM 14.    PRINCIPAL ACCOUNTANT FEES AND SERVICES

 

Fees Paid to the Independent Registered Public Accounting Firm

 

The following table represents aggregate fees billed to us for the years ended December 31, 2022 and 2021 by
Moss Adams, as applicable.  All fees below were approved by our Audit Committee.

 

Year ending December 31,

  

2022

    

2021

  

Audit fees(1)(2)

   $ 454,515     $ 414,750  

Tax fees(3)

     36,250       —  

All other fees(4)

     —       1,725  

Total

   $ 490,765     $ 416,475  

 

 

(1)

Audit fees consist of fees incurred for professional services rendered for the audit of our annual financial statements and review of the quarterly financial statements, assistance with registration statements filed with the SEC, and services that are normally provided by our independent registered public accounting firm in connection with regulatory filings or engagements.  

(2)

For the years ended December 31, 2022 and 2021, audit fees also include fees related to our public offerings and review of documents filed with the SEC of $72,315 and $52,500, respectively.

(3)

For the year ended December 31, 2022, tax fees were comprised of compilation and filing activities relating to federal and state income tax returns, and consultations relating to general tax matters.

(4)

For the year ended December 31, 2021, all other fees were comprised of consultations relating to sales tax and other miscellaneous matters.

 

Auditor Independence

 

In our fiscal year ended December 31, 2022, there were no other professional services provided by Moss Adams that would have required our audit committee to consider their compatibility with maintaining the independence of Moss Adams.

 

Audit Committee Policy on Pre-Approval of Audit and Permissible Non-Audit Services of Independent Registered Public Accounting Firm

 

Our audit committee has established a policy governing our use of the services of our independent registered public accounting firm.  Under this policy, our audit committee is required to pre-approve all audit and permissible non-audit services performed by our independent registered public accounting firm in order to ensure that the provision of such services does not impair the public accountants’ independence.  All fees paid to Moss Adams for our fiscal years ended December 31, 2022 and 2021 were pre-approved by our audit committee.

 

81
 

 

PART IV

 

 

ITEM 15.    EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

 

(a)(1)

Financial Statements

 

The following Financial Statements are filed as part of this Annual Report on Form 10-K:

 

Report of Independent Registered Public Accounting Firm (Moss Adams LLP, San Francisco, CA, PCAOB ID: 659)

F-2

Financial Statements

  

Balance Sheets

F-3

Statements of Operations and Comprehensive Loss

F-4

Statements of Stockholders’ Equity

F-5

Statements of Cash Flows

F-6

Notes to Financial Statements

F-7

 

 

(a)(2)

Financial Statement Schedules

 

All other schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto. Financial statement schedules relating to the allowance for doubtful accounts receivable and for sales returns follows (in thousands):

 

Description

  

Balance at
Beginning
of Year

    

Charged to
costs and
expenses

    

Write offs

    

Balance at
End of
Year

  

Allowance for doubtful accounts receivable:

                                

Fiscal year ended 2021

   $ 19     $ 2     $ 15     $ 6  

Fiscal year ended 2022

   $ 6     $ 70     $ 3     $ 73  

 

   

Balance at
Beginning
of Year

    

Charged to
costs and
expenses

    

Write offs

    

Balance at
End of
Year

  

Allowance for sales returns:

                                

Fiscal year ended 2021

   $ 20     $ 10     $ 10     $ 20  

Fiscal year ended 2022

   $ 20     $ —     $ 5     $ 15  

 

82
 

 
 

(a)(3)

Exhibits

 

The following exhibits are filed as part of, or incorporated by reference into, this Annual Report on Form 10-K.

 

Exhibit
Number

  

Exhibit Title

3.1 (1)

  

Amended and Restated Certificate of Incorporation of the registrant.

3.2 (1)

  

Bylaws of the registrant.

3.3 (2)

  

Certificate of Amendment to the Amended and Restated Certificate of Incorporation.

3.4 (3)

  

Avinger, Inc. Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock

3.5 (4)

  

Avinger, Inc. Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock

3.6 (5)

  

Avinger, Inc. Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock

3.7 (5)

  

Certificate of Amendment to the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock

3.8 (6)

  

Certificate of Amendment to the Restated Certificate of Incorporation of Avinger, Inc.

3.9 (7)

  

Amendment to the Amended and Restated Bylaws of Avinger, Inc., dated as of October 27, 2021.

3.10 (8)

  

Avinger, Inc. Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock.

3.11(32)

  

Certificate of Amendment to the Restated Certificate of Incorporation Avinger, Inc. dated March 11, 2022.

3.12(38)

  

Certificate of Amendment to the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock, as filed with the Secretary of State of the State of Delaware on December 22, 2022.

4.1 (9)

  

Specimen Common Stock certificate of the registrant.

4.2 (5)

  

Specimen Series 1/2 warrant of the registrant.

4.3 (10)

  

Form of Common Stock Purchase Warrant

4.4 (11)

  

Description of Registrant’s Securities

4.5 (12)

  

Form of Common Stock Purchase Warrant.

4.6 (12)

  

Form of Placement Agent Warrant.

4.7 (35)

  

Form of Pre-Funded Common Stock Purchase Warrant - Registered Direct Offering

4.8 (35)

  

Form of Pre-Funded Common Stock Purchase Warrant - Private Placement Offering

4.9 (35)

  

Form of Series A Preferred Investment Option

4.10 (35)

  

Form of Series B Preferred Investment Option

4.11 (35)

  

Form of Placement Agent Preferred Investment Option

10.1# (13)

  

Form of Indemnification Agreement for directors and executive officers.

10.2# (14)

  

2009 Stock Plan and Form of Option Agreement thereunder.

10.3# (14)

  

2014 Preferred Stock Plan.

10.5# (13)

  

Form of Restricted Stock Unit Award Agreement.

10.6# (13)

  

Form of Stock Option Agreement.

10.7# (13)

  

2015 Employee Stock Purchase Plan.

10.8# (13)

  

Executive Incentive Compensation Plan.

10.9 (14)

  

Amended and Restated Investors’ Rights Agreement dated September 2, 2014 by and among the registrant and certain stockholders.

 

83
 

 

Exhibit
Number

  

Exhibit Title

10.10 (14)

  

Lease Agreement, dated July 30, 2010, by and between the registrant and HCP LS Redwood City, LLC for office space located at 400 and 600 Chesapeake Drive, Redwood City, California.

10.11 (14)

  

First Amendment to Lease Agreement dated September 30, 2011 by and between registrant and HCP LS Redwood City, LLC.

10.12 (17)

  

Second Amendment to Lease Agreement dated March 4, 2016 by and between the registrant and HCP LS Redwood City, LLC.

10.14# (14)

  

Employment Letter dated December 17, 2014 by and between the registrant and Jeffrey M. Soinski.

10.16# (18)

  

Change of Control and Severance Agreement dated March 29, 2018 by and between the registrant and Jeffrey M. Soinski.

10.17 (4)

  

Registration Rights Agreement, dated as of February  , 2018, by and among the registrant, CRG Partners III L.P. and certain of its affiliated funds, as purchasers.

10.20 (16)

  

Term Loan Agreement, dated as of September 22, 2015, by and among the registrant, certain of its subsidiaries from time to time party thereto as guarantors and CRG Partners III L.P. and certain of its affiliated funds, as lenders.

10.21 (16)

  

Securities Purchase Agreement, dated as of September 22, 2015, by and among the registrant, CRG Partners III L.P. and certain of its affiliated funds, as purchasers.

10.24 (19)

  

Registration Rights Agreement, dated as of November 3, 2017, by and between the registrant and Lincoln Park Capital Fund, LLC.

10.26 (20)

  

Waiver and Consent, dated as of December 14, 2017, by and among the registrant and the lenders party thereto.

10.27 (21)

  

Waiver and Consent, dated as of January 24, 2018, by and among the registrant and the lenders party thereto.

10.28 (4)

  

Amendment No. 2 to Term Loan Agreement, dated as of February 14, 2018, by and among the registrant and the lenders party thereto.

10.29 (4)

  

Series A Preferred Stock Purchase Agreement, dated as of February 14, 2018, by and among the registrant, CRG Partners III L.P. and certain of its affiliated funds, as purchasers.

10.30 (22)

  

Securities Purchase Agreement, dated as of July 12, 2018, by and among the registrant and the purchasers identified on the signature pages thereto.

10.36# (25)

  

Change of Control and Severance Agreement, dated as of October 10, 2013, between the registrant and Himanshu Patel.

10.37 (26)

  

Third Amendment to Lease Agreement dated April 1, 2019 by and between the registrant and HCP LS Redwood City, LLC.

10.41 (11)

  

Amendment No. 3 to Term Loan Agreement dated as of March 2, 2020, by and among the registrant and the lenders party thereto

10.42# (11)

  

Amendment No. 1 dated March 4, 2020 to the Change of Control and Severance Agreement, dated March 29, 2018, by and between the registrant and Jeff Soinski

10.43# (11)

  

Amendment No. 1 dated March 4, 2020 to the Change of Control and Severance Agreement, dated October 10, 2013, by and between the registrant and Himanshu Patel

10.46 (30)

  

Amendment No. 4 and Waiver to Term Loan Agreement

10.47 (31)

  

Amendment No. 5 to Term Loan Agreement, dated January 22, 2021, made by and among Avinger, Inc. and GRG Partners III L.P. and certain of its affiliated funds, as lenders.

10.48 (12)

  

Form of Securities Purchase Agreement, dated January 12, 2022 by and between Avinger, Inc. and the purchasers party thereto.

10.49 (33)

  

At the Market Offering Agreement dated May 20, 2022, by and between Avinger Inc., and H.C. Wainwright & Co., LLC

10.50# (34)

  

Change of Control and Severance Agreement dated May 16, 2022, by and between Avinger Inc., Nabeel Subainati

10.51 (35)

  

Form of Registration Rights Agreement between the Company and the purchasers identified therein dated August 3, 2022.

10.52 (36)

  

Amendment No. 6 to Term Loan Agreement, dated August 10, 2022, made by and among Avinger, Inc. and GRG Partners III L.P. and certain of its affiliated funds, as lenders.

10.53# (37)

  

Form of 2015 Equity Incentive Plan Restricted Stock Award Agreement.

10.54# (37)

  

Form of 2015 Equity Incentive Plan Restricted Stock Unit Award Agreement.

10.55(39)

  

Form of Registered Direct Securities Purchase Agreement.

 

84
 

 

10.56(39)

  

Form of Private Placement Securities Purchase Agreement.

10.57#(40)

  

Amended and Restated 2015 Equity Incentive Plan.

10.58#

  

Amendment No. 1 to Change in Control and Severance Agreement dated March 14, 2023 by and between the registrant and Nabeel Subainati

10.59#

  

Form of Retention Bonus Agreement

10.60#

  

Form of Restricted Stock Unit Award Grant Agreement

23.1

  

Consent of Independent Registered Public Accounting Firm.

24.1

  

Power of Attorney (included on signature page).

31.1

  

Certification of the Chief Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2

  

Certification of the Chief Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1

  

Certifications of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS

  

XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

101.SCH

  

Inline XBRL Taxonomy Extension Schema Document

101.CAL

  

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

  

Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

  

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE

  

Inline XBRL Taxonomy Extension Presentation Linkbase Document
104   Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document and contained in Exhibit 101.

 

# Management contract or compensatory plan or arrangement.

 

 

(1)

Previously filed as an Exhibit to the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 6, 2015, and incorporated by reference herein.
 

(2)

Previously filed as an Exhibit to the registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 2, 2018.
 

(3)

Previously filed as an Exhibit to Amendment No. 2 to the registrant’s Registration Statement on Form S-1 (File No. 333-222517) filed with the Securities and Exchange Commission on February 12, 2018, and incorporated by reference herein.
 

(4)

Previously filed as an Exhibit to Amendment No. 3 to the registrant’s Registration Statement on Form S-1 (File No. 333-222517) filed with the Securities and Exchange Commission on February 13, 2018, and incorporated by reference herein.
 

(5)

Previously filed as an Exhibit to the registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 6, 2018, and incorporated by reference herein.
 

(6)

Previously filed as an Exhibit to the registrant's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 21, 2019, and incorporated by reference herein.
 

(7)

Previously filed as an Exhibit to the registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 29, 2021, and incorporated by reference herein.
 

(8)

Previously filed as an Exhibit to Amendment No. 2 to the registrant’s Registration Statement on Form S-1 (File No. 333-201322) filed with the Securities and Exchange Commission on January 28, 2015, and incorporated by reference herein.
 

(9)

Previously filed as an Exhibit to Amendment No. 1 to the registrant’s Registration Statement on Form S-1 (File No. 333-227689) filed with the Securities and Exchange Commission on October 19, 2018, and incorporated by reference herein.
 

(10)

Previously filed as an Exhibit to the registrant’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 6, 2020, and incorporated by reference herein.
 

(11)

Previously filed as an Exhibit to the registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 12, 2022, and incorporated by reference herein.
 

(12)

Previously filed as an Exhibit to Amendment No. 1 to the registrant’s Registration Statement on Form S-1 (File No. 333-201322) filed with the Securities and Exchange Commission on January 20, 2015, and incorporated by reference herein.

 

85
 

 

 

(13)

Previously filed as an Exhibit to the registrant’s Registration Statement on Form S-1 (File No. 333-201322), filed with the Securities and Exchange Commission on December 30, 2014, and incorporated by reference herein.
 

(14)

Previously filed as an Exhibit to the registrant’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 13, 2018, and incorporated by reference herein.
 

(15)

Previously filed as an Exhibit to the registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 12, 2015, and incorporated by reference herein.
 

(16)

Previously filed as an Exhibit to the registrant’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 8, 2016, and incorporated by reference herein.
 

(17)

Previously filed as an Exhibit to the registrant’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2018, and incorporated by reference herein.
 

(18)

Previously filed as an Exhibit to the registrant’s Registration Statement on Form S-1 (File No. 333-221368), filed with the Securities and Exchange Commission on November 6, 2017, and incorporated by reference herein.
 

(19)

Previously filed as an Exhibit to the registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 14, 2017, and incorporated by reference herein.
 

(20)

Previously filed as an Exhibit to the registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 30, 2018, and incorporated by reference herein.
 

(21)

Previously filed as an Exhibit to the registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 13, 2018, and incorporated by reference herein.
 

(22)

Previously filed as an Exhibit to the registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 24, 2018, and incorporated by reference herein.
 

(23)

Previously filed as an Exhibit to the registrant’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 6, 2019, and incorporated by reference herein.
 

(24)

Previously filed as an Exhibit to the registrant's Current Report on Form 8-K filed with the Securities and Exchange Commission on April 5, 2019, and incorporated by reference herein.
 

(25)

Previously filed as an Exhibit to the registrant's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 8, 2019, and incorporated by reference herein.
 

(26)

Previously filed as an Exhibit to the registrant's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 5, 2019, and incorporated by reference herein.
 

(27)

Previously filed as an Exhibit to the registrant's Current Report on Form 8-K filed with the Securities and Exchange Commission on April 24, 2020, and incorporated by reference herein.
 

(28)

Previously filed as an Exhibit to the registrant's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 13, 2020, and incorporated by reference herein.
 

(29)

Previously filed as an Exhibit to the registrant's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 26, 2021, and incorporated by reference herein.
 

(30)

Previously filed as an Exhibit to the registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 14, 2022, and incorporated by reference herein.
 

(31)

Previously filed as an Exhibit to the registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 20, 2022, and incorporated by reference herein.
 

(32)

Previously filed as an Exhibit to the registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 22, 2022, and incorporated by reference herein.
 

(33)

Previously filed as an Exhibit to the registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 8, 2022, and incorporated by reference herein.
 

(34)

Previously filed as an Exhibit to the registrant’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 11, 2022, and incorporated by reference herein.
 

(35)

Previously filed as an Exhibit to the registrant’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2022, and incorporated by reference herein.
 

(36)

Previously filed as an Exhibit to the registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 23, 2022, and incorporated by reference herein.
 

(37)

Previously filed as an Exhibit to the Current Report on Form 8-K (File No. 001-36817) filed with the Securities and Exchange Commission on August 8, 2022, and incorporated by reference herein.
 

(38)

Previously filed as an Exhibit to the registrant’s Current Report on Form 8-K (File No. 001-36817) filed with the Securities and Exchange Commission on October 14, 2022, and incorporated by reference herein.

 

ITEM 16.     FORM 10-K SUMMARY

 

None.

 

86
 

 

AVINGER, INC.

INDEX TO FINANCIAL STATEMENTS

As of December 31, 2022 and 2021, and for the

Years Ended December 31, 2022 and 2021

 
 

Report of Independent Registered Public Accounting Firm (Moss Adams LLP, San Francisco, CA, PCAOB ID: 659)

F-2

Financial Statements:

  

Balance Sheets

F-4

Statements of Operations and Comprehensive Loss

F-5

Statements of Stockholders’ Equity

F-6

Statements of Cash Flows

F-7

Notes to Financial Statements

F-8

 

F-1
 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

The Stockholders and the Board of Directors

Avinger, Inc.

 

Opinion on the Financial Statements

 

We have audited the accompanying balance sheets of Avinger, Inc. (the “Company”) as of December 31, 2022 and 2021, the related statements of operations and comprehensive loss, stockholders’ equity, and cash flows for the years then ended, and the related notes and the financial statement schedules (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

 

Going Concern Uncertainty

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company’s recurring losses from operations and its need for additional capital raise substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures to respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matter

 

The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

 

F-2
 

 

Valuation of Inventories

 

As described in Note 2 and 4 to the financial statements, the Company’s inventories balance was $5.0 million as of December 31, 2021. The Company values its inventories at lower of cost (determined using the first-in, first-out method) or net realizable value. The Company writes down inventory that has expired or become obsolete, inventory that has a cost basis in excess of its expected net realizable value, and inventory in excess of expected requirements. The estimate of excess quantities is subjective and primarily dependent on the estimates of future demand for a particular product. Changes in assumptions of product demand could have a significant impact on the amount of write-down recorded. The evaluation by management includes analysis of historical sales levels by product, projections of future demand, the risk of technological or competitive obsolescence for products, general market conditions, as well as the feasibility of reworking or using excess or obsolete products or components in the production or assembly of other products that are not obsolete or for which there are not excess quantities in inventory.

 

We identified auditing the valuation of inventories, in particular the estimates for excess quantities and obsolescence, as a critical audit matter because of the significant assumptions and subjective judgments used by management, which involved significant audit effort and the use of especially challenging and subjective auditor judgment when performing audit procedures and evaluating the results of those procedures.

 

The primary procedures we performed to address the critical audit matter included:

 

 

●

Evaluating management’s process for developing the estimates of excess and obsolete inventories by:

 

 

●

 Evaluating the methodology utilized to calculate the estimate;

 

 

●

Assessing the appropriateness of the formulaic calculation and subjective management adjustments by product type;

 

 

●

Testing the mathematical accuracy of the formulaic calculation;

 

 

●

Performing inquiries with management as to the composition of the reserve for inventory items without recent sales.

 

 

●

Evaluating the reasonableness of the significant assumptions used by management including those related to future demand by:

 

 

●

Evaluating management’s ability to provide reasonable forecast of sales by comparing management’s prior period sales forecasts to actual results;

 

 

●

Performing inquiries with non-financial personnel, including sales and production employees, regarding obsolete or discontinued inventory items and other factors to corroborate management’s assertions regarding qualitative judgments about excess and obsolete inventories.

 

 

●

Testing the completeness, accuracy, and relevance of the underlying data used in management’s estimate

 

 

●

Testing the calculations related to the application of the methodology to specific inventory categories by agreement to supporting documentation and recalculation.

 

 

●

Developing an independent expectation of the excess and obsolescence reserve based primarily on historical trends, and compared that expectation to the recorded amount for reasonableness.

 

/s/ Moss Adams LLP

 

San Francisco, California

March 15, 2023

 

We have served as the Company’s auditor since 2017.

 

F-3
 

 

 

AVINGER, INC.

BALANCE SHEETS

(In thousands, except share and per share data)

 

   

December 31,

    

December 31,

  
   

2022

    

2021

  
Assets                
Current assets:                

Cash and cash equivalents

   $ 14,603     $ 19,497  

Accounts receivable, net of allowance for doubtful accounts of $73 and $6 at December 31, 2022 and 2021, respectively

     1,057       1,393  

Inventories, net

     4,965       4,601  

Prepaid expenses and other current assets

     362       300  

Total current assets

     20,987       25,791  
                 

Right of use asset

     2,194       3,179  

Property and equipment, net

     702       95  

Other assets

     312       420  

Total assets

   $ 24,195     $ 29,485  
                 
Liabilities and stockholders’ equity                
Current liabilities:                

Accounts payable

   $ 631     $ 1,394  

Accrued compensation

     1,401       1,609  

Accrued expenses and other current liabilities

     657       718  

Leasehold liability, current portion

     1,092       985  

Borrowings, current portion

     14,165       —  

Total current liabilities

     17,946       4,706  
                 

Borrowings, long-term portion

     —       12,287  

Leasehold liability, long-term portion

     1,102       2,194  

Other long-term liabilities

     1,001       575  

Total liabilities

     20,049       19,762  
                 
Commitments and contingencies (Note 9)            
                 
Stockholders’ equity:                

Convertible preferred stock issuable in series, par value of $0.001

                

Shares authorized: 5,000,000 at December 31, 2022 and 2021

                

Shares issued and outstanding: 60,961 and 56,451 at December 31, 2022 and 2021, respectively; aggregate liquidation preference related to Series A convertible preferred stock of $60,876 and $56,366 at December 31, 2022 and 2021, respectively

     —       —  

Common stock, par value of $0.001

                

Shares authorized: 100,000,000 at December 31, 2022 and 2021

                

Shares issued and outstanding: 7,832,644 and 4,778,263 at December 31, 2022 and 2021, respectively

     8       5  

Additional paid-in capital

     406,514       394,471  

Accumulated deficit

     (402,376

)

     (384,753

)

Total stockholders’ equity

     4,146       9,723  

Total liabilities and stockholders’ equity

   $ 24,195     $ 29,485  

 

All share, per share data, par values, and additional paid-in-capital amounts reflect the impact of the reverse stock split effective March 14, 2022. See accompanying notes.

 

F-4
 

 

 

AVINGER, INC.

STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except per share data)

 

   

Year Ended December 31,

  
   

2022

    

2021

  

Revenues

   $ 8,273     $ 10,130  

Cost of revenues

     5,619       6,706  

Gross profit

     2,654       3,424  
                 
Operating expenses:                

Research and development

     4,390       5,900  

Selling, general and administrative

     14,221       15,625  

Total operating expenses

     18,611       21,525  

Loss from operations

     (15,957

)

     (18,101

)
                 

Interest expense, net

     (1,665

)

     (1,648

)

Other (expense) income, net

     (1

)

     2,337  

Net loss and comprehensive loss

     (17,623

)

     (17,412

)

Accretion of preferred stock dividends

     (4,510

)

     (4,175

)

Deemed dividend arising from beneficial conversion feature of convertible preferred stock

     (5,111

)

     —  

Net loss applicable to common stockholders

   $ (27,244

)

   $ (21,587

)

Net loss per share attributable to common stockholders, basic and diluted

   $ (4.36

)

   $ (4.57

)
                 

Weighted average common shares used to compute net loss per share, basic and diluted

     6,249       4,722  

 

All share and per share data reflect the impact of the reverse stock split effective March 14, 2022. See accompanying notes.

 

F-5
 

 

 

AVINGER, INC.

STATEMENTS OF STOCKHOLDERS’ EQUITY

(In thousands, except share data)

 

   

Convertible

Preferred Stock

    

Common Stock

                    

 

  
   

Shares

    

Amount

    

Shares

    

Amount

    

Additional

Paid-
In Capital

    

Accumulated
Deficit

    

 

Total

Stockholders’
Equity

 

Balance at December 31, 2020

     52,369     $ —       4,246,308     $ 4     $ 380,413     $ (367,341

)

   $ 13,076  

Issuance of common stock in public offerings, net of commissions and issuance costs

     —       —       500,000       1       13,043       —       13,043  

Conversion of Series B preferred stock into common stock

     (93

)

     —       18,600       —       —       —       —  

Issuance of common stock upon vesting of restricted stock units

     —       —       13,355       —       —       —       —  

Employee stock-based compensation

     —       —       —       —       1,015       —       1,015  

Issuance of Series A preferred stock to pay dividends

     4,175       —       —       —       4,175      

—

       4,175  

Accretion of Series A preferred stock dividends

     —       —       —       —       (4,175

)

     —       (4,175

)

Net and comprehensive loss

     —       —       —       —       —       (17,412

)

     (17,412

)

Balance at December 31, 2021

     56,451       —       4,778,263       5       394,471       (384,753

)

     9,723  

Issuance of common stock in public offerings, net of commissions and issuance costs

     —       —       1,285,603       1       5,195       —       5,196  

Issuance of Series D preferred stock, net of commissions and issuance costs

     7,600       —       —       —       6,721       —       6,721  

Conversion of Series D preferred stock into common stock

     (7,600

)

     —       950,000       1       —       —       1  

Exercise of pre-funded warrants for common stock

     —       —       784,019       1       —       —       1  

Reclassifications and adjustments due to rounding impact from reverse stock split for fractional shares

     —       —       26,169       —       —       —       —  

Issuance of common stock upon vesting of restricted stock units

     —       —       8,590       —       —       —       —  

Employee stock-based compensation

     —       —       —       —       127       —       127  

Issuance of Series A preferred stock to pay dividends

     4,510       —       —       —       4,510       —       4,510  

Accretion of Series A preferred stock dividends

     —       —       —       —       (4,510

)

     —       (4,510

)

Net and comprehensive loss

     —       —       —       —       —       (17,623

)

     (17,623

)

Balance at December 31, 2022

     60,961     $ —       7,832,644     $ 8     $ 406,514     $ (402,376

)

   $ 4,146  

 

All share and per share data reflect the impact of the reverse stock split effective March 14, 2022. See accompanying notes.

 

F-6
 

 

 

AVINGER, INC.

STATEMENTS OF CASH FLOWS

(In thousands)

 

   

Year Ended December 31,

  
   

2022

    

2021

  
Cash flows from operating activities                

Net loss

   $ (17,623

)

   $ (17,412

)

Adjustments to reconcile net loss to net cash used in operating activities:

                

Depreciation and amortization

     196       687  

Amortization of debt issuance costs and debt discount

     83       86  

Stock-based compensation

     127       1,015  

Noncash interest expense and other charges

     1,795       1,564  

Change in right of use asset

     93       133  

Provision for excess and obsolete inventories

     272       125  

Gain on extinguishment of debt

     —       (2,353

)

Other non-cash charges

     69       2  

Changes in operating assets and liabilities:

                

Accounts receivable

     269       89  

Inventories

     (1,387

)

     (849

)

Prepaid expenses and other current assets

     (62

)

     50  

Other assets

     15       (43 )

Accounts payable

     (764

)

     679  

Accrued compensation

     (208 )     (94

)

Accrued expenses and other current liabilities

     (61 )     49  

Other long-term liabilities

     426       575  

Net cash used in operating activities

     (16,760

)

     (15,697

)
                 
Cash flows from investing activities                

Purchase of property and equipment

     (51

)

     (34

)

Net cash used in investing activities

     (51

)

     (34

)
                 
Cash flows from financing activities                

Proceeds from the issuance of convertible preferred stock, net of commissions and issuance costs

     6,721       —  

Proceeds from the issuance of common stock in public offerings, net of commissions and issuance costs

     5,196       13,043  

Net cash provided by financing activities

     11,917       13,043  
                 

Net change in cash and cash equivalents

     (4,894 )     (2,688

)

Cash and cash equivalents, beginning of period

     19,497       22,185  

Cash and cash equivalents, end of period

   $ 14,603     $ 19,497  
                 
Supplemental disclosure of cash flow information                
                 
Noncash investing and financing activities:                
                 

Accretion of Series A preferred stock dividends

   $ 4,510     $ 4,175  

Issuance of Series A preferred stock as dividend payment

   $ 4,510     $ 4,175  

Transfers between inventory and property and equipment

   $ 751     $ (1

)

Purchases of property and equipment in accounts payable

   $ —     $ 21  

 

See accompanying notes.

 

F-7
 

 

AVINGER, INC.

 

Notes to Financial Statements

 

 

 

1.

Organization

 

Organization, Nature of Business

 

Avinger, Inc. (the “Company”), a Delaware corporation, was incorporated in March 2007. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease (“PAD”). Patients with PAD have a build-up of plaque in the arteries that supply blood to areas away from the heart, particularly the pelvis and legs. The Company manufactures and sells a suite of products in the United States (“U.S.”) and in select international markets. The Company has developed its Lumivascular platform, which integrates optical coherence tomography (“OCT”) visualization with interventional catheters and is the industry’s only system that provides real-time intravascular imaging during the treatment portion of PAD procedures. The Company’s Lumivascular platform consists of a capital component, Lightbox consoles, as well as a variety of disposable catheter products. The Company’s current catheter products include Ocelot and Tigereye, which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (“CTO”). The Company also has image-guided atherectomy products, Pantheris and Pantheris SV, which are designed to allow physicians to precisely remove arterial plaque in PAD patients. The Company is in the process of developing next-generation CTO crossing devices to target coronary CTO markets. The Company is located in Redwood City, California.

 

Liquidity Matters

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40) requires the Company to make certain disclosures if it concludes that there is substantial doubt about the entity’s ability to continue as a going concern within one year from the date of the issuance of these financial statements.

 

In the course of its activities, the Company has incurred losses and negative cash flows from operations since its inception. As of December 31, 2022, the Company had an accumulated deficit of $402.4 million. The Company expects to incur losses for the foreseeable future. The Company believes that its cash and cash equivalents of $14.6 million at December 31, 2022 and expected revenues from operations will be sufficient to allow the Company to fund its current operations through the end of the third quarter of 2023. The Company received net proceeds of approximately $4.4 million from the sale of its common stock in August 2022, $0.8 million from the sale of its common stock under an At The Market Offering Agreement during the year ended December 31, 2022, $6.7 million from the January 2022 Series D preferred stock and $13.0 million from the sale of its common stock in February 2021. The Company may seek to raise additional funds in future equity offerings to meet its operational needs and capital requirements for product development, clinical trials and commercialization or other strategic objectives.

 

The Company can provide no assurance that it will be successful in raising funds pursuant to additional equity or debt financings or that such funds will be raised at prices that do not create substantial dilution for its existing stockholders. Given the volatility in the Company’s stock price, any financing that the Company may undertake in the next twelve months could cause substantial dilution to its existing stockholders, and there can be no assurance that the Company will be successful in acquiring additional funding at levels sufficient to fund its various endeavors. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. In addition, the COVID-19 pandemic and macroeconomic environment have in the past and could result in reduced consumer and investor confidence, instability in the credit and financial markets, volatile corporate profits, restrictions on elective medical procedures, and reduced business and consumer spending, which could increase the cost of capital and/or limit the availability of capital to the Company.

 

If the Company is unable to raise additional capital in sufficient amounts or on terms acceptable to it, the Company may have to significantly reduce its operations or delay, scale back or discontinue the development and sale of one or more of its products. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company’s ultimate success will largely depend on its continued development of innovative medical technologies, its ability to successfully commercialize its products and its ability to raise significant additional funding.

 

F-8
 

 

Additionally, due to the substantial doubt about the Company’s ability to continue operating as a going concern and the “Material Adverse Change” clause in the Loan Agreement with CRG Partners III L.P. and certain of its affiliated funds (collectively “CRG”), the entire amount of outstanding borrowings at December 31, 2022 and 2021 has been classified as current in these financial statements. CRG has not purported that an Event of Default (as defined in the Loan Agreement) has occurred due to a Material Adverse Change.

 

Currently all of our cash and cash equivalents are held at a single financial institution, Silicon Valley Bank. On March 10, 2023, the Federal Deposit Insurance Corporation announced that Silicon Valley Bank had been closed by the California Department of Financial Protection and Innovation. While we have regained access to our accounts at Silicon Valley Bank and are evaluating our banking relationships, future disruptions of financial institutions where we bank or have credit arrangements, or disruptions of the financial services industry in general, could adversely affect our ability to access our cash and cash equivalents. If we are unable to access our cash and cash equivalents as needed, our financial position and ability to operate our business will be adversely affected.

 

Public Offerings

 

Past Offerings

 

On February 2, 2021, under a shelf registration statement, the Company completed a bought deal offering of 500,000 shares of common stock at an offering price of $28.80 per share. As a result, the Company received aggregate net proceeds of approximately $13.0 million after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses.

 

January 2022 Offering

 

On January 14, 2022, the Company entered into a securities purchase agreement with several institutional investors pursuant to which the Company agreed to sell and issue, in a registered direct offering (“January 2022 Offering”), an aggregate of 7,600 shares of the Company’s Series D Convertible Preferred Stock, par value of $0.001 per share, at an offering price of $1,000 per share which was convertible into common stock at a conversion price of $8.00 per share. Concurrently, the Company agreed to issue to these investors warrants to purchase up to an aggregate of 807,500 shares of the Company’s common stock (the “Common Warrants”). As a result, the Company received aggregate net proceeds of approximately $6.7 million after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses.

 

The 807,500 Common Warrants have an exercise price of $9.60 per share and became exercisable beginning July 14, 2022. The Common Warrants will expire five years following the time they become exercisable, or July 14, 2027. The Company also issued to the Placement Agent or its designees warrants to purchase up to an aggregate of 66,500 shares of common stock (the “Placement Agent Warrants”). The Placement Agent Warrants are subject to the same terms as the Common Warrants, except that the Placement Agent Warrants have an exercise price of $10.00 per share and a term of five years from the commencement of the sales pursuant to the January 2022 Offering, or January 12, 2027.

 

August 2022 Offering

 

On August 4, 2022, the Company entered into a securities purchase agreement with a single institutional investor for the issuance and sale of 1,484,019 shares of its common stock in a registered direct offering (“RD” or “Registered Direct”) at a purchase price of $1.752 per share, or pre-funded warrants in lieu thereof. In a concurrent private placement, the Company also agreed to issue and sell to the investor 1,369,864 shares of common stock at the same purchase price as in the registered direct offering, or pre-funded warrants in lieu thereof (“Private Placement” and together with the Registered Direct offering the “August 2022 Offering”). As a result, the Company received aggregate net proceeds of approximately $4.4 million after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses.

 

As a result, in the Registered Direct offering, the Company issued (i) 700,000 shares of common stock, (ii) and pre-funded warrants in lieu of common stock to purchase up to an aggregate of 784,019 shares of common stock (the “RD Pre-Funded Warrants”) and in the Private Placement, the Company issued pre-funded warrants to purchase up to an aggregate of 1,369,864 shares of common stock (the “Private Placement Pre-Funded Warrants” and together with the RD Pre-Funded Warrants the “August 2022 Pre-Funded Warrants”). As of December 31, 2022, Pre-Funded Warrants exercisable for 622,000 shares of the Company’s common stock remained outstanding.

 

F-9
 

 

In addition, the Company issued to the investor in the August 2022 Offering Series A preferred investment options to purchase up to 2,853,883 additional shares of the Company’s common stock and Series B preferred investment options to purchase up to 2,853,883 additional shares of the Company’s common stock (the “Preferred Investment Options”). The Series A preferred investment options have an exercise price of $1.502 per share, are immediately exercisable, and will expire five and one-half years from the date of issuance, or February 8, 2028, and the Series B preferred investment options have an exercise price of $1.502 per share, are immediately exercisable, and will expire two years from the date of issuance, or August 8, 2024. The Company also issued to the Placement Agent or its designees preferred investment options to purchase up to an aggregate of 171,233 shares of common stock (the “Placement Agent Preferred Investment Options”). The Placement Agent Preferred Investment Options are subject to the same terms as the Preferred Investment Options, except that the Placement Agent Preferred Investment Options have an exercise price of $2.19 per share and a term of five years from the commencement of the sales pursuant to the August 2022 Offering, or August 3, 2027.

 

At The Market Offering Agreement

 

On May 20, 2022, the Company entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (the “Agent”), as sales agent, pursuant to which the Company may offer and sell shares of common stock, par value $0.001 per share (the “Shares”) up to an aggregate offering price of $7,000,000 from time to time, in an at the market public offering. Sales of the Shares are to be made at prevailing market prices at the time of sale, or as otherwise agreed with the Agent. The Agent will receive a commission from the Company of 3.0% of the gross proceeds of any Shares sold under the ATM Agreement. The Shares sold under the ATM Agreement are offered and sold pursuant to the Company’s shelf registration statement on Form S-3, which was initially filed with the Securities and Exchange Commission (the “SEC”) on March 29, 2022 and declared effective on April 7, 2022, and a prospectus supplement and the accompanying prospectus relating to the At The Market Offering filed with the SEC on May 20, 2022. During the year ended December 31, 2022, the Company sold 585,603 shares of common stock pursuant to the ATM Agreement at an average price of $1.67 per share for aggregate proceeds of $1.0 million, of which approximately $29,000 was paid in the form of commissions to the Agent. Other than the ATM Agreement, the Company currently does not have any commitments to obtain additional funds. On August 3, 2022, the Company suspended sales under the ATM Agreement. The Company plans to reactivate the ATM Agreement in March 2023 and may resume sales in the future. However, there can be no assurance that the Company will be successful in acquiring additional funding through these means.

 
 

2. Summary of Significant Accounting Policies

 

Basis of Presentation

 

The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”).

 

On March 11, 2022, the Company’s Board of Directors approved an amendment to the Company’s amended and restated certificate of incorporation to effect a 1-for-20 reverse stock split of the Company’s issued and outstanding common stock. The reverse stock split became effective on March 14, 2022. The par value of the common stock and preferred stock was not adjusted as a result of the reverse stock split. All common stock, stock options, restricted stock units, and per share amounts in the financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split. Additionally, the common stock at par and related additional paid-in capital amounts as of December 31, 2021 in the balance sheet, the common stock at par and related additional paid-in capital amounts in the Statement of Stockholder’s Equity as of December 31, 2021 and 2020, and for the year ended December 31, 2021 have also been retroactively reclassified to give effect to the reverse stock split.

 

Use of Estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to its stock-based compensation, accruals related to compensation, the valuation of the common stock warrants, provisions for doubtful accounts receivable and excess and obsolete inventories, clinical trial accruals, and its reserves for sales returns and warranty costs. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.

 

F-10
 

 

Fair Value of Financial Instruments

 

The Company has evaluated the estimated fair value of its financial instruments as of December 31, 2022 and 2021. Financial instruments consist of cash and cash equivalents, accounts receivable and payable, and other current liabilities and borrowings. The carrying amounts of cash and cash equivalents, accounts receivable and payable, and other current liabilities approximate their respective fair values because of the short-term nature of those instruments. Based upon the borrowing terms and conditions currently available to the Company, the carrying values of the borrowings approximate their fair value.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents are considered available-for-sale marketable securities and are recorded at fair value, based on quoted market prices. As of December 31, 2022 and 2021, the Company’s cash equivalents are entirely comprised of investments in money market funds. Any related unrealized gains and losses are recorded in other comprehensive income (loss) and included as a separate component of stockholders’ equity. There were no unrealized gains and losses as of December 31, 2022 and 2021. Any realized gains and losses and interest and dividends on available-for-sale securities are included in interest income or expense and computed using the specific identification cost method.

 

Concentration of Credit Risk, and Other Risks and Uncertainties

 

Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and accounts receivable to the extent of the amounts recorded on the balance sheets.

 

The Company’s policy is to invest in cash and cash equivalents, consisting of money market funds. These financial instruments are held in Company accounts at one financial institution, Silicon Valley Bank. The counterparties to the agreements relating to the Company’s investments consist of financial institutions of high credit standing. The Company provides for uncollectible amounts when specific credit problems arise. Management’s estimates for uncollectible amounts have been adequate, and management believes that all significant credit risks have been identified at December 31, 2022 and 2021. On March 10, 2023, the Federal Deposit Insurance Corporation announced that Silicon Valley Bank had been closed by the California Department of Financial Protection and Innovation. While we have regained access to our accounts at Silicon Valley Bank and are evaluating our banking relationships, future disruptions of financial institutions where we bank or have credit arrangements, or disruptions of the financial services industry in general, could adversely affect our ability to access our cash and cash equivalents. If we are unable to access our cash and cash equivalents as needed, our financial position and ability to operate our business will be adversely affected.

 

The Company’s accounts receivable are due from a variety of healthcare organizations in the United States and select international markets. The Company provides for uncollectible amounts when specific credit problems arise. Management's estimates for uncollectible amounts have been adequate, and management believes that all significant credit risks have been identified at December 31, 2022 and 2021. At December 31, 2022, there was no customer that represented 10% or more of the Company’s accounts receivable, whereas at December 31 2021, there was one customer that represented 21% of accounts receivable. For the year ended December 31, 2022 and 2021, there was one customer that represented approximately 14% and 10% of revenues, respectively. Disruption of sales orders or a deterioration of financial condition of its customers would have a negative impact on the Company’s financial position and results of operations.

 

The Company manufactures its commercial products in-house, including the Pantheris and Ocelot family of catheters. Certain of the Company’s product components and sub-assemblies are manufactured by sole suppliers, including internally. Disruption in component or sub-assembly supply from these manufacturers or from in-house production would have a negative impact on the Company’s financial position and results of operations.

 

The Company is subject to certain risks, including that its devices may not be approved or cleared for marketing by governmental authorities or be successfully marketed. There can be no assurance that the Company’s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and with appropriate performance characteristics. The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, dependence upon third-party payors to provide adequate coverage and reimbursement, dependence on key personnel and suppliers, protection of proprietary technology, product liability claims, and compliance with government regulations.

 

Existing or future devices developed by the Company may require approvals or clearances from the FDA or international regulatory agencies. In addition, in order to continue the Company’s operations, compliance with various federal and state laws is required. If the Company were denied or delayed in receiving such approvals or clearances, it may be necessary to adjust operations to align with the Company’s currently approved portfolio. If clearance for the products in the current portfolio were withdrawn by the FDA, this may have a material adverse impact on the Company.

 

F-11
 

 

Disruption of our supply chain capabilities due to trade restrictions, political instability, severe weather, natural disasters, public health crises, terrorism, product recalls, labor supply or stoppages, the financial or operational instability of key suppliers and carriers, government restrictions or measures, or other reasons could impair our ability to distribute our products. The Company believes COVID-19 and the subsequent burdens on the hospital systems has had and will continue to have an adverse effect on its ability to generate sales due to the fluctuating and unpredictable levels of capacity medical providers have to perform procedures that require the use of its products.

 

The Company is closely monitoring general economic conditions on global supply chain, manufacturing, and logistics operations. As inflationary pressures increase, the Company anticipates that its production and operating costs may similarly increase, including costs and availability of materials and labor. While the Company has sufficient inventory on-hand to meet its current production requirements and customer demand, it has experienced some constraints with respect to the availability of certain materials and extended lead times from certain key suppliers. The Company has also experienced some delays in shipping products to its customers. Any significant delay or interruption in our supply chain could impair the Company’s ability to meet the demands of its customers in the future and could harm its business.

 

We use technology in substantially all aspects of our business operations, and our ability to serve customers most effectively depends on the reliability of our technology systems. Cybersecurity incidents can include computer viruses, computer denial-of-service attacks, worms, and other malicious software programs or other attacks, covert introduction of malware to computers and networks, impersonation of authorized users, and efforts to discover and exploit any design flaws, bugs, security vulnerabilities or security weaknesses, as well as intentional or unintentional acts by employees or other insiders with access privileges, intentional acts of vandalism by third parties and sabotage.

 

In addition, our technology infrastructure and systems are vulnerable to damage or interruption from natural disasters, power loss and telecommunications failures. Any such disruption to our systems, or the technology systems of third parties on which we rely, the failure of these systems to otherwise perform as anticipated, or the theft, destruction, loss, misappropriation, or release of sensitive and/or confidential information or intellectual property, could require us to notify affected individuals, federal or state agencies or media outlets of the incident and could result in business disruption, negative publicity, loss of customers, potential liability, including litigation or other legal actions against us or the imposition of penalties, fines, fees or liabilities, which may not be covered by our insurance policies, and competitive disadvantage, any or all of which would potentially adversely affect our customer service, decrease the volume of our business and result in increased costs and lower profits. Moreover, a cybersecurity breach could require us to devote significant management resources to address the problems associated with the breach and to expend significant additional resources to upgrade further the security measures we employ to protect information against cyber-attacks and other wrongful attempts to access such information, which could result in a disruption of our operations.

 

While we have invested, and continue to invest, in technology security initiatives and other measures to prevent security breaches and cyber incidents, as well as disaster recovery plans, these initiatives and measures may not be entirely effective to insulate us from technology disruption that could result in adverse effects on our results of operations.

 

Accounts Receivable

 

Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable. The Company determines the allowance for doubtful accounts based upon an aging of accounts receivable, historical experience, and management judgment. Accounts receivable balances are reviewed individually for collectability. To date, the Company has not experienced significant credit-related losses.

 

Accounts receivable allowance for doubtful accounts provision and recoveries or write-offs are summarized as follows (in thousands):

 

   

2022

    

2021

  

Beginning balance

   $ 6     $ 19  

Provision

     70       2  

Recoveries/write-offs

     (3

)

     (15

)

Ending balance

   $ 73     $ 6  

 

F-12
 

 

Inventories

 

Inventories are valued at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method for all inventories. The Company’s policy is to write down inventory that has expired or become obsolete, inventory that has a cost basis in excess of its expected net realizable value, and inventory in excess of expected requirements. At each balance sheet date, management evaluates inventories for excess quantities, and obsolescence. This evaluation by management includes analysis of historical sales levels by product, projections of future demand, the risk of technological or competitive obsolescence for products, general market conditions, as well as the feasibility of reworking or using excess or obsolete products or components in the production or assembly of other products that are not obsolete or for which there are not excess quantities in inventory. To the extent that management determines there are excess or obsolete inventory, management adjusts the carrying value to estimated net realizable value. When quantities on hand exceed sales forecasts, a write-down is recorded for such excess inventories along with a corresponding charge to cost of revenues. The estimate of excess quantities is subjective and primarily dependent on the estimates of future demand for a particular product. Specifically, the future demand is derived based on our historical experience, from discussion with users of our products and general market conditions. Changes in assumptions of product demand could have a significant impact on the amount of write-down recorded. Inventory used in clinical trials is expensed at the time of production and recorded as research and development expense if the inventory is contractually being provided at no cost to the clinical site. The cost of inventories are regularly reviewed against estimated market value and record a lower of cost or market reserve for inventories that have a cost in excess of estimated market value, which could have a material impact on the gross margin and inventory balances based on additional write-downs to net realizable value or a benefit from inventories previously written down.

 

Property and Equipment

 

Property and equipment are recorded at cost. Repairs and maintenance costs are expensed as incurred. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets of generally three to five years. Depreciation expense includes the amortization of assets acquired under capital leases and equipment located with the Company’s sales personnel or at customer sites. Equipment held by customers is comprised of the Lightbox consoles located at customer sites under a lease or placement agreement. Equipment held by field sales personnel is also comprised of the Lightbox consoles in their possession. The related equipment is reclassified from inventory to the property and equipment account either upon execution of a lease or placement agreement for customers or upon shipment to a field salesperson. Depreciation expense for equipment held by customers or field sales personnel is recorded as a component of cost of revenues. Leasehold improvements and assets recorded under capital leases are amortized using the straight-line method over the shorter of the lease term or estimated useful economic life of the asset.

 

Impairment of Long-Lived Assets

 

The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. If indicators of impairment exist, an impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Impairment, if any, is measured as the amount by which the carrying amount of the long-lived asset exceeds its fair value. The Company has not recorded any impairment of long-lived assets since inception through December 31, 2022.

 

F-13
 

 

Revenue Recognition

 

The Company’s revenues are derived from (1) sale of Lightbox consoles, (2) sale of disposables, which consist of catheters and accessories, and (3) sale of customer service contracts and maintenance. The Company sells its products directly to hospitals and medical centers as well as through distributors. The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. The Company’s revenues are measured based on consideration specified in the contract with each customer, net of any sales incentives and taxes collected from customers that are remitted to government authorities. For all sales, the Company uses either a signed agreement or a binding purchase order as evidence of an arrangement. The Company’s revenue recognition policies generally result in revenue recognition at the following points:

 

 

1.

Lightbox console sales: Provided all other criteria for revenue recognition have been met, the Company recognizes revenue for Lightbox console sales directly to end customers when delivery and acceptance occurs, which is defined as receipt by the Company of an executed form that the installation process is complete.
   

 
 

2.

Sales of disposables: Disposable revenues consist of sales of the Company’s catheters and accessories and are recognized when the product has shipped, risk of loss and title has passed to the customer and collectability is reasonably assured.
   

 
 

3.

Service revenue: Service contract revenue consists of preventative maintenance, upgrades, and service contracts. Service contracts are recognized ratably over the term of the service period and maintenance contract revenue is recognized when work is completed. To date, service revenue has been insignificant.

 

The Company offers its customers the ability to purchase or lease the Lightbox console. In addition, the Company provides a Lightbox under a limited commercial evaluation program to allow accounts to install and utilize the Lightbox for a limited trial period. When a Lightbox is placed under a lease agreement or under a commercial evaluation program, the Company retains title to the equipment and it remains capitalized on its balance sheet under property and equipment. Depreciation expense on these placed Lightboxes is recorded to cost of revenues on a straight-line basis. The costs to maintain these placed Lightboxes are charged to cost of revenues as incurred.

 

The Company evaluates its lease and commercial evaluation program agreements and accounts for these contracts under the guidance in Accounting Standards Codification (“ASC”) 842, Leases and ASU No. 2014 09, Revenue from Contracts with Customers (Topic 606). The guidance requires arrangement consideration to be allocated between a lease deliverable and a non-lease deliverable based upon the relative selling-price of the deliverables.

 

The Company assessed whether the embedded lease is an operating lease or sales-type lease. Based on the Company’s assessment of the guidance and given that any payments under the lease agreements are dependent upon contingent future sales, it was determined that collectability of the minimum lease payments is not reasonably predictable. Accordingly, the Company concluded the embedded lease did not meet the criteria of a sales-type lease and accounts for it as an operating lease. The Company recognizes revenue allocated to the lease as the contingent disposable product purchases are delivered and are included in revenues within the statement of operations and comprehensive loss.

 

For sales through distributors, the Company recognizes revenue when control of the product transfers from the Company to the distributor. The distributors are responsible for all marketing, sales, training and warranty in their respective territories. The standard terms and conditions contained in the Company’s distribution agreements do not provide price protection or stock rotation rights to any of its distributors. In addition, its distributor agreements do not allow the distributor to return or exchange products, and the distributor is obligated to pay the Company upon invoice regardless of its ability to resell the product.

 

Cost of Revenues

 

Cost of revenues consists primarily of manufacturing overhead costs, material costs and direct labor. A significant portion of the Company’s cost of revenues currently consists of manufacturing overhead costs. These overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management. Cost of revenues also includes depreciation expense for the Lightboxes under lease, deployed with sales personnel and evaluation agreements, product warranty costs, product written-off due to excess or obsolescence, and certain direct costs such as shipping costs.

 

F-14
 

 

Product Warranty Costs

 

The Company typically offers a one-year warranty on its products commencing upon the transfer of title and risk of loss to the customer. The Company accrues for the estimated cost of product warranties upon invoicing its customers, based on historical results. Warranty costs are reflected in the statement of operations and comprehensive loss as a cost of revenues. The warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Should actual product failure rates, material usage or service delivery costs differ from these estimates, revisions to the estimated warranty liability would be required. Periodically the Company assesses the adequacy of its recorded warranty liabilities and adjusts the amounts as necessary. Warranty provisions and claims are summarized as follows (in thousands):

 

 

   

2022

    

2021

  

Beginning balance

   $ 187     $ 193  

Warranty provision

     22       49  

Usage/Release

     (100

)

     (55

)

Ending balance

   $ 109     $ 187  

 

Research and Development

 

The Company expenses research and development costs as incurred. Research and development expenses include personnel and personnel-related costs, costs associated with pre-clinical and clinical development activities, and costs for prototype products that are manufactured prior to market approval for that prototype product, and internal and external costs associated with the Company’s regulatory compliance, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs, including allocated facility and related expenses.

 

Clinical Trials

 

The Company accrues and expenses costs for its clinical trial activities performed by third parties, including clinical research organizations and other service providers, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company determines these estimates through discussion with internal personnel and outside service providers as to progress or stage of completion of trials or services pursuant to contracts with clinical research organizations and other service providers and the agreed-upon fee to be paid for such services.

 

Stock-Based Compensation

 

Stock-based compensation for the Company includes amortization related to all stock options, restricted stock units (“RSU”), and restricted stock awards (“RSA”) based on the grant-date estimated fair value. The fair value of stock options is estimated on the date of grant using the Black-Scholes option pricing model and recognized as expense on a straight-line basis over the vesting period of the award. The Company has not granted any stock options since 2017. The Company measures the fair value of RSUs and RSAs using the closing stock price of a share of the Company’s common stock on the grant date and is recognized as expense on a straight-line basis over the vesting period of the award. As allowed under ASU No. 2016‑09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, the Company accounts for forfeitures as they occur.

 

Foreign Currency

 

The Company records net gains and losses resulting from foreign exchange transactions as a component of foreign currency exchange losses in other income, net. During the years ended December 31, 2022 and 2021, the Company recorded $12,000 and $16,000 of foreign currency exchange net losses, respectively.

 

Income Taxes

 

The Company utilizes the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax reporting bases of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense when they occur. During the years ended December 31, 2022 and 2021, the Company did not recognize accrued interest or penalties related to unrecognized tax benefits.

 

F-15
 

 

Net Loss per Share Attributable to Common Stockholders

 

Basic net loss per share attributable to common stockholders is computed by dividing the net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss applicable to common stockholders by the weighted average number of shares of common stock and dilutive potential shares of common stock outstanding during the period. Any common stock shares subject to repurchase are excluded from the calculations as the continued vesting of such shares is contingent upon the holders’ continued service to the Company. As of December 31, 2022 and 2021, there were no shares subject to repurchase. Since the Company was in a loss position for both periods presented, basic net loss per share attributable to common stockholders is the same as diluted net loss per share attributable to common stockholders as the inclusion of all potentially dilutive common shares would have been anti-dilutive.

 

Net loss per share attributable to common stockholders was determined as follows (in thousands, except per share data):

 

   

Year Ended December 31,

  
   

2022

    

2021

  

Net loss applicable to common stockholders

   $ (27,244

)

   $ (21,587

)

Weighted average common stock outstanding, basic and diluted

     6,249       4,722  

Net loss per share attributable to common stockholders, basic and diluted

   $ (4.36

)

   $ (4.57

)

 

The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted average shares outstanding because such securities have an anti-dilutive impact due to losses reported:

 

   

Year Ended December 31,

  
   

2022

    

2021

  

Common stock warrants equivalents

     4,009,679       135,429  

Common stock options

     303       304  

Convertible preferred stock

     58,080       52,289  

Unvested restricted stock units

     6,626       17,817  
      4,074,688       205,839  

 

Comprehensive Loss

 

For the years ended December 31, 2022 and 2021, there was no difference between comprehensive loss and the Company’s net loss.

 

Segment and Geographical Information

 

The Company operates and manages its business as one reportable and operating segment. The Company’s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. Primarily all of the Company’s long-lived assets, which are comprised of property and equipment, are based in the United States. For the years ended December 31, 2022 and 2021, 92% and 94% of the Company’s revenues were in the United States, based on the shipping location of the external customer. The remaining revenues for the years ended December 31, 2022 and 2021, were principally in Germany.

 

Recent Accounting Pronouncements

 

Recently adopted accounting standards

 

In May 2021, ASU No. 2021-04, Issuer’s Accounting for Certain Modifications of Exchanges of Freestanding Equity-Classified Written Call Options was issued to clarify the accounting for modifications or exchanges of freestanding equity-classified written call options, such was warrants, that remain equity classified after modification or exchange. The standard was adopted by the Company on January 1, 2022. This new standard did not have a material impact on the Company’s financial statements.

 

F-16
 

 

Recent accounting standards not yet adopted

 

In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which among other things, simplifies the accounting models for the allocation of proceeds attributable to the issuance of a convertible debt instrument.  As a result, after adopting the ASU’s guidance, entities will not separately present in equity an embedded conversion feature in such debt. Instead, they will account for a convertible debt instrument wholly as debt, and for convertible preferred stock wholly as preferred stock (i.e., as a single unit of account), unless (i) a convertible instrument contains features that require bifurcation as a derivative under ASC 815 or (ii) a convertible debt instrument was issued at a substantial premium. The standard becomes effective for the Company, as a smaller reporting company as defined by the SEC, in the first quarter of 2024 and early adoption is permitted.  This new standard is not expected to have a material impact on the Company’s financial statements.

 
 

3. Fair Value Measurements

 

The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:

 

Level 1—Quoted prices in active markets for identical assets or liabilities.

 

Level 2—Inputs other than quoted prices included within Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

As of December 31, 2022 and 2021, the Company’s cash equivalents were all categorized as Level 1 and consisted of money market funds. As of December 31, 2022 and 2021, there were no financial assets and liabilities categorized as Level 2 or Level 3. There were no transfers between fair value hierarchy levels during the years ended December 31, 2022 and 2021.

 
 

4. Inventories

 

Inventories consisted of the following (in thousands):

 

   

December 31,

  
   

2022

    

2021

  

Raw materials

   $ 3,374     $ 2,503  

Work-in-process

     17       1  

Finished products

     1,574       2,097  

Total inventories

   $ 4,965     $ 4,601  

 

F-17
 

 
 

5. Property and Equipment, Net

 

Property and equipment, net, consisted of the following (in thousands):

 

   

December 31,

  
   

2022

    

2021

  

Equipment held by customers and field sales personnel

   $ 2,566     $ 2,362  

Machinery and equipment

     1,372       1,391  

Computer software

     122       122  

Computer equipment

     200       173  

Furniture and fixture

     78       78  

Leasehold improvements

     320       320  

Total property and equipment, gross

     4,658       4,446  

Less: Accumulated depreciation and amortization

     (3,956

)

     (4,351

)

Total property and equipment, net

   $ 702     $ 95  

 

Depreciation expense for the years ended December 31, 2022 and 2021, was approximately $196,000 and $687,000, respectively.

 

Property and equipment include certain equipment that is leased to customers and located at customer premises. Also, included is equipment held by the Company’s field sales personnel for use in cases with customers. The Company retains ownership of the equipment held for evaluation by customers and has the right to remove the equipment if it is not being utilized according to expectations. Depreciation expense relating to the leased equipment held by customers and those held by the Company’s field sales personnel of $119,000 and $539,000 was recorded in cost of revenues during the years ended December 31, 2022 and 2021, respectively. The net book value of this equipment was $527,000 and $0 at December 31, 2022 and December 31, 2021, respectively.

 
 

6. Accrued Expenses and Other Current Liabilities

 

Accrued expenses and other current liabilities consisted of the following (in thousands):

 

   

December 31,

  
   

2022

    

2021

  

Deferred revenue

   $ 141     $ 123  

Accrued travel and entertainment expenses

     129       118  

Accrued product warranty costs

     109       187  

Accrued clinical trial costs

     106       153  

Accrued professional fees

     60       —  

Accrued sales and use tax

     40       33  

Other accrued liabilities

     72       104  

Total accrued expenses and other current liabilities

   $ 657     $ 718  

 
 

7. Borrowings

 

CRG

 

On September 22, 2015, the Company entered into a Term Loan Agreement, as amended (the “Loan Agreement”) with CRG under which, subject to certain conditions, the Company had the right to borrow up to $50 million in principal amount from CRG on or before the end of the twenty-fourth (24th) month period commencing on the first Borrowing Date (as defined in the Loan Agreement). The Company borrowed $30 million on September 22, 2015. The Company borrowed an additional $10 million on June 15, 2016 under the Loan Agreement.

 

On February 14, 2018, the Company and CRG further amended the Loan Agreement concurrent with the conversion of $38 million of the principal amount of the senior secured term loan (plus $3.8 million in back-end fees and prepayment premium applicable thereto) into a newly authorized Series A convertible preferred stock (see below).

 

F-18
 

 

The Company has entered into several amendments to the Loan Agreement (the “Amendments”) with CRG since September 2015, the most recent of which was entered into on August 10, 2022. The Amendments, among other things: (1) extended the interest-only period through December 31, 2023; (2) extended the period during which the Company may elect to pay a portion of interest in payment-in-kind, or PIK, interest payments through December 31, 2023 so long as no Default (as defined in the Loan Agreement) has occurred and is continuing; (3) permitted the Company to make the entire interest payments in PIK interest payments for through December 31, 2023 so long as no Default has occurred and is continuing; (4) extended the Stated Maturity Date (as defined in the Loan Agreement) to December 31, 2025; (5) reduced the minimum liquidity covenant to $3.5 million at all times; (6) eliminated the minimum revenue covenant for 2018, 2019 and 2020; (7) reduced the minimum revenue covenant to $8 million for 2021 and 2022; (8) added minimum revenue covenants of $10 million for 2023, $14.5 million for 2024 and $17 million for 2025; (9) changed the date under the on-going stand-alone representation regarding no “Material Adverse Change” to December 31, 2020; (10) amended the on-going stand-alone representation and stand-alone Event of Default (as defined in the Loan Agreement) regarding Material Adverse Change such that any adverse change in or effect upon the revenue of the Company and its subsidiaries due to the outbreak of COVID-19 will not constitute a Material Adverse Change; and (11) provided CRG with board observer rights.

 

Under the amended Loan Agreement, no cash payments for either principal or interest are required until the first quarter of 2024. The interest will be accrued and included in the debt balance based (to the extent not paid) on principal amounts outstanding at the beginning of the quarter at an interest rate of 12.5%. Beginning in the first quarter of 2024, the Company will be required to make quarterly principal payments (in addition to the interest) of $1.9 million with total principal payments of $7.5 million in 2024 and $7.5 million in 2025. The maturity date of the Loan (as defined in the Loan Agreement) is December 31, 2025.

 

The Company may voluntarily prepay the borrowings in full, with a prepayment premium beginning at 5.0% and declining by 1.0% annually thereafter, with no premium being payable if prepayment occurs after seven and half years of the loan. Each tranche of borrowing required the payment, on the borrowing date, of a financing fee equal to 1.5% of the borrowed loan principal, which is recorded as a discount to the debt. In addition, a facility fee equal to 15.0% of the amounts borrowed plus any PIK is to be payable at the end of the term or when the borrowings are repaid in full. A long-term liability is being accreted using the effective interest method for the facility fee over the term of the Loan Agreement with a corresponding discount to the debt. The borrowings are collateralized by a security interest in substantially all of the Company’s assets.

 

The Loan Agreement requires that the Company adheres to certain affirmative and negative covenants, including financial reporting requirements, certain minimum financial covenants for pre-specified liquidity and revenue requirements and a prohibition against the incurrence of indebtedness, or creation of additional liens, other than as specifically permitted by the terms of the Loan Agreement. In particular, the covenants of the amended Loan Agreement included a covenant that the Company maintain a minimum of $3.5 million of cash and certain cash equivalents, and the Company has to achieve certain minimum revenues. If the Company fails to meet the applicable minimum revenue target in any calendar year, the Loan Agreement provides the Company with a cure right if it prepays a portion of the outstanding principal equal to 2.0 times the revenue shortfall. In addition, the Loan Agreement prohibits the payment of cash dividends on the Company’s capital stock and also places restrictions on mergers, sales of assets, investments, incurrence of liens, incurrence of indebtedness and transactions with affiliates. CRG may accelerate the payment terms of the Loan Agreement upon the occurrence of certain “Events of Default” set forth therein, which include the failure of the Company to make timely payments of amounts due under the Loan Agreement, the failure of the Company to adhere to the covenants set forth in the Loan Agreement, the insolvency of the Company or upon the occurrence of a “Material Adverse Change” thereunder.

 

As of December 31, 2022, the Company was in compliance with all applicable covenants under the Loan Agreement.

 

As of December 31, 2022, principal, final facility fee and PIK payments under the Loan Agreement, as amended, were as follows (in thousands):

 

Year Ending December 31,

        

2023

   $ —  

2024

     9,045  

2025

     10,339  

Total

     19,384  

Less: Amount of PIK additions and final facility fee to be incurred subsequent to December 31, 2022

     (4,970

)

Less: Amount representing debt issuance costs

     (249

)

Borrowings, current portion, as of December 31, 2022

   $ 14,165  

 

F-19
 

 

In connection with drawdowns under the Loan Agreement, the Company recorded aggregate debt discounts of $1.3 million as contra-debt. The debt discounts are being amortized as non-cash interest expense using the effective interest method over the term of the Loan Agreement. As of December 31, 2022 and 2021, the balance of the aggregate debt discount was approximately $249,000 and $332,000, respectively. The Company’s interest expense associated with the amortization of debt discount was approximately $83,000 and $86,000 during the years ended December 31, 2022 and 2021, respectively. The Company incurred total interest expense of approximately $1.9 million and $1.6 million during the years ended December 31, 2022 and 2021, respectively.

 

Due to the substantial doubt about the Company’s ability to continue operating as a going concern and the Event of Default (as defined in the Loan Agreement) that could result due to a “Material Adverse Change” under the Loan Agreement, the entire outstanding amount of borrowings under the Loan Agreement and associated aggregate debt discount at December 31, 2022 was classified as current in these financial statements as compared with long-term as of December 31, 2021. CRG has not purported that an Event of Default has resulted due to a Material Adverse Change.

 

Paycheck Protection Program

 

On April 23, 2020, the Company received loan proceeds of $2.3 million (the “PPP Loan”) pursuant to the Paycheck Protection Program under the CARES Act.

 

The PPP Loan, which was in the form of a promissory note, dated April 20, 2020 (the “Promissory Note”), between the Company and Silicon Valley Bank (“SVB”) as the lender, was set to mature on April 20, 2022 and bore interest at a fixed rate of 1% per annum, payable monthly commencing six months from the date of the Loan, with prepayment of the borrowings permitted with no associated penalty or premium.

 

The PPP Loan was administered by the U.S. Small Business Administration (“SBA”). The SBA was given the authority under the PPP to forgive loans if all employees were kept on the payroll for a required period and the loan proceeds were used for payroll, rent and utilities. The Company applied for debt forgiveness in December 2020.

 

On April 17, 2021, the Company was notified by SVB that its PPP Loan had been fully forgiven by the SBA and that there was no remaining balance on the PPP Loan. The Company recorded the forgiveness as other income in April 2021 in the amount of $2.4 million, of which approximately $23,000 was accrued interest. For the year ended December 31, 2021, the Company incurred interest expense of approximately $7,000 related to the PPP Loan.

 
 

8. Leases

 

The Company’s operating lease obligations primarily consist of leased office, laboratory, and manufacturing space under a non-cancelable operating lease. In addition to the minimum future lease commitments presented below, the lease requires the Company to pay property taxes, insurance, maintenance, and repair costs. The lease includes a rent holiday concession and escalation clauses for increased rent over the lease term. Rent expense is recognized using the straight-line method over the term of the lease.

 

The lease will expire on November 30, 2024. The Company is obligated to pay approximately $5.8 million in base rent payments through November 2024, beginning on December 1, 2019. The weighted average remaining lease term as of December 31, 2022 is 1.9 years.

 

The operating lease was included on the balance sheet at the present value of the future base payments discounted at a 6.5% discount rate using the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment as the lease does provide an implicit rate.

 

The Company’s operating lease expense, excluding variable maintenance fees and other expenses on a monthly basis, was approximately $105,000. Rent expense for each of the years ended December 31, 2022 and 2021 was approximately $1.3 million. The Company’s variable expenses for the years ended December 31, 2022 and 2021 was approximately $0.3 million and $0.2 million, respectively. Operating right-of-use asset amortization for the year ended December 31, 2022 and 2021 was approximately $1.1 million and $1.0 million, respectively. Due to payments being made in excess of operating lease expense recognized, the Company recorded approximately $65,000 and $158,000 as prepaid rent included in other assets on the balance sheet as of December 31, 2022 and 2021, respectively.

 

F-20
 

 

The following table presents the future operating lease payments and leasehold liability included on the balance sheet related to the Company’s operating lease as of December 31, 2022 (in thousands):

 

Year Ending December 31,

        

2023

   $ 1,203  

2024

     1,138  

Total

     2,341  

Less: Imputed interest

     (147

)

Leasehold liability as of December 31, 2022

   $ 2,194  

 

The following table shows ROU assets and lease liabilities, and the associated financial statement line items (in thousands):

 

       

December 31,

  

Lease-Related Assets and Liabilities

   Financial Statement Line

Items

   2022     2021  
Right of use assets:                    

Operating lease

   Right of use asset   $ 2,194     $ 3,179  
Total right of use assets   $ 2,194     $ 3,179  
Lease liabilities:                    

Operating lease

   Leasehold liability, current portion   $ 1,092     $ 985  
    Leasehold liability, long-term portion     1,102       2,194  

Total lease liabilities

   $ 2,194     $ 3,179  

 
 

9. Commitments and Contingencies

 

Purchase Obligations

 

Purchase obligations consist of agreements to purchase goods and services entered into in the ordinary course of business. The Company had non-cancelable commitments to suppliers for purchases totaling approximately $1.1 million as of December 31, 2022. The majority of this amount is related to commitments to purchase inventory components for our various product lines.

 

Indemnification

 

In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and may provide for indemnification of the counterparty. The Company’s exposure under these agreements is unknown because it involves claims that may be made against it in the future, but have not yet been made. To date, the Company has not been subject to any claims or been required to defend any action related to its indemnification obligations.

 

The Company indemnifies each of its directors and officers for certain events or occurrences, subject to certain limits, while the director is or was serving at the Company’s request in such capacity, as permitted under Delaware law and in accordance with its certificate of incorporation and bylaws. The term of the indemnification period lasts as long as a director may be subject to any proceeding arising out of acts or omissions of such director in such capacity. The maximum amount of potential future indemnification is unlimited; however, the Company currently holds director liability insurance. This insurance allows the transfer of risk associated with the Company’s exposure and may enable it to recover a portion of any future amounts paid. The Company believes that the fair value of these indemnification obligations is minimal. Accordingly, it has not recognized any liabilities relating to these obligations for any period presented.

 

Legal Proceedings

 

The Company is not currently involved in any pending legal proceedings that it believes could have a material adverse effect on our financial condition, results of operations or cash flows. From time to time, the Company may be involved in legal proceedings or investigations, which could harm our reputation, business and financial condition and divert the attention of our management from the operation of our business.

 

F-21
 

 
 

10. Stockholders’ Equity

 

Convertible Preferred Stock

 

As of December 31, 2022, the Company’s certificate of incorporation, as amended and restated, authorizes the Company to issue up to 5,000,000 shares of convertible preferred stock with $0.001 par value per share. As of December 31, 2022 and 2021, 60,961 and 56,451 shares of convertible preferred stock, respectively, were issued and outstanding.

 

Series A Convertible Preferred Stock

 

The holders of Series A preferred stock are entitled to receive annual accruing dividends at a rate of 8%, payable in additional shares of Series A preferred stock or cash, at the Company’s option. The shares of Series A preferred stock have a liquidation preference of $1,000 per share, no voting rights and rank senior to all other classes and series of the Company’s equity in terms of repayment and certain other rights. During the years ended December 31, 2022 and 2021, 4,510 and 4,175 additional shares, respectively, were issued to CRG as payment of dividends. As of December 31, 2022 and 2021, 60,876 and 56,366 shares of Series A preferred stock were outstanding, respectively, which are currently convertible into shares of the Company’s common stock at $400 per share. The Series A preferred stock accrued additional dividends of approximately $4.5 million and $4.2 million during the years ended December 31, 2022 and 2021, respectively.

 

Series B Convertible Preferred Stock

 

The Series B preferred stock has a liquidation preference of $0.001 per share, full ratchet price based anti-dilution protection, has no voting rights and is subject to certain ownership limitations. The Series B preferred stock is immediately convertible at the option of the holder, has no stated maturity, and does not pay regularly stated dividends or interest. During the year ended December 31, 2021, 93 of these shares converted into 18,600 shares of common stock. As of December 31, 2022 and 2021, 85 shares of Series B preferred stock remained outstanding, which are currently convertible into shares of the Company’s common stock at $1.502 per share.

 

Series D Convertible Preferred Stock

 

On January 14, 2022, the Company entered into a security purchase agreement with several institutional investors, pursuant to which the Company agreed to sell and issue, in a registered direct offering (“January 2022 offering”), an aggregate of 7,600 shares of the Company’s Series D convertible preferred stock, par value $0.001 per share at an offering price of $1,000 per share. Concurrently, the Company agreed to issue to these investors warrants to purchase up to an aggregate of 807,500 shares of the Company’s common stock (the “Common Warrants”). The shares of Series D Preferred Stock has a stated value of $1,000 per share and are convertible into an aggregate of 950,000 shares of common stock at a conversion price of $8.00 per share.

 

On January 14, 2022, the Company entered into a security purchase agreement with several institutional investors, pursuant to which the Company agreed to sell and issue, in a registered direct offering (“January 2022 Offering”), an aggregate of 7,600 shares of the Company’s Series D convertible preferred stock, par value $0.001 per share at an offering price of $1,000 per share. Concurrently, the Company agreed to issue to these investors warrants to purchase up to an aggregate of 807,500 shares of the Company’s common stock (the “Common Warrants”). The shares of Series D preferred stock had a stated value of $1,000 per share and were convertible into an aggregate of 950,000 shares of common stock at a conversion price of $8.00 per share. During the year ended December 31, 2022, all 7,600 shares of Series D preferred stock were converted into a total of 950,000 shares of common stock. Consequently, there were no shares of Series D preferred stock outstanding as of December 31, 2022.

 

At the time of issuance, the Company evaluated the classification of the Series D preferred stock and determined equity classification was appropriate due to no mandatory or contingently redeemable redemption features. The warrants issued to the investors were considered freestanding equity classified instruments. The Company first allocated gross proceeds from the registered direct offering between the preferred stock and the warrants issued to investors using a relative fair value approach, resulting in an initial allocation to each instrument of $4.0 million and $3.6 million, respectively. On the issuance date, the Company estimated the fair value of the Common Warrants issued to investors and warrants issued to the placement agent designees using a Black-Scholes option pricing model using the following assumptions: (i) contractual term of 5.5 years, (ii) expected volatility rate of 136.61%, (iii) risk-free interest rate of 1.51%, (iv) expected dividend rate of 0%, and (v) closing price of the Company’s common stock of the day immediately preceding the registered direct offering. The fair value of preferred stock was estimated based upon equivalent common shares that preferred stock could have been converted into at the closing price of the day immediately preceding the purchase date.

 

F-22
 

 

The embedded conversion feature was evaluated and bifurcation from the preferred stock equity host was not considered necessary. The issuance of the Series D convertible preferred stock generated a beneficial conversion feature (“BCF”) which arose as the equity security was issued with an embedded conversion option that is beneficial to the investor or in the money at inception because the conversion option has an effective conversion price that is less than the market price of the underlying stock at the commitment date. The Company recorded the BCF as a discount to the preferred stock resulting in the amount of $5.1 million based on the intrinsic value of the beneficial conversion. As the preferred stock was immediately convertible into common stock subject to the consummation of the reverse stock split on March 14, 2022, a deemed dividend related to the discount associated with the beneficial conversion feature was recorded on that date. This one-time, non-cash charge impacted net loss applicable to common stockholders and net loss per share attributable to common stockholders for the year ended December 31, 2022.

 

Common Stock

 

At December 31, 2022, the Company’s certificate of incorporation, as amended and restated, authorizes the Company to issue up to 100,000,000 shares of common stock with $0.001 par value per share, of which 7,832,644 shares were issued and outstanding.

 

Common Stock Warrants

 

As of December 31, 2022, the Company had outstanding warrants to purchase common stock as follows:

 

   

Total

Outstanding

and

Exercisable

    

Underlying

Shares of

Common

Stock

    

Exercise

Price per

Share

    

Expiration Date

  

Series 1 Warrants issued in the February 2018 Series B financing

     8,979,000       44,895     $ 400.00     February 2025  

Series 2 Warrants issued in the February 2018 Series B financing

     8,709,500       43,548     $ 400.00     February 2025  

Warrants issued in the November 2018 financing

     8,768,395       43,842     $ 80.00     November 2023  

Placement agent warrants issued in the January 2022 financing

     1,330,000       66,500     $ 10.00     January 2027  

Warrants issued in the January 2022 financing

     16,150,000       807,500     $ 9.60     July 2027  

Pre-funded warrants issued in the August 2022 financing

     1,369,864       1,369,864     $ 0.0001       n/a  

Series A Preferred Investment Options issued in August 2022 financing

     2,853,883       2,853,883     $ 1.502    

February 2028

  

Series B Preferred Investment Options issued in August 2022 financing

     2,853,883       2,853,883     $ 1.502    

August 2024

  

Placement agent Preferred Investment Options issued in the August 2022 financing

     171,233       171,233     $ 2.19    

August 2027

  

Total as of December 31, 2022

     51,185,758       8,255,148                  

 

As of December 31, 2021, the Company had outstanding warrants to purchase common stock as follows:

 

   

Total

Outstanding

and

Exercisable

    

Underlying

Shares of

Common

Stock

    

Exercise

Price per

Share

  

Expiration Date

Series 1 Warrants issued in the February 2018 Series B financing

     8,979,000       44,895     $ 400.00  

February 2025

Series 2 Warrants issued in the February 2018 Series B financing

     8,709,500       43,548     $ 400.00  

February 2025

Warrants issued in the November 2018 financing

     8,768,395       43,842     $ 80.00   November 2023

Total as of December 31, 2021

     26,456,895       132,265            

 

F-23
 

 

January 2022 Offering

 

Pursuant to a purchase agreement entered into on January 14, 2022, the Company issued warrants to purchase up to an aggregate of 807,500 shares of the Company’s common stock at an exercise price of $9.60 per share and which became exercisable beginning July 14, 2022. The Common Warrants will expire five years following the time they become exercisable, or July 14, 2027.

 

The Company issued to the placement agent of the January 2022 Offering warrants to purchase up to an aggregate of 66,500 shares of common stock (the “Placement Agent Warrants”). The Placement Agent Warrants are subject to the same terms as the Common Warrants, except that the Placement Agent Warrants have an exercise price of $10.00 per share and a term of five years from the commencement of the sales pursuant to the January 2022 Offering, or January 12, 2027.

 

August 2022 Offering

 

Pursuant to a purchase agreement entered into on August 4, 2022, the Company issued, in a registered direct offering, Pre-Funded Warrants to purchase up to 784,019 shares of common stock (the “RD Pre-Funded Warrants”) and, in a concurrent private placement, Pre-Funded Warrants to purchase up to 1,369,864 shares of common stock (the “Private Placement Pre-Funded Warrants” and together with the RD Pre-Funded Warrants the “August 2022 Pre-Funded Warrants”). The August 2022 Pre-Funded Warrants have an exercise price of $0.0001 per share, are immediately exercisable, and have no expiration date. During the year ended December 31, 2022, 784,019 of shares of RD Pre-Funded Warrants were exercised into the equivalent number of the Company’s common stock. As of December 31, 2022, August 2022 Pre-Funded Warrants exercisable for 1,369,864 shares of the Company’s common stock remained outstanding. On February 14, 2023, an additional 747,864 Private Placement Pre-Funded Warrants were exercised leaving 622,000 August 2022 Pre-Funded Warrants outstanding.

 

Also in the August 2022 offering, the Company issued Series A preferred investment options to purchase up to 2,853,883 additional shares of the Company’s common stock and Series B preferred investment options to purchase up to 2,853,883 additional shares of the Company’s common stock, collectively referred to as Preferred Investment Options. The Series A preferred investment options have an exercise price of $1.502 per share, are immediately exercisable, and will expire five and one-half years from the date of issuance, or February 8, 2028, and the Series B preferred investment options have an exercise price of $1.502 per share, are immediately exercisable, and will expire two years from the date of issuance, or August 8, 2024.

 

The Company also issued to the placement agent of the August 2022 Offering preferred investment options to purchase up to 171,233 shares of common stock (the “Placement Agent Preferred Investment Options”). The Placement Agent Preferred Investment Options are subject to the same terms as the Preferred Investment Options, except that the Placement Agent Preferred Investment Options have an exercise price of $2.19 per share and a term of five years from the commencement of the sales pursuant to the August 2022 Offering, or August 3, 2027.

 

The exercise price and the number of shares of common stock issuable upon exercise of each Common Warrants, Pre-Funded Warrants, Preferred Investment Options, and Placement Agent Preferred Investment Options are subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock. In addition, in certain circumstances, upon a fundamental transaction, a holder of Common Warrants, Pre-Funded Warrants, Preferred Investment Options, or Placement Agent Preferred Investment Options will be entitled to receive, upon exercise, the kind and amount of securities, cash or other property that such holder would have received had they exercised the Common Warrants, Pre-Funded Warrants, Preferred Investment Options, or Placement Agent Preferred Investment Options immediately prior to the fundamental transaction.

 

The Common Warrants, Pre-Funded Warrants, Preferred Investment Options, and Placement Agent Preferred Investment Options can be exercised at the option of the holders at any time after they become exercisable provided that shares of the Common Warrants, Pre-Funded Warrants, Preferred Investment Options, or Placement Agent Preferred Investment Options cannot be exercised into common stock if the applicable holder would beneficially own in excess of 4.99% (or, upon election by such holder prior to the issuance of any shares of Common Warrants, Pre-Funded Warrants, Preferred Investment Options, or Placement Agent Preferred Investment Options, 9.99%) of the Company’s outstanding common stock immediately after giving effect to the exercise. A holder of the Common Warrants, Pre-Funded Warrants, Preferred Investment Options or Placement Agent Preferred Investment Options may, upon notice to the Company, increase or decrease such beneficial ownership limitation, but not in excess of 9.99%.

 

F-24
 

 

In the event of a fundamental transaction in which the holders of our voting securities immediately prior to such fundamental transaction will not, following such fundamental transaction, directly or indirectly own more than 50% of the voting securities of the surviving entity or successor entity, and in which the Company is not the successor entity or does not continue as a reporting issuer under the Exchange Act, then, at the request of the holder, the Company or the successor entity shall purchase the unexercised portion of the Common Warrants, Preferred Investment Options, and Placement Agent Preferred Investment Options from the holder by paying to the holder an amount, in cash, equal to the fair value of the remaining unexercised portion of the Common Warrants, Preferred Investment Options, and Placement Agent Preferred Investment Options on the date of such fundamental transaction, subject to certain limitations in the event of a fundamental transaction not within our control.

 

As of December 31, 2022 and 2021, warrants and preferred investment options to purchase an aggregate of 8,255,148 and 132,265 shares of common stock were outstanding, respectively, all of which were classified within the equity section of the respective balance sheets.

 
 

11. Stock-Based Compensation

 

Stock Plans

 

In January 2015, the Board of Directors adopted and the Company’s stockholders approved the 2015 Equity Incentive Plan (“2015 Plan”). The 2015 Plan provides for the grant of incentive stock options (“ISOs”) to employees and for the grant of non-statutory stock options (“NSOs”), restricted stock, restricted stock awards (“RSAs”), restricted stock units (“RSUs”), stock appreciation rights, performance units and performance shares to employees, directors and consultants. The shares reserved for issuance under the 2015 Plan includes share awards granted under the prior equity incentive plan that expire or terminate without having been exercised in full or that are forfeited or repurchased. On October 14, 2022, the Company’s stockholders approved an additional 1,750,000 shares of common stock for issuance under the 2015 Plan. As of December 31, 2022, 1,759,566 shares were available for grant under the 2015 Plan.

 

Pursuant to the 2015 Plan, ISOs and NSOs may be granted with exercise prices at not less than 100% of the fair value of the common stock on the date of grant and the exercise price of ISOs granted to a stockholder, who, at the time of grant, owns stock representing more than 10% of the voting power of all classes of the stock of the Company, shall be not less than 110% of the fair market value per share of common stock on the date of grant. The Company’s Board of Directors determines the vesting schedule of the options.

 

Stock option activity under the Plans is set forth below:

   

Number of
Shares

(in thousands)

    

Weighted

Average
Exercise

Price

    

Weighted

Average

Remaining

Contractual

Life

(in years)

    

Intrinsic

Value

(in thousands)

  

Balance at December 31, 2020

     307     $ 19,577.10       5.95     $ —  

Options expired

     (4

)

   $ 36,000.00                  

Balance at December 31, 2021

     303     $ 19,360.30       5.02     $ —  

Balance at December 31, 2022

     303     $ 19,360.30       4.02     $ —  
                                 

Exercisable at December 31, 2022

     303     $ 19,360.30       4.02     $ —  
                                 

Vested and expected to vest at December 31, 2022

     303     $ 19,360.30       4.02     $ —  

 

F-25
 

 

Additional information related to the Company’s stock options as of December 31, 2022 is summarized as follows:

 

Options Outstanding     Options Vested  
                Weighted    

Weighted

            

Weighted

  
                Average    

Average

            

Average

  

Exercise

    

Options

    

Remaining

    

Exercise

     Number    

Exercise

  

Price

    

Outstanding

   

Contractual Life

    

Price

     Exercisable    

Price

  
$ 334.00       155       5.44     $ 334.00       155     $ 334.00  
$ 16,400.00 - 28,400.00       31       4.18     $ 17,323.87       31     $ 17,323.87  
$ 36,000.00       103       2.00     $ 36,000.00       103     $ 36,000.00  
$ 103,680.00 - 162,000.00       14       2.85     $ 112,097.14       14     $ 112,097.14  
          303       4.02     $ 19,360.30       303     $ 19,360.30  

 

There were no options granted or exercised during either of the years ended December 31, 2022 or 2021. For the years ended December 31, 2022 and 2021, stock-based compensation expense recognized associated with stock options vesting was approximately $0 and $4,000, respectively. As of December 31, 2022, there is no remaining unamortized stock-based compensation expense associated with unvested stock options. Because of the Company’s net operating losses, the Company did not realize any tax benefits from share-based payment arrangements for the years ended December 31, 2022 and 2021.

 

The Company’s RSUs generally vest annually over three years in equal increments. The Company measures the fair value of RSUs using the closing stock price of a share of the Company’s common stock on the grant date and is recognized as expense on a straight-line basis over the vesting period of the award. A summary of all RSU activity is presented below:

 

   

Number of

Shares

    

Weighted

Average

Grant Date

Fair Value

    

Weighted

Average

Remaining

Contractual

Term

  

Awards outstanding at December 31, 2020

     20,671     $ 76.03       0.98  

Awarded

     4,500     $ 32.20          

Released

     (13,386

)

   $ 104.31          

Forfeited

     (1,725

)

   $ 53.62          

Awards outstanding at December 31, 2021

     10,060     $ 24.39       0.72  

Released

     (8,590

)

   $ 25.02          

Forfeited

     (1,053

)

   $ 24.25          

Awards outstanding at December 31, 2022

     417     $ 11.64       0.17  

 

As of December 31, 2022, there was less than $0.1 million of remaining unamortized stock-based compensation expense associated with RSUs, which will be expensed over a weighted average remaining service period of 0.2 years. The outstanding non-vested and expected to vest RSUs at December 31, 2022 have an aggregate fair value of approximately less than $0.1 million. The Company used the closing market price of $1.09 per share at December 31, 2022 to determine the aggregate fair value for the RSUs outstanding at that date. For the years ended December 31, 2022 and 2021, the fair value of RSUs vested was approximately $14,000 and $273,000, respectively. For the years ended December 31, 2022 and 2021, stock-based compensation expense recognized associated with the vesting of RSUs was approximately $0.1 million and $1.0 million, respectively.

 

2018 Officer and Director Share Purchase Plan

 

On August 22, 2018, the Board of Directors of the Company approved the adoption of an Officer and Director Share Purchase Plan (“ODPP”), which allowed executive officers and directors to purchase shares of our common stock at fair market value in lieu of salary or, in the case of directors, director fees. Eligible individuals were allowed voluntarily participate in the ODPP by authorizing payroll deductions or, in the case of directors, deductions from director fees for the purpose of purchasing common stock. There was no common stock issued under the ODPP during either of the years ended December 31, 2022 or 2021. On May 16, 2022, the Board of Directors of the Company terminated the Amended and Restated Officer and Director Share Purchase Plan due to the administrative costs of maintaining such plan and the limited amount of remaining shares. Consequently, there are no longer any shares reserved for issuance under this plan.

 

F-26
 

 

Total noncash stock-based compensation expense relating to the Company’s stock options and RSUs recognized, before taxes, during the years ended December 31, 2022 and 2021, is as follows (in thousands):

 

   

Year Ended December 31,

  
   

2022

    

2021

  

Cost of revenues

   $ 18     $ 101  

Research and development expenses

     37       287  

Selling, general and administrative expenses

     72       627  
    $ 127     $ 1,015  

 
 

12. Income Taxes

 

For the years ended December 31, 2022 and 2021, the Company’s provision for income taxes consisted of zero state income tax expense. A reconciliation of the statutory U.S. federal rate to the Company’s effective tax rate is as follows (in thousands):

 

   

Year Ended December 31,

  
   

2022

    

2021

  

Tax at federal statutory rate

   $ (3,701

)

   $ (3,657

)

State taxes, net of federal benefit

     (916

)

     (711

)

Permanent differences

     (484

)

     (445

)

Change in valuation allowance

     5,084       5,104  

Research credits

     (273

)

     (286

)

Nondeductible interest expense

     290       —  

Other

     —       (5

)

Provision for taxes

   $ —     $ —  

 

Significant components of the Company’s net deferred tax assets as of December 31, 2022 and 2021 consist of the following (in thousands):

 

   

As of December 31,

  
   

2022

    

2021

  

Deferred tax assets:

                

Federal, state and foreign net operating losses

   $ 85,547     $ 83,211  

Research and other credits

     5,343       4,892  

Operating lease liability

     544       752  

Fixed assets

     471       —  

Accruals and other

     3,628       2,845  

Capitalized research and development

     1,019       —  

Total deferred tax assets

     96,552       91,700  

Less: Valuation allowance

     (95,992

)

     (90,908

)

Total net deferred tax assets

     560       792  

Deferred liabilities:

                

Property and equipment

     —       (2

)

Operating lease right of use asset

     (560

)

     (790

)

Total deferred tax liabilities

     (560

)

     (792

)

Net deferred tax assets (liabilities)

   $ —     $ —  

 

The valuation allowance increased by $5.1 million and $4.7 million during the years ended December 31, 2022 and 2021, respectively.

 

As of December 31, 2022, the Company had approximately $344.3 million of federal and $208.0 million of state net operating loss carryforwards available to offset future taxable income. If not utilized, the federal and state net operating loss carryforwards begin to expire in 2027 and 2023, respectively. Out of the Federal net operating loss carryforwards, $86.8 million were generated post December 31, 2017 and have no expiration.

 

F-27
 

 

As of December 31, 2022, the Company also had approximately $4.3 million and $4.2 million of research and development tax credit carryforwards available to reduce future taxable income, if any, for both federal and California purposes, respectively. The federal credit carryforwards expire beginning in 2027, and the California research credits do not expire and may be carried forward indefinitely.

 

The Company's ability to utilize the net operating loss and tax credit carryforwards in the future may be subject to substantial restrictions in the event of past or future ownership changes as defined in Section 382 of the Internal Revenue Code and similar state tax laws. In the event the Company should experience an ownership change, as defined, utilization of the Company's net operating loss carryforwards and tax credits could be limited.

 

The Company evaluates tax positions for recognition using a more-likely-than-not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information.

 

A reconciliation of the beginning and ending amount of the gross recognized tax benefit is as follows (in thousands):

 

   

As of December 31,

  
   

2022

    

2021

  

Balance at beginning of year

   $ 2,366     $ 2,307  

Increase based on the tax positions in the current year

     203       228  

Increase (Decrease) for tax positions of prior year

     12       (169

)

Balance at end of year

   $ 2,581     $ 2,366  

 

As of December 31, 2022, all unrecognized tax benefits would be subject to a full valuation allowance, if recognized, and would not affect the Company’s tax rate.

 

The Company does not anticipate that the total amounts of unrecognized tax benefits will significantly increase or decrease in the next twelve months.

 

The Company's policy is to include interest and penalties related to unrecognized tax benefits within its provision for income taxes. Due to the Company's net operating loss position, the Company has not recorded an accrual for interest or penalties related to uncertain tax positions for the years ended December 31, 2022 or 2021.

 
 

13. 401(k) Plan

 

The Company has a qualified retirement plan under section 401(k) of the Internal Revenue Code (“IRC”) under which participants may contribute up to 99% of their eligible compensation, subject to maximum deferral limits specified by the IRC. The Company may make a discretionary matching contribution to the 401(k) plan, and may make a discretionary employer contribution to each eligible employee each year. To date, the Company has made no contributions to the 401(k) plan.

 
 

14. Subsequent Events

 

Pre-Funded Warrant Exercise

 

On February 14, 2023, a holder of Private Placement Pre-Funded Warrants opted to exercise a portion of the warrant into common stock. A total of 747,864 shares of the Private Placement Pre-Funded Warrants were exercised resulting in the issuance of an aggregate of 747,864 shares of common stock. After giving effect to these aforementioned exercise, there remains 622,000 shares of Private Placement Pre-Funded Warrant shares outstanding, which if exercised, would result in the issuance of an equivalent number of shares of common stock.

 

Restricted Stock Award Grant

 

On January 18, 2023, the Company granted a total of 1,502,928 shares of RSAs to various employees. These RSAs generally vest annually over two years in equal increments, with certain exceptions. The Company measured the fair value of RSAs using the closing stock price of a share of the Company’s common stock of $1.23 on the day of grant. The resulting expense will be recognized on a straight-line basis over the vesting period of the awards.

  

F-28
 

 

Silicon Valley Bank

 

Currently all of our cash and cash equivalents are held at a single financial institution, Silicon Valley Bank. On March 10, 2023, the Federal Deposit Insurance Corporation announced that Silicon Valley Bank had been closed by the California Department of Financial Protection and Innovation. While we have regained access to our accounts at Silicon Valley Bank and are evaluating our banking relationships, future disruptions of financial institutions where we bank or have credit arrangements, or disruptions of the financial services industry in general, could adversely affect our ability to access our cash and cash equivalents. If we are unable to access our cash and cash equivalents as needed, our financial position and ability to operate our business will be adversely affected.

 

F-29
 

 
 

SIGNATURES

 

Pursuant to the requirements of Section 13 and 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

Avinger, Inc.
 

(Registrant)
   
   

Date: March 15, 2023

/s/ Jeffrey M. Soinski
 

Jeffrey M. Soinski
 

Chief Executive Officer
 

(Principal Executive Officer)
   

Date: March 15, 2023

/s/ Nabeel Subainati
 

Nabeel Subainati
 

Vice President, Finance
 

(Principal Financial and Accounting Officer)

 

POWER OF ATTORNEY

 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jeffrey Soinski and Nabeel Subainati, jointly and severally, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her, and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises hereby ratifying and confirming all that said attorneys-in-fact and agents, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

Signature

  

Title

  

Date
         

/s/ Jeffrey M. Soinski

  

President and Chief Executive Officer (Principal Executive Officer);

  

March 15, 2023

Jeffrey M. Soinski

  

Director

    
         

/s/ Nabeel Subainati

  

Vice President, Finance (Principal Financial and Accounting Officer)

  

March 15, 2023

Nabeel Subainati

        
         

/s/ James B. McElwee

  

Director

  

March 15, 2023

James B. McElwee

        
         

/s/ James G. Cullen

  

Director

  

March 15, 2023

James G. Cullen

        

 

/s/ Tamara Elias

  

Director

  

March 15, 2023

Tamara Elias

        

 

F-30
 EX-10.58 2 ex_488855.htm EXHIBIT 10.58 ex_488855.htm

Exhibit 10.58

 

AMENDMENT NO. 1 TO THE

CHANGE OF CONTROL AND SEVERANCE AGREEMENT

 

 

This Amendment No. 1 (this “Amendment”) to the Agreement (defined below) is entered into and made effective on March 14, 2023 (“Effective Date”), by Nabeel Subainati (“Executive”) and Avinger, Inc. (“Company”). This Amendment amends the Change of Control and Severance Agreement entered into between Executive and Company on May 16, 2022 (the “Agreement”).

 

WHEREAS, the Agreement may be amended or modified by a written instrument executed by Company and Executive;

 

WHEREAS, Company and Executive desire to amend certain provisions of the Agreement;

 

NOW, THERFORE, Company and Executive intending to be legally bound hereby enter into this Amendment and agree as follows:

 

1.            Termination for other than Cause, Death or Disability or Good Reason in the Event of a Change of Control. Section 1(a) of the Agreement is hereby amended and restated to read as follows:

 

(a)          Termination for other than Cause, Death or Disability or Good Reason in the Event of a Change of Control. If upon or within twelve (12) months following a Change of Control (i) the Company (or any parent or subsidiary or successor of the Company) terminates Executive’s employment with the Company other than for Cause, death or disability, or (ii) the Executive resigns from such employment for Good Reason, then, subject to Section 2, Executive will be entitled to: (A) receive continuing payments of severance pay at a rate equal to Executive’s monthly base salary and prorated target bonus, as then in effect, for a period of six (6) months plus one (1) month for every year of service completed (measured from Executive’s date of hire until the Change of Control) for the Company (or any parent or subsidiary or successor of the Company); provided that, such severance period shall not exceed twelve (12) months and such continuing payments will be paid in accordance with the Company’s regular payroll procedures; (B) if Executive timely elects continuation coverage pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”) for Executive and Executive’s dependents, within the time period prescribed pursuant to COBRA, the Company will reimburse Executive for the COBRA premiums for such coverage for Executive and his covered dependents for six (6) months from the date of Executive’s termination of employment or such earlier date if Executive no longer constitutes a “Qualified Beneficiary” (as such term is defined in Section 4980B(g) of the Code); (C) accelerated vesting as to 100% of Executive’s outstanding unvested stock options and/or restricted stock; and (D) the extension of the post-termination exercise period for any options held by Executive for a period of one (1) year. Notwithstanding the foregoing, Executive will not be entitled to any payment under Section 1(a)(A) if Executive has received a bonus pursuant to Section 1(e).

 

2.            Stay Bonus. Section 1(e) of the Agreement is hereby added and will read as follows:

 

(e)         Stay Bonus. If upon the date that is twelve (12) months following a Change of Control, Executive is employed by the Company (or any parent or subsidiary or successor of the Company), then Executive will be entitled to receive a lump sum bonus payment in an amount equal to what Executive would be entitled to receive under Section 1(a) had Executive been terminated other than for Cause, death or disability. Any bonus payable pursuant to this Section 1(e) shall be paid upon the date that is twelve (12) months following a Change of Control. If payment is made pursuant to this Section 1(e), Executive will not be entitled to any payment under Section 1(a)(A).

 

 
 

 

3.            Amendment. This Amendment shall be binding upon and inure to the benefit of the parties hereto, and their respective heirs, executors, administrators, successors, and assigns, who are obligated to take any action which may be necessary or proper to carry out the purpose and intent hereof.

 

4.            Effect on Agreement; Capitalized Terms. Except as expressly modified or amended by this Amendment, the Agreement shall continue in full force and effect in accordance with its terms. All capitalized terms not otherwise defined herein shall have the meaning set forth in the Agreement.

 

5.            Counterparts. This Amendment may be executed in any number of counterparts, each of which shall be deemed an original and all of which taken together shall constitute a single instrument.

 

6.            Governing Law. This Amendment shall be construed and enforced with, and governed by, the laws of the State of California.

 

 
 

 

IN WITNESS WHEREOF, the following, being Company and Executive, have executed this Amendment to be effective as of the Effective Date.

 

 

 

 

 

 

 

COMPANY:

 

AVINGER, INC.

 

 

 

By: /s/ Jeffrey M. Soinski________________________

Name: Jeffrey Soinski

Title: President and Chief Executive Officer

 

 

 

EXECUTIVE:

 

 

/s/ Nabeel Subainati_____________________________

Nabeel Subainati

 

 

 

 

 

 

 
 EX-10.59 3 ex_488856.htm EXHIBIT 10.59 ex_488856.htm

Exhibit 10.59

 

AVINGER, INC.

 

RETENTION BONUS AGREEMENT

 

This Retention Bonus Agreement (the “Agreement”) is entered into as of                    (the “Effective Date”) by and between Avinger, Inc. (the “Company”), and the undersigned employee of the Company.

 

1.    Retention Bonus Payment.  The Company will pay you a retention award in an amount equal to 100% of the amount of your annual salary in effect on December 31, 2023; 50% of the retention award will be paid within five business days of December 31, 2023 if you continue to be employed by the Company on the date of such payment, and 50% will be paid within five business days of December 31, 2024 if you continue to be employed by the Company on December 31, 2024 on the date of such payment (each, a “Retention Bonus Payment”). Any Retention Bonus Payment may be paid in cash or equity of the Company, or a combination of both, in the sole discretion of the Compensation Committee (the “Committee”) of the Board of Directors of the Company. Any equity of the Company issued in satisfaction of all or a portion of any Retention Bonus Payment will be issued under, and subject to the terms of, the Company’s Amended and Restated 2015 Equity Incentive Plan.

 

2.    Adjustment of Retention Bonus Payment. Each Retention Bonus Payment shall be increased in the event that the most recent closing price of the common stock of the Company is greater than $3.00 (subject to adjustment for any stock splits, reverse stock splits, or similar transactions) as of the date of such Retention Bonus Payment, according to the schedule below:

 

 

●

If the most recent closing price is between $60.00 and $79.99 (subject to adjustment for any stock splits, reverse stock splits, or similar transactions) as of the date of the Retention Bonus Payment, such Retention Bonus Payment shall be increased by 25%;

 

 

●

If the most recent closing price is between $80.00 and $99.99 (subject to adjustment for any stock splits, reverse stock splits, or similar transactions) as of the date of the Retention Bonus Payment, such Retention Bonus Payment shall be increased by 50%; and

 

 

●

If the most recent closing price is $100.00 or above (subject to adjustment for any stock splits, reverse stock splits, or similar transactions) as of the date of the Retention Bonus Payment, such Retention Bonus Payment shall be increased by 100%.

 

3.    Acceleration of Retention Bonus Payment.

 

 

a.

In the event of a Change in Control, any unpaid Retention Bonus Payment shall become immediately payable, subject to adjustment as set forth in Section 2; provided, however, that you must be continue to be employed by the Company immediately prior to such Change in Control.

 

 

b.

For purposes of this Agreement, a “Change in Control” means:

 

 

i.

any “person” (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended) is or becomes the “beneficial owner” (as defined in Rule 13d-3 under said Act), directly or indirectly, of securities of the Company representing more than 50% of the total voting power represented by the Company’s then outstanding voting securities; or

 

 

ii.

the date of the consummation of a merger or consolidation of the Company with any other corporation that has been approved by the stockholders of the Company, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation; or

 

 
 

 

 

iii.

the date of the consummation of the sale or disposition by the Company of all or substantially all the Company’s assets; or

 

 

iv.

the date that a majority of members of the Board of Directors (the “Board”) is replaced during any twelve (12) month period by directors whose appointment or election is not endorsed by a majority of the members of the Board prior to the date of the appointment or election. For purposes of this clause (iv), if any person is considered to be in effective control of the Company, the acquisition of additional control of the Company by the same person will not be considered a Change of Control.

 

Further, notwithstanding the foregoing provisions, the following shall not constitute a Change of Control:

 

 

x.

any bona fide equity financing for capital raising purposes;

 

 

y.

any merger or acquisition done exclusively to effect a change of domicile of the Company; and

 

 

z.

any transfer of assets by the Company to a new company for tax planning purposes.

 

 

4.    Termination of Employment.  In order to be eligible to receive a Retention Bonus Payment, you must continue to be employed by the Company at the time such Retention Bonus Payment becomes payable. If, prior to the payment of any Retention Bonus Payment, your employment is terminated for any reason, any unpaid Retention Bonus Payment will be forfeited and you will have no further rights to any unpaid Retention Bonus Payment.

 

5.    Withholding.  The Company may deduct and withhold from any amount payable under this Agreement all applicable U.S. federal, state and local taxes and non-U.S. taxes required to be withheld pursuant to any applicable law or regulation. If any amount payable is satisfied, in whole or in part, using equity of the Company, the Board of Directors or Compensation Committee of the Company may authorize the Company to satisfy any tax withholding obligations by reducing the number of shares or other form of equity otherwise deliverable to you.

 

6.    Assignment. This Agreement is personal to you and, without the prior written consent of the Company, shall not be assignable by you, and any assignment in violation of this Agreement shall be void. 

 

7.    Amendment/Waiver.  No provisions of this Agreement may be amended, modified, waived or discharged except by a written document signed by you and a duly authorized officer of the Company.  The failure of a party to insist upon strict adherence to any term of this Agreement on any occasion shall not be considered a waiver of such party’s rights or deprive such party of the right thereafter to insist upon strict adherence to that term or any other term of this Agreement.

 

8.    Entire Agreement.  This Agreement sets forth the entire agreement of the parties hereto in respect of the subject matter contained herein and supersedes all prior agreements, promises, covenants, arrangements, communications, representations or warranties, whether oral or written, by any officer, employee or representative of any party hereto.  None of the parties shall be liable or bound to any other party in any manner by any representations and warranties or covenants relating to such subject matter except as specifically set forth herein.  Notwithstanding anything herein to the contrary, you shall be entitled to the Retention Bonus Payment in addition to any payments or benefits to which you may also be entitled under any change of control agreement and any other bonus or other incentive arrangement previously entered into between you and the Company.

 

 
 

 

9.    Governing Law.  The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the State of California (without giving effect to its conflicts of laws provisions).

 

10.    Section 409A Compliance.  It is intended that the provisions of this Agreement are exempt from Section 409A of the Internal Revenue Code (“Section 409A”), and all provisions of this Agreement shall be construed and interpreted in a manner consistent with the requirements for avoiding taxes or penalties under Section 409A. .

 

11.    Headings.  Headings in this Agreement are for purposes of reference only and will not limit or otherwise affect the meaning hereof.

 

12.    Counterparts.  This Agreement may be executed in two or more counterparts (including by facsimile of PDF), each of which will be deemed an original but all of which together will constitute one and the same instrument.

 

[Signature Page Follows]

 

 
 

 

IN WITNESS WHEREOF, each of the parties has executed this Agreement, in the case of the Company by their duly authorized officers, as of the day and year first above written.

 

COMPANY:

  
   

AVINGER, INC.

  
   

By:

    

Date:

  
   

Title:

      
   
   

EMPLOYEE:

  
   
   

Date:

  
   

 

[SIGNATURE PAGE TO AVINGER, INC. RETENTION BONUS AGREEMENT]

 

 

 

 
 EX-10.60 4 ex_488857.htm EXHIBIT 10.60 ex_488857.htm

Exhibit 10.60

 

AVINGER, INC.
2015 EQUITY INCENTIVE PLAN
RESTRICTED STOCK AWARD AGREEMENT

 

NOTICE OF GRANT OF RESTRICTED STOCK

 

Unless otherwise defined herein, the terms defined in the 2015 Equity Incentive Plan (the “Plan”) shall have the same defined meanings in this Restricted Stock Award Agreement, including the Notice of Grant of Restricted Stock (the “Notice of Grant”), the Terms and Conditions of Restricted Stock Grant, and any appendices and exhibits attached thereto (all together, the “Award Agreement”).

 

Name (“Participant”): «Name»
Address:  «Address»

 

The undersigned Participant has been granted the right to receive an Award of Restricted Stock, subject to the terms and conditions of the Plan and this Award Agreement, as follows:

 

Date of Grant: «GrantDate»
Vesting Commencement Date:  «VCD»
Number of Shares of Restricted Stock:    «Shares»

 

Vesting Schedule:

 

Subject to any acceleration provisions contained in the Plan or set forth below, the Shares of Restricted Stock will vest in accordance with the following schedule:

 

[INSERT VESTING SCHEDULE]

 

In the event Participant ceases to be a Service Provider for any or no reason before the Restricted Stock is fully vested, all unvested Shares of Restricted Stock will be immediately forfeited.

 

Participant acknowledges receipt of a copy of the Plan and represents that he or she is familiar with the terms and provisions thereof, and hereby accepts this Award Agreement subject to all of the terms and provisions thereof. Participant has reviewed the Plan and this Award Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Award Agreement and fully understands all provisions of this Award Agreement. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan or this Award Agreement. Participant further agrees to notify the Company upon any change in the residence address indicated below.

 

 
 
 

  

PARTICIPANT   AVINGER, INC.  
       
       
       
Signature     By  
       
       
«Name»      
Print Name   Print Name  
         
Address:        
«Address»   Title  
         

 

2
 

 

AVINGER, INC.
2015 EQUITY INCENTIVE PLAN
RESTRICTED STOCK AWARD AGREEMENT

 

TERMS AND CONDITIONS OF RESTRICTED STOCK GRANT

 

1.         Grant of Restricted Stock. The Company hereby grants to the individual (“Participant”) named in the Notice of Grant of Restricted Stock of this Award Agreement (the “Notice of Grant”) under the Plan the number of Shares of Restricted Stock specified in the Notice of Grant, subject to all of the terms and conditions in this Award Agreement and the Plan, which is incorporated herein by reference. Subject to Section 19(c) of the Plan, in the event of a conflict between the terms and conditions of the Plan and this Award Agreement, the terms and conditions of the Plan shall prevail.

 

2.         Rights As a Stockholder. A Share of Restricted Stock may not be sold, assigned, hypothecated or transferred, whether by operation of law or otherwise (including without limitation, transfer by gift, donation, execution, attachment or similar process) prior to vesting as set forth in the Notice of Grant and in Section 3 below (other than a transfer by beneficiary designation upon death as contemplated under Section 3(c)). Such period of vesting shall be referred to herein as the “Restriction Period”). During the Restriction Period, Participant shall have the right to vote the Shares of Restricted Stock. During the Restriction Period, Participant shall not have the right to receive payment of cash dividends; but rather, shall accumulate an unvested right to dividend equivalent amounts on the Restricted Stock if cash dividends are declared on the underlying Shares on or after the Date of Grant. Each time a dividend is paid on Shares, Participant shall accrue an amount equal to the amount of the dividend payable on the Shares on the dividend record date. The accrued amounts shall be subject to the same vesting, forfeiture and share delivery terms described in this Award Agreement as if they had been awarded on the Date of Grant. Participant shall not be entitled to amounts with respect to cash dividends declared prior to the Date of Grant. All dividend equivalent amounts accumulated with respect to forfeited Restricted Stock shall also be irrevocably forfeited. After lapse of the Restriction Period, Participant will have all the rights of a stockholder of the Company with respect to voting such Shares and receipt of dividends and distributions on such Shares. Shares shall be issued and recorded by the Company or its transfer agents or registrars (in either certificate or book entry form, at the Company’s discretion) and delivered to Participant through electronic delivery to a brokerage account.

 

3.         Vesting Schedule. Except as provided below, the Restricted Stock awarded by this Award Agreement will vest in accordance with the vesting schedule set forth in the Notice of Grant, subject to Participant continuing to be a Service Provider through each applicable vesting date.

 

(a)         Discretionary Acceleration. The Administrator, in its discretion, may accelerate the vesting of the balance, or some lesser portion of the balance, of the unvested Restricted Stock at any time, subject to the terms of the Plan. If so accelerated, such Shares of Restricted Stock will be considered as having vested as of the date specified by the Administrator, and the Restriction Period will lapse as to such Shares.

 

(b)         Forfeiture Upon Termination as a Service Provider. Notwithstanding any contrary provision of this Award Agreement, if Participant ceases to be a Service Provider for any or no reason, the then‑unvested Shares of Restricted Stock awarded by this Award Agreement will thereupon be forfeited at no cost to the Company and Participant will have no further rights thereunder.

 

(c)         Death of Participant. Any delivery or release of Shares to be made to Participant under this Award Agreement upon expiration of the Restriction Period will, if Participant is then deceased, be made to Participant’s designated beneficiary, or if no beneficiary survives Participant, the administrator or executor of Participant’s estate. Any such transferee must furnish the Company with (a) written notice of his or her status as transferee, and (b) evidence satisfactory to the Company to establish the validity of the transfer and compliance with any laws or regulations pertaining to said transfer.

 

3
 

 

4.         Tax Consequences. Participant has reviewed with its own tax advisors the U.S. federal, state, local and foreign tax consequences of this investment and the transactions contemplated by this Award Agreement. With respect to such matters, Participant relies solely on such advisors and not on any statements or representations of the Company or any of its agents, written or oral. Participant understands that Participant (and not the Company) shall be responsible for Participant’s own tax liability that may arise as a result of this investment or the transactions contemplated by this Award Agreement.

 

5.         Tax Obligations.

 

(a)         Responsibility for Taxes. Participant acknowledges that, regardless of any action taken by the Company or, if different, Participant’s employer (the “Employer”), the ultimate liability for any tax and/or social insurance liability obligations and requirements in connection with the Restricted Stock, including, without limitation, (a) all federal, state, and local taxes (including Participant’s Federal Insurance Contributions Act (FICA) obligation) that are required to be withheld by the Company or the Employer or other payment of tax‑related items related to Participant’s participation in the Plan and legally applicable to Participant, (b) Participant’s and, to the extent required by the Company (or Employer), the Company’s (or Employer’s) fringe benefit tax liability, if any, associated with the grant, vesting or delivery of the Restricted Stock or sale of Shares, and (c) any other Company (or Employer) taxes the responsibility for which Participant has, or has agreed to bear, with respect to the Restricted Stock (or the grant, vesting or delivery of Shares thereunder) (collectively, the “Tax Obligations”), is and remains Participant’s responsibility and may exceed the amount actually withheld by the Company or the Employer. Participant further acknowledges that the Company and/or the Employer (i) make no representations or undertakings regarding the treatment of any Tax Obligations in connection with any aspect of the Restricted Stock, including, but not limited to, the grant, vesting or delivery of the Restricted Stock, the subsequent sale of Shares acquired pursuant to such grant and the receipt of any dividends or other distributions, and (ii) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Restricted Stock to reduce or eliminate Participant’s liability for Tax Obligations or achieve any particular tax result. Further, if Participant is subject to Tax Obligations in more than one jurisdiction between the Date of Grant and the date of any relevant taxable or tax withholding event, as applicable, Participant acknowledges that the Company and/or the Employer (or former employer, as applicable) may be required to withhold or account for Tax Obligations in more than one jurisdiction. If Participant fails to make satisfactory arrangements for the payment of any required Tax Obligations hereunder at the time of the applicable taxable event, Participant acknowledges and agrees that the Company may refuse to issue or deliver the Shares.

 

4
 

 

(b)         Tax Withholding. When Shares of Restricted Stock vest (or upon such earlier time a participant makes an election under Section 83(b) of the Code), Participant generally will recognize immediate U.S. taxable income if Participant is a U.S. taxpayer. If Participant is a non‑U.S. taxpayer, Participant will be subject to applicable taxes in his or her jurisdiction. Pursuant to such procedures as the Administrator may specify from time to time, the Company and/or Employer shall withhold the minimum amount required to be withheld for the payment of Tax Obligations. The Participant may satisfy such Tax Obligations, in whole or in part (without limitation), if permissible by applicable local law, by (a) paying cash, (b) electing to have the Company withhold otherwise deliverable Shares having a Fair Market Value equal to the amount of such Tax Obligations, (c) electing to have the Company withhold the amount of such Tax Obligations from Participant’s wages or other cash compensation payable to Participant by the Company and/or the Employer, (d) delivering to the Company already vested and owned Shares having a Fair Market Value equal to such Tax Obligations, or (e) selling a sufficient number of such Shares otherwise deliverable to Participant through such means as the Company may determine in its sole discretion (whether through a broker or otherwise) equal to the amount of the Tax Obligations. To the extent determined appropriate by the Company in its discretion, it will have the right (but not the obligation) to satisfy any Tax Obligations by reducing the number of Shares otherwise deliverable to Participant and, until determined otherwise by the Company, this will be the method by which such Tax Obligations are satisfied. Further, if Participant is subject to tax in more than one jurisdiction between the Date of Grant and a date of any relevant taxable or tax withholding event, as applicable, Participant acknowledges and agrees that the Company and/or the Employer (and/or former employer, as applicable) may be required to withhold or account for tax in more than one jurisdiction. If Participant fails to make satisfactory arrangements for the payment of such Tax Obligations hereunder, Participant will permanently forfeit such Restricted Stock, and the Restricted Stock will be returned to the Company at no cost to the Company. Participant acknowledges and agrees that the Company may refuse to deliver the Shares if such Tax Obligations are not delivered at the time they are due.

 

6.         No Guarantee of Continued Service. PARTICIPANT ACKNOWLEDGES AND AGREES THAT THE VESTING OF THE RESTRICTED STOCK PURSUANT TO THE VESTING SCHEDULE HEREOF IS EARNED ONLY BY CONTINUING AS A SERVICE PROVIDER AT THE WILL OF THE COMPANY (OR THE EMPLOYER) AND NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS RESTRICTED STOCK AWARD OR ACQUIRING SHARES HEREUNDER. PARTICIPANT FURTHER ACKNOWLEDGES AND AGREES THAT THIS AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN DO NOT CONSTITUTE AN EXPRESS OR IMPLIED PROMISE OF CONTINUED ENGAGEMENT AS A SERVICE PROVIDER FOR THE VESTING PERIOD, FOR ANY PERIOD, OR AT ALL, AND SHALL NOT INTERFERE IN ANY WAY WITH PARTICIPANT’S RIGHT OR THE RIGHT OF THE COMPANY (OR THE EMPLOYER) TO TERMINATE PARTICIPANT’S RELATIONSHIP AS A SERVICE PROVIDER AT ANY TIME, WITH OR WITHOUT CAUSE.

 

7.         Nature of Grant. In accepting the grant, Participant acknowledges, understands and agrees that:

 

(a)         the grant of the Restricted Stock is voluntary and occasional and does not create any contractual or other right to receive future grants of Restricted Stock, or benefits in lieu of Restricted Stock, even if Shares of Restricted Stock have been granted in the past;

 

(b)         all decisions with respect to future Restricted Stock or other grants, if any, will be at the sole discretion of the Company;

 

(c)         Participant is voluntarily participating in the Plan;

 

(d)         the Shares subject to the Restricted Stock are not intended to replace any pension rights or compensation;

 

(e)         the Shares of Restricted Stock, and the income and value of same, are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end‑of‑service payments, bonuses, long‑service awards, pension or retirement or welfare benefits or similar payments;

 

5
 

 

(f)         the future value of the Shares of Restricted Stock is unknown, indeterminable and cannot be predicted;

 

(g)         for purposes of the Restricted Stock, Participant’s status as a Service Provider will be considered terminated as of the date Participant is no longer actively providing services to the Company or any Parent or Subsidiary (regardless of the reason for such termination and whether or not later to be found invalid or in breach of employment laws in the jurisdiction where Participant is a Service Provider or the terms of Participant’s employment or service agreement, if any), and unless otherwise expressly provided in this Award Agreement (including by reference in the Notice of Grant to other arrangements or contracts) or determined by the Administrator, Participant’s right to vest in the Restricted Stock under the Plan, if any, will terminate as of such date and will not be extended by any notice period (e.g., Participant’s period of service would not include any contractual notice period or any period of “garden leave” or similar period mandated under employment laws in the jurisdiction where Participant is a Service Provider or the terms of Participant’s employment or service agreement, if any, unless Participant is providing bona fide services during such time); the Administrator shall have the exclusive discretion to determine when Participant is no longer actively providing services for purposes of the Restricted Stock grant (including whether Participant may still be considered to be providing services while on a leave of absence);

 

(h)         unless otherwise provided in the Plan or by the Company in its discretion, the Restricted Stock and the benefits evidenced by this Award Agreement do not create any entitlement to have the Restricted Stock or any such benefits transferred to, or assumed by, another company nor be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares; and

 

(i)         the following provisions apply only if Participant is providing services outside the United States:

 

(i)          the Shares of Restricted Stock are not part of normal or expected compensation or salary for any purpose;

 

(ii)         Participant acknowledges and agrees that none of the Company, the Employer or any Parent or Subsidiary shall be liable for any foreign exchange rate fluctuation between Participant’s local currency and the United States Dollar that may affect the value of the Restricted Stock or of any amounts due to Participant pursuant to the grant, vesting or delivery of the Restricted Stock or the subsequent sale of any Shares; and

 

(iii)         no claim or entitlement to compensation or damages shall arise from forfeiture of the Restricted Stock resulting from the termination of Participant’s status as a Service Provider (for any reason whatsoever whether or not later found to be invalid or in breach of employment laws in the jurisdiction where Participant is a Service Provider or the terms of Participant’s employment or service agreement, if any), and in consideration of the grant of the Restricted Stock to which Participant is otherwise not entitled, Participant irrevocably agrees never to institute any claim against the Company, any Parent or Subsidiary or the Employer, waives his or her ability, if any, to bring any such claim, and releases the Company, any Parent or Subsidiary and the Employer from any such claim; if, notwithstanding the foregoing, any such claim is allowed by a court of competent jurisdiction, then, by participating in the Plan, Participant shall be deemed irrevocably to have agreed not to pursue such claim and agrees to execute any and all documents necessary to request dismissal or withdrawal of such claim.

 

8.         No Advice Regarding Grant. The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding Participant’s participation in the Plan, or Participant’s acquisition or sale of the underlying Shares. Participant is hereby advised to consult with his or her own personal tax, legal and financial advisors regarding his or her participation in the Plan before taking any action related to the Plan.

 

6
 

 

9.         Data Privacy. Participant hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of Participant’s personal data as described in this Award Agreement and any other Restricted Stock grant materials by and among, as applicable, the Employer, the Company and any Parent or Subsidiary for the exclusive purpose of implementing, administering and managing Participant’s participation in the Plan.

 

Participant understands that the Company and the Employer may hold certain personal information about Participant, including, but not limited to, Participant’s name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any Shares or directorships held in the Company, details of all Shares of Restricted Stock or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in Participant’s favor (“Data”), for the exclusive purpose of implementing, administering and managing the Plan.

 

Participant understands that Data will be transferred to a stock plan service provider as may be selected by the Company in the future, which is assisting the Company with the implementation, administration and management of the Plan. Participant understands that the recipients of the Data may be located in the United States or elsewhere, and that the recipients’ country of operation (e.g., the United States) may have different data privacy laws and protections than Participant’s country. Participant understands that if he or she resides outside the United States, he or she may request a list with the names and addresses of any potential recipients of the Data by contacting his or her local human resources representative. Participant authorizes the Company, any stock plan service provider selected by the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing his or her participation in the Plan. Participant understands that Data will be held only as long as is necessary to implement, administer and manage Participant’s participation in the Plan. Participant understands if he or she resides outside the United States, he or she may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing his or her local human resources representative. Further, Participant understands that he or she is providing the consents herein on a purely voluntary basis. If Participant does not consent, or if Participant later seeks to revoke his or her consent, his or her status as a Service Provider and career with the Employer will not be adversely affected; the only adverse consequence of refusing or withdrawing Participant’s consent is that the Company would not be able to grant Participant Restricted Stock or other equity awards or administer or maintain such awards. Therefore, Participant understands that refusing or withdrawing his or her consent may affect Participant’s ability to participate in the Plan. For more information on the consequences of Participant’s refusal to consent or withdrawal of consent, Participant understands that he or she may contact his or her local human resources representative.

 

10.         Address for Notices. Any notice to be given to the Company under the terms of this Award Agreement will be addressed to the Company at Avinger, Inc., 400 Chesapeake Drive, Redwood City, CA 94063, or at such other address as the Company may hereafter designate in writing.

 

11.         Electronic Delivery and Acceptance. The Company may, in its sole discretion, decide to deliver any documents related to the Restricted Stock awarded under the Plan or future Shares of Restricted Stock that may be awarded under the Plan by electronic means or request Participant’s consent to participate in the Plan by electronic means. Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through any on‑line or electronic system established and maintained by the Company or another third party designated by the Company.

 

7
 

 

12.         No Waiver. Either party’s failure to enforce any provision or provisions of this Agreement shall not in any way be construed as a waiver of any such provision or provisions, nor prevent that party from thereafter enforcing each and every other provision of this Agreement. The rights granted both parties herein are cumulative and shall not constitute a waiver of either party’s right to assert all other legal remedies available to it under the circumstances.

 

13.         Successors and Assigns. The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement shall inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer herein set forth, this Agreement shall be binding upon Participant and his or her heirs, executors, administrators, successors and assigns. The rights and obligations of Participant under this Agreement may only be assigned with the prior written consent of the Company.

 

14.         Additional Conditions to Issuance of Stock. If at any time the Company will determine, in its discretion, that the listing, registration, qualification or rule compliance of the Shares upon any securities exchange or under any state, federal or foreign law, the tax code and related regulations or under the rulings or regulations of the United States Securities and Exchange Commission or any other governmental regulatory body or the clearance, consent or approval of the United States Securities and Exchange Commission or any other governmental regulatory authority is necessary or desirable as a condition to the issuance of Shares to Participant (or his or her estate) hereunder, such issuance will not occur unless and until such listing, registration, qualification, rule compliance, clearance, consent or approval will have been completed, effected or obtained free of any conditions not acceptable to the Company.

 

15.         Language. If Participant has received this Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.

 

16.         Interpretation. The Administrator will have the power to interpret the Plan and this Award Agreement and to adopt such rules for the administration, interpretation and application of the Plan as are consistent therewith and to interpret or revoke any such rules (including, but not limited to, the determination of whether or not any Shares of Restricted Stock have vested). All actions taken and all interpretations and determinations made by the Administrator in good faith will be final and binding upon Participant, the Company and all other interested persons. Neither the Administrator nor any person acting on behalf of the Administrator will be personally liable for any action, determination or interpretation made in good faith with respect to the Plan or this Award Agreement.

 

17.         Captions. Captions provided herein are for convenience only and are not to serve as a basis for interpretation or construction of this Award Agreement.

 

18.         Modifications to the Agreement. This Award Agreement constitutes the entire understanding of the parties on the subjects covered. Participant expressly warrants that he or she is not accepting this Award Agreement in reliance on any promises, representations, or inducements other than those contained herein. Modifications to this Award Agreement or the Plan can be made only in an express written contract executed by a duly authorized officer of the Company.

 

8
 

 

19.         Governing Law and Venue. This Award Agreement will be governed by the laws of Delaware, without giving effect to the conflict of law principles thereof. For purposes of litigating any dispute that arises under this Award Agreement, the parties hereby submit to and consent to the jurisdiction of the State of California, and agree that such litigation will be conducted in the courts of San Mateo County, California, or the federal courts for the United States for the Northern District of California, and no other courts.

 

20.         Agreement Severable. In the event that any provision in this Award Agreement will be held invalid or unenforceable, such provision will be severable from, and such invalidity or unenforceability will not be construed to have any effect on, the remaining provisions of this Award Agreement.

 

21.         Amendment, Suspension or Termination of the Plan. By accepting this Award, Participant expressly warrants that he or she has received Shares of Restricted Stock under the Plan, and has received, read and understood a description of the Plan.  Participant understands that the Plan is discretionary in nature and may be amended, suspended or terminated by the Company at any time.

 

22.         Entire Agreement. The Plan is incorporated herein by reference. The Plan and this Award Agreement (including the exhibits referenced herein) constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof, and may not be modified adversely to Participant’s interest except by means of a writing signed by the Company and Participant.

 

23.         Country Addendum. Notwithstanding any provisions in this Award Agreement, the Restricted Stock grant shall be subject to any special terms and conditions set forth in any appendix to this Award Agreement for Participant’s country. Moreover, if Participant relocates to one of the countries included in the Country Addendum, the special terms and conditions for such country will apply to Participant, to the extent the Company determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons. The Country Addendum constitutes part of this Award Agreement.]

 

9
 

 

AVINGER, INC.
2015 EQUITY INCENTIVE PLAN
RESTRICTED STOCK AGREEMENT
COUNTRY ADDENDUM

 

TERMS AND CONDITIONS

 

This Country Addendum includes additional terms and conditions that govern the award of Restricted Stock under the Plan if Participant works in one of the countries listed below. If Participant is a citizen or resident of a country (or is considered as such for local law purposes) other than the one in which he or she is currently working or if Participant relocates to another country after receiving the Award of Restricted Stock, the Company will, in its discretion, determine the extent to which the terms and conditions contained herein will be applicable to Participant.

 

Certain capitalized terms used but not defined in this Country Addendum shall have the meanings set forth in the Plan and/or the Award Agreement to which this Country Addendum is attached.

 

NOTIFICATIONS

 

This Country Addendum also includes notifications relating to exchange control and other issues of which Participant should be aware with respect to his or her participation in the Plan. The information is based on the exchange control, securities and other laws in effect in the countries listed in this Country Addendum, as of [DATE]. Such laws are often complex and change frequently. As a result, the Company strongly recommends that Participant not rely on the notifications herein as the only source of information relating to the consequences of his or her participation in the Plan because the information may be outdated when Participant vests in the Restricted Stock, or when Participant subsequently sell Shares acquired under the Plan.

 

In addition, the notifications are general in nature and may not apply to Participant’s particular situation, and the Company is not in a position to assure Participant of any particular result. Accordingly, Participant is advised to seek appropriate professional advice as to how the relevant laws in Participant’s country may apply to Participant’s situation.

 

Finally, if Participant is a citizen or resident of a country other than the one in which Participant is currently working (or is considered as such for local law purposes) or if Participant moves to another country after receiving an Award of Restricted Stock, the information contained herein may not be applicable to Participant.

 

10
 

 

ELECTION TO INCLUDE VALUE OF RESTRICTED PROPERTY IN GROSS INCOME IN

YEAR OF TRANSFER UNDER CODE §83(B)

 

The undersigned hereby elects, pursuant to §83(b) of the Internal Revenue Code of 1986, as amended, to include in gross income as compensation for services the excess (if any) of the fair market value of the property described below over the purchase price thereof, and supplies the following information in accordance with the regulations promulgated under §83(b) and Rev. Proc. 2012-29, 2012-28 IRB 49:

 

Name:   (“Recipient”)
Address:    
     

 

Property Description:         Restricted Shares (the “Shares”) of Avinger, Inc. (the “Company”).

 

1.

The date on which the Shares were acquired was [______] (“Grant Date”).

 

2.

The taxable year for which the election is made is the calendar year [____].

 

3.

Restrictions:

 

(a)

The Shares are subject to forfeiture in the event Recipient does not fulfill the service obligations under a vesting schedule (the “Restriction Period”) forth in the Restricted Stock Award Agreement.

 

(b)

The Shares may not be directly or indirectly transferred, sold, assigned, pledged, hypothecated, or otherwise disposed of during the Restriction Period.

 

4.

The fair market value as of the Grant Date of the Shares, determined without regard to any restriction other than a restriction which by its terms will never lapse, is: $[___] per Share x [___] Shares = $[____].

 

5.

The amount paid by the Recipient for the Shares is: $0.00.

 

6.

The amount to include in gross income is $[____].

 

Recipient will file this election with the Internal Revenue Service office with which Recipient files his or her annual income tax return not later than thirty (30) days after the Grant Date. A copy of this election will also be furnished to the Company. The Recipient is the person performing services in connection with which the Recipient’s Shares were transferred.

 

Dated: ____________, 202_

 

Recipient/Taxpayer Signature: ___________________________

 

Print Taxpayer Name: __________________

 

 

11
 EX-23.1 5 ex_486885.htm EXHIBIT 23.1

Exhibit 23.1

 

Consent of Independent Registered Public Accounting Firm

 

We consent to the incorporation by reference in the Registration Statements on Form S-1 (Nos. 333-222517, 333-227308, 333-227689, and 333-266987), Form S-3 (Nos. 333-263921 and 333-263922) and Form S-8 (Nos. 333-201928, 333-209364, 333-216695, 333-227072, 333-233498, and 333-268296) of Avinger, Inc. (the “Company”), of our report dated March 15, 2023, relating to the financial statements and schedules of the Company (which report expresses an unqualified opinion and includes an explanatory paragraph relating to going concern uncertainty), appearing in this Annual Report on Form 10-K of the Company for the year ended December 31, 2022.

 

/s/ Moss Adams LLP

 

San Francisco, California

March 15, 2023

 

 

 
 EX-31.1 6 ex_486886.htm EXHIBIT 31.1

Exhibit 31.1

 

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER
Pursuant to

Securities Exchange Act Rules 13a-14(a) and 15d-14(a),

As Adopted Pursuant to

Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Jeffrey Soinski, hereby certify that:

 

1.     I have reviewed this Annual Report on Form 10-K of Avinger, Inc.;

 

2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.     Based on my knowledge, the financial statements, and other financial information included in this Annual Report on Form 10-K, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.     The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)     designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)     designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)     evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Annual Report on Form 10-K based on such evaluation; and

 

d)     disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

 

5.     The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a)     all significant deficiencies and material weakness in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and

 

b)     any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated: March 15, 2023

 

 

/s/ Jeffrey M. Soinski
 

Jeffrey M. Soinski
 

Chief Executive Officer
 

(Principal Executive Officer)

 

 
 EX-31.2 7 ex_486887.htm EXHIBIT 31.2

Exhibit 31.2

 

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER
Pursuant to

Securities Exchange Act Rules 13a-14(a) and 15d-14(a),

As Adopted Pursuant to

Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Nabeel Subainati, hereby certify that:

 

1.     I have reviewed this Annual Report on Form 10-K of Avinger, Inc.;

 

2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.     The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)     designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)     designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)     evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report; and

 

d)     disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

 

5.     The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a)     all significant deficiencies and material weakness in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and

 

b)     any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated: March 15, 2023

 

 

/s/ Nabeel Subainati
 

Nabeel Subainati
 

Vice President, Finance
 

(Principal Financial and Accounting Officer)

 

 

 
 EX-32.1 8 ex_486888.htm EXHIBIT 32.1

Exhibit 32.1

 

CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER

AND CHIEF FINANCIAL OFFICER

PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Avinger, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2022, as filed with the Securities and Exchange Commission (the “Report”), Jeffrey Soinski, as Chief Executive Officer of the Company, and Mark Weinswig, Chief Financial Officer of the Company, each hereby certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350), to his knowledge:

 

 

1.

The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and

 

 

2.

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 15th day of March, 2023.

 

/s/ Jeffrey M. Soinski

  

/s/ Nabeel Subainati

Jeffrey M. Soinski

  

Nabeel Subainati

Chief Executive Officer

  

Vice President, Finance

(Principal Executive Officer)

  

(Principal Financial and Accounting Officer)

 

This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.

 

 

 
 EX-101.SCH 9 avgr-20221231.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Balance Sheets link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Balance Sheets (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Statements of Operations and Comprehensive Loss link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Statements of Stockholders' Equity link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Statements of Cash Flows link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Financial Statements Schedules link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 1 - Organization link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 2 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 3 - Fair Value Measurements link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 4 - Inventories link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 5 - Property and Equipment, Net link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 6 - Accrued Expenses and Other Current Liabilities link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 7 - Borrowings link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 8 - Leases link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 9 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 10 - Stockholders' Equity link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 11 - Stock-based Compensation link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 12 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 13 - 401(k) Plan link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 14 - Subsequent Events link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Financial Statements Schedules (Tables) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 4 - Inventories (Tables) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 5 - Property and Equipment, Net (Tables) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 6 - Accrued Expenses and Other Current Liabilities (Tables) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 7 - Borrowings (Tables) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 8 - Leases (Tables) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 10 - Stockholders' Equity (Tables) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 11 - Stock-based Compensation (Tables) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 12 - Income Taxes (Tables) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Financial Statements Schedules - Allowance of Doubtful Accounts and Sales Returns (Details) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 1 - Organization (Details Textual) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Accounts Receivable, Allowance for Credit Loss (Details) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Product Warranty (Details) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Net Loss Per Share (Details) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note 3 - Fair Value Measurements (Details Textual) link:calculationLink link:definitionLink link:presentationLink 040 - Disclosure - Note 4 - Inventories - Schedule of Inventory (Details) link:calculationLink link:definitionLink link:presentationLink 041 - Disclosure - Note 5 - Property and Equipment, Net (Details Textual) link:calculationLink link:definitionLink link:presentationLink 042 - Disclosure - Note 5 - Property and Equipment, Net - Property and Equipment (Details) link:calculationLink link:definitionLink link:presentationLink 043 - Disclosure - Note 6 - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 044 - Disclosure - Note 7 - Borrowings (Details Textual) link:calculationLink link:definitionLink link:presentationLink 045 - Disclosure - Note 7 - Borrowings - Schedule of Debt (Details) link:calculationLink link:definitionLink link:presentationLink 046 - Disclosure - Note 8 - Leases (Details Textual) link:calculationLink link:definitionLink link:presentationLink 047 - Disclosure - Note 8 - Leases - Future Operating Lease Payments (Details) link:calculationLink link:definitionLink link:presentationLink 048 - Disclosure - Note 8 - Leases - ROU Assets and Lease Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 049 - Disclosure - Note 9 - Commitments and Contingencies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 050 - Disclosure - Note 10 - Stockholders' Equity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 051 - Disclosure - Note 10 - Stockholder's Equity - Outstanding Warrants (Details) link:calculationLink link:definitionLink link:presentationLink 052 - Disclosure - Note 11 - Stock-based Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 053 - Disclosure - Note 11 - Stock-Based Compensation - Stock Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 054 - Disclosure - Note 11 - Stock-Based Compensation - Options Outstanding and Vested (Details) link:calculationLink link:definitionLink link:presentationLink 055 - Disclosure - Note 11 - Stock-Based Compensation - Restricted Stock Units Award Activity (Details) link:calculationLink link:definitionLink link:presentationLink 056 - Disclosure - Note 11 - Stock-based Compensation - Noncash Stock-based Compensation Expense Related to Stock Options, ESPP, and RSUs (Details) link:calculationLink link:definitionLink link:presentationLink 057 - Disclosure - Note 12 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 058 - Disclosure - Note 12 - Income Taxes - Effective Income Tax Reconciliation (Details) link:calculationLink link:definitionLink link:presentationLink 059 - Disclosure - Note 12 - Income Taxes - Deferred Tax Assets and Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 060 - Disclosure - Note 12 - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) link:calculationLink link:definitionLink link:presentationLink 061 - Disclosure - Note 13 - 401(k) Plan (Details Textual) link:calculationLink link:definitionLink link:presentationLink 062 - Disclosure - Note 14 - Subsequent Events (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 10 avgr-20221231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 11 avgr-20221231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information avgr_DebtInstrumentCovenantComplianceTargetMinimumRevenueNextTwelveMonths Debt Instrument, Covenant Compliance Target Minimum Revenue, Next Twelve Months The target minimum annual revenue the entity is required to achieve under the terms of the debt agreement for the next twelve months during which the agreement is in effect. Note To Financial Statement Details Textual Significant Accounting Policies Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block] Tax at federal statutory rate Financial Statements Schedules Note 2 - Summary of Significant Accounting Policies Note 4 - Inventories Borrowings, long-term portion Note 5 - Property and Equipment, Net Note 6 - Accrued Expenses and Other Current Liabilities Note 7 - Borrowings Note 8 - Leases us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss), before Tax, Total Note 10 - Stockholders' Equity Income Tax Disclosure [Text Block] Note 11 - Stock-based Compensation Note 12 - Income Taxes Financial Statements Schedules - Allowance of Doubtful Accounts and Sales Returns (Details) us-gaap_LiabilitiesCurrent Total current liabilities Note 2 - Summary of Significant Accounting Policies - Accounts Receivable, Allowance for Credit Loss (Details) Operating lease liability Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liability. Note 2 - Summary of Significant Accounting Policies - Product Warranty (Details) Schedule of Debt [Table Text Block] Note 2 - Summary of Significant Accounting Policies - Net Loss Per Share (Details) Note 2 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) Note 4 - Inventories - Schedule of Inventory (Details) Note 5 - Property and Equipment, Net - Property and Equipment (Details) Note 6 - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) Awards outstanding, Weighted Average Remaining Contractual Term (Year) Note 7 - Borrowings - Schedule of Debt (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value avgr_DeferredTaxLiabilityOperatingLeaseRightOfUseAsset Operating lease right of use asset Amount of deferred tax consequences attributable to taxable temporary differences derived from operating lease right of use asset. Note 8 - Leases - Future Operating Lease Payments (Details) Note 8 - Leases - ROU Assets and Lease Liabilities (Details) Purchase Commitment, Excluding Long-Term Commitment [Axis] Note 10 - Stockholder's Equity - Outstanding Warrants (Details) Purchase Commitment, Excluding Long-Term Commitment [Domain] Purchase Commitment [Member] Note 11 - Stock-Based Compensation - Stock Option Activity (Details) Note 11 - Stock-Based Compensation - Options Outstanding and Vested (Details) Proceeds from the issuance of convertible preferred stock, net of commissions and issuance costs The cash inflow from issuance of common stocks, and preferred stocks identified as being convertible, into another form of financial instrument, typically the entity's common stock, after deduction of issuance costs. Note 11 - Stock-Based Compensation - Restricted Stock Units Award Activity (Details) Share-Based Payment Arrangement, Option, Activity [Table Text Block] Note 11 - Stock-based Compensation - Noncash Stock-based Compensation Expense Related to Stock Options, ESPP, and RSUs (Details) Note 12 - Income Taxes - Effective Income Tax Reconciliation (Details) Awarded, Weighted Average Grant Date Fair Value (in dollars per share) Note 12 - Income Taxes - Deferred Tax Assets and Liabilities (Details) Released, Weighted Average Grant Date Fair Value (in dollars per share) Note 12 - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) Forfeited, , Weighted Average Grant Date Fair Value (in dollars per share) Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Notes To Financial Statements Exercise of pre-funded warrants for common stock Aggregate change in value for shares issued as a result of the exercise of warrants. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Awards outstanding, Weighted Average Grant Date Fair Value (in dollars per share) Awards outstanding, Weighted Average Grant Date Fair Value (in dollars per share) Notes To Financial Statements [Abstract] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Forfeited, shares (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Awards outstanding, shares (in shares) Awards outstanding, shares (in shares) Awarded, shares (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Released, shares (in shares) The 2015 Employee Stock Purchase Plan [Member] Represents information about the 2015 employee stock purchase plan. Vested and expected to vest, weighted average remaining contractual life (Year) Vested and expected to vest (in shares) Vested and expected to vest, weighted average exercise price (in dollars per share) Vested and expected to vest, intrinsic value avgr_SaleOfStockNumberOfShares Sale of Stock, Number of Shares (in shares) The number of shares available in a sale of stock. Exercisable, weighted average exercise price (in dollars per share) Exercisable, weighted average remaining contractual life (Year) Exercisable, intrinsic value avgr_ClassOfWarrantOrRightExercised Class of Warrant or Right, Exercised (in shares) The number of warrants or rights exercised during the period. Exercisable (in shares) Loan Agreement [Member] Represents information about Term Loan Agreement (Loan Agreement). CRG [Member] Represents information about CRG. Options, weighted average remaining contractual life (Year) avgr_DebtAgreementMaximumBorrowingCapacity Debt Agreement, Maximum Borrowing Capacity Maximum borrowing capacity under a debt agreement on the amount that could be borrowed with a combination of, but not limited to, a line of credit and term loan. Options, intrinsic value Retirement Plan Name [Axis] Retirement Plan Name [Domain] Borrowings, current portion Borrowings, current portion, as of December 31, 2022 us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Options, weighted average exercise price (in dollars per share) Options, weighted average exercise price (in dollars per share) us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet Property, Plant, and Equipment, Lessor Asset under Operating Lease, after Accumulated Depreciation, Total Less: Amount of PIK additions and final facility fee to be incurred subsequent to December 31, 2022 Cumulative paid-in-kind interest treated as additional principal and added to the total carrying amount of the debt. Options expired, weighted average exercise price (in dollars per share) Accrued sales and use tax avgr_DebtConversionFeesAndPrepaymentPremiumAmount Debt Conversion, Fees and Prepayment Premium Amount The amount of related back-end fees and prepayment premium being converted together with the original debt in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Accrued expenses and other current liabilities Total accrued expenses and other current liabilities Accrued compensation Conversion of Principal Amount of Senior Secured Loan to Newly Authorized Series A Preferred Stock [Member] Represents information bout conversion of principal amount of senior secured loan to newly authorized series A preferred stock. Pension Plan [Member] Lessee, Operating Leases [Text Block] Accounts payable us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Options (in shares) Options (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Options expired (in shares) Retirement Plan Type [Axis] Purchases of property and equipment in accounts payable Conversion of Series B Preferred Stock into Common Stock [Member] Represents information about conversion of series B preferred stock into common stock. Retirement Plan Type [Domain] Credit Facility [Axis] Credit Facility [Domain] Other accrued liabilities us-gaap_PolicyTextBlockAbstract Accounting Policies Common Stock Warrants [Member] Represents information about common stock warrants. Exercise of pre-funded warrants for common stock (in shares) Stock Issued During Period, Shares, Warrants Exercised Number of shares issued as a result of the exercise of warrants. Accrued product warranty costs Common Stock Options [ member] Issuance of Series A preferred stock as dividend payment Accrued professional fees us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant avgr_DebtInstrumentCovenantComplianceTargetMinimumRevenueSecondYear Debt Instrument Covenant Compliance Target Minimum Revenue Second Year us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent avgr_WarrantyPeriod Warranty Period (Year) Represents the typical period of product warranty for parts and labor. us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchase of property and equipment avgr_NumberOfMajorCustomers Number of Major Customers Represents the number of major customers accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc. Reverse Stock Split [Member] The conversion of a reverse stock split where there is a reduction in the shares outstanding. Concentration of Credit Risk and Other Risks and Uncertainties [Policy Text Block] Disclosure of accounting policies for credit risk and other risks and uncertainties. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation avgr_ProductWarrantyAccrualPaymentsAndRelease Usage/Release Represents the aggregate decrease in the liability related to payments to satisfy claims for standard and extended product warranties and adjustment to release accrued amounts. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) Grantee Status [Domain] Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Grantee Status [Axis] Current liabilities: us-gaap_Assets Total assets Plan Name [Axis] Plan Name [Domain] us-gaap_OperatingLeaseExpense Operating Lease, Expense us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total Net loss applicable to common stockholders Net loss applicable to common stockholders us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition First Tranche, Borrowed on September 22, 2015 [Member] Represents information about first tranche, borrowed on September 22, 2015. us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense Share-Based Payment Arrangement, Expense, Tax Benefit Second Tranche, Borrowed on June 15, 2016 [Member] Represents information about second tranche, borrowed on June 15, 2016. Share-Based Payment Arrangement [Text Block] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Accretion of Series A preferred stock dividends Value of accretion of preferred stock dividends. Series A Preferred Stock Purchase Agreement with CRG [Member] Represents information about series A preferred stock purchase agreement with CRG. us-gaap_PreferredStockRedemptionDiscount Deemed dividend arising from beneficial conversion feature of convertible preferred stock Preferred Stock Redemption Discount avgr_DebtInstrumentRedemptionInitialPrepaymentPremiumPercentage Debt Instrument, Redemption Initial Prepayment Premium Percentage The initial premium percentage to be paid if the entity voluntarily prepays the amount outstanding under the debt instrument. Award Type [Domain] us-gaap_PreferredStockDividendsIncomeStatementImpact Accretion of preferred stock dividends avgr_DebtInstrumentFinancingFeePercentage Debt Instrument, Financing Fee Percentage The debt instrument fee required on the borrowing date for each tranche of borrowing, as a percentage of the principal amount borrowed. avgr_DebtInstrumentRedemptionAnnualDeclineInPrepaymentPremiumPercentage Debt Instrument, Redemption Annual Decline in Prepayment Premium Percentage The annual decline in the premium percentage to be paid if the entity voluntarily prepays the amount outstanding under the debt instrument. Net loss Net loss and comprehensive loss Net and comprehensive loss Basis of Presentation and Significant Accounting Policies [Text Block] Award Type [Axis] Noncash interest expense and other charges The amount of noncash interest expense (income) and other charges, net. avgr_DebtInstrumentCovenantComplianceTargetMinimumRevenueThirdYear Debt Instrument Covenant Compliance Target Minimum Revenue Third Year avgr_DebtInstrumentCovenantComplianceCashAndCertainCashEquivalentsMinimum Debt Instrument, Covenant Compliance Cash and Certain Cash Equivalents Minimum The minimum amount of cash and certain cash equivalents the entity is required to maintain under the terms of the debt agreement. avgr_DebtInstrumentFinalFacilityFeePercentage Debt Instrument, Final Facility Fee Percentage The facility fee payable at the end of the debt instrument term or upon prepayment in full, as a percentage of the amount borrowed. avgr_DebtInstrumentCovenantCompliancePrepaymentMultiplierForRevenueShortfall Debt Instrument, Covenant Compliance Prepayment Multiplier for Revenue Shortfall The multiplier applied to the amount of a revenue shortfall relative to required minimum targets, to determine the amount of outstanding principal the entity must prepay to be eligible for a cure right under the terms of the debt agreement. Restricted Stock Units (RSUs) [Member] avgr_DebtInstrumentCovenantComplianceTargetMinimumRevenueFourthYear Debt Instrument, Covenant Compliance Target Minimum Revenue Fourth Year The target minimum annual revenue the entity is required to achieve under the terms of the debt agreement for the fourth fiscal year during which the agreement is in effect. Restricted Stock [Member] Share-Based Payment Arrangement, Option [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] us-gaap_PreferredStockConvertibleSharesIssuable Preferred Stock, Convertible, Shares Issuable us-gaap_PreferredStockConvertibleConversionPrice Preferred Stock, Convertible, Conversion Price us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Less: Accumulated depreciation and amortization Commitments and Contingencies Disclosure [Text Block] Property and equipment, net Total property and equipment, net us-gaap_PropertyPlantAndEquipmentGross Property and Equipment Long-Term Debt, Type [Axis] Long-Term Debt, Type [Domain] Cash flows from investing activities us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities Accrued compensation us-gaap_IncomeTaxExpenseBenefit Income Tax Expense (Benefit), Total Provision for taxes us-gaap_IncreaseDecreaseInAccountsPayable Accounts payable Clinical Trials [Policy Text Block] Disclosure of accounting policy for clinical trial activities performed by third parties. Accrued clinical trial costs Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trial costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued travel and entertainment expenses Carrying value as of the balance sheet date of obligations incurred through that date and payable for travel expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Equipment Held by Customers [Member] Represents information related to equipment held by customers. us-gaap_OperatingExpenses Total operating expenses us-gaap_DefinedContributionPlanCostRecognized Defined Contribution Plan, Cost us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Total us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities Other long-term liabilities SEC Schedule, 12-09, Allowance, Credit Loss [Member] Allocated Share-based Compensation Expense Share-Based Payment Arrangement, Expense Amendment Flag dei_CityAreaCode City Area Code Use of Estimates, Policy [Policy Text Block] us-gaap_DebtInstrumentPeriodicPayment Debt Instrument, Periodic Payment, Total New Accounting Pronouncements, Policy [Policy Text Block] us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Accrued expenses and other current liabilities Reclassifications and adjustments due to rounding impact from reverse stock split for fractional shares (in shares) us-gaap_SharesOutstanding Balance at December 31, 2020 (in shares) Balance at December 31, 2021 (in shares) Common Stock, Shares, Outstanding, Ending Balance (in shares) Common Stock, Shares, Outstanding, Ending Balance (in shares) Preferred Stock, Shares Outstanding, Ending Balance (in shares) Preferred Stock, Shares Outstanding, Ending Balance (in shares) Current Fiscal Year End Date us-gaap_DebtInstrumentInterestRateStatedPercentage Debt Instrument, Interest Rate, Stated Percentage us-gaap_VariableLeaseCost Variable Lease, Cost us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses and other current assets Document Fiscal Period Focus Document Fiscal Year Focus dei_DocumentPeriodEndDate Document Period End Date us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Operating Lease, Weighted Average Remaining Lease Term dei_EntityFileNumber Entity File Number Entity Emerging Growth Company us-gaap_DebtInstrumentFaceAmount Debt Instrument, Face Amount dei_DocumentType Document Type us-gaap_GainsLossesOnExtinguishmentOfDebt Gain on extinguishment of debt Gain (Loss) on Extinguishment of Debt, Total Entity Small Business dei_EntityShellCompany Entity Shell Company Document Information [Line Items] us-gaap_DividendsPreferredStock Dividends, Preferred Stock, Total The 401(k) Plan [Member] Represents information related to the 401(k) plan of the reporting entity. Document Information [Table] dei_EntityPublicFloat Entity Public Float Entity Filer Category Debt Instrument [Axis] dei_EntityCurrentReportingStatus Entity Current Reporting Status Debt Instrument, Name [Domain] dei_EntityVoluntaryFilers Entity Voluntary Filers dei_EntityWellKnownSeasonedIssuer Entity Well-known Seasoned Issuer us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings Accretion of Series A preferred stock dividends avgr_OperatingLossCarryforwardsNotSubjectToExpiration Operating Loss Carryforwards, Not Subject to Expiration Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws which are not subject to expiration. Employee stock-based compensation us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivable us-gaap_ConcentrationRiskPercentage1 Concentration Risk, Percentage Entity Tax Identification Number Entity Central Index Key dei_EntityRegistrantName Entity Registrant Name Entity [Domain] Customer Concentration Risk [Member] Legal Entity [Axis] dei_EntityAddressAddressLine1 Entity Address, Address Line One dei_EntityAddressCityOrTown Entity Address, City or Town dei_EntityAddressPostalZipCode Entity Address, Postal Zip Code Supplemental disclosure of cash flow information Exercise Price Range 2 [Member] Represents the second exercise price range. dei_EntityAddressStateOrProvince Entity Address, State or Province Concentration Risk Type [Axis] Exercise Price Range 1 [Member] Represents the first exercise price range. Concentration Risk Type [Domain] us-gaap_AllowanceForDoubtfulAccountsReceivable Beginning balance Ending balance Exercise Price Range 4 [Member] Represents the fourth exercise price range. Exercise Price Range 3 [Member] Represents the third exercise price range. dei_EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding (in shares) Revenue Benchmark [Member] Accounts Receivable [Member] us-gaap_PreferredStockDividendsShares Preferred Stock Dividends, Shares Issuance of Series A preferred stock to pay dividends (in shares) us-gaap_IncreaseDecreaseInOtherNoncurrentAssets Other assets Paycheck Protection Program CARES Act [Member] Represents loan designed to provide funds for small businesses to keep their employees on the payroll. Issuance of Series A preferred stock to pay dividends us-gaap_IncreaseDecreaseInInventories Inventories Trading Symbol Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Nature of Operations [Text Block] Conversion of Series D preferred stock into common stock Conversion of Series B preferred stock into common stock (in shares) dei_LocalPhoneNumber Local Phone Number us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares) us-gaap_TableTextBlock Notes Tables Right of Use Asset and Liabilities [Table Text Block] Tabular disclosure of information pertaining to right of use assets and liabilities. Issuance of common stock upon vesting of restricted stock units (in shares) Selling, general and administrative Provision Issuance of common stock upon vesting of restricted stock units avgr_OperatingLeaseExpenseExcludingMaintenanceFeeAndOtherExpenseMonthly Operating Lease, Expense, Excluding Maintenance Fee and Other Expense, Monthly Represents information related to operating expense excluding maintenance fee and other expenses on a monthly basis. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) us-gaap_WarrantsAndRightsOutstandingMeasurementInput Warrants and Rights Outstanding, Measurement Input us-gaap_WarrantsAndRightsOutstandingTerm Warrants and Rights Outstanding, Term Line of Credit Facility, Lender [Domain] Issuance of common stock in public offerings, net of commissions and issuance costs (in shares) Stock Issued During Period, Shares, New Issues Raw materials Lender Name [Axis] us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and stockholders’ equity Finished products Work-in-process Issuance of common stock in public offerings, net of commissions and issuance costs UNITED STATES November 2018 Warrants [Member] Related to November 2018 warrants. Accumulated deficit Retained Earnings (Accumulated Deficit), Total Research and development Series 1 February 2018 Warrants [Member] Related to series 1 February 2018 warrants. Series 2 February 2018 Warrants [Member] Related to series 2 February 2018 warrants. Measurement Input, Discount Rate [Member] Debt Disclosure [Text Block] us-gaap_InterestExpense Interest expense, net Interest Expense, Total us-gaap_InterestExpenseDebt Interest Expense, Debt, Total Measurement Input, Price Volatility [Member] Changes in operating assets and liabilities: us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements us-gaap_OtherNoncashIncomeExpense Other non-cash charges Leasehold liability, long-term portion Operating Lease, Liability, Noncurrent Inventory Disclosure [Text Block] Measurement Input, Expected Dividend Rate [Member] Subsequent Event [Member] Measurement Input, Expected Term [Member] Schedule of Inventory, Current [Table Text Block] Leasehold liability as of December 31, 2022 Total lease liabilities Leasehold liability, current portion Subsequent Event Type [Axis] Subsequent Event Type [Domain] Retirement Benefits [Text Block] Subsequent Events [Text Block] Right of use asset Operating lease Total right of use assets us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid, Total Total us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Less: Imputed interest Measurement Input Type [Axis] Measurement Input Type [Domain] Fair Value Measurement, Policy [Policy Text Block] 2023 2024 Segment Reporting, Policy [Policy Text Block] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Share-Based Payment Arrangement, Employee [Member] Foreign Currency Transactions and Translations Policy [Policy Text Block] Other assets Stock-based compensation Lessee, Operating Lease, Liability, Maturity [Table Text Block] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] Amortization of debt issuance costs and debt discount Earnings Per Share, Policy [Policy Text Block] us-gaap_DebtConversionOriginalDebtAmount1 Debt Conversion, Original Debt, Amount Common Warrants [Member] Represents the common warrants Debt Conversion Description [Axis] Debt Conversion, Name [Domain] Operating expenses: Comprehensive Income, Policy [Policy Text Block] us-gaap_AmortizationOfDebtDiscountPremium Amortization of Debt Discount (Premium) January 2022 Public Offering [Member] Represents the January 2022 Public Offering. Income Tax, Policy [Policy Text Block] us-gaap_AssetsFairValueDisclosure Assets, Fair Value Disclosure, Total Research and Development Expense, Policy [Policy Text Block] us-gaap_Depreciation Depreciation, Total us-gaap_StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio us-gaap_ConversionOfStockSharesIssued1 Conversion of Stock, Shares Issued Depreciation and amortization us-gaap_LiabilitiesFairValueDisclosure Liabilities, Fair Value Disclosure, Total us-gaap_ConversionOfStockSharesConverted1 Conversion of Stock, Shares Converted us-gaap_SharesIssuedPricePerShare Shares Issued, Price Per Share (in dollars per share) Stock Conversion Description [Axis] Conversion of Stock, Name [Domain] us-gaap_AssetsCurrent Total current assets Share-Based Payment Arrangement [Policy Text Block] Stockholders' Equity Note Disclosure [Text Block] avgr_ProceedsFromIssuanceOrSaleOfEquityNet Proceeds from Issuance or Sale of Equity, Net The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity, net of underwriting discounts, commissions, legal and accounting fees. Warrants Issued in the January 2022 Financing [Member] represents warrants issued in the January 2022 financing. January 2022 offering [Member] represents January 2022 offering. Common stock, par value of $0.001; Shares authorized: 100,000,000 at December 31, 2021 and 2020; Shares issued and outstanding: 7,832,644 and 4,778,263 at December 31, 2022 and 2021, respectively Placement agent warrants issued in the January 2022 financing [Member] Represents placement agent warrants issued in the January 2022 financing. Adjustments to reconcile net loss to net cash used in operating activities: Officer and Director Share Purchase Plan [Member] Represents the information pertaining to officer and director share purchase plan. avgr_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedFairValue Sharebased Compensation Arrangement by Sharebased Payment Award Equity Instruments Other than Options Nonvested Fair Value Represents sharebased compensation arrangement by sharebased payment award equity instruments other than options nonvested fair value. Common Stock, Shares Authorized (in shares) Common Stock, Shares Authorized Common Stock, Shares, Issued (in shares) Common Stock, Shares, Issued (in shares) us-gaap_LesseeOperatingLeaseDiscountRate Lessee, Operating Lease, Discount Rate Common Stock, Par or Stated Value Per Share (in dollars per share) Common Stock, Par or Stated Value Per Share (in dollars per share) us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Standard Product Warranty, Policy [Policy Text Block] us-gaap_DeferredTaxAssetsValuationAllowance Less: Valuation allowance Statistical Measurement [Domain] Noncash investing and financing activities: Maximum [Member] Minimum [Member] us-gaap_DeferredTaxAssetsNet Total net deferred tax assets Statistical Measurement [Axis] Preferred Stock, Liquidation Preference, Value us-gaap_PreferredStockLiquidationPreference Preferred Stock, Liquidation Preference Per Share Convertible preferred stock issuable in series, par value of $0.001 Shares authorized: 5,000,000 at December 31, 2021 and 2020 Shares issued and outstanding: 60,961 and 56,451 at December 31, 2022 and 2021, respectively; aggregate liquidation preference related to Series A convertible preferred stock of $60,876 and $56,366 at December 31, 2022 and 2021, respectively us-gaap_DeferredTaxAssetsLiabilitiesNet Net deferred tax assets (liabilities) Preferred Stock, Shares Issued (in shares) Preferred Stock, Shares Issued Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] us-gaap_PrepaidRent Prepaid Rent Geographical [Axis] Property, Plant and Equipment Disclosure [Text Block] Leased Equipment [Member] Represents leased equipment. Geographical [Domain] us-gaap_DeferredTaxAssetsGross Total deferred tax assets Property, Plant and Equipment [Table Text Block] Preferred Stock, Shares Authorized (in shares) Preferred Stock, Shares Authorized us-gaap_DeferredIncomeTaxLiabilities Total deferred tax liabilities Inventories, net Total inventories Preferred Stock, Par or Stated Value Per Share (in dollars per share) Preferred Stock, Par or Stated Value Per Share Revenues Fair Value, Inputs, Level 3 [Member] avgr_ConversionOfWarrantsAllowedMaximumOwnershipOfCommonStockPercentage Conversion of Warrants Allowed Maximum Ownership of Common Stock Percentage Represents conversion of warrants allowed maximum ownership of common stock percentage. us-gaap_ForeignCurrencyTransactionGainLossBeforeTax Foreign Currency Transaction Gain (Loss), before Tax, Total avgr_ConversionOfWarrantsAllowedMaximumOwnershipOfCommonStockPercentageUponElection Conversion of Warrants Allowed Maximum Ownership of Common Stock Percentage upon Election Represents conversion of warrants allowed maximum ownership of common stock percentage upon election. Fair Value Hierarchy and NAV [Domain] Customer [Axis] Customer [Domain] Fair Value, Inputs, Level 2 [Member] Fixed assets Fair Value Hierarchy and NAV [Axis] Warranty provision Accruals and other us-gaap_PropertyPlantAndEquipmentUsefulLife Property, Plant and Equipment, Useful Life (Year) us-gaap_PreferredStockDividendRatePercentage Preferred Stock, Dividend Rate, Percentage Cash flows from operating activities Revenue [Policy Text Block] Statement [Line Items] Accounts Receivable, Allowance for Credit Loss, Current Accounts receivable, net of allowance for doubtful accounts of $73 and $6 at December 31, 2022 and 2021, respectively Furniture and Fixtures [Member] us-gaap_NumberOfReportableSegments Number of Reportable Segments Additional paid-in capital Stockholders’ equity: Schedule of Product Warranty Liability [Table Text Block] Leasehold Improvements [Member] Property, Plant and Equipment, Policy [Policy Text Block] Other (expense) income, net Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Domain] Research and other credits Federal, state and foreign net operating losses Current assets: Fair Value Disclosures [Text Block] us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Inventory, Policy [Policy Text Block] Private Placement [Member] us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net change in cash and cash equivalents us-gaap_Liabilities Total liabilities us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash provided by financing activities Commitments and Contingencies Sale of Stock [Axis] Sale of Stock [Domain] us-gaap_OperatingIncomeLoss Loss from operations us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash used in operating activities Prepaid expenses and other current assets us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used in investing activities Cost of revenues us-gaap_GrossProfit Gross profit Counterparty Name [Axis] Counterparty Name [Domain] Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Provision for excess and obsolete inventories us-gaap_CostOfGoodsAndServicesSoldDepreciation Cost, Depreciation us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total us-gaap_PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs Permanent differences Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent differences. us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment Property and equipment Change in right of use asset The amount of change in right-of-use asset during the period. us-gaap_ProductWarrantyAccrual Beginning balance Ending balance us-gaap_ProceedsFromIssuanceOrSaleOfEquity Proceeds from Issuance or Sale of Equity, Total Cost of Goods and Service [Policy Text Block] us-gaap_ProceedsFromIssuanceOfWarrants Proceeds from Issuance of Warrants us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock Proceeds from Issuance of Convertible Preferred Stock Retained Earnings [Member] Additional Paid-in Capital [Member] Common Stock [Member] Preferred Stock [Member] Equity Components [Axis] Equity Component [Domain] us-gaap_LongTermDebt Total Exercise price per share (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Total outstanding and exercisable (in shares) Class of Warrant or Right, Outstanding Transfers between inventory and property and equipment The amount of transfers between inventory and property and equipment during the reporting period. Valuation Allowances and Reserves [Table Text Block] Tabular disclosure of a schedule of allowance and reserve accounts where the valuation and qualifying accounts are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs. Underlying shares of common stock (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Accounts Receivable, Allowance for Credit Loss [Table Text Block] February 2021 Public Offering [Member] Information related to the February 2021 public offering. dei_IcfrAuditorAttestationFlag ICFR Auditor Attestation Flag SEC Schedule, 12-09, Allowance, Sales Returns [Member] Allowance for sales returns Conversion of Series D Preferred Stock into Common Stock [Member] Represents information related to the conversion of Series D preferred stock into common stock. State and Local Jurisdiction [Member] One Customer [Member] Information related to one customer. Less: Amount representing debt issuance costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total Deferred revenue Income Tax Authority [Axis] Income Tax Authority [Domain] avgr_DebtInstrumentCovenantComplianceMinimumLiquidityRequirement Debt Instrument, Covenant Compliance, Minimum Liquidity Requirement The minimum amount of liquidity required at all times for compliance with the debt instrument covenant. Domestic Tax Authority [Member] avgr_DebtInstrumentCovenantComplianceTargetMinimumRevenuePastTwelveMonths Debt Instrument, Covenant Compliance, Target Minimum Revenue, Past Twelve Months The target minimum annual revenue the entity is required to achieve under the terms of the debt agreement for the past twelve months during which the agreement is in effect. Common Stock Warrants, Issued with Series D Convertible Preferred Stock [Member] Represents information related to common stock warrants, issued with series B convertible preferred stock. Document Annual Report Machinery and Equipment [Member] Computer Equipment [Member] Cash and Cash Equivalents, Policy [Policy Text Block] Receivable [Policy Text Block] Software Development [Member] Entity Incorporation, State or Country Code us-gaap_UnrecognizedTaxBenefits Balance at beginning of year Balance at end of year Accounting Policies [Abstract] Document Transition Report Basis of Accounting, Policy [Policy Text Block] Selling, General and Administrative Expenses [Member] dei_EntityInteractiveDataCurrent Entity Interactive Data Current Other Nonoperating Income (Expense) [Member] Increase (Decrease) for tax positions of prior year Security Exchange Name us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions Increase (Decrease) for tax positions of prior year Increase based on the tax positions in the current year Title of 12(b) Security us-gaap_ProceedsFromIssuanceOfLongTermDebt Proceeds from Issuance of Long-Term Debt, Total Cost of Sales [Member] Research and Development Expense [Member] us-gaap_ValuationAllowancesAndReservesBalance Balance at Beginning of Year Balance at End of Year Charged to costs and expenses, additions Income Statement Location [Axis] Write offs Income Statement Location [Domain] Nonmonetary Transaction Type [Domain] Nonmonetary Transaction Type [Axis] dei_AuditorName Auditor Name dei_AuditorFirmId Auditor Firm ID dei_AuditorLocation Auditor Location us-gaap_TaxCreditCarryforwardAmount Tax Credit Carryforward, Amount us-gaap_SharePrice Share Price Research Tax Credit Carryforward [Member] Antidilutive Securities (in shares) us-gaap_PurchaseObligation Purchase Obligation, Total Tax Credit Carryforward [Axis] Tax Credit Carryforward, Name [Domain] us-gaap_OperatingLossCarryforwards Operating Loss Carryforwards SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] Statement [Table] Statement of Financial Position [Abstract] Weighted average common shares used to compute net loss per share, basic and diluted (in shares) Weighted average common stock outstanding, basic and diluted (in shares) August 2022 Purchase Agreement [Member] Relating to the August 2022 purchase agreement. August 2022 Public Offering [Member] Represents the August 2022 Public Offering. Net loss per share attributable to common stockholders, basic and diluted (in dollars per share) Series B Financing Warrants [Member] Represents series B financing warrants. Statement of Cash Flows [Abstract] Statement of Stockholders' Equity [Abstract] Placement Agent Preferred Investment Options [Member] Relating to Placement Agent Preferred Investment Options Income Statement [Abstract] us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree 2025 us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour Long-Term Debt, Maturity, Year Four us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive Long-Term Debt, Maturity, Year Five Registered Direct Pre-funded Warrants [Member] Related to registered direct pre-funded warrants. Schedule of Accrued Liabilities [Table Text Block] us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths 2023 us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo 2024 Placement Agent Private Investment Options Issued in August 2022 Financing [Member] Relating to Placement Agent Private Investment Options Issued in August 2022 Financing Private Pre-funded Warrants [Member] Relating to Private Pre-funded Warrants avgr_DebtInstrumentInterestForgiven Debt Instrument Interest Forgiven Represents the debt instrument interest forgiven. Pre-funded Warrants Issued in August 2022 Financing [Member] Relating to Pre-funded Warrants Issued in August 2022 Financing. Series A Private Investment Options Issued in August 2022 Financing [Member] Relating to Series A Private Investment Options Issued in August 2022 Financing Series B Private Investment Options Issued in August 2022 Financing [Member] Relating to Series B Private Investment Options Issued in August 2022 Financing. Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Reclassifications and adjustments due to rounding impact from reverse stock split for fractional shares Reduction in the number of shares during the period as a result of a reverse stock split. Schedule of Deferred Tax Assets and Liabilities [Table Text Block] The Market Offering Agreement (the “ATM Agreement”) [Member] Represents the market offering agreement (the “ATM Agreement”). Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Common Stock in June, 2022 [Member] Represents common stock in June 2022. avgr_CommissionPercentage Commission Percentage Represents commission percentage. Other Cash flows from financing activities Other long-term liabilities Capitalized research and development Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development. Change in valuation allowance Series A Preferred Investment Options [Member] Related to Series A preferred investment options. Series B Preferred Investment Options [Member] Related to Series B preferred investment options. avgr_ShareOfferingAgreementAggregateOffering Share Offering Agreement, Aggregate Offering The value of the aggregate offering under share offering agreement. Series D Preferred Stock [Member] Pre-funded Warrants [Member] Represents pre-funded warrants. Series A Preferred Stock [Member] Series B Preferred Stock [Member] us-gaap_StockholdersEquity Total stockholders’ equity Balance at December 31, 2020 Balance at December 31, 2021 us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense Operating Lease, Right-of-Use Asset, Amortization Expense Nondeductible interest expense Class of Stock [Axis] Class of Stock [Domain] Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Recoveries/write-offs Amount of increase (decrease) in allowance for credit loss on accounts receivable, from recovery (writeoff). Weighted Average Exercise Price (in dollars per share) Weighted Average Remaining Contractual Life (Year) Number Exercisable (in shares) Weighted Average Exercise Price, options vested (in dollars per share) Exercise Price, Upper Limit (in dollars per share) Options Outstanding (in shares) Exercise Price Range [Axis] State taxes, net of federal benefit Exercise Price Range [Domain] Exercise Price, Lower Limit (in dollars per share) us-gaap_IncomeTaxReconciliationTaxCreditsResearch Research credits EX-101.PRE 12 avgr-20221231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.CAL 13 avgr-20221231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE XML 14 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document And Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Mar. 10, 2023
Jun. 30, 2022
Document Information [Line Items]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2022    
Document Transition Report false    
Entity File Number 001-36817    
Entity Registrant Name AVINGER, INC.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 20-8873453    
Entity Address, Address Line One 400 Chesapeake Drive    
Entity Address, City or Town Redwood City    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 94063    
City Area Code 650    
Local Phone Number 241-7900    
Title of 12(b) Security Common Stock, par value $0.001 per share    
Trading Symbol AVGR    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag false    
Entity Shell Company false    
Entity Public Float     $ 8.8
Entity Common Stock, Shares Outstanding (in shares)   8,614,508  
Auditor Name Moss Adams LLP    
Auditor Location San Francisco, CA    
Auditor Firm ID 659    
Entity Central Index Key 0001506928    
Current Fiscal Year End Date --12-31    
Document Fiscal Year Focus 2022    
Document Fiscal Period Focus FY    
Amendment Flag false    
XML 15 R2.htm IDEA: XBRL DOCUMENT v3.22.4
Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 14,603 $ 19,497
Accounts receivable, net of allowance for doubtful accounts of $73 and $6 at December 31, 2022 and 2021, respectively 1,057 1,393
Inventories, net 4,965 4,601
Prepaid expenses and other current assets 362 300
Total current assets 20,987 25,791
Right of use asset 2,194 3,179
Property and equipment, net 702 95
Other assets 312 420
Total assets 24,195 29,485
Current liabilities:    
Accounts payable 631 1,394
Accrued compensation 1,401 1,609
Accrued expenses and other current liabilities 657 718
Leasehold liability, current portion 1,092 985
Borrowings, current portion 14,165 0
Total current liabilities 17,946 4,706
Borrowings, long-term portion 0 12,287
Leasehold liability, long-term portion 1,102 2,194
Other long-term liabilities 1,001 575
Total liabilities 20,049 19,762
Commitments and Contingencies  
Stockholders’ equity:    
Convertible preferred stock issuable in series, par value of $0.001 Shares authorized: 5,000,000 at December 31, 2021 and 2020 Shares issued and outstanding: 60,961 and 56,451 at December 31, 2022 and 2021, respectively; aggregate liquidation preference related to Series A convertible preferred stock of $60,876 and $56,366 at December 31, 2022 and 2021, respectively $ 0 $ 0
Common Stock, Shares Authorized (in shares) 100,000,000 100,000,000
Common stock, par value of $0.001; Shares authorized: 100,000,000 at December 31, 2021 and 2020; Shares issued and outstanding: 7,832,644 and 4,778,263 at December 31, 2022 and 2021, respectively $ 8 $ 5
Additional paid-in capital 406,514 394,471
Accumulated deficit (402,376) (384,753)
Total stockholders’ equity 4,146 9,723
Total liabilities and stockholders’ equity $ 24,195 $ 29,485
XML 16 R3.htm IDEA: XBRL DOCUMENT v3.22.4
Balance Sheets (Parentheticals) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Accounts Receivable, Allowance for Credit Loss, Current $ 73 $ 6
Preferred Stock, Par or Stated Value Per Share (in dollars per share) $ 0.001 $ 0.001
Preferred Stock, Shares Authorized (in shares) 5,000,000 5,000,000
Preferred Stock, Shares Issued (in shares) 60,961 56,451
Preferred Stock, Shares Outstanding, Ending Balance (in shares) 60,961 56,451
Preferred Stock, Liquidation Preference, Value $ 60,876 $ 56,366
Common Stock, Par or Stated Value Per Share (in dollars per share) $ 0.001 $ 0.001
Common Stock, Shares Authorized (in shares) 100,000,000 100,000,000
Common Stock, Shares, Issued (in shares) 7,832,644 4,778,263
Common Stock, Shares, Outstanding, Ending Balance (in shares) 7,832,644 4,778,263
XML 17 R4.htm IDEA: XBRL DOCUMENT v3.22.4
Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Revenues $ 8,273 $ 10,130
Cost of revenues 5,619 6,706
Gross profit 2,654 3,424
Operating expenses:    
Research and development 4,390 5,900
Selling, general and administrative 14,221 15,625
Total operating expenses 18,611 21,525
Loss from operations (15,957) (18,101)
Interest expense, net (1,665) (1,648)
Other (expense) income, net (1) 2,337
Net loss and comprehensive loss (17,623) (17,412)
Accretion of preferred stock dividends (4,510) (4,175)
Deemed dividend arising from beneficial conversion feature of convertible preferred stock (5,111) 0
Net loss applicable to common stockholders $ (27,244) $ (21,587)
Net loss per share attributable to common stockholders, basic and diluted (in dollars per share) $ (4.36) $ (4.57)
Weighted average common shares used to compute net loss per share, basic and diluted (in shares) 6,249 4,722
XML 18 R5.htm IDEA: XBRL DOCUMENT v3.22.4
Statements of Stockholders' Equity - USD ($)
$ in Thousands
Preferred Stock [Member]
January 2022 Public Offering [Member]
Preferred Stock [Member]
Series D Preferred Stock [Member]
Preferred Stock [Member]
Common Stock [Member]
January 2022 Public Offering [Member]
Common Stock [Member]
Series D Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
January 2022 Public Offering [Member]
Additional Paid-in Capital [Member]
Series D Preferred Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
January 2022 Public Offering [Member]
Retained Earnings [Member]
Series D Preferred Stock [Member]
Retained Earnings [Member]
January 2022 Public Offering [Member]
Series D Preferred Stock [Member]
Total
Balance at December 31, 2020 (in shares) at Dec. 31, 2020     52,369     4,246,308                  
Balance at December 31, 2020 at Dec. 31, 2020           $ 4     $ 380,413     $ (367,341)     $ 13,076
Issuance of common stock in public offerings, net of commissions and issuance costs (in shares)     0     500,000                  
Issuance of common stock in public offerings, net of commissions and issuance costs           $ 1     13,043     0     13,043
Conversion of Series B preferred stock into common stock (in shares)     (93)     18,600                  
Issuance of common stock upon vesting of restricted stock units (in shares)     0     13,355                  
Employee stock-based compensation           $ 0     1,015     0     1,015
Issuance of Series A preferred stock to pay dividends (in shares)     4,175     0                  
Issuance of Series A preferred stock to pay dividends           $ 0     4,175     0     4,175
Accretion of Series A preferred stock dividends           0     (4,175)     0     (4,175)
Net and comprehensive loss           $ 0     0     (17,412)     (17,412)
Balance at December 31, 2021 (in shares) at Dec. 31, 2021     56,451     4,778,263                  
Balance at December 31, 2021 at Dec. 31, 2021           $ 5     394,471     (384,753)     9,723
Issuance of common stock in public offerings, net of commissions and issuance costs (in shares) 0 7,600   1,285,603 0                    
Issuance of common stock in public offerings, net of commissions and issuance costs       $ 1 $ 0   $ 5,195 $ 6,721   $ 0 $ 0   $ 5,196 $ 6,721  
Conversion of Series B preferred stock into common stock (in shares)     (7,600)     950,000                  
Issuance of common stock upon vesting of restricted stock units (in shares)     0     8,590                  
Employee stock-based compensation           $ 0     127     0     127
Issuance of Series A preferred stock to pay dividends (in shares)     4,510     0                  
Issuance of Series A preferred stock to pay dividends           $ 0     4,510     0     4,510
Accretion of Series A preferred stock dividends           0     (4,510)     0     (4,510)
Net and comprehensive loss           0     0     (17,623)     (17,623)
Conversion of Series D preferred stock into common stock           $ 1     0     0     1
Exercise of pre-funded warrants for common stock (in shares)     0     784,019                  
Exercise of pre-funded warrants for common stock           $ 1     0     0     1
Reclassifications and adjustments due to rounding impact from reverse stock split for fractional shares (in shares)     0     26,169                  
Reclassifications and adjustments due to rounding impact from reverse stock split for fractional shares           $ 0     0     0     0
Issuance of common stock upon vesting of restricted stock units           $ 0     0     0     0
Balance at December 31, 2021 (in shares) at Dec. 31, 2022     60,961     7,832,644                  
Balance at December 31, 2021 at Dec. 31, 2022           $ 8     $ 406,514     $ (402,376)     $ 4,146
XML 19 R6.htm IDEA: XBRL DOCUMENT v3.22.4
Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Cash flows from operating activities    
Net loss $ (17,623) $ (17,412)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 196 687
Amortization of debt issuance costs and debt discount 83 86
Stock-based compensation 127 1,015
Noncash interest expense and other charges 1,795 1,564
Change in right of use asset 93 133
Provision for excess and obsolete inventories 272 125
Gain on extinguishment of debt 0 (2,353)
Other non-cash charges 69 2
Changes in operating assets and liabilities:    
Accounts receivable 269 89
Inventories (1,387) (849)
Prepaid expenses and other current assets (62) 50
Other assets 15 (43)
Accounts payable (764) 679
Accrued compensation (208) (94)
Accrued expenses and other current liabilities (61) 49
Other long-term liabilities 426 575
Net cash used in operating activities (16,760) (15,697)
Cash flows from investing activities    
Purchase of property and equipment (51) (34)
Net cash used in investing activities (51) (34)
Cash flows from financing activities    
Net cash provided by financing activities 11,917 13,043
Net change in cash and cash equivalents (4,894) (2,688)
Cash and cash equivalents, beginning of period 19,497 22,185
Cash and cash equivalents, end of period 14,603 19,497
Noncash investing and financing activities:    
Accretion of Series A preferred stock dividends 4,510 4,175
Issuance of Series A preferred stock as dividend payment 4,510 4,175
Transfers between inventory and property and equipment 751 (1)
Purchases of property and equipment in accounts payable 0 21
Common Stock [Member]    
Cash flows from financing activities    
Proceeds from the issuance of convertible preferred stock, net of commissions and issuance costs 6,721 0
Preferred Stock [Member]    
Cash flows from financing activities    
Proceeds from the issuance of convertible preferred stock, net of commissions and issuance costs $ 5,196 $ 13,043
XML 20 R7.htm IDEA: XBRL DOCUMENT v3.22.4
Financial Statements Schedules
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]

(a)(2)

Financial Statement Schedules

 

All other schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto. Financial statement schedules relating to the allowance for doubtful accounts receivable and for sales returns follows (in thousands):

 

Description

  

Balance at
Beginning
of Year

    

Charged to
costs and
expenses

    

Write offs

    

Balance at
End of
Year

  

Allowance for doubtful accounts receivable:

                                

Fiscal year ended 2021

   $ 19     $ 2     $ 15     $ 6  

Fiscal year ended 2022

   $ 6     $ 70     $ 3     $ 73  

 

   

Balance at
Beginning
of Year

    

Charged to
costs and
expenses

    

Write offs

    

Balance at
End of
Year

  

Allowance for sales returns:

                                

Fiscal year ended 2021

   $ 20     $ 10     $ 10     $ 20  

Fiscal year ended 2022

   $ 20     $ —     $ 5     $ 15  

 

 
XML 21 R8.htm IDEA: XBRL DOCUMENT v3.22.4
Note 1 - Organization
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Nature of Operations [Text Block]

1.

Organization

 

Organization, Nature of Business

 

Avinger, Inc. (the “Company”), a Delaware corporation, was incorporated in March 2007. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease (“PAD”). Patients with PAD have a build-up of plaque in the arteries that supply blood to areas away from the heart, particularly the pelvis and legs. The Company manufactures and sells a suite of products in the United States (“U.S.”) and in select international markets. The Company has developed its Lumivascular platform, which integrates optical coherence tomography (“OCT”) visualization with interventional catheters and is the industry’s only system that provides real-time intravascular imaging during the treatment portion of PAD procedures. The Company’s Lumivascular platform consists of a capital component, Lightbox consoles, as well as a variety of disposable catheter products. The Company’s current catheter products include Ocelot and Tigereye, which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (“CTO”). The Company also has image-guided atherectomy products, Pantheris and Pantheris SV, which are designed to allow physicians to precisely remove arterial plaque in PAD patients. The Company is in the process of developing next-generation CTO crossing devices to target coronary CTO markets. The Company is located in Redwood City, California.

 

Liquidity Matters

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40) requires the Company to make certain disclosures if it concludes that there is substantial doubt about the entity’s ability to continue as a going concern within one year from the date of the issuance of these financial statements.

 

In the course of its activities, the Company has incurred losses and negative cash flows from operations since its inception. As of December 31, 2022, the Company had an accumulated deficit of $402.4 million. The Company expects to incur losses for the foreseeable future. The Company believes that its cash and cash equivalents of $14.6 million at December 31, 2022 and expected revenues from operations will be sufficient to allow the Company to fund its current operations through the end of the third quarter of 2023. The Company received net proceeds of approximately $4.4 million from the sale of its common stock in August 2022, $0.8 million from the sale of its common stock under an At The Market Offering Agreement during the year ended December 31, 2022, $6.7 million from the January 2022 Series D preferred stock and $13.0 million from the sale of its common stock in February 2021. The Company may seek to raise additional funds in future equity offerings to meet its operational needs and capital requirements for product development, clinical trials and commercialization or other strategic objectives.

 

The Company can provide no assurance that it will be successful in raising funds pursuant to additional equity or debt financings or that such funds will be raised at prices that do not create substantial dilution for its existing stockholders. Given the volatility in the Company’s stock price, any financing that the Company may undertake in the next twelve months could cause substantial dilution to its existing stockholders, and there can be no assurance that the Company will be successful in acquiring additional funding at levels sufficient to fund its various endeavors. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. In addition, the COVID-19 pandemic and macroeconomic environment have in the past and could result in reduced consumer and investor confidence, instability in the credit and financial markets, volatile corporate profits, restrictions on elective medical procedures, and reduced business and consumer spending, which could increase the cost of capital and/or limit the availability of capital to the Company.

 

If the Company is unable to raise additional capital in sufficient amounts or on terms acceptable to it, the Company may have to significantly reduce its operations or delay, scale back or discontinue the development and sale of one or more of its products. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company’s ultimate success will largely depend on its continued development of innovative medical technologies, its ability to successfully commercialize its products and its ability to raise significant additional funding.

 

 

Additionally, due to the substantial doubt about the Company’s ability to continue operating as a going concern and the “Material Adverse Change” clause in the Loan Agreement with CRG Partners III L.P. and certain of its affiliated funds (collectively “CRG”), the entire amount of outstanding borrowings at December 31, 2022 and 2021 has been classified as current in these financial statements. CRG has not purported that an Event of Default (as defined in the Loan Agreement) has occurred due to a Material Adverse Change.

 

Currently all of our cash and cash equivalents are held at a single financial institution, Silicon Valley Bank. On March 10, 2023, the Federal Deposit Insurance Corporation announced that Silicon Valley Bank had been closed by the California Department of Financial Protection and Innovation. While we have regained access to our accounts at Silicon Valley Bank and are evaluating our banking relationships, future disruptions of financial institutions where we bank or have credit arrangements, or disruptions of the financial services industry in general, could adversely affect our ability to access our cash and cash equivalents. If we are unable to access our cash and cash equivalents as needed, our financial position and ability to operate our business will be adversely affected.

 

Public Offerings

 

Past Offerings

 

On February 2, 2021, under a shelf registration statement, the Company completed a bought deal offering of 500,000 shares of common stock at an offering price of $28.80 per share. As a result, the Company received aggregate net proceeds of approximately $13.0 million after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses.

 

January 2022 Offering

 

On January 14, 2022, the Company entered into a securities purchase agreement with several institutional investors pursuant to which the Company agreed to sell and issue, in a registered direct offering (“January 2022 Offering”), an aggregate of 7,600 shares of the Company’s Series D Convertible Preferred Stock, par value of $0.001 per share, at an offering price of $1,000 per share which was convertible into common stock at a conversion price of $8.00 per share. Concurrently, the Company agreed to issue to these investors warrants to purchase up to an aggregate of 807,500 shares of the Company’s common stock (the “Common Warrants”). As a result, the Company received aggregate net proceeds of approximately $6.7 million after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses.

 

The 807,500 Common Warrants have an exercise price of $9.60 per share and became exercisable beginning July 14, 2022. The Common Warrants will expire five years following the time they become exercisable, or July 14, 2027. The Company also issued to the Placement Agent or its designees warrants to purchase up to an aggregate of 66,500 shares of common stock (the “Placement Agent Warrants”). The Placement Agent Warrants are subject to the same terms as the Common Warrants, except that the Placement Agent Warrants have an exercise price of $10.00 per share and a term of five years from the commencement of the sales pursuant to the January 2022 Offering, or January 12, 2027.

 

August 2022 Offering

 

On August 4, 2022, the Company entered into a securities purchase agreement with a single institutional investor for the issuance and sale of 1,484,019 shares of its common stock in a registered direct offering (“RD” or “Registered Direct”) at a purchase price of $1.752 per share, or pre-funded warrants in lieu thereof. In a concurrent private placement, the Company also agreed to issue and sell to the investor 1,369,864 shares of common stock at the same purchase price as in the registered direct offering, or pre-funded warrants in lieu thereof (“Private Placement” and together with the Registered Direct offering the “August 2022 Offering”). As a result, the Company received aggregate net proceeds of approximately $4.4 million after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses.

 

As a result, in the Registered Direct offering, the Company issued (i) 700,000 shares of common stock, (ii) and pre-funded warrants in lieu of common stock to purchase up to an aggregate of 784,019 shares of common stock (the “RD Pre-Funded Warrants”) and in the Private Placement, the Company issued pre-funded warrants to purchase up to an aggregate of 1,369,864 shares of common stock (the “Private Placement Pre-Funded Warrants” and together with the RD Pre-Funded Warrants the “August 2022 Pre-Funded Warrants”). As of December 31, 2022, Pre-Funded Warrants exercisable for 622,000 shares of the Company’s common stock remained outstanding.

 

 

In addition, the Company issued to the investor in the August 2022 Offering Series A preferred investment options to purchase up to 2,853,883 additional shares of the Company’s common stock and Series B preferred investment options to purchase up to 2,853,883 additional shares of the Company’s common stock (the “Preferred Investment Options”). The Series A preferred investment options have an exercise price of $1.502 per share, are immediately exercisable, and will expire five and one-half years from the date of issuance, or February 8, 2028, and the Series B preferred investment options have an exercise price of $1.502 per share, are immediately exercisable, and will expire two years from the date of issuance, or August 8, 2024. The Company also issued to the Placement Agent or its designees preferred investment options to purchase up to an aggregate of 171,233 shares of common stock (the “Placement Agent Preferred Investment Options”). The Placement Agent Preferred Investment Options are subject to the same terms as the Preferred Investment Options, except that the Placement Agent Preferred Investment Options have an exercise price of $2.19 per share and a term of five years from the commencement of the sales pursuant to the August 2022 Offering, or August 3, 2027.

 

At The Market Offering Agreement

 

On May 20, 2022, the Company entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (the “Agent”), as sales agent, pursuant to which the Company may offer and sell shares of common stock, par value $0.001 per share (the “Shares”) up to an aggregate offering price of $7,000,000 from time to time, in an at the market public offering. Sales of the Shares are to be made at prevailing market prices at the time of sale, or as otherwise agreed with the Agent. The Agent will receive a commission from the Company of 3.0% of the gross proceeds of any Shares sold under the ATM Agreement. The Shares sold under the ATM Agreement are offered and sold pursuant to the Company’s shelf registration statement on Form S-3, which was initially filed with the Securities and Exchange Commission (the “SEC”) on March 29, 2022 and declared effective on April 7, 2022, and a prospectus supplement and the accompanying prospectus relating to the At The Market Offering filed with the SEC on May 20, 2022. During the year ended December 31, 2022, the Company sold 585,603 shares of common stock pursuant to the ATM Agreement at an average price of $1.67 per share for aggregate proceeds of $1.0 million, of which approximately $29,000 was paid in the form of commissions to the Agent. Other than the ATM Agreement, the Company currently does not have any commitments to obtain additional funds. On August 3, 2022, the Company suspended sales under the ATM Agreement. The Company plans to reactivate the ATM Agreement in March 2023 and may resume sales in the future. However, there can be no assurance that the Company will be successful in acquiring additional funding through these means.

 
XML 22 R9.htm IDEA: XBRL DOCUMENT v3.22.4
Note 2 - Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Basis of Presentation and Significant Accounting Policies [Text Block]

2. Summary of Significant Accounting Policies

 

Basis of Presentation

 

The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”).

 

On March 11, 2022, the Company’s Board of Directors approved an amendment to the Company’s amended and restated certificate of incorporation to effect a 1-for-20 reverse stock split of the Company’s issued and outstanding common stock. The reverse stock split became effective on March 14, 2022. The par value of the common stock and preferred stock was not adjusted as a result of the reverse stock split. All common stock, stock options, restricted stock units, and per share amounts in the financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split. Additionally, the common stock at par and related additional paid-in capital amounts as of December 31, 2021 in the balance sheet, the common stock at par and related additional paid-in capital amounts in the Statement of Stockholder’s Equity as of December 31, 2021 and 2020, and for the year ended December 31, 2021 have also been retroactively reclassified to give effect to the reverse stock split.

 

Use of Estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to its stock-based compensation, accruals related to compensation, the valuation of the common stock warrants, provisions for doubtful accounts receivable and excess and obsolete inventories, clinical trial accruals, and its reserves for sales returns and warranty costs. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.

 

 

Fair Value of Financial Instruments

 

The Company has evaluated the estimated fair value of its financial instruments as of December 31, 2022 and 2021. Financial instruments consist of cash and cash equivalents, accounts receivable and payable, and other current liabilities and borrowings. The carrying amounts of cash and cash equivalents, accounts receivable and payable, and other current liabilities approximate their respective fair values because of the short-term nature of those instruments. Based upon the borrowing terms and conditions currently available to the Company, the carrying values of the borrowings approximate their fair value.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents are considered available-for-sale marketable securities and are recorded at fair value, based on quoted market prices. As of December 31, 2022 and 2021, the Company’s cash equivalents are entirely comprised of investments in money market funds. Any related unrealized gains and losses are recorded in other comprehensive income (loss) and included as a separate component of stockholders’ equity. There were no unrealized gains and losses as of December 31, 2022 and 2021. Any realized gains and losses and interest and dividends on available-for-sale securities are included in interest income or expense and computed using the specific identification cost method.

 

Concentration of Credit Risk, and Other Risks and Uncertainties

 

Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and accounts receivable to the extent of the amounts recorded on the balance sheets.

 

The Company’s policy is to invest in cash and cash equivalents, consisting of money market funds. These financial instruments are held in Company accounts at one financial institution, Silicon Valley Bank. The counterparties to the agreements relating to the Company’s investments consist of financial institutions of high credit standing. The Company provides for uncollectible amounts when specific credit problems arise. Management’s estimates for uncollectible amounts have been adequate, and management believes that all significant credit risks have been identified at December 31, 2022 and 2021. On March 10, 2023, the Federal Deposit Insurance Corporation announced that Silicon Valley Bank had been closed by the California Department of Financial Protection and Innovation. While we have regained access to our accounts at Silicon Valley Bank and are evaluating our banking relationships, future disruptions of financial institutions where we bank or have credit arrangements, or disruptions of the financial services industry in general, could adversely affect our ability to access our cash and cash equivalents. If we are unable to access our cash and cash equivalents as needed, our financial position and ability to operate our business will be adversely affected.

 

The Company’s accounts receivable are due from a variety of healthcare organizations in the United States and select international markets. The Company provides for uncollectible amounts when specific credit problems arise. Management's estimates for uncollectible amounts have been adequate, and management believes that all significant credit risks have been identified at December 31, 2022 and 2021. At December 31, 2022, there was no customer that represented 10% or more of the Company’s accounts receivable, whereas at December 31 2021, there was one customer that represented 21% of accounts receivable. For the year ended December 31, 2022 and 2021, there was one customer that represented approximately 14% and 10% of revenues, respectively. Disruption of sales orders or a deterioration of financial condition of its customers would have a negative impact on the Company’s financial position and results of operations.

 

The Company manufactures its commercial products in-house, including the Pantheris and Ocelot family of catheters. Certain of the Company’s product components and sub-assemblies are manufactured by sole suppliers, including internally. Disruption in component or sub-assembly supply from these manufacturers or from in-house production would have a negative impact on the Company’s financial position and results of operations.

 

The Company is subject to certain risks, including that its devices may not be approved or cleared for marketing by governmental authorities or be successfully marketed. There can be no assurance that the Company’s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and with appropriate performance characteristics. The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, dependence upon third-party payors to provide adequate coverage and reimbursement, dependence on key personnel and suppliers, protection of proprietary technology, product liability claims, and compliance with government regulations.

 

Existing or future devices developed by the Company may require approvals or clearances from the FDA or international regulatory agencies. In addition, in order to continue the Company’s operations, compliance with various federal and state laws is required. If the Company were denied or delayed in receiving such approvals or clearances, it may be necessary to adjust operations to align with the Company’s currently approved portfolio. If clearance for the products in the current portfolio were withdrawn by the FDA, this may have a material adverse impact on the Company.

 

 

Disruption of our supply chain capabilities due to trade restrictions, political instability, severe weather, natural disasters, public health crises, terrorism, product recalls, labor supply or stoppages, the financial or operational instability of key suppliers and carriers, government restrictions or measures, or other reasons could impair our ability to distribute our products. The Company believes COVID-19 and the subsequent burdens on the hospital systems has had and will continue to have an adverse effect on its ability to generate sales due to the fluctuating and unpredictable levels of capacity medical providers have to perform procedures that require the use of its products.

 

The Company is closely monitoring general economic conditions on global supply chain, manufacturing, and logistics operations. As inflationary pressures increase, the Company anticipates that its production and operating costs may similarly increase, including costs and availability of materials and labor. While the Company has sufficient inventory on-hand to meet its current production requirements and customer demand, it has experienced some constraints with respect to the availability of certain materials and extended lead times from certain key suppliers. The Company has also experienced some delays in shipping products to its customers. Any significant delay or interruption in our supply chain could impair the Company’s ability to meet the demands of its customers in the future and could harm its business.

 

We use technology in substantially all aspects of our business operations, and our ability to serve customers most effectively depends on the reliability of our technology systems. Cybersecurity incidents can include computer viruses, computer denial-of-service attacks, worms, and other malicious software programs or other attacks, covert introduction of malware to computers and networks, impersonation of authorized users, and efforts to discover and exploit any design flaws, bugs, security vulnerabilities or security weaknesses, as well as intentional or unintentional acts by employees or other insiders with access privileges, intentional acts of vandalism by third parties and sabotage.

 

In addition, our technology infrastructure and systems are vulnerable to damage or interruption from natural disasters, power loss and telecommunications failures. Any such disruption to our systems, or the technology systems of third parties on which we rely, the failure of these systems to otherwise perform as anticipated, or the theft, destruction, loss, misappropriation, or release of sensitive and/or confidential information or intellectual property, could require us to notify affected individuals, federal or state agencies or media outlets of the incident and could result in business disruption, negative publicity, loss of customers, potential liability, including litigation or other legal actions against us or the imposition of penalties, fines, fees or liabilities, which may not be covered by our insurance policies, and competitive disadvantage, any or all of which would potentially adversely affect our customer service, decrease the volume of our business and result in increased costs and lower profits. Moreover, a cybersecurity breach could require us to devote significant management resources to address the problems associated with the breach and to expend significant additional resources to upgrade further the security measures we employ to protect information against cyber-attacks and other wrongful attempts to access such information, which could result in a disruption of our operations.

 

While we have invested, and continue to invest, in technology security initiatives and other measures to prevent security breaches and cyber incidents, as well as disaster recovery plans, these initiatives and measures may not be entirely effective to insulate us from technology disruption that could result in adverse effects on our results of operations.

 

Accounts Receivable

 

Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable. The Company determines the allowance for doubtful accounts based upon an aging of accounts receivable, historical experience, and management judgment. Accounts receivable balances are reviewed individually for collectability. To date, the Company has not experienced significant credit-related losses.

 

Accounts receivable allowance for doubtful accounts provision and recoveries or write-offs are summarized as follows (in thousands):

 

   

2022

    

2021

  

Beginning balance

   $ 6     $ 19  

Provision

     70       2  

Recoveries/write-offs

     (3

)

     (15

)

Ending balance

   $ 73     $ 6  

 

 

Inventories

 

Inventories are valued at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method for all inventories. The Company’s policy is to write down inventory that has expired or become obsolete, inventory that has a cost basis in excess of its expected net realizable value, and inventory in excess of expected requirements. At each balance sheet date, management evaluates inventories for excess quantities, and obsolescence. This evaluation by management includes analysis of historical sales levels by product, projections of future demand, the risk of technological or competitive obsolescence for products, general market conditions, as well as the feasibility of reworking or using excess or obsolete products or components in the production or assembly of other products that are not obsolete or for which there are not excess quantities in inventory. To the extent that management determines there are excess or obsolete inventory, management adjusts the carrying value to estimated net realizable value. When quantities on hand exceed sales forecasts, a write-down is recorded for such excess inventories along with a corresponding charge to cost of revenues. The estimate of excess quantities is subjective and primarily dependent on the estimates of future demand for a particular product. Specifically, the future demand is derived based on our historical experience, from discussion with users of our products and general market conditions. Changes in assumptions of product demand could have a significant impact on the amount of write-down recorded. Inventory used in clinical trials is expensed at the time of production and recorded as research and development expense if the inventory is contractually being provided at no cost to the clinical site. The cost of inventories are regularly reviewed against estimated market value and record a lower of cost or market reserve for inventories that have a cost in excess of estimated market value, which could have a material impact on the gross margin and inventory balances based on additional write-downs to net realizable value or a benefit from inventories previously written down.

 

Property and Equipment

 

Property and equipment are recorded at cost. Repairs and maintenance costs are expensed as incurred. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets of generally three to five years. Depreciation expense includes the amortization of assets acquired under capital leases and equipment located with the Company’s sales personnel or at customer sites. Equipment held by customers is comprised of the Lightbox consoles located at customer sites under a lease or placement agreement. Equipment held by field sales personnel is also comprised of the Lightbox consoles in their possession. The related equipment is reclassified from inventory to the property and equipment account either upon execution of a lease or placement agreement for customers or upon shipment to a field salesperson. Depreciation expense for equipment held by customers or field sales personnel is recorded as a component of cost of revenues. Leasehold improvements and assets recorded under capital leases are amortized using the straight-line method over the shorter of the lease term or estimated useful economic life of the asset.

 

Impairment of Long-Lived Assets

 

The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. If indicators of impairment exist, an impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Impairment, if any, is measured as the amount by which the carrying amount of the long-lived asset exceeds its fair value. The Company has not recorded any impairment of long-lived assets since inception through December 31, 2022.

 

 

Revenue Recognition

 

The Company’s revenues are derived from (1) sale of Lightbox consoles, (2) sale of disposables, which consist of catheters and accessories, and (3) sale of customer service contracts and maintenance. The Company sells its products directly to hospitals and medical centers as well as through distributors. The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. The Company’s revenues are measured based on consideration specified in the contract with each customer, net of any sales incentives and taxes collected from customers that are remitted to government authorities. For all sales, the Company uses either a signed agreement or a binding purchase order as evidence of an arrangement. The Company’s revenue recognition policies generally result in revenue recognition at the following points:

 

 

1.

Lightbox console sales: Provided all other criteria for revenue recognition have been met, the Company recognizes revenue for Lightbox console sales directly to end customers when delivery and acceptance occurs, which is defined as receipt by the Company of an executed form that the installation process is complete.
   

 
 

2.

Sales of disposables: Disposable revenues consist of sales of the Company’s catheters and accessories and are recognized when the product has shipped, risk of loss and title has passed to the customer and collectability is reasonably assured.
   

 
 

3.

Service revenue: Service contract revenue consists of preventative maintenance, upgrades, and service contracts. Service contracts are recognized ratably over the term of the service period and maintenance contract revenue is recognized when work is completed. To date, service revenue has been insignificant.

 

The Company offers its customers the ability to purchase or lease the Lightbox console. In addition, the Company provides a Lightbox under a limited commercial evaluation program to allow accounts to install and utilize the Lightbox for a limited trial period. When a Lightbox is placed under a lease agreement or under a commercial evaluation program, the Company retains title to the equipment and it remains capitalized on its balance sheet under property and equipment. Depreciation expense on these placed Lightboxes is recorded to cost of revenues on a straight-line basis. The costs to maintain these placed Lightboxes are charged to cost of revenues as incurred.

 

The Company evaluates its lease and commercial evaluation program agreements and accounts for these contracts under the guidance in Accounting Standards Codification (“ASC”) 842, Leases and ASU No. 2014 09, Revenue from Contracts with Customers (Topic 606). The guidance requires arrangement consideration to be allocated between a lease deliverable and a non-lease deliverable based upon the relative selling-price of the deliverables.

 

The Company assessed whether the embedded lease is an operating lease or sales-type lease. Based on the Company’s assessment of the guidance and given that any payments under the lease agreements are dependent upon contingent future sales, it was determined that collectability of the minimum lease payments is not reasonably predictable. Accordingly, the Company concluded the embedded lease did not meet the criteria of a sales-type lease and accounts for it as an operating lease. The Company recognizes revenue allocated to the lease as the contingent disposable product purchases are delivered and are included in revenues within the statement of operations and comprehensive loss.

 

For sales through distributors, the Company recognizes revenue when control of the product transfers from the Company to the distributor. The distributors are responsible for all marketing, sales, training and warranty in their respective territories. The standard terms and conditions contained in the Company’s distribution agreements do not provide price protection or stock rotation rights to any of its distributors. In addition, its distributor agreements do not allow the distributor to return or exchange products, and the distributor is obligated to pay the Company upon invoice regardless of its ability to resell the product.

 

Cost of Revenues

 

Cost of revenues consists primarily of manufacturing overhead costs, material costs and direct labor. A significant portion of the Company’s cost of revenues currently consists of manufacturing overhead costs. These overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management. Cost of revenues also includes depreciation expense for the Lightboxes under lease, deployed with sales personnel and evaluation agreements, product warranty costs, product written-off due to excess or obsolescence, and certain direct costs such as shipping costs.

 

 

Product Warranty Costs

 

The Company typically offers a one-year warranty on its products commencing upon the transfer of title and risk of loss to the customer. The Company accrues for the estimated cost of product warranties upon invoicing its customers, based on historical results. Warranty costs are reflected in the statement of operations and comprehensive loss as a cost of revenues. The warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Should actual product failure rates, material usage or service delivery costs differ from these estimates, revisions to the estimated warranty liability would be required. Periodically the Company assesses the adequacy of its recorded warranty liabilities and adjusts the amounts as necessary. Warranty provisions and claims are summarized as follows (in thousands):

 

 

   

2022

    

2021

  

Beginning balance

   $ 187     $ 193  

Warranty provision

     22       49  

Usage/Release

     (100

)

     (55

)

Ending balance

   $ 109     $ 187  

 

Research and Development

 

The Company expenses research and development costs as incurred. Research and development expenses include personnel and personnel-related costs, costs associated with pre-clinical and clinical development activities, and costs for prototype products that are manufactured prior to market approval for that prototype product, and internal and external costs associated with the Company’s regulatory compliance, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs, including allocated facility and related expenses.

 

Clinical Trials

 

The Company accrues and expenses costs for its clinical trial activities performed by third parties, including clinical research organizations and other service providers, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company determines these estimates through discussion with internal personnel and outside service providers as to progress or stage of completion of trials or services pursuant to contracts with clinical research organizations and other service providers and the agreed-upon fee to be paid for such services.

 

Stock-Based Compensation

 

Stock-based compensation for the Company includes amortization related to all stock options, restricted stock units (“RSU”), and restricted stock awards (“RSA”) based on the grant-date estimated fair value. The fair value of stock options is estimated on the date of grant using the Black-Scholes option pricing model and recognized as expense on a straight-line basis over the vesting period of the award. The Company has not granted any stock options since 2017. The Company measures the fair value of RSUs and RSAs using the closing stock price of a share of the Company’s common stock on the grant date and is recognized as expense on a straight-line basis over the vesting period of the award. As allowed under ASU No. 2016‑09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, the Company accounts for forfeitures as they occur.

 

Foreign Currency

 

The Company records net gains and losses resulting from foreign exchange transactions as a component of foreign currency exchange losses in other income, net. During the years ended December 31, 2022 and 2021, the Company recorded $12,000 and $16,000 of foreign currency exchange net losses, respectively.

 

Income Taxes

 

The Company utilizes the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax reporting bases of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense when they occur. During the years ended December 31, 2022 and 2021, the Company did not recognize accrued interest or penalties related to unrecognized tax benefits.

 

 

Net Loss per Share Attributable to Common Stockholders

 

Basic net loss per share attributable to common stockholders is computed by dividing the net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss applicable to common stockholders by the weighted average number of shares of common stock and dilutive potential shares of common stock outstanding during the period. Any common stock shares subject to repurchase are excluded from the calculations as the continued vesting of such shares is contingent upon the holders’ continued service to the Company. As of December 31, 2022 and 2021, there were no shares subject to repurchase. Since the Company was in a loss position for both periods presented, basic net loss per share attributable to common stockholders is the same as diluted net loss per share attributable to common stockholders as the inclusion of all potentially dilutive common shares would have been anti-dilutive.

 

Net loss per share attributable to common stockholders was determined as follows (in thousands, except per share data):

 

   

Year Ended December 31,

  
   

2022

    

2021

  

Net loss applicable to common stockholders

   $ (27,244

)

   $ (21,587

)

Weighted average common stock outstanding, basic and diluted

     6,249       4,722  

Net loss per share attributable to common stockholders, basic and diluted

   $ (4.36

)

   $ (4.57

)

 

The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted average shares outstanding because such securities have an anti-dilutive impact due to losses reported:

 

   

Year Ended December 31,

  
   

2022

    

2021

  

Common stock warrants equivalents

     4,009,679       135,429  

Common stock options

     303       304  

Convertible preferred stock

     58,080       52,289  

Unvested restricted stock units

     6,626       17,817  
      4,074,688       205,839  

 

Comprehensive Loss

 

For the years ended December 31, 2022 and 2021, there was no difference between comprehensive loss and the Company’s net loss.

 

Segment and Geographical Information

 

The Company operates and manages its business as one reportable and operating segment. The Company’s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. Primarily all of the Company’s long-lived assets, which are comprised of property and equipment, are based in the United States. For the years ended December 31, 2022 and 2021, 92% and 94% of the Company’s revenues were in the United States, based on the shipping location of the external customer. The remaining revenues for the years ended December 31, 2022 and 2021, were principally in Germany.

 

Recent Accounting Pronouncements

 

Recently adopted accounting standards

 

In May 2021, ASU No. 2021-04, Issuer’s Accounting for Certain Modifications of Exchanges of Freestanding Equity-Classified Written Call Options was issued to clarify the accounting for modifications or exchanges of freestanding equity-classified written call options, such was warrants, that remain equity classified after modification or exchange. The standard was adopted by the Company on January 1, 2022. This new standard did not have a material impact on the Company’s financial statements.

 

 

Recent accounting standards not yet adopted

 

In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which among other things, simplifies the accounting models for the allocation of proceeds attributable to the issuance of a convertible debt instrument.  As a result, after adopting the ASU’s guidance, entities will not separately present in equity an embedded conversion feature in such debt. Instead, they will account for a convertible debt instrument wholly as debt, and for convertible preferred stock wholly as preferred stock (i.e., as a single unit of account), unless (i) a convertible instrument contains features that require bifurcation as a derivative under ASC 815 or (ii) a convertible debt instrument was issued at a substantial premium. The standard becomes effective for the Company, as a smaller reporting company as defined by the SEC, in the first quarter of 2024 and early adoption is permitted.  This new standard is not expected to have a material impact on the Company’s financial statements.

 
XML 23 R10.htm IDEA: XBRL DOCUMENT v3.22.4
Note 3 - Fair Value Measurements
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Fair Value Disclosures [Text Block]

3. Fair Value Measurements

 

The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:

 

Level 1—Quoted prices in active markets for identical assets or liabilities.

 

Level 2—Inputs other than quoted prices included within Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

As of December 31, 2022 and 2021, the Company’s cash equivalents were all categorized as Level 1 and consisted of money market funds. As of December 31, 2022 and 2021, there were no financial assets and liabilities categorized as Level 2 or Level 3. There were no transfers between fair value hierarchy levels during the years ended December 31, 2022 and 2021.

 
XML 24 R11.htm IDEA: XBRL DOCUMENT v3.22.4
Note 4 - Inventories
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Inventory Disclosure [Text Block]

4. Inventories

 

Inventories consisted of the following (in thousands):

 

   

December 31,

  
   

2022

    

2021

  

Raw materials

   $ 3,374     $ 2,503  

Work-in-process

     17       1  

Finished products

     1,574       2,097  

Total inventories

   $ 4,965     $ 4,601  

 

 
XML 25 R12.htm IDEA: XBRL DOCUMENT v3.22.4
Note 5 - Property and Equipment, Net
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Property, Plant and Equipment Disclosure [Text Block]

5. Property and Equipment, Net

 

Property and equipment, net, consisted of the following (in thousands):

 

   

December 31,

  
   

2022

    

2021

  

Equipment held by customers and field sales personnel

   $ 2,566     $ 2,362  

Machinery and equipment

     1,372       1,391  

Computer software

     122       122  

Computer equipment

     200       173  

Furniture and fixture

     78       78  

Leasehold improvements

     320       320  

Total property and equipment, gross

     4,658       4,446  

Less: Accumulated depreciation and amortization

     (3,956

)

     (4,351

)

Total property and equipment, net

   $ 702     $ 95  

 

Depreciation expense for the years ended December 31, 2022 and 2021, was approximately $196,000 and $687,000, respectively.

 

Property and equipment include certain equipment that is leased to customers and located at customer premises. Also, included is equipment held by the Company’s field sales personnel for use in cases with customers. The Company retains ownership of the equipment held for evaluation by customers and has the right to remove the equipment if it is not being utilized according to expectations. Depreciation expense relating to the leased equipment held by customers and those held by the Company’s field sales personnel of $119,000 and $539,000 was recorded in cost of revenues during the years ended December 31, 2022 and 2021, respectively. The net book value of this equipment was $527,000 and $0 at December 31, 2022 and December 31, 2021, respectively.

 
XML 26 R13.htm IDEA: XBRL DOCUMENT v3.22.4
Note 6 - Accrued Expenses and Other Current Liabilities
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]

6. Accrued Expenses and Other Current Liabilities

 

Accrued expenses and other current liabilities consisted of the following (in thousands):

 

   

December 31,

  
   

2022

    

2021

  

Deferred revenue

   $ 141     $ 123  

Accrued travel and entertainment expenses

     129       118  

Accrued product warranty costs

     109       187  

Accrued clinical trial costs

     106       153  

Accrued professional fees

     60       —  

Accrued sales and use tax

     40       33  

Other accrued liabilities

     72       104  

Total accrued expenses and other current liabilities

   $ 657     $ 718  

 
XML 27 R14.htm IDEA: XBRL DOCUMENT v3.22.4
Note 7 - Borrowings
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Debt Disclosure [Text Block]

7. Borrowings

 

CRG

 

On September 22, 2015, the Company entered into a Term Loan Agreement, as amended (the “Loan Agreement”) with CRG under which, subject to certain conditions, the Company had the right to borrow up to $50 million in principal amount from CRG on or before the end of the twenty-fourth (24th) month period commencing on the first Borrowing Date (as defined in the Loan Agreement). The Company borrowed $30 million on September 22, 2015. The Company borrowed an additional $10 million on June 15, 2016 under the Loan Agreement.

 

On February 14, 2018, the Company and CRG further amended the Loan Agreement concurrent with the conversion of $38 million of the principal amount of the senior secured term loan (plus $3.8 million in back-end fees and prepayment premium applicable thereto) into a newly authorized Series A convertible preferred stock (see below).

 

 

The Company has entered into several amendments to the Loan Agreement (the “Amendments”) with CRG since September 2015, the most recent of which was entered into on August 10, 2022. The Amendments, among other things: (1) extended the interest-only period through December 31, 2023; (2) extended the period during which the Company may elect to pay a portion of interest in payment-in-kind, or PIK, interest payments through December 31, 2023 so long as no Default (as defined in the Loan Agreement) has occurred and is continuing; (3) permitted the Company to make the entire interest payments in PIK interest payments for through December 31, 2023 so long as no Default has occurred and is continuing; (4) extended the Stated Maturity Date (as defined in the Loan Agreement) to December 31, 2025; (5) reduced the minimum liquidity covenant to $3.5 million at all times; (6) eliminated the minimum revenue covenant for 2018, 2019 and 2020; (7) reduced the minimum revenue covenant to $8 million for 2021 and 2022; (8) added minimum revenue covenants of $10 million for 2023, $14.5 million for 2024 and $17 million for 2025; (9) changed the date under the on-going stand-alone representation regarding no “Material Adverse Change” to December 31, 2020; (10) amended the on-going stand-alone representation and stand-alone Event of Default (as defined in the Loan Agreement) regarding Material Adverse Change such that any adverse change in or effect upon the revenue of the Company and its subsidiaries due to the outbreak of COVID-19 will not constitute a Material Adverse Change; and (11) provided CRG with board observer rights.

 

Under the amended Loan Agreement, no cash payments for either principal or interest are required until the first quarter of 2024. The interest will be accrued and included in the debt balance based (to the extent not paid) on principal amounts outstanding at the beginning of the quarter at an interest rate of 12.5%. Beginning in the first quarter of 2024, the Company will be required to make quarterly principal payments (in addition to the interest) of $1.9 million with total principal payments of $7.5 million in 2024 and $7.5 million in 2025. The maturity date of the Loan (as defined in the Loan Agreement) is December 31, 2025.

 

The Company may voluntarily prepay the borrowings in full, with a prepayment premium beginning at 5.0% and declining by 1.0% annually thereafter, with no premium being payable if prepayment occurs after seven and half years of the loan. Each tranche of borrowing required the payment, on the borrowing date, of a financing fee equal to 1.5% of the borrowed loan principal, which is recorded as a discount to the debt. In addition, a facility fee equal to 15.0% of the amounts borrowed plus any PIK is to be payable at the end of the term or when the borrowings are repaid in full. A long-term liability is being accreted using the effective interest method for the facility fee over the term of the Loan Agreement with a corresponding discount to the debt. The borrowings are collateralized by a security interest in substantially all of the Company’s assets.

 

The Loan Agreement requires that the Company adheres to certain affirmative and negative covenants, including financial reporting requirements, certain minimum financial covenants for pre-specified liquidity and revenue requirements and a prohibition against the incurrence of indebtedness, or creation of additional liens, other than as specifically permitted by the terms of the Loan Agreement. In particular, the covenants of the amended Loan Agreement included a covenant that the Company maintain a minimum of $3.5 million of cash and certain cash equivalents, and the Company has to achieve certain minimum revenues. If the Company fails to meet the applicable minimum revenue target in any calendar year, the Loan Agreement provides the Company with a cure right if it prepays a portion of the outstanding principal equal to 2.0 times the revenue shortfall. In addition, the Loan Agreement prohibits the payment of cash dividends on the Company’s capital stock and also places restrictions on mergers, sales of assets, investments, incurrence of liens, incurrence of indebtedness and transactions with affiliates. CRG may accelerate the payment terms of the Loan Agreement upon the occurrence of certain “Events of Default” set forth therein, which include the failure of the Company to make timely payments of amounts due under the Loan Agreement, the failure of the Company to adhere to the covenants set forth in the Loan Agreement, the insolvency of the Company or upon the occurrence of a “Material Adverse Change” thereunder.

 

As of December 31, 2022, the Company was in compliance with all applicable covenants under the Loan Agreement.

 

As of December 31, 2022, principal, final facility fee and PIK payments under the Loan Agreement, as amended, were as follows (in thousands):

 

Year Ending December 31,

        

2023

   $ —  

2024

     9,045  

2025

     10,339  

Total

     19,384  

Less: Amount of PIK additions and final facility fee to be incurred subsequent to December 31, 2022

     (4,970

)

Less: Amount representing debt issuance costs

     (249

)

Borrowings, current portion, as of December 31, 2022

   $ 14,165  

 

 

In connection with drawdowns under the Loan Agreement, the Company recorded aggregate debt discounts of $1.3 million as contra-debt. The debt discounts are being amortized as non-cash interest expense using the effective interest method over the term of the Loan Agreement. As of December 31, 2022 and 2021, the balance of the aggregate debt discount was approximately $249,000 and $332,000, respectively. The Company’s interest expense associated with the amortization of debt discount was approximately $83,000 and $86,000 during the years ended December 31, 2022 and 2021, respectively. The Company incurred total interest expense of approximately $1.9 million and $1.6 million during the years ended December 31, 2022 and 2021, respectively.

 

Due to the substantial doubt about the Company’s ability to continue operating as a going concern and the Event of Default (as defined in the Loan Agreement) that could result due to a “Material Adverse Change” under the Loan Agreement, the entire outstanding amount of borrowings under the Loan Agreement and associated aggregate debt discount at December 31, 2022 was classified as current in these financial statements as compared with long-term as of December 31, 2021. CRG has not purported that an Event of Default has resulted due to a Material Adverse Change.

 

Paycheck Protection Program

 

On April 23, 2020, the Company received loan proceeds of $2.3 million (the “PPP Loan”) pursuant to the Paycheck Protection Program under the CARES Act.

 

The PPP Loan, which was in the form of a promissory note, dated April 20, 2020 (the “Promissory Note”), between the Company and Silicon Valley Bank (“SVB”) as the lender, was set to mature on April 20, 2022 and bore interest at a fixed rate of 1% per annum, payable monthly commencing six months from the date of the Loan, with prepayment of the borrowings permitted with no associated penalty or premium.

 

The PPP Loan was administered by the U.S. Small Business Administration (“SBA”). The SBA was given the authority under the PPP to forgive loans if all employees were kept on the payroll for a required period and the loan proceeds were used for payroll, rent and utilities. The Company applied for debt forgiveness in December 2020.

 

On April 17, 2021, the Company was notified by SVB that its PPP Loan had been fully forgiven by the SBA and that there was no remaining balance on the PPP Loan. The Company recorded the forgiveness as other income in April 2021 in the amount of $2.4 million, of which approximately $23,000 was accrued interest. For the year ended December 31, 2021, the Company incurred interest expense of approximately $7,000 related to the PPP Loan.

 
XML 28 R15.htm IDEA: XBRL DOCUMENT v3.22.4
Note 8 - Leases
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Lessee, Operating Leases [Text Block]

8. Leases

 

The Company’s operating lease obligations primarily consist of leased office, laboratory, and manufacturing space under a non-cancelable operating lease. In addition to the minimum future lease commitments presented below, the lease requires the Company to pay property taxes, insurance, maintenance, and repair costs. The lease includes a rent holiday concession and escalation clauses for increased rent over the lease term. Rent expense is recognized using the straight-line method over the term of the lease.

 

The lease will expire on November 30, 2024. The Company is obligated to pay approximately $5.8 million in base rent payments through November 2024, beginning on December 1, 2019. The weighted average remaining lease term as of December 31, 2022 is 1.9 years.

 

The operating lease was included on the balance sheet at the present value of the future base payments discounted at a 6.5% discount rate using the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment as the lease does provide an implicit rate.

 

The Company’s operating lease expense, excluding variable maintenance fees and other expenses on a monthly basis, was approximately $105,000. Rent expense for each of the years ended December 31, 2022 and 2021 was approximately $1.3 million. The Company’s variable expenses for the years ended December 31, 2022 and 2021 was approximately $0.3 million and $0.2 million, respectively. Operating right-of-use asset amortization for the year ended December 31, 2022 and 2021 was approximately $1.1 million and $1.0 million, respectively. Due to payments being made in excess of operating lease expense recognized, the Company recorded approximately $65,000 and $158,000 as prepaid rent included in other assets on the balance sheet as of December 31, 2022 and 2021, respectively.

 

 

The following table presents the future operating lease payments and leasehold liability included on the balance sheet related to the Company’s operating lease as of December 31, 2022 (in thousands):

 

Year Ending December 31,

        

2023

   $ 1,203  

2024

     1,138  

Total

     2,341  

Less: Imputed interest

     (147

)

Leasehold liability as of December 31, 2022

   $ 2,194  

 

The following table shows ROU assets and lease liabilities, and the associated financial statement line items (in thousands):

 

       

December 31,

  

Lease-Related Assets and Liabilities

   Financial Statement Line

Items

   2022     2021  
Right of use assets:                    

Operating lease

   Right of use asset   $ 2,194     $ 3,179  
Total right of use assets   $ 2,194     $ 3,179  
Lease liabilities:                    

Operating lease

   Leasehold liability, current portion   $ 1,092     $ 985  
    Leasehold liability, long-term portion     1,102       2,194  

Total lease liabilities

   $ 2,194     $ 3,179  

 
XML 29 R16.htm IDEA: XBRL DOCUMENT v3.22.4
Note 9 - Commitments and Contingencies
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Commitments and Contingencies Disclosure [Text Block]

9. Commitments and Contingencies

 

Purchase Obligations

 

Purchase obligations consist of agreements to purchase goods and services entered into in the ordinary course of business. The Company had non-cancelable commitments to suppliers for purchases totaling approximately $1.1 million as of December 31, 2022. The majority of this amount is related to commitments to purchase inventory components for our various product lines.

 

Indemnification

 

In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and may provide for indemnification of the counterparty. The Company’s exposure under these agreements is unknown because it involves claims that may be made against it in the future, but have not yet been made. To date, the Company has not been subject to any claims or been required to defend any action related to its indemnification obligations.

 

The Company indemnifies each of its directors and officers for certain events or occurrences, subject to certain limits, while the director is or was serving at the Company’s request in such capacity, as permitted under Delaware law and in accordance with its certificate of incorporation and bylaws. The term of the indemnification period lasts as long as a director may be subject to any proceeding arising out of acts or omissions of such director in such capacity. The maximum amount of potential future indemnification is unlimited; however, the Company currently holds director liability insurance. This insurance allows the transfer of risk associated with the Company’s exposure and may enable it to recover a portion of any future amounts paid. The Company believes that the fair value of these indemnification obligations is minimal. Accordingly, it has not recognized any liabilities relating to these obligations for any period presented.

 

Legal Proceedings

 

The Company is not currently involved in any pending legal proceedings that it believes could have a material adverse effect on our financial condition, results of operations or cash flows. From time to time, the Company may be involved in legal proceedings or investigations, which could harm our reputation, business and financial condition and divert the attention of our management from the operation of our business.

 

 
XML 30 R17.htm IDEA: XBRL DOCUMENT v3.22.4
Note 10 - Stockholders' Equity
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Stockholders' Equity Note Disclosure [Text Block]

10. Stockholders’ Equity

 

Convertible Preferred Stock

 

As of December 31, 2022, the Company’s certificate of incorporation, as amended and restated, authorizes the Company to issue up to 5,000,000 shares of convertible preferred stock with $0.001 par value per share. As of December 31, 2022 and 2021, 60,961 and 56,451 shares of convertible preferred stock, respectively, were issued and outstanding.

 

Series A Convertible Preferred Stock

 

The holders of Series A preferred stock are entitled to receive annual accruing dividends at a rate of 8%, payable in additional shares of Series A preferred stock or cash, at the Company’s option. The shares of Series A preferred stock have a liquidation preference of $1,000 per share, no voting rights and rank senior to all other classes and series of the Company’s equity in terms of repayment and certain other rights. During the years ended December 31, 2022 and 2021, 4,510 and 4,175 additional shares, respectively, were issued to CRG as payment of dividends. As of December 31, 2022 and 2021, 60,876 and 56,366 shares of Series A preferred stock were outstanding, respectively, which are currently convertible into shares of the Company’s common stock at $400 per share. The Series A preferred stock accrued additional dividends of approximately $4.5 million and $4.2 million during the years ended December 31, 2022 and 2021, respectively.

 

Series B Convertible Preferred Stock

 

The Series B preferred stock has a liquidation preference of $0.001 per share, full ratchet price based anti-dilution protection, has no voting rights and is subject to certain ownership limitations. The Series B preferred stock is immediately convertible at the option of the holder, has no stated maturity, and does not pay regularly stated dividends or interest. During the year ended December 31, 2021, 93 of these shares converted into 18,600 shares of common stock. As of December 31, 2022 and 2021, 85 shares of Series B preferred stock remained outstanding, which are currently convertible into shares of the Company’s common stock at $1.502 per share.

 

Series D Convertible Preferred Stock

 

On January 14, 2022, the Company entered into a security purchase agreement with several institutional investors, pursuant to which the Company agreed to sell and issue, in a registered direct offering (“January 2022 offering”), an aggregate of 7,600 shares of the Company’s Series D convertible preferred stock, par value $0.001 per share at an offering price of $1,000 per share. Concurrently, the Company agreed to issue to these investors warrants to purchase up to an aggregate of 807,500 shares of the Company’s common stock (the “Common Warrants”). The shares of Series D Preferred Stock has a stated value of $1,000 per share and are convertible into an aggregate of 950,000 shares of common stock at a conversion price of $8.00 per share.

 

On January 14, 2022, the Company entered into a security purchase agreement with several institutional investors, pursuant to which the Company agreed to sell and issue, in a registered direct offering (“January 2022 Offering”), an aggregate of 7,600 shares of the Company’s Series D convertible preferred stock, par value $0.001 per share at an offering price of $1,000 per share. Concurrently, the Company agreed to issue to these investors warrants to purchase up to an aggregate of 807,500 shares of the Company’s common stock (the “Common Warrants”). The shares of Series D preferred stock had a stated value of $1,000 per share and were convertible into an aggregate of 950,000 shares of common stock at a conversion price of $8.00 per share. During the year ended December 31, 2022, all 7,600 shares of Series D preferred stock were converted into a total of 950,000 shares of common stock. Consequently, there were no shares of Series D preferred stock outstanding as of December 31, 2022.

 

At the time of issuance, the Company evaluated the classification of the Series D preferred stock and determined equity classification was appropriate due to no mandatory or contingently redeemable redemption features. The warrants issued to the investors were considered freestanding equity classified instruments. The Company first allocated gross proceeds from the registered direct offering between the preferred stock and the warrants issued to investors using a relative fair value approach, resulting in an initial allocation to each instrument of $4.0 million and $3.6 million, respectively. On the issuance date, the Company estimated the fair value of the Common Warrants issued to investors and warrants issued to the placement agent designees using a Black-Scholes option pricing model using the following assumptions: (i) contractual term of 5.5 years, (ii) expected volatility rate of 136.61%, (iii) risk-free interest rate of 1.51%, (iv) expected dividend rate of 0%, and (v) closing price of the Company’s common stock of the day immediately preceding the registered direct offering. The fair value of preferred stock was estimated based upon equivalent common shares that preferred stock could have been converted into at the closing price of the day immediately preceding the purchase date.

 

 

The embedded conversion feature was evaluated and bifurcation from the preferred stock equity host was not considered necessary. The issuance of the Series D convertible preferred stock generated a beneficial conversion feature (“BCF”) which arose as the equity security was issued with an embedded conversion option that is beneficial to the investor or in the money at inception because the conversion option has an effective conversion price that is less than the market price of the underlying stock at the commitment date. The Company recorded the BCF as a discount to the preferred stock resulting in the amount of $5.1 million based on the intrinsic value of the beneficial conversion. As the preferred stock was immediately convertible into common stock subject to the consummation of the reverse stock split on March 14, 2022, a deemed dividend related to the discount associated with the beneficial conversion feature was recorded on that date. This one-time, non-cash charge impacted net loss applicable to common stockholders and net loss per share attributable to common stockholders for the year ended December 31, 2022.

 

Common Stock

 

At December 31, 2022, the Company’s certificate of incorporation, as amended and restated, authorizes the Company to issue up to 100,000,000 shares of common stock with $0.001 par value per share, of which 7,832,644 shares were issued and outstanding.

 

Common Stock Warrants

 

As of December 31, 2022, the Company had outstanding warrants to purchase common stock as follows:

 

   

Total

Outstanding

and

Exercisable

    

Underlying

Shares of

Common

Stock

    

Exercise

Price per

Share

    

Expiration Date

  

Series 1 Warrants issued in the February 2018 Series B financing

     8,979,000       44,895     $ 400.00     February 2025  

Series 2 Warrants issued in the February 2018 Series B financing

     8,709,500       43,548     $ 400.00     February 2025  

Warrants issued in the November 2018 financing

     8,768,395       43,842     $ 80.00     November 2023  

Placement agent warrants issued in the January 2022 financing

     1,330,000       66,500     $ 10.00     January 2027  

Warrants issued in the January 2022 financing

     16,150,000       807,500     $ 9.60     July 2027  

Pre-funded warrants issued in the August 2022 financing

     1,369,864       1,369,864     $ 0.0001       n/a  

Series A Preferred Investment Options issued in August 2022 financing

     2,853,883       2,853,883     $ 1.502    

February 2028

  

Series B Preferred Investment Options issued in August 2022 financing

     2,853,883       2,853,883     $ 1.502    

August 2024

  

Placement agent Preferred Investment Options issued in the August 2022 financing

     171,233       171,233     $ 2.19    

August 2027

  

Total as of December 31, 2022

     51,185,758       8,255,148                  

 

As of December 31, 2021, the Company had outstanding warrants to purchase common stock as follows:

 

   

Total

Outstanding

and

Exercisable

    

Underlying

Shares of

Common

Stock

    

Exercise

Price per

Share

  

Expiration Date

Series 1 Warrants issued in the February 2018 Series B financing

     8,979,000       44,895     $ 400.00  

February 2025

Series 2 Warrants issued in the February 2018 Series B financing

     8,709,500       43,548     $ 400.00  

February 2025

Warrants issued in the November 2018 financing

     8,768,395       43,842     $ 80.00   November 2023

Total as of December 31, 2021

     26,456,895       132,265            

 

 

January 2022 Offering

 

Pursuant to a purchase agreement entered into on January 14, 2022, the Company issued warrants to purchase up to an aggregate of 807,500 shares of the Company’s common stock at an exercise price of $9.60 per share and which became exercisable beginning July 14, 2022. The Common Warrants will expire five years following the time they become exercisable, or July 14, 2027.

 

The Company issued to the placement agent of the January 2022 Offering warrants to purchase up to an aggregate of 66,500 shares of common stock (the “Placement Agent Warrants”). The Placement Agent Warrants are subject to the same terms as the Common Warrants, except that the Placement Agent Warrants have an exercise price of $10.00 per share and a term of five years from the commencement of the sales pursuant to the January 2022 Offering, or January 12, 2027.

 

August 2022 Offering

 

Pursuant to a purchase agreement entered into on August 4, 2022, the Company issued, in a registered direct offering, Pre-Funded Warrants to purchase up to 784,019 shares of common stock (the “RD Pre-Funded Warrants”) and, in a concurrent private placement, Pre-Funded Warrants to purchase up to 1,369,864 shares of common stock (the “Private Placement Pre-Funded Warrants” and together with the RD Pre-Funded Warrants the “August 2022 Pre-Funded Warrants”). The August 2022 Pre-Funded Warrants have an exercise price of $0.0001 per share, are immediately exercisable, and have no expiration date. During the year ended December 31, 2022, 784,019 of shares of RD Pre-Funded Warrants were exercised into the equivalent number of the Company’s common stock. As of December 31, 2022, August 2022 Pre-Funded Warrants exercisable for 1,369,864 shares of the Company’s common stock remained outstanding. On February 14, 2023, an additional 747,864 Private Placement Pre-Funded Warrants were exercised leaving 622,000 August 2022 Pre-Funded Warrants outstanding.

 

Also in the August 2022 offering, the Company issued Series A preferred investment options to purchase up to 2,853,883 additional shares of the Company’s common stock and Series B preferred investment options to purchase up to 2,853,883 additional shares of the Company’s common stock, collectively referred to as Preferred Investment Options. The Series A preferred investment options have an exercise price of $1.502 per share, are immediately exercisable, and will expire five and one-half years from the date of issuance, or February 8, 2028, and the Series B preferred investment options have an exercise price of $1.502 per share, are immediately exercisable, and will expire two years from the date of issuance, or August 8, 2024.

 

The Company also issued to the placement agent of the August 2022 Offering preferred investment options to purchase up to 171,233 shares of common stock (the “Placement Agent Preferred Investment Options”). The Placement Agent Preferred Investment Options are subject to the same terms as the Preferred Investment Options, except that the Placement Agent Preferred Investment Options have an exercise price of $2.19 per share and a term of five years from the commencement of the sales pursuant to the August 2022 Offering, or August 3, 2027.

 

The exercise price and the number of shares of common stock issuable upon exercise of each Common Warrants, Pre-Funded Warrants, Preferred Investment Options, and Placement Agent Preferred Investment Options are subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock. In addition, in certain circumstances, upon a fundamental transaction, a holder of Common Warrants, Pre-Funded Warrants, Preferred Investment Options, or Placement Agent Preferred Investment Options will be entitled to receive, upon exercise, the kind and amount of securities, cash or other property that such holder would have received had they exercised the Common Warrants, Pre-Funded Warrants, Preferred Investment Options, or Placement Agent Preferred Investment Options immediately prior to the fundamental transaction.

 

The Common Warrants, Pre-Funded Warrants, Preferred Investment Options, and Placement Agent Preferred Investment Options can be exercised at the option of the holders at any time after they become exercisable provided that shares of the Common Warrants, Pre-Funded Warrants, Preferred Investment Options, or Placement Agent Preferred Investment Options cannot be exercised into common stock if the applicable holder would beneficially own in excess of 4.99% (or, upon election by such holder prior to the issuance of any shares of Common Warrants, Pre-Funded Warrants, Preferred Investment Options, or Placement Agent Preferred Investment Options, 9.99%) of the Company’s outstanding common stock immediately after giving effect to the exercise. A holder of the Common Warrants, Pre-Funded Warrants, Preferred Investment Options or Placement Agent Preferred Investment Options may, upon notice to the Company, increase or decrease such beneficial ownership limitation, but not in excess of 9.99%.

 

 

In the event of a fundamental transaction in which the holders of our voting securities immediately prior to such fundamental transaction will not, following such fundamental transaction, directly or indirectly own more than 50% of the voting securities of the surviving entity or successor entity, and in which the Company is not the successor entity or does not continue as a reporting issuer under the Exchange Act, then, at the request of the holder, the Company or the successor entity shall purchase the unexercised portion of the Common Warrants, Preferred Investment Options, and Placement Agent Preferred Investment Options from the holder by paying to the holder an amount, in cash, equal to the fair value of the remaining unexercised portion of the Common Warrants, Preferred Investment Options, and Placement Agent Preferred Investment Options on the date of such fundamental transaction, subject to certain limitations in the event of a fundamental transaction not within our control.

 

As of December 31, 2022 and 2021, warrants and preferred investment options to purchase an aggregate of 8,255,148 and 132,265 shares of common stock were outstanding, respectively, all of which were classified within the equity section of the respective balance sheets.

 
XML 31 R18.htm IDEA: XBRL DOCUMENT v3.22.4
Note 11 - Stock-based Compensation
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Share-Based Payment Arrangement [Text Block]

11. Stock-Based Compensation

 

Stock Plans

 

In January 2015, the Board of Directors adopted and the Company’s stockholders approved the 2015 Equity Incentive Plan (“2015 Plan”). The 2015 Plan provides for the grant of incentive stock options (“ISOs”) to employees and for the grant of non-statutory stock options (“NSOs”), restricted stock, restricted stock awards (“RSAs”), restricted stock units (“RSUs”), stock appreciation rights, performance units and performance shares to employees, directors and consultants. The shares reserved for issuance under the 2015 Plan includes share awards granted under the prior equity incentive plan that expire or terminate without having been exercised in full or that are forfeited or repurchased. On October 14, 2022, the Company’s stockholders approved an additional 1,750,000 shares of common stock for issuance under the 2015 Plan. As of December 31, 2022, 1,759,566 shares were available for grant under the 2015 Plan.

 

Pursuant to the 2015 Plan, ISOs and NSOs may be granted with exercise prices at not less than 100% of the fair value of the common stock on the date of grant and the exercise price of ISOs granted to a stockholder, who, at the time of grant, owns stock representing more than 10% of the voting power of all classes of the stock of the Company, shall be not less than 110% of the fair market value per share of common stock on the date of grant. The Company’s Board of Directors determines the vesting schedule of the options.

 

Stock option activity under the Plans is set forth below:

   

Number of
Shares

(in thousands)

    

Weighted

Average
Exercise

Price

    

Weighted

Average

Remaining

Contractual

Life

(in years)

    

Intrinsic

Value

(in thousands)

  

Balance at December 31, 2020

     307     $ 19,577.10       5.95     $ —  

Options expired

     (4

)

   $ 36,000.00                  

Balance at December 31, 2021

     303     $ 19,360.30       5.02     $ —  

Balance at December 31, 2022

     303     $ 19,360.30       4.02     $ —  
                                 

Exercisable at December 31, 2022

     303     $ 19,360.30       4.02     $ —  
                                 

Vested and expected to vest at December 31, 2022

     303     $ 19,360.30       4.02     $ —  

 

 

Additional information related to the Company’s stock options as of December 31, 2022 is summarized as follows:

 

Options Outstanding     Options Vested  
                Weighted    

Weighted

            

Weighted

  
                Average    

Average

            

Average

  

Exercise

    

Options

    

Remaining

    

Exercise

     Number    

Exercise

  

Price

    

Outstanding

   

Contractual Life

    

Price

     Exercisable    

Price

  
$ 334.00       155       5.44     $ 334.00       155     $ 334.00  
$ 16,400.00 - 28,400.00       31       4.18     $ 17,323.87       31     $ 17,323.87  
$ 36,000.00       103       2.00     $ 36,000.00       103     $ 36,000.00  
$ 103,680.00 - 162,000.00       14       2.85     $ 112,097.14       14     $ 112,097.14  
          303       4.02     $ 19,360.30       303     $ 19,360.30  

 

There were no options granted or exercised during either of the years ended December 31, 2022 or 2021. For the years ended December 31, 2022 and 2021, stock-based compensation expense recognized associated with stock options vesting was approximately $0 and $4,000, respectively. As of December 31, 2022, there is no remaining unamortized stock-based compensation expense associated with unvested stock options. Because of the Company’s net operating losses, the Company did not realize any tax benefits from share-based payment arrangements for the years ended December 31, 2022 and 2021.

 

The Company’s RSUs generally vest annually over three years in equal increments. The Company measures the fair value of RSUs using the closing stock price of a share of the Company’s common stock on the grant date and is recognized as expense on a straight-line basis over the vesting period of the award. A summary of all RSU activity is presented below:

 

   

Number of

Shares

    

Weighted

Average

Grant Date

Fair Value

    

Weighted

Average

Remaining

Contractual

Term

  

Awards outstanding at December 31, 2020

     20,671     $ 76.03       0.98  

Awarded

     4,500     $ 32.20          

Released

     (13,386

)

   $ 104.31          

Forfeited

     (1,725

)

   $ 53.62          

Awards outstanding at December 31, 2021

     10,060     $ 24.39       0.72  

Released

     (8,590

)

   $ 25.02          

Forfeited

     (1,053

)

   $ 24.25          

Awards outstanding at December 31, 2022

     417     $ 11.64       0.17  

 

As of December 31, 2022, there was less than $0.1 million of remaining unamortized stock-based compensation expense associated with RSUs, which will be expensed over a weighted average remaining service period of 0.2 years. The outstanding non-vested and expected to vest RSUs at December 31, 2022 have an aggregate fair value of approximately less than $0.1 million. The Company used the closing market price of $1.09 per share at December 31, 2022 to determine the aggregate fair value for the RSUs outstanding at that date. For the years ended December 31, 2022 and 2021, the fair value of RSUs vested was approximately $14,000 and $273,000, respectively. For the years ended December 31, 2022 and 2021, stock-based compensation expense recognized associated with the vesting of RSUs was approximately $0.1 million and $1.0 million, respectively.

 

2018 Officer and Director Share Purchase Plan

 

On August 22, 2018, the Board of Directors of the Company approved the adoption of an Officer and Director Share Purchase Plan (“ODPP”), which allowed executive officers and directors to purchase shares of our common stock at fair market value in lieu of salary or, in the case of directors, director fees. Eligible individuals were allowed voluntarily participate in the ODPP by authorizing payroll deductions or, in the case of directors, deductions from director fees for the purpose of purchasing common stock. There was no common stock issued under the ODPP during either of the years ended December 31, 2022 or 2021. On May 16, 2022, the Board of Directors of the Company terminated the Amended and Restated Officer and Director Share Purchase Plan due to the administrative costs of maintaining such plan and the limited amount of remaining shares. Consequently, there are no longer any shares reserved for issuance under this plan.

 

 

Total noncash stock-based compensation expense relating to the Company’s stock options and RSUs recognized, before taxes, during the years ended December 31, 2022 and 2021, is as follows (in thousands):

 

   

Year Ended December 31,

  
   

2022

    

2021

  

Cost of revenues

   $ 18     $ 101  

Research and development expenses

     37       287  

Selling, general and administrative expenses

     72       627  
    $ 127     $ 1,015  

 
XML 32 R19.htm IDEA: XBRL DOCUMENT v3.22.4
Note 12 - Income Taxes
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Income Tax Disclosure [Text Block]

12. Income Taxes

 

For the years ended December 31, 2022 and 2021, the Company’s provision for income taxes consisted of zero state income tax expense. A reconciliation of the statutory U.S. federal rate to the Company’s effective tax rate is as follows (in thousands):

 

   

Year Ended December 31,

  
   

2022

    

2021

  

Tax at federal statutory rate

   $ (3,701

)

   $ (3,657

)

State taxes, net of federal benefit

     (916

)

     (711

)

Permanent differences

     (484

)

     (445

)

Change in valuation allowance

     5,084       5,104  

Research credits

     (273

)

     (286

)

Nondeductible interest expense

     290       —  

Other

     —       (5

)

Provision for taxes

   $ —     $ —  

 

Significant components of the Company’s net deferred tax assets as of December 31, 2022 and 2021 consist of the following (in thousands):

 

   

As of December 31,

  
   

2022

    

2021

  

Deferred tax assets:

                

Federal, state and foreign net operating losses

   $ 85,547     $ 83,211  

Research and other credits

     5,343       4,892  

Operating lease liability

     544       752  

Fixed assets

     471       —  

Accruals and other

     3,628       2,845  

Capitalized research and development

     1,019       —  

Total deferred tax assets

     96,552       91,700  

Less: Valuation allowance

     (95,992

)

     (90,908

)

Total net deferred tax assets

     560       792  

Deferred liabilities:

                

Property and equipment

     —       (2

)

Operating lease right of use asset

     (560

)

     (790

)

Total deferred tax liabilities

     (560

)

     (792

)

Net deferred tax assets (liabilities)

   $ —     $ —  

 

The valuation allowance increased by $5.1 million and $4.7 million during the years ended December 31, 2022 and 2021, respectively.

 

As of December 31, 2022, the Company had approximately $344.3 million of federal and $208.0 million of state net operating loss carryforwards available to offset future taxable income. If not utilized, the federal and state net operating loss carryforwards begin to expire in 2027 and 2023, respectively. Out of the Federal net operating loss carryforwards, $86.8 million were generated post December 31, 2017 and have no expiration.

 

 

As of December 31, 2022, the Company also had approximately $4.3 million and $4.2 million of research and development tax credit carryforwards available to reduce future taxable income, if any, for both federal and California purposes, respectively. The federal credit carryforwards expire beginning in 2027, and the California research credits do not expire and may be carried forward indefinitely.

 

The Company's ability to utilize the net operating loss and tax credit carryforwards in the future may be subject to substantial restrictions in the event of past or future ownership changes as defined in Section 382 of the Internal Revenue Code and similar state tax laws. In the event the Company should experience an ownership change, as defined, utilization of the Company's net operating loss carryforwards and tax credits could be limited.

 

The Company evaluates tax positions for recognition using a more-likely-than-not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information.

 

A reconciliation of the beginning and ending amount of the gross recognized tax benefit is as follows (in thousands):

 

   

As of December 31,

  
   

2022

    

2021

  

Balance at beginning of year

   $ 2,366     $ 2,307  

Increase based on the tax positions in the current year

     203       228  

Increase (Decrease) for tax positions of prior year

     12       (169

)

Balance at end of year

   $ 2,581     $ 2,366  

 

As of December 31, 2022, all unrecognized tax benefits would be subject to a full valuation allowance, if recognized, and would not affect the Company’s tax rate.

 

The Company does not anticipate that the total amounts of unrecognized tax benefits will significantly increase or decrease in the next twelve months.

 

The Company's policy is to include interest and penalties related to unrecognized tax benefits within its provision for income taxes. Due to the Company's net operating loss position, the Company has not recorded an accrual for interest or penalties related to uncertain tax positions for the years ended December 31, 2022 or 2021.

 
XML 33 R20.htm IDEA: XBRL DOCUMENT v3.22.4
Note 13 - 401(k) Plan
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Retirement Benefits [Text Block]

13. 401(k) Plan

 

The Company has a qualified retirement plan under section 401(k) of the Internal Revenue Code (“IRC”) under which participants may contribute up to 99% of their eligible compensation, subject to maximum deferral limits specified by the IRC. The Company may make a discretionary matching contribution to the 401(k) plan, and may make a discretionary employer contribution to each eligible employee each year. To date, the Company has made no contributions to the 401(k) plan.

 
XML 34 R21.htm IDEA: XBRL DOCUMENT v3.22.4
Note 14 - Subsequent Events
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Subsequent Events [Text Block]

14. Subsequent Events

 

Pre-Funded Warrant Exercise

 

On February 14, 2023, a holder of Private Placement Pre-Funded Warrants opted to exercise a portion of the warrant into common stock. A total of 747,864 shares of the Private Placement Pre-Funded Warrants were exercised resulting in the issuance of an aggregate of 747,864 shares of common stock. After giving effect to these aforementioned exercise, there remains 622,000 shares of Private Placement Pre-Funded Warrant shares outstanding, which if exercised, would result in the issuance of an equivalent number of shares of common stock.

 

Restricted Stock Award Grant

 

On January 18, 2023, the Company granted a total of 1,502,928 shares of RSAs to various employees. These RSAs generally vest annually over two years in equal increments, with certain exceptions. The Company measured the fair value of RSAs using the closing stock price of a share of the Company’s common stock of $1.23 on the day of grant. The resulting expense will be recognized on a straight-line basis over the vesting period of the awards.

  

 

Silicon Valley Bank

 

Currently all of our cash and cash equivalents are held at a single financial institution, Silicon Valley Bank. On March 10, 2023, the Federal Deposit Insurance Corporation announced that Silicon Valley Bank had been closed by the California Department of Financial Protection and Innovation. While we have regained access to our accounts at Silicon Valley Bank and are evaluating our banking relationships, future disruptions of financial institutions where we bank or have credit arrangements, or disruptions of the financial services industry in general, could adversely affect our ability to access our cash and cash equivalents. If we are unable to access our cash and cash equivalents as needed, our financial position and ability to operate our business will be adversely affected.

 

 
XML 35 R22.htm IDEA: XBRL DOCUMENT v3.22.4
Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Basis of Accounting, Policy [Policy Text Block] Basis of PresentationThe accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”).On March 11, 2022, the Company’s Board of Directors approved an amendment to the Company’s amended and restated certificate of incorporation to effect a 1-for-20 reverse stock split of the Company’s issued and outstanding common stock. The reverse stock split became effective on March 14, 2022. The par value of the common stock and preferred stock was not adjusted as a result of the reverse stock split. All common stock, stock options, restricted stock units, and per share amounts in the financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split. Additionally, the common stock at par and related additional paid-in capital amounts as of December 31, 2021 in the balance sheet, the common stock at par and related additional paid-in capital amounts in the Statement of Stockholder’s Equity as of December 31, 2021 and 2020, and for the year ended December 31, 2021 have also been retroactively reclassified to give effect to the reverse stock split.
Use of Estimates, Policy [Policy Text Block] Use of EstimatesThe preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to its stock-based compensation, accruals related to compensation, the valuation of the common stock warrants, provisions for doubtful accounts receivable and excess and obsolete inventories, clinical trial accruals, and its reserves for sales returns and warranty costs. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.
Fair Value Measurement, Policy [Policy Text Block] Fair Value of Financial InstrumentsThe Company has evaluated the estimated fair value of its financial instruments as of December 31, 2022 and 2021. Financial instruments consist of cash and cash equivalents, accounts receivable and payable, and other current liabilities and borrowings. The carrying amounts of cash and cash equivalents, accounts receivable and payable, and other current liabilities approximate their respective fair values because of the short-term nature of those instruments. Based upon the borrowing terms and conditions currently available to the Company, the carrying values of the borrowings approximate their fair value.
Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash EquivalentsThe Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents are considered available-for-sale marketable securities and are recorded at fair value, based on quoted market prices. As of December 31, 2022 and 2021, the Company’s cash equivalents are entirely comprised of investments in money market funds. Any related unrealized gains and losses are recorded in other comprehensive income (loss) and included as a separate component of stockholders’ equity. There were no unrealized gains and losses as of December 31, 2022 and 2021. Any realized gains and losses and interest and dividends on available-for-sale securities are included in interest income or expense and computed using the specific identification cost method.
Concentration of Credit Risk and Other Risks and Uncertainties [Policy Text Block] Concentration of Credit Risk, and Other Risks and UncertaintiesFinancial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and accounts receivable to the extent of the amounts recorded on the balance sheets.The Company’s policy is to invest in cash and cash equivalents, consisting of money market funds. These financial instruments are held in Company accounts at one financial institution, Silicon Valley Bank. The counterparties to the agreements relating to the Company’s investments consist of financial institutions of high credit standing. The Company provides for uncollectible amounts when specific credit problems arise. Management’s estimates for uncollectible amounts have been adequate, and management believes that all significant credit risks have been identified at December 31, 2022 and 2021. On March 10, 2023, the Federal Deposit Insurance Corporation announced that Silicon Valley Bank had been closed by the California Department of Financial Protection and Innovation. While we have regained access to our accounts at Silicon Valley Bank and are evaluating our banking relationships, future disruptions of financial institutions where we bank or have credit arrangements, or disruptions of the financial services industry in general, could adversely affect our ability to access our cash and cash equivalents. If we are unable to access our cash and cash equivalents as needed, our financial position and ability to operate our business will be adversely affected. The Company’s accounts receivable are due from a variety of healthcare organizations in the United States and select international markets. The Company provides for uncollectible amounts when specific credit problems arise. Management's estimates for uncollectible amounts have been adequate, and management believes that all significant credit risks have been identified at December 31, 2022 and 2021. At December 31, 2022, there was no customer that represented 10% or more of the Company’s accounts receivable, whereas at December 31 2021, there was one customer that represented 21% of accounts receivable. For the year ended December 31, 2022 and 2021, there was one customer that represented approximately 14% and 10% of revenues, respectively. Disruption of sales orders or a deterioration of financial condition of its customers would have a negative impact on the Company’s financial position and results of operations.The Company manufactures its commercial products in-house, including the Pantheris and Ocelot family of catheters. Certain of the Company’s product components and sub-assemblies are manufactured by sole suppliers, including internally. Disruption in component or sub-assembly supply from these manufacturers or from in-house production would have a negative impact on the Company’s financial position and results of operations.The Company is subject to certain risks, including that its devices may not be approved or cleared for marketing by governmental authorities or be successfully marketed. There can be no assurance that the Company’s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and with appropriate performance characteristics. The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, dependence upon third-party payors to provide adequate coverage and reimbursement, dependence on key personnel and suppliers, protection of proprietary technology, product liability claims, and compliance with government regulations.Existing or future devices developed by the Company may require approvals or clearances from the FDA or international regulatory agencies. In addition, in order to continue the Company’s operations, compliance with various federal and state laws is required. If the Company were denied or delayed in receiving such approvals or clearances, it may be necessary to adjust operations to align with the Company’s currently approved portfolio. If clearance for the products in the current portfolio were withdrawn by the FDA, this may have a material adverse impact on the Company.Disruption of our supply chain capabilities due to trade restrictions, political instability, severe weather, natural disasters, public health crises, terrorism, product recalls, labor supply or stoppages, the financial or operational instability of key suppliers and carriers, government restrictions or measures, or other reasons could impair our ability to distribute our products. The Company believes COVID-19 and the subsequent burdens on the hospital systems has had and will continue to have an adverse effect on its ability to generate sales due to the fluctuating and unpredictable levels of capacity medical providers have to perform procedures that require the use of its products.The Company is closely monitoring general economic conditions on global supply chain, manufacturing, and logistics operations. As inflationary pressures increase, the Company anticipates that its production and operating costs may similarly increase, including costs and availability of materials and labor. While the Company has sufficient inventory on-hand to meet its current production requirements and customer demand, it has experienced some constraints with respect to the availability of certain materials and extended lead times from certain key suppliers. The Company has also experienced some delays in shipping products to its customers. Any significant delay or interruption in our supply chain could impair the Company’s ability to meet the demands of its customers in the future and could harm its business.We use technology in substantially all aspects of our business operations, and our ability to serve customers most effectively depends on the reliability of our technology systems. Cybersecurity incidents can include computer viruses, computer denial-of-service attacks, worms, and other malicious software programs or other attacks, covert introduction of malware to computers and networks, impersonation of authorized users, and efforts to discover and exploit any design flaws, bugs, security vulnerabilities or security weaknesses, as well as intentional or unintentional acts by employees or other insiders with access privileges, intentional acts of vandalism by third parties and sabotage.In addition, our technology infrastructure and systems are vulnerable to damage or interruption from natural disasters, power loss and telecommunications failures. Any such disruption to our systems, or the technology systems of third parties on which we rely, the failure of these systems to otherwise perform as anticipated, or the theft, destruction, loss, misappropriation, or release of sensitive and/or confidential information or intellectual property, could require us to notify affected individuals, federal or state agencies or media outlets of the incident and could result in business disruption, negative publicity, loss of customers, potential liability, including litigation or other legal actions against us or the imposition of penalties, fines, fees or liabilities, which may not be covered by our insurance policies, and competitive disadvantage, any or all of which would potentially adversely affect our customer service, decrease the volume of our business and result in increased costs and lower profits. Moreover, a cybersecurity breach could require us to devote significant management resources to address the problems associated with the breach and to expend significant additional resources to upgrade further the security measures we employ to protect information against cyber-attacks and other wrongful attempts to access such information, which could result in a disruption of our operations.While we have invested, and continue to invest, in technology security initiatives and other measures to prevent security breaches and cyber incidents, as well as disaster recovery plans, these initiatives and measures may not be entirely effective to insulate us from technology disruption that could result in adverse effects on our results of operations.
Receivable [Policy Text Block] Accounts ReceivableTrade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable. The Company determines the allowance for doubtful accounts based upon an aging of accounts receivable, historical experience, and management judgment. Accounts receivable balances are reviewed individually for collectability. To date, the Company has not experienced significant credit-related losses.Accounts receivable allowance for doubtful accounts provision and recoveries or write-offs are summarized as follows (in thousands):
   

2022

    

2021

  

Beginning balance

   $ 6     $ 19  

Provision

     70       2  

Recoveries/write-offs

     (3

)

     (15

)

Ending balance

   $ 73     $ 6  
Inventory, Policy [Policy Text Block] InventoriesInventories are valued at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method for all inventories. The Company’s policy is to write down inventory that has expired or become obsolete, inventory that has a cost basis in excess of its expected net realizable value, and inventory in excess of expected requirements. At each balance sheet date, management evaluates inventories for excess quantities, and obsolescence. This evaluation by management includes analysis of historical sales levels by product, projections of future demand, the risk of technological or competitive obsolescence for products, general market conditions, as well as the feasibility of reworking or using excess or obsolete products or components in the production or assembly of other products that are not obsolete or for which there are not excess quantities in inventory. To the extent that management determines there are excess or obsolete inventory, management adjusts the carrying value to estimated net realizable value. When quantities on hand exceed sales forecasts, a write-down is recorded for such excess inventories along with a corresponding charge to cost of revenues. The estimate of excess quantities is subjective and primarily dependent on the estimates of future demand for a particular product. Specifically, the future demand is derived based on our historical experience, from discussion with users of our products and general market conditions. Changes in assumptions of product demand could have a significant impact on the amount of write-down recorded. Inventory used in clinical trials is expensed at the time of production and recorded as research and development expense if the inventory is contractually being provided at no cost to the clinical site. The cost of inventories are regularly reviewed against estimated market value and record a lower of cost or market reserve for inventories that have a cost in excess of estimated market value, which could have a material impact on the gross margin and inventory balances based on additional write-downs to net realizable value or a benefit from inventories previously written down.
Property, Plant and Equipment, Policy [Policy Text Block] Property and EquipmentProperty and equipment are recorded at cost. Repairs and maintenance costs are expensed as incurred. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets of generally three to five years. Depreciation expense includes the amortization of assets acquired under capital leases and equipment located with the Company’s sales personnel or at customer sites. Equipment held by customers is comprised of the Lightbox consoles located at customer sites under a lease or placement agreement. Equipment held by field sales personnel is also comprised of the Lightbox consoles in their possession. The related equipment is reclassified from inventory to the property and equipment account either upon execution of a lease or placement agreement for customers or upon shipment to a field salesperson. Depreciation expense for equipment held by customers or field sales personnel is recorded as a component of cost of revenues. Leasehold improvements and assets recorded under capital leases are amortized using the straight-line method over the shorter of the lease term or estimated useful economic life of the asset.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Impairment of Long-Lived AssetsThe Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. If indicators of impairment exist, an impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Impairment, if any, is measured as the amount by which the carrying amount of the long-lived asset exceeds its fair value. The Company has not recorded any impairment of long-lived assets since inception through December 31, 2022.
Revenue [Policy Text Block] Revenue RecognitionThe Company’s revenues are derived from (1) sale of Lightbox consoles, (2) sale of disposables, which consist of catheters and accessories, and (3) sale of customer service contracts and maintenance. The Company sells its products directly to hospitals and medical centers as well as through distributors. The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. The Company’s revenues are measured based on consideration specified in the contract with each customer, net of any sales incentives and taxes collected from customers that are remitted to government authorities. For all sales, the Company uses either a signed agreement or a binding purchase order as evidence of an arrangement. The Company’s revenue recognition policies generally result in revenue recognition at the following points:The Company offers its customers the ability to purchase or lease the Lightbox console. In addition, the Company provides a Lightbox under a limited commercial evaluation program to allow accounts to install and utilize the Lightbox for a limited trial period. When a Lightbox is placed under a lease agreement or under a commercial evaluation program, the Company retains title to the equipment and it remains capitalized on its balance sheet under property and equipment. Depreciation expense on these placed Lightboxes is recorded to cost of revenues on a straight-line basis. The costs to maintain these placed Lightboxes are charged to cost of revenues as incurred.The Company evaluates its lease and commercial evaluation program agreements and accounts for these contracts under the guidance in Accounting Standards Codification (“ASC”) 842, Leases and ASU No. 2014 09, Revenue from Contracts with Customers (Topic 606). The guidance requires arrangement consideration to be allocated between a lease deliverable and a non-lease deliverable based upon the relative selling-price of the deliverables.The Company assessed whether the embedded lease is an operating lease or sales-type lease. Based on the Company’s assessment of the guidance and given that any payments under the lease agreements are dependent upon contingent future sales, it was determined that collectability of the minimum lease payments is not reasonably predictable. Accordingly, the Company concluded the embedded lease did not meet the criteria of a sales-type lease and accounts for it as an operating lease. The Company recognizes revenue allocated to the lease as the contingent disposable product purchases are delivered and are included in revenues within the statement of operations and comprehensive loss.For sales through distributors, the Company recognizes revenue when control of the product transfers from the Company to the distributor. The distributors are responsible for all marketing, sales, training and warranty in their respective territories. The standard terms and conditions contained in the Company’s distribution agreements do not provide price protection or stock rotation rights to any of its distributors. In addition, its distributor agreements do not allow the distributor to return or exchange products, and the distributor is obligated to pay the Company upon invoice regardless of its ability to resell the product.
Cost of Goods and Service [Policy Text Block] Cost of RevenuesCost of revenues consists primarily of manufacturing overhead costs, material costs and direct labor. A significant portion of the Company’s cost of revenues currently consists of manufacturing overhead costs. These overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management. Cost of revenues also includes depreciation expense for the Lightboxes under lease, deployed with sales personnel and evaluation agreements, product warranty costs, product written-off due to excess or obsolescence, and certain direct costs such as shipping costs.
Standard Product Warranty, Policy [Policy Text Block] Product Warranty CostsThe Company typically offers a one-year warranty on its products commencing upon the transfer of title and risk of loss to the customer. The Company accrues for the estimated cost of product warranties upon invoicing its customers, based on historical results. Warranty costs are reflected in the statement of operations and comprehensive loss as a cost of revenues. The warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Should actual product failure rates, material usage or service delivery costs differ from these estimates, revisions to the estimated warranty liability would be required. Periodically the Company assesses the adequacy of its recorded warranty liabilities and adjusts the amounts as necessary. Warranty provisions and claims are summarized as follows (in thousands):
   

2022

    

2021

  

Beginning balance

   $ 187     $ 193  

Warranty provision

     22       49  

Usage/Release

     (100

)

     (55

)

Ending balance

   $ 109     $ 187  
Research and Development Expense, Policy [Policy Text Block] Research and DevelopmentThe Company expenses research and development costs as incurred. Research and development expenses include personnel and personnel-related costs, costs associated with pre-clinical and clinical development activities, and costs for prototype products that are manufactured prior to market approval for that prototype product, and internal and external costs associated with the Company’s regulatory compliance, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs, including allocated facility and related expenses.
Clinical Trials [Policy Text Block] Clinical TrialsThe Company accrues and expenses costs for its clinical trial activities performed by third parties, including clinical research organizations and other service providers, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company determines these estimates through discussion with internal personnel and outside service providers as to progress or stage of completion of trials or services pursuant to contracts with clinical research organizations and other service providers and the agreed-upon fee to be paid for such services.
Share-Based Payment Arrangement [Policy Text Block] Stock-Based CompensationStock-based compensation for the Company includes amortization related to all stock options, restricted stock units (“RSU”), and restricted stock awards (“RSA”) based on the grant-date estimated fair value. The fair value of stock options is estimated on the date of grant using the Black-Scholes option pricing model and recognized as expense on a straight-line basis over the vesting period of the award. The Company has not granted any stock options since 2017. The Company measures the fair value of RSUs and RSAs using the closing stock price of a share of the Company’s common stock on the grant date and is recognized as expense on a straight-line basis over the vesting period of the award. As allowed under ASU No. 2016‑09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, the Company accounts for forfeitures as they occur.
Foreign Currency Transactions and Translations Policy [Policy Text Block] Foreign CurrencyThe Company records net gains and losses resulting from foreign exchange transactions as a component of foreign currency exchange losses in other income, net. During the years ended December 31, 2022 and 2021, the Company recorded $12,000 and $16,000 of foreign currency exchange net losses, respectively.
Income Tax, Policy [Policy Text Block] Income TaxesThe Company utilizes the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax reporting bases of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense when they occur. During the years ended December 31, 2022 and 2021, the Company did not recognize accrued interest or penalties related to unrecognized tax benefits.
Earnings Per Share, Policy [Policy Text Block] Net Loss per Share Attributable to Common StockholdersBasic net loss per share attributable to common stockholders is computed by dividing the net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss applicable to common stockholders by the weighted average number of shares of common stock and dilutive potential shares of common stock outstanding during the period. Any common stock shares subject to repurchase are excluded from the calculations as the continued vesting of such shares is contingent upon the holders’ continued service to the Company. As of December 31, 2022 and 2021, there were no shares subject to repurchase. Since the Company was in a loss position for both periods presented, basic net loss per share attributable to common stockholders is the same as diluted net loss per share attributable to common stockholders as the inclusion of all potentially dilutive common shares would have been anti-dilutive.Net loss per share attributable to common stockholders was determined as follows (in thousands, except per share data):
   

Year Ended December 31,

  
   

2022

    

2021

  

Net loss applicable to common stockholders

   $ (27,244

)

   $ (21,587

)

Weighted average common stock outstanding, basic and diluted

     6,249       4,722  

Net loss per share attributable to common stockholders, basic and diluted

   $ (4.36

)

   $ (4.57

)
The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted average shares outstanding because such securities have an anti-dilutive impact due to losses reported:
   

Year Ended December 31,

  
   

2022

    

2021

  

Common stock warrants equivalents

     4,009,679       135,429  

Common stock options

     303       304  

Convertible preferred stock

     58,080       52,289  

Unvested restricted stock units

     6,626       17,817  
      4,074,688       205,839  
Comprehensive Income, Policy [Policy Text Block] Comprehensive LossFor the years ended December 31, 2022 and 2021, there was no difference between comprehensive loss and the Company’s net loss.
Segment Reporting, Policy [Policy Text Block] Segment and Geographical Information The Company operates and manages its business as one reportable and operating segment. The Company’s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. Primarily all of the Company’s long-lived assets, which are comprised of property and equipment, are based in the United States. For the years ended December 31, 2022 and 2021, 92% and 94% of the Company’s revenues were in the United States, based on the shipping location of the external customer. The remaining revenues for the years ended December 31, 2022 and 2021, were principally in Germany.
New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting PronouncementsRecently adopted accounting standardsIn May 2021, ASU No. 2021-04, Issuer’s Accounting for Certain Modifications of Exchanges of Freestanding Equity-Classified Written Call Options was issued to clarify the accounting for modifications or exchanges of freestanding equity-classified written call options, such was warrants, that remain equity classified after modification or exchange. The standard was adopted by the Company on January 1, 2022. This new standard did not have a material impact on the Company’s financial statements.Recent accounting standards not yet adopted In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which among other things, simplifies the accounting models for the allocation of proceeds attributable to the issuance of a convertible debt instrument.  As a result, after adopting the ASU’s guidance, entities will not separately present in equity an embedded conversion feature in such debt. Instead, they will account for a convertible debt instrument wholly as debt, and for convertible preferred stock wholly as preferred stock (i.e., as a single unit of account), unless (i) a convertible instrument contains features that require bifurcation as a derivative under ASC 815 or (ii) a convertible debt instrument was issued at a substantial premium. The standard becomes effective for the Company, as a smaller reporting company as defined by the SEC, in the first quarter of 2024 and early adoption is permitted.  This new standard is not expected to have a material impact on the Company’s financial statements.
XML 36 R23.htm IDEA: XBRL DOCUMENT v3.22.4
Financial Statements Schedules (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Valuation Allowances and Reserves [Table Text Block]

Description

  

Balance at
Beginning
of Year

    

Charged to
costs and
expenses

    

Write offs

    

Balance at
End of
Year

  

Allowance for doubtful accounts receivable:

                                

Fiscal year ended 2021

   $ 19     $ 2     $ 15     $ 6  

Fiscal year ended 2022

   $ 6     $ 70     $ 3     $ 73  
   

Balance at
Beginning
of Year

    

Charged to
costs and
expenses

    

Write offs

    

Balance at
End of
Year

  

Allowance for sales returns:

                                

Fiscal year ended 2021

   $ 20     $ 10     $ 10     $ 20  

Fiscal year ended 2022

   $ 20     $ —     $ 5     $ 15  
XML 37 R24.htm IDEA: XBRL DOCUMENT v3.22.4
Note 2 - Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Accounts Receivable, Allowance for Credit Loss [Table Text Block]
   

2022

    

2021

  

Beginning balance

   $ 6     $ 19  

Provision

     70       2  

Recoveries/write-offs

     (3

)

     (15

)

Ending balance

   $ 73     $ 6  
Schedule of Product Warranty Liability [Table Text Block]
   

2022

    

2021

  

Beginning balance

   $ 187     $ 193  

Warranty provision

     22       49  

Usage/Release

     (100

)

     (55

)

Ending balance

   $ 109     $ 187  
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
   

Year Ended December 31,

  
   

2022

    

2021

  

Net loss applicable to common stockholders

   $ (27,244

)

   $ (21,587

)

Weighted average common stock outstanding, basic and diluted

     6,249       4,722  

Net loss per share attributable to common stockholders, basic and diluted

   $ (4.36

)

   $ (4.57

)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
   

Year Ended December 31,

  
   

2022

    

2021

  

Common stock warrants equivalents

     4,009,679       135,429  

Common stock options

     303       304  

Convertible preferred stock

     58,080       52,289  

Unvested restricted stock units

     6,626       17,817  
      4,074,688       205,839  
XML 38 R25.htm IDEA: XBRL DOCUMENT v3.22.4
Note 4 - Inventories (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Inventory, Current [Table Text Block]
   

December 31,

  
   

2022

    

2021

  

Raw materials

   $ 3,374     $ 2,503  

Work-in-process

     17       1  

Finished products

     1,574       2,097  

Total inventories

   $ 4,965     $ 4,601  
XML 39 R26.htm IDEA: XBRL DOCUMENT v3.22.4
Note 5 - Property and Equipment, Net (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Property, Plant and Equipment [Table Text Block]
   

December 31,

  
   

2022

    

2021

  

Equipment held by customers and field sales personnel

   $ 2,566     $ 2,362  

Machinery and equipment

     1,372       1,391  

Computer software

     122       122  

Computer equipment

     200       173  

Furniture and fixture

     78       78  

Leasehold improvements

     320       320  

Total property and equipment, gross

     4,658       4,446  

Less: Accumulated depreciation and amortization

     (3,956

)

     (4,351

)

Total property and equipment, net

   $ 702     $ 95  
XML 40 R27.htm IDEA: XBRL DOCUMENT v3.22.4
Note 7 - Borrowings (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Debt [Table Text Block]

Year Ending December 31,

        

2023

   $ —  

2024

     9,045  

2025

     10,339  

Total

     19,384  

Less: Amount of PIK additions and final facility fee to be incurred subsequent to December 31, 2022

     (4,970

)

Less: Amount representing debt issuance costs

     (249

)

Borrowings, current portion, as of December 31, 2022

   $ 14,165  
XML 41 R28.htm IDEA: XBRL DOCUMENT v3.22.4
Note 8 - Leases (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Lessee, Operating Lease, Liability, Maturity [Table Text Block]

Year Ending December 31,

        

2023

   $ 1,203  

2024

     1,138  

Total

     2,341  

Less: Imputed interest

     (147

)

Leasehold liability as of December 31, 2022

   $ 2,194  
Right of Use Asset and Liabilities [Table Text Block]
       

December 31,

  

Lease-Related Assets and Liabilities

   Financial Statement Line

Items

   2022     2021  
Right of use assets:                    

Operating lease

   Right of use asset   $ 2,194     $ 3,179  
Total right of use assets   $ 2,194     $ 3,179  
Lease liabilities:                    

Operating lease

   Leasehold liability, current portion   $ 1,092     $ 985  
    Leasehold liability, long-term portion     1,102       2,194  

Total lease liabilities

   $ 2,194     $ 3,179  
XML 42 R29.htm IDEA: XBRL DOCUMENT v3.22.4
Note 10 - Stockholders' Equity (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]
   

Total

Outstanding

and

Exercisable

    

Underlying

Shares of

Common

Stock

    

Exercise

Price per

Share

    

Expiration Date

  

Series 1 Warrants issued in the February 2018 Series B financing

     8,979,000       44,895     $ 400.00     February 2025  

Series 2 Warrants issued in the February 2018 Series B financing

     8,709,500       43,548     $ 400.00     February 2025  

Warrants issued in the November 2018 financing

     8,768,395       43,842     $ 80.00     November 2023  

Placement agent warrants issued in the January 2022 financing

     1,330,000       66,500     $ 10.00     January 2027  

Warrants issued in the January 2022 financing

     16,150,000       807,500     $ 9.60     July 2027  

Pre-funded warrants issued in the August 2022 financing

     1,369,864       1,369,864     $ 0.0001       n/a  

Series A Preferred Investment Options issued in August 2022 financing

     2,853,883       2,853,883     $ 1.502    

February 2028

  

Series B Preferred Investment Options issued in August 2022 financing

     2,853,883       2,853,883     $ 1.502    

August 2024

  

Placement agent Preferred Investment Options issued in the August 2022 financing

     171,233       171,233     $ 2.19    

August 2027

  

Total as of December 31, 2022

     51,185,758       8,255,148                  
   

Total

Outstanding

and

Exercisable

    

Underlying

Shares of

Common

Stock

    

Exercise

Price per

Share

  

Expiration Date

Series 1 Warrants issued in the February 2018 Series B financing

     8,979,000       44,895     $ 400.00  

February 2025

Series 2 Warrants issued in the February 2018 Series B financing

     8,709,500       43,548     $ 400.00  

February 2025

Warrants issued in the November 2018 financing

     8,768,395       43,842     $ 80.00   November 2023

Total as of December 31, 2021

     26,456,895       132,265            
XML 43 R30.htm IDEA: XBRL DOCUMENT v3.22.4
Note 11 - Stock-based Compensation (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Share-Based Payment Arrangement, Option, Activity [Table Text Block]
   

Number of
Shares

(in thousands)

    

Weighted

Average
Exercise

Price

    

Weighted

Average

Remaining

Contractual

Life

(in years)

    

Intrinsic

Value

(in thousands)

  

Balance at December 31, 2020

     307     $ 19,577.10       5.95     $ —  

Options expired

     (4

)

   $ 36,000.00                  

Balance at December 31, 2021

     303     $ 19,360.30       5.02     $ —  

Balance at December 31, 2022

     303     $ 19,360.30       4.02     $ —  
                                 

Exercisable at December 31, 2022

     303     $ 19,360.30       4.02     $ —  
                                 

Vested and expected to vest at December 31, 2022

     303     $ 19,360.30       4.02     $ —  
Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]
Options Outstanding     Options Vested  
                Weighted    

Weighted

            

Weighted

  
                Average    

Average

            

Average

  

Exercise

    

Options

    

Remaining

    

Exercise

     Number    

Exercise

  

Price

    

Outstanding

   

Contractual Life

    

Price

     Exercisable    

Price

  
$ 334.00       155       5.44     $ 334.00       155     $ 334.00  
$ 16,400.00 - 28,400.00       31       4.18     $ 17,323.87       31     $ 17,323.87  
$ 36,000.00       103       2.00     $ 36,000.00       103     $ 36,000.00  
$ 103,680.00 - 162,000.00       14       2.85     $ 112,097.14       14     $ 112,097.14  
          303       4.02     $ 19,360.30       303     $ 19,360.30  
Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]
   

Number of

Shares

    

Weighted

Average

Grant Date

Fair Value

    

Weighted

Average

Remaining

Contractual

Term

  

Awards outstanding at December 31, 2020

     20,671     $ 76.03       0.98  

Awarded

     4,500     $ 32.20          

Released

     (13,386

)

   $ 104.31          

Forfeited

     (1,725

)

   $ 53.62          

Awards outstanding at December 31, 2021

     10,060     $ 24.39       0.72  

Released

     (8,590

)

   $ 25.02          

Forfeited

     (1,053

)

   $ 24.25          

Awards outstanding at December 31, 2022

     417     $ 11.64       0.17  
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
   

Year Ended December 31,

  
   

2022

    

2021

  

Cost of revenues

   $ 18     $ 101  

Research and development expenses

     37       287  

Selling, general and administrative expenses

     72       627  
    $ 127     $ 1,015  
XML 44 R31.htm IDEA: XBRL DOCUMENT v3.22.4
Note 12 - Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
   

Year Ended December 31,

  
   

2022

    

2021

  

Tax at federal statutory rate

   $ (3,701

)

   $ (3,657

)

State taxes, net of federal benefit

     (916

)

     (711

)

Permanent differences

     (484

)

     (445

)

Change in valuation allowance

     5,084       5,104  

Research credits

     (273

)

     (286

)

Nondeductible interest expense

     290       —  

Other

     —       (5

)

Provision for taxes

   $ —     $ —  
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
   

As of December 31,

  
   

2022

    

2021

  

Deferred tax assets:

                

Federal, state and foreign net operating losses

   $ 85,547     $ 83,211  

Research and other credits

     5,343       4,892  

Operating lease liability

     544       752  

Fixed assets

     471       —  

Accruals and other

     3,628       2,845  

Capitalized research and development

     1,019       —  

Total deferred tax assets

     96,552       91,700  

Less: Valuation allowance

     (95,992

)

     (90,908

)

Total net deferred tax assets

     560       792  

Deferred liabilities:

                

Property and equipment

     —       (2

)

Operating lease right of use asset

     (560

)

     (790

)

Total deferred tax liabilities

     (560

)

     (792

)

Net deferred tax assets (liabilities)

   $ —     $ —  
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]
   

As of December 31,

  
   

2022

    

2021

  

Balance at beginning of year

   $ 2,366     $ 2,307  

Increase based on the tax positions in the current year

     203       228  

Increase (Decrease) for tax positions of prior year

     12       (169

)

Balance at end of year

   $ 2,581     $ 2,366  
XML 45 R32.htm IDEA: XBRL DOCUMENT v3.22.4
Financial Statements Schedules - Allowance of Doubtful Accounts and Sales Returns (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
SEC Schedule, 12-09, Allowance, Sales Returns [Member]    
Balance at Beginning of Year $ 20 $ 20
Charged to costs and expenses, additions 0 10
Write offs 5 10
Balance at End of Year 15 20
SEC Schedule, 12-09, Allowance, Credit Loss [Member]    
Balance at Beginning of Year 6 19
Charged to costs and expenses, additions 70 2
Write offs 3 15
Balance at End of Year $ 73 $ 6
XML 46 R33.htm IDEA: XBRL DOCUMENT v3.22.4
Note 1 - Organization (Details Textual) - USD ($)
 1 Months Ended 12 Months Ended
Aug. 04, 2022
Jan. 14, 2022
Feb. 02, 2021
Aug. 31, 2022
Feb. 28, 2021
Dec. 31, 2022
May 20, 2022
Dec. 31, 2021
Retained Earnings (Accumulated Deficit), Total           $ (402,376,000)   $ (384,753,000)
Cash and Cash Equivalents, at Carrying Value, Total           $ 14,603,000   $ 19,497,000
Share Price           $ 1.09    
Preferred Stock, Par or Stated Value Per Share           $ 0.001   $ 0.001
Class of Warrant or Right, Number of Securities Called by Warrants or Rights           8,255,148   132,265
Class of Warrant or Right, Outstanding           51,185,758   26,456,895
Common Stock, Par or Stated Value Per Share (in dollars per share)           $ 0.001   $ 0.001
Common Warrants [Member]                
Class of Warrant or Right, Number of Securities Called by Warrants or Rights   807,500            
Class of Warrant or Right, Exercise Price of Warrants or Rights   $ 9.60            
Warrants and Rights Outstanding, Term   5 years            
Placement agent warrants issued in the January 2022 financing [Member]                
Class of Warrant or Right, Number of Securities Called by Warrants or Rights   66,500       66,500    
Class of Warrant or Right, Outstanding           1,330,000    
Class of Warrant or Right, Exercise Price of Warrants or Rights   $ 10.00       $ 10.00    
Warrants and Rights Outstanding, Term   5 years            
Registered Direct Pre-funded Warrants [Member]                
Class of Warrant or Right, Number of Securities Called by Warrants or Rights 784,019              
Pre-funded Warrants [Member]                
Class of Warrant or Right, Outstanding           622,000    
Series A Preferred Investment Options [Member]                
Class of Warrant or Right, Number of Securities Called by Warrants or Rights       2,853,883        
Class of Warrant or Right, Exercise Price of Warrants or Rights       $ 1.502        
Warrants and Rights Outstanding, Term       5 years 6 months        
Series B Preferred Investment Options [Member]                
Class of Warrant or Right, Number of Securities Called by Warrants or Rights       2,853,883        
Class of Warrant or Right, Exercise Price of Warrants or Rights       $ 1.502        
Warrants and Rights Outstanding, Term       2 years        
Placement Agent Preferred Investment Options [Member]                
Class of Warrant or Right, Number of Securities Called by Warrants or Rights       171,233        
Class of Warrant or Right, Exercise Price of Warrants or Rights       $ 2.19        
Warrants and Rights Outstanding, Term       5 years        
Series D Preferred Stock [Member]                
Preferred Stock, Par or Stated Value Per Share   $ 0.001            
Series D Preferred Stock [Member] | Common Warrants [Member]                
Class of Warrant or Right, Outstanding   807,500            
Class of Warrant or Right, Exercise Price of Warrants or Rights   $ 9.60            
Warrants and Rights Outstanding, Term   5 years            
Series D Preferred Stock [Member] | Placement agent warrants issued in the January 2022 financing [Member]                
Class of Warrant or Right, Number of Securities Called by Warrants or Rights   66,500            
Class of Warrant or Right, Exercise Price of Warrants or Rights   $ 10.00            
Warrants and Rights Outstanding, Term   5 years            
August 2022 Public Offering [Member]                
Proceeds from Issuance or Sale of Equity, Net       $ 4,400,000        
The Market Offering Agreement (the “ATM Agreement”) [Member]                
Proceeds from Issuance or Sale of Equity, Net           $ 800,000    
January 2022 Public Offering [Member]                
Proceeds from Issuance or Sale of Equity, Net   $ 6,700,000       $ 6,700,000    
January 2022 Public Offering [Member] | Series D Preferred Stock [Member]                
Stock Issued During Period, Shares, New Issues   7,600            
Preferred Stock, Par or Stated Value Per Share   $ 1,000            
Preferred Stock, Convertible, Conversion Price   $ 8.00            
February 2021 Public Offering [Member]                
Proceeds from Issuance or Sale of Equity, Net     $ 13,000,000.0   $ 13,000,000.0      
Stock Issued During Period, Shares, New Issues     500,000          
Share Price     $ 28.80          
August 2022 Purchase Agreement [Member]                
Stock Issued During Period, Shares, New Issues 700,000              
Sale of Stock, Number of Shares (in shares) 1,484,019              
Shares Issued, Price Per Share (in dollars per share) $ 1.752              
Proceeds from Issuance or Sale of Equity, Total $ 4,400,000              
Private Placement [Member]                
Stock Issued During Period, Shares, New Issues 1,369,864              
Shares Issued, Price Per Share (in dollars per share) $ 1.752              
Private Placement [Member] | Registered Direct Pre-funded Warrants [Member]                
Class of Warrant or Right, Number of Securities Called by Warrants or Rights 1,369,864              
Common Stock in June, 2022 [Member]                
Stock Issued During Period, Shares, New Issues           585,603    
Shares Issued, Price Per Share (in dollars per share)           $ 1.67    
Proceeds from Issuance or Sale of Equity, Total           $ 1,000,000.0    
Common Stock, Par or Stated Value Per Share (in dollars per share)             $ 0.001  
Share Offering Agreement, Aggregate Offering             $ 7,000,000  
Commission Percentage             3.00%  
Payments of Stock Issuance Costs           $ 29,000    
XML 47 R34.htm IDEA: XBRL DOCUMENT v3.22.4
Note 2 - Summary of Significant Accounting Policies (Details Textual)
shares in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Mar. 11, 2022
Jan. 31, 2022
USD ($)
Mar. 31, 2022
Dec. 31, 2022
USD ($)
shares
Dec. 31, 2021
USD ($)
shares
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss), before Tax, Total       $ 0 $ 0
Warranty Period (Year)       1 year  
Foreign Currency Transaction Gain (Loss), before Tax, Total   $ 12,000     16,000
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total       $ 0 $ 0
Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation | shares       0 0
Number of Reportable Segments       1  
Minimum [Member]          
Property, Plant and Equipment, Useful Life (Year)       3 years  
Maximum [Member]          
Property, Plant and Equipment, Useful Life (Year)       5 years  
Customer Concentration Risk [Member] | Accounts Receivable [Member]          
Number of Major Customers       0 1
Customer Concentration Risk [Member] | Accounts Receivable [Member] | One Customer [Member]          
Concentration Risk, Percentage         21.00%
Customer Concentration Risk [Member] | Revenue Benchmark [Member]          
Number of Major Customers       1 1
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | UNITED STATES          
Concentration Risk, Percentage       92.00% 94.00%
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | One Customer [Member]          
Concentration Risk, Percentage     14.00%   10.00%
Reverse Stock Split [Member]          
Stockholders' Equity Note, Stock Split, Conversion Ratio 20        
XML 48 R35.htm IDEA: XBRL DOCUMENT v3.22.4
Note 2 - Summary of Significant Accounting Policies - Accounts Receivable, Allowance for Credit Loss (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Beginning balance $ 6 $ 19
Provision 70 2
Recoveries/write-offs (3) (15)
Ending balance $ 73 $ 6
XML 49 R36.htm IDEA: XBRL DOCUMENT v3.22.4
Note 2 - Summary of Significant Accounting Policies - Product Warranty (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Beginning balance $ 187 $ 193
Warranty provision 22 49
Usage/Release (100) (55)
Ending balance $ 109 $ 187
XML 50 R37.htm IDEA: XBRL DOCUMENT v3.22.4
Note 2 - Summary of Significant Accounting Policies - Net Loss Per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Net loss applicable to common stockholders $ (27,244) $ (21,587)
Weighted average common stock outstanding, basic and diluted (in shares) 6,249 4,722
Net loss per share attributable to common stockholders, basic and diluted (in dollars per share) $ (4.36) $ (4.57)
XML 51 R38.htm IDEA: XBRL DOCUMENT v3.22.4
Note 2 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) - shares
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Antidilutive Securities (in shares) 4,074,688 205,839
Common Stock Warrants [Member]    
Antidilutive Securities (in shares) 4,009,679 135,429
Common Stock Options [ member]    
Antidilutive Securities (in shares) 303 304
Preferred Stock [Member]    
Antidilutive Securities (in shares) 58,080 52,289
Restricted Stock Units (RSUs) [Member]    
Antidilutive Securities (in shares) 6,626 17,817
XML 52 R39.htm IDEA: XBRL DOCUMENT v3.22.4
Note 3 - Fair Value Measurements (Details Textual) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Fair Value, Inputs, Level 2 [Member]    
Assets, Fair Value Disclosure, Total $ 0 $ 0
Liabilities, Fair Value Disclosure, Total 0 0
Fair Value, Inputs, Level 3 [Member]    
Assets, Fair Value Disclosure, Total 0 0
Liabilities, Fair Value Disclosure, Total $ 0 $ 0
XML 53 R40.htm IDEA: XBRL DOCUMENT v3.22.4
Note 4 - Inventories - Schedule of Inventory (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Raw materials $ 3,374 $ 2,503
Work-in-process 17 1
Finished products 1,574 2,097
Total inventories $ 4,965 $ 4,601
XML 54 R41.htm IDEA: XBRL DOCUMENT v3.22.4
Note 5 - Property and Equipment, Net (Details Textual) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Depreciation, Total $ 196,000 $ 687,000
Property, Plant, and Equipment, Lessor Asset under Operating Lease, after Accumulated Depreciation, Total 527,000 0
Leased Equipment [Member]    
Cost, Depreciation $ 119,000 $ 539,000
XML 55 R42.htm IDEA: XBRL DOCUMENT v3.22.4
Note 5 - Property and Equipment, Net - Property and Equipment (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Property and Equipment $ 4,658 $ 4,446
Less: Accumulated depreciation and amortization (3,956) (4,351)
Total property and equipment, net 702 95
Equipment Held by Customers [Member]    
Property and Equipment 2,566 2,362
Machinery and Equipment [Member]    
Property and Equipment 1,372 1,391
Software Development [Member]    
Property and Equipment 122 122
Computer Equipment [Member]    
Property and Equipment 200 173
Furniture and Fixtures [Member]    
Property and Equipment 78 78
Leasehold Improvements [Member]    
Property and Equipment $ 320 $ 320
XML 56 R43.htm IDEA: XBRL DOCUMENT v3.22.4
Note 6 - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Deferred revenue $ 141 $ 123
Accrued travel and entertainment expenses 129 118
Accrued product warranty costs 109 187
Accrued clinical trial costs 106 153
Accrued professional fees 60 0
Accrued sales and use tax 40 33
Other accrued liabilities 72 104
Total accrued expenses and other current liabilities $ 657 $ 718
XML 57 R44.htm IDEA: XBRL DOCUMENT v3.22.4
Note 7 - Borrowings (Details Textual) - USD ($)
 1 Months Ended 12 Months Ended
Aug. 10, 2022
Apr. 23, 2020
Feb. 14, 2018
Apr. 30, 2021
Dec. 31, 2022
Dec. 31, 2021
Jun. 15, 2016
Sep. 22, 2015
Gain (Loss) on Extinguishment of Debt, Total         $ (0) $ 2,353,000    
Interest Expense, Total         1,665,000 1,648,000    
Paycheck Protection Program CARES Act [Member]                
Proceeds from Issuance of Long-Term Debt, Total   $ 2,300,000            
Debt Instrument Interest Forgiven       $ 23,000        
Interest Expense, Total         7,000      
Paycheck Protection Program CARES Act [Member] | Other Nonoperating Income (Expense) [Member]                
Gain (Loss) on Extinguishment of Debt, Total       $ 2,400,000        
CRG [Member] | Loan Agreement [Member]                
Debt Agreement, Maximum Borrowing Capacity               $ 50,000,000
Debt Instrument, Covenant Compliance, Minimum Liquidity Requirement     $ 3,500,000          
Debt Instrument, Covenant Compliance, Target Minimum Revenue, Past Twelve Months $ 8,000,000              
Debt Instrument, Covenant Compliance Target Minimum Revenue, Next Twelve Months 8,000,000              
Debt Instrument Covenant Compliance Target Minimum Revenue Second Year 10,000,000              
Debt Instrument Covenant Compliance Target Minimum Revenue Third Year 14,500,000              
Debt Instrument, Covenant Compliance Target Minimum Revenue Fourth Year $ 17,000,000              
Debt Instrument, Interest Rate, Stated Percentage 12.50%              
Debt Instrument, Periodic Payment, Total $ 1,900,000              
Long-Term Debt, Maturity, Year Four 7,500,000              
Long-Term Debt, Maturity, Year Five $ 7,500,000              
Debt Instrument, Redemption Initial Prepayment Premium Percentage 5.00%              
Debt Instrument, Redemption Annual Decline in Prepayment Premium Percentage 1.00%              
Debt Instrument, Financing Fee Percentage 1.50%              
Debt Instrument, Final Facility Fee Percentage 15.00%              
Debt Instrument, Covenant Compliance Cash and Certain Cash Equivalents Minimum $ 3,500,000              
Debt Instrument, Covenant Compliance Prepayment Multiplier for Revenue Shortfall 2.0              
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total         249,000 332,000   1,300,000
Amortization of Debt Discount (Premium)         83,000 86,000    
Interest Expense, Debt, Total         $ 1,900,000 $ 1,600,000    
CRG [Member] | Loan Agreement [Member] | Series A Preferred Stock Purchase Agreement with CRG [Member]                
Debt Conversion, Original Debt, Amount     38,000,000          
Debt Conversion, Fees and Prepayment Premium Amount     $ 3,800,000          
CRG [Member] | Loan Agreement [Member] | First Tranche, Borrowed on September 22, 2015 [Member]                
Debt Instrument, Face Amount               $ 30,000,000
CRG [Member] | Loan Agreement [Member] | Second Tranche, Borrowed on June 15, 2016 [Member]                
Debt Instrument, Face Amount             $ 10,000,000  
XML 58 R45.htm IDEA: XBRL DOCUMENT v3.22.4
Note 7 - Borrowings - Schedule of Debt (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
2023 $ 0  
Borrowings, current portion, as of December 31, 2022 14,165 $ 0
CRG [Member] | Loan Agreement [Member]    
2024 9,045  
2025 10,339  
Total 19,384  
Less: Amount of PIK additions and final facility fee to be incurred subsequent to December 31, 2022 (4,970)  
Less: Amount representing debt issuance costs (249)  
Borrowings, current portion, as of December 31, 2022 $ 14,165  
XML 59 R46.htm IDEA: XBRL DOCUMENT v3.22.4
Note 8 - Leases (Details Textual) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Apr. 01, 2019
Lessee, Operating Lease, Liability, to be Paid, Total $ 2,341,000   $ 5,800,000
Operating Lease, Weighted Average Remaining Lease Term 1 year 10 months 24 days    
Lessee, Operating Lease, Discount Rate 6.50%    
Operating Lease, Expense, Excluding Maintenance Fee and Other Expense, Monthly $ 105,000    
Operating Lease, Expense 314,000,000,000 $ 314,000,000,000  
Variable Lease, Cost 300,000 200,000  
Operating Lease, Right-of-Use Asset, Amortization Expense 1,100,000 1,000,000.0  
Prepaid Rent $ 65,000 $ 158,000  
XML 60 R47.htm IDEA: XBRL DOCUMENT v3.22.4
Note 8 - Leases - Future Operating Lease Payments (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Apr. 01, 2019
2023 $ 1,203    
2024 1,138    
Total 2,341   $ 5,800
Less: Imputed interest (147)    
Leasehold liability as of December 31, 2022 $ 2,194 $ 3,179  
XML 61 R48.htm IDEA: XBRL DOCUMENT v3.22.4
Note 8 - Leases - ROU Assets and Lease Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Operating lease $ 2,194 $ 3,179
Total right of use assets 2,194 3,179
Leasehold liability, current portion 1,092 985
Operating Lease, Liability, Noncurrent 1,102 2,194
Total lease liabilities $ 2,194 $ 3,179
XML 62 R49.htm IDEA: XBRL DOCUMENT v3.22.4
Note 9 - Commitments and Contingencies (Details Textual)
$ in Millions
Dec. 31, 2022
USD ($)
Purchase Commitment [Member]  
Purchase Obligation, Total $ 1.1
XML 63 R50.htm IDEA: XBRL DOCUMENT v3.22.4
Note 10 - Stockholders' Equity (Details Textual) - USD ($)
 12 Months Ended
Feb. 14, 2023
Jan. 14, 2022
Feb. 14, 2018
Dec. 31, 2022
Dec. 31, 2021
Aug. 31, 2022
Aug. 04, 2022
Feb. 16, 2018
Preferred Stock, Shares Authorized       5,000,000 5,000,000      
Preferred Stock, Par or Stated Value Per Share       $ 0.001 $ 0.001      
Preferred Stock, Shares Issued       60,961 56,451      
Preferred Stock, Shares Outstanding, Ending Balance (in shares)       60,961 56,451      
Class of Warrant or Right, Number of Securities Called by Warrants or Rights       8,255,148 132,265      
Preferred Stock Redemption Discount       $ 5,111,000 $ (0)      
Common Stock, Shares Authorized       100,000,000 100,000,000      
Common Stock, Par or Stated Value Per Share (in dollars per share)       $ 0.001 $ 0.001      
Common Stock, Shares, Issued (in shares)       7,832,644 4,778,263      
Common Stock, Shares, Outstanding, Ending Balance (in shares)       7,832,644 4,778,263      
Class of Warrant or Right, Outstanding       51,185,758 26,456,895      
Measurement Input, Expected Term [Member]                
Warrants and Rights Outstanding, Measurement Input   5.5            
Measurement Input, Price Volatility [Member]                
Warrants and Rights Outstanding, Measurement Input   1.3661            
Measurement Input, Discount Rate [Member]                
Warrants and Rights Outstanding, Measurement Input   0.0151            
Measurement Input, Expected Dividend Rate [Member]                
Warrants and Rights Outstanding, Measurement Input   0            
Common Warrants [Member]                
Class of Warrant or Right, Number of Securities Called by Warrants or Rights   807,500            
Class of Warrant or Right, Exercise Price of Warrants or Rights   $ 9.60            
Warrants and Rights Outstanding, Term   5 years            
Common Stock Warrants, Issued with Series D Convertible Preferred Stock [Member]                
Proceeds from Issuance of Warrants   $ 3,600,000            
Placement agent warrants issued in the January 2022 financing [Member]                
Class of Warrant or Right, Number of Securities Called by Warrants or Rights   66,500   66,500        
Class of Warrant or Right, Exercise Price of Warrants or Rights   $ 10.00   $ 10.00        
Warrants and Rights Outstanding, Term   5 years            
Class of Warrant or Right, Outstanding       1,330,000        
Registered Direct Pre-funded Warrants [Member]                
Class of Warrant or Right, Number of Securities Called by Warrants or Rights             784,019  
Stock Issued During Period, Shares, Warrants Exercised       784,019        
Private Pre-funded Warrants [Member]                
Class of Warrant or Right, Number of Securities Called by Warrants or Rights             1,369,864  
Private Pre-funded Warrants [Member] | Subsequent Event [Member]                
Stock Issued During Period, Shares, Warrants Exercised 747,864              
Class of Warrant or Right, Outstanding 622,000              
Class of Warrant or Right, Exercised (in shares) 747,864              
Pre-funded Warrants Issued in August 2022 Financing [Member]                
Class of Warrant or Right, Number of Securities Called by Warrants or Rights       1,369,864        
Class of Warrant or Right, Exercise Price of Warrants or Rights       $ 0.0001     $ 0.0001  
Class of Warrant or Right, Outstanding       1,369,864        
Series A Preferred Investment Options [Member]                
Class of Warrant or Right, Number of Securities Called by Warrants or Rights           2,853,883    
Class of Warrant or Right, Exercise Price of Warrants or Rights           $ 1.502    
Warrants and Rights Outstanding, Term           5 years 6 months    
Series B Financing Warrants [Member]                
Class of Warrant or Right, Number of Securities Called by Warrants or Rights           2,853,883    
Class of Warrant or Right, Exercise Price of Warrants or Rights           $ 1.502    
Warrants and Rights Outstanding, Term           2 years    
Placement Agent Preferred Investment Options [Member]                
Class of Warrant or Right, Number of Securities Called by Warrants or Rights           171,233    
Class of Warrant or Right, Exercise Price of Warrants or Rights           $ 2.19    
Warrants and Rights Outstanding, Term           5 years    
January 2022 Public Offering [Member]                
Proceeds from Issuance of Convertible Preferred Stock   $ 4.0            
Conversion of Series B Preferred Stock into Common Stock [Member]                
Conversion of Stock, Shares Converted         93      
Conversion of Stock, Shares Issued         18,600      
Conversion of Series D Preferred Stock into Common Stock [Member]                
Conversion of Stock, Shares Converted       7,600        
Conversion of Stock, Shares Issued       950,000        
Series A Preferred Stock [Member]                
Preferred Stock, Shares Outstanding, Ending Balance (in shares)       60,876 56,366      
Preferred Stock, Liquidation Preference Per Share       $ 1,000        
Preferred Stock, Convertible, Conversion Price       $ 400        
Dividends, Preferred Stock, Total       $ 4,500,000 $ 4,200,000      
Series A Preferred Stock [Member] | CRG [Member]                
Preferred Stock Dividends, Shares       4,510 4,175      
Series A Preferred Stock [Member] | Conversion of Principal Amount of Senior Secured Loan to Newly Authorized Series A Preferred Stock [Member]                
Preferred Stock, Dividend Rate, Percentage     8.00%          
Series B Preferred Stock [Member]                
Preferred Stock, Par or Stated Value Per Share               $ 0.001
Preferred Stock, Shares Outstanding, Ending Balance (in shares)       85 85      
Preferred Stock, Convertible, Conversion Price       $ 1.502 $ 1.502      
Series D Preferred Stock [Member]                
Preferred Stock, Par or Stated Value Per Share   $ 0.001            
Preferred Stock, Shares Outstanding, Ending Balance (in shares)       0        
Series D Preferred Stock [Member] | Common Warrants [Member]                
Class of Warrant or Right, Exercise Price of Warrants or Rights   $ 9.60            
Warrants and Rights Outstanding, Term   5 years            
Class of Warrant or Right, Outstanding   807,500            
Series D Preferred Stock [Member] | Placement agent warrants issued in the January 2022 financing [Member]                
Class of Warrant or Right, Number of Securities Called by Warrants or Rights   66,500            
Class of Warrant or Right, Exercise Price of Warrants or Rights   $ 10.00            
Warrants and Rights Outstanding, Term   5 years            
Series D Preferred Stock [Member] | January 2022 offering [Member]                
Preferred Stock, Par or Stated Value Per Share   $ 0.001            
Preferred Stock, Convertible, Conversion Price   $ 8.00            
Stock Issued During Period, Shares, New Issues   7,600            
Shares Issued, Price Per Share (in dollars per share)   $ 1,000            
Preferred Stock, Convertible, Shares Issuable   950,000            
Series D Preferred Stock [Member] | January 2022 offering [Member] | Common Warrants [Member]                
Conversion of Warrants Allowed Maximum Ownership of Common Stock Percentage   4.99%            
Conversion of Warrants Allowed Maximum Ownership of Common Stock Percentage upon Election   9.99%            
Series D Preferred Stock [Member] | January 2022 Public Offering [Member]                
Preferred Stock, Par or Stated Value Per Share   $ 1,000            
Preferred Stock, Convertible, Conversion Price   $ 8.00            
Stock Issued During Period, Shares, New Issues   7,600            
XML 64 R51.htm IDEA: XBRL DOCUMENT v3.22.4
Note 10 - Stockholder's Equity - Outstanding Warrants (Details) - $ / shares
Dec. 31, 2022
Aug. 04, 2022
Jan. 14, 2022
Dec. 31, 2021
Total outstanding and exercisable (in shares) 51,185,758     26,456,895
Underlying shares of common stock (in shares) 8,255,148     132,265
Series 1 February 2018 Warrants [Member]        
Total outstanding and exercisable (in shares) 8,979,000     8,979,000
Underlying shares of common stock (in shares) 44,895     44,895
Exercise price per share (in dollars per share) $ 400.00     $ 400.00
Series 2 February 2018 Warrants [Member]        
Total outstanding and exercisable (in shares) 8,709,500     8,709,500
Underlying shares of common stock (in shares) 43,548     43,548
Exercise price per share (in dollars per share) $ 400.00     $ 400.00
November 2018 Warrants [Member]        
Total outstanding and exercisable (in shares) 8,768,395     8,768,395
Underlying shares of common stock (in shares) 43,842     43,842
Exercise price per share (in dollars per share) $ 80.00     $ 80.00
Placement agent warrants issued in the January 2022 financing [Member]        
Total outstanding and exercisable (in shares) 1,330,000      
Underlying shares of common stock (in shares) 66,500   66,500  
Exercise price per share (in dollars per share) $ 10.00   $ 10.00  
Warrants Issued in the January 2022 Financing [Member]        
Total outstanding and exercisable (in shares) 16,150,000      
Underlying shares of common stock (in shares) 807,500      
Exercise price per share (in dollars per share) $ 9.60      
Pre-funded Warrants Issued in August 2022 Financing [Member]        
Total outstanding and exercisable (in shares) 1,369,864      
Underlying shares of common stock (in shares) 1,369,864      
Exercise price per share (in dollars per share) $ 0.0001 $ 0.0001    
Series A Private Investment Options Issued in August 2022 Financing [Member]        
Total outstanding and exercisable (in shares) 2,853,883      
Underlying shares of common stock (in shares) 2,853,883      
Exercise price per share (in dollars per share) $ 1.502      
Series B Private Investment Options Issued in August 2022 Financing [Member]        
Total outstanding and exercisable (in shares) 2,853,883      
Underlying shares of common stock (in shares) 2,853,883      
Exercise price per share (in dollars per share) $ 1.502      
Placement Agent Private Investment Options Issued in August 2022 Financing [Member]        
Total outstanding and exercisable (in shares) 171,233      
Underlying shares of common stock (in shares) 171,233      
Exercise price per share (in dollars per share) $ 2.19      
XML 65 R52.htm IDEA: XBRL DOCUMENT v3.22.4
Note 11 - Stock-based Compensation (Details Textual) - USD ($)
 12 Months Ended
Oct. 14, 2022
Dec. 31, 2022
Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)   0 0
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)   0 0
Share-Based Payment Arrangement, Expense   $ 127,000 $ 1,015,000
Share Price   $ 1.09  
Common Stock, Shares, Issued (in shares)   7,832,644 4,778,263
Share-Based Payment Arrangement, Option [Member]      
Share-Based Payment Arrangement, Expense   $ 0 $ 4,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total   0  
Share-Based Payment Arrangement, Expense, Tax Benefit   0 0
Restricted Stock Units (RSUs) [Member]      
Share-Based Payment Arrangement, Expense   100,000 1,000,000.0
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total   $ 100,000  
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition   2 months 12 days  
Sharebased Compensation Arrangement by Sharebased Payment Award Equity Instruments Other than Options Nonvested Fair Value   $ 100,000  
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value   $ 14,000 $ 273,000
Minimum [Member] | Common Stock Options [ member]      
Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent   110.00%  
Minimum [Member] | Restricted Stock Units (RSUs) [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)   3 years  
The 2015 Employee Stock Purchase Plan [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized 1,750,000    
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant   1,759,566  
Officer and Director Share Purchase Plan [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant   0  
Common Stock, Shares, Issued (in shares)   0 0
XML 66 R53.htm IDEA: XBRL DOCUMENT v3.22.4
Note 11 - Stock-Based Compensation - Stock Option Activity (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 12 Months Ended 228 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Options (in shares) 303 307  
Options, weighted average exercise price (in dollars per share) $ 19,360.30 $ 19,577.10  
Options, weighted average remaining contractual life (Year) 4 years 7 days 5 years 7 days 5 years 11 months 12 days
Options, intrinsic value $ 0 $ 0 $ 0
Options expired (in shares)   (4)  
Options expired, weighted average exercise price (in dollars per share)   $ 36,000.00  
Options (in shares) 303 303 307
Options, weighted average exercise price (in dollars per share) $ 19,360.30 $ 19,360.30 $ 19,577.10
Exercisable (in shares) 303    
Exercisable, weighted average exercise price (in dollars per share) $ 19,360.30    
Exercisable, weighted average remaining contractual life (Year) 4 years 7 days    
Exercisable, intrinsic value $ 0    
Vested and expected to vest (in shares) 303    
Vested and expected to vest, weighted average exercise price (in dollars per share) $ 19,360.30    
Vested and expected to vest, weighted average remaining contractual life (Year) 4 years 7 days    
Vested and expected to vest, intrinsic value $ 0    
XML 67 R54.htm IDEA: XBRL DOCUMENT v3.22.4
Note 11 - Stock-Based Compensation - Options Outstanding and Vested (Details)
shares in Thousands
 12 Months Ended
Dec. 31, 2022
$ / shares
shares
Options Outstanding (in shares) | shares 303
Weighted Average Remaining Contractual Life (Year) 4 years 7 days
Weighted Average Exercise Price (in dollars per share) $ 19,360.30
Number Exercisable (in shares) | shares 303
Weighted Average Exercise Price, options vested (in dollars per share) $ 19,360.30
Exercise Price Range 1 [Member]  
Exercise Price, Upper Limit (in dollars per share) $ 334.00
Options Outstanding (in shares) | shares 155
Weighted Average Remaining Contractual Life (Year) 5 years 5 months 8 days
Weighted Average Exercise Price (in dollars per share) $ 334.00
Number Exercisable (in shares) | shares 155
Weighted Average Exercise Price, options vested (in dollars per share) $ 334.00
Exercise Price Range 2 [Member]  
Exercise Price, Upper Limit (in dollars per share) $ 28,400.00
Options Outstanding (in shares) | shares 31
Weighted Average Remaining Contractual Life (Year) 4 years 2 months 4 days
Weighted Average Exercise Price (in dollars per share) $ 17,323.87
Number Exercisable (in shares) | shares 31
Weighted Average Exercise Price, options vested (in dollars per share) $ 17,323.87
Exercise Price, Lower Limit (in dollars per share) 16,400.00
Exercise Price Range 3 [Member]  
Exercise Price, Upper Limit (in dollars per share) $ 36,000.00
Options Outstanding (in shares) | shares 103
Weighted Average Remaining Contractual Life (Year) 2 years
Weighted Average Exercise Price (in dollars per share) $ 36,000.00
Number Exercisable (in shares) | shares 103
Weighted Average Exercise Price, options vested (in dollars per share) $ 36,000.00
Exercise Price Range 4 [Member]  
Exercise Price, Upper Limit (in dollars per share) $ 162,000.00
Options Outstanding (in shares) | shares 14
Weighted Average Remaining Contractual Life (Year) 2 years 10 months 6 days
Weighted Average Exercise Price (in dollars per share) $ 112,097.14
Number Exercisable (in shares) | shares 14
Weighted Average Exercise Price, options vested (in dollars per share) $ 112,097.14
Exercise Price, Lower Limit (in dollars per share) $ 103,680.00
XML 68 R55.htm IDEA: XBRL DOCUMENT v3.22.4
Note 11 - Stock-Based Compensation - Restricted Stock Units Award Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Awards outstanding, shares (in shares) 10,060 20,671  
Awards outstanding, Weighted Average Grant Date Fair Value (in dollars per share) $ 24.39 $ 76.03  
Awards outstanding, Weighted Average Remaining Contractual Term (Year) 2 months 1 day 8 months 19 days 11 months 23 days
Awarded, shares (in shares)   4,500  
Awarded, Weighted Average Grant Date Fair Value (in dollars per share)   $ 32.20  
Released, shares (in shares) (8,590) (13,386)  
Released, Weighted Average Grant Date Fair Value (in dollars per share) $ 25.02 $ 104.31  
Forfeited, shares (in shares) (1,053) (1,725)  
Forfeited, , Weighted Average Grant Date Fair Value (in dollars per share) $ 24.25 $ 53.62  
Awards outstanding, shares (in shares) 417 10,060 20,671
Awards outstanding, Weighted Average Grant Date Fair Value (in dollars per share) $ 11.64 $ 24.39 $ 76.03
XML 69 R56.htm IDEA: XBRL DOCUMENT v3.22.4
Note 11 - Stock-based Compensation - Noncash Stock-based Compensation Expense Related to Stock Options, ESPP, and RSUs (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Allocated Share-based Compensation Expense $ 127 $ 1,015
Cost of Sales [Member]    
Allocated Share-based Compensation Expense 18 101
Research and Development Expense [Member]    
Allocated Share-based Compensation Expense 37 287
Selling, General and Administrative Expenses [Member]    
Allocated Share-based Compensation Expense $ 72 $ 627
XML 70 R57.htm IDEA: XBRL DOCUMENT v3.22.4
Note 12 - Income Taxes (Details Textual) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Tax Expense (Benefit), Total $ 0 $ 0
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 5,100 4,700
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total 0 0
State and Local Jurisdiction [Member]    
Income Tax Expense (Benefit), Total 0 0
Operating Loss Carryforwards 208,000  
Domestic Tax Authority [Member]    
Operating Loss Carryforwards 344,300  
Operating Loss Carryforwards, Not Subject to Expiration 86,800  
Domestic Tax Authority [Member] | Research Tax Credit Carryforward [Member]    
Tax Credit Carryforward, Amount $ 4,300 $ 4,200
XML 71 R58.htm IDEA: XBRL DOCUMENT v3.22.4
Note 12 - Income Taxes - Effective Income Tax Reconciliation (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Tax at federal statutory rate $ (3,701) $ (3,657)
State taxes, net of federal benefit (916) (711)
Permanent differences (484) (445)
Change in valuation allowance 5,084 5,104
Research credits (273) (286)
Nondeductible interest expense 290 0
Other 0 (5)
Provision for taxes $ 0 $ 0
XML 72 R59.htm IDEA: XBRL DOCUMENT v3.22.4
Note 12 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Federal, state and foreign net operating losses $ 85,547 $ 83,211
Research and other credits 5,343 4,892
Operating lease liability 544 752
Fixed assets 471 0
Accruals and other 3,628 2,845
Capitalized research and development 1,019 0
Total deferred tax assets 96,552 91,700
Less: Valuation allowance (95,992) (90,908)
Total net deferred tax assets 560 792
Property and equipment 0 (2)
Operating lease right of use asset (560) (790)
Total deferred tax liabilities (560) (792)
Net deferred tax assets (liabilities) $ 0 $ 0
XML 73 R60.htm IDEA: XBRL DOCUMENT v3.22.4
Note 12 - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Balance at beginning of year $ 2,366 $ 2,307
Increase based on the tax positions in the current year 203 228
Increase (Decrease) for tax positions of prior year 12  
Increase (Decrease) for tax positions of prior year   (169)
Balance at end of year $ 2,581 $ 2,366
XML 74 R61.htm IDEA: XBRL DOCUMENT v3.22.4
Note 13 - 401(k) Plan (Details Textual) - Pension Plan [Member] - The 401(k) Plan [Member]
$ in Thousands
 12 Months Ended
Dec. 31, 2022
USD ($)
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent 99.00%
Defined Contribution Plan, Cost $ 0
XML 75 R62.htm IDEA: XBRL DOCUMENT v3.22.4
Note 14 - Subsequent Events (Details Textual) - $ / shares
Feb. 14, 2023
Jan. 18, 2023
Dec. 31, 2022
Dec. 31, 2021
Class of Warrant or Right, Outstanding     51,185,758 26,456,895
Share Price     $ 1.09  
Subsequent Event [Member]        
Share Price   $ 1.23    
Subsequent Event [Member] | Restricted Stock [Member] | Share-Based Payment Arrangement, Employee [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted   1,502,928    
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)   2 years    
Subsequent Event [Member] | Private Pre-funded Warrants [Member]        
Class of Warrant or Right, Exercised (in shares) 747,864      
Stock Issued During Period, Shares, Warrants Exercised 747,864      
Class of Warrant or Right, Outstanding 622,000      
XML 76 avgr20221231_10k_htm.xml IDEA: XBRL DOCUMENT 0001506928 2022-01-01 2022-12-31 0001506928 us-gaap:SubsequentEventMember 2023-01-18 0001506928 us-gaap:RestrictedStockMember us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:SubsequentEventMember 2023-01-18 2023-01-18 0001506928 avgr:PrivatePrefundedWarrantsMember us-gaap:SubsequentEventMember 2023-02-14 0001506928 avgr:PrivatePrefundedWarrantsMember us-gaap:SubsequentEventMember 2023-02-14 2023-02-14 0001506928 avgr:The401kPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-12-31 0001506928 2021-12-31 0001506928 2022-12-31 0001506928 2021-01-01 2021-12-31 0001506928 2020-12-31 0001506928 us-gaap:DomesticCountryMember us-gaap:ResearchMember 2021-12-31 0001506928 us-gaap:DomesticCountryMember us-gaap:ResearchMember 2022-12-31 0001506928 us-gaap:DomesticCountryMember 2022-12-31 0001506928 us-gaap:StateAndLocalJurisdictionMember 2022-12-31 0001506928 us-gaap:StateAndLocalJurisdictionMember 2021-01-01 2021-12-31 0001506928 us-gaap:StateAndLocalJurisdictionMember 2022-01-01 2022-12-31 0001506928 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-12-31 0001506928 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-12-31 0001506928 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001506928 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0001506928 us-gaap:CostOfSalesMember 2021-01-01 2021-12-31 0001506928 us-gaap:CostOfSalesMember 2022-01-01 2022-12-31 0001506928 avgr:OfficerAndDirectorSharePurchasePlanMember 2022-12-31 0001506928 avgr:OfficerAndDirectorSharePurchasePlanMember 2021-12-31 0001506928 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001506928 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001506928 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001506928 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001506928 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0001506928 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001506928 srt:MinimumMember us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001506928 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001506928 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001506928 us-gaap:EmployeeStockOptionMember 2022-12-31 0001506928 avgr:ExercisePriceRange4Member 2022-12-31 0001506928 avgr:ExercisePriceRange4Member 2022-01-01 2022-12-31 0001506928 avgr:ExercisePriceRange3Member 2022-12-31 0001506928 avgr:ExercisePriceRange3Member 2022-01-01 2022-12-31 0001506928 avgr:ExercisePriceRange2Member 2022-12-31 0001506928 avgr:ExercisePriceRange2Member 2022-01-01 2022-12-31 0001506928 avgr:ExercisePriceRange1Member 2022-12-31 0001506928 avgr:ExercisePriceRange1Member 2022-01-01 2022-12-31 0001506928 2002-01-01 2020-12-31 0001506928 srt:MinimumMember avgr:CommonStockOptionsMember 2022-01-01 2022-12-31 0001506928 avgr:The2015EmployeeStockPurchasePlanMember 2022-12-31 0001506928 avgr:The2015EmployeeStockPurchasePlanMember 2022-10-14 2022-10-14 0001506928 avgr:CommonWarrantsMember us-gaap:SeriesDPreferredStockMember avgr:January2022OfferingMember 2022-01-14 0001506928 avgr:PlacementAgentPreferredInvestmentOptionsMember 2022-08-31 0001506928 avgr:SeriesBFinancingWarrantsMember 2022-08-31 0001506928 avgr:SeriesAPreferredInvestmentOptionsMember 2022-08-31 0001506928 avgr:PrefundedWarrantsIssuedInAugust2022FinancingMember 2022-12-31 0001506928 avgr:RegisteredDirectPrefundedWarrantsMember 2022-01-01 2022-12-31 0001506928 avgr:PrefundedWarrantsIssuedInAugust2022FinancingMember 2022-08-04 0001506928 avgr:PrivatePrefundedWarrantsMember 2022-08-04 0001506928 avgr:RegisteredDirectPrefundedWarrantsMember 2022-08-04 0001506928 avgr:PlacementAgentWarrantsIssuedInTheJanuary2022FinancingMember 2022-01-14 0001506928 avgr:CommonWarrantsMember 2022-01-14 0001506928 avgr:November2018WarrantsMember 2021-12-31 0001506928 avgr:Series2February2018WarrantsMember 2021-12-31 0001506928 avgr:Series1February2018WarrantsMember 2021-12-31 0001506928 avgr:PlacementAgentPrivateInvestmentOptionsIssuedInAugust2022FinancingMember 2022-12-31 0001506928 avgr:SeriesBPrivateInvestmentOptionsIssuedInAugust2022FinancingMember 2022-12-31 0001506928 avgr:SeriesAPrivateInvestmentOptionsIssuedInAugust2022FinancingMember 2022-12-31 0001506928 avgr:WarrantsIssuedInTheJanuary2022FinancingMember 2022-12-31 0001506928 avgr:PlacementAgentWarrantsIssuedInTheJanuary2022FinancingMember 2022-12-31 0001506928 avgr:November2018WarrantsMember 2022-12-31 0001506928 avgr:Series2February2018WarrantsMember 2022-12-31 0001506928 avgr:Series1February2018WarrantsMember 2022-12-31 0001506928 us-gaap:MeasurementInputExpectedDividendRateMember 2022-01-14 0001506928 us-gaap:MeasurementInputDiscountRateMember 2022-01-14 0001506928 us-gaap:MeasurementInputPriceVolatilityMember 2022-01-14 0001506928 us-gaap:MeasurementInputExpectedTermMember 2022-01-14 0001506928 avgr:CommonStockWarrantsIssuedWithSeriesDConvertiblePreferredStockMember 2022-01-14 2022-01-14 0001506928 avgr:January2022PublicOfferingMember 2022-01-14 2022-01-14 0001506928 us-gaap:SeriesDPreferredStockMember 2022-12-31 0001506928 avgr:ConversionOfSeriesDPreferredStockIntoCommonStockMember 2022-01-01 2022-12-31 0001506928 us-gaap:SeriesDPreferredStockMember avgr:January2022OfferingMember 2022-01-14 0001506928 us-gaap:SeriesDPreferredStockMember avgr:January2022OfferingMember 2022-01-14 2022-01-14 0001506928 us-gaap:SeriesBPreferredStockMember 2021-12-31 0001506928 us-gaap:SeriesBPreferredStockMember 2022-12-31 0001506928 avgr:ConversionOfSeriesBPreferredStockIntoCommonStockMember 2021-01-01 2021-12-31 0001506928 us-gaap:SeriesBPreferredStockMember 2018-02-16 0001506928 us-gaap:SeriesAPreferredStockMember 2021-01-01 2021-12-31 0001506928 us-gaap:SeriesAPreferredStockMember 2022-01-01 2022-12-31 0001506928 us-gaap:SeriesAPreferredStockMember 2022-12-31 0001506928 us-gaap:SeriesAPreferredStockMember 2021-12-31 0001506928 avgr:CRGMember us-gaap:SeriesAPreferredStockMember 2021-01-01 2021-12-31 0001506928 avgr:CRGMember us-gaap:SeriesAPreferredStockMember 2022-01-01 2022-12-31 0001506928 avgr:ConversionOfPrincipalAmountOfSeniorSecuredLoanToNewlyAuthorizedSeriesAPreferredStockMember us-gaap:SeriesAPreferredStockMember 2018-02-14 2018-02-14 0001506928 us-gaap:PurchaseCommitmentMember 2022-12-31 0001506928 2019-04-01 0001506928 avgr:PaycheckProtectionProgramCARESActMember 2022-01-01 2022-12-31 0001506928 avgr:PaycheckProtectionProgramCARESActMember 2021-04-01 2021-04-30 0001506928 avgr:PaycheckProtectionProgramCARESActMember us-gaap:OtherNonoperatingIncomeExpenseMember 2021-04-01 2021-04-30 0001506928 avgr:PaycheckProtectionProgramCARESActMember 2020-04-23 2020-04-23 0001506928 avgr:CRGMember avgr:LoanAgreementMember 2021-01-01 2021-12-31 0001506928 avgr:CRGMember avgr:LoanAgreementMember 2022-01-01 2022-12-31 0001506928 avgr:CRGMember avgr:LoanAgreementMember 2021-12-31 0001506928 avgr:CRGMember avgr:LoanAgreementMember 2022-12-31 0001506928 avgr:CRGMember avgr:LoanAgreementMember 2015-09-22 0001506928 avgr:LoanAgreementMember avgr:CRGMember 2022-12-31 0001506928 avgr:CRGMember avgr:LoanAgreementMember 2022-08-10 0001506928 avgr:CRGMember avgr:LoanAgreementMember 2022-08-10 2022-08-10 0001506928 avgr:CRGMember avgr:LoanAgreementMember 2018-02-14 0001506928 avgr:SeriesAPreferredStockPurchaseAgreementWithCRGMember avgr:CRGMember avgr:LoanAgreementMember 2018-02-14 2018-02-14 0001506928 avgr:SecondTrancheBorrowedOnJune152016Member avgr:CRGMember avgr:LoanAgreementMember 2016-06-15 0001506928 avgr:FirstTrancheBorrowedOnSeptember222015Member avgr:CRGMember avgr:LoanAgreementMember 2015-09-22 0001506928 avgr:LeasedEquipmentMember 2021-01-01 2021-12-31 0001506928 avgr:LeasedEquipmentMember 2022-01-01 2022-12-31 0001506928 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001506928 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001506928 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001506928 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001506928 us-gaap:ComputerEquipmentMember 2021-12-31 0001506928 us-gaap:ComputerEquipmentMember 2022-12-31 0001506928 us-gaap:SoftwareDevelopmentMember 2021-12-31 0001506928 us-gaap:SoftwareDevelopmentMember 2022-12-31 0001506928 us-gaap:MachineryAndEquipmentMember 2021-12-31 0001506928 us-gaap:MachineryAndEquipmentMember 2022-12-31 0001506928 avgr:EquipmentHeldByCustomersMember 2021-12-31 0001506928 avgr:EquipmentHeldByCustomersMember 2022-12-31 0001506928 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001506928 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001506928 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001506928 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001506928 country:US us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001506928 country:US us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001506928 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001506928 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001506928 us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001506928 us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001506928 avgr:CommonStockOptionsMember 2021-01-01 2021-12-31 0001506928 avgr:CommonStockOptionsMember 2022-01-01 2022-12-31 0001506928 avgr:CommonStockWarrantsMember 2021-01-01 2021-12-31 0001506928 avgr:CommonStockWarrantsMember 2022-01-01 2022-12-31 0001506928 2022-01-01 2022-01-31 0001506928 srt:MaximumMember 2022-01-01 2022-12-31 0001506928 srt:MinimumMember 2022-01-01 2022-12-31 0001506928 avgr:OneCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001506928 avgr:OneCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001506928 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001506928 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001506928 avgr:OneCustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001506928 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001506928 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001506928 avgr:ReverseStockSplitMember 2022-03-11 2022-03-11 0001506928 avgr:CommonStockInJune2022Member 2022-01-01 2022-12-31 0001506928 avgr:CommonStockInJune2022Member 2022-12-31 0001506928 avgr:CommonStockInJune2022Member 2022-05-20 0001506928 avgr:SeriesBPreferredInvestmentOptionsMember 2022-08-31 0001506928 avgr:PrefundedWarrantsMember 2022-12-31 0001506928 avgr:RegisteredDirectPrefundedWarrantsMember us-gaap:PrivatePlacementMember 2022-08-04 0001506928 avgr:August2022PurchaseAgreementMember 2022-08-04 2022-08-04 0001506928 us-gaap:PrivatePlacementMember 2022-08-04 2022-08-04 0001506928 us-gaap:PrivatePlacementMember 2022-08-04 0001506928 avgr:August2022PurchaseAgreementMember 2022-08-04 0001506928 avgr:PlacementAgentWarrantsIssuedInTheJanuary2022FinancingMember us-gaap:SeriesDPreferredStockMember 2022-01-14 0001506928 avgr:CommonWarrantsMember us-gaap:SeriesDPreferredStockMember 2022-01-14 0001506928 us-gaap:SeriesDPreferredStockMember avgr:January2022PublicOfferingMember 2022-01-14 0001506928 us-gaap:SeriesDPreferredStockMember 2022-01-14 0001506928 us-gaap:SeriesDPreferredStockMember avgr:January2022PublicOfferingMember 2022-01-14 2022-01-14 0001506928 avgr:February2021PulicOfferingMember 2021-02-02 2021-02-02 0001506928 avgr:February2021PulicOfferingMember 2021-02-02 0001506928 avgr:February2021PulicOfferingMember 2021-02-01 2021-02-28 0001506928 avgr:January2022PublicOfferingMember 2022-01-01 2022-12-31 0001506928 avgr:TheMarketOfferingAgreementTheAtmAgreementMember 2022-01-01 2022-12-31 0001506928 avgr:August2022PublicOfferingMember 2022-08-01 2022-08-31 0001506928 us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001506928 us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001506928 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001506928 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001506928 us-gaap:RetainedEarningsMember 2022-12-31 0001506928 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001506928 us-gaap:CommonStockMember 2022-12-31 0001506928 us-gaap:PreferredStockMember 2022-12-31 0001506928 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001506928 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001506928 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001506928 us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001506928 us-gaap:SeriesDPreferredStockMember 2022-01-01 2022-12-31 0001506928 us-gaap:RetainedEarningsMember us-gaap:SeriesDPreferredStockMember 2022-01-01 2022-12-31 0001506928 us-gaap:AdditionalPaidInCapitalMember us-gaap:SeriesDPreferredStockMember 2022-01-01 2022-12-31 0001506928 us-gaap:CommonStockMember us-gaap:SeriesDPreferredStockMember 2022-01-01 2022-12-31 0001506928 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2022-01-01 2022-12-31 0001506928 us-gaap:RetainedEarningsMember avgr:January2022PublicOfferingMember 2022-01-01 2022-12-31 0001506928 us-gaap:AdditionalPaidInCapitalMember avgr:January2022PublicOfferingMember 2022-01-01 2022-12-31 0001506928 us-gaap:CommonStockMember avgr:January2022PublicOfferingMember 2022-01-01 2022-12-31 0001506928 us-gaap:PreferredStockMember avgr:January2022PublicOfferingMember 2022-01-01 2022-12-31 0001506928 us-gaap:RetainedEarningsMember 2021-12-31 0001506928 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001506928 us-gaap:CommonStockMember 2021-12-31 0001506928 us-gaap:PreferredStockMember 2021-12-31 0001506928 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001506928 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001506928 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001506928 us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001506928 us-gaap:RetainedEarningsMember 2020-12-31 0001506928 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001506928 us-gaap:CommonStockMember 2020-12-31 0001506928 us-gaap:PreferredStockMember 2020-12-31 0001506928 avgr:SecSchedule1209AllowanceSalesReturnsMember 2022-12-31 0001506928 avgr:SecSchedule1209AllowanceSalesReturnsMember 2022-01-01 2022-12-31 0001506928 avgr:SecSchedule1209AllowanceSalesReturnsMember 2021-12-31 0001506928 avgr:SecSchedule1209AllowanceSalesReturnsMember 2021-01-01 2021-12-31 0001506928 avgr:SecSchedule1209AllowanceSalesReturnsMember 2020-12-31 0001506928 us-gaap:AllowanceForCreditLossMember 2022-12-31 0001506928 us-gaap:AllowanceForCreditLossMember 2022-01-01 2022-12-31 0001506928 us-gaap:AllowanceForCreditLossMember 2021-12-31 0001506928 us-gaap:AllowanceForCreditLossMember 2021-01-01 2021-12-31 0001506928 us-gaap:AllowanceForCreditLossMember 2020-12-31 0001506928 2023-03-10 0001506928 2022-06-30 thunderdome:item iso4217:USD shares utr:Y shares iso4217:USD pure 0001506928 false --12-31 2022 FY P2Y 0 0 0 0 0 0 0 0 P3Y 0 0 0 0 0 0 0 0.0999 P5Y P2Y P5Y6M P5Y P5Y 0 314000000000 314000000000 0 0 0 0 0 0 0 0 1 0 0 0 0 P1Y P5Y P3Y 1 1 1 0 0 0 P5Y P2Y P5Y6M P5Y P5Y 10-K true 2022-12-31 false 001-36817 AVINGER, INC. DE 20-8873453 400 Chesapeake Drive Redwood City CA 94063 650 241-7900 Common Stock, par value $0.001 per share AVGR NASDAQ No No Yes Yes Non-accelerated Filer true false false false 8800000 8614508 Moss Adams LLP San Francisco, CA 659 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 36pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>(a)(2)</b></p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Financial Statement Schedules</b></p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">All other schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto. Financial statement schedules relating to the allowance for doubtful accounts receivable and for sales returns follows (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Description</b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Balance at</b><br/> <b>Beginning</b><br/> <b>of Year</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Charged to</b><br/> <b>costs and</b><br/> <b>expenses</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Write offs</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Balance at</b><br/> <b>End of</b><br/> <b>Year</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Allowance for doubtful accounts receivable:</b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Fiscal year ended 2021</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">19</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Fiscal year ended 2022</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">70</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">73</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Balance at</b><br/> <b>Beginning</b><br/> <b>of Year</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Charged to</b><br/> <b>costs and</b><br/> <b>expenses</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Write offs</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Balance at</b><br/> <b>End of</b><br/> <b>Year</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Allowance for sales returns:</b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Fiscal year ended 2021</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">20</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">20</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Fiscal year ended 2022</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">20</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Description</b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Balance at</b><br/> <b>Beginning</b><br/> <b>of Year</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Charged to</b><br/> <b>costs and</b><br/> <b>expenses</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Write offs</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Balance at</b><br/> <b>End of</b><br/> <b>Year</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Allowance for doubtful accounts receivable:</b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Fiscal year ended 2021</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">19</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Fiscal year ended 2022</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">70</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">73</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Balance at</b><br/> <b>Beginning</b><br/> <b>of Year</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Charged to</b><br/> <b>costs and</b><br/> <b>expenses</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Write offs</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Balance at</b><br/> <b>End of</b><br/> <b>Year</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Allowance for sales returns:</b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Fiscal year ended 2021</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">20</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">20</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Fiscal year ended 2022</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">20</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> 19000 2000 15000 6000 6000 70000 3000 73000 20000 10000 10000 20000 20000 0 5000 15000 14603000 19497000 73000 6000 1057000 1393000 4965000 4601000 362000 300000 20987000 25791000 2194000 3179000 702000 95000 312000 420000 24195000 29485000 631000 1394000 1401000 1609000 657000 718000 1092000 985000 14165000 0 17946000 4706000 0 12287000 1102000 2194000 1001000 575000 20049000 19762000 0.001 0.001 5000000 5000000 60961 60961 56451 56451 60876000 56366000 0 0 0.001 0.001 100000000 100000000 7832644 7832644 4778263 4778263 8000 5000 406514000 394471000 -402376000 -384753000 4146000 9723000 24195000 29485000 8273000 10130000 5619000 6706000 2654000 3424000 4390000 5900000 14221000 15625000 18611000 21525000 -15957000 -18101000 1665000 1648000 -1000 2337000 -17623000 -17412000 4510000 4175000 5111000 -0 -27244000 -21587000 -4.36 -4.57 6249000 4722000 52369 4246308 4000 380413000 -367341000 13076000 0 500000 1000 13043000 0 13043000 -93 18600 0 13355 0 1015000 0 1015000 4175 0 0 4175000 0 4175000 -0 4175000 -0 4175000 0 0 -17412000 -17412000 56451 4778263 5000 394471000 -384753000 9723000 0 1285603 1000 5195000 0 5196000 7600 0 0 6721000 0 6721000 -7600 950000 1000 0 0 1000 0 784019 1000 0 0 1000 0 26169 0 0 0 0 0 8590 0 0 0 0 0 127000 0 127000 4510 0 0 4510000 0 4510000 -0 4510000 -0 4510000 0 0 -17623000 -17623000 60961 7832644 8000 406514000 -402376000 4146000 -17623000 -17412000 196000 687000 83000 86000 127000 1015000 1795000 1564000 93000 133000 272000 125000 -0 2353000 -69000 -2000 -269000 -89000 1387000 849000 62000 -50000 -15000 43000 -764000 679000 -208000 -94000 -61000 49000 426000 575000 -16760000 -15697000 51000 34000 -51000 -34000 6721000 0 5196000 13043000 11917000 13043000 -4894000 -2688000 19497000 22185000 14603000 19497000 4510000 4175000 4510000 4175000 751000 -1000 0 21000 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>1.</b></p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Organization</b></p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Organization, Nature of Business</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Avinger, Inc. (the “Company”), a Delaware corporation, was incorporated in March 2007. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease (“PAD”). Patients with PAD have a build-up of plaque in the arteries that supply blood to areas away from the heart, particularly the pelvis and legs. The Company manufactures and sells a suite of products in the United States (“U.S.”) and in select international markets. The Company has developed its Lumivascular platform, which integrates optical coherence tomography (“OCT”) visualization with interventional catheters and is the industry’s only system that provides real-time intravascular imaging during the treatment portion of PAD procedures. The Company’s Lumivascular platform consists of a capital component, Lightbox consoles, as well as a variety of disposable catheter products. The Company’s current catheter products include Ocelot and Tigereye, which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (“CTO”). The Company also has image-guided atherectomy products, Pantheris and Pantheris SV, which are designed to allow physicians to precisely remove arterial plaque in PAD patients. The Company is in the process of developing next-generation CTO crossing devices to target coronary CTO markets. The Company is located in Redwood City, California.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Liquidity Matters</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2014-15, <i>Presentation of Financial Statements - Going Concern (Subtopic 205-40)</i> requires the Company to make certain disclosures if it concludes that there is substantial doubt about the entity’s ability to continue as a going concern within one year from the date of the issuance of these financial statements.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In the course of its activities, the Company has incurred losses and negative cash flows from operations since its inception. As of December 31, 2022, the Company had an accumulated deficit of $402.4 million. The Company expects to incur losses for the foreseeable future. The Company believes that its cash and cash equivalents of $14.6 million at December 31, 2022 and expected revenues from operations will be sufficient to allow the Company to fund its current operations through the end of the third quarter of 2023. The Company received net proceeds of approximately $4.4 million from the sale of its common stock in August 2022, $0.8 million from the sale of its common stock under an At The Market Offering Agreement during the year ended December 31, 2022, $6.7 million from the January 2022 Series D preferred stock and $13.0 million from the sale of its common stock in February 2021. The Company may seek to raise additional funds in future equity offerings to meet its operational needs and capital requirements for product development, clinical trials and commercialization or other strategic objectives.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company can provide no assurance that it will be successful in raising funds pursuant to additional equity or debt financings or that such funds will be raised at prices that do not create substantial dilution for its existing stockholders. Given the volatility in the Company’s stock price, any financing that the Company may undertake in the next twelve months could cause substantial dilution to its existing stockholders, and there can be no assurance that the Company will be successful in acquiring additional funding at levels sufficient to fund its various endeavors. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. In addition, the COVID-19 pandemic and macroeconomic environment have in the past and could result in reduced consumer and investor confidence, instability in the credit and financial markets, volatile corporate profits, restrictions on elective medical procedures, and reduced business and consumer spending, which could increase the cost of capital and/or limit the availability of capital to the Company.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">If the Company is unable to raise additional capital in sufficient amounts or on terms acceptable to it, the Company may have to significantly reduce its operations or delay, scale back or discontinue the development and sale of one or more of its products. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company’s ultimate success will largely depend on its continued development of innovative medical technologies, its ability to successfully commercialize its products and its ability to raise significant additional funding.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Additionally, due to the substantial doubt about the Company’s ability to continue operating as a going concern and the “Material Adverse Change” clause in the Loan Agreement with CRG Partners III L.P. and certain of its affiliated funds (collectively “CRG”), the entire amount of outstanding borrowings at December 31, 2022 and 2021 has been classified as current in these financial statements. CRG has not purported that an Event of Default (as defined in the Loan Agreement) has occurred due to a Material Adverse Change.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Currently all of our cash and cash equivalents are held at a single financial institution, Silicon Valley Bank. On March 10, 2023, the Federal Deposit Insurance Corporation announced that Silicon Valley Bank had been closed by the California Department of Financial Protection and Innovation. While we have regained access to our accounts at Silicon Valley Bank and are evaluating our banking relationships, future disruptions of financial institutions where we bank or have credit arrangements, or disruptions of the financial services industry in general, could adversely affect our ability to access our cash and cash equivalents. If we are unable to access our cash and cash equivalents as needed, our financial position and ability to operate our business will be adversely affected.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Public Offerings</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Past Offerings</i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On February 2, 2021, under a shelf registration statement, the Company completed a bought deal offering of 500,000 shares of common stock at an offering price of $28.80 per share. As a result, the Company received aggregate net proceeds of approximately $13.0 million after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><i>January 2022 Offering</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On January 14, 2022, the Company entered into a securities purchase agreement with several institutional investors pursuant to which the Company agreed to sell and issue, in a registered direct offering (“January 2022 Offering”), an aggregate of 7,600 shares of the Company’s Series D Convertible Preferred Stock, par value of $0.001 per share, at an offering price of $1,000 per share which was convertible into common stock at a conversion price of $8.00 per share. Concurrently, the Company agreed to issue to these investors warrants to purchase up to an aggregate of 807,500 shares of the Company’s common stock (the “Common Warrants”). As a result, the Company received aggregate net proceeds of approximately $6.7 million after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The 807,500 Common Warrants have an exercise price of $9.60 per share and became exercisable beginning July 14, 2022. The Common Warrants will expire <span style="-sec-ix-hidden:c423">five</span> years following the time they become exercisable, or July 14, 2027. The Company also issued to the Placement Agent or its designees warrants to purchase up to an aggregate of 66,500 shares of common stock (the “Placement Agent Warrants”). The Placement Agent Warrants are subject to the same terms as the Common Warrants, except that the Placement Agent Warrants have an exercise price of $10.00 per share and a term of <span style="-sec-ix-hidden:c426">five</span> years from the commencement of the sales pursuant to the January 2022 Offering, or January 12, 2027.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>August 2022 Offering</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On August 4, 2022, the Company entered into a securities purchase agreement with a single institutional investor for the issuance and sale of 1,484,019 shares of its common stock in a registered direct offering (“RD” or “Registered Direct”) at a purchase price of $1.752 per share, or pre-funded warrants in lieu thereof. In a concurrent private placement, the Company also agreed to issue and sell to the investor 1,369,864 shares of common stock at the same purchase price as in the registered direct offering, or pre-funded warrants in lieu thereof (“Private Placement” and together with the Registered Direct offering the “August 2022 Offering”). As a result, the Company received aggregate net proceeds of approximately $4.4 million after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As a result, in the Registered Direct offering, the Company issued (i) 700,000 shares of common stock, (ii) and pre-funded warrants in lieu of common stock to purchase up to an aggregate of 784,019 shares of common stock (the “RD Pre-Funded Warrants”) and in the Private Placement, the Company issued pre-funded warrants to purchase up to an aggregate of 1,369,864 shares of common stock (the “Private Placement Pre-Funded Warrants” and together with the RD Pre-Funded Warrants the “August 2022 Pre-Funded Warrants”). As of December 31, 2022, Pre-Funded Warrants exercisable for 622,000 shares of the Company’s common stock remained outstanding.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In addition, the Company issued to the investor in the August 2022 Offering Series A preferred investment options to purchase up to 2,853,883 additional shares of the Company’s common stock and Series B preferred investment options to purchase up to 2,853,883 additional shares of the Company’s common stock (the “Preferred Investment Options”). The Series A preferred investment options have an exercise price of $1.502 per share, are immediately exercisable, and will expire <span style="-sec-ix-hidden:c439">five</span> and one-half years from the date of issuance, or February 8, 2028, and the Series B preferred investment options have an exercise price of $1.502 per share, are immediately exercisable, and will expire <span style="-sec-ix-hidden:c441">two</span> years from the date of issuance, or August 8, 2024. The Company also issued to the Placement Agent or its designees preferred investment options to purchase up to an aggregate of 171,233 shares of common stock (the “Placement Agent Preferred Investment Options”). The Placement Agent Preferred Investment Options are subject to the same terms as the Preferred Investment Options, except that the Placement Agent Preferred Investment Options have an exercise price of $2.19 per share and a term of <span style="-sec-ix-hidden:c444">five</span> years from the commencement of the sales pursuant to the August 2022 Offering, or August 3, 2027.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><i>At The Market Offering Agreement</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On May 20, 2022, the Company entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright &amp; Co., LLC (the “Agent”), as sales agent, pursuant to which the Company may offer and sell shares of common stock, par value $0.001 per share (the “Shares”) up to an aggregate offering price of $7,000,000 from time to time, in an at the market public offering. Sales of the Shares are to be made at prevailing market prices at the time of sale, or as otherwise agreed with the Agent. The Agent will receive a commission from the Company of 3.0% of the gross proceeds of any Shares sold under the ATM Agreement. The Shares sold under the ATM Agreement are offered and sold pursuant to the Company’s shelf registration statement on Form S-3, which was initially filed with the Securities and Exchange Commission (the “SEC”) on March 29, 2022 and declared effective on April 7, 2022, and a prospectus supplement and the accompanying prospectus relating to the At The Market Offering filed with the SEC on May 20, 2022. During the year ended December 31, 2022, the Company sold 585,603 shares of common stock pursuant to the ATM Agreement at an average price of $1.67 per share for aggregate proceeds of $1.0 million, of which approximately $29,000 was paid in the form of commissions to the Agent. Other than the ATM Agreement, the Company currently does not have any commitments to obtain additional funds. On August 3, 2022, the Company suspended sales under the ATM Agreement. The Company plans to reactivate the ATM Agreement in March 2023 and may resume sales in the future. However, there can be no assurance that the Company will be successful in acquiring additional funding through these means.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> -402400000 14600000 4400000 800000 6700000 13000000.0 500000 28.80 13000000.0 7600 0.001 1000 8.00 807500 6700000 807500 9.60 66500 10.00 1484019 1.752 1.752 1369864 4400000 700000 784019 1369864 622000 2853883 2853883 1.502 1.502 171233 2.19 0.001 7000000 0.030 585603 1.67 1000000.0 29000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>2. Summary of Significant Accounting Policies</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Basis of Presentation</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”).</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On March 11, 2022, the Company’s Board of Directors approved an amendment to the Company’s amended and restated certificate of incorporation to effect a 1-for-20 reverse stock split of the Company’s issued and outstanding common stock. The reverse stock split became effective on March 14, 2022. The par value of the common stock and preferred stock was not adjusted as a result of the reverse stock split. All common stock, stock options, restricted stock units, and per share amounts in the financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split. Additionally, the common stock at par and related additional paid-in capital amounts as of December 31, 2021 in the balance sheet, the common stock at par and related additional paid-in capital amounts in the Statement of Stockholder’s Equity as of December 31, 2021 and 2020, and for the year ended December 31, 2021 have also been retroactively reclassified to give effect to the reverse stock split.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Use of Estimates</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to its stock-based compensation, accruals related to compensation, the valuation of the common stock warrants, provisions for doubtful accounts receivable and excess and obsolete inventories, clinical trial accruals, and its reserves for sales returns and warranty costs. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Fair Value of Financial Instruments</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company has evaluated the estimated fair value of its financial instruments as of December 31, 2022 and 2021. Financial instruments consist of cash and cash equivalents, accounts receivable and payable, and other current liabilities and borrowings. The carrying amounts of cash and cash equivalents, accounts receivable and payable, and other current liabilities approximate their respective fair values because of the short-term nature of those instruments. Based upon the borrowing terms and conditions currently available to the Company, the carrying values of the borrowings approximate their fair value.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Cash and Cash Equivalents</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents are considered available-for-sale marketable securities and are recorded at fair value, based on quoted market prices. As of December 31, 2022 and 2021, the Company’s cash equivalents are entirely comprised of investments in money market funds. Any related unrealized gains and losses are recorded in other comprehensive income (loss) and included as a separate component of stockholders’ equity. There were <span style="-sec-ix-hidden:c459"><span style="-sec-ix-hidden:c460">no</span></span> unrealized gains and losses as of December 31, 2022 and 2021. Any realized gains and losses and interest and dividends on available-for-sale securities are included in interest income or expense and computed using the specific identification cost method.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Concentration of Credit Risk, and Other Risks and Uncertainties</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and accounts receivable to the extent of the amounts recorded on the balance sheets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company’s policy is to invest in cash and cash equivalents, consisting of money market funds. These financial instruments are held in Company accounts at one financial institution, Silicon Valley Bank. The counterparties to the agreements relating to the Company’s investments consist of financial institutions of high credit standing. The Company provides for uncollectible amounts when specific credit problems arise. Management’s estimates for uncollectible amounts have been adequate, and management believes that all significant credit risks have been identified at December 31, 2022 and 2021. On March 10, 2023, the Federal Deposit Insurance Corporation announced that Silicon Valley Bank had been closed by the California Department of Financial Protection and Innovation. While we have regained access to our accounts at Silicon Valley Bank and are evaluating our banking relationships, future disruptions of financial institutions where we bank or have credit arrangements, or disruptions of the financial services industry in general, could adversely affect our ability to access our cash and cash equivalents. If we are unable to access our cash and cash equivalents as needed, our financial position and ability to operate our business will be adversely affected. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company’s accounts receivable are due from a variety of healthcare organizations in the United States and select international markets. The Company provides for uncollectible amounts when specific credit problems arise. Management's estimates for uncollectible amounts have been adequate, and management believes that all significant credit risks have been identified at December 31, 2022 and 2021. At December 31, 2022, there was <span style="-sec-ix-hidden:c461">no</span> customer that represented 10% or more of the Company’s accounts receivable, whereas at December 31 2021, there was <span style="-sec-ix-hidden:c462">one</span> customer that represented 21% of accounts receivable. For the year ended December 31, 2022 and 2021, there was <span style="-sec-ix-hidden:c464"><span style="-sec-ix-hidden:c465">one</span></span> customer that represented approximately 14% and 10% of revenues, respectively. Disruption of sales orders or a deterioration of financial condition of its customers would have a negative impact on the Company’s financial position and results of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company manufactures its commercial products in-house, including the Pantheris and Ocelot family of catheters. Certain of the Company’s product components and sub-assemblies are manufactured by sole suppliers, including internally. Disruption in component or sub-assembly supply from these manufacturers or from in-house production would have a negative impact on the Company’s financial position and results of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company is subject to certain risks, including that its devices may not be approved or cleared for marketing by governmental authorities or be successfully marketed. There can be no assurance that the Company’s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and with appropriate performance characteristics. The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, dependence upon third-party payors to provide adequate coverage and reimbursement, dependence on key personnel and suppliers, protection of proprietary technology, product liability claims, and compliance with government regulations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Existing or future devices developed by the Company may require approvals or clearances from the FDA or international regulatory agencies. In addition, in order to continue the Company’s operations, compliance with various federal and state laws is required. If the Company were denied or delayed in receiving such approvals or clearances, it may be necessary to adjust operations to align with the Company’s currently approved portfolio. If clearance for the products in the current portfolio were withdrawn by the FDA, this may have a material adverse impact on the Company.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Disruption of our supply chain capabilities due to trade restrictions, political instability, severe weather, natural disasters, public health crises, terrorism, product recalls, labor supply or stoppages, the financial or operational instability of key suppliers and carriers, government restrictions or measures, or other reasons could impair our ability to distribute our products. The Company believes COVID-19 and the subsequent burdens on the hospital systems has had and will continue to have an adverse effect on its ability to generate sales due to the fluctuating and unpredictable levels of capacity medical providers have to perform procedures that require the use of its products.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company is closely monitoring general economic conditions on global supply chain, manufacturing, and logistics operations. As inflationary pressures increase, the Company anticipates that its production and operating costs may similarly increase, including costs and availability of materials and labor. While the Company has sufficient inventory on-hand to meet its current production requirements and customer demand, it has experienced some constraints with respect to the availability of certain materials and extended lead times from certain key suppliers. The Company has also experienced some delays in shipping products to its customers. Any significant delay or interruption in our supply chain could impair the Company’s ability to meet the demands of its customers in the future and could harm its business.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We use technology in substantially all aspects of our business operations, and our ability to serve customers most effectively depends on the reliability of our technology systems. Cybersecurity incidents can include computer viruses, computer denial-of-service attacks, worms, and other malicious software programs or other attacks, covert introduction of malware to computers and networks, impersonation of authorized users, and efforts to discover and exploit any design flaws, bugs, security vulnerabilities or security weaknesses, as well as intentional or unintentional acts by employees or other insiders with access privileges, intentional acts of vandalism by third parties and sabotage.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In addition, our technology infrastructure and systems are vulnerable to damage or interruption from natural disasters, power loss and telecommunications failures. Any such disruption to our systems, or the technology systems of third parties on which we rely, the failure of these systems to otherwise perform as anticipated, or the theft, destruction, loss, misappropriation, or release of sensitive and/or confidential information or intellectual property, could require us to notify affected individuals, federal or state agencies or media outlets of the incident and could result in business disruption, negative publicity, loss of customers, potential liability, including litigation or other legal actions against us or the imposition of penalties, fines, fees or liabilities, which may not be covered by our insurance policies, and competitive disadvantage, any or all of which would potentially adversely affect our customer service, decrease the volume of our business and result in increased costs and lower profits. Moreover, a cybersecurity breach could require us to devote significant management resources to address the problems associated with the breach and to expend significant additional resources to upgrade further the security measures we employ to protect information against cyber-attacks and other wrongful attempts to access such information, which could result in a disruption of our operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">While we have invested, and continue to invest, in technology security initiatives and other measures to prevent security breaches and cyber incidents, as well as disaster recovery plans, these initiatives and measures may not be entirely effective to insulate us from technology disruption that could result in adverse effects on our results of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Accounts Receivable</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable. The Company determines the allowance for doubtful accounts based upon an aging of accounts receivable, historical experience, and management judgment. Accounts receivable balances are reviewed individually for collectability. To date, the Company has not experienced significant credit-related losses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Accounts receivable allowance for doubtful accounts provision and recoveries or write-offs are summarized as follows (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Beginning balance</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">19</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Provision</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">70</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Recoveries/write-offs</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(15</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Ending balance</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">73</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Inventories</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Inventories are valued at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method for all inventories. The Company’s policy is to write down inventory that has expired or become obsolete, inventory that has a cost basis in excess of its expected net realizable value, and inventory in excess of expected requirements. At each balance sheet date, management evaluates inventories for excess quantities, and obsolescence. This evaluation by management includes analysis of historical sales levels by product, projections of future demand, the risk of technological or competitive obsolescence for products, general market conditions, as well as the feasibility of reworking or using excess or obsolete products or components in the production or assembly of other products that are not obsolete or for which there are not excess quantities in inventory. To the extent that management determines there are excess or obsolete inventory, management adjusts the carrying value to estimated net realizable value. When quantities on hand exceed sales forecasts, a write-down is recorded for such excess inventories along with a corresponding charge to cost of revenues. The estimate of excess quantities is subjective and primarily dependent on the estimates of future demand for a particular product. Specifically, the future demand is derived based on our historical experience, from discussion with users of our products and general market conditions. Changes in assumptions of product demand could have a significant impact on the amount of write-down recorded. Inventory used in clinical trials is expensed at the time of production and recorded as research and development expense if the inventory is contractually being provided at no cost to the clinical site. The cost of inventories are regularly reviewed against estimated market value and record a lower of cost or market reserve for inventories that have a cost in excess of estimated market value, which could have a material impact on the gross margin and inventory balances based on additional write-downs to net realizable value or a benefit from inventories previously written down.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Property and Equipment</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Property and equipment are recorded at cost. Repairs and maintenance costs are expensed as incurred. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets of generally <span style="-sec-ix-hidden:c476">three</span> to <span style="-sec-ix-hidden:c477">five</span> years. Depreciation expense includes the amortization of assets acquired under capital leases and equipment located with the Company’s sales personnel or at customer sites. Equipment held by customers is comprised of the Lightbox consoles located at customer sites under a lease or placement agreement. Equipment held by field sales personnel is also comprised of the Lightbox consoles in their possession. The related equipment is reclassified from inventory to the property and equipment account either upon execution of a lease or placement agreement for customers or upon shipment to a field salesperson. Depreciation expense for equipment held by customers or field sales personnel is recorded as a component of cost of revenues. Leasehold improvements and assets recorded under capital leases are amortized using the straight-line method over the shorter of the lease term or estimated useful economic life of the asset.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Impairment of Long-Lived Assets</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. If indicators of impairment exist, an impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Impairment, if any, is measured as the amount by which the carrying amount of the long-lived asset exceeds its fair value. The Company has not recorded any impairment of long-lived assets since inception through December 31, 2022.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Revenue Recognition</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company’s revenues are derived from (1) sale of Lightbox consoles, (2) sale of disposables, which consist of catheters and accessories, and (3) sale of customer service contracts and maintenance. The Company sells its products directly to hospitals and medical centers as well as through distributors. The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. The Company’s revenues are measured based on consideration specified in the contract with each customer, net of any sales incentives and taxes collected from customers that are remitted to government authorities. For all sales, the Company uses either a signed agreement or a binding purchase order as evidence of an arrangement. The Company’s revenue recognition policies generally result in revenue recognition at the following points:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 36pt;"> </td> <td style="width: 36pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">1.</p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Lightbox console sales: Provided all other criteria for revenue recognition have been met, the Company recognizes revenue for Lightbox console sales directly to end customers when delivery and acceptance occurs, which is defined as receipt by the Company of an executed form that the installation process is complete.</p> </td> </tr> <tr style="vertical-align: top;"> <td style="width: 36pt;"> </td> <td style="width: 36pt;"> </td> <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p> </td> </tr> <tr style="vertical-align: top;"> <td style="width: 36pt;"> </td> <td style="width: 36pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">2.</p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Sales of disposables: Disposable revenues consist of sales of the Company’s catheters and accessories and are recognized when the product has shipped, risk of loss and title has passed to the customer and collectability is reasonably assured.</p> </td> </tr> <tr style="vertical-align: top;"> <td style="width: 36pt;"> </td> <td style="width: 36pt;"> </td> <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p> </td> </tr> <tr style="vertical-align: top;"> <td style="width: 36pt;"> </td> <td style="width: 36pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">3.</p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Service revenue: Service contract revenue consists of preventative maintenance, upgrades, and service contracts. Service contracts are recognized ratably over the term of the service period and maintenance contract revenue is recognized when work is completed. To date, service revenue has been insignificant.</p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company offers its customers the ability to purchase or lease the Lightbox console. In addition, the Company provides a Lightbox under a limited commercial evaluation program to allow accounts to install and utilize the Lightbox for a limited trial period. When a Lightbox is placed under a lease agreement or under a commercial evaluation program, the Company retains title to the equipment and it remains capitalized on its balance sheet under property and equipment. Depreciation expense on these placed Lightboxes is recorded to cost of revenues on a straight-line basis. The costs to maintain these placed Lightboxes are charged to cost of revenues as incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company evaluates its lease and commercial evaluation program agreements and accounts for these contracts under the guidance in Accounting Standards Codification (“ASC”) 842, <i>Leases</i> and ASU No. 2014 09, <i>Revenue from Contracts with Customers (Topic 606)</i>. The guidance requires arrangement consideration to be allocated between a lease deliverable and a non-lease deliverable based upon the relative selling-price of the deliverables.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company assessed whether the embedded lease is an operating lease or sales-type lease. Based on the Company’s assessment of the guidance and given that any payments under the lease agreements are dependent upon contingent future sales, it was determined that collectability of the minimum lease payments is not reasonably predictable. Accordingly, the Company concluded the embedded lease did not meet the criteria of a sales-type lease and accounts for it as an operating lease. The Company recognizes revenue allocated to the lease as the contingent disposable product purchases are delivered and are included in revenues within the statement of operations and comprehensive loss.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For sales through distributors, the Company recognizes revenue when control of the product transfers from the Company to the distributor. The distributors are responsible for all marketing, sales, training and warranty in their respective territories. The standard terms and conditions contained in the Company’s distribution agreements do not provide price protection or stock rotation rights to any of its distributors. In addition, its distributor agreements do not allow the distributor to return or exchange products, and the distributor is obligated to pay the Company upon invoice regardless of its ability to resell the product.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Cost of Revenues</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Cost of revenues consists primarily of manufacturing overhead costs, material costs and direct labor. A significant portion of the Company’s cost of revenues currently consists of manufacturing overhead costs. These overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management. Cost of revenues also includes depreciation expense for the Lightboxes under lease, deployed with sales personnel and evaluation agreements, product warranty costs, product written-off due to excess or obsolescence, and certain direct costs such as shipping costs.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Product Warranty Costs</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company typically offers a <span style="-sec-ix-hidden:c478">one</span>-year warranty on its products commencing upon the transfer of title and risk of loss to the customer. The Company accrues for the estimated cost of product warranties upon invoicing its customers, based on historical results. Warranty costs are reflected in the statement of operations and comprehensive loss as a cost of revenues. The warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Should actual product failure rates, material usage or service delivery costs differ from these estimates, revisions to the estimated warranty liability would be required. Periodically the Company assesses the adequacy of its recorded warranty liabilities and adjusts the amounts as necessary. Warranty provisions and claims are summarized as follows (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Beginning balance</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">187</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">193</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Warranty provision</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">22</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">49</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Usage/Release</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(100</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(55</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Ending balance</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">109</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">187</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Research and Development</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company expenses research and development costs as incurred. Research and development expenses include personnel and personnel-related costs, costs associated with pre-clinical and clinical development activities, and costs for prototype products that are manufactured prior to market approval for that prototype product, and internal and external costs associated with the Company’s regulatory compliance, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs, including allocated facility and related expenses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Clinical Trials</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company accrues and expenses costs for its clinical trial activities performed by third parties, including clinical research organizations and other service providers, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company determines these estimates through discussion with internal personnel and outside service providers as to progress or stage of completion of trials or services pursuant to contracts with clinical research organizations and other service providers and the agreed-upon fee to be paid for such services.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Stock-Based Compensation</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Stock-based compensation for the Company includes amortization related to all stock options, restricted stock units (“RSU”), and restricted stock awards (“RSA”) based on the grant-date estimated fair value. The fair value of stock options is estimated on the date of grant using the Black-Scholes option pricing model and recognized as expense on a straight-line basis over the vesting period of the award. The Company has not granted any stock options since 2017. The Company measures the fair value of RSUs and RSAs using the closing stock price of a share of the Company’s common stock on the grant date and is recognized as expense on a straight-line basis over the vesting period of the award. As allowed under ASU No. 2016‑09, <i>Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</i>, the Company accounts for forfeitures as they occur.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Foreign Currency</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company records net gains and losses resulting from foreign exchange transactions as a component of foreign currency exchange losses in other income, net. During the years ended December 31, 2022 and 2021, the Company recorded $12,000 and $16,000 of foreign currency exchange net losses, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Income Taxes</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company utilizes the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax reporting bases of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense when they occur. During the years ended December 31, 2022 and 2021, the Company did <span style="-sec-ix-hidden:c489"><span style="-sec-ix-hidden:c490">not</span></span> recognize accrued interest or penalties related to unrecognized tax benefits.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Net Loss per Share Attributable to Common Stockholders</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Basic net loss per share attributable to common stockholders is computed by dividing the net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss applicable to common stockholders by the weighted average number of shares of common stock and dilutive potential shares of common stock outstanding during the period. Any common stock shares subject to repurchase are excluded from the calculations as the continued vesting of such shares is contingent upon the holders’ continued service to the Company. As of December 31, 2022 and 2021, there were <span style="-sec-ix-hidden:c491"><span style="-sec-ix-hidden:c492">no</span></span> shares subject to repurchase. Since the Company was in a loss position for both periods presented, basic net loss per share attributable to common stockholders is the same as diluted net loss per share attributable to common stockholders as the inclusion of all potentially dilutive common shares would have been anti-dilutive.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Net loss per share attributable to common stockholders was determined as follows (in thousands, except per share data):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss applicable to common stockholders</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(27,244</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(21,587</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average common stock outstanding, basic and diluted</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,249</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,722</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss per share attributable to common stockholders, basic and diluted</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(4.36</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(4.57</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted average shares outstanding because such securities have an anti-dilutive impact due to losses reported:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock warrants equivalents</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,009,679</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">135,429</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock options</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">303</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">304</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible preferred stock</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">58,080</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">52,289</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested restricted stock units</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,626</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,817</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,074,688</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">205,839</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Comprehensive Loss</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For the years ended December 31, 2022 and 2021, there was no difference between comprehensive loss and the Company’s net loss.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Segment and Geographical Information </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company operates and manages its business as <span style="-sec-ix-hidden:c509">one</span> reportable and operating segment. The Company’s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. Primarily all of the Company’s long-lived assets, which are comprised of property and equipment, are based in the United States. For the years ended December 31, 2022 and 2021, 92% and 94% of the Company’s revenues were in the United States, based on the shipping location of the external customer. The remaining revenues for the years ended December 31, 2022 and 2021, were principally in Germany.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Recent Accounting Pronouncements</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Recently adopted accounting standards</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In May 2021, ASU No. 2021-04, <i>Issuer</i>’<i>s Accounting for Certain Modifications of Exchanges of Freestanding Equity-Classified Written Call Options</i> was issued to clarify the accounting for modifications or exchanges of freestanding equity-classified written call options, such was warrants, that remain equity classified after modification or exchange. The standard was adopted by the Company on January 1, 2022. This new standard did not have a material impact on the Company’s financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Recent accounting standards not yet adopted </i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In August 2020, the FASB issued ASU No. 2020-06, <i>Debt</i>—<i>Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging</i>—<i>Contracts in Entity</i>’<i>s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity</i>’<i>s Own Equity</i>, which among other things, simplifies the accounting models for the allocation of proceeds attributable to the issuance of a convertible debt instrument.  As a result, after adopting the ASU’s guidance, entities will not separately present in equity an embedded conversion feature in such debt. Instead, they will account for a convertible debt instrument wholly as debt, and for convertible preferred stock wholly as preferred stock (i.e., as a single unit of account), unless (i) a convertible instrument contains features that require bifurcation as a derivative under ASC 815 or (ii) a convertible debt instrument was issued at a substantial premium. The standard becomes effective for the Company, as a smaller reporting company as defined by the SEC, in the first quarter of 2024 and early adoption is permitted.  This new standard is not expected to have a material impact on the Company’s financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <b>Basis of Presentation</b>The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”).On March 11, 2022, the Company’s Board of Directors approved an amendment to the Company’s amended and restated certificate of incorporation to effect a 1-for-20 reverse stock split of the Company’s issued and outstanding common stock. The reverse stock split became effective on March 14, 2022. The par value of the common stock and preferred stock was not adjusted as a result of the reverse stock split. All common stock, stock options, restricted stock units, and per share amounts in the financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split. Additionally, the common stock at par and related additional paid-in capital amounts as of December 31, 2021 in the balance sheet, the common stock at par and related additional paid-in capital amounts in the Statement of Stockholder’s Equity as of December 31, 2021 and 2020, and for the year ended December 31, 2021 have also been retroactively reclassified to give effect to the reverse stock split. 20 <b>Use of Estimates</b>The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to its stock-based compensation, accruals related to compensation, the valuation of the common stock warrants, provisions for doubtful accounts receivable and excess and obsolete inventories, clinical trial accruals, and its reserves for sales returns and warranty costs. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. <b>Fair Value of Financial Instruments</b>The Company has evaluated the estimated fair value of its financial instruments as of December 31, 2022 and 2021. Financial instruments consist of cash and cash equivalents, accounts receivable and payable, and other current liabilities and borrowings. The carrying amounts of cash and cash equivalents, accounts receivable and payable, and other current liabilities approximate their respective fair values because of the short-term nature of those instruments. Based upon the borrowing terms and conditions currently available to the Company, the carrying values of the borrowings approximate their fair value. <b>Cash and Cash Equivalents</b>The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents are considered available-for-sale marketable securities and are recorded at fair value, based on quoted market prices. As of December 31, 2022 and 2021, the Company’s cash equivalents are entirely comprised of investments in money market funds. Any related unrealized gains and losses are recorded in other comprehensive income (loss) and included as a separate component of stockholders’ equity. There were <span style="-sec-ix-hidden:c459"><span style="-sec-ix-hidden:c460">no</span></span> unrealized gains and losses as of December 31, 2022 and 2021. Any realized gains and losses and interest and dividends on available-for-sale securities are included in interest income or expense and computed using the specific identification cost method. <b>Concentration of Credit Risk, and Other Risks and Uncertainties</b>Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and accounts receivable to the extent of the amounts recorded on the balance sheets.The Company’s policy is to invest in cash and cash equivalents, consisting of money market funds. These financial instruments are held in Company accounts at one financial institution, Silicon Valley Bank. The counterparties to the agreements relating to the Company’s investments consist of financial institutions of high credit standing. The Company provides for uncollectible amounts when specific credit problems arise. Management’s estimates for uncollectible amounts have been adequate, and management believes that all significant credit risks have been identified at December 31, 2022 and 2021. On March 10, 2023, the Federal Deposit Insurance Corporation announced that Silicon Valley Bank had been closed by the California Department of Financial Protection and Innovation. While we have regained access to our accounts at Silicon Valley Bank and are evaluating our banking relationships, future disruptions of financial institutions where we bank or have credit arrangements, or disruptions of the financial services industry in general, could adversely affect our ability to access our cash and cash equivalents. If we are unable to access our cash and cash equivalents as needed, our financial position and ability to operate our business will be adversely affected. The Company’s accounts receivable are due from a variety of healthcare organizations in the United States and select international markets. The Company provides for uncollectible amounts when specific credit problems arise. Management's estimates for uncollectible amounts have been adequate, and management believes that all significant credit risks have been identified at December 31, 2022 and 2021. At December 31, 2022, there was <span style="-sec-ix-hidden:c461">no</span> customer that represented 10% or more of the Company’s accounts receivable, whereas at December 31 2021, there was <span style="-sec-ix-hidden:c462">one</span> customer that represented 21% of accounts receivable. For the year ended December 31, 2022 and 2021, there was <span style="-sec-ix-hidden:c464"><span style="-sec-ix-hidden:c465">one</span></span> customer that represented approximately 14% and 10% of revenues, respectively. Disruption of sales orders or a deterioration of financial condition of its customers would have a negative impact on the Company’s financial position and results of operations.The Company manufactures its commercial products in-house, including the Pantheris and Ocelot family of catheters. Certain of the Company’s product components and sub-assemblies are manufactured by sole suppliers, including internally. Disruption in component or sub-assembly supply from these manufacturers or from in-house production would have a negative impact on the Company’s financial position and results of operations.The Company is subject to certain risks, including that its devices may not be approved or cleared for marketing by governmental authorities or be successfully marketed. There can be no assurance that the Company’s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and with appropriate performance characteristics. The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, dependence upon third-party payors to provide adequate coverage and reimbursement, dependence on key personnel and suppliers, protection of proprietary technology, product liability claims, and compliance with government regulations.Existing or future devices developed by the Company may require approvals or clearances from the FDA or international regulatory agencies. In addition, in order to continue the Company’s operations, compliance with various federal and state laws is required. If the Company were denied or delayed in receiving such approvals or clearances, it may be necessary to adjust operations to align with the Company’s currently approved portfolio. If clearance for the products in the current portfolio were withdrawn by the FDA, this may have a material adverse impact on the Company.Disruption of our supply chain capabilities due to trade restrictions, political instability, severe weather, natural disasters, public health crises, terrorism, product recalls, labor supply or stoppages, the financial or operational instability of key suppliers and carriers, government restrictions or measures, or other reasons could impair our ability to distribute our products. The Company believes COVID-19 and the subsequent burdens on the hospital systems has had and will continue to have an adverse effect on its ability to generate sales due to the fluctuating and unpredictable levels of capacity medical providers have to perform procedures that require the use of its products.The Company is closely monitoring general economic conditions on global supply chain, manufacturing, and logistics operations. As inflationary pressures increase, the Company anticipates that its production and operating costs may similarly increase, including costs and availability of materials and labor. While the Company has sufficient inventory on-hand to meet its current production requirements and customer demand, it has experienced some constraints with respect to the availability of certain materials and extended lead times from certain key suppliers. The Company has also experienced some delays in shipping products to its customers. Any significant delay or interruption in our supply chain could impair the Company’s ability to meet the demands of its customers in the future and could harm its business.We use technology in substantially all aspects of our business operations, and our ability to serve customers most effectively depends on the reliability of our technology systems. Cybersecurity incidents can include computer viruses, computer denial-of-service attacks, worms, and other malicious software programs or other attacks, covert introduction of malware to computers and networks, impersonation of authorized users, and efforts to discover and exploit any design flaws, bugs, security vulnerabilities or security weaknesses, as well as intentional or unintentional acts by employees or other insiders with access privileges, intentional acts of vandalism by third parties and sabotage.In addition, our technology infrastructure and systems are vulnerable to damage or interruption from natural disasters, power loss and telecommunications failures. Any such disruption to our systems, or the technology systems of third parties on which we rely, the failure of these systems to otherwise perform as anticipated, or the theft, destruction, loss, misappropriation, or release of sensitive and/or confidential information or intellectual property, could require us to notify affected individuals, federal or state agencies or media outlets of the incident and could result in business disruption, negative publicity, loss of customers, potential liability, including litigation or other legal actions against us or the imposition of penalties, fines, fees or liabilities, which may not be covered by our insurance policies, and competitive disadvantage, any or all of which would potentially adversely affect our customer service, decrease the volume of our business and result in increased costs and lower profits. Moreover, a cybersecurity breach could require us to devote significant management resources to address the problems associated with the breach and to expend significant additional resources to upgrade further the security measures we employ to protect information against cyber-attacks and other wrongful attempts to access such information, which could result in a disruption of our operations.While we have invested, and continue to invest, in technology security initiatives and other measures to prevent security breaches and cyber incidents, as well as disaster recovery plans, these initiatives and measures may not be entirely effective to insulate us from technology disruption that could result in adverse effects on our results of operations. 0.21 0.14 0.10 <b>Accounts Receivable</b>Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable. The Company determines the allowance for doubtful accounts based upon an aging of accounts receivable, historical experience, and management judgment. Accounts receivable balances are reviewed individually for collectability. To date, the Company has not experienced significant credit-related losses.Accounts receivable allowance for doubtful accounts provision and recoveries or write-offs are summarized as follows (in thousands): <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Beginning balance</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">19</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Provision</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">70</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Recoveries/write-offs</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(15</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Ending balance</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">73</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Beginning balance</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">19</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Provision</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">70</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Recoveries/write-offs</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(15</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Ending balance</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">73</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 6000 19000 70000 2000 -3000 -15000 73000 6000 <b>Inventories</b>Inventories are valued at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method for all inventories. The Company’s policy is to write down inventory that has expired or become obsolete, inventory that has a cost basis in excess of its expected net realizable value, and inventory in excess of expected requirements. At each balance sheet date, management evaluates inventories for excess quantities, and obsolescence. This evaluation by management includes analysis of historical sales levels by product, projections of future demand, the risk of technological or competitive obsolescence for products, general market conditions, as well as the feasibility of reworking or using excess or obsolete products or components in the production or assembly of other products that are not obsolete or for which there are not excess quantities in inventory. To the extent that management determines there are excess or obsolete inventory, management adjusts the carrying value to estimated net realizable value. When quantities on hand exceed sales forecasts, a write-down is recorded for such excess inventories along with a corresponding charge to cost of revenues. The estimate of excess quantities is subjective and primarily dependent on the estimates of future demand for a particular product. Specifically, the future demand is derived based on our historical experience, from discussion with users of our products and general market conditions. Changes in assumptions of product demand could have a significant impact on the amount of write-down recorded. Inventory used in clinical trials is expensed at the time of production and recorded as research and development expense if the inventory is contractually being provided at no cost to the clinical site. The cost of inventories are regularly reviewed against estimated market value and record a lower of cost or market reserve for inventories that have a cost in excess of estimated market value, which could have a material impact on the gross margin and inventory balances based on additional write-downs to net realizable value or a benefit from inventories previously written down. <b>Property and Equipment</b>Property and equipment are recorded at cost. Repairs and maintenance costs are expensed as incurred. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets of generally <span style="-sec-ix-hidden:c476">three</span> to <span style="-sec-ix-hidden:c477">five</span> years. Depreciation expense includes the amortization of assets acquired under capital leases and equipment located with the Company’s sales personnel or at customer sites. Equipment held by customers is comprised of the Lightbox consoles located at customer sites under a lease or placement agreement. Equipment held by field sales personnel is also comprised of the Lightbox consoles in their possession. The related equipment is reclassified from inventory to the property and equipment account either upon execution of a lease or placement agreement for customers or upon shipment to a field salesperson. Depreciation expense for equipment held by customers or field sales personnel is recorded as a component of cost of revenues. Leasehold improvements and assets recorded under capital leases are amortized using the straight-line method over the shorter of the lease term or estimated useful economic life of the asset. <b>Impairment of Long-Lived Assets</b>The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. If indicators of impairment exist, an impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Impairment, if any, is measured as the amount by which the carrying amount of the long-lived asset exceeds its fair value. The Company has not recorded any impairment of long-lived assets since inception through December 31, 2022. <b>Revenue Recognition</b>The Company’s revenues are derived from (1) sale of Lightbox consoles, (2) sale of disposables, which consist of catheters and accessories, and (3) sale of customer service contracts and maintenance. The Company sells its products directly to hospitals and medical centers as well as through distributors. The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. The Company’s revenues are measured based on consideration specified in the contract with each customer, net of any sales incentives and taxes collected from customers that are remitted to government authorities. For all sales, the Company uses either a signed agreement or a binding purchase order as evidence of an arrangement. The Company’s revenue recognition policies generally result in revenue recognition at the following points:The Company offers its customers the ability to purchase or lease the Lightbox console. In addition, the Company provides a Lightbox under a limited commercial evaluation program to allow accounts to install and utilize the Lightbox for a limited trial period. When a Lightbox is placed under a lease agreement or under a commercial evaluation program, the Company retains title to the equipment and it remains capitalized on its balance sheet under property and equipment. Depreciation expense on these placed Lightboxes is recorded to cost of revenues on a straight-line basis. The costs to maintain these placed Lightboxes are charged to cost of revenues as incurred.The Company evaluates its lease and commercial evaluation program agreements and accounts for these contracts under the guidance in Accounting Standards Codification (“ASC”) 842, <i>Leases</i> and ASU No. 2014 09, <i>Revenue from Contracts with Customers (Topic 606)</i>. The guidance requires arrangement consideration to be allocated between a lease deliverable and a non-lease deliverable based upon the relative selling-price of the deliverables.The Company assessed whether the embedded lease is an operating lease or sales-type lease. Based on the Company’s assessment of the guidance and given that any payments under the lease agreements are dependent upon contingent future sales, it was determined that collectability of the minimum lease payments is not reasonably predictable. Accordingly, the Company concluded the embedded lease did not meet the criteria of a sales-type lease and accounts for it as an operating lease. The Company recognizes revenue allocated to the lease as the contingent disposable product purchases are delivered and are included in revenues within the statement of operations and comprehensive loss.For sales through distributors, the Company recognizes revenue when control of the product transfers from the Company to the distributor. The distributors are responsible for all marketing, sales, training and warranty in their respective territories. The standard terms and conditions contained in the Company’s distribution agreements do not provide price protection or stock rotation rights to any of its distributors. In addition, its distributor agreements do not allow the distributor to return or exchange products, and the distributor is obligated to pay the Company upon invoice regardless of its ability to resell the product. <b>Cost of Revenues</b>Cost of revenues consists primarily of manufacturing overhead costs, material costs and direct labor. A significant portion of the Company’s cost of revenues currently consists of manufacturing overhead costs. These overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management. Cost of revenues also includes depreciation expense for the Lightboxes under lease, deployed with sales personnel and evaluation agreements, product warranty costs, product written-off due to excess or obsolescence, and certain direct costs such as shipping costs. <b>Product Warranty Costs</b>The Company typically offers a <span style="-sec-ix-hidden:c478">one</span>-year warranty on its products commencing upon the transfer of title and risk of loss to the customer. The Company accrues for the estimated cost of product warranties upon invoicing its customers, based on historical results. Warranty costs are reflected in the statement of operations and comprehensive loss as a cost of revenues. The warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Should actual product failure rates, material usage or service delivery costs differ from these estimates, revisions to the estimated warranty liability would be required. Periodically the Company assesses the adequacy of its recorded warranty liabilities and adjusts the amounts as necessary. Warranty provisions and claims are summarized as follows (in thousands): <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Beginning balance</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">187</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">193</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Warranty provision</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">22</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">49</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Usage/Release</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(100</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(55</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Ending balance</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">109</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">187</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Beginning balance</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">187</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">193</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Warranty provision</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">22</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">49</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Usage/Release</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(100</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(55</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Ending balance</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">109</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">187</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 187000 193000 22000 49000 100000 55000 109000 187000 <b>Research and Development</b>The Company expenses research and development costs as incurred. Research and development expenses include personnel and personnel-related costs, costs associated with pre-clinical and clinical development activities, and costs for prototype products that are manufactured prior to market approval for that prototype product, and internal and external costs associated with the Company’s regulatory compliance, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs, including allocated facility and related expenses. <b>Clinical Trials</b>The Company accrues and expenses costs for its clinical trial activities performed by third parties, including clinical research organizations and other service providers, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company determines these estimates through discussion with internal personnel and outside service providers as to progress or stage of completion of trials or services pursuant to contracts with clinical research organizations and other service providers and the agreed-upon fee to be paid for such services. <b>Stock-Based Compensation</b>Stock-based compensation for the Company includes amortization related to all stock options, restricted stock units (“RSU”), and restricted stock awards (“RSA”) based on the grant-date estimated fair value. The fair value of stock options is estimated on the date of grant using the Black-Scholes option pricing model and recognized as expense on a straight-line basis over the vesting period of the award. The Company has not granted any stock options since 2017. The Company measures the fair value of RSUs and RSAs using the closing stock price of a share of the Company’s common stock on the grant date and is recognized as expense on a straight-line basis over the vesting period of the award. As allowed under ASU No. 2016‑09, <i>Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</i>, the Company accounts for forfeitures as they occur. <b>Foreign Currency</b>The Company records net gains and losses resulting from foreign exchange transactions as a component of foreign currency exchange losses in other income, net. During the years ended December 31, 2022 and 2021, the Company recorded $12,000 and $16,000 of foreign currency exchange net losses, respectively. 12000 16000 <b>Income Taxes</b>The Company utilizes the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax reporting bases of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense when they occur. During the years ended December 31, 2022 and 2021, the Company did <span style="-sec-ix-hidden:c489"><span style="-sec-ix-hidden:c490">not</span></span> recognize accrued interest or penalties related to unrecognized tax benefits. <b>Net Loss per Share Attributable to Common Stockholders</b>Basic net loss per share attributable to common stockholders is computed by dividing the net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss applicable to common stockholders by the weighted average number of shares of common stock and dilutive potential shares of common stock outstanding during the period. Any common stock shares subject to repurchase are excluded from the calculations as the continued vesting of such shares is contingent upon the holders’ continued service to the Company. As of December 31, 2022 and 2021, there were <span style="-sec-ix-hidden:c491"><span style="-sec-ix-hidden:c492">no</span></span> shares subject to repurchase. Since the Company was in a loss position for both periods presented, basic net loss per share attributable to common stockholders is the same as diluted net loss per share attributable to common stockholders as the inclusion of all potentially dilutive common shares would have been anti-dilutive.Net loss per share attributable to common stockholders was determined as follows (in thousands, except per share data): <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss applicable to common stockholders</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(27,244</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(21,587</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average common stock outstanding, basic and diluted</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,249</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,722</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss per share attributable to common stockholders, basic and diluted</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(4.36</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(4.57</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> </tbody></table> The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted average shares outstanding because such securities have an anti-dilutive impact due to losses reported: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock warrants equivalents</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,009,679</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">135,429</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock options</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">303</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">304</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible preferred stock</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">58,080</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">52,289</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested restricted stock units</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,626</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,817</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,074,688</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">205,839</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss applicable to common stockholders</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(27,244</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(21,587</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average common stock outstanding, basic and diluted</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,249</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,722</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss per share attributable to common stockholders, basic and diluted</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(4.36</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(4.57</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> </tbody></table> -27244000 -21587000 6249000 4722000 -4.36 -4.57 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock warrants equivalents</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,009,679</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">135,429</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock options</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">303</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">304</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Convertible preferred stock</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">58,080</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">52,289</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested restricted stock units</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,626</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,817</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,074,688</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">205,839</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 4009679 135429 303 304 58080 52289 6626 17817 4074688 205839 <b>Comprehensive Loss</b>For the years ended December 31, 2022 and 2021, there was no difference between comprehensive loss and the Company’s net loss. <b>Segment and Geographical Information </b>The Company operates and manages its business as <span style="-sec-ix-hidden:c509">one</span> reportable and operating segment. The Company’s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. Primarily all of the Company’s long-lived assets, which are comprised of property and equipment, are based in the United States. For the years ended December 31, 2022 and 2021, 92% and 94% of the Company’s revenues were in the United States, based on the shipping location of the external customer. The remaining revenues for the years ended December 31, 2022 and 2021, were principally in Germany. 0.92 0.94 <b>Recent Accounting Pronouncements</b><i>Recently adopted accounting standards</i>In May 2021, ASU No. 2021-04, <i>Issuer</i>’<i>s Accounting for Certain Modifications of Exchanges of Freestanding Equity-Classified Written Call Options</i> was issued to clarify the accounting for modifications or exchanges of freestanding equity-classified written call options, such was warrants, that remain equity classified after modification or exchange. The standard was adopted by the Company on January 1, 2022. This new standard did not have a material impact on the Company’s financial statements.<i>Recent accounting standards not yet adopted </i>In August 2020, the FASB issued ASU No. 2020-06, <i>Debt</i>—<i>Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging</i>—<i>Contracts in Entity</i>’<i>s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity</i>’<i>s Own Equity</i>, which among other things, simplifies the accounting models for the allocation of proceeds attributable to the issuance of a convertible debt instrument.  As a result, after adopting the ASU’s guidance, entities will not separately present in equity an embedded conversion feature in such debt. Instead, they will account for a convertible debt instrument wholly as debt, and for convertible preferred stock wholly as preferred stock (i.e., as a single unit of account), unless (i) a convertible instrument contains features that require bifurcation as a derivative under ASC 815 or (ii) a convertible debt instrument was issued at a substantial premium. The standard becomes effective for the Company, as a smaller reporting company as defined by the SEC, in the first quarter of 2024 and early adoption is permitted.  This new standard is not expected to have a material impact on the Company’s financial statements. <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>3. Fair Value Measurements</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Level 1—Quoted prices in active markets for identical assets or liabilities.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Level 2—Inputs other than quoted prices included within Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As of December 31, 2022 and 2021, the Company’s cash equivalents were all categorized as Level 1 and consisted of money market funds. As of December 31, 2022 and 2021, there were <span style="-sec-ix-hidden:c630"><span style="-sec-ix-hidden:c631"><span style="-sec-ix-hidden:c632"><span style="-sec-ix-hidden:c633">no</span></span></span></span> financial assets and liabilities categorized as Level 2 or Level 3. There were <span style="-sec-ix-hidden:c636"><span style="-sec-ix-hidden:c637"><span style="-sec-ix-hidden:c638"><span style="-sec-ix-hidden:c639">no</span></span></span></span> transfers between fair value hierarchy levels during the years ended December 31, 2022 and 2021.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>4. Inventories</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Inventories consisted of the following (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>December 31,</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Raw materials</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3,374</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,503</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Work-in-process</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">17</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Finished products</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,574</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,097</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Total inventories</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,965</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,601</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>December 31,</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Raw materials</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3,374</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,503</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Work-in-process</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">17</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Finished products</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,574</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,097</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Total inventories</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,965</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,601</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 3374000 2503000 17000 1000 1574000 2097000 4965000 4601000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>5. Property and Equipment, Net</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Property and equipment, net, consisted of the following (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Equipment held by customers and field sales personnel</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,566</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,362</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Machinery and equipment</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,372</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,391</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Computer software</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">122</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">122</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Computer equipment</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">200</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">173</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture and fixture</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">78</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">78</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">320</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">320</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Total property and equipment, gross</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,658</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,446</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: Accumulated depreciation and amortization</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,956</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4,351</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Total property and equipment, net</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">702</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">95</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Depreciation expense for the years ended December 31, 2022 and 2021, was approximately $196,000 and $687,000, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Property and equipment include certain equipment that is leased to customers and located at customer premises. Also, included is equipment held by the Company’s field sales personnel for use in cases with customers. The Company retains ownership of the equipment held for evaluation by customers and has the right to remove the equipment if it is not being utilized according to expectations. Depreciation expense relating to the leased equipment held by customers and those held by the Company’s field sales personnel of $119,000 and $539,000 was recorded in cost of revenues during the years ended December 31, 2022 and 2021, respectively. The net book value of this equipment was $527,000 and $0 at December 31, 2022 and December 31, 2021, respectively.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Equipment held by customers and field sales personnel</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,566</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,362</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Machinery and equipment</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,372</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,391</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Computer software</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">122</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">122</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Computer equipment</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">200</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">173</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture and fixture</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">78</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">78</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">320</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">320</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Total property and equipment, gross</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,658</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,446</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: Accumulated depreciation and amortization</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,956</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4,351</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Total property and equipment, net</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">702</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">95</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 2566000 2362000 1372000 1391000 122000 122000 200000 173000 78000 78000 320000 320000 4658000 4446000 3956000 4351000 702000 95000 196000 687000 119000 539000 527000 0 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>6. Accrued Expenses and Other Current Liabilities</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Accrued expenses and other current liabilities consisted of the following (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <div> <table cellpadding="0" cellspacing="0" class="finTable" style="width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: auto;"> <tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 18%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred revenue</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">141</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">123</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued travel and entertainment expenses</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">129</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">118</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued product warranty costs</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">109</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">187</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued clinical trial costs</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">106</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">153</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued professional fees</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">60</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued sales and use tax</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">40</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other accrued liabilities</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">72</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">104</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total accrued expenses and other current liabilities</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">657</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">718</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> </div> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 141000 123000 129000 118000 109000 187000 106000 153000 60000 0 40000 33000 72000 104000 657000 718000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>7. Borrowings</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>CRG</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On September 22, 2015, the Company entered into a Term Loan Agreement, as amended (the “Loan Agreement”) with CRG under which, subject to certain conditions, the Company had the right to borrow up to $50 million in principal amount from CRG on or before the end of the twenty-fourth (24th) month period commencing on the first Borrowing Date (as defined in the Loan Agreement). The Company borrowed $30 million on September 22, 2015. The Company borrowed an additional $10 million on June 15, 2016 under the Loan Agreement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On February 14, 2018, the Company and CRG further amended the Loan Agreement concurrent with the conversion of $38 million of the principal amount of the senior secured term loan (plus $3.8 million in back-end fees and prepayment premium applicable thereto) into a newly authorized Series A convertible preferred stock (see below).</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company has entered into several amendments to the Loan Agreement (the “Amendments”) with CRG since September 2015, the most recent of which was entered into on August 10, 2022. The Amendments, among other things: (1) extended the interest-only period through December 31, 2023; (2) extended the period during which the Company may elect to pay a portion of interest in payment-in-kind, or PIK, interest payments through December 31, 2023 so long as no Default (as defined in the Loan Agreement) has occurred and is continuing; (3) permitted the Company to make the entire interest payments in PIK interest payments for through December 31, 2023 so long as no Default has occurred and is continuing; (4) extended the Stated Maturity Date (as defined in the Loan Agreement) to December 31, 2025; (5) reduced the minimum liquidity covenant to $3.5 million at all times; (6) eliminated the minimum revenue covenant for 2018, 2019 and 2020; (7) reduced the minimum revenue covenant to $8 million for 2021 and 2022; (8) added minimum revenue covenants of $10 million for 2023, $14.5 million for 2024 and $17 million for 2025; (9) changed the date under the on-going stand-alone representation regarding no “Material Adverse Change” to December 31, 2020; (10) amended the on-going stand-alone representation and stand-alone Event of Default (as defined in the Loan Agreement) regarding Material Adverse Change such that any adverse change in or effect upon the revenue of the Company and its subsidiaries due to the outbreak of COVID-19 will not constitute a Material Adverse Change; and (11) provided CRG with board observer rights.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Under the amended Loan Agreement, no cash payments for either principal or interest are required until the first quarter of 2024. The interest will be accrued and included in the debt balance based (to the extent not paid) on principal amounts outstanding at the beginning of the quarter at an interest rate of 12.5%. Beginning in the first quarter of 2024, the Company will be required to make quarterly principal payments (in addition to the interest) of $1.9 million with total principal payments of $7.5 million in 2024 and $7.5 million in 2025. The maturity date of the Loan (as defined in the Loan Agreement) is December 31, 2025.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company may voluntarily prepay the borrowings in full, with a prepayment premium beginning at 5.0% and declining by 1.0% annually thereafter, with no premium being payable if prepayment occurs after seven and half years of the loan. Each tranche of borrowing required the payment, on the borrowing date, of a financing fee equal to 1.5% of the borrowed loan principal, which is recorded as a discount to the debt. In addition, a facility fee equal to 15.0% of the amounts borrowed plus any PIK is to be payable at the end of the term or when the borrowings are repaid in full. A long-term liability is being accreted using the effective interest method for the facility fee over the term of the Loan Agreement with a corresponding discount to the debt. The borrowings are collateralized by a security interest in substantially all of the Company’s assets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Loan Agreement requires that the Company adheres to certain affirmative and negative covenants, including financial reporting requirements, certain minimum financial covenants for pre-specified liquidity and revenue requirements and a prohibition against the incurrence of indebtedness, or creation of additional liens, other than as specifically permitted by the terms of the Loan Agreement. In particular, the covenants of the amended Loan Agreement included a covenant that the Company maintain a minimum of $3.5 million of cash and certain cash equivalents, and the Company has to achieve certain minimum revenues. If the Company fails to meet the applicable minimum revenue target in any calendar year, the Loan Agreement provides the Company with a cure right if it prepays a portion of the outstanding principal equal to 2.0 times the revenue shortfall. In addition, the Loan Agreement prohibits the payment of cash dividends on the Company’s capital stock and also places restrictions on mergers, sales of assets, investments, incurrence of liens, incurrence of indebtedness and transactions with affiliates. CRG may accelerate the payment terms of the Loan Agreement upon the occurrence of certain “Events of Default” set forth therein, which include the failure of the Company to make timely payments of amounts due under the Loan Agreement, the failure of the Company to adhere to the covenants set forth in the Loan Agreement, the insolvency of the Company or upon the occurrence of a “Material Adverse Change” thereunder.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As of December 31, 2022, the Company was in compliance with all applicable covenants under the Loan Agreement.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As of December 31, 2022, principal, final facility fee and PIK payments under the Loan Agreement, as amended, were as follows (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px; margin-left: 36pt;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 83%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Year Ending December 31,</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"><b> </b></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2023</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">9,045</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10,339</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">19,384</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: Amount of PIK additions and final facility fee to be incurred subsequent to December 31, 2022</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(4,970</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: Amount representing debt issuance costs</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(249</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Borrowings, current portion, as of December 31, 2022</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,165</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In connection with drawdowns under the Loan Agreement, the Company recorded aggregate debt discounts of $1.3 million as contra-debt. The debt discounts are being amortized as non-cash interest expense using the effective interest method over the term of the Loan Agreement. As of December 31, 2022 and 2021, the balance of the aggregate debt discount was approximately $249,000 and $332,000, respectively. The Company’s interest expense associated with the amortization of debt discount was approximately $83,000 and $86,000 during the years ended December 31, 2022 and 2021, respectively. The Company incurred total interest expense of approximately $1.9 million and $1.6 million during the years ended December 31, 2022 and 2021, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Due to the substantial doubt about the Company’s ability to continue operating as a going concern and the Event of Default (as defined in the Loan Agreement) that could result due to a “Material Adverse Change” under the Loan Agreement, the entire outstanding amount of borrowings under the Loan Agreement and associated aggregate debt discount at December 31, 2022 was classified as current in these financial statements as compared with long-term as of December 31, 2021. CRG has not purported that an Event of Default has resulted due to a Material Adverse Change.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Paycheck Protection Program</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On April 23, 2020, the Company received loan proceeds of $2.3 million (the “PPP Loan”) pursuant to the Paycheck Protection Program under the CARES Act.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The PPP Loan, which was in the form of a promissory note, dated April 20, 2020 (the “Promissory Note”), between the Company and Silicon Valley Bank (“SVB”) as the lender, was set to mature on April 20, 2022 and bore interest at a fixed rate of 1% per annum, payable monthly commencing six months from the date of the Loan, with prepayment of the borrowings permitted with no associated penalty or premium.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The PPP Loan was administered by the U.S. Small Business Administration (“SBA”). The SBA was given the authority under the PPP to forgive loans if all employees were kept on the payroll for a required period and the loan proceeds were used for payroll, rent and utilities. The Company applied for debt forgiveness in December 2020.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On April 17, 2021, the Company was notified by SVB that its PPP Loan had been fully forgiven by the SBA and that there was no remaining balance on the PPP Loan. The Company recorded the forgiveness as other income in April 2021 in the amount of $2.4 million, of which approximately $23,000 was accrued interest. For the year ended December 31, 2021, the Company incurred interest expense of approximately $7,000 related to the PPP Loan.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 50000000 30000000 10000000 38000000 3800000 3500000 8000000 8000000 10000000 14500000 17000000 0.125 1900000 7500000 7500000 0.050 0.010 0.015 0.150 3500000 2.0 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px; margin-left: 36pt;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 83%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Year Ending December 31,</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"><b> </b></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2023</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">9,045</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10,339</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">19,384</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: Amount of PIK additions and final facility fee to be incurred subsequent to December 31, 2022</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(4,970</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: Amount representing debt issuance costs</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(249</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Borrowings, current portion, as of December 31, 2022</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,165</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 0 9045000 10339000 19384000 -4970000 -249000 14165000 1300000 249000 332000 83000 86000 1900000 1600000 2300000 2400000 23000 7000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>8. Leases</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company’s operating lease obligations primarily consist of leased office, laboratory, and manufacturing space under a non-cancelable operating lease. In addition to the minimum future lease commitments presented below, the lease requires the Company to pay property taxes, insurance, maintenance, and repair costs. The lease includes a rent holiday concession and escalation clauses for increased rent over the lease term. Rent expense is recognized using the straight-line method over the term of the lease.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The lease will expire on November 30, 2024. The Company is obligated to pay approximately $5.8 million in base rent payments through November 2024, beginning on December 1, 2019. The weighted average remaining lease term as of December 31, 2022 is 1.9 years.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The operating lease was included on the balance sheet at the present value of the future base payments discounted at a 6.5% discount rate using the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment as the lease does provide an implicit rate.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company’s operating lease expense, excluding variable maintenance fees and other expenses on a monthly basis, was approximately $105,000. Rent expense for each of the years ended December 31, 2022 and 2021 was approximately $<span style="-sec-ix-hidden:c830"><span style="-sec-ix-hidden:c831">1.3</span></span> million. The Company’s variable expenses for the years ended December 31, 2022 and 2021 was approximately $0.3 million and $0.2 million, respectively. Operating right-of-use asset amortization for the year ended December 31, 2022 and 2021 was approximately $1.1 million and $1.0 million, respectively. Due to payments being made in excess of operating lease expense recognized, the Company recorded approximately $65,000 and $158,000 as prepaid rent included in other assets on the balance sheet as of December 31, 2022 and 2021, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The following table presents the future operating lease payments and leasehold liability included on the balance sheet related to the Company’s operating lease as of December 31, 2022 (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 83%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Year Ending December 31,</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"><b> </b></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2023</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,203</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,138</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,341</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: Imputed interest</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(147</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold liability as of December 31, 2022</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,194</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The following table shows ROU assets and lease liabilities, and the associated financial statement line items (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 39%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center; width: 26%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 18%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 39%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Lease-Related Assets and Liabilities</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 26%; border-bottom: 1px solid rgb(0, 0, 0);"><b>Financial Statement Line </b> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Items</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><b><b>2022</b></b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><b><b>2021</b></b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 39%;">Right of use assets:</td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 26%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 14%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 14%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 39%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease</p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 26%;">Right of use asset</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,194</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,179</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="3" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;">Total right of use assets</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,194</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,179</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 39%;">Lease liabilities:</td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 26%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 14%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 14%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 39%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease</p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 26%;">Leasehold liability, current portion</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,092</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">985</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 39%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 26%;">Leasehold liability, long-term portion</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,102</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,194</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="3" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Total lease liabilities</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,194</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,179</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 5800000 P1Y10M24D 0.065 105000 300000 200000 1100000 1000000.0 65000 158000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 83%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Year Ending December 31,</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"><b> </b></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2023</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,203</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,138</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,341</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: Imputed interest</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(147</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold liability as of December 31, 2022</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,194</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 1203000 1138000 2341000 147000 2194000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 39%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center; width: 26%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 18%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 39%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Lease-Related Assets and Liabilities</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 26%; border-bottom: 1px solid rgb(0, 0, 0);"><b>Financial Statement Line </b> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Items</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><b><b>2022</b></b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><b><b>2021</b></b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 39%;">Right of use assets:</td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 26%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 14%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 14%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 39%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease</p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 26%;">Right of use asset</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,194</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,179</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="3" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;">Total right of use assets</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,194</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,179</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 39%;">Lease liabilities:</td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 26%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 14%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 14%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 39%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease</p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 26%;">Leasehold liability, current portion</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,092</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">985</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 39%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 26%;">Leasehold liability, long-term portion</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,102</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,194</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="3" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Total lease liabilities</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,194</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,179</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 2194000 3179000 2194000 3179000 1092000 985000 1102000 2194000 2194000 3179000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>9. Commitments and Contingencies</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Purchase Obligations</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Purchase obligations consist of agreements to purchase goods and services entered into in the ordinary course of business. The Company had non-cancelable commitments to suppliers for purchases totaling approximately $1.1 million as of December 31, 2022. The majority of this amount is related to commitments to purchase inventory components for our various product lines.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Indemnification</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and may provide for indemnification of the counterparty. The Company’s exposure under these agreements is unknown because it involves claims that may be made against it in the future, but have not yet been made. To date, the Company has not been subject to any claims or been required to defend any action related to its indemnification obligations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company indemnifies each of its directors and officers for certain events or occurrences, subject to certain limits, while the director is or was serving at the Company’s request in such capacity, as permitted under Delaware law and in accordance with its certificate of incorporation and bylaws. The term of the indemnification period lasts as long as a director may be subject to any proceeding arising out of acts or omissions of such director in such capacity. The maximum amount of potential future indemnification is unlimited; however, the Company currently holds director liability insurance. This insurance allows the transfer of risk associated with the Company’s exposure and may enable it to recover a portion of any future amounts paid. The Company believes that the fair value of these indemnification obligations is minimal. Accordingly, it has not recognized any liabilities relating to these obligations for any period presented.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Legal Proceedings</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company is not currently involved in any pending legal proceedings that it believes could have a material adverse effect on our financial condition, results of operations or cash flows. From time to time, the Company may be involved in legal proceedings or investigations, which could harm our reputation, business and financial condition and divert the attention of our management from the operation of our business.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> 1100000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>10. Stockholders</b>’<b> Equity </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Convertible Preferred Stock</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As of December 31, 2022, the Company’s certificate of incorporation, as amended and restated, authorizes the Company to issue up to 5,000,000 shares of convertible preferred stock with $0.001 par value per share. As of December 31, 2022 and 2021, 60,961 and 56,451 shares of convertible preferred stock, respectively, were issued and outstanding.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Series</i> <i>A Convertible Preferred Stock</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The holders of Series A preferred stock are entitled to receive annual accruing dividends at a rate of 8%, payable in additional shares of Series A preferred stock or cash, at the Company’s option. The shares of Series A preferred stock have a liquidation preference of $1,000 per share, no voting rights and rank senior to all other classes and series of the Company’s equity in terms of repayment and certain other rights. During the years ended December 31, 2022 and 2021, 4,510 and 4,175 additional shares, respectively, were issued to CRG as payment of dividends. As of December 31, 2022 and 2021, 60,876 and 56,366 shares of Series A preferred stock were outstanding, respectively, which are currently convertible into shares of the Company’s common stock at $400 per share. The Series A preferred stock accrued additional dividends of approximately $4.5 million and $4.2 million during the years ended December 31, 2022 and 2021, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Series</i> <i>B Convertible Preferred Stock</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Series B preferred stock has a liquidation preference of $0.001 per share, full ratchet price based anti-dilution protection, has no voting rights and is subject to certain ownership limitations. The Series B preferred stock is immediately convertible at the option of the holder, has no stated maturity, and does not pay regularly stated dividends or interest. During the year ended December 31, 2021, 93 of these shares converted into 18,600 shares of common stock. As of December 31, 2022 and 2021, 85 shares of Series B preferred stock remained outstanding, which are currently convertible into shares of the Company’s common stock at $1.502 per share.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Series D Convertible Preferred Stock</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On January 14, 2022, the Company entered into a security purchase agreement with several institutional investors, pursuant to which the Company agreed to sell and issue, in a registered direct offering (“January 2022 offering”), an aggregate of 7,600 shares of the Company’s Series D convertible preferred stock, par value $0.001 per share at an offering price of $1,000 per share. Concurrently, the Company agreed to issue to these investors warrants to purchase up to an aggregate of 807,500 shares of the Company’s common stock (the “Common Warrants”). The shares of Series D Preferred Stock has a stated value of $1,000 per share and are convertible into an aggregate of 950,000 shares of common stock at a conversion price of $8.00 per share.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On January 14, 2022, the Company entered into a security purchase agreement with several institutional investors, pursuant to which the Company agreed to sell and issue, in a registered direct offering (“January 2022 Offering”), an aggregate of 7,600 shares of the Company’s Series D convertible preferred stock, par value $0.001 per share at an offering price of $1,000 per share. Concurrently, the Company agreed to issue to these investors warrants to purchase up to an aggregate of 807,500 shares of the Company’s common stock (the “Common Warrants”). The shares of Series D preferred stock had a stated value of $1,000 per share and were convertible into an aggregate of 950,000 shares of common stock at a conversion price of $8.00 per share. During the year ended December 31, 2022, all 7,600 shares of Series D preferred stock were converted into a total of 950,000 shares of common stock. Consequently, there were <span style="-sec-ix-hidden:c924">no</span> shares of Series D preferred stock outstanding as of December 31, 2022.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">At the time of issuance, the Company evaluated the classification of the Series D preferred stock and determined equity classification was appropriate due to no mandatory or contingently redeemable redemption features. The warrants issued to the investors were considered freestanding equity classified instruments. The Company first allocated gross proceeds from the registered direct offering between the preferred stock and the warrants issued to investors using a relative fair value approach, resulting in an initial allocation to each instrument of $4.0 million and $3.6 million, respectively. On the issuance date, the Company estimated the fair value of the Common Warrants issued to investors and warrants issued to the placement agent designees using a Black-Scholes option pricing model using the following assumptions: (i) contractual term of 5.5 years, (ii) expected volatility rate of 136.61%, (iii) risk-free interest rate of 1.51%, (iv) expected dividend rate of 0%, and (v) closing price of the Company’s common stock of the day immediately preceding the registered direct offering. The fair value of preferred stock was estimated based upon equivalent common shares that preferred stock could have been converted into at the closing price of the day immediately preceding the purchase date.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The embedded conversion feature was evaluated and bifurcation from the preferred stock equity host was not considered necessary. The issuance of the Series D convertible preferred stock generated a beneficial conversion feature (“BCF”) which arose as the equity security was issued with an embedded conversion option that is beneficial to the investor or in the money at inception because the conversion option has an effective conversion price that is less than the market price of the underlying stock at the commitment date. The Company recorded the BCF as a discount to the preferred stock resulting in the amount of $5.1 million based on the intrinsic value of the beneficial conversion. As the preferred stock was immediately convertible into common stock subject to the consummation of the reverse stock split on March 14, 2022, a deemed dividend related to the discount associated with the beneficial conversion feature was recorded on that date. This one-time, non-cash charge impacted net loss applicable to common stockholders and net loss per share attributable to common stockholders for the year ended December 31, 2022.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Common Stock</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">At December 31, 2022, the Company’s certificate of incorporation, as amended and restated, authorizes the Company to issue up to 100,000,000 shares of common stock with $0.001 par value per share, of which 7,832,644 shares were issued and outstanding.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Common Stock Warrants</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As of December 31, 2022, the Company had outstanding warrants to purchase common stock as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Total</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Outstanding</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>and</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Exercisable</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Underlying</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Shares of</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Common </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Stock</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Exercise</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Price per</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Share</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Expiration Date</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Series 1 Warrants issued in the February 2018 Series B financing</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">8,979,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">44,895</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">400.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">February 2025</td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Series 2 Warrants issued in the February 2018 Series B financing</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">8,709,500</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">43,548</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">400.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">February 2025</td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Warrants issued in the November 2018 financing</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">8,768,395</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">43,842</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">80.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">November 2023</td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Placement agent warrants issued in the January 2022 financing</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,330,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">66,500</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">10.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">January 2027</td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Warrants issued in the January 2022 financing</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">16,150,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">807,500</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">9.60</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">July 2027</td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Pre-funded warrants issued in the August 2022 financing</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,369,864</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,369,864</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.0001</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">n/a</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Series A Preferred Investment Options issued in August 2022 financing</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,853,883</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,853,883</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1.502</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">February 2028</p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Series B Preferred Investment Options issued in August 2022 financing</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,853,883</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,853,883</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1.502</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">August 2024</p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Placement agent Preferred Investment Options issued in the August 2022 financing</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">171,233</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">171,233</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2.19</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">August 2027</p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;">Total as of December 31, 2022</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">51,185,758</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,255,148</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As of December 31, 2021, the Company had outstanding warrants to purchase common stock as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Total</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Outstanding</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>and</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Exercisable</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Underlying</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Shares of</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Common </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Stock</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Exercise</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Price per</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Share</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 17.2%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Expiration Date</b></p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 37.8%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Series 1 Warrants issued in the February 2018 Series B financing</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">8,979,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">44,895</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">400.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">February 2025</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Series 2 Warrants issued in the February 2018 Series B financing</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">8,709,500</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">43,548</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">400.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">February 2025</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Warrants issued in the November 2018 financing</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,768,395</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">43,842</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">80.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">November 2023</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Total as of December 31, 2021</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">26,456,895</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">132,265</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>January 2022 Offering</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Pursuant to a purchase agreement entered into on January 14, 2022, the Company issued warrants to purchase up to an aggregate of 807,500 shares of the Company’s common stock at an exercise price of $9.60 per share and which became exercisable beginning July 14, 2022. The Common Warrants will expire <span style="-sec-ix-hidden:c985">five</span> years following the time they become exercisable, or July 14, 2027.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company issued to the placement agent of the January 2022 Offering warrants to purchase up to an aggregate of 66,500 shares of common stock (the “Placement Agent Warrants”). The Placement Agent Warrants are subject to the same terms as the Common Warrants, except that the Placement Agent Warrants have an exercise price of $10.00 per share and a term of <span style="-sec-ix-hidden:c988">five</span> years from the commencement of the sales pursuant to the January 2022 Offering, or January 12, 2027.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>August 2022 Offering</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Pursuant to a purchase agreement entered into on August 4, 2022, the Company issued, in a registered direct offering, Pre-Funded Warrants to purchase up to 784,019 shares of common stock (the “RD Pre-Funded Warrants”) and, in a concurrent private placement, Pre-Funded Warrants to purchase up to 1,369,864 shares of common stock (the “Private Placement Pre-Funded Warrants” and together with the RD Pre-Funded Warrants the “August 2022 Pre-Funded Warrants”). The August 2022 Pre-Funded Warrants have an exercise price of $0.0001 per share, are immediately exercisable, and have no expiration date. During the year ended December 31, 2022, 784,019 of shares of RD Pre-Funded Warrants were exercised into the equivalent number of the Company’s common stock. As of December 31, 2022, August 2022 Pre-Funded Warrants exercisable for 1,369,864 shares of the Company’s common stock remained outstanding. On February 14, 2023, an additional 747,864 Private Placement Pre-Funded Warrants were exercised leaving 622,000 August 2022 Pre-Funded Warrants outstanding.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Also in the August 2022 offering, the Company issued Series A preferred investment options to purchase up to 2,853,883 additional shares of the Company’s common stock and Series B preferred investment options to purchase up to 2,853,883 additional shares of the Company’s common stock, collectively referred to as Preferred Investment Options. The Series A preferred investment options have an exercise price of $1.502 per share, are immediately exercisable, and will expire <span style="-sec-ix-hidden:c999">five</span> and one-half years from the date of issuance, or February 8, 2028, and the Series B preferred investment options have an exercise price of $1.502 per share, are immediately exercisable, and will expire <span style="-sec-ix-hidden:c1001">two</span> years from the date of issuance, or August 8, 2024.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company also issued to the placement agent of the August 2022 Offering preferred investment options to purchase up to 171,233 shares of common stock (the “Placement Agent Preferred Investment Options”). The Placement Agent Preferred Investment Options are subject to the same terms as the Preferred Investment Options, except that the Placement Agent Preferred Investment Options have an exercise price of $2.19 per share and a term of <span style="-sec-ix-hidden:c1004">five</span> years from the commencement of the sales pursuant to the August 2022 Offering, or August 3, 2027.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The exercise price and the number of shares of common stock issuable upon exercise of each Common Warrants, Pre-Funded Warrants, Preferred Investment Options, and Placement Agent Preferred Investment Options are subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock. In addition, in certain circumstances, upon a fundamental transaction, a holder of Common Warrants, Pre-Funded Warrants, Preferred Investment Options, or Placement Agent Preferred Investment Options will be entitled to receive, upon exercise, the kind and amount of securities, cash or other property that such holder would have received had they exercised the Common Warrants, Pre-Funded Warrants, Preferred Investment Options, or Placement Agent Preferred Investment Options immediately prior to the fundamental transaction.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Common Warrants, Pre-Funded Warrants, Preferred Investment Options, and Placement Agent Preferred Investment Options can be exercised at the option of the holders at any time after they become exercisable provided that shares of the Common Warrants, Pre-Funded Warrants, Preferred Investment Options, or Placement Agent Preferred Investment Options cannot be exercised into common stock if the applicable holder would beneficially own in excess of 4.99% (or, upon election by such holder prior to the issuance of any shares of Common Warrants, Pre-Funded Warrants, Preferred Investment Options, or Placement Agent Preferred Investment Options, <span style="-sec-ix-hidden:c1006">9.99</span>%) of the Company’s outstanding common stock immediately after giving effect to the exercise. A holder of the Common Warrants, Pre-Funded Warrants, Preferred Investment Options or Placement Agent Preferred Investment Options may, upon notice to the Company, increase or decrease such beneficial ownership limitation, but not in excess of 9.99%.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In the event of a fundamental transaction in which the holders of our voting securities immediately prior to such fundamental transaction will not, following such fundamental transaction, directly or indirectly own more than 50% of the voting securities of the surviving entity or successor entity, and in which the Company is not the successor entity or does not continue as a reporting issuer under the Exchange Act, then, at the request of the holder, the Company or the successor entity shall purchase the unexercised portion of the Common Warrants, Preferred Investment Options, and Placement Agent Preferred Investment Options from the holder by paying to the holder an amount, in cash, equal to the fair value of the remaining unexercised portion of the Common Warrants, Preferred Investment Options, and Placement Agent Preferred Investment Options on the date of such fundamental transaction, subject to certain limitations in the event of a fundamental transaction not within our control.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As of December 31, 2022 and 2021, warrants and preferred investment options to purchase an aggregate of 8,255,148 and 132,265 shares of common stock were outstanding, respectively, all of which were classified within the equity section of the respective balance sheets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 5000000 5000000 0.001 0.001 60961 60961 56451 56451 0.08 1000 4510 4175 60876 56366 400 4500000 4200000 0.001 93 18600 85 85 1.502 1.502 7600 0.001 1000 807500 1000 950000 8.00 7600 0.001 1000 807500 1000 950000 8.00 7600 950000 4.0 3600000 5.5 1.3661 0.0151 0 5100000 100000000 0.001 7832644 7832644 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Total</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Outstanding</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>and</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Exercisable</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Underlying</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Shares of</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Common </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Stock</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Exercise</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Price per</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Share</b></b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Expiration Date</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Series 1 Warrants issued in the February 2018 Series B financing</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">8,979,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">44,895</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">400.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">February 2025</td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Series 2 Warrants issued in the February 2018 Series B financing</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">8,709,500</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">43,548</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">400.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">February 2025</td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Warrants issued in the November 2018 financing</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">8,768,395</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">43,842</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">80.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">November 2023</td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Placement agent warrants issued in the January 2022 financing</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,330,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">66,500</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">10.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">January 2027</td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Warrants issued in the January 2022 financing</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">16,150,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">807,500</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">9.60</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">July 2027</td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Pre-funded warrants issued in the August 2022 financing</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,369,864</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,369,864</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.0001</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">n/a</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Series A Preferred Investment Options issued in August 2022 financing</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,853,883</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,853,883</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1.502</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">February 2028</p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Series B Preferred Investment Options issued in August 2022 financing</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,853,883</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,853,883</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1.502</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">August 2024</p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Placement agent Preferred Investment Options issued in the August 2022 financing</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">171,233</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">171,233</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2.19</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">August 2027</p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;">Total as of December 31, 2022</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">51,185,758</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,255,148</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> </tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Total</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Outstanding</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>and</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Exercisable</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Underlying</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Shares of</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Common </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Stock</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Exercise</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Price per</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Share</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 17.2%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Expiration Date</b></p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 37.8%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Series 1 Warrants issued in the February 2018 Series B financing</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">8,979,000</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">44,895</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">400.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">February 2025</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Series 2 Warrants issued in the February 2018 Series B financing</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">8,709,500</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">43,548</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">400.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">February 2025</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Warrants issued in the November 2018 financing</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,768,395</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">43,842</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">80.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">November 2023</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Total as of December 31, 2021</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">26,456,895</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">132,265</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> </tbody></table> 8979000 44895 400.00 8709500 43548 400.00 8768395 43842 80.00 1330000 66500 10.00 16150000 807500 9.60 1369864 1369864 0.0001 2853883 2853883 1.502 2853883 2853883 1.502 171233 171233 2.19 51185758 8255148 8979000 44895 400.00 8709500 43548 400.00 8768395 43842 80.00 26456895 132265 807500 9.60 66500 10.00 784019 1369864 0.0001 784019 1369864 747864 622000 2853883 2853883 1.502 1.502 171233 2.19 0.0499 8255148 132265 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>11. Stock-Based Compensation</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Stock Plans</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In January 2015, the Board of Directors adopted and the Company’s stockholders approved the 2015 Equity Incentive Plan (“2015 Plan”). The 2015 Plan provides for the grant of incentive stock options (“ISOs”) to employees and for the grant of non-statutory stock options (“NSOs”), restricted stock, restricted stock awards (“RSAs”), restricted stock units (“RSUs”), stock appreciation rights, performance units and performance shares to employees, directors and consultants. The shares reserved for issuance under the 2015 Plan includes share awards granted under the prior equity incentive plan that expire or terminate without having been exercised in full or that are forfeited or repurchased. On October 14, 2022, the Company’s stockholders approved an additional 1,750,000 shares of common stock for issuance under the 2015 Plan. As of December 31, 2022, 1,759,566 shares were available for grant under the 2015 Plan.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Pursuant to the 2015 Plan, ISOs and NSOs may be granted with exercise prices at not less than 100% of the fair value of the common stock on the date of grant and the exercise price of ISOs granted to a stockholder, who, at the time of grant, owns stock representing more than 10% of the voting power of all classes of the stock of the Company, shall be not less than 110% of the fair market value per share of common stock on the date of grant. The Company’s Board of Directors determines the vesting schedule of the options.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Stock option activity under the Plans is set forth below:</p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number of</b><br/> <b>Shares </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(in thousands)</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Average</b><br/> <b>Exercise</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Price</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Average </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Remaining </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Contractual </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Life</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(in years)</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Intrinsic</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Value</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(in thousands)</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2020</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">307</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">19,577.10</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5.95</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Options expired</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">36,000.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2021</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">303</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">19,360.30</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5.02</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2022</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">303</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">19,360.30</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4.02</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable at December 31, 2022</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">303</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">19,360.30</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4.02</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested and expected to vest at December 31, 2022</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">303</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">19,360.30</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4.02</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Additional information related to the Company’s stock options as of December 31, 2022 is summarized as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr> <td colspan="16" rowspan="1" style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid black; text-align: center; border-top: 1px solid black;"><b><b><b>Options Outstanding</b></b></b></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-top: 1px solid black;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-top: 1px solid black;"> </td> <td colspan="6" rowspan="1" style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid black; text-align: center; border-top: 1px solid black;"><b><b>Options Vested</b></b></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td> <td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 10%;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 13%;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" rowspan="1" style="font-family: Times New Roman; font-size: 10pt; width: 1%; text-align: center;"><b><b><b>Weighted</b></b></b></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Weighted</b></b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 13%;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Weighted</b></b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td> <td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 10%;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 13%;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" rowspan="1" style="font-family: Times New Roman; font-size: 10pt; width: 1%; text-align: center;"><b><b><b>Average</b></b></b></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Average</b></b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 13%;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Average</b></b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="4" style="font-family: Times New Roman; font-size: 10pt; width: 11%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Exercise</b></b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Options</b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Remaining</b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Exercise</b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b><b>Number</b></b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Exercise</b></b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="4" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 11%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Price</b></b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Outstanding </b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Contractual Life</b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Price</b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><b><b>Exercisable </b></b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Price</b></b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</td> <td colspan="3" style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">334.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">155</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">5.44</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">334.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">155</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">334.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</td> <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">16,400.00</td> <td style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">28,400.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">31</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">4.18</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">17,323.87</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">31</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">17,323.87</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</td> <td colspan="3" style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">36,000.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">103</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">2.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">36,000.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">103</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">36,000.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</td> <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">103,680.00</td> <td style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">162,000.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">14</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">2.85</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">112,097.14</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">14</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">112,097.14</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 10%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">303</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">4.02</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">19,360.30</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">303</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">19,360.30</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">There were <span style="-sec-ix-hidden:c1135"><span style="-sec-ix-hidden:c1136"><span style="-sec-ix-hidden:c1137"><span style="-sec-ix-hidden:c1138">no</span></span></span></span> options granted or exercised during either of the years ended December 31, 2022 or 2021. For the years ended December 31, 2022 and 2021, stock-based compensation expense recognized associated with stock options vesting was approximately $0 and $4,000, respectively. As of December 31, 2022, there is <span style="-sec-ix-hidden:c1149">no</span> remaining unamortized stock-based compensation expense associated with unvested stock options. Because of the Company’s net operating losses, the Company did <span style="-sec-ix-hidden:c1150"><span style="-sec-ix-hidden:c1151">not</span></span> realize any tax benefits from share-based payment arrangements for the years ended December 31, 2022 and 2021.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Company’s RSUs generally vest annually over <span style="-sec-ix-hidden:c1155">three</span> years in equal increments. The Company measures the fair value of RSUs using the closing stock price of a share of the Company’s common stock on the grant date and is recognized as expense on a straight-line basis over the vesting period of the award. A summary of all RSU activity is presented below:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number of</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Shares</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Average</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Grant Date</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Fair Value</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Average</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Remaining</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Contractual</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Term</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Awards outstanding at December 31, 2020</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">20,671</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">76.03</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.98</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Awarded</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,500</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">32.20</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Released</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(13,386</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">104.31</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,725</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">53.62</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Awards outstanding at December 31, 2021</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10,060</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">24.39</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.72</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Released</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(8,590</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">25.02</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,053</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">24.25</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Awards outstanding at December 31, 2022</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">417</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">11.64</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.17</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As of December 31, 2022, there was less than $0.1 million of remaining unamortized stock-based compensation expense associated with RSUs, which will be expensed over a weighted average remaining service period of 0.2 years. The outstanding non-vested and expected to vest RSUs at December 31, 2022 have an aggregate fair value of approximately less than $0.1 million. The Company used the closing market price of $1.09 per share at December 31, 2022 to determine the aggregate fair value for the RSUs outstanding at that date. For the years ended December 31, 2022 and 2021, the fair value of RSUs vested was approximately $14,000 and $273,000, respectively. For the years ended December 31, 2022 and 2021, stock-based compensation expense recognized associated with the vesting of RSUs was approximately $0.1 million and $1.0 million, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>2018 Officer and Director Share Purchase Plan</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On August 22, 2018, the Board of Directors of the Company approved the adoption of an Officer and Director Share Purchase Plan (“ODPP”), which allowed executive officers and directors to purchase shares of our common stock at fair market value in lieu of salary or, in the case of directors, director fees. Eligible individuals were allowed voluntarily participate in the ODPP by authorizing payroll deductions or, in the case of directors, deductions from director fees for the purpose of purchasing common stock. There was <span style="-sec-ix-hidden:c1201"><span style="-sec-ix-hidden:c1202">no</span></span> common stock issued under the ODPP during either of the years ended December 31, 2022 or 2021. On May 16, 2022, the Board of Directors of the Company terminated the Amended and Restated Officer and Director Share Purchase Plan due to the administrative costs of maintaining such plan and the limited amount of remaining shares. Consequently, there are <span style="-sec-ix-hidden:c1208">no</span> longer any shares reserved for issuance under this plan.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Total noncash stock-based compensation expense relating to the Company’s stock options and RSUs recognized, before taxes, during the years ended December 31, 2022 and 2021, is as follows (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Cost of revenues</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">18</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">101</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development expenses</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">37</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">287</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Selling, general and administrative expenses</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">72</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">627</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">127</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,015</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 1750000 1759566 1 1.10 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number of</b><br/> <b>Shares </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(in thousands)</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Average</b><br/> <b>Exercise</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Price</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Average </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Remaining </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Contractual </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Life</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(in years)</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Intrinsic</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Value</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(in thousands)</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2020</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">307</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">19,577.10</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5.95</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Options expired</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">36,000.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2021</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">303</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">19,360.30</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5.02</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2022</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">303</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">19,360.30</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4.02</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable at December 31, 2022</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">303</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">19,360.30</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4.02</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested and expected to vest at December 31, 2022</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">303</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">19,360.30</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4.02</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> 307000 19577.10 P5Y11M12D 0 4000 36000.00 303000 19360.30 P5Y7D 0 303000 19360.30 P4Y7D 0 303000 19360.30 P4Y7D 0 303000 19360.30 P4Y7D 0 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr> <td colspan="16" rowspan="1" style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid black; text-align: center; border-top: 1px solid black;"><b><b><b>Options Outstanding</b></b></b></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-top: 1px solid black;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-top: 1px solid black;"> </td> <td colspan="6" rowspan="1" style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid black; text-align: center; border-top: 1px solid black;"><b><b>Options Vested</b></b></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td> <td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 10%;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 13%;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" rowspan="1" style="font-family: Times New Roman; font-size: 10pt; width: 1%; text-align: center;"><b><b><b>Weighted</b></b></b></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Weighted</b></b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 13%;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Weighted</b></b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td> <td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 10%;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 13%;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" rowspan="1" style="font-family: Times New Roman; font-size: 10pt; width: 1%; text-align: center;"><b><b><b>Average</b></b></b></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Average</b></b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 13%;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Average</b></b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="4" style="font-family: Times New Roman; font-size: 10pt; width: 11%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Exercise</b></b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Options</b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Remaining</b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Exercise</b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b><b>Number</b></b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Exercise</b></b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="4" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 11%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Price</b></b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Outstanding </b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Contractual Life</b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Price</b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><b><b>Exercisable </b></b></td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Price</b></b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</td> <td colspan="3" style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">334.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">155</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">5.44</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">334.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">155</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">334.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</td> <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">16,400.00</td> <td style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">28,400.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">31</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">4.18</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">17,323.87</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">31</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">17,323.87</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</td> <td colspan="3" style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">36,000.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">103</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">2.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">36,000.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">103</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">36,000.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</td> <td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">103,680.00</td> <td style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td> <td style="width: 7%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">162,000.00</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;">14</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">2.85</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">112,097.14</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid black;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">14</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">112,097.14</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 10%;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">303</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">4.02</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">19,360.30</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">303</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">19,360.30</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 334.00 155000 P5Y5M8D 334.00 155000 334.00 16400.00 28400.00 31000 P4Y2M4D 17323.87 31000 17323.87 36000.00 103000 P2Y 36000.00 103000 36000.00 103680.00 162000.00 14000 P2Y10M6D 112097.14 14000 112097.14 303000 P4Y7D 19360.30 303000 19360.30 0 4000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number of</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Shares</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Average</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Grant Date</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Fair Value</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Average</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Remaining</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Contractual</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Term</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Awards outstanding at December 31, 2020</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">20,671</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">76.03</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.98</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Awarded</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,500</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">32.20</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Released</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(13,386</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">104.31</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,725</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">53.62</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Awards outstanding at December 31, 2021</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10,060</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">24.39</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.72</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Released</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(8,590</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">25.02</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,053</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">24.25</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Awards outstanding at December 31, 2022</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">417</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">11.64</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.17</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> 20671 76.03 P0Y11M23D 4500 32.20 13386 104.31 1725 53.62 10060 24.39 P0Y8M19D 8590 25.02 1053 24.25 417 11.64 P0Y2M1D 100000 P0Y2M12D 100000 1.09 14000 273000 100000 1000000.0 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Cost of revenues</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">18</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">101</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development expenses</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">37</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">287</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Selling, general and administrative expenses</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">72</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">627</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">127</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,015</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 18000 101000 37000 287000 72000 627000 127000 1015000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>12. Income Taxes</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For the years ended December 31, 2022 and 2021, the Company’s provision for income taxes consisted of <span style="-sec-ix-hidden:c1315"><span style="-sec-ix-hidden:c1316">zero</span></span> state income tax expense. A reconciliation of the statutory U.S. federal rate to the Company’s effective tax rate is as follows (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Tax at federal statutory rate</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(3,701</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(3,657</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">State taxes, net of federal benefit</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(916</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(711</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Permanent differences</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(484</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(445</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in valuation allowance</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5,084</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5,104</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Research credits</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(273</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(286</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Nondeductible interest expense</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">290</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Provision for taxes</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Significant components of the Company’s net deferred tax assets as of December 31, 2022 and 2021 consist of the following (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>As of December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax assets:</p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Federal, state and foreign net operating losses</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">85,547</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">83,211</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Research and other credits</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5,343</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,892</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Operating lease liability</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">544</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">752</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Fixed assets</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">471</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accruals and other</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3,628</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,845</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Capitalized research and development</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,019</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total deferred tax assets</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">96,552</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">91,700</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Less: Valuation allowance</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(95,992</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(90,908</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total net deferred tax assets</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">560</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">792</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred liabilities:</p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Property and equipment</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(2</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Operating lease right of use asset</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(560</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(790</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total deferred tax liabilities</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(560</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(792</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred tax assets (liabilities)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The valuation allowance increased by $5.1 million and $4.7 million during the years ended December 31, 2022 and 2021, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As of December 31, 2022, the Company had approximately $344.3 million of federal and $208.0 million of state net operating loss carryforwards available to offset future taxable income. If not utilized, the federal and state net operating loss carryforwards begin to expire in 2027 and 2023, respectively. Out of the Federal net operating loss carryforwards, $86.8 million were generated post December 31, 2017 and have no expiration.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As of December 31, 2022, the Company also had approximately $4.3 million and $4.2 million of research and development tax credit carryforwards available to reduce future taxable income, if any, for both federal and California purposes, respectively. The federal credit carryforwards expire beginning in 2027, and the California research credits do not expire and may be carried forward indefinitely.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company's ability to utilize the net operating loss and tax credit carryforwards in the future may be subject to substantial restrictions in the event of past or future ownership changes as defined in Section 382 of the Internal Revenue Code and similar state tax laws. In the event the Company should experience an ownership change, as defined, utilization of the Company's net operating loss carryforwards and tax credits could be limited.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company evaluates tax positions for recognition using a more-likely-than-not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A reconciliation of the beginning and ending amount of the gross recognized tax benefit is as follows (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>As of December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at beginning of year</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,366</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,307</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Increase based on the tax positions in the current year</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">203</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">228</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Increase (Decrease) for tax positions of prior year</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(169</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at end of year</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,581</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,366</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As of December 31, 2022, all unrecognized tax benefits would be subject to a full valuation allowance, if recognized, and would not affect the Company’s tax rate.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company does not anticipate that the total amounts of unrecognized tax benefits will significantly increase or decrease in the next twelve months.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company's policy is to include interest and penalties related to unrecognized tax benefits within its provision for income taxes. Due to the Company's net operating loss position, the Company has <span style="-sec-ix-hidden:c1403"><span style="-sec-ix-hidden:c1404">not</span></span> recorded an accrual for interest or penalties related to uncertain tax positions for the years ended December 31, 2022 or 2021.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Tax at federal statutory rate</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(3,701</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(3,657</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">State taxes, net of federal benefit</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(916</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(711</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Permanent differences</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(484</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(445</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in valuation allowance</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5,084</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5,104</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Research credits</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(273</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(286</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Nondeductible interest expense</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">290</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Provision for taxes</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> -3701000 -3657000 -916000 -711000 -484000 -445000 5084000 5104000 273000 286000 290000 0 0 -5000 0 0 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>As of December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax assets:</p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Federal, state and foreign net operating losses</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">85,547</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">83,211</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Research and other credits</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5,343</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,892</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Operating lease liability</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">544</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">752</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Fixed assets</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">471</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accruals and other</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3,628</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,845</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Capitalized research and development</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,019</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total deferred tax assets</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">96,552</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">91,700</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Less: Valuation allowance</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(95,992</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(90,908</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total net deferred tax assets</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">560</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">792</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred liabilities:</p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Property and equipment</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(2</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Operating lease right of use asset</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(560</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(790</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total deferred tax liabilities</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(560</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(792</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred tax assets (liabilities)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 85547000 83211000 5343000 4892000 544000 752000 471000 0 3628000 2845000 1019000 0 96552000 91700000 95992000 90908000 560000 792000 -0 2000 560000 790000 560000 792000 0 0 5100000 4700000 344300000 208000000.0 86800000 4300000 4200000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"> <tbody><tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>As of December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at beginning of year</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,366</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,307</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Increase based on the tax positions in the current year</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">203</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">228</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Increase (Decrease) for tax positions of prior year</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(169</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at end of year</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,581</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,366</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 2366000 2307000 203000 228000 12000 169000 2581000 2366000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>13. 401(k)</b> <b>Plan</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company has a qualified retirement plan under section 401(k) of the Internal Revenue Code (“IRC”) under which participants may contribute up to 99% of their eligible compensation, subject to maximum deferral limits specified by the IRC. The Company may make a discretionary matching contribution to the 401(k) plan, and may make a discretionary employer contribution to each eligible employee each year. To date, the Company has made <span style="-sec-ix-hidden:c1469">no</span> contributions to the 401(k) plan.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 0.99 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>14. Subsequent Events</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Pre-Funded Warrant Exercise</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On February 14, 2023, a holder of Private Placement Pre-Funded Warrants opted to exercise a portion of the warrant into common stock. A total of 747,864 shares of the Private Placement Pre-Funded Warrants were exercised resulting in the issuance of an aggregate of 747,864 shares of common stock. After giving effect to these aforementioned exercise, there remains 622,000 shares of Private Placement Pre-Funded Warrant shares outstanding, which if exercised, would result in the issuance of an equivalent number of shares of common stock.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Restricted Stock Award Grant</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On January 18, 2023, the Company granted a total of 1,502,928 shares of RSAs to various employees. These RSAs generally vest annually over <span style="-sec-ix-hidden:c1480">two</span> years in equal increments, with certain exceptions. The Company measured the fair value of RSAs using the closing stock price of a share of the Company’s common stock of $1.23 on the day of grant. The resulting expense will be recognized on a straight-line basis over the vesting period of the awards.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">  </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Silicon Valley Bank</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Currently all of our cash and cash equivalents are held at a single financial institution, Silicon Valley Bank. On March 10, 2023, the Federal Deposit Insurance Corporation announced that Silicon Valley Bank had been closed by the California Department of Financial Protection and Innovation. While we have regained access to our accounts at Silicon Valley Bank and are evaluating our banking relationships, future disruptions of financial institutions where we bank or have credit arrangements, or disruptions of the financial services industry in general, could adversely affect our ability to access our cash and cash equivalents. If we are unable to access our cash and cash equivalents as needed, our financial position and ability to operate our business will be adversely affected.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> 747864 747864 622000 1502928 1.23 EXCEL 77 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

.V&)>K1 5W7 MJ$1XD2E!>6$0$^Z/AZ&_;S%\%$M%H:KM'4L1#>BVJOC\U@:QP MV&+Y/T2#=>,2^9TY'A:Y01OESQ*-()C+?)[F@ON?J37I';+.;E1.L9\8?!/U MWDCVB^ZJ,\EH'M59_HEG@ QVOK+2@IU-RO!8A6Q_R5UT"_J2 _8 MV!=C'L8A@Q1494PY7XV,-686CZ.P;$[0%@W_7:J^(0W>.6!_Q^G37N@VX&:C MTZ1.0&3U,]TR56L_:CTW(IAW=('"^.;N/4>PUSR-B:TN2GI963TU H(C96F- MY@'*^#ZC2?@W*B'R\J5DY'A?=OTBUQ55F"O]-B-47)?ZHP?.>]BB@DUX=PO M-SZUV3G?UK<]V52'V[A3=/*+"<&RFZ=!2, MIM/R/YQU/E4]V9^T,4V5<3ODLMI[<8%1 /"]GB@<413-G^1[0..O3NL9N:6! M-ZQ1>.QE<73M#:<+S!@MJ#)+#D!.YL,&[*NM@7DILN,AM+2K=T6KP(B2W2/C MB:_C3ZK*U"Y5E_)XTPD4C\2(NE]+^>R_P9"MX%UOGS](-JGF\+WTC\M=77:/)_5RF@> M.^L/6I]CMA*UA#\Z^:J8N?++3/.T^:[UH?R<\[2\_"CV&TJ10L:F<@71L#^; M=,NYNKYQ.O&UL M?57;3MM $/V5D5$12&E\2:!F M68:V-,BR.DB*,(FBTU RKH+)J-Z[-Y.1KIS@"N\-V$I*9C93%'H]#N+@=6/. MEX7S&^%D5+(E/J#[4=X;LL(.)>,2E>5:@<%\'%S%%].A]Z\=?G)"4+ MK5?>N,W&0>0)H<#4>01&KV>

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end XML 78 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 79 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 80 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 212 364 1 false 96 0 false 6 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.avinger.com/20221231/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Balance Sheets Sheet http://www.avinger.com/20221231/role/statement-balance-sheets Balance Sheets Statements 2 false false R3.htm 002 - Statement - Balance Sheets (Parentheticals) Sheet http://www.avinger.com/20221231/role/statement-balance-sheets-parentheticals Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Statements of Operations and Comprehensive Loss Sheet http://www.avinger.com/20221231/role/statement-statements-of-operations-and-comprehensive-loss Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 004 - Statement - Statements of Stockholders' Equity Sheet http://www.avinger.com/20221231/role/statement-statements-of-stockholders-equity Statements of Stockholders' Equity Statements 5 false false R6.htm 005 - Statement - Statements of Cash Flows Sheet http://www.avinger.com/20221231/role/statement-statements-of-cash-flows Statements of Cash Flows Statements 6 false false R7.htm 006 - Disclosure - Financial Statements Schedules Sheet http://www.avinger.com/20221231/role/statement-financial-statements-schedules- Financial Statements Schedules Notes 7 false false R8.htm 007 - Disclosure - Note 1 - Organization Sheet http://www.avinger.com/20221231/role/statement-note-1-organization Note 1 - Organization Notes 8 false false R9.htm 008 - Disclosure - Note 2 - Summary of Significant Accounting Policies Sheet http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies Note 2 - Summary of Significant Accounting Policies Notes 9 false false R10.htm 009 - Disclosure - Note 3 - Fair Value Measurements Sheet http://www.avinger.com/20221231/role/statement-note-3-fair-value-measurements Note 3 - Fair Value Measurements Notes 10 false false R11.htm 010 - Disclosure - Note 4 - Inventories Sheet http://www.avinger.com/20221231/role/statement-note-4-inventories Note 4 - Inventories Notes 11 false false R12.htm 011 - Disclosure - Note 5 - Property and Equipment, Net Sheet http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net- Note 5 - Property and Equipment, Net Notes 12 false false R13.htm 012 - Disclosure - Note 6 - Accrued Expenses and Other Current Liabilities Sheet http://www.avinger.com/20221231/role/statement-note-6-accrued-expenses-and-other-current-liabilities- Note 6 - Accrued Expenses and Other Current Liabilities Notes 13 false false R14.htm 013 - Disclosure - Note 7 - Borrowings Sheet http://www.avinger.com/20221231/role/statement-note-7-borrowings Note 7 - Borrowings Notes 14 false false R15.htm 014 - Disclosure - Note 8 - Leases Sheet http://www.avinger.com/20221231/role/statement-note-8-leases Note 8 - Leases Notes 15 false false R16.htm 015 - Disclosure - Note 9 - Commitments and Contingencies Sheet http://www.avinger.com/20221231/role/statement-note-9-commitments-and-contingencies Note 9 - Commitments and Contingencies Notes 16 false false R17.htm 016 - Disclosure - Note 10 - Stockholders' Equity Sheet http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity Note 10 - Stockholders' Equity Notes 17 false false R18.htm 017 - Disclosure - Note 11 - Stock-based Compensation Sheet http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation Note 11 - Stock-based Compensation Notes 18 false false R19.htm 018 - Disclosure - Note 12 - Income Taxes Sheet http://www.avinger.com/20221231/role/statement-note-12-income-taxes Note 12 - Income Taxes Notes 19 false false R20.htm 019 - Disclosure - Note 13 - 401(k) Plan Sheet http://www.avinger.com/20221231/role/statement-note-13-401k-plan- Note 13 - 401(k) Plan Notes 20 false false R21.htm 020 - Disclosure - Note 14 - Subsequent Events Sheet http://www.avinger.com/20221231/role/statement-note-14-subsequent-events Note 14 - Subsequent Events Notes 21 false false R22.htm 021 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.avinger.com/20221231/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies 22 false false R23.htm 022 - Disclosure - Financial Statements Schedules (Tables) Sheet http://www.avinger.com/20221231/role/statement-financial-statements-schedules-tables Financial Statements Schedules (Tables) Tables http://www.avinger.com/20221231/role/statement-financial-statements-schedules- 23 false false R24.htm 023 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) Sheet http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables Note 2 - Summary of Significant Accounting Policies (Tables) Tables http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies 24 false false R25.htm 024 - Disclosure - Note 4 - Inventories (Tables) Sheet http://www.avinger.com/20221231/role/statement-note-4-inventories-tables Note 4 - Inventories (Tables) Tables http://www.avinger.com/20221231/role/statement-note-4-inventories 25 false false R26.htm 025 - Disclosure - Note 5 - Property and Equipment, Net (Tables) Sheet http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-tables Note 5 - Property and Equipment, Net (Tables) Tables http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net- 26 false false R27.htm 027 - Disclosure - Note 7 - Borrowings (Tables) Sheet http://www.avinger.com/20221231/role/statement-note-7-borrowings-tables Note 7 - Borrowings (Tables) Tables http://www.avinger.com/20221231/role/statement-note-7-borrowings 27 false false R28.htm 028 - Disclosure - Note 8 - Leases (Tables) Sheet http://www.avinger.com/20221231/role/statement-note-8-leases-tables Note 8 - Leases (Tables) Tables http://www.avinger.com/20221231/role/statement-note-8-leases 28 false false R29.htm 029 - Disclosure - Note 10 - Stockholders' Equity (Tables) Sheet http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-tables Note 10 - Stockholders' Equity (Tables) Tables http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity 29 false false R30.htm 030 - Disclosure - Note 11 - Stock-based Compensation (Tables) Sheet http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-tables Note 11 - Stock-based Compensation (Tables) Tables http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation 30 false false R31.htm 031 - Disclosure - Note 12 - Income Taxes (Tables) Sheet http://www.avinger.com/20221231/role/statement-note-12-income-taxes-tables Note 12 - Income Taxes (Tables) Tables http://www.avinger.com/20221231/role/statement-note-12-income-taxes 31 false false R32.htm 032 - Disclosure - Financial Statements Schedules - Allowance of Doubtful Accounts and Sales Returns (Details) Sheet http://www.avinger.com/20221231/role/statement-financial-statements-schedules-allowance-of-doubtful-accounts-and-sales-returns-details Financial Statements Schedules - Allowance of Doubtful Accounts and Sales Returns (Details) Details 32 false false R33.htm 033 - Disclosure - Note 1 - Organization (Details Textual) Sheet http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual Note 1 - Organization (Details Textual) Details http://www.avinger.com/20221231/role/statement-note-1-organization 33 false false R34.htm 034 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) Sheet http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual Note 2 - Summary of Significant Accounting Policies (Details Textual) Details http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables 34 false false R35.htm 035 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Accounts Receivable, Allowance for Credit Loss (Details) Sheet http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-accounts-receivable-allowance-for-credit-loss-details Note 2 - Summary of Significant Accounting Policies - Accounts Receivable, Allowance for Credit Loss (Details) Details 35 false false R36.htm 036 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Product Warranty (Details) Sheet http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-product-warranty-details Note 2 - Summary of Significant Accounting Policies - Product Warranty (Details) Details 36 false false R37.htm 037 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Net Loss Per Share (Details) Sheet http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-net-loss-per-share-details Note 2 - Summary of Significant Accounting Policies - Net Loss Per Share (Details) Details 37 false false R38.htm 038 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) Sheet http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details Note 2 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) Details 38 false false R39.htm 039 - Disclosure - Note 3 - Fair Value Measurements (Details Textual) Sheet http://www.avinger.com/20221231/role/statement-note-3-fair-value-measurements-details-textual Note 3 - Fair Value Measurements (Details Textual) Details http://www.avinger.com/20221231/role/statement-note-3-fair-value-measurements 39 false false R40.htm 040 - Disclosure - Note 4 - Inventories - Schedule of Inventory (Details) Sheet http://www.avinger.com/20221231/role/statement-note-4-inventories-schedule-of-inventory-details Note 4 - Inventories - Schedule of Inventory (Details) Details 40 false false R41.htm 041 - Disclosure - Note 5 - Property and Equipment, Net (Details Textual) Sheet http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-details-textual Note 5 - Property and Equipment, Net (Details Textual) Details http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-tables 41 false false R42.htm 042 - Disclosure - Note 5 - Property and Equipment, Net - Property and Equipment (Details) Sheet http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-property-and-equipment-details Note 5 - Property and Equipment, Net - Property and Equipment (Details) Details 42 false false R43.htm 043 - Disclosure - Note 6 - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) Sheet http://www.avinger.com/20221231/role/statement-note-6-accrued-expenses-and-other-current-liabilities-schedule-of-accrued-expenses-and-other-current-liabilities-details Note 6 - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) Details 43 false false R44.htm 044 - Disclosure - Note 7 - Borrowings (Details Textual) Sheet http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual Note 7 - Borrowings (Details Textual) Details http://www.avinger.com/20221231/role/statement-note-7-borrowings-tables 44 false false R45.htm 045 - Disclosure - Note 7 - Borrowings - Schedule of Debt (Details) Sheet http://www.avinger.com/20221231/role/statement-note-7-borrowings-schedule-of-debt-details Note 7 - Borrowings - Schedule of Debt (Details) Details 45 false false R46.htm 046 - Disclosure - Note 8 - Leases (Details Textual) Sheet http://www.avinger.com/20221231/role/statement-note-8-leases-details-textual Note 8 - Leases (Details Textual) Details http://www.avinger.com/20221231/role/statement-note-8-leases-tables 46 false false R47.htm 047 - Disclosure - Note 8 - Leases - Future Operating Lease Payments (Details) Sheet http://www.avinger.com/20221231/role/statement-note-8-leases-future-operating-lease-payments-details Note 8 - Leases - Future Operating Lease Payments (Details) Details 47 false false R48.htm 048 - Disclosure - Note 8 - Leases - ROU Assets and Lease Liabilities (Details) Sheet http://www.avinger.com/20221231/role/statement-note-8-leases-rou-assets-and-lease-liabilities-details Note 8 - Leases - ROU Assets and Lease Liabilities (Details) Details 48 false false R49.htm 049 - Disclosure - Note 9 - Commitments and Contingencies (Details Textual) Sheet http://www.avinger.com/20221231/role/statement-note-9-commitments-and-contingencies-details-textual Note 9 - Commitments and Contingencies (Details Textual) Details http://www.avinger.com/20221231/role/statement-note-9-commitments-and-contingencies 49 false false R50.htm 050 - Disclosure - Note 10 - Stockholders' Equity (Details Textual) Sheet http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual Note 10 - Stockholders' Equity (Details Textual) Details http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-tables 50 false false R51.htm 051 - Disclosure - Note 10 - Stockholder's Equity - Outstanding Warrants (Details) Sheet http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-outstanding-warrants-details Note 10 - Stockholder's Equity - Outstanding Warrants (Details) Details 51 false false R52.htm 052 - Disclosure - Note 11 - Stock-based Compensation (Details Textual) Sheet http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-details-textual Note 11 - Stock-based Compensation (Details Textual) Details http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-tables 52 false false R53.htm 053 - Disclosure - Note 11 - Stock-Based Compensation - Stock Option Activity (Details) Sheet http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-stock-option-activity-details Note 11 - Stock-Based Compensation - Stock Option Activity (Details) Details 53 false false R54.htm 054 - Disclosure - Note 11 - Stock-Based Compensation - Options Outstanding and Vested (Details) Sheet http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-options-outstanding-and-vested-details Note 11 - Stock-Based Compensation - Options Outstanding and Vested (Details) Details 54 false false R55.htm 055 - Disclosure - Note 11 - Stock-Based Compensation - Restricted Stock Units Award Activity (Details) Sheet http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-restricted-stock-units-award-activity-details Note 11 - Stock-Based Compensation - Restricted Stock Units Award Activity (Details) Details 55 false false R56.htm 056 - Disclosure - Note 11 - Stock-based Compensation - Noncash Stock-based Compensation Expense Related to Stock Options, ESPP, and RSUs (Details) Sheet http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-noncash-stockbased-compensation-expense-related-to-stock-options-espp-and-rsus-details Note 11 - Stock-based Compensation - Noncash Stock-based Compensation Expense Related to Stock Options, ESPP, and RSUs (Details) Details 56 false false R57.htm 057 - Disclosure - Note 12 - Income Taxes (Details Textual) Sheet http://www.avinger.com/20221231/role/statement-note-12-income-taxes-details-textual Note 12 - Income Taxes (Details Textual) Details http://www.avinger.com/20221231/role/statement-note-12-income-taxes-tables 57 false false R58.htm 058 - Disclosure - Note 12 - Income Taxes - Effective Income Tax Reconciliation (Details) Sheet http://www.avinger.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details Note 12 - Income Taxes - Effective Income Tax Reconciliation (Details) Details 58 false false R59.htm 059 - Disclosure - Note 12 - Income Taxes - Deferred Tax Assets and Liabilities (Details) Sheet http://www.avinger.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-and-liabilities-details Note 12 - Income Taxes - Deferred Tax Assets and Liabilities (Details) Details 59 false false R60.htm 060 - Disclosure - Note 12 - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) Sheet http://www.avinger.com/20221231/role/statement-note-12-income-taxes-reconciliation-of-unrecognized-tax-benefits-details Note 12 - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) Details 60 false false R61.htm 061 - Disclosure - Note 13 - 401(k) Plan (Details Textual) Sheet http://www.avinger.com/20221231/role/statement-note-13-401k-plan-details-textual Note 13 - 401(k) Plan (Details Textual) Details http://www.avinger.com/20221231/role/statement-note-13-401k-plan- 61 false false R62.htm 062 - Disclosure - Note 14 - Subsequent Events (Details Textual) Sheet http://www.avinger.com/20221231/role/statement-note-14-subsequent-events-details-textual Note 14 - Subsequent Events (Details Textual) Details http://www.avinger.com/20221231/role/statement-note-14-subsequent-events 62 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 54 fact(s) appearing in ix:hidden were eligible for transformation: avgr:ConversionOfWarrantsAllowedMaximumOwnershipOfCommonStockPercentageUponElection, avgr:NumberOfMajorCustomers, avgr:WarrantyPeriod, dei:CurrentFiscalYearEndDate, us-gaap:AssetsFairValueDisclosure, us-gaap:CommonStockSharesIssued, us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax, us-gaap:DefinedContributionPlanCostRecognized, us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized, us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense, us-gaap:IncomeTaxExpenseBenefit, us-gaap:LiabilitiesFairValueDisclosure, us-gaap:NumberOfReportableSegments, us-gaap:OperatingLeaseExpense, us-gaap:PreferredStockSharesOutstanding, us-gaap:PropertyPlantAndEquipmentUsefulLife, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross, us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised, us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued, us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense, us-gaap:WarrantsAndRightsOutstandingTerm, us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation - avgr20221231_10k.htm 10, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65 avgr20221231_10k.htm avgr-20221231.xsd avgr-20221231_cal.xml avgr-20221231_def.xml avgr-20221231_lab.xml avgr-20221231_pre.xml ex_486885.htm ex_486886.htm ex_486887.htm ex_486888.htm ex_488855.htm ex_488856.htm ex_488857.htm http://fasb.org/srt/2022 http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 83 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "avgr20221231_10k.htm": { "axisCustom": 0, "axisStandard": 33, "baseTaxonomies": { "http://fasb.org/srt/2022": 1, "http://fasb.org/us-gaap/2022": 765, "http://xbrl.sec.gov/dei/2022": 36 }, "contextCount": 212, "dts": { "calculationLink": { "local": [ "avgr-20221231_cal.xml" ] }, "definitionLink": { "local": [ "avgr-20221231_def.xml" ] }, "inline": { "local": [ "avgr20221231_10k.htm" ] }, "labelLink": { "local": [ "avgr-20221231_lab.xml" ] }, "presentationLink": { "local": [ "avgr-20221231_pre.xml" ] }, "schema": { "local": [ "avgr-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 576, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 47, "http://www.avinger.com/20221231": 6, "http://xbrl.sec.gov/dei/2022": 5, "total": 58 }, "keyCustom": 48, "keyStandard": 316, "memberCustom": 48, "memberStandard": 40, "nsprefix": "avgr", "nsuri": "http://www.avinger.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.avinger.com/20221231/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Note 3 - Fair Value Measurements", "menuCat": "Notes", "order": "10", "role": "http://www.avinger.com/20221231/role/statement-note-3-fair-value-measurements", "shortName": "Note 3 - Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Note 4 - Inventories", "menuCat": "Notes", "order": "11", "role": "http://www.avinger.com/20221231/role/statement-note-4-inventories", "shortName": "Note 4 - Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Note 5 - Property and Equipment, Net", "menuCat": "Notes", "order": "12", "role": "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-", "shortName": "Note 5 - Property and Equipment, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Note 6 - Accrued Expenses and Other Current Liabilities", "menuCat": "Notes", "order": "13", "role": "http://www.avinger.com/20221231/role/statement-note-6-accrued-expenses-and-other-current-liabilities-", "shortName": "Note 6 - Accrued Expenses and Other Current Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Note 7 - Borrowings", "menuCat": "Notes", "order": "14", "role": "http://www.avinger.com/20221231/role/statement-note-7-borrowings", "shortName": "Note 7 - Borrowings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Note 8 - Leases", "menuCat": "Notes", "order": "15", "role": "http://www.avinger.com/20221231/role/statement-note-8-leases", "shortName": "Note 8 - Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Note 9 - Commitments and Contingencies", "menuCat": "Notes", "order": "16", "role": "http://www.avinger.com/20221231/role/statement-note-9-commitments-and-contingencies", "shortName": "Note 9 - Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Note 10 - Stockholders' Equity", "menuCat": "Notes", "order": "17", "role": "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "shortName": "Note 10 - Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Note 11 - Stock-based Compensation", "menuCat": "Notes", "order": "18", "role": "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation", "shortName": "Note 11 - Stock-based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Note 12 - Income Taxes", "menuCat": "Notes", "order": "19", "role": "http://www.avinger.com/20221231/role/statement-note-12-income-taxes", "shortName": "Note 12 - Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://www.avinger.com/20221231/role/statement-balance-sheets", "shortName": "Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Note 13 - 401(k) Plan", "menuCat": "Notes", "order": "20", "role": "http://www.avinger.com/20221231/role/statement-note-13-401k-plan-", "shortName": "Note 13 - 401(k) Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Note 14 - Subsequent Events", "menuCat": "Notes", "order": "21", "role": "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events", "shortName": "Note 14 - Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "p", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "22", "role": "http://www.avinger.com/20221231/role/statement-significant-accounting-policies-policies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "avgr:ValuationAllowancesAndReservesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Financial Statements Schedules (Tables)", "menuCat": "Tables", "order": "23", "role": "http://www.avinger.com/20221231/role/statement-financial-statements-schedules-tables", "shortName": "Financial Statements Schedules (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "avgr:ValuationAllowancesAndReservesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "24", "role": "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "shortName": "Note 2 - Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Note 4 - Inventories (Tables)", "menuCat": "Tables", "order": "25", "role": "http://www.avinger.com/20221231/role/statement-note-4-inventories-tables", "shortName": "Note 4 - Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Note 5 - Property and Equipment, Net (Tables)", "menuCat": "Tables", "order": "26", "role": "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-tables", "shortName": "Note 5 - Property and Equipment, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Note 7 - Borrowings (Tables)", "menuCat": "Tables", "order": "27", "role": "http://www.avinger.com/20221231/role/statement-note-7-borrowings-tables", "shortName": "Note 7 - Borrowings (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Note 8 - Leases (Tables)", "menuCat": "Tables", "order": "28", "role": "http://www.avinger.com/20221231/role/statement-note-8-leases-tables", "shortName": "Note 8 - Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Note 10 - Stockholders' Equity (Tables)", "menuCat": "Tables", "order": "29", "role": "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-tables", "shortName": "Note 10 - Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Balance Sheets (Parentheticals)", "menuCat": "Statements", "order": "3", "role": "http://www.avinger.com/20221231/role/statement-balance-sheets-parentheticals", "shortName": "Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Note 11 - Stock-based Compensation (Tables)", "menuCat": "Tables", "order": "30", "role": "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-tables", "shortName": "Note 11 - Stock-based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Note 12 - Income Taxes (Tables)", "menuCat": "Tables", "order": "31", "role": "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-tables", "shortName": "Note 12 - Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2021-12-31_ValuationAllowancesAndReservesTypeAxis-SecSchedule1209AllowanceSalesReturnsMember", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Financial Statements Schedules - Allowance of Doubtful Accounts and Sales Returns (Details)", "menuCat": "Details", "order": "32", "role": "http://www.avinger.com/20221231/role/statement-financial-statements-schedules-allowance-of-doubtful-accounts-and-sales-returns-details", "shortName": "Financial Statements Schedules - Allowance of Doubtful Accounts and Sales Returns (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2020-12-31_ValuationAllowancesAndReservesTypeAxis-SecSchedule1209AllowanceSalesReturnsMember", "decimals": "-4", "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Note 1 - Organization (Details Textual)", "menuCat": "Details", "order": "33", "role": "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual", "shortName": "Note 1 - Organization (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:NatureOfOperations", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2022-12-31_ClassOfWarrantOrRightAxis-PrefundedWarrantsMember", "decimals": "INF", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "p", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-01-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)", "menuCat": "Details", "order": "34", "role": "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "shortName": "Note 2 - Summary of Significant Accounting Policies (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "p", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-01-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Accounts Receivable, Allowance for Credit Loss (Details)", "menuCat": "Details", "order": "35", "role": "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-accounts-receivable-allowance-for-credit-loss-details", "shortName": "Note 2 - Summary of Significant Accounting Policies - Accounts Receivable, Allowance for Credit Loss (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProductWarrantyAccrual", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Product Warranty (Details)", "menuCat": "Details", "order": "36", "role": "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-product-warranty-details", "shortName": "Note 2 - Summary of Significant Accounting Policies - Product Warranty (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:ProductWarrantyAccrual", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Net Loss Per Share (Details)", "menuCat": "Details", "order": "37", "role": "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-net-loss-per-share-details", "shortName": "Note 2 - Summary of Significant Accounting Policies - Net Loss Per Share (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details)", "menuCat": "Details", "order": "38", "role": "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details", "shortName": "Note 2 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R39": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Note 3 - Fair Value Measurements (Details Textual)", "menuCat": "Details", "order": "39", "role": "http://www.avinger.com/20221231/role/statement-note-3-fair-value-measurements-details-textual", "shortName": "Note 3 - Fair Value Measurements (Details Textual)", "subGroupType": "details", "uniqueAnchor": null }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Statements of Operations and Comprehensive Loss", "menuCat": "Statements", "order": "4", "role": "http://www.avinger.com/20221231/role/statement-statements-of-operations-and-comprehensive-loss", "shortName": "Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Note 4 - Inventories - Schedule of Inventory (Details)", "menuCat": "Details", "order": "40", "role": "http://www.avinger.com/20221231/role/statement-note-4-inventories-schedule-of-inventory-details", "shortName": "Note 4 - Inventories - Schedule of Inventory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Note 5 - Property and Equipment, Net (Details Textual)", "menuCat": "Details", "order": "41", "role": "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-details-textual", "shortName": "Note 5 - Property and Equipment, Net (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Note 5 - Property and Equipment, Net - Property and Equipment (Details)", "menuCat": "Details", "order": "42", "role": "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-property-and-equipment-details", "shortName": "Note 5 - Property and Equipment, Net - Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredRevenue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Note 6 - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)", "menuCat": "Details", "order": "43", "role": "http://www.avinger.com/20221231/role/statement-note-6-accrued-expenses-and-other-current-liabilities-schedule-of-accrued-expenses-and-other-current-liabilities-details", "shortName": "Note 6 - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredRevenue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "044 - Disclosure - Note 7 - Borrowings (Details Textual)", "menuCat": "Details", "order": "44", "role": "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual", "shortName": "Note 7 - Borrowings (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2020-04-23_2020-04-23_DebtInstrumentAxis-PaycheckProtectionProgramCARESActMember", "decimals": "-5", "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "045 - Disclosure - Note 7 - Borrowings - Schedule of Debt (Details)", "menuCat": "Details", "order": "45", "role": "http://www.avinger.com/20221231/role/statement-note-7-borrowings-schedule-of-debt-details", "shortName": "Note 7 - Borrowings - Schedule of Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "046 - Disclosure - Note 8 - Leases (Details Textual)", "menuCat": "Details", "order": "46", "role": "http://www.avinger.com/20221231/role/statement-note-8-leases-details-textual", "shortName": "Note 8 - Leases (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": null, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "047 - Disclosure - Note 8 - Leases - Future Operating Lease Payments (Details)", "menuCat": "Details", "order": "47", "role": "http://www.avinger.com/20221231/role/statement-note-8-leases-future-operating-lease-payments-details", "shortName": "Note 8 - Leases - Future Operating Lease Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "048 - Disclosure - Note 8 - Leases - ROU Assets and Lease Liabilities (Details)", "menuCat": "Details", "order": "48", "role": "http://www.avinger.com/20221231/role/statement-note-8-leases-rou-assets-and-lease-liabilities-details", "shortName": "Note 8 - Leases - ROU Assets and Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R49": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2022-12-31_PurchaseCommitmentExcludingLongtermCommitmentAxis-PurchaseCommitmentMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PurchaseObligation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "049 - Disclosure - Note 9 - Commitments and Contingencies (Details Textual)", "menuCat": "Details", "order": "49", "role": "http://www.avinger.com/20221231/role/statement-note-9-commitments-and-contingencies-details-textual", "shortName": "Note 9 - Commitments and Contingencies (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2022-12-31_PurchaseCommitmentExcludingLongtermCommitmentAxis-PurchaseCommitmentMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PurchaseObligation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "b", "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Statements of Stockholders' Equity", "menuCat": "Statements", "order": "5", "role": "http://www.avinger.com/20221231/role/statement-statements-of-stockholders-equity", "shortName": "Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "050 - Disclosure - Note 10 - Stockholders' Equity (Details Textual)", "menuCat": "Details", "order": "50", "role": "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual", "shortName": "Note 10 - Stockholders' Equity (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2022-01-14_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember", "decimals": "INF", "lang": null, "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "051 - Disclosure - Note 10 - Stockholder's Equity - Outstanding Warrants (Details)", "menuCat": "Details", "order": "51", "role": "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-outstanding-warrants-details", "shortName": "Note 10 - Stockholder's Equity - Outstanding Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2022-12-31_ClassOfWarrantOrRightAxis-Series1February2018WarrantsMember", "decimals": "INF", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "052 - Disclosure - Note 11 - Stock-based Compensation (Details Textual)", "menuCat": "Details", "order": "52", "role": "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-details-textual", "shortName": "Note 11 - Stock-based Compensation (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember", "decimals": "-3", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "053 - Disclosure - Note 11 - Stock-Based Compensation - Stock Option Activity (Details)", "menuCat": "Details", "order": "53", "role": "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-stock-option-activity-details", "shortName": "Note 11 - Stock-Based Compensation - Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "054 - Disclosure - Note 11 - Stock-Based Compensation - Options Outstanding and Vested (Details)", "menuCat": "Details", "order": "54", "role": "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-options-outstanding-and-vested-details", "shortName": "Note 11 - Stock-Based Compensation - Options Outstanding and Vested (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "055 - Disclosure - Note 11 - Stock-Based Compensation - Restricted Stock Units Award Activity (Details)", "menuCat": "Details", "order": "55", "role": "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-restricted-stock-units-award-activity-details", "shortName": "Note 11 - Stock-Based Compensation - Restricted Stock Units Award Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember", "decimals": null, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "056 - Disclosure - Note 11 - Stock-based Compensation - Noncash Stock-based Compensation Expense Related to Stock Options, ESPP, and RSUs (Details)", "menuCat": "Details", "order": "56", "role": "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-noncash-stockbased-compensation-expense-related-to-stock-options-espp-and-rsus-details", "shortName": "Note 11 - Stock-based Compensation - Noncash Stock-based Compensation Expense Related to Stock Options, ESPP, and RSUs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_IncomeStatementLocationAxis-CostOfSalesMember", "decimals": "-3", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "057 - Disclosure - Note 12 - Income Taxes (Details Textual)", "menuCat": "Details", "order": "57", "role": "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-details-textual", "shortName": "Note 12 - Income Taxes (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-5", "lang": null, "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "058 - Disclosure - Note 12 - Income Taxes - Effective Income Tax Reconciliation (Details)", "menuCat": "Details", "order": "58", "role": "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details", "shortName": "Note 12 - Income Taxes - Effective Income Tax Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "059 - Disclosure - Note 12 - Income Taxes - Deferred Tax Assets and Liabilities (Details)", "menuCat": "Details", "order": "59", "role": "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-and-liabilities-details", "shortName": "Note 12 - Income Taxes - Deferred Tax Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Statements of Cash Flows", "menuCat": "Statements", "order": "6", "role": "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows", "shortName": "Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060 - Disclosure - Note 12 - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)", "menuCat": "Details", "order": "60", "role": "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-reconciliation-of-unrecognized-tax-benefits-details", "shortName": "Note 12 - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_RetirementPlanNameAxis-The401kPlanMember_RetirementPlanTypeAxis-PensionPlansDefinedBenefitMember", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061 - Disclosure - Note 13 - 401(k) Plan (Details Textual)", "menuCat": "Details", "order": "61", "role": "http://www.avinger.com/20221231/role/statement-note-13-401k-plan-details-textual", "shortName": "Note 13 - 401(k) Plan (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_RetirementPlanNameAxis-The401kPlanMember_RetirementPlanTypeAxis-PensionPlansDefinedBenefitMember", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "062 - Disclosure - Note 14 - Subsequent Events (Details Textual)", "menuCat": "Details", "order": "62", "role": "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events-details-textual", "shortName": "Note 14 - Subsequent Events (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "i_2023-01-18_SubsequentEventTypeAxis-SubsequentEventMember", "decimals": "INF", "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "006 - Disclosure - Financial Statements Schedules", "menuCat": "Notes", "order": "7", "role": "http://www.avinger.com/20221231/role/statement-financial-statements-schedules-", "shortName": "Financial Statements Schedules", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Note 1 - Organization", "menuCat": "Notes", "order": "8", "role": "http://www.avinger.com/20221231/role/statement-note-1-organization", "shortName": "Note 1 - Organization", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Note 2 - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "9", "role": "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "shortName": "Note 2 - Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "avgr20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 96, "tag": { "avgr_AccountsReceivableAllowanceForCreditLossRecoveryWriteoff": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in allowance for credit loss on accounts receivable, from recovery (writeoff).", "label": "Recoveries/write-offs" } } }, "localname": "AccountsReceivableAllowanceForCreditLossRecoveryWriteoff", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-accounts-receivable-allowance-for-credit-loss-details" ], "xbrltype": "monetaryItemType" }, "avgr_AccretionOfPreferredStockDividends": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of accretion of preferred stock dividends.", "label": "Accretion of Series A preferred stock dividends" } } }, "localname": "AccretionOfPreferredStockDividends", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "avgr_AccruedClinicalTrialCostsCurrent": { "auth_ref": [], "calculation": { "http://www.avinger.com/20221231/role/statement-note-6-accrued-expenses-and-other-current-liabilities-schedule-of-accrued-expenses-and-other-current-liabilities-details": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trial costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued clinical trial costs" } } }, "localname": "AccruedClinicalTrialCostsCurrent", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-6-accrued-expenses-and-other-current-liabilities-schedule-of-accrued-expenses-and-other-current-liabilities-details" ], "xbrltype": "monetaryItemType" }, "avgr_AccruedTravelExpensesCurrent": { "auth_ref": [], "calculation": { "http://www.avinger.com/20221231/role/statement-note-6-accrued-expenses-and-other-current-liabilities-schedule-of-accrued-expenses-and-other-current-liabilities-details": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for travel expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued travel and entertainment expenses" } } }, "localname": "AccruedTravelExpensesCurrent", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-6-accrued-expenses-and-other-current-liabilities-schedule-of-accrued-expenses-and-other-current-liabilities-details" ], "xbrltype": "monetaryItemType" }, "avgr_August2022PublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the August 2022 Public Offering.", "label": "August 2022 Public Offering [Member]" } } }, "localname": "August2022PublicOfferingMember", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-1-organization", "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual" ], "xbrltype": "domainItemType" }, "avgr_August2022PurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Relating to the August 2022 purchase agreement.", "label": "August 2022 Purchase Agreement [Member]" } } }, "localname": "August2022PurchaseAgreementMember", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-1-organization", "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual" ], "xbrltype": "domainItemType" }, "avgr_CRGMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information about CRG.", "label": "CRG [Member]" } } }, "localname": "CRGMember", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual", "http://www.avinger.com/20221231/role/statement-note-7-borrowings", "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual", "http://www.avinger.com/20221231/role/statement-note-7-borrowings-schedule-of-debt-details" ], "xbrltype": "domainItemType" }, "avgr_ChangeInRightofuseAsset": { "auth_ref": [], "calculation": { "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of change in right-of-use asset during the period.", "label": "Change in right of use asset" } } }, "localname": "ChangeInRightofuseAsset", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "avgr_ClassOfWarrantOrRightExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of warrants or rights exercised during the period.", "label": "avgr_ClassOfWarrantOrRightExercised", "terseLabel": "Class of Warrant or Right, Exercised (in shares)" } } }, "localname": "ClassOfWarrantOrRightExercised", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual", "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events-details-textual" ], "xbrltype": "sharesItemType" }, "avgr_ClinicalTrialsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for clinical trial activities performed by third parties.", "label": "Clinical Trials [Policy Text Block]" } } }, "localname": "ClinicalTrialsPolicyTextBlock", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "avgr_CommissionPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents commission percentage.", "label": "avgr_CommissionPercentage", "terseLabel": "Commission Percentage" } } }, "localname": "CommissionPercentage", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual" ], "xbrltype": "percentItemType" }, "avgr_CommonStockInJune2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents common stock in June 2022.", "label": "Common Stock in June, 2022 [Member]" } } }, "localname": "CommonStockInJune2022Member", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-1-organization", "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual" ], "xbrltype": "domainItemType" }, "avgr_CommonStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Options [ member]" } } }, "localname": "CommonStockOptionsMember", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-details-textual", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details" ], "xbrltype": "domainItemType" }, "avgr_CommonStockWarrantsIssuedWithSeriesDConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to common stock warrants, issued with series B convertible preferred stock.", "label": "Common Stock Warrants, Issued with Series D Convertible Preferred Stock [Member]" } } }, "localname": "CommonStockWarrantsIssuedWithSeriesDConvertiblePreferredStockMember", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "avgr_CommonStockWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information about common stock warrants.", "label": "Common Stock Warrants [Member]" } } }, "localname": "CommonStockWarrantsMember", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details" ], "xbrltype": "domainItemType" }, "avgr_CommonWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the common warrants", "label": "Common Warrants [Member]" } } }, "localname": "CommonWarrantsMember", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-1-organization", "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "avgr_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policies for credit risk and other risks and uncertainties.", "label": "Concentration of Credit Risk and Other Risks and Uncertainties [Policy Text Block]" } } }, "localname": "ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "avgr_ConversionOfPrincipalAmountOfSeniorSecuredLoanToNewlyAuthorizedSeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information bout conversion of principal amount of senior secured loan to newly authorized series A preferred stock.", "label": "Conversion of Principal Amount of Senior Secured Loan to Newly Authorized Series A Preferred Stock [Member]" } } }, "localname": "ConversionOfPrincipalAmountOfSeniorSecuredLoanToNewlyAuthorizedSeriesAPreferredStockMember", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "avgr_ConversionOfSeriesBPreferredStockIntoCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information about conversion of series B preferred stock into common stock.", "label": "Conversion of Series B Preferred Stock into Common Stock [Member]" } } }, "localname": "ConversionOfSeriesBPreferredStockIntoCommonStockMember", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "avgr_ConversionOfSeriesDPreferredStockIntoCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to the conversion of Series D preferred stock into common stock.", "label": "Conversion of Series D Preferred Stock into Common Stock [Member]" } } }, "localname": "ConversionOfSeriesDPreferredStockIntoCommonStockMember", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "avgr_ConversionOfWarrantsAllowedMaximumOwnershipOfCommonStockPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents conversion of warrants allowed maximum ownership of common stock percentage.", "label": "avgr_ConversionOfWarrantsAllowedMaximumOwnershipOfCommonStockPercentage", "terseLabel": "Conversion of Warrants Allowed Maximum Ownership of Common Stock Percentage" } } }, "localname": "ConversionOfWarrantsAllowedMaximumOwnershipOfCommonStockPercentage", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "percentItemType" }, "avgr_ConversionOfWarrantsAllowedMaximumOwnershipOfCommonStockPercentageUponElection": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents conversion of warrants allowed maximum ownership of common stock percentage upon election.", "label": "avgr_ConversionOfWarrantsAllowedMaximumOwnershipOfCommonStockPercentageUponElection", "terseLabel": "Conversion of Warrants Allowed Maximum Ownership of Common Stock Percentage upon Election" } } }, "localname": "ConversionOfWarrantsAllowedMaximumOwnershipOfCommonStockPercentageUponElection", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "percentItemType" }, "avgr_DebtAgreementMaximumBorrowingCapacity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under a debt agreement on the amount that could be borrowed with a combination of, but not limited to, a line of credit and term loan.", "label": "avgr_DebtAgreementMaximumBorrowingCapacity", "terseLabel": "Debt Agreement, Maximum Borrowing Capacity" } } }, "localname": "DebtAgreementMaximumBorrowingCapacity", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual" ], "xbrltype": "monetaryItemType" }, "avgr_DebtConversionFeesAndPrepaymentPremiumAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of related back-end fees and prepayment premium being converted together with the original debt in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "avgr_DebtConversionFeesAndPrepaymentPremiumAmount", "terseLabel": "Debt Conversion, Fees and Prepayment Premium Amount" } } }, "localname": "DebtConversionFeesAndPrepaymentPremiumAmount", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual" ], "xbrltype": "monetaryItemType" }, "avgr_DebtInstrumentCovenantComplianceCashAndCertainCashEquivalentsMinimum": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The minimum amount of cash and certain cash equivalents the entity is required to maintain under the terms of the debt agreement.", "label": "avgr_DebtInstrumentCovenantComplianceCashAndCertainCashEquivalentsMinimum", "terseLabel": "Debt Instrument, Covenant Compliance Cash and Certain Cash Equivalents Minimum" } } }, "localname": "DebtInstrumentCovenantComplianceCashAndCertainCashEquivalentsMinimum", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual" ], "xbrltype": "monetaryItemType" }, "avgr_DebtInstrumentCovenantComplianceMinimumLiquidityRequirement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The minimum amount of liquidity required at all times for compliance with the debt instrument covenant.", "label": "avgr_DebtInstrumentCovenantComplianceMinimumLiquidityRequirement", "terseLabel": "Debt Instrument, Covenant Compliance, Minimum Liquidity Requirement" } } }, "localname": "DebtInstrumentCovenantComplianceMinimumLiquidityRequirement", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual" ], "xbrltype": "monetaryItemType" }, "avgr_DebtInstrumentCovenantCompliancePrepaymentMultiplierForRevenueShortfall": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The multiplier applied to the amount of a revenue shortfall relative to required minimum targets, to determine the amount of outstanding principal the entity must prepay to be eligible for a cure right under the terms of the debt agreement.", "label": "avgr_DebtInstrumentCovenantCompliancePrepaymentMultiplierForRevenueShortfall", "terseLabel": "Debt Instrument, Covenant Compliance Prepayment Multiplier for Revenue Shortfall" } } }, "localname": "DebtInstrumentCovenantCompliancePrepaymentMultiplierForRevenueShortfall", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual" ], "xbrltype": "pureItemType" }, "avgr_DebtInstrumentCovenantComplianceTargetMinimumRevenueFourthYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The target minimum annual revenue the entity is required to achieve under the terms of the debt agreement for the fourth fiscal year during which the agreement is in effect.", "label": "avgr_DebtInstrumentCovenantComplianceTargetMinimumRevenueFourthYear", "terseLabel": "Debt Instrument, Covenant Compliance Target Minimum Revenue Fourth Year" } } }, "localname": "DebtInstrumentCovenantComplianceTargetMinimumRevenueFourthYear", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual" ], "xbrltype": "monetaryItemType" }, "avgr_DebtInstrumentCovenantComplianceTargetMinimumRevenueNextTwelveMonths": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The target minimum annual revenue the entity is required to achieve under the terms of the debt agreement for the next twelve months during which the agreement is in effect.", "label": "avgr_DebtInstrumentCovenantComplianceTargetMinimumRevenueNextTwelveMonths", "terseLabel": "Debt Instrument, Covenant Compliance Target Minimum Revenue, Next Twelve Months" } } }, "localname": "DebtInstrumentCovenantComplianceTargetMinimumRevenueNextTwelveMonths", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual" ], "xbrltype": "monetaryItemType" }, "avgr_DebtInstrumentCovenantComplianceTargetMinimumRevenuePastTwelveMonths": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The target minimum annual revenue the entity is required to achieve under the terms of the debt agreement for the past twelve months during which the agreement is in effect.", "label": "avgr_DebtInstrumentCovenantComplianceTargetMinimumRevenuePastTwelveMonths", "terseLabel": "Debt Instrument, Covenant Compliance, Target Minimum Revenue, Past Twelve Months" } } }, "localname": "DebtInstrumentCovenantComplianceTargetMinimumRevenuePastTwelveMonths", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual" ], "xbrltype": "monetaryItemType" }, "avgr_DebtInstrumentCovenantComplianceTargetMinimumRevenueSecondYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "avgr_DebtInstrumentCovenantComplianceTargetMinimumRevenueSecondYear", "terseLabel": "Debt Instrument Covenant Compliance Target Minimum Revenue Second Year" } } }, "localname": "DebtInstrumentCovenantComplianceTargetMinimumRevenueSecondYear", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual" ], "xbrltype": "monetaryItemType" }, "avgr_DebtInstrumentCovenantComplianceTargetMinimumRevenueThirdYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "avgr_DebtInstrumentCovenantComplianceTargetMinimumRevenueThirdYear", "terseLabel": "Debt Instrument Covenant Compliance Target Minimum Revenue Third Year" } } }, "localname": "DebtInstrumentCovenantComplianceTargetMinimumRevenueThirdYear", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual" ], "xbrltype": "monetaryItemType" }, "avgr_DebtInstrumentCumulativePaidInKindInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cumulative paid-in-kind interest treated as additional principal and added to the total carrying amount of the debt.", "label": "Less: Amount of PIK additions and final facility fee to be incurred subsequent to December 31, 2022" } } }, "localname": "DebtInstrumentCumulativePaidInKindInterest", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings-schedule-of-debt-details" ], "xbrltype": "monetaryItemType" }, "avgr_DebtInstrumentFinalFacilityFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The facility fee payable at the end of the debt instrument term or upon prepayment in full, as a percentage of the amount borrowed.", "label": "avgr_DebtInstrumentFinalFacilityFeePercentage", "terseLabel": "Debt Instrument, Final Facility Fee Percentage" } } }, "localname": "DebtInstrumentFinalFacilityFeePercentage", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual" ], "xbrltype": "percentItemType" }, "avgr_DebtInstrumentFinancingFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The debt instrument fee required on the borrowing date for each tranche of borrowing, as a percentage of the principal amount borrowed.", "label": "avgr_DebtInstrumentFinancingFeePercentage", "terseLabel": "Debt Instrument, Financing Fee Percentage" } } }, "localname": "DebtInstrumentFinancingFeePercentage", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual" ], "xbrltype": "percentItemType" }, "avgr_DebtInstrumentInterestForgiven": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the debt instrument interest forgiven.", "label": "avgr_DebtInstrumentInterestForgiven", "terseLabel": "Debt Instrument Interest Forgiven" } } }, "localname": "DebtInstrumentInterestForgiven", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual" ], "xbrltype": "monetaryItemType" }, "avgr_DebtInstrumentRedemptionAnnualDeclineInPrepaymentPremiumPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The annual decline in the premium percentage to be paid if the entity voluntarily prepays the amount outstanding under the debt instrument.", "label": "avgr_DebtInstrumentRedemptionAnnualDeclineInPrepaymentPremiumPercentage", "terseLabel": "Debt Instrument, Redemption Annual Decline in Prepayment Premium Percentage" } } }, "localname": "DebtInstrumentRedemptionAnnualDeclineInPrepaymentPremiumPercentage", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual" ], "xbrltype": "percentItemType" }, "avgr_DebtInstrumentRedemptionInitialPrepaymentPremiumPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The initial premium percentage to be paid if the entity voluntarily prepays the amount outstanding under the debt instrument.", "label": "avgr_DebtInstrumentRedemptionInitialPrepaymentPremiumPercentage", "terseLabel": "Debt Instrument, Redemption Initial Prepayment Premium Percentage" } } }, "localname": "DebtInstrumentRedemptionInitialPrepaymentPremiumPercentage", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual" ], "xbrltype": "percentItemType" }, "avgr_DeferredTaxAssetsCapitalizedResearchAndDevelopment": { "auth_ref": [], "calculation": { "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development.", "label": "Capitalized research and development" } } }, "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopment", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "avgr_DeferredTaxAssetsOperatingLeaseLiability": { "auth_ref": [], "calculation": { "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liability.", "label": "Operating lease liability" } } }, "localname": "DeferredTaxAssetsOperatingLeaseLiability", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "avgr_DeferredTaxLiabilityOperatingLeaseRightOfUseAsset": { "auth_ref": [], "calculation": { "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from operating lease right of use asset.", "label": "avgr_DeferredTaxLiabilityOperatingLeaseRightOfUseAsset", "negatedLabel": "Operating lease right of use asset" } } }, "localname": "DeferredTaxLiabilityOperatingLeaseRightOfUseAsset", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "avgr_EffectiveIncomeTaxRateReconciliationPermanentDifferencesAmount": { "auth_ref": [], "calculation": { "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent differences.", "label": "Permanent differences" } } }, "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferencesAmount", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "avgr_EquipmentHeldByCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to equipment held by customers.", "label": "Equipment Held by Customers [Member]" } } }, "localname": "EquipmentHeldByCustomersMember", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-", "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "avgr_ExercisePriceRange1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the first exercise price range.", "label": "Exercise Price Range 1 [Member]" } } }, "localname": "ExercisePriceRange1Member", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-options-outstanding-and-vested-details" ], "xbrltype": "domainItemType" }, "avgr_ExercisePriceRange2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the second exercise price range.", "label": "Exercise Price Range 2 [Member]" } } }, "localname": "ExercisePriceRange2Member", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-options-outstanding-and-vested-details" ], "xbrltype": "domainItemType" }, "avgr_ExercisePriceRange3Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the third exercise price range.", "label": "Exercise Price Range 3 [Member]" } } }, "localname": "ExercisePriceRange3Member", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-options-outstanding-and-vested-details" ], "xbrltype": "domainItemType" }, "avgr_ExercisePriceRange4Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the fourth exercise price range.", "label": "Exercise Price Range 4 [Member]" } } }, "localname": "ExercisePriceRange4Member", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-options-outstanding-and-vested-details" ], "xbrltype": "domainItemType" }, "avgr_February2021PulicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to the February 2021 public offering.", "label": "February 2021 Public Offering [Member]" } } }, "localname": "February2021PulicOfferingMember", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-1-organization", "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual" ], "xbrltype": "domainItemType" }, "avgr_FirstTrancheBorrowedOnSeptember222015Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information about first tranche, borrowed on September 22, 2015.", "label": "First Tranche, Borrowed on September 22, 2015 [Member]" } } }, "localname": "FirstTrancheBorrowedOnSeptember222015Member", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings", "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual" ], "xbrltype": "domainItemType" }, "avgr_January2022OfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "represents January 2022 offering.", "label": "January 2022 offering [Member]" } } }, "localname": "January2022OfferingMember", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "avgr_January2022PublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the January 2022 Public Offering.", "label": "January 2022 Public Offering [Member]" } } }, "localname": "January2022PublicOfferingMember", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-1-organization", "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual", "http://www.avinger.com/20221231/role/statement-statements-of-stockholders-equity" ], "xbrltype": "domainItemType" }, "avgr_LeasedEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents leased equipment.", "label": "Leased Equipment [Member]" } } }, "localname": "LeasedEquipmentMember", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-", "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-details-textual" ], "xbrltype": "domainItemType" }, "avgr_LoanAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information about Term Loan Agreement (Loan Agreement).", "label": "Loan Agreement [Member]" } } }, "localname": "LoanAgreementMember", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings", "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual", "http://www.avinger.com/20221231/role/statement-note-7-borrowings-schedule-of-debt-details" ], "xbrltype": "domainItemType" }, "avgr_NoncashInterestExpenseIncomeAndOtherChargesNet": { "auth_ref": [], "calculation": { "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of noncash interest expense (income) and other charges, net.", "label": "Noncash interest expense and other charges" } } }, "localname": "NoncashInterestExpenseIncomeAndOtherChargesNet", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "avgr_NoteToFinancialStatementDetailsTextual": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "localname": "NoteToFinancialStatementDetailsTextual", "nsuri": "http://www.avinger.com/20221231", "xbrltype": "stringItemType" }, "avgr_NotesToFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "localname": "NotesToFinancialStatementsAbstract", "nsuri": "http://www.avinger.com/20221231", "xbrltype": "stringItemType" }, "avgr_November2018WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to November 2018 warrants.", "label": "November 2018 Warrants [Member]" } } }, "localname": "November2018WarrantsMember", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-outstanding-warrants-details" ], "xbrltype": "domainItemType" }, "avgr_NumberOfMajorCustomers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of major customers accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc.", "label": "avgr_NumberOfMajorCustomers", "terseLabel": "Number of Major Customers" } } }, "localname": "NumberOfMajorCustomers", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "integerItemType" }, "avgr_OfficerAndDirectorSharePurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to officer and director share purchase plan.", "label": "Officer and Director Share Purchase Plan [Member]" } } }, "localname": "OfficerAndDirectorSharePurchasePlanMember", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "avgr_OneCustomerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to one customer.", "label": "One Customer [Member]" } } }, "localname": "OneCustomerMember", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "avgr_OperatingLeaseExpenseExcludingMaintenanceFeeAndOtherExpenseMonthly": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents information related to operating expense excluding maintenance fee and other expenses on a monthly basis.", "label": "avgr_OperatingLeaseExpenseExcludingMaintenanceFeeAndOtherExpenseMonthly", "terseLabel": "Operating Lease, Expense, Excluding Maintenance Fee and Other Expense, Monthly" } } }, "localname": "OperatingLeaseExpenseExcludingMaintenanceFeeAndOtherExpenseMonthly", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-8-leases-details-textual" ], "xbrltype": "monetaryItemType" }, "avgr_OperatingLossCarryforwardsNotSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws which are not subject to expiration.", "label": "avgr_OperatingLossCarryforwardsNotSubjectToExpiration", "terseLabel": "Operating Loss Carryforwards, Not Subject to Expiration" } } }, "localname": "OperatingLossCarryforwardsNotSubjectToExpiration", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "avgr_PaycheckProtectionProgramCARESActMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents loan designed to provide funds for small businesses to keep their employees on the payroll.", "label": "Paycheck Protection Program CARES Act [Member]" } } }, "localname": "PaycheckProtectionProgramCARESActMember", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings", "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual" ], "xbrltype": "domainItemType" }, "avgr_PlacementAgentPreferredInvestmentOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Relating to Placement Agent Preferred Investment Options", "label": "Placement Agent Preferred Investment Options [Member]" } } }, "localname": "PlacementAgentPreferredInvestmentOptionsMember", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-1-organization", "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "avgr_PlacementAgentPrivateInvestmentOptionsIssuedInAugust2022FinancingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Relating to Placement Agent Private Investment Options Issued in August 2022 Financing", "label": "Placement Agent Private Investment Options Issued in August 2022 Financing [Member]" } } }, "localname": "PlacementAgentPrivateInvestmentOptionsIssuedInAugust2022FinancingMember", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-outstanding-warrants-details" ], "xbrltype": "domainItemType" }, "avgr_PlacementAgentWarrantsIssuedInTheJanuary2022FinancingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents placement agent warrants issued in the January 2022 financing.", "label": "Placement agent warrants issued in the January 2022 financing [Member]" } } }, "localname": "PlacementAgentWarrantsIssuedInTheJanuary2022FinancingMember", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-1-organization", "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-outstanding-warrants-details" ], "xbrltype": "domainItemType" }, "avgr_PrefundedWarrantsIssuedInAugust2022FinancingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Relating to Pre-funded Warrants Issued in August 2022 Financing.", "label": "Pre-funded Warrants Issued in August 2022 Financing [Member]" } } }, "localname": "PrefundedWarrantsIssuedInAugust2022FinancingMember", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-outstanding-warrants-details" ], "xbrltype": "domainItemType" }, "avgr_PrefundedWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents pre-funded warrants.", "label": "Pre-funded Warrants [Member]" } } }, "localname": "PrefundedWarrantsMember", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-1-organization", "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual" ], "xbrltype": "domainItemType" }, "avgr_PrivatePrefundedWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Relating to Private Pre-funded Warrants", "label": "Private Pre-funded Warrants [Member]" } } }, "localname": "PrivatePrefundedWarrantsMember", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual", "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events", "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "avgr_ProceedsFromIssuanceOrSaleOfEquityNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity, net of underwriting discounts, commissions, legal and accounting fees.", "label": "avgr_ProceedsFromIssuanceOrSaleOfEquityNet", "terseLabel": "Proceeds from Issuance or Sale of Equity, Net" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquityNet", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual" ], "xbrltype": "monetaryItemType" }, "avgr_ProceedsFromTheIssuanceOfCommonStockAndConvertiblePreferredStockNetOfIssuanceCosts": { "auth_ref": [], "calculation": { "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of common stocks, and preferred stocks identified as being convertible, into another form of financial instrument, typically the entity's common stock, after deduction of issuance costs.", "label": "Proceeds from the issuance of convertible preferred stock, net of commissions and issuance costs" } } }, "localname": "ProceedsFromTheIssuanceOfCommonStockAndConvertiblePreferredStockNetOfIssuanceCosts", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "avgr_ProductWarrantyAccrualPaymentsAndRelease": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the aggregate decrease in the liability related to payments to satisfy claims for standard and extended product warranties and adjustment to release accrued amounts.", "label": "avgr_ProductWarrantyAccrualPaymentsAndRelease", "negatedLabel": "Usage/Release" } } }, "localname": "ProductWarrantyAccrualPaymentsAndRelease", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-product-warranty-details" ], "xbrltype": "monetaryItemType" }, "avgr_RegisteredDirectPrefundedWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to registered direct pre-funded warrants.", "label": "Registered Direct Pre-funded Warrants [Member]" } } }, "localname": "RegisteredDirectPrefundedWarrantsMember", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-1-organization", "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "avgr_ReverseStockSplitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The conversion of a reverse stock split where there is a reduction in the shares outstanding.", "label": "Reverse Stock Split [Member]" } } }, "localname": "ReverseStockSplitMember", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "avgr_RightOfUseAssetAndLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to right of use assets and liabilities.", "label": "Right of Use Asset and Liabilities [Table Text Block]" } } }, "localname": "RightOfUseAssetAndLiabilitiesTableTextBlock", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-8-leases-tables" ], "xbrltype": "textBlockItemType" }, "avgr_SaleOfStockNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares available in a sale of stock.", "label": "avgr_SaleOfStockNumberOfShares", "terseLabel": "Sale of Stock, Number of Shares (in shares)" } } }, "localname": "SaleOfStockNumberOfShares", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual" ], "xbrltype": "sharesItemType" }, "avgr_SecSchedule1209AllowanceSalesReturnsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Allowance for sales returns", "label": "SEC Schedule, 12-09, Allowance, Sales Returns [Member]" } } }, "localname": "SecSchedule1209AllowanceSalesReturnsMember", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-financial-statements-schedules-", "http://www.avinger.com/20221231/role/statement-financial-statements-schedules-allowance-of-doubtful-accounts-and-sales-returns-details" ], "xbrltype": "domainItemType" }, "avgr_SecondTrancheBorrowedOnJune152016Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information about second tranche, borrowed on June 15, 2016.", "label": "Second Tranche, Borrowed on June 15, 2016 [Member]" } } }, "localname": "SecondTrancheBorrowedOnJune152016Member", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings", "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual" ], "xbrltype": "domainItemType" }, "avgr_Series1February2018WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to series 1 February 2018 warrants.", "label": "Series 1 February 2018 Warrants [Member]" } } }, "localname": "Series1February2018WarrantsMember", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-outstanding-warrants-details" ], "xbrltype": "domainItemType" }, "avgr_Series2February2018WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to series 2 February 2018 warrants.", "label": "Series 2 February 2018 Warrants [Member]" } } }, "localname": "Series2February2018WarrantsMember", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-outstanding-warrants-details" ], "xbrltype": "domainItemType" }, "avgr_SeriesAPreferredInvestmentOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to Series A preferred investment options.", "label": "Series A Preferred Investment Options [Member]" } } }, "localname": "SeriesAPreferredInvestmentOptionsMember", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-1-organization", "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "avgr_SeriesAPreferredStockPurchaseAgreementWithCRGMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information about series A preferred stock purchase agreement with CRG.", "label": "Series A Preferred Stock Purchase Agreement with CRG [Member]" } } }, "localname": "SeriesAPreferredStockPurchaseAgreementWithCRGMember", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings", "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual" ], "xbrltype": "domainItemType" }, "avgr_SeriesAPrivateInvestmentOptionsIssuedInAugust2022FinancingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Relating to Series A Private Investment Options Issued in August 2022 Financing", "label": "Series A Private Investment Options Issued in August 2022 Financing [Member]" } } }, "localname": "SeriesAPrivateInvestmentOptionsIssuedInAugust2022FinancingMember", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-outstanding-warrants-details" ], "xbrltype": "domainItemType" }, "avgr_SeriesBFinancingWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents series B financing warrants.", "label": "Series B Financing Warrants [Member]" } } }, "localname": "SeriesBFinancingWarrantsMember", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "avgr_SeriesBPreferredInvestmentOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to Series B preferred investment options.", "label": "Series B Preferred Investment Options [Member]" } } }, "localname": "SeriesBPreferredInvestmentOptionsMember", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-1-organization", "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual" ], "xbrltype": "domainItemType" }, "avgr_SeriesBPrivateInvestmentOptionsIssuedInAugust2022FinancingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Relating to Series B Private Investment Options Issued in August 2022 Financing.", "label": "Series B Private Investment Options Issued in August 2022 Financing [Member]" } } }, "localname": "SeriesBPrivateInvestmentOptionsIssuedInAugust2022FinancingMember", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-outstanding-warrants-details" ], "xbrltype": "domainItemType" }, "avgr_ShareOfferingAgreementAggregateOffering": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the aggregate offering under share offering agreement.", "label": "avgr_ShareOfferingAgreementAggregateOffering", "terseLabel": "Share Offering Agreement, Aggregate Offering" } } }, "localname": "ShareOfferingAgreementAggregateOffering", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual" ], "xbrltype": "monetaryItemType" }, "avgr_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents sharebased compensation arrangement by sharebased payment award equity instruments other than options nonvested fair value.", "label": "avgr_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedFairValue", "terseLabel": "Sharebased Compensation Arrangement by Sharebased Payment Award Equity Instruments Other than Options Nonvested Fair Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedFairValue", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-details-textual" ], "xbrltype": "monetaryItemType" }, "avgr_StockIssuedDuringPeriodSharesWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued as a result of the exercise of warrants.", "label": "Exercise of pre-funded warrants for common stock (in shares)", "terseLabel": "Stock Issued During Period, Shares, Warrants Exercised" } } }, "localname": "StockIssuedDuringPeriodSharesWarrantsExercised", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual", "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events-details-textual", "http://www.avinger.com/20221231/role/statement-statements-of-stockholders-equity" ], "xbrltype": "sharesItemType" }, "avgr_StockIssuedDuringPeriodValueReverseStockSplits": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split.", "label": "Reclassifications and adjustments due to rounding impact from reverse stock split for fractional shares" } } }, "localname": "StockIssuedDuringPeriodValueReverseStockSplits", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "avgr_StockIssuedDuringPeriodValueWarrantsExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for shares issued as a result of the exercise of warrants.", "label": "Exercise of pre-funded warrants for common stock" } } }, "localname": "StockIssuedDuringPeriodValueWarrantsExercised", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "avgr_The2015EmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information about the 2015 employee stock purchase plan.", "label": "The 2015 Employee Stock Purchase Plan [Member]" } } }, "localname": "The2015EmployeeStockPurchasePlanMember", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "avgr_The401kPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to the 401(k) plan of the reporting entity.", "label": "The 401(k) Plan [Member]" } } }, "localname": "The401kPlanMember", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-13-401k-plan-", "http://www.avinger.com/20221231/role/statement-note-13-401k-plan-details-textual" ], "xbrltype": "domainItemType" }, "avgr_TheMarketOfferingAgreementTheAtmAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the market offering agreement (the \u201cATM Agreement\u201d).", "label": "The Market Offering Agreement (the \u201cATM Agreement\u201d) [Member]" } } }, "localname": "TheMarketOfferingAgreementTheAtmAgreementMember", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-1-organization", "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual" ], "xbrltype": "domainItemType" }, "avgr_TransfersBetweenInventoryAndPropertyAndEquipment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of transfers between inventory and property and equipment during the reporting period.", "label": "Transfers between inventory and property and equipment" } } }, "localname": "TransfersBetweenInventoryAndPropertyAndEquipment", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "avgr_ValuationAllowancesAndReservesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of a schedule of allowance and reserve accounts where the valuation and qualifying accounts are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.", "label": "Valuation Allowances and Reserves [Table Text Block]" } } }, "localname": "ValuationAllowancesAndReservesTableTextBlock", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-financial-statements-schedules-tables" ], "xbrltype": "textBlockItemType" }, "avgr_WarrantsIssuedInTheJanuary2022FinancingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "represents warrants issued in the January 2022 financing.", "label": "Warrants Issued in the January 2022 Financing [Member]" } } }, "localname": "WarrantsIssuedInTheJanuary2022FinancingMember", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-outstanding-warrants-details" ], "xbrltype": "domainItemType" }, "avgr_WarrantyPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the typical period of product warranty for parts and labor.", "label": "avgr_WarrantyPeriod", "terseLabel": "Warranty Period (Year)" } } }, "localname": "WarrantyPeriod", "nsuri": "http://www.avinger.com/20221231", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "durationItemType" }, "avgr_statement-statement-financial-statements-schedules-allowance-of-doubtful-accounts-and-sales-returns-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Statements Schedules - Allowance of Doubtful Accounts and Sales Returns (Details)" } } }, "localname": "statement-statement-financial-statements-schedules-allowance-of-doubtful-accounts-and-sales-returns-details", "nsuri": "http://www.avinger.com/20221231", "xbrltype": "stringItemType" }, "avgr_statement-statement-financial-statements-schedules-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Statements Schedules" } } }, "localname": "statement-statement-financial-statements-schedules-tables", "nsuri": "http://www.avinger.com/20221231", "xbrltype": "stringItemType" }, "avgr_statement-statement-note-10-stockholders-equity-outstanding-warrants-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Stockholder's Equity - Outstanding Warrants (Details)" } } }, "localname": "statement-statement-note-10-stockholders-equity-outstanding-warrants-details", "nsuri": "http://www.avinger.com/20221231", "xbrltype": "stringItemType" }, "avgr_statement-statement-note-10-stockholders-equity-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Stockholders' Equity" } } }, "localname": "statement-statement-note-10-stockholders-equity-tables", "nsuri": "http://www.avinger.com/20221231", "xbrltype": "stringItemType" }, "avgr_statement-statement-note-11-stockbased-compensation-noncash-stockbased-compensation-expense-related-to-stock-options-espp-and-rsus-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 11 - Stock-based Compensation - Noncash Stock-based Compensation Expense Related to Stock Options, ESPP, and RSUs (Details)" } } }, "localname": "statement-statement-note-11-stockbased-compensation-noncash-stockbased-compensation-expense-related-to-stock-options-espp-and-rsus-details", "nsuri": "http://www.avinger.com/20221231", "xbrltype": "stringItemType" }, "avgr_statement-statement-note-11-stockbased-compensation-options-outstanding-and-vested-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 11 - Stock-Based Compensation - Options Outstanding and Vested (Details)" } } }, "localname": "statement-statement-note-11-stockbased-compensation-options-outstanding-and-vested-details", "nsuri": "http://www.avinger.com/20221231", "xbrltype": "stringItemType" }, "avgr_statement-statement-note-11-stockbased-compensation-restricted-stock-units-award-activity-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 11 - Stock-Based Compensation - Restricted Stock Units Award Activity (Details)" } } }, "localname": "statement-statement-note-11-stockbased-compensation-restricted-stock-units-award-activity-details", "nsuri": "http://www.avinger.com/20221231", "xbrltype": "stringItemType" }, "avgr_statement-statement-note-11-stockbased-compensation-stock-option-activity-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 11 - Stock-Based Compensation - Stock Option Activity (Details)" } } }, "localname": "statement-statement-note-11-stockbased-compensation-stock-option-activity-details", "nsuri": "http://www.avinger.com/20221231", "xbrltype": "stringItemType" }, "avgr_statement-statement-note-11-stockbased-compensation-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 11 - Stock-based Compensation" } } }, "localname": "statement-statement-note-11-stockbased-compensation-tables", "nsuri": "http://www.avinger.com/20221231", "xbrltype": "stringItemType" }, "avgr_statement-statement-note-12-income-taxes-deferred-tax-assets-and-liabilities-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 12 - Income Taxes - Deferred Tax Assets and Liabilities (Details)" } } }, "localname": "statement-statement-note-12-income-taxes-deferred-tax-assets-and-liabilities-details", "nsuri": "http://www.avinger.com/20221231", "xbrltype": "stringItemType" }, "avgr_statement-statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 12 - Income Taxes - Effective Income Tax Reconciliation (Details)" } } }, "localname": "statement-statement-note-12-income-taxes-effective-income-tax-reconciliation-details", "nsuri": "http://www.avinger.com/20221231", "xbrltype": "stringItemType" }, "avgr_statement-statement-note-12-income-taxes-reconciliation-of-unrecognized-tax-benefits-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 12 - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)" } } }, "localname": "statement-statement-note-12-income-taxes-reconciliation-of-unrecognized-tax-benefits-details", "nsuri": "http://www.avinger.com/20221231", "xbrltype": "stringItemType" }, "avgr_statement-statement-note-12-income-taxes-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 12 - Income Taxes" } } }, "localname": "statement-statement-note-12-income-taxes-tables", "nsuri": "http://www.avinger.com/20221231", "xbrltype": "stringItemType" }, "avgr_statement-statement-note-2-summary-of-significant-accounting-policies-accounts-receivable-allowance-for-credit-loss-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies - Accounts Receivable, Allowance for Credit Loss (Details)" } } }, "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-accounts-receivable-allowance-for-credit-loss-details", "nsuri": "http://www.avinger.com/20221231", "xbrltype": "stringItemType" }, "avgr_statement-statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details)" } } }, "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details", "nsuri": "http://www.avinger.com/20221231", "xbrltype": "stringItemType" }, "avgr_statement-statement-note-2-summary-of-significant-accounting-policies-net-loss-per-share-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies - Net Loss Per Share (Details)" } } }, "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-net-loss-per-share-details", "nsuri": "http://www.avinger.com/20221231", "xbrltype": "stringItemType" }, "avgr_statement-statement-note-2-summary-of-significant-accounting-policies-product-warranty-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies - Product Warranty (Details)" } } }, "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-product-warranty-details", "nsuri": "http://www.avinger.com/20221231", "xbrltype": "stringItemType" }, "avgr_statement-statement-note-2-summary-of-significant-accounting-policies-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies" } } }, "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-tables", "nsuri": "http://www.avinger.com/20221231", "xbrltype": "stringItemType" }, "avgr_statement-statement-note-4-inventories-schedule-of-inventory-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Inventories - Schedule of Inventory (Details)" } } }, "localname": "statement-statement-note-4-inventories-schedule-of-inventory-details", "nsuri": "http://www.avinger.com/20221231", "xbrltype": "stringItemType" }, "avgr_statement-statement-note-4-inventories-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Inventories" } } }, "localname": "statement-statement-note-4-inventories-tables", "nsuri": "http://www.avinger.com/20221231", "xbrltype": "stringItemType" }, "avgr_statement-statement-note-5-property-and-equipment-net-property-and-equipment-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Property and Equipment, Net - Property and Equipment (Details)" } } }, "localname": "statement-statement-note-5-property-and-equipment-net-property-and-equipment-details", "nsuri": "http://www.avinger.com/20221231", "xbrltype": "stringItemType" }, "avgr_statement-statement-note-5-property-and-equipment-net-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Property and Equipment, Net" } } }, "localname": "statement-statement-note-5-property-and-equipment-net-tables", "nsuri": "http://www.avinger.com/20221231", "xbrltype": "stringItemType" }, "avgr_statement-statement-note-6-accrued-expenses-and-other-current-liabilities-schedule-of-accrued-expenses-and-other-current-liabilities-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)" } } }, "localname": "statement-statement-note-6-accrued-expenses-and-other-current-liabilities-schedule-of-accrued-expenses-and-other-current-liabilities-details", "nsuri": "http://www.avinger.com/20221231", "xbrltype": "stringItemType" }, "avgr_statement-statement-note-6-accrued-expenses-and-other-current-liabilities-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Accrued Expenses and Other Current Liabilities" } } }, "localname": "statement-statement-note-6-accrued-expenses-and-other-current-liabilities-tables", "nsuri": "http://www.avinger.com/20221231", "xbrltype": "stringItemType" }, "avgr_statement-statement-note-7-borrowings-schedule-of-debt-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Borrowings - Schedule of Debt (Details)" } } }, "localname": "statement-statement-note-7-borrowings-schedule-of-debt-details", "nsuri": "http://www.avinger.com/20221231", "xbrltype": "stringItemType" }, "avgr_statement-statement-note-7-borrowings-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Borrowings" } } }, "localname": "statement-statement-note-7-borrowings-tables", "nsuri": "http://www.avinger.com/20221231", "xbrltype": "stringItemType" }, "avgr_statement-statement-note-8-leases-future-operating-lease-payments-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 8 - Leases - Future Operating Lease Payments (Details)" } } }, "localname": "statement-statement-note-8-leases-future-operating-lease-payments-details", "nsuri": "http://www.avinger.com/20221231", "xbrltype": "stringItemType" }, "avgr_statement-statement-note-8-leases-rou-assets-and-lease-liabilities-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 8 - Leases - ROU Assets and Lease Liabilities (Details)" } } }, "localname": "statement-statement-note-8-leases-rou-assets-and-lease-liabilities-details", "nsuri": "http://www.avinger.com/20221231", "xbrltype": "stringItemType" }, "avgr_statement-statement-note-8-leases-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 8 - Leases" } } }, "localname": "statement-statement-note-8-leases-tables", "nsuri": "http://www.avinger.com/20221231", "xbrltype": "stringItemType" }, "avgr_statement-statement-significant-accounting-policies-policies": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "localname": "statement-statement-significant-accounting-policies-policies", "nsuri": "http://www.avinger.com/20221231", "xbrltype": "stringItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r620", "r621", "r622" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "dei_AuditorFirmId", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r620", "r621", "r622" ], "lang": { "en-us": { "role": { "label": "dei_AuditorLocation", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r620", "r621", "r622" ], "lang": { "en-us": { "role": { "label": "dei_AuditorName", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "dei_CityAreaCode", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r620", "r621", "r622" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "dei_DocumentPeriodEndDate", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r623" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "dei_DocumentType", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "dei_EntityAddressAddressLine1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "dei_EntityAddressCityOrTown", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "dei_EntityAddressPostalZipCode", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "dei_EntityAddressStateOrProvince", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r618" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "dei_EntityCommonStockSharesOutstanding", "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "dei_EntityCurrentReportingStatus", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets", "http://www.avinger.com/20221231/role/statement-balance-sheets-parentheticals", "http://www.avinger.com/20221231/role/statement-document-and-entity-information", "http://www.avinger.com/20221231/role/statement-financial-statements-schedules-", "http://www.avinger.com/20221231/role/statement-financial-statements-schedules-allowance-of-doubtful-accounts-and-sales-returns-details", "http://www.avinger.com/20221231/role/statement-financial-statements-schedules-tables", "http://www.avinger.com/20221231/role/statement-note-1-organization", "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-outstanding-warrants-details", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-tables", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-details-textual", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-noncash-stockbased-compensation-expense-related-to-stock-options-espp-and-rsus-details", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-options-outstanding-and-vested-details", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-restricted-stock-units-award-activity-details", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-stock-option-activity-details", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-tables", "http://www.avinger.com/20221231/role/statement-note-12-income-taxes", "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-and-liabilities-details", "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-details-textual", "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details", "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-reconciliation-of-unrecognized-tax-benefits-details", "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-tables", "http://www.avinger.com/20221231/role/statement-note-13-401k-plan-", "http://www.avinger.com/20221231/role/statement-note-13-401k-plan-details-textual", "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events", "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events-details-textual", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-accounts-receivable-allowance-for-credit-loss-details", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-net-loss-per-share-details", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-product-warranty-details", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.avinger.com/20221231/role/statement-note-3-fair-value-measurements", "http://www.avinger.com/20221231/role/statement-note-3-fair-value-measurements-details-textual", "http://www.avinger.com/20221231/role/statement-note-4-inventories", "http://www.avinger.com/20221231/role/statement-note-4-inventories-schedule-of-inventory-details", "http://www.avinger.com/20221231/role/statement-note-4-inventories-tables", "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-", "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-details-textual", "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-property-and-equipment-details", "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-tables", "http://www.avinger.com/20221231/role/statement-note-6-accrued-expenses-and-other-current-liabilities-", "http://www.avinger.com/20221231/role/statement-note-6-accrued-expenses-and-other-current-liabilities-schedule-of-accrued-expenses-and-other-current-liabilities-details", "http://www.avinger.com/20221231/role/statement-note-6-accrued-expenses-and-other-current-liabilities-tables", "http://www.avinger.com/20221231/role/statement-note-7-borrowings", "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual", "http://www.avinger.com/20221231/role/statement-note-7-borrowings-schedule-of-debt-details", "http://www.avinger.com/20221231/role/statement-note-7-borrowings-tables", "http://www.avinger.com/20221231/role/statement-note-8-leases", "http://www.avinger.com/20221231/role/statement-note-8-leases-details-textual", "http://www.avinger.com/20221231/role/statement-note-8-leases-future-operating-lease-payments-details", "http://www.avinger.com/20221231/role/statement-note-8-leases-rou-assets-and-lease-liabilities-details", "http://www.avinger.com/20221231/role/statement-note-8-leases-tables", "http://www.avinger.com/20221231/role/statement-note-9-commitments-and-contingencies", "http://www.avinger.com/20221231/role/statement-note-9-commitments-and-contingencies-details-textual", "http://www.avinger.com/20221231/role/statement-significant-accounting-policies-policies", "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows", "http://www.avinger.com/20221231/role/statement-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r618" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "dei_EntityFileNumber", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r618" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r624" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "dei_EntityInteractiveDataCurrent", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "dei_EntityPublicFloat", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r618" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "dei_EntityRegistrantName", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r618" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "dei_EntityShellCompany", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r618" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r618" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "dei_EntityVoluntaryFilers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r625" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "dei_EntityWellKnownSeasonedIssuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r620", "r621", "r622" ], "lang": { "en-us": { "role": { "label": "dei_IcfrAuditorAttestationFlag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets", "http://www.avinger.com/20221231/role/statement-balance-sheets-parentheticals", "http://www.avinger.com/20221231/role/statement-document-and-entity-information", "http://www.avinger.com/20221231/role/statement-financial-statements-schedules-", "http://www.avinger.com/20221231/role/statement-financial-statements-schedules-allowance-of-doubtful-accounts-and-sales-returns-details", "http://www.avinger.com/20221231/role/statement-financial-statements-schedules-tables", "http://www.avinger.com/20221231/role/statement-note-1-organization", "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-outstanding-warrants-details", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-tables", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-details-textual", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-noncash-stockbased-compensation-expense-related-to-stock-options-espp-and-rsus-details", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-options-outstanding-and-vested-details", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-restricted-stock-units-award-activity-details", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-stock-option-activity-details", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-tables", "http://www.avinger.com/20221231/role/statement-note-12-income-taxes", "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-and-liabilities-details", "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-details-textual", "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details", "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-reconciliation-of-unrecognized-tax-benefits-details", "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-tables", "http://www.avinger.com/20221231/role/statement-note-13-401k-plan-", "http://www.avinger.com/20221231/role/statement-note-13-401k-plan-details-textual", "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events", "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events-details-textual", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-accounts-receivable-allowance-for-credit-loss-details", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-net-loss-per-share-details", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-product-warranty-details", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.avinger.com/20221231/role/statement-note-3-fair-value-measurements", "http://www.avinger.com/20221231/role/statement-note-3-fair-value-measurements-details-textual", "http://www.avinger.com/20221231/role/statement-note-4-inventories", "http://www.avinger.com/20221231/role/statement-note-4-inventories-schedule-of-inventory-details", "http://www.avinger.com/20221231/role/statement-note-4-inventories-tables", "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-", "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-details-textual", "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-property-and-equipment-details", "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-tables", "http://www.avinger.com/20221231/role/statement-note-6-accrued-expenses-and-other-current-liabilities-", "http://www.avinger.com/20221231/role/statement-note-6-accrued-expenses-and-other-current-liabilities-schedule-of-accrued-expenses-and-other-current-liabilities-details", "http://www.avinger.com/20221231/role/statement-note-6-accrued-expenses-and-other-current-liabilities-tables", "http://www.avinger.com/20221231/role/statement-note-7-borrowings", "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual", "http://www.avinger.com/20221231/role/statement-note-7-borrowings-schedule-of-debt-details", "http://www.avinger.com/20221231/role/statement-note-7-borrowings-tables", "http://www.avinger.com/20221231/role/statement-note-8-leases", "http://www.avinger.com/20221231/role/statement-note-8-leases-details-textual", "http://www.avinger.com/20221231/role/statement-note-8-leases-future-operating-lease-payments-details", "http://www.avinger.com/20221231/role/statement-note-8-leases-rou-assets-and-lease-liabilities-details", "http://www.avinger.com/20221231/role/statement-note-8-leases-tables", "http://www.avinger.com/20221231/role/statement-note-9-commitments-and-contingencies", "http://www.avinger.com/20221231/role/statement-note-9-commitments-and-contingencies-details-textual", "http://www.avinger.com/20221231/role/statement-significant-accounting-policies-policies", "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows", "http://www.avinger.com/20221231/role/statement-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "dei_LocalPhoneNumber", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r617" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r619" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r179", "r180", "r281", "r310", "r566", "r573", "r575" ], "lang": { "en-us": { "role": { "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "stringItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r247", "r590", "r665", "r774" ], "lang": { "en-us": { "role": { "documentation": "Information by name or description of a single external customer or a group of external customers.", "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r265", "r266", "r267", "r268", "r400", "r523", "r530", "r552", "r553", "r588", "r601", "r616", "r662", "r767", "r768", "r769", "r770", "r771", "r772" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r265", "r266", "r267", "r268", "r400", "r523", "r530", "r552", "r553", "r588", "r601", "r616", "r662", "r767", "r768", "r769", "r770", "r771", "r772" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-details-textual", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r247", "r590", "r665", "r774" ], "lang": { "en-us": { "role": { "documentation": "Single external customer or group of external customers.", "label": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r265", "r266", "r267", "r268", "r349", "r400", "r437", "r438", "r439", "r522", "r523", "r530", "r552", "r553", "r588", "r601", "r616", "r658", "r662", "r768", "r769", "r770", "r771", "r772" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-details-textual", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r265", "r266", "r267", "r268", "r349", "r400", "r437", "r438", "r439", "r522", "r523", "r530", "r552", "r553", "r588", "r601", "r616", "r658", "r662", "r768", "r769", "r770", "r771", "r772" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-details-textual", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r179", "r180", "r281", "r310", "r574", "r575" ], "lang": { "en-us": { "role": { "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": { "auth_ref": [ "r188", "r565" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]" } } }, "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-financial-statements-schedules-" ], "xbrltype": "textBlockItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r245", "r246", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r555", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r589", "r615", "r665" ], "lang": { "en-us": { "role": { "documentation": "Geographical area.", "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r245", "r246", "r537", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r555", "r556", "r589", "r615", "r665" ], "lang": { "en-us": { "role": { "documentation": "Information by geographical components.", "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-6-accrued-expenses-and-other-current-liabilities-" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r17", "r614" ], "calculation": { "http://www.avinger.com/20221231/role/statement-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "auth_ref": [ "r654" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]" } } }, "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r538" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r248", "r249" ], "calculation": { "http://www.avinger.com/20221231/role/statement-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable, net of allowance for doubtful accounts of $73 and $6 at December 31, 2022 and 2021, respectively" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r20" ], "calculation": { "http://www.avinger.com/20221231/role/statement-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.avinger.com/20221231/role/statement-note-6-accrued-expenses-and-other-current-liabilities-schedule-of-accrued-expenses-and-other-current-liabilities-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses and other current liabilities", "totalLabel": "Total accrued expenses and other current liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets", "http://www.avinger.com/20221231/role/statement-note-6-accrued-expenses-and-other-current-liabilities-schedule-of-accrued-expenses-and-other-current-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r20" ], "calculation": { "http://www.avinger.com/20221231/role/statement-note-6-accrued-expenses-and-other-current-liabilities-schedule-of-accrued-expenses-and-other-current-liabilities-details": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-6-accrued-expenses-and-other-current-liabilities-schedule-of-accrued-expenses-and-other-current-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r64", "r153" ], "calculation": { "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-property-and-equipment-details": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "negatedLabel": "Less: Accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-property-and-equipment-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r9" ], "calculation": { "http://www.avinger.com/20221231/role/statement-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r446", "r447", "r448", "r642", "r643", "r644", "r758" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-stockholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings": { "auth_ref": [ "r81", "r84" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from dividends legally declared (or paid) in excess of retained earnings balance.", "label": "us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings", "negatedLabel": "Accretion of Series A preferred stock dividends" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r104", "r105", "r409" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Employee stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r441" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share-based Compensation Expense", "terseLabel": "Share-Based Payment Arrangement, Expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-details-textual", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-noncash-stockbased-compensation-expense-related-to-stock-options-espp-and-rsus-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForCreditLossMember": { "auth_ref": [ "r637", "r638", "r639", "r640", "r641" ], "lang": { "en-us": { "role": { "documentation": "Allowance for credit loss from right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "SEC Schedule, 12-09, Allowance, Credit Loss [Member]" } } }, "localname": "AllowanceForCreditLossMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-financial-statements-schedules-", "http://www.avinger.com/20221231/role/statement-financial-statements-schedules-allowance-of-doubtful-accounts-and-sales-returns-details" ], "xbrltype": "domainItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r159", "r250", "r253", "r254", "r256" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "us-gaap_AllowanceForDoubtfulAccountsReceivable", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-accounts-receivable-allowance-for-credit-loss-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r159", "r250", "r253" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets-parentheticals" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r32", "r41", "r117", "r300" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "us-gaap_AmortizationOfDebtDiscountPremium", "terseLabel": "Amortization of Debt Discount (Premium)" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r300", "r505", "r586", "r587", "r633" ], "calculation": { "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of debt issuance costs and debt discount" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r211" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r121", "r135", "r155", "r176", "r229", "r238", "r242", "r251", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r479", "r481", "r491", "r614", "r660", "r661", "r765" ], "calculation": { "http://www.avinger.com/20221231/role/statement-balance-sheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r148", "r162", "r176", "r251", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r479", "r481", "r491", "r614", "r660", "r661", "r765" ], "calculation": { "http://www.avinger.com/20221231/role/statement-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r113" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_AssetsFairValueDisclosure", "terseLabel": "Assets, Fair Value Disclosure, Total" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-3-fair-value-measurements-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r412", "r413", "r414", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r436", "r437", "r438", "r439", "r440" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-details-textual", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-restricted-stock-units-award-activity-details", "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events", "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r45", "r46", "r47" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Purchases of property and equipment in accounts payable" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r43", "r151", "r567" ], "calculation": { "http://www.avinger.com/20221231/role/statement-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents", "terseLabel": "Cash and Cash Equivalents, at Carrying Value, Total" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets", "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r38", "r43", "r48" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r38", "r116" ], "calculation": { "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net change in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r156", "r157", "r158", "r176", "r204", "r205", "r208", "r210", "r216", "r217", "r251", "r269", "r271", "r272", "r273", "r276", "r277", "r307", "r308", "r312", "r316", "r322", "r491", "r554", "r626", "r634", "r645" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-1-organization", "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual", "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r86", "r90" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-1-organization", "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-outstanding-warrants-details", "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events", "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-1-organization", "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-outstanding-warrants-details", "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events", "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Exercise price per share (in dollars per share)", "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-outstanding-warrants-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Underlying shares of common stock (in shares)", "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-outstanding-warrants-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Total outstanding and exercisable (in shares)", "terseLabel": "Class of Warrant or Right, Outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-outstanding-warrants-details", "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r25", "r128", "r142" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r68", "r263", "r264", "r539", "r659" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-9-commitments-and-contingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r642", "r643", "r758" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows", "http://www.avinger.com/20221231/role/statement-statements-of-stockholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share (in dollars per share)", "terseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets-parentheticals", "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized (in shares)", "terseLabel": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets", "http://www.avinger.com/20221231/role/statement-balance-sheets-parentheticals", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued (in shares)", "terseLabel": "Common Stock, Shares, Issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets-parentheticals", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r8", "r81" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding, Ending Balance (in shares)", "terseLabel": "Common Stock, Shares, Outstanding, Ending Balance (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets-parentheticals", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r8", "r614" ], "calculation": { "http://www.avinger.com/20221231/role/statement-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, par value of $0.001; Shares authorized: 100,000,000 at December 31, 2021 and 2020; Shares issued and outstanding: 7,832,644 and 4,778,263 at December 31, 2022 and 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-", "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r54", "r55", "r114", "r115", "r247", "r538" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r54", "r55", "r114", "r115", "r247", "r536", "r538" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r54", "r55", "r114", "r115", "r247", "r538", "r775" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r54", "r55", "r114", "r115", "r247" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "us-gaap_ConcentrationRiskPercentage1", "terseLabel": "Concentration Risk, Percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r54", "r55", "r114", "r115", "r247", "r538" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ConversionOfStockByUniqueDescriptionAxis": { "auth_ref": [ "r45", "r46", "r47" ], "lang": { "en-us": { "role": { "documentation": "Information by description of stock conversions.", "label": "Stock Conversion Description [Axis]" } } }, "localname": "ConversionOfStockByUniqueDescriptionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConversionOfStockNameDomain": { "auth_ref": [ "r45", "r46", "r47" ], "lang": { "en-us": { "role": { "documentation": "The unique name of a noncash or part noncash stock conversion.", "label": "Conversion of Stock, Name [Domain]" } } }, "localname": "ConversionOfStockNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r45", "r46", "r47" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "us-gaap_ConversionOfStockSharesConverted1", "terseLabel": "Conversion of Stock, Shares Converted" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r45", "r46", "r47" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "us-gaap_ConversionOfStockSharesIssued1", "terseLabel": "Conversion of Stock, Shares Issued" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_CostOfGoodsAndServicesSoldDepreciation": { "auth_ref": [ "r631", "r656" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for allocation of cost of tangible asset over its useful life directly used in production of good and rendering of service.", "label": "us-gaap_CostOfGoodsAndServicesSoldDepreciation", "terseLabel": "Cost, Depreciation" } } }, "localname": "CostOfGoodsAndServicesSoldDepreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r30", "r176", "r251", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r491", "r660" ], "calculation": { "http://www.avinger.com/20221231/role/statement-statements-of-operations-and-comprehensive-loss": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of revenues" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-noncash-stockbased-compensation-expense-related-to-stock-options-espp-and-rsus-details" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfSalesPolicyTextBlock": { "auth_ref": [ "r666" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.", "label": "Cost of Goods and Service [Policy Text Block]" } } }, "localname": "CostOfSalesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings", "http://www.avinger.com/20221231/role/statement-note-7-borrowings-schedule-of-debt-details" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings", "http://www.avinger.com/20221231/role/statement-note-7-borrowings-schedule-of-debt-details" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r53", "r247" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionByUniqueDescriptionAxis": { "auth_ref": [ "r45", "r47" ], "lang": { "en-us": { "role": { "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction.", "label": "Debt Conversion Description [Axis]" } } }, "localname": "DebtConversionByUniqueDescriptionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual", "http://www.avinger.com/20221231/role/statement-note-7-borrowings", "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_DebtConversionNameDomain": { "auth_ref": [ "r45", "r47" ], "lang": { "en-us": { "role": { "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Name [Domain]" } } }, "localname": "DebtConversionNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual", "http://www.avinger.com/20221231/role/statement-note-7-borrowings", "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionOriginalDebtAmount1": { "auth_ref": [ "r45", "r47" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "us-gaap_DebtConversionOriginalDebtAmount1", "terseLabel": "Debt Conversion, Original Debt, Amount" } } }, "localname": "DebtConversionOriginalDebtAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r80", "r173", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r294", "r301", "r302", "r303" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r1", "r2", "r3", "r122", "r124", "r134", "r181", "r278", "r279", "r280", "r281", "r282", "r284", "r290", "r291", "r292", "r293", "r295", "r296", "r297", "r298", "r299", "r300", "r506", "r583", "r584", "r585", "r586", "r587", "r635" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings", "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r118", "r120", "r278", "r506", "r584", "r585" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "us-gaap_DebtInstrumentFaceAmount", "terseLabel": "Debt Instrument, Face Amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r22", "r279" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "us-gaap_DebtInstrumentInterestRateStatedPercentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r23", "r181", "r278", "r279", "r280", "r281", "r282", "r284", "r290", "r291", "r292", "r293", "r295", "r296", "r297", "r298", "r299", "r300", "r506", "r583", "r584", "r585", "r586", "r587", "r635" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings", "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r23", "r132" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "us-gaap_DebtInstrumentPeriodicPayment", "terseLabel": "Debt Instrument, Periodic Payment, Total" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r119", "r290", "r304", "r584", "r585" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Less: Amount representing debt issuance costs", "terseLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual", "http://www.avinger.com/20221231/role/statement-note-7-borrowings-schedule-of-debt-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain (loss) in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax", "terseLabel": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss), before Tax, Total" } } }, "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r5", "r6", "r123", "r133", "r463" ], "calculation": { "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "us-gaap_DeferredIncomeTaxLiabilities", "negatedTotalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenue": { "auth_ref": [ "r627" ], "calculation": { "http://www.avinger.com/20221231/role/statement-note-6-accrued-expenses-and-other-current-liabilities-schedule-of-accrued-expenses-and-other-current-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred revenue" } } }, "localname": "DeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-6-accrued-expenses-and-other-current-liabilities-schedule-of-accrued-expenses-and-other-current-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r464" ], "calculation": { "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "us-gaap_DeferredTaxAssetsGross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r756" ], "calculation": { "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "totalLabel": "Net deferred tax assets (liabilities)" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r756" ], "calculation": { "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "us-gaap_DeferredTaxAssetsNet", "totalLabel": "Total net deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r112", "r757" ], "calculation": { "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Federal, state and foreign net operating losses" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": { "auth_ref": [], "calculation": { "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.", "label": "Fixed assets" } } }, "localname": "DeferredTaxAssetsPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r110", "r112", "r757" ], "calculation": { "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Research and other credits" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "auth_ref": [ "r112", "r757" ], "calculation": { "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.", "label": "Accruals and other" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r465" ], "calculation": { "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "us-gaap_DeferredTaxAssetsValuationAllowance", "negatedLabel": "Less: Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r112", "r757" ], "calculation": { "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-and-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment", "negatedLabel": "Property and equipment" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r394" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "us-gaap_DefinedContributionPlanCostRecognized", "terseLabel": "Defined Contribution Plan, Cost" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-13-401k-plan-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.", "label": "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "terseLabel": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent" } } }, "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-13-401k-plan-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r41", "r62" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "us-gaap_Depreciation", "terseLabel": "Depreciation, Total" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r41", "r227" ], "calculation": { "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r411", "r442", "r443", "r445", "r450", "r602" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-financial-statements-schedules-", "http://www.avinger.com/20221231/role/statement-note-1-organization", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation", "http://www.avinger.com/20221231/role/statement-note-12-income-taxes", "http://www.avinger.com/20221231/role/statement-note-13-401k-plan-", "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20221231/role/statement-note-3-fair-value-measurements", "http://www.avinger.com/20221231/role/statement-note-4-inventories", "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-", "http://www.avinger.com/20221231/role/statement-note-6-accrued-expenses-and-other-current-liabilities-", "http://www.avinger.com/20221231/role/statement-note-7-borrowings", "http://www.avinger.com/20221231/role/statement-note-8-leases", "http://www.avinger.com/20221231/role/statement-note-9-commitments-and-contingencies" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsPreferredStock": { "auth_ref": [ "r84", "r131" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "us-gaap_DividendsPreferredStock", "terseLabel": "Dividends, Preferred Stock, Total" } } }, "localname": "DividendsPreferredStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-12-income-taxes", "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r170", "r194", "r195", "r196", "r197", "r198", "r202", "r204", "r208", "r209", "r210", "r212", "r485", "r486", "r526", "r528", "r579" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Net loss per share attributable to common stockholders, basic and diluted (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-net-loss-per-share-details", "http://www.avinger.com/20221231/role/statement-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r51", "r52" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r20" ], "calculation": { "http://www.avinger.com/20221231/role/statement-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r444" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r444" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "auth_ref": [ "r441" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.", "label": "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "terseLabel": "Share-Based Payment Arrangement, Expense, Tax Benefit" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r81", "r146", "r166", "r167", "r168", "r189", "r190", "r191", "r193", "r199", "r201", "r215", "r252", "r324", "r446", "r447", "r448", "r470", "r471", "r484", "r496", "r497", "r498", "r499", "r500", "r501", "r515", "r531", "r532", "r533" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-stockholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r292", "r352", "r353", "r354", "r355", "r356", "r357", "r487", "r519", "r520", "r521", "r584", "r585", "r591", "r592", "r593" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-3-fair-value-measurements", "http://www.avinger.com/20221231/role/statement-note-3-fair-value-measurements-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r490" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-3-fair-value-measurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r292", "r352", "r357", "r487", "r520", "r584", "r585", "r591", "r592", "r593" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-3-fair-value-measurements", "http://www.avinger.com/20221231/role/statement-note-3-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r292", "r352", "r353", "r354", "r355", "r356", "r357", "r487", "r521", "r584", "r585", "r591", "r592", "r593" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-3-fair-value-measurements", "http://www.avinger.com/20221231/role/statement-note-3-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r292", "r352", "r353", "r354", "r355", "r356", "r357", "r519", "r520", "r521", "r584", "r585", "r591", "r592", "r593" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-3-fair-value-measurements", "http://www.avinger.com/20221231/role/statement-note-3-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r492", "r493", "r494", "r495" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax", "terseLabel": "Foreign Currency Transaction Gain (Loss), before Tax, Total" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r503" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-", "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r41", "r78", "r79" ], "calculation": { "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "us-gaap_GainsLossesOnExtinguishmentOfDebt", "negatedLabel": "Gain on extinguishment of debt", "terseLabel": "Gain (Loss) on Extinguishment of Debt, Total" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual", "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GranteeStatusAxis": { "auth_ref": [ "r408", "r410", "r412", "r413", "r414", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r436", "r437", "r438", "r439", "r440" ], "lang": { "en-us": { "role": { "documentation": "Information by status of recipient to whom award is granted.", "label": "Grantee Status [Axis]" } } }, "localname": "GranteeStatusAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events", "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_GranteeStatusDomain": { "auth_ref": [ "r408", "r410", "r412", "r413", "r414", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r436", "r437", "r438", "r439", "r440" ], "lang": { "en-us": { "role": { "documentation": "Status of recipient to whom award is granted.", "label": "Grantee Status [Domain]" } } }, "localname": "GranteeStatusDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events", "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r29", "r176", "r229", "r237", "r241", "r243", "r251", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r491", "r581", "r660" ], "calculation": { "http://www.avinger.com/20221231/role/statement-statements-of-operations-and-comprehensive-loss": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "us-gaap_GrossProfit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r61", "r66" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r261", "r262" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-noncash-stockbased-compensation-expense-related-to-stock-options-espp-and-rsus-details", "http://www.avinger.com/20221231/role/statement-note-7-borrowings", "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-noncash-stockbased-compensation-expense-related-to-stock-options-espp-and-rsus-details", "http://www.avinger.com/20221231/role/statement-note-7-borrowings", "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r108" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-12-income-taxes", "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-12-income-taxes", "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r177", "r456", "r461", "r468", "r472", "r474", "r476", "r477", "r478" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-12-income-taxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r178", "r200", "r201", "r228", "r454", "r473", "r475", "r529" ], "calculation": { "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "us-gaap_IncomeTaxExpenseBenefit", "terseLabel": "Income Tax Expense (Benefit), Total", "totalLabel": "Provision for taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-details-textual", "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r165", "r452", "r453", "r461", "r462", "r467", "r469" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r754" ], "calculation": { "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Change in valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r455" ], "calculation": { "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "order": 0.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Tax at federal statutory rate" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpense": { "auth_ref": [ "r754" ], "calculation": { "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.", "label": "Nondeductible interest expense" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "auth_ref": [ "r754" ], "calculation": { "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "order": 6.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Other" } } }, "localname": "IncomeTaxReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r754" ], "calculation": { "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "State taxes, net of federal benefit" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": { "auth_ref": [ "r754" ], "calculation": { "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "us-gaap_IncomeTaxReconciliationTaxCreditsResearch", "negatedLabel": "Research credits" } } }, "localname": "IncomeTaxReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r40" ], "calculation": { "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "us-gaap_IncreaseDecreaseInAccountsPayable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r40" ], "calculation": { "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r632" ], "calculation": { "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r40" ], "calculation": { "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities", "terseLabel": "Accrued compensation" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r40" ], "calculation": { "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "us-gaap_IncreaseDecreaseInInventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r632" ], "calculation": { "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.", "label": "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities", "terseLabel": "Other long-term liabilities" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r40" ], "calculation": { "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r119", "r130", "r169", "r226", "r504" ], "calculation": { "http://www.avinger.com/20221231/role/statement-statements-of-operations-and-comprehensive-loss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "us-gaap_InterestExpense", "negatedLabel": "Interest expense, net", "terseLabel": "Interest Expense, Total" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual", "http://www.avinger.com/20221231/role/statement-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r32", "r298", "r306", "r586", "r587" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "us-gaap_InterestExpenseDebt", "terseLabel": "Interest Expense, Debt, Total" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-4-inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r60", "r570" ], "calculation": { "http://www.avinger.com/20221231/role/statement-note-4-inventories-schedule-of-inventory-details": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Finished products" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-4-inventories-schedule-of-inventory-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r161", "r568", "r614" ], "calculation": { "http://www.avinger.com/20221231/role/statement-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.avinger.com/20221231/role/statement-note-4-inventories-schedule-of-inventory-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventories, net", "totalLabel": "Total inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets", "http://www.avinger.com/20221231/role/statement-note-4-inventories-schedule-of-inventory-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r150", "r160", "r214", "r257", "r259", "r260", "r524", "r576" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r60", "r572" ], "calculation": { "http://www.avinger.com/20221231/role/statement-note-4-inventories-schedule-of-inventory-details": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-4-inventories-schedule-of-inventory-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r60", "r571" ], "calculation": { "http://www.avinger.com/20221231/role/statement-note-4-inventories-schedule-of-inventory-details": { "order": 0.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Work-in-process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-4-inventories-schedule-of-inventory-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWriteDown": { "auth_ref": [ "r258" ], "calculation": { "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.", "label": "Provision for excess and obsolete inventories" } } }, "localname": "InventoryWriteDown", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-", "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "auth_ref": [ "r604" ], "lang": { "en-us": { "role": { "documentation": "Discount rate used by lessee to determine present value of operating lease payments.", "label": "us-gaap_LesseeOperatingLeaseDiscountRate", "terseLabel": "Lessee, Operating Lease, Discount Rate" } } }, "localname": "LesseeOperatingLeaseDiscountRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-8-leases-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r763" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-8-leases-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r511" ], "calculation": { "http://www.avinger.com/20221231/role/statement-note-8-leases-future-operating-lease-payments-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "terseLabel": "Lessee, Operating Lease, Liability, to be Paid, Total", "totalLabel": "Total" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-8-leases-details-textual", "http://www.avinger.com/20221231/role/statement-note-8-leases-future-operating-lease-payments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r511" ], "calculation": { "http://www.avinger.com/20221231/role/statement-note-8-leases-future-operating-lease-payments-details": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-8-leases-future-operating-lease-payments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r511" ], "calculation": { "http://www.avinger.com/20221231/role/statement-note-8-leases-future-operating-lease-payments-details": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-8-leases-future-operating-lease-payments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r511" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "negatedLabel": "Less: Imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-8-leases-future-operating-lease-payments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r512" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-8-leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r19", "r176", "r251", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r480", "r481", "r482", "r491", "r580", "r660", "r765", "r766" ], "calculation": { "http://www.avinger.com/20221231/role/statement-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "us-gaap_Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r13", "r126", "r140", "r614", "r636", "r653", "r761" ], "calculation": { "http://www.avinger.com/20221231/role/statement-balance-sheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r21", "r149", "r176", "r251", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r480", "r481", "r482", "r491", "r614", "r660", "r765", "r766" ], "calculation": { "http://www.avinger.com/20221231/role/statement-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r113" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "us-gaap_LiabilitiesFairValueDisclosure", "terseLabel": "Liabilities, Fair Value Disclosure, Total" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-3-fair-value-measurements-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r18", "r635" ], "lang": { "en-us": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings", "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual", "http://www.avinger.com/20221231/role/statement-note-7-borrowings-schedule-of-debt-details" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r18", "r635" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings", "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual", "http://www.avinger.com/20221231/role/statement-note-7-borrowings-schedule-of-debt-details" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r3", "r124", "r137", "r291", "r305", "r584", "r585" ], "calculation": { "http://www.avinger.com/20221231/role/statement-note-7-borrowings-schedule-of-debt-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "us-gaap_LongTermDebt", "totalLabel": "Total" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings-schedule-of-debt-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r76", "r181", "r296" ], "calculation": { "http://www.avinger.com/20221231/role/statement-note-7-borrowings-schedule-of-debt-details": { "order": 0.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings-schedule-of-debt-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r76", "r181", "r296" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "terseLabel": "Long-Term Debt, Maturity, Year Five" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r76", "r181", "r296" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "terseLabel": "Long-Term Debt, Maturity, Year Four" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r76", "r181", "r296" ], "calculation": { "http://www.avinger.com/20221231/role/statement-note-7-borrowings-schedule-of-debt-details": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings-schedule-of-debt-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r76", "r181", "r296" ], "calculation": { "http://www.avinger.com/20221231/role/statement-note-7-borrowings-schedule-of-debt-details": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings-schedule-of-debt-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings", "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r23", "r77" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings", "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment [Member]" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-", "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r759" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input, Discount Rate [Member]" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r759" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input, Expected Dividend Rate [Member]" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r759" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r759" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r488" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r218", "r223" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-1-organization" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r172" ], "calculation": { "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r172" ], "calculation": { "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r38", "r39", "r42" ], "calculation": { "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r28", "r42", "r129", "r143", "r147", "r163", "r164", "r168", "r176", "r192", "r194", "r195", "r196", "r197", "r200", "r201", "r206", "r229", "r237", "r241", "r243", "r251", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r486", "r491", "r581", "r660" ], "calculation": { "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.avinger.com/20221231/role/statement-statements-of-operations-and-comprehensive-loss": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "terseLabel": "Net and comprehensive loss", "totalLabel": "Net loss and comprehensive loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows", "http://www.avinger.com/20221231/role/statement-statements-of-operations-and-comprehensive-loss", "http://www.avinger.com/20221231/role/statement-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r194", "r195", "r196", "r197", "r202", "r203", "r207", "r210", "r229", "r237", "r241", "r243", "r581" ], "calculation": { "http://www.avinger.com/20221231/role/statement-statements-of-operations-and-comprehensive-loss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net loss applicable to common stockholders", "totalLabel": "Net loss applicable to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-net-loss-per-share-details", "http://www.avinger.com/20221231/role/statement-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonmonetaryTransactionTypeAxis": { "auth_ref": [ "r513", "r514", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613" ], "lang": { "en-us": { "role": { "documentation": "Information by nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange.", "label": "Nonmonetary Transaction Type [Axis]" } } }, "localname": "NonmonetaryTransactionTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_NonmonetaryTransactionTypeDomain": { "auth_ref": [ "r513", "r514", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613" ], "lang": { "en-us": { "role": { "documentation": "Identifies the nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange.", "label": "Nonmonetary Transaction Type [Domain]" } } }, "localname": "NonmonetaryTransactionTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r648" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "us-gaap_NumberOfReportableSegments", "terseLabel": "Number of Reportable Segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.avinger.com/20221231/role/statement-statements-of-operations-and-comprehensive-loss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "us-gaap_OperatingExpenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r229", "r237", "r241", "r243", "r581" ], "calculation": { "http://www.avinger.com/20221231/role/statement-statements-of-operations-and-comprehensive-loss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r762" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "us-gaap_OperatingLeaseExpense", "terseLabel": "Operating Lease, Expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-8-leases-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r508" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Leasehold liability as of December 31, 2022", "terseLabel": "Total lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-8-leases-future-operating-lease-payments-details", "http://www.avinger.com/20221231/role/statement-note-8-leases-rou-assets-and-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r508" ], "calculation": { "http://www.avinger.com/20221231/role/statement-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Leasehold liability, current portion" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets", "http://www.avinger.com/20221231/role/statement-note-8-leases-rou-assets-and-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r508" ], "calculation": { "http://www.avinger.com/20221231/role/statement-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "verboseLabel": "Leasehold liability, long-term portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets", "http://www.avinger.com/20221231/role/statement-note-8-leases-rou-assets-and-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r507" ], "calculation": { "http://www.avinger.com/20221231/role/statement-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease", "terseLabel": "Total right of use assets", "verboseLabel": "Right of use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets", "http://www.avinger.com/20221231/role/statement-note-8-leases-rou-assets-and-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r633" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense", "terseLabel": "Operating Lease, Right-of-Use Asset, Amortization Expense" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-8-leases-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r510", "r605" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1", "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-8-leases-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r110" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "us-gaap_OperatingLossCarryforwards", "terseLabel": "Operating Loss Carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r20" ], "calculation": { "http://www.avinger.com/20221231/role/statement-note-6-accrued-expenses-and-other-current-liabilities-schedule-of-accrued-expenses-and-other-current-liabilities-details": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other accrued liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-6-accrued-expenses-and-other-current-liabilities-schedule-of-accrued-expenses-and-other-current-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r154" ], "calculation": { "http://www.avinger.com/20221231/role/statement-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r24" ], "calculation": { "http://www.avinger.com/20221231/role/statement-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r42" ], "calculation": { "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "us-gaap_OtherNoncashIncomeExpense", "negatedLabel": "Other non-cash charges" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r33" ], "calculation": { "http://www.avinger.com/20221231/role/statement-statements-of-operations-and-comprehensive-loss": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other (expense) income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).", "label": "Other Nonoperating Income (Expense) [Member]" } } }, "localname": "OtherNonoperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings", "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r37" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "us-gaap_PaymentsOfStockIssuanceCosts", "terseLabel": "Payments of Stock Issuance Costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r34" ], "calculation": { "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r349", "r351", "r357", "r374", "r376", "r377", "r378", "r379", "r380", "r392", "r393", "r394", "r407", "r593" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-13-401k-plan-" ], "xbrltype": "textBlockItemType" }, "us-gaap_PensionPlansDefinedBenefitMember": { "auth_ref": [ "r88", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r375", "r378", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r394", "r395", "r406", "r593", "r594", "r598", "r599", "r600" ], "lang": { "en-us": { "role": { "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.", "label": "Pension Plan [Member]" } } }, "localname": "PensionPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-13-401k-plan-", "http://www.avinger.com/20221231/role/statement-note-13-401k-plan-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_PolicyTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "localname": "PolicyTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockConvertibleConversionPrice": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Per share conversion price of preferred stock.", "label": "us-gaap_PreferredStockConvertibleConversionPrice", "terseLabel": "Preferred Stock, Convertible, Conversion Price" } } }, "localname": "PreferredStockConvertibleConversionPrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockConvertibleSharesIssuable": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Number of common shares issuable upon conversion of preferred stock.", "label": "us-gaap_PreferredStockConvertibleSharesIssuable", "terseLabel": "Preferred Stock, Convertible, Shares Issuable" } } }, "localname": "PreferredStockConvertibleSharesIssuable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockDividendRatePercentage": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "The percentage rate used to calculate dividend payments on preferred stock.", "label": "us-gaap_PreferredStockDividendRatePercentage", "terseLabel": "Preferred Stock, Dividend Rate, Percentage" } } }, "localname": "PreferredStockDividendRatePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_PreferredStockDividendsIncomeStatementImpact": { "auth_ref": [], "calculation": { "http://www.avinger.com/20221231/role/statement-statements-of-operations-and-comprehensive-loss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.", "label": "us-gaap_PreferredStockDividendsIncomeStatementImpact", "negatedLabel": "Accretion of preferred stock dividends" } } }, "localname": "PreferredStockDividendsIncomeStatementImpact", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockDividendsShares": { "auth_ref": [ "r81" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of preferred stock issued as dividends during the period. Excludes stock splits.", "label": "us-gaap_PreferredStockDividendsShares", "terseLabel": "Preferred Stock Dividends, Shares" } } }, "localname": "PreferredStockDividendsShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockLiquidationPreference": { "auth_ref": [ "r7", "r82", "r83", "r634", "r663" ], "lang": { "en-us": { "role": { "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.", "label": "us-gaap_PreferredStockLiquidationPreference", "terseLabel": "Preferred Stock, Liquidation Preference Per Share" } } }, "localname": "PreferredStockLiquidationPreference", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockLiquidationPreferenceValue": { "auth_ref": [ "r174", "r312" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares.", "label": "Preferred Stock, Liquidation Preference, Value" } } }, "localname": "PreferredStockLiquidationPreferenceValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets-parentheticals" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details", "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows", "http://www.avinger.com/20221231/role/statement-statements-of-stockholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r7", "r307" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share (in dollars per share)", "terseLabel": "Preferred Stock, Par or Stated Value Per Share" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets-parentheticals", "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockRedemptionDiscount": { "auth_ref": [ "r213" ], "calculation": { "http://www.avinger.com/20221231/role/statement-statements-of-operations-and-comprehensive-loss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The excess of (1) the carrying amount of the preferred stock in the registrant's balance sheet over (2) the fair value of the consideration transferred to the holders of the preferred stock, during the accounting period, which will be added to net earnings to arrive at net earnings available to common shareholders in the calculation of earnings per share.", "label": "us-gaap_PreferredStockRedemptionDiscount", "negatedLabel": "Deemed dividend arising from beneficial conversion feature of convertible preferred stock", "terseLabel": "Preferred Stock Redemption Discount" } } }, "localname": "PreferredStockRedemptionDiscount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual", "http://www.avinger.com/20221231/role/statement-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized (in shares)", "terseLabel": "Preferred Stock, Shares Authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets-parentheticals", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r7", "r307" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued (in shares)", "terseLabel": "Preferred Stock, Shares Issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets-parentheticals", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding, Ending Balance (in shares)", "terseLabel": "Preferred Stock, Shares Outstanding, Ending Balance (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets-parentheticals", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r7", "r614" ], "calculation": { "http://www.avinger.com/20221231/role/statement-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Convertible preferred stock issuable in series, par value of $0.001 Shares authorized: 5,000,000 at December 31, 2021 and 2020 Shares issued and outstanding: 60,961 and 56,451 at December 31, 2022 and 2021, respectively; aggregate liquidation preference related to Series A convertible preferred stock of $60,876 and $56,366 at December 31, 2022 and 2021, respectively" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r630" ], "calculation": { "http://www.avinger.com/20221231/role/statement-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidRent": { "auth_ref": [ "r569", "r582", "r655" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "us-gaap_PrepaidRent", "terseLabel": "Prepaid Rent" } } }, "localname": "PrepaidRent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-8-leases-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-1-organization", "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "auth_ref": [ "r35" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.", "label": "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock", "terseLabel": "Proceeds from Issuance of Convertible Preferred Stock" } } }, "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r36" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "us-gaap_ProceedsFromIssuanceOfLongTermDebt", "terseLabel": "Proceeds from Issuance of Long-Term Debt, Total" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r35" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "us-gaap_ProceedsFromIssuanceOfWarrants", "terseLabel": "Proceeds from Issuance of Warrants" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r35" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "us-gaap_ProceedsFromIssuanceOrSaleOfEquity", "terseLabel": "Proceeds from Issuance or Sale of Equity, Total" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrual": { "auth_ref": [ "r73", "r74", "r127" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.", "label": "us-gaap_ProductWarrantyAccrual", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "ProductWarrantyAccrual", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-product-warranty-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrualClassifiedCurrent": { "auth_ref": [ "r20", "r69", "r70" ], "calculation": { "http://www.avinger.com/20221231/role/statement-note-6-accrued-expenses-and-other-current-liabilities-schedule-of-accrued-expenses-and-other-current-liabilities-details": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued product warranty costs" } } }, "localname": "ProductWarrantyAccrualClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-6-accrued-expenses-and-other-current-liabilities-schedule-of-accrued-expenses-and-other-current-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrualWarrantiesIssued": { "auth_ref": [ "r71" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in the standard and extended product warranty accrual from warranties issued.", "label": "Warranty provision" } } }, "localname": "ProductWarrantyAccrualWarrantiesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-product-warranty-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r65" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-", "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-details-textual", "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-property-and-equipment-details" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r67", "r540", "r541", "r542" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r63", "r152" ], "calculation": { "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-property-and-equipment-details": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "us-gaap_PropertyPlantAndEquipmentGross", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-property-and-equipment-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r65", "r141", "r527", "r614" ], "calculation": { "http://www.avinger.com/20221231/role/statement-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-property-and-equipment-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net", "totalLabel": "Total property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets", "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-property-and-equipment-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r65", "r540", "r541" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r65" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-", "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-details-textual", "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife", "terseLabel": "Property, Plant and Equipment, Useful Life (Year)" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet": { "auth_ref": [ "r145", "r657", "r764" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated depreciation, of lessor's underlying asset for which right to use has been conveyed to lessee under operating lease.", "label": "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet", "terseLabel": "Property, Plant, and Equipment, Lessor Asset under Operating Lease, after Accumulated Depreciation, Total" } } }, "localname": "PropertySubjectToOrAvailableForOperatingLeaseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r171", "r255" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Provision" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-accounts-receivable-allowance-for-credit-loss-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": { "auth_ref": [ "r4", "r125", "r138" ], "lang": { "en-us": { "role": { "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers.", "label": "Purchase Commitment, Excluding Long-Term Commitment [Axis]" } } }, "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-9-commitments-and-contingencies", "http://www.avinger.com/20221231/role/statement-note-9-commitments-and-contingencies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": { "auth_ref": [ "r4", "r125", "r138" ], "lang": { "en-us": { "role": { "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate.", "label": "Purchase Commitment, Excluding Long-Term Commitment [Domain]" } } }, "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-9-commitments-and-contingencies", "http://www.avinger.com/20221231/role/statement-note-9-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_PurchaseCommitmentMember": { "auth_ref": [ "r4", "r125", "r138" ], "lang": { "en-us": { "role": { "documentation": "Purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier. Excludes long-term commitments.", "label": "Purchase Commitment [Member]" } } }, "localname": "PurchaseCommitmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-9-commitments-and-contingencies", "http://www.avinger.com/20221231/role/statement-note-9-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_PurchaseObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.", "label": "us-gaap_PurchaseObligation", "terseLabel": "Purchase Obligation, Total" } } }, "localname": "PurchaseObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-9-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r649", "r650", "r651", "r652" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "Receivable [Policy Text Block]" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r106", "r144", "r773" ], "calculation": { "http://www.avinger.com/20221231/role/statement-statements-of-operations-and-comprehensive-loss": { "order": 0.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-noncash-stockbased-compensation-expense-related-to-stock-options-espp-and-rsus-details" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchMember": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.", "label": "Research Tax Credit Carryforward [Member]" } } }, "localname": "ResearchMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-12-income-taxes", "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events", "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-details-textual", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-restricted-stock-units-award-activity-details", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r10", "r84", "r139", "r534", "r535", "r614" ], "calculation": { "http://www.avinger.com/20221231/role/statement-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit", "terseLabel": "Retained Earnings (Accumulated Deficit), Total" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets", "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r146", "r189", "r190", "r191", "r193", "r199", "r201", "r252", "r446", "r447", "r448", "r470", "r471", "r484", "r531", "r533" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-stockholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanNameAxis": { "auth_ref": [ "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r601", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727" ], "lang": { "en-us": { "role": { "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.", "label": "Retirement Plan Name [Axis]" } } }, "localname": "RetirementPlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-13-401k-plan-", "http://www.avinger.com/20221231/role/statement-note-13-401k-plan-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanNameDomain": { "auth_ref": [ "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r601", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727" ], "lang": { "en-us": { "role": { "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.", "label": "Retirement Plan Name [Domain]" } } }, "localname": "RetirementPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-13-401k-plan-", "http://www.avinger.com/20221231/role/statement-note-13-401k-plan-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r88", "r89", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r375", "r378", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r394", "r395", "r396", "r406", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600" ], "lang": { "en-us": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-13-401k-plan-", "http://www.avinger.com/20221231/role/statement-note-13-401k-plan-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r88", "r89", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r375", "r378", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r394", "r395", "r396", "r406", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600" ], "lang": { "en-us": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-13-401k-plan-", "http://www.avinger.com/20221231/role/statement-note-13-401k-plan-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r224", "r225", "r236", "r239", "r240", "r244", "r245", "r247", "r325", "r326", "r525" ], "calculation": { "http://www.avinger.com/20221231/role/statement-statements-of-operations-and-comprehensive-loss": { "order": 0.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenues" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r577", "r578" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-1-organization", "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual", "http://www.avinger.com/20221231/role/statement-statements-of-stockholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_SalesAndExciseTaxPayableCurrent": { "auth_ref": [ "r17" ], "calculation": { "http://www.avinger.com/20221231/role/statement-note-6-accrued-expenses-and-other-current-liabilities-schedule-of-accrued-expenses-and-other-current-liabilities-details": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued sales and use tax" } } }, "localname": "SalesAndExciseTaxPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-6-accrued-expenses-and-other-current-liabilities-schedule-of-accrued-expenses-and-other-current-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r247", "r647" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-6-accrued-expenses-and-other-current-liabilities-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-7-borrowings-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r109" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r646" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r107" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r102" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r0", "r14", "r15", "r16" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-4-inventories-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": { "auth_ref": [ "r75" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.", "label": "Schedule of Product Warranty Liability [Table Text Block]" } } }, "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r91" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "auth_ref": [ "r103" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r91", "r96", "r98" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r86", "r90" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r603", "r755" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebtCurrent": { "auth_ref": [ "r1", "r122", "r136" ], "calculation": { "http://www.avinger.com/20221231/role/statement-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.", "label": "Borrowings, current portion", "terseLabel": "Borrowings, current portion, as of December 31, 2022" } } }, "localname": "SecuredDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets", "http://www.avinger.com/20221231/role/statement-note-7-borrowings-schedule-of-debt-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_SecuredLongTermDebt": { "auth_ref": [ "r23" ], "calculation": { "http://www.avinger.com/20221231/role/statement-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.", "label": "Borrowings, long-term portion" } } }, "localname": "SecuredLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r230", "r231", "r232", "r233", "r234", "r235", "r245" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r31" ], "calculation": { "http://www.avinger.com/20221231/role/statement-statements-of-operations-and-comprehensive-loss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-noncash-stockbased-compensation-expense-related-to-stock-options-espp-and-rsus-details" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [ "r628", "r629", "r664" ], "lang": { "en-us": { "role": { "documentation": "Series A preferred stock.", "label": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [ "r628", "r629", "r664" ], "lang": { "en-us": { "role": { "documentation": "Series B preferred stock.", "label": "Series B Preferred Stock [Member]" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesDPreferredStockMember": { "auth_ref": [ "r628", "r629", "r664" ], "lang": { "en-us": { "role": { "documentation": "Series D preferred stock.", "label": "Series D Preferred Stock [Member]" } } }, "localname": "SeriesDPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-1-organization", "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual", "http://www.avinger.com/20221231/role/statement-statements-of-stockholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r40" ], "calculation": { "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r602" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-details-textual", "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "negatedLabel": "Forfeited, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-restricted-stock-units-award-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Forfeited, , Weighted Average Grant Date Fair Value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-restricted-stock-units-award-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Awarded, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-restricted-stock-units-award-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Awarded, Weighted Average Grant Date Fair Value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-restricted-stock-units-award-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r424", "r425" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "periodEndLabel": "Awards outstanding, shares (in shares)", "periodStartLabel": "Awards outstanding, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-restricted-stock-units-award-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r424", "r425" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "periodEndLabel": "Awards outstanding, Weighted Average Grant Date Fair Value (in dollars per share)", "periodStartLabel": "Awards outstanding, Weighted Average Grant Date Fair Value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-restricted-stock-units-award-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r99" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Awards outstanding, Weighted Average Remaining Contractual Term (Year)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-restricted-stock-units-award-activity-details" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "negatedLabel": "Released, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-restricted-stock-units-award-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r431" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Released, Weighted Average Grant Date Fair Value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-restricted-stock-units-award-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r94" ], "lang": { "en-us": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r103" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Exercisable, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "negatedLabel": "Options expired (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r420" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r103" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Options, intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-stock-option-activity-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r416", "r417" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "periodEndLabel": "Options (in shares)", "periodStartLabel": "Options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r416", "r417" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "periodEndLabel": "Options, weighted average exercise price (in dollars per share)", "periodStartLabel": "Options, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r432" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Vested and expected to vest, intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-stock-option-activity-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Vested and expected to vest (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Vested and expected to vest, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r412", "r413", "r414", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r436", "r437", "r438", "r439", "r440" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-details-textual", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-restricted-stock-units-award-activity-details", "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events", "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Options expired, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r415", "r434", "r435", "r436", "r437", "r440", "r449", "r450" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r100" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-options-outstanding-and-vested-details" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r101" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Exercise Price Range [Domain]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-options-outstanding-and-vested-details" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "auth_ref": [ "r101" ], "lang": { "en-us": { "role": { "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Exercise Price, Lower Limit (in dollars per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-options-outstanding-and-vested-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "auth_ref": [ "r95" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.", "label": "Number Exercisable (in shares)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-options-outstanding-and-vested-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "auth_ref": [ "r92" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.", "label": "Options Outstanding (in shares)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-options-outstanding-and-vested-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "auth_ref": [ "r101" ], "lang": { "en-us": { "role": { "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Exercise Price, Upper Limit (in dollars per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-options-outstanding-and-vested-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedPaymentArrangementEmployeeMember": { "auth_ref": [ "r410", "r412", "r413", "r414", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r436", "r437", "r438", "r439", "r440" ], "lang": { "en-us": { "role": { "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.", "label": "Share-Based Payment Arrangement, Employee [Member]" } } }, "localname": "ShareBasedPaymentArrangementEmployeeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events", "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "us-gaap_SharePrice", "terseLabel": "Share Price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-details-textual", "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r103" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Exercisable, intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-stock-option-activity-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r103" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Exercisable, weighted average remaining contractual life (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-stock-option-activity-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r99" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Options, weighted average remaining contractual life (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-stock-option-activity-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Vested and expected to vest, weighted average remaining contractual life (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-stock-option-activity-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": { "auth_ref": [ "r93" ], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.", "label": "Weighted Average Exercise Price, options vested (in dollars per share)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-options-outstanding-and-vested-details" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": { "auth_ref": [ "r92" ], "lang": { "en-us": { "role": { "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.", "label": "Weighted Average Exercise Price (in dollars per share)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-options-outstanding-and-vested-details" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r99" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Remaining Contractual Life (Year)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-options-outstanding-and-vested-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "us-gaap_SharesIssuedPricePerShare", "terseLabel": "Shares Issued, Price Per Share (in dollars per share)" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "us-gaap_SharesOutstanding", "periodEndLabel": "Balance at December 31, 2021 (in shares)", "periodStartLabel": "Balance at December 31, 2020 (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-stockholders-equity" ], "xbrltype": "sharesItemType" }, "us-gaap_SoftwareDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Internally developed software for sale, licensing or long-term internal use.", "label": "Software Development [Member]" } } }, "localname": "SoftwareDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-", "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_StandardProductWarrantyPolicy": { "auth_ref": [ "r72" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.", "label": "Standard Product Warranty, Policy [Policy Text Block]" } } }, "localname": "StandardProductWarrantyPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-12-income-taxes", "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r156", "r157", "r158", "r176", "r204", "r205", "r208", "r210", "r216", "r217", "r251", "r269", "r271", "r272", "r273", "r276", "r277", "r307", "r308", "r312", "r316", "r322", "r491", "r554", "r626", "r634", "r645" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-1-organization", "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual", "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r27", "r81", "r146", "r166", "r167", "r168", "r189", "r190", "r191", "r193", "r199", "r201", "r215", "r252", "r324", "r446", "r447", "r448", "r470", "r471", "r484", "r496", "r497", "r498", "r499", "r500", "r501", "r515", "r531", "r532", "r533" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-stockholders-equity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets", "http://www.avinger.com/20221231/role/statement-balance-sheets-parentheticals", "http://www.avinger.com/20221231/role/statement-financial-statements-schedules-", "http://www.avinger.com/20221231/role/statement-financial-statements-schedules-allowance-of-doubtful-accounts-and-sales-returns-details", "http://www.avinger.com/20221231/role/statement-financial-statements-schedules-tables", "http://www.avinger.com/20221231/role/statement-note-1-organization", "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-outstanding-warrants-details", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-tables", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-details-textual", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-noncash-stockbased-compensation-expense-related-to-stock-options-espp-and-rsus-details", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-options-outstanding-and-vested-details", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-restricted-stock-units-award-activity-details", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-stock-option-activity-details", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-tables", "http://www.avinger.com/20221231/role/statement-note-12-income-taxes", "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-and-liabilities-details", "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-details-textual", "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details", "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-reconciliation-of-unrecognized-tax-benefits-details", "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-tables", "http://www.avinger.com/20221231/role/statement-note-13-401k-plan-", "http://www.avinger.com/20221231/role/statement-note-13-401k-plan-details-textual", "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events", "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events-details-textual", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-accounts-receivable-allowance-for-credit-loss-details", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-net-loss-per-share-details", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-product-warranty-details", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.avinger.com/20221231/role/statement-note-3-fair-value-measurements", "http://www.avinger.com/20221231/role/statement-note-3-fair-value-measurements-details-textual", "http://www.avinger.com/20221231/role/statement-note-4-inventories", "http://www.avinger.com/20221231/role/statement-note-4-inventories-schedule-of-inventory-details", "http://www.avinger.com/20221231/role/statement-note-4-inventories-tables", "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-", "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-details-textual", "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-property-and-equipment-details", "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-tables", "http://www.avinger.com/20221231/role/statement-note-6-accrued-expenses-and-other-current-liabilities-", "http://www.avinger.com/20221231/role/statement-note-6-accrued-expenses-and-other-current-liabilities-schedule-of-accrued-expenses-and-other-current-liabilities-details", "http://www.avinger.com/20221231/role/statement-note-6-accrued-expenses-and-other-current-liabilities-tables", "http://www.avinger.com/20221231/role/statement-note-7-borrowings", "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual", "http://www.avinger.com/20221231/role/statement-note-7-borrowings-schedule-of-debt-details", "http://www.avinger.com/20221231/role/statement-note-7-borrowings-tables", "http://www.avinger.com/20221231/role/statement-note-8-leases", "http://www.avinger.com/20221231/role/statement-note-8-leases-details-textual", "http://www.avinger.com/20221231/role/statement-note-8-leases-future-operating-lease-payments-details", "http://www.avinger.com/20221231/role/statement-note-8-leases-rou-assets-and-lease-liabilities-details", "http://www.avinger.com/20221231/role/statement-note-8-leases-tables", "http://www.avinger.com/20221231/role/statement-note-9-commitments-and-contingencies", "http://www.avinger.com/20221231/role/statement-note-9-commitments-and-contingencies-details-textual", "http://www.avinger.com/20221231/role/statement-significant-accounting-policies-policies", "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows", "http://www.avinger.com/20221231/role/statement-statements-of-operations-and-comprehensive-loss", "http://www.avinger.com/20221231/role/statement-statements-of-stockholders-equity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r189", "r190", "r191", "r215", "r525" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets", "http://www.avinger.com/20221231/role/statement-balance-sheets-parentheticals", "http://www.avinger.com/20221231/role/statement-financial-statements-schedules-", "http://www.avinger.com/20221231/role/statement-financial-statements-schedules-allowance-of-doubtful-accounts-and-sales-returns-details", "http://www.avinger.com/20221231/role/statement-financial-statements-schedules-tables", "http://www.avinger.com/20221231/role/statement-note-1-organization", "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-outstanding-warrants-details", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-tables", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-details-textual", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-noncash-stockbased-compensation-expense-related-to-stock-options-espp-and-rsus-details", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-options-outstanding-and-vested-details", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-restricted-stock-units-award-activity-details", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-stock-option-activity-details", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-tables", "http://www.avinger.com/20221231/role/statement-note-12-income-taxes", "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-and-liabilities-details", "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-details-textual", "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details", "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-reconciliation-of-unrecognized-tax-benefits-details", "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-tables", "http://www.avinger.com/20221231/role/statement-note-13-401k-plan-", "http://www.avinger.com/20221231/role/statement-note-13-401k-plan-details-textual", "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events", "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events-details-textual", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-accounts-receivable-allowance-for-credit-loss-details", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-net-loss-per-share-details", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-product-warranty-details", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.avinger.com/20221231/role/statement-note-3-fair-value-measurements", "http://www.avinger.com/20221231/role/statement-note-3-fair-value-measurements-details-textual", "http://www.avinger.com/20221231/role/statement-note-4-inventories", "http://www.avinger.com/20221231/role/statement-note-4-inventories-schedule-of-inventory-details", "http://www.avinger.com/20221231/role/statement-note-4-inventories-tables", "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-", "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-details-textual", "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-property-and-equipment-details", "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-tables", "http://www.avinger.com/20221231/role/statement-note-6-accrued-expenses-and-other-current-liabilities-", "http://www.avinger.com/20221231/role/statement-note-6-accrued-expenses-and-other-current-liabilities-schedule-of-accrued-expenses-and-other-current-liabilities-details", "http://www.avinger.com/20221231/role/statement-note-6-accrued-expenses-and-other-current-liabilities-tables", "http://www.avinger.com/20221231/role/statement-note-7-borrowings", "http://www.avinger.com/20221231/role/statement-note-7-borrowings-details-textual", "http://www.avinger.com/20221231/role/statement-note-7-borrowings-schedule-of-debt-details", "http://www.avinger.com/20221231/role/statement-note-7-borrowings-tables", "http://www.avinger.com/20221231/role/statement-note-8-leases", "http://www.avinger.com/20221231/role/statement-note-8-leases-details-textual", "http://www.avinger.com/20221231/role/statement-note-8-leases-future-operating-lease-payments-details", "http://www.avinger.com/20221231/role/statement-note-8-leases-rou-assets-and-lease-liabilities-details", "http://www.avinger.com/20221231/role/statement-note-8-leases-tables", "http://www.avinger.com/20221231/role/statement-note-9-commitments-and-contingencies", "http://www.avinger.com/20221231/role/statement-note-9-commitments-and-contingencies-details-textual", "http://www.avinger.com/20221231/role/statement-significant-accounting-policies-policies", "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows", "http://www.avinger.com/20221231/role/statement-statements-of-operations-and-comprehensive-loss", "http://www.avinger.com/20221231/role/statement-statements-of-stockholders-equity" ], "xbrltype": "stringItemType" }, "us-gaap_StockDividendsShares": { "auth_ref": [ "r81" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common and preferred stock issued as dividends during the period. Excludes stock splits.", "label": "Issuance of Series A preferred stock to pay dividends (in shares)" } } }, "localname": "StockDividendsShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-stockholders-equity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r45", "r46", "r47" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Issuance of Series A preferred stock as dividend payment" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r26", "r81", "r82", "r84", "r295" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Conversion of Series B preferred stock into common stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-stockholders-equity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r7", "r8", "r81", "r84" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Issuance of common stock in public offerings, net of commissions and issuance costs (in shares)", "terseLabel": "Stock Issued During Period, Shares, New Issues" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual", "http://www.avinger.com/20221231/role/statement-statements-of-stockholders-equity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": { "auth_ref": [ "r81" ], "lang": { "en-us": { "role": { "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split.", "label": "Reclassifications and adjustments due to rounding impact from reverse stock split for fractional shares (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesReverseStockSplits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-stockholders-equity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r7", "r8", "r81", "r84" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Issuance of common stock upon vesting of restricted stock units (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-stockholders-equity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r7", "r8", "r81", "r84", "r421" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r27", "r81", "r84" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Conversion of Series D preferred stock into common stock" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r7", "r8", "r81", "r84" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Issuance of common stock in public offerings, net of commissions and issuance costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r7", "r8", "r84", "r97" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Issuance of common stock upon vesting of restricted stock units" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockDividend": { "auth_ref": [ "r27", "r81", "r84" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued to shareholders as a dividend during the period.", "label": "Issuance of Series A preferred stock to pay dividends" } } }, "localname": "StockIssuedDuringPeriodValueStockDividend", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r8", "r11", "r12", "r59", "r614", "r636", "r653", "r761" ], "calculation": { "http://www.avinger.com/20221231/role/statement-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "us-gaap_StockholdersEquity", "periodEndLabel": "Balance at December 31, 2021", "periodStartLabel": "Balance at December 31, 2020", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets", "http://www.avinger.com/20221231/role/statement-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r87", "r175", "r308", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r324", "r483" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "auth_ref": [ "r85" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1", "terseLabel": "Stockholders' Equity Note, Stock Split, Conversion Ratio" } } }, "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "pureItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r502", "r517" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual", "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events", "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r502", "r517" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual", "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events", "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r502", "r517" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual", "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events", "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r516", "r518" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-14-subsequent-events" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-1-organization", "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual", "http://www.avinger.com/20221231/role/statement-statements-of-stockholders-equity" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_TableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "localname": "TableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-financial-statements-schedules-tables", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-tables", "http://www.avinger.com/20221231/role/statement-note-11-stockbased-compensation-tables", "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-tables", "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.avinger.com/20221231/role/statement-note-4-inventories-tables", "http://www.avinger.com/20221231/role/statement-note-5-property-and-equipment-net-tables", "http://www.avinger.com/20221231/role/statement-note-6-accrued-expenses-and-other-current-liabilities-tables", "http://www.avinger.com/20221231/role/statement-note-7-borrowings-tables", "http://www.avinger.com/20221231/role/statement-note-8-leases-tables" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r110" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "us-gaap_TaxCreditCarryforwardAmount", "terseLabel": "Tax Credit Carryforward, Amount" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-12-income-taxes", "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward, Name [Domain]" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-12-income-taxes", "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r451", "r458" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "us-gaap_UnrecognizedTaxBenefits", "periodEndLabel": "Balance at end of year", "periodStartLabel": "Balance at beginning of year" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-reconciliation-of-unrecognized-tax-benefits-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r459" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "negatedLabel": "Increase (Decrease) for tax positions of prior year" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-reconciliation-of-unrecognized-tax-benefits-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r457" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "auth_ref": [ "r457" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r460" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Increase based on the tax positions in the current year" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-reconciliation-of-unrecognized-tax-benefits-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r459" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Increase (Decrease) for tax positions of prior year" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-reconciliation-of-unrecognized-tax-benefits-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r56", "r57", "r58", "r219", "r220", "r221", "r222" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r466" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount", "terseLabel": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-12-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesBalance": { "auth_ref": [ "r182", "r187" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation and qualifying accounts and reserves.", "label": "us-gaap_ValuationAllowancesAndReservesBalance", "periodEndLabel": "Balance at End of Year", "periodStartLabel": "Balance at Beginning of Year" } } }, "localname": "ValuationAllowancesAndReservesBalance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-financial-statements-schedules-allowance-of-doubtful-accounts-and-sales-returns-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": { "auth_ref": [ "r185" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.", "label": "Charged to costs and expenses, additions" } } }, "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-financial-statements-schedules-allowance-of-doubtful-accounts-and-sales-returns-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "auth_ref": [ "r186" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.", "label": "Write offs" } } }, "localname": "ValuationAllowancesAndReservesDeductions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-financial-statements-schedules-allowance-of-doubtful-accounts-and-sales-returns-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDomain": { "auth_ref": [ "r182", "r183", "r184", "r186", "r187" ], "lang": { "en-us": { "role": { "documentation": "Valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]" } } }, "localname": "ValuationAllowancesAndReservesDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-financial-statements-schedules-", "http://www.avinger.com/20221231/role/statement-financial-statements-schedules-allowance-of-doubtful-accounts-and-sales-returns-details" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "auth_ref": [ "r182", "r183", "r184", "r186", "r187" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]" } } }, "localname": "ValuationAllowancesAndReservesTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-financial-statements-schedules-", "http://www.avinger.com/20221231/role/statement-financial-statements-schedules-allowance-of-doubtful-accounts-and-sales-returns-details" ], "xbrltype": "stringItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r509", "r605" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "us-gaap_VariableLeaseCost", "terseLabel": "Variable Lease, Cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-8-leases-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "us-gaap_WarrantsAndRightsOutstandingMeasurementInput", "terseLabel": "Warrants and Rights Outstanding, Measurement Input" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "decimalItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r760" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_WarrantsAndRightsOutstandingTerm", "terseLabel": "Warrants and Rights Outstanding, Term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-1-organization-details-textual", "http://www.avinger.com/20221231/role/statement-note-10-stockholders-equity-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).", "label": "us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation", "terseLabel": "Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation" } } }, "localname": "WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r202", "r210" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average common shares used to compute net loss per share, basic and diluted (in shares)", "terseLabel": "Weighted average common stock outstanding, basic and diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.avinger.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-net-loss-per-share-details", "http://www.avinger.com/20221231/role/statement-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(17))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123405975&loc=d3e41551-112718", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column B))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(1)))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(2)))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column D))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column E))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=122038299&loc=d3e42851-122695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "https://asc.fasb.org/topic&trid=2235017", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2646-109256", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "https://asc.fasb.org/topic&trid=2175825", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "845", "URI": "https://asc.fasb.org/extlink&oid=126934811&loc=d3e32049-108421", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "845", "URI": "https://asc.fasb.org/extlink&oid=6457341&loc=d3e32102-108422", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Footnote": "2", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column B", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column C", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column D", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column E", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column F", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column G", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column H", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column I", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "09", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(m)", "Publisher": "SEC", "Section": "4", "Subparagraph": "(1)(iii)", "Subsection": "08", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(3)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "845", "URI": "https://asc.fasb.org/extlink&oid=126934302&loc=d3e29470-108402", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "845", "URI": "https://asc.fasb.org/extlink&oid=126934302&loc=d3e29470-108402", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "845", "URI": "https://asc.fasb.org/extlink&oid=126934302&loc=d3e29470-108402", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "845", "URI": "https://asc.fasb.org/extlink&oid=126934302&loc=d3e29470-108402", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "845", "URI": "https://asc.fasb.org/extlink&oid=126934302&loc=d3e29502-108402", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "845", "URI": "https://asc.fasb.org/extlink&oid=126934302&loc=d3e29515-108402", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "845", "URI": "https://asc.fasb.org/extlink&oid=126934302&loc=d3e29515-108402", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "845", "URI": "https://asc.fasb.org/extlink&oid=126934302&loc=d3e29515-108402", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r617": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r618": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r619": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r621": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r622": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r623": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r624": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r625": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(2))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column B))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(1)))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(2)))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column D))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column E))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r659": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r666": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "705", "URI": "https://asc.fasb.org/topic&trid=2122478", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r67": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r68": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907644&loc=d3e11281-110244", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12524-110249", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(3))", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(5)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919398-209981", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r771": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r772": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r773": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r774": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r775": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.C)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 84 0001437749-23-006751-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-23-006751-xbrl.zip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ȫ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

!.VQ;$>S=V/T]@+ M6+R476SK?SC >^MT)KI"]9^ ,%ED6Z#5GEKOL6,C-[6&/UUPG8C_ZO[TP;8< MZY+YSK,382/&:!)&XO*>G=CR ODG/@?D5R<:/EJ-6JU[:GV%5<5JH &CCPEP M&-YH.@*M%U5J#<77]/3P75, ;$YO7*8T!'1"!,R.K$- MZ@34Y0 PY#.JR(/P&ST9^B@$X/:? ?#XKV,A'V#)"W[?Y>4\*)?EE2B$*#B4 MF 8^_SR2M3]UF74#L PV N3<$4ZY%3-.)[[6*61I4BPGEF"L(>C M)B&^&Y#%\$^']^EQ D&3MO5G$#X'_)6&CU$8@ [#GP^' M="M,@F1<;] '?(.:X%;VX-HS"."2W9DS?D M:F\"O!X[((5P<6B#8!\R'@&?<7&,E'44*^N(2[?QO!!/!)>//C8]YR!YU.EAB00?@FP\#3BHST'0E_C")X:?GT>G,!# M@=P+7"=R8^MC"/^D'.13__YC*F)RO_';Q$6VI;[2O_\M_<:7\-1"M_1)O6U; M/WOGM\#WL7A-GC_/#+5.K%_HJB[X55GO[Z<#L&. TS5J[9-6[P!T"P)Y:61(IVZZ&R MV"T@";ANCPMP-L$_GEI]$BN7;$A]A:UFW;;0#3"[JTOR>#B47 M-B!<=)?M;;HA8+OG;)EW/[EPH@CY_N^./V6;7.=YO74ZW^U<7B+H5?-(Q8/% M=*& 01%<"S"0>3PE.3( QC\=(;!1!U4*U@S/&TT#;F1(955;)@%56D P*7^/85W)P6;G.O"7$LREZ.I6FVJYX.H C+^2;BOOK/\0 M,1(E\$D_&:M?#WB7M=/YQGQKW"6@/" NL.-^0EC+W]>2+VRI5]1M4Y+#0 6 MU#F\O@@V+^^L7).=\2U0V7\]4-P%>*+J\@ MN:NA(LWP8Z.WX/(^L4$D;J]^.ZW Y76PG_/I?&K^>HQ OA9>;7W6B?5B@3#] M$UE[Y(#I;&'00+ARD->3QL_%+$E.J01M=K$"O R+4$E5!@L($52FX071E_& LVL& M_V:HO^TW9'Q04U)"<.@$TG<&5AD9BQ%I^4+]T83[$'T:HZF/($5@DQ%*,)Z M)@PXR\5^B@ 2X!& "$UIVX$Y*QII@%A\@O:<-'#AUJWDF?F@X0,Q)8](5E,?,7H:%[P M:JQ%Y[>E=8U>>P#9( ]:<[;]'-@<&AY/W1.R=$I_2BP?R2F>4>24SH9X%TYC M$DO.4QAQ:SU&4RC@J\6""RRR4>S4C]=0"NTN>6E@[-[]?7Y[4SRQ8SV5C M(&2\I+$SC$(&WPKQ+RQX\J(P(/%*SA'IHG/B1# (! O8!%.?TB%!5DR'S"47 M+<9?A4<=>U @L%?1U@;AWCA!?".@PPB 7[" ?5&%:G;W9:(E\9=R%,X\O"S M2#1XHDL$9"#_/=J'8U@1>5KJD^:X(,\I/2?B9<2A8\IT"AY2%PZ^I2>:&0O[ M->9CN@2/A>__ &_H>V./ \IY9Z B7=T!_33F#AP%9Y8A M!G+T@:4SH', 20SL*?1%@O M]S$H.2&S,1!:C&A^EGE??*\@")^<#&TE;/@8A'[X0.X;D/"GEH+"'KDZP MS!5Q/I']JF"&*>QRV.X^Z0?40/:-X'2^NX2U3U_S\[=R$M9FOOLX.HG"Y_D_ M8O:)M3P3;OWDMUXV=>R84^%6O\BO-Q>?O>#/_.RYS#]D-TB$*4+1I0DN14G" M.8-3\;VJPO+[BE)]X*CNE$FYM[5N(U@V:ESSKG@91)&1BE\=$8'LNT\,_G7%L0L0?I MP@99Y7OD+.8J^7M 4*&& .M3 =N[7[1L$AEU )G!)1Q)DFF"5T1:)= )X")I M_84N1C0LR5-.D2O"5V"8%+M2CD+^AD51!WI+7 %E$9@C&-#'."^EF 36U9-@ M_I=LY* 0>D]9#R-T6N??W0=:+1P*S[V OV,5P*/LL,?:Z+J<:%;(-,\O,=(I M5!XFAX9EZI\XT 6'FX]Q?)\C1;3 E8[A^4?FD^'G8.3CP==!C;JVETRY[G\/ M: KT8OT.*[,7ZZ,3_'EJWF"K0*3H:+XO4QN,LI9RSXM0%\AC]'S.<* MXJ,W :8LG#&@%$;3B5 <1_DW#?H5&9S/C!9#Y9#.*:V<*$+4'_,VW5S1U-=, MLBHCBWB&@TSF0;KCV1"^+>P3A],4X@Q-5.&OG[)0<2\+,0GLQ!&>F!++E)*^ MRC>1VZ#K"5/6\,'T[(0Z$G[:>3@G9_RZI1TF+>_9EV'N,9I*LPF7W"NLG->5 MR,?>^K6\\UMT!V@OY;V!K-$;W;5+/!-DL@A66#$PXQ%R)(_]^_>73N_-VK6:#5C_O>X]I];E)ZEQ149=&OL<% M >9Z,[?=>'D7]MO])=Q&_K7A'V_Q@)M=3:-WVLNYF GZK7!I2G)PA+\@BVPJ MTNL\/*"X3-AF,=]Z7A? ':%>58(]S@@#Z$3@SY%'>@*YAJ8DOQ$9O1AS,^$7 M'Z[6Y](N3:<:,>E[Y/$3%(Z^C]P#4P2"^+5'3\ZDL,B$&B78E\F,HW_]5&K( M]Z^W\G*/R!M#9A493#$#$XHG_TU$0P(@WHR%&K,GTM$UU9-^XS[W;'B)N[/U M_6@Q2NF-*9&:TL:!;]L4\! BC$[D>A$IE9+'JG3 7(#J)1.!QF^*Q5E>J_-O+?4I5AT8"JWL-#B M62@E.[EI6%O 834)F?WFK1,!?\?=7,K>2K^UR9W63FNU^9+S5'K::ZL2W;(O MJ:P$DT-<;SU?:U/7*S@05DL--?0D;C>GT(E'J.)A*1CRY@P>$1@T8KU0;[V% MEM@[70B'4TJ]EDXFNT DD"00GEMRDTJ9\DS>"YXGJN32=$*^@M6X?=Z4/ DN M :4_^"8WT1T&!.CB+PA%Q ?Q:APZ=[4O4_PJP%3)UPOT";D?7^3BXL$-67>O MUK7;&S#O# W,EB+B)_)X6M7/SM7]1F%7G!G1_'H2XXRV7UJN5 %.Y0W\VHP! M;*V*K,XV;M+03,E\88:\1:%M .B" ?.8+16 C49U+G2!U,L]R95X29)WZD/% M@NN;W?79:6>A*H+4.6!#.)Z\9=[(0"P3Q(\"G^>Y\!-SXYQ_PL7-*4<9L3,SS5R6U6'@+/V = M!25W:.>B&(%^HFY.O2<);%?&6F]]9\@-Q?X#Q55XBI^HXV0EB/%&?M'+,J13 M!Z-SR4G?U#JEH']& MP7 I>R_PSI0(@641-R$5B/MNY^,J>,4"C\:25X3S/($<4H+L@.]5/^VV&SG= M.!?X2JF6B)U@PAO@B%(G >U\CTUYQ44XXL4'E*0GTM$F_*VQ,<@P)RA.NNRL M&TIV^9$R1G&$?'@T"YP6!(]R0+/W@$#=;G;.[%XGISBU."ZN=+L9:G54/XEB M!K$JA+4&4@*RZM847Z'Y@4 VW)3W09:LUQR4_=',R^-2-YXL=6: I_#'@U-.ND1!#:ZR[708J_% MW24&HD\^<;#,^2QD^SUR+N>"WC6+/%DE\H"MHQ0=N((E7'=Y M]#)B8YZ/K]6SF'*]PY7KG9ER/5.N5]R4;:8Y0%;.SIK<0DCG665YLW'Y][C; M6%2XS$OI G9:D(/66\Q.^2'ZRH5_K4YPPP]082';L'OMIMWK->?YKU8 O0XK M1DDJP/*Q)+ 4NE17 ,M' Y8\W4B");T42]S*3%1O-0I;.P;7+'32EDQJ%8F< MG;9K\^[.3"8HM@P=8YL#[AO*1..1IE:/_C?/LI$US83;9-E1& M.,@)IVJ->J2B]E1+FQ4)>VUL:-7V1.%O$!M:]7?GR7-8$&;-A;\0M1SZK>U3 M/]:4 JN9T*V"'*0E.).-XA^E<*AWZW:CF2,:-DGF6$,4K//5U9(^%JVP/ -D MX?[K\Z!"_]IN\*D:K*AQFN=?VRRCH]4J*:,C3]77&5-SA72.\N==5:6F;5EO MTC>4#?*K@VD_RW-!5FCHFF&2_:^_IA^E+F/R"_[S].+4^L/Q@F=RU5C_SQE/ M?H)]3VWK\^>+F74>]._3"!&.\9D7E\MA5S&*U*3AZ*)(1%IA5<3="G+> MVB>-V@)W,<_*XT&7X'^F <-OK<7*T@7V6UN5!02/#Z60S%4T5BS":A5X"/U2L3AO#(D@JQ/:QO0\Z MYI\]F<+EICYZHC&NH'"U@%1C$8NG3! 9.DY%D:2P8N6RP.50"HQOIS/I6Q?J MB$ 3*'J /2B(GC16!&GCW7E>4?GW$AX/., FFXT 5R"@%(>^*SI*T*7J#% X M I8_2+ F;, D".19^/"L=)]OX;J@@07V"/R$$YON3YJV5M#GP65ZV/#+&GF^ MC@ZITDTGN/HVI*Y/5GK',YSAZB)E"Z&:HW:F];R"*_9I/@NC[C"(5O!@'Y#6 MM[I2^'!%"6XWQA[\TYB/(V.J=2.UZ=2'PFB/\KX_F(4B])]\837[IE<7_,"I M##RU+E?M2ZZ3 8&I@!"V[E.^&DWLO^E'KVUW:JL;47,Z:A;QJ8[7P>+XAQ5, MC?STO7)NU?N;(,;6N& FBW.-LBG MSG49$W26CTZIF3-SA9:_4)[*+TU\,=(N8C29"&EEGL%H$SX;3=$\^X42O<;2 MBI9W)B;E_#-\QF8=]HY;D6NC8&)LTPLOL[_ N\0@,7YY5R.:/SJQ![BO3QOK M!^Y]VBPXG61V&_K813K^"EM\Q)&+8\ZXZOX$><#\=C]&##\2CG5,? MN29/^CK:PI4$XAE OO#_/PO,>J/5[O3JK5:MT^W4NKT9R*8-K?M)SM/_5R<@ MT8XTQE1#*PZ,+%(?(7#6]N4@ ,6M.:G(R[FY97?;V&+\(K&Z81BYQ!Q)S\X. M\A4],+%/)+6#9YD,9-#Z8)>)/SOQU_JEW[_-YAW.*I/1U!?V"BA+4U]VB1^M M;-'D63.GA$CZK1I4RB!*VHZ<<<5LKQ%9\ M+X'%DL_EOE"F??O\Y25TNYQV^(!,30U%:P$80#H:1;R6DYML6Y>O.W!\8O+Q M(V-):9N*Q>]3Y]7(TH@DQ4E.+86'%(W6:QQFL@AU@3^G+DP9C,WGP"MB6J/V MU2'S*N1'R7KB;S$Z!&(^W"06^N!9O=GHMGN]=JO5HSJ-1>K@S,-"&_R-SZ=5 M*QM%4)?>.7=&7)'(9F& 8H;I#BNU$FES%+SGN%U'-X?78U[9A(4 MW+6+H[EEQ@J-*A#D\YBR4O(5:\.AX71\ML$"'GL*XD1M/<7IM_H,FG]/W0=> MK?X(1 W'0LF5'DRR)C&.C&CW9.#$-!-KC%5O#L^R!2TUFN*T;V2?P?*(I M/;_,.98H:UYL/H2..V.0-]%D#705J.[W//A"M0M\+.U03KT*!W&(':@I$2@ M58K&^&2G :K3VFI0#XJ5Z$F,!N;>#N!PTRC@JXJCO="@K.R5XFW$?%B;NC9X MI4'MZN#HHH! MIW,]%-L3M',",==)3%8,IQ$<#]6*Y%%SY&C8']'I&%U-KH;U9Q ^^\Q]( XF MJZYQ K$XF"-FI8$^E3N!CWNL$$N3*4V0Y)=$SXHQ4CY&P_DX#W3@>105E^&\ M> &Q'E:(F;*0;%E(O6;J0MY*74C)BM17X+53/F!VL8^N6^MUFIVS M>J?>:=1:RWQTV:>%5H:;6K]+NRZ=$W,=@(DU)?9L%+6LFV7^'O5@!TYJ$L-O M&(^)2\X-=@Y>MC*B461G1]V("R^PFM+Q5*<:H/3OX<1-3P[2+!@L8QH(TEH@7#'<* G4BW!?I'D*9GH%#@X?H@S!F^BV>6A])%YA.A#:@7E9F]O+9IG+(;!IU$S-* M?3;C)K.+5)O,ZGGOE;Z,,55S..8%8%8_] MA%O./"VXY87$:?I!V]/PR R/S+D]G4<2GT*?*KG6'D&S >KQ/;A.O7XB%AW, M<$JZ!V>@Z<4)!@I>./%$3,VSQEG!9(%E\^M4V04W8N;'T$=D'F?C%OA=X&BHQ-'HN)1Z[=2^^&L:HBC(I 465LXKCE_@M\^= M7,=H B*?#POKT[ZCS+V"58*^\A=Y"A'[[U.''VX^3P.PJ7"NK&OA'#AA?X5Q M+.PE]9XXLI%S:MR-@14?>S39FCJNOL>OR$X4I/0)-W#,_1ID@0.C%:Y$?GEPW6H=<<> ^Z(!D!!-X\F40!C+/#D4CNAPL7!+ M$9)!8J6IVV,&(M U\D63+R)E-4 SD#O?;D87-&?PSHO_!(E#.3GXYTSA;+GIF'I>C1CX/(R ]DX2FXPL03A>A4]'OF M7$9 Z0)J_HJ7P* !MGVNRDUNJ FP]$ DZZJ*,$W>H2^20PO8\9\KJ>EZ\Z^, MGBQ42WA3KXHJC@*-92C0S.@PJ0R>$,5;'F6X<2E++OEB M\T? 7XPCS)/$7V>&"V>,0SF<%C91):O:5%98;JU9M62_X;=9A"-CR;?*<4RU MDIW/WYZ/06OJA8;?!:-3\9S(6!;Y3T$!) M-[$:? ^>04,-E1_=5YX>-_6F%B^>QH8=%^ '3]LB+3'UO7,GN?1&8_F2%MO0 M:%Y?30IAKB0NTBG,&&$S1IA5?(RP981*L5!I+A,JK0*ADNLA0Q2?,AX443UVO?(:,9AI!R5JZ"#S1F9 M$\^\1>HN6.V4H-F"QK#\F/G9>9UF3G9>/36LZK)3GVZ]H(GR\>4C"X:/B'*\ M;:IXPSOU@J+18\XW55+?A3CMW#/BN[\Z_PXC^5!,7[D)F/S#2AF X)UP>UV2Z+$-W"[=1STDD^&$7]QGF0J M8DK^RZEUJ?1 6;>-3F?R86.&*"R.N1MA7JJ6BA6IF1+R*JQG4A%Y9B/H:0\. MA; \X/[#I# 9I4"'TS)ON YW^.20BFMGK67:63L;MH#33D>8PA.)A"OJ]Q)Q M4$2A.QV2;_WD,9S&U$\ ?;;2!WL+[P/LV>/ZU\V0^2%&"/!*N",(/@44PI@$ M]]H5*@-BJ]1S+E2ZZ> $9*]99 M- >M@/=%XV8QYK=A>AY:CK*!8@(>D[X*\5=Q;/@5&,*$WT^&;$7=/55C MD1E(01O>("\1==63R*/ZMP30A>/O>V.,YN'!7@.\)&SX&H1\^T J> M MQ9N"3U1!78K$>JF;X4<+^%%G&3_JOCN_DO2$8B5+0RGQ2 >FUEY*), +!H09 MXI(#4=9RVC'GTV6?^CIF7"("@F'T0@VML)J8CU]2[9U14$>4$!VJE\CG.:EP MLN>01B9DCX1KE_ 4W366[SQCA9=\#Y=\@9F*=D97$7B<>;C,=UYXH)A;DGAG MP#D?BV[ EEG+R#T9,EC"_U#40&G'IC\B\-,.+?,9"6DVE.3X6"(P"GTOI*.K MC575CZ8Z\40I.=5*?H^_(N[I1LYS(*$, $.3U^-R1N@2,H=:NBKS=0J3,UVI MG.FZR9E^*SG3.Y(@W642I/?N/&O"8WQ#6#"@*_%2QS3%%/WL&.J,L*&;+#?E MK!OCO8E09(!%: +\B"29.]9 M%52Y[B]N?K^^/*F?J19BH)3&(.O(OS\%V@YBR;P?PYA7H\8O<*/CF'*M,8:I MVD6G CA4[7&E(!#5H(A!5'*DSLL#=HEL,B-!C_?K3[%@A]0.W&,:3#"F,.2* MN(]JATAU!AF#JTDE6>BKD8@[H ;+=7/>(\HE#X)PHG+U!+<3JA()G MRN#6/"N4.L_7IQX L:@SB\$F\YW(?]'634UW_AR%@GDNHN(=4J$2Z8S(D&2, M7S\6DF(\'8VPX0XU<^+%C[!$2+HOLB]&^5087_'1^D\(@\DT MD(]G>&B6E^&QR)Z>.QLIXZ388J;"1#1%Y-JN*&E5SF">0JH',.G;RB;1?'+S MLDMGQ_D1Q)3?$1CP(7ZS\;Q;.E.U*(Q<[J\##H:/RL2 -=G3V]91SI8F>M;> MG?_!Q4#J?B#D 9&8.#+#$./<#J%X+!49E:BAVYB\'TA&-%.-L0;H,?J25.L/ MK#LEWXF2N!%+?1YB*^UD0@R?6A>0:(9(:> GR Q:"I'(>CY!F]W$!1#Y$S MCE,M17V=W$24YI!R&N)I_K-HVBL/P;E P!+8D;R:8^XT4O$@2_Z)4*6QK\#<& &>N$$@%#W*GM#_X"!6@(',QG" %\:T6_%DT05W'/+L M(1P=#;R<5,JY=>"UG^!MX,KC,;>ZO0BKM")5\A"#/, @G'%O+T= S"0!#O=TRL M1A3*B>U$_ L[MHCOXTZ);)(M%6J4O4HEVB/0V2S1&4A2BZK MB6?16@D$AI('*9SL-,S&[5"R6@GLU-- B 0[369/_=VZIHA\ZD&]/^P,&$Q";3%&>$J;)EM3"5=:Y"D[86LA).*NW,F+ M".>IK->)Z/.8^N-9PB&(:.X""T,691,S%NV<5'L*'HC4$_AS$S:5-BHD%&(6 MUZ)Y7Y'0G_**LXPT3J.3O&Z'?\/5M&V?B \09^116X\P8B&U-'6L84:H#K!W MZF,N8KGL*43K5=,B+%SN=A4)>G$<#CVJ^E)^7;&=4-RI MO,C-[*#UBLKL,)T\D,]D-(V21]$F1+V$="@@O7,!)8(["4]&3$E+XA!=PHF0 MYYH:\!R%P0-U9$F -4RX!!8BC1B4MIA$I5DB<70N)D!G LBK23205]D\;Y[_ MCPQ8E$1 M$$3,>\59#"57?:5A4V\ET5"O=S%30 MZ1QA_MJ6W"NVK27)4)3:KE=.#*Y*.?U"C*45-)';C:O[C.B?,$Q MJ@E\QR7''Z0M*6BDCZ@=R\T+S^W\-9<[+[MOG5K]'("(PD%9Z_WDL>>,RHIY M7Z0:D_(KU$1XPY#&+=ISKD&$6L8[-I>G?R(KS_D5OP[.MR-BFZM5G'V@^>X\ M#ZK+L$RUO1.:*PE-880\@^AE)^%H) R*,.LF\G9^9+$OKR_CZ%$2^__@S(^A4_FI5![>YLE?>*L&UBN)@'F'AHFYH) M8\1X@CIW\*!^CS'H)'_GL66PI^@T*EJ=S1.H8U1W3!(3>2GMM!F( M1<_C MXVZNIWCAWK/'3B&?N#M>%3@>UD)@AO[2)(B-=LU)]N!X<,+O#1Z;?,-,7@\H M]&'POF9;^-\'>9][&A4).A*.80#BX7J1F+" )R@5"); >OWM#;P/".]Z!> - M_T;T[U(FDY/F@Y?8J&%O\R:.?VZW/Y3)BB1[[72^7PBA-5?-0,P2(,L$Q]Z= M?V3P2T"IU%Q[6P0AF;3T_3:XNX@.2]E@GCC>G?]MT6ZM[[-10A)\99\@MP"K MW:OGC#RK2]5BT>PI7:VX%$K9O/*ARIR:JT[G E6B,U?EM%=8[1@]#/[I^)PN10WTP5W6#"G1Y^0-Q!5!E$[9 <0'X MZ=WY_-CJ/?*' B=$J?Z6C'?E@R&K(R.KO%XVJPK5 Y)5O?VVZ3W M%=J:;QK+>V_?^V5=X*=>G&:,ZI-=1EX4X_%L M\1/.4>4#7=3DH:=&_"'T!R_ZXJ+>%2L*'/\% MWYN&':B47-YD0O2.&+S(>G!J_O%O)IMOC-(>5[SZG:IQ<7@(IBAGVJF%4:;D M23\KO9,L.+=5'P,Q:R+M8I IFB"T8@"QM.XW8E@5*YIO<>23L(C2@<>JLEV< M2/2F%+G26JU_2".'>1-)+'>@BH^T+EX?[*L6QZY?F(5*E3R\[YY\9@YHO-A* M( XE)6L34VAY#5[91&RQ;,[;J04SJ,1[9,4Y _ZH;DI-?LPG[3^P<;IV;AS; M+,=)8Y(TH0J\-ALZ,96VB"Q<3IW:N!<:&HUE3^+@.EX[?@AGXC6_ )<(VR.$ MW/C')H$/H@R:S^N0[6\YI]#SXG-N676%%,626$R,2<&JCIRZA@:9(9CSN,T9 M%:\)'4Y]1Z'"J74O>LICOKFMMR00WR2N&'G89$S-5\-:FH(,>*K4P3+M:4Q) MSG0G5,PMR[\4$N+JA>0"//D1IT00HNG#LWG! +7P$2<J$9_J60DH1:.@K61&3NV.VEG"V MYUP6J*!-Q[%0*F>$F2JO4&BKU5.F*,#KAG-8!^\Y/0 $'7F)[+*;OAE6S&&/ M!+A)7 SX'@GTU]FMHV0-^E84<=\"A))^X.*0STDZBGENK&BMT^B M[-5Z2\:*SCPM=&JY)V&)VM"HUYF9HCE7E[DW)N]MKIH,B?O4NF/8'4=4>CK4 MZX)WRN7%V"3U)0>EYDO8I B8[R6..1AZCN*@P*Q!5/U'_(%:#_O#J1B;FG_B"Z.*1F(EB#XU,5JJP_ ^V(EX(*&80S%1;.:^AVWIW3 M0%0YJ@$8QY)O=-^=CV!3^04<,1'/O*T2 U*G%;(J?7VL0>.'=8:\/ZDU#; ; M*M M6JCM@KQ#(" ?K+EYG,F"5=]TKZ]R.\2K0H?."0<5I$*'X@&VK36PRC. MSC_%;3XC0 ;A-^H9%9(>+DXRM[AX#<<2?2$BBWH_<_R2<]'R3C#R\(?9\\N. MRRLO+7H1-SN'J4%/A8E,6R*7WR%5 =*/P>3890? B)?"D@$JX ]1B'NG? M5%O(OK'A5 %VX;OS^C]UW:%8 ?M3X MWK.L0+69\[T1R["$UU$46;;+B[J>(1QOHDL/;!O D9O19S!Z/J-ET">P%@CO M=J->JW6;M4ZW?=;"-CT+A??,T](AIO9'6.&^)[2QQ7@RJMZ! MFR;HCL-KFO+F4.F C8CQR>IP'[QSZLQ]P$NJX]MH, (8;>3+HIN&*WU*XOJ MKRLG3M'=SD)?.$3XT)5TJOI\%T:$1"H/L*%GACCGL ID?4###'"Z N_8$873 MAT4NO^T">YB<)>5/ MG?-,9,5;C!T?,KW!X6 @ZW#4!G8[%[W192<,]$Q$S1O>1= [)2%K=>&3 PK$E\>L.29L4S;'-7Q7:XH MHUP %^4*4J@:E"7.-Q;+ M]Y&(G5K)*G(6L3%Z?4G]T_K[:Q.U^&A1FICK^'*<@(0+MN>5;@$>M2!/O#3\ MN>_9XR&DR30"I9J\!.0O0372$\.71M2K*)VHO?A"I;9+]R9;.FH.L+2#6MX7 MA++.&]'0P4+L"'[8%C1KMW')T^(V;[22A)/Y!&6Q]DPS_\*4-?'<@M3D90K$ MK/ZP] KKIRMD(P,NA[L_UV(!]^Y\5H9P:OK1NE7Q,.PU2H0TQ*@.+$Y<-0^# MTPG58Y9D"5+9@2FQX"KYNV?$ M,ZZ8M!W2Y#"RAZ4?)J0KS2"H?#::0D'(56 M1Y1MXH@>4I-D=KX6IW#N-.11Z'%J-],,$I\/-N!C+V+EE<6(^AR45\C-+Q&C MESZW',,69&^NI41GN,;!+F2?)-XX'A*_YZ-^,VK@C]:E^B75!S2E,)9?RI^1 M5J0R\M^C><>/ED##)VW@- E4@V1*4-J^VTM\1L],T,7AJC"\U-IR-")RHN-< M'P;Y=\FP>$7D**TI0X8_6_8Q9I22F($^1I4/.3MX.73.Y;-F_ M6EAO,\P5Q*+7[> MVCJA"3,X[RR!X_YGYF3<*Z!&_%+B$T=GD="HG0>M:0P=NS/A](PQ*3]:>-A9 MA1AG,L5"V@D1IX6V*:*!9C ])6*X1$)B_%LV0YB?(#^L5!"QYCE>.(>"OY]\ M919G8M(YJ964[343,*8$Z30YC@!!?,'QBO>AU!/*X,S?1\]B>16!XUW1=W,I M?;>R]*TED">Q1.E@&;DII%=Z7^IFXS!.90K'2,HBG'JNPX-4LE,SNC?N$QS, M$[DQ',HEODY[O>=:YO"G_OT%_]']Z8/5:S5LZV?OG+(?8L"%<8(.V -R7F23C21RBYA+!4>>MBO#&,UIS,?Z8UQTYDG@P*=G298KW<)/*& M*N:I?=$TF5Y(%JVE9-'.DH5#^4I<3U'#/S",ZHK!>C'W% ?:@$*58D0FTTGR M,A'Y,:?61^E2S1]H1YO)R&Z&4BAY&X L!C"0L'1>..6EA#4CB63(0.:M$SKQ M]W^@="<>9!?N4I NSTZF)D?,>LAS-<,#WG@Z%CNJHW@R7JU,+VVZ*&_+'J&G M4.:^RVN&0U%,S\V[7]=S:54UY$_YG2BC:_:6YSD1#BW+@U$V1I#CD4KI6,AC ML4&L_-[B)E-#6MFT4AF20" 29:ZRASWYQJGWE[,CX56GF4D2%[2!Y7(>4,0> M<:K3$R-#V9#](K('HOXDZ3$W6K34-TEF"LFRT%=Q' %I$"5!3-JQ2DB1*PFT MT;;B.*?O+8PMK&")/<0@6>7&D_1IUJJ,:.!,4#FY]YFD$(V;$=F58DHH#71A M4>3I%7*Q$*YDNDDL4B-?\(P8GR%T-PM+I?$^"-1& 7" M=?BG!7_B(!+!,-34N;_52^*9T%W&0)CY.&=SKO'/7#3/$P(&1V=@WWB>E%8Z M)D-U^G>PM&W@XS P3O/ V+)AI E-*Z4I'EC; 1?J:]5_FBV$%1H 0PU/7@>) MEIRU@)6@-R-R2!:D*[3JM4:MW0)]K]=H-Y=D*V0?%LD*%\**$"J@25_,,LOY M.[N8-;N4GRFMAJ.1H]H\:/(-/>*@8;+V[+2"*)T,QZ,X]@GCL3'[CLOV2\8(O.1(P0-;/,7]4TUT0KX_IKZA AD^.8>]'4^V#<9\KK M<_4"82$<; NV5P/_LO:[)L7CZ03]6FHP25I_*:JC,U8OIMFK@@6W*-M<=VFH M;'^?C\6&+^'L5%&?,)MR3MZ!U+I+.:RMA)R2-@*\ZN^\& L;*YY2SC#\%)N+R? MJ3EL=VOU3J.[3,[//)W6'!)/DCL0)S7B/K?F4+NZ99>;34RTP-+FY>LR)N L M*\OKO3L'PA=5>2=8E9>*$^&\5@F Y&\,,'LH]7Y) XN4 W*/4Y&T'B>>"0G/ M9?]%4Z:\DEK-@93W,U(.X]::JH^'R00^[#0W3JO+%^,N3U/\2^LP(S;RY8SD M#Z@==#@ M52 $P("A7N1@_PZ%(6H\G8"\[WCC8YE&=Q03[^Z'C\R=^NQF-"-^/DO,R)]U MUUMQUET>MS3#[LRPNZ,9?F:&W;TM>)MA=V;8G1DVEM.+]VSC87MTI39 S&[13C-AYO5R;&G1UT+HF99[?*W*)Y>_'X94-%QJ84$F=) M@^URZ/0/Y66ZCN,I;-E:I<6,&_4NG_IO1:YF/W %9JQ/_VU0&VL'';%Z^+%;AGXJ3C]; MC[/;'?V _&R;J77&SIN8J76O:Y[7V<93Z\KTZ-3VJ9N;,75O *TW'E-WM*[Q MUSJ8KJ(Y@G=B; =H59?IT(XKGMV"S943QP7CB>[Q0 M(6TJ+2L:Q"R@!.N4J5IBZB>.K-F6!=JAZK874\N?=,:5'!\33P?8@T_6G\EB M?OQ=.\K(PP)E.65LIB@D/5M:6BGJ)5[$Y!LQ$$ @@RF:TI@E6:47 H^_TI2D MHB;PS4Z]WNGT6ITN$.ZR'J\S3\NR*4DP?"?#&K.LGB19IJ_ MS =DZ&/,D.2I&X]JQ9,V_=%G-V"K3%@+F]>IEN9KB98IM9\2#9V]R[4K5VR#M6B+*D.*&LXY%\25EWQN>. MI=G(,19QQS@=CCDI78M[0F 8,2:Z1TP<3QM_)\]B.&%>=N\C MR&-JJH 8!51&%W-#C>]!E;R6O69Q\E6<52,;C4:]VZN=M6OUSEEC-MMWED7. M/"U8Y#U6-I_PI@[Z 0ROS/#*G,OC-\>YT%"[.56C(3E$.GM4G]$DU03>[DE4 MF(<3,?D3*!)HF8H?^"=HH<9I(YF[^]]4(QE;J!TSWW">J1&-]I5^VGMFH'?Q M>$##]@1[E6GU![,#'=+?29'2CTMS#M47Q:*NF%!)BVLS>3[Z#ES;_?"1QBKQ M%:CF'A\8AZY@AEI_-2?6^SOE-FE*.?P3'@0;#?-6;G*D!MY%_F *.I^82Y%] M*SZ% BZLF_VFZ"XM9K)FK@7 PEDC7':LO?30#^EGOH'J? /O@M2_H&)X/,9V MU?Q8&K#X[8IAFSNYJG[,>Q*H)F&S;8DZ_)CUGT1W(IUYG!!M9/B)[$O4K?<^ M_(C#2=(Q3T !5V.J[646<4/!CD280NNOA V-LGTN,DU2X'\CYB4$&][@Y(7W MSS6")T?P? HC!GSQ@HK000''"C7ND\+ $/W*VP07:>B-;J/=:K2[O7JCWL+U M%XN?[--"_(A#6/(41NQDQ<[\ICQWJ:20KL02?)M2)6CXD<*H]&XF; M5FU$$@W@.5/:Y/-# 9GTBV)]4)>Y<@AL,APSZI-_:EWRM@5(HS2[$'M=,[=@ M<@\=%_VP\\UKJ#SM;[F^W%:ONRRO 'YO7ZN2_UD*$0?3D2&-K#7[\%\.6\P;G M$34!> JX+ICKG;->K=7H]5K+:LPSS\K!>+2^]16'5AANF^&V<]>E\UK1=346 M?@19DRN'2HZD*D(,-Y1=BOVR)RG5C3"R8G+IW\94#\W;4#L[(ZBMYL: MH<*56!8X?'(=+D;.#?JB\ZSYE/7Q=@/JC,FH@#MMEJX?>_8;6!'^_[/WILUM M(TG^\.NG/P5"NXZQ(R@-[\/=H0A:EGJ]X[;T2')/[*L.B"R*&$, !X=DSJ?_ M9V85[@((@A= HJ.[)9$XJK+RKJQ?6@AH]V< XH(.J!I<;>-.E&;//$QDXOH:[FE,"!X8BLOJ'J1#L8 MLFMX\##X?J]?G[=_(!C"]]$]PGANZE:L)V(-9J,9#$<@ IE7C$#50W D\ Z\ M9L1^H"%R@R%"X':#3X=0:.L:H>@$IRZZH]?0..6"QNG5T#@U-$XA?^5:M7#_ MS+YC%@7OET^SU$,>RWQ^V^KT5.]ZQBX7C\@V\2/1?,5_!\P3*V.&PAP15 M -KFBN=+*/N [:3!H-0N3MC%25)V!>G;9Y>?5!LXP_/AB?H\:Z7&J!_.5@GJ M>QT17('B0CLNGH7S'ZDN%L S68\1'8[>2)U@G@NQHC&R<-$L4D(2AV2+'9%0 MTLQU"#84WSD-C"M/>35H&P0NB2%@T^:YZ6#>G?KNZBX!DGH/IC>!K<;/82P5 MI0Q',Q13"V9;A(X7RI@ D$/7B\?8[M._T ,DU\GOK?VCDX"<3:TAH M@1"2;H)S !N$;3S61 K#)MD-AB"Q,W0WQVU)PD(+N M;'@:[-R[]N@2"X45?*))2OR"SAD9U@*+%T-:3T-X:A"8YL()/7VJ.NJ!@9^V M",H4=X#(7F(1()<-.3;3*"I.!_6F%(UAM@IKG>-(596#+%ON8/?^J!A-4YDR8\W]YNM+<#3 +?P M'4U,#8Y?54TG?]ODJ--K=;JE./7=JT(!:R+*$ MK+V%HI+]"EFKT3LLA.#AA:R&%O"\@7_&$]MI:6DOL>GGM=GT"%17;O$O)>#) MFH>T^\VU >LHXQ975Q[/C#G+?*.MD-L976O?!BQ36%E=]L$/J!$*:G[?E-_7 M1L@[$+]W&X.]@C5N!%U0QGCZ4#'T6ELZQVE"3]K[+X+ YVUDK:KTB:J3O$7D M7[[=A)S][D6G?]JN?BU1U9*H(IA\^Y6H7AT\GPB"T8ZJ KNKB@QZ_&@$K_>@ M(Z2R@AV;35R+GRH(EX\%-3N2&C"JB!,U8.;,KR]*E+=Y96JAYSZQB>K:S(,< M\-]-[U-C%4**]K( V?#ZO?I'YO"8!)L>36W*&&;@3?G!)\FUH/L-D/TJH'BR ME"5>MM)O#HJ5K?3JJI1*5 /452F'JDJI"U!.F>7J I236^^Z *6L!2A7X1TF MT2'75K#E[BO$989S!'4G)>AO6T!_6O_ M0;[ JFS\AH,:TRGE0DF RVZCV1PU^H-2-;:II6/+TM%JYDI!U=(1DXY6I]?H MMDLE&W6=A]3H"@2VVL[N6I/DJ\#!V[[;5H)EC^GUA>0!)9&IK$[MK79*OI'&GNN3.6W-2)Z77([UA MHSD\:&O&4C#M44M%OL+'6BI"4M%NM(=U\%I* _O=0'@:)@%A)]CVZAO9(^V[ MFJ*<\A5-[E0YW?N,1-KI.[+1_0ZQ358?=M!]U&?S@L_1&K6AC* M+@QK-Y$HFS"TF[W&L%/^T[6G<\Q@RXC1R#D6FS/#!N;BN!(<-%H.'=UO]IN] M=K\Y[+6;_5Z\ #UV4B%VL=<'-/Q& I&N8:'#Y?H2JMV()G;KMB% =%SJK!9J M]N"WJ)A$UH&#/(D^DHF^"QZD[-%AN6ZE:21[QM9H]UY;CRSY&75[K4&GV^\V MAYUFIY:K%7C;W9 MH0XT6H@OL)$+_/O\;+%G[%K(NQ 2QKIK+4RO'0UOILT[<=NF:TT$<=@K[P># M;77\YXOVPM@;YD*YL\!]L&"Y"3LZK9>B;H*%UV&*4]$6!J>H81-WBY\[LS1J MKC/#)K?P?-'-&\M^J=%Z@R[D'7A$8W%,"L!?#PZNY(522&5*O;B>M,1/DH*\ M,JD]+,>MO]?L'Y^6GT#CSK&1.Z4Q'L#_LN_9*P,)_\8> !, M#Q;92EPC[J79(D'"BH#N_/X0\BKOW*13F7@DN(OX 3!_R_<5S]LYG<7VV>4H MB4GQCFB;0E59N9,DKW3J5$V6<;Q+%2N+4\'FF/@RP6A$F\W:-CUVFWAMU!Q1\OR5? M+4G*%;3NG%U^,90_U*50,*(WLL+-29?Z(7^Q;9=92&I/6<*'=IBU48U=B6YQ M?Y@0+FF3X.3[M6B>27_<6(SYY]ROP2-QEN=7>#@:[H$U_J>E.0Z$5U?H_]QZ MM=/:)>\.@N.@7FP3':@WX_UB8LT*7Z*OM_S>G?3Z6?CUC+]^$KS^3;Q^0NZ7 MU\&*9#K<_$8)?08=0;Z/S*2\$"X,?!8F![LL;AH@1.8)F T MN/E_55AD:ZD(>X /T#"L? N>@JWRL XK!P<0%BMA\P(_U/;, M=MW/KES][/IU/[N3[6>W6L$GNJC$+^B&C*G4A)+:6#+'5T*U39=,YMA] MAF>B/F[RIJ4WXX=/GHD*6='F>;/?$-/3+C^S)RIO#B9DI'H,=_ M2RW)A1%4WC^X3XZY #<8AG+>;GZ@:SX#][ZJF.[@*8;_85.8WW/L%?!@!^,? M:K!U#?-SE@EK?OMF"'L<>M6PU3OO-C]\3-CZ4!GV%\,&KY@L!PTA\C(UQ_OP M*S^#\6)B9S2:N3/'?1B04+!A.AI6.V[OP<(R/0BBO,0+#\06ECEA#/@[#A=( M?;I@G3#E0OD:E"!_.E-<#LV?TX7"UVZ,7>5Y'_J&L.\D+U[[.%CQP*H^N]H4 MG]Y0$$J(H'O>--!J*&DV6ZB8+P/'5G0R4P(? LB%H=\4P\!)P TSICHNCTG) M%\$Q7A#AF3IM\+:[] )!&Z)(YK0P)X;A(S6^>L(IP-O7Y'QZ/?:G'#U?(M>AOO=<2;TI0(? JL?,S-JM#O4CM V&.+YK[ M$O/6GAAN\MBB'S2^U^,^X5MY5 %I,-X@G;5$Y$O)9+/>!-L[NX]7%\)#2&2 M#C/- M7R;_#Y'-[X$/1(E^?P5,N+B$@_$2SF"SJM4X]3D[ZAQG5\N%ETQ=U$ MR2XD^@(19V$+Z%,WJF9A#V_V6;,GNHE=Q.W$GEXKT?]L5P[!TV7G0L$Q46-Q MIOS!&YN'T@G';Z+#.P^BL;NM>(W* S9-:PD/JA'I]TKT0R6"G5]OXQ$SM_ @,"*.ADE E$1L^8F& MH1&>'0Y>7'W.TY8O ;_P =MS;\2A[H=^BA-&[+X([X,NE[Q:S!G!ZF#H2"0D M3'BZH=G!..%!$(&?PV)8X;'.X6_5FLRI.3T&Z$^Z9L]Y*T8UM,WB-;9@S-Z<0TSPC/VB&( HY-OYX/IZ")'UEKTQ7 M6IZ;^/^[)MH&XG/NNG'SQA>=DU_#^VFW5,@7?!82KXO3(5O;(]L7SFR>QPJ< M_^\8(04P)'KX0%5!=2Y0N UG/F$?7_1-P5O4Z#%3<'4FF/DD9O;^:G@<'WL# M+@RXR)JN6O)E^34Q)']1_5&@?\ 7_%>\FT]'"))DJ'C-1$6E!")I6>:3B2XM M.32ABX2^P!ZI?)2!=Z5SSV?F@G)$S>/MG)PZ7W4\OOINA @97PC;77!T3R0X MT,CA*V*8'LEI*36Q[QO'%0V!J>^@I$^V;+=M^DOO%$M>=A2"V^ M1X<)9 A4V+-IP2C)D'FBC\\C0T;GK."5$/-" ">6;@9QC!UOXITRF%S]N_N= MYHK^W?W.J@[?_4Y[Y16=9 _P6$?PE>Z9E&!MY$4A'12,Y9QU?^6(!RNO&*Z\ M8K1RUIZ?9_LNG-3QT7&&=K@C?;X]X?V)YIZ"KB\0KAN.:2V#H"L1@;<&?4["/%< DK7B7%?C ->XSZ>XWC7N[_[7NFL'I_>(OWC3FWLWN&J2!F%VIXV&ET!J5"LZOY M;Z?\UY?P7Z[6V#OBOW:C5RZ0T1KLR>](;5H_(%P\IU(9^P@,14E.OJ?*YF!C MVX!+]L6XXPNVN7#N%5_E""U#V1ENN+$QV#;#E8G?2AP\[-D2W&@&+[@ 4S!U M)S70WZ'!4M;$&>N--K8L'@O\;IK3;0AZH[?7L*.&SSM"MNXW-[9?6V;K=J,Y M.@5,NJ,(V-@59^=^2JCI*^_QY*^'B)MA9"QK@-D+-"@92CQ2\A7D;1.M!Q,^,!W*9!@ M!H/_'6?Q7RH[)IAP)#G+5Y?]E;X JR[[DU;^5:0PI^+,5U>#U=5_I[C>=?5? M6:O_?/\&(B>=S@AZ.)3BD+2&']N(_(GP$;9I&$P_QE3HX7-"*;F>03,C=?E7 MJK\:0F'U/_L?6,M/2P^4-=E:5Y(N2GW^[Y9I%R[RZN^S6=9)I#Y+S+X9J*\P!F0P9\Z;:K':$.U:LC,.5.62 M[ >Q4I\18<,\J%RW:R-TU*R:I;VI*HC%1=D%%[L7@>O,/2H_A%S9,+<.UATT['XI[.>"&3;" MXUAKM&IL*&_8SWH!=O.GANU9]*7RWW(LN&',8TQ%NLGBU_"0??YLYN3/YMEE M:]1O-"4E@S2AM($/) -O!0//)6B;#AQ&(1TX]F^W%XSZ'.O+DVAJ*X=[\MI2 M*Q/X3M6,T#?4+5BS%9U1'WC'C($'Z.:$4C]PE?<%.(+L1;,9MJW5;;,1-+W& M;NX), )I%UTI)@')E^@M/X'AV-1%.Q@0M8/UG@5KBU.Q%?/-@._FVL(#L8H- M 1_*@H[P"7B$N6K3;62[D P._.5Q1ZES12-"(6MLY\80F2YCJ9KU+MV,@$; M17U<3=(5$X?>!0.6JA&+080G+L>W"-HG21<=J#,WX>8"9 6ZI(GO,)?>R;\A MN=Y9NBO3=FYG!-4,#WU@UBMV+'\P]>G&NJPU6E^7C7+ILNH1H]=)(0;:)W@R M.EA3$CH8 G*+Q5Z9X;("[8EC*I<$%N)#<.+,'^'&XQ%-@<-(69/1QEMC#^[3 MOV \C^:M-7Y5-1W=F1O3NH4O20AII<(>W3J$;?=G9C-!'E4W& M25GP^*?QU=^K,3P$\.48%+]K./:=NL1%@#\METV_!BW.09!OL7%[Z*, $]/K M2!Q#)1RT)*B$NX+&[%\H8M3*-;=.W-;0J!4Q0B4T_#*@96XV;XG7Y)& A4E@ M$@DF@@21OO5EA,WDP+,=V6\31SXA:OO\_BSV-8'%IMY>#D.7$9/:*;Y+L% MXUPY;&DM7/JZK[&_48M347':#F+D[L6IM-*T;731;4M1S5T5YZZM8ID>@8[> M\6;V>II\KTP399#/;,; W9]Z"9 M;VNO-I5;W0=<7\9WN]M79#SR/;U.X?:' MW@K?\P4N=EJ]N[,JF2(DVBO/U"R:DT6[A5L9;H5%VSL#5-B<14MDX+94JET9 M ^G5("ACE9_ER[C^&.^+.ULV-K1V7S3BVH\VR>:'6OO*F6!9[-G0E4B2;[/7CTOY3K"RMN*I?X2Z7-M/8=".UTJS-7HE>5QYNW:2.8W?< M.MQ9M_JC,H*G&OA-=,U >D,$J,'_:Q-8,J6R]IG; M.SMF6QN^*O/HVJ=;=\BCO3K/6<=\F3'?C(%;91I@[&:LSFN628\4/G4J5O+<:C_V$0&ZKV/&[G^ F? M[J_E9=(2&;M3C>WXL2_WXR315V#P]?#+MF*U=>1#4 M=E8ZGJJ6UBZ \=02\4KR5.8F6FEW?86+U9&?F#T]93%8N\YFAV+0:G8K)@6 +A\-7M-L(Y-0"US0$+\>/"!%"F&,J MJO+(K!?EJZD:ROC98HR#0"/2Y0M'!WN/]_(=J\FOT>OXI]-?/W!D/R S*#10 MELK;7)O,01]P:"N"(110A2 <4XW0]**#FJO3*&S?$S&AXB[P#SGXUJ G2<.W M>N?-T7F[_==7S6"WLRN8J>;)OG^=P[@]M=7TW@&6KR@^ 58;S!% M?X992&]4!X.W!E>K/[47]\67GRL547J8-A+L]GIFO!@KUO=YWY M!^4%2#A'@$'-1&2"%Y@*8@OA@P@.2;-L)U *RF?58K148S)GG\2S;PV?]=MM MO-U;YEUS0EB-!^.$5[$QK4VA]>]DK+\ID_(4@L.BH/EU>-5,&ODEV8A6_[S9 M/V_U9.1_8"C("?K_KVNP5@]OK33I6]FDQUDJJ%5QHD+C)07@) !JP=S!./'DJ&Q,85Q M+M0EWG^'T,ON2U%5U8.5N\A8.C#,F+,\1P< RR5)&!?^VSGRL_N"H.:Z-B&L M0911YI@?/._08&_Z$B'\YJ9%Z,B[S,QFT(O MB-T[GYV#G4Q^B'B.RMWOW[[_L1H,*A7",:[MSRYOSC'DYT"2D1^__#;WD^9W MX]^OSS_=7X__<3Z^>;R^_ZBH^INZM+V\!R:!#1:9U:_*G''RM#&.%ZGP_VK2 M/[(LN?CJ3/E[G);_\UE.2UR0PI1\O+T"X?YQ%HW293](-1)<&D.9-( MDO)$G%=93/=C)/JRHV&AS4"V2=>#[J!>Q!ZZ>1SM"H4/!**=&1(H,_&[C-,#8C,48NYPQN\M(&F">,6; LL_S! ARYU>(DF(/$+<(-&T^W+#+ M\Z)"D*V+P!=T+:C1!7;YXL;4>ST%<5P1P\J<_X#5:6#@=O?E'XW@(G&%G3Y MQ3;!X,) 5$2SA^]GJJL[.0(T6G5S0B[7E$R#1F"XCF:X,#&8>.<#SO5%!^#0J3L13W_1#(ST%1W<$6VJT?'S5V:HAI.1KNC+TA6>I[,_ M?R0(DZ[$F'%9=5 F$_8'G]=7;UKW".MNL4@3NO77#T8G_<#^3HEGI"^2@-9V5S[O#D\ M;S5+LDJ/H-B9(]9* $O=J;;S^,;T5_8'IG/L0G% "D7D%3MEI\@W&._&%)%M MFJ3Q,^?*=LOCQS;PX_ #9E^ &],XTR&I'R$YXGA_Z/J=;6LR^"Q)U& M*LGD&]!E)]GC7+,*4JR'$(99:E;0K)O1QF(PD.U2EI]L-Y3'+D8W$.Y6LD@@ M3C6T_:,/RF2N&L_"IDS1DPBR?J9Q_FRB(V@[0&!PP2%> BF'D-B&>?!6019[ M5GE+(7!I/&\97!-&Q_;'4\P/@'=%+_%<9YDG@A:NU?P02:+E>3^N?/CKZU?A M:Z_A+09S2!FX8KOD"*-9Q\2?^)*3#I^*G9MF,_2+W8786_"TH4@FA9.&&JA& MVWVRP0]1*>4PA>M$$&*ZSI/%U!]XW]7MGU\^GX,7\ 8K1_V([^ >OB=EGT0^][O/UAZ+Q7<& M@8$GJCV/>O-,HY KR!'"9[[?KUJXSN1'3D%N'$T/;2O]VU4MN X7$G44#^G\ M6VE)GYA?;$9\X;S8<07HI;VR7=%+;%:_>-F9J5"DON.1PR'1[&2FYB2, M]&,LU_AJZF#(X*&D'G%!N1'SR[B0@C-7UQMK/A,=+84.P1WH"^5:Q8"$%ZG@-[Y$A!P,S.?SIS>\@J?@ M,E1+#;Q3!>\%PE$JBYHQZB2+J&MFVLKO/W&S8N5OO.'?,+:IPR?S]SS"^V5' M5 /@NQ4-L4VBA3J48HVA,M5L:KKH^6WHS5\H7P*'KH&T%U3*1?K])X!RD%[W MWK8A^5&TY#I)T-\+:OQUH"H,M!2T%T/;>$_,%R\1[X0K!+& P\023F;$S0B/ MY#"4\BS*A3*FW9IS7OI;G ,"Y".*H%^;,S:GB M-62/K+?Y*B)2/K*9Q!?PS!HP%G8L-7DL)V>MQ^24)J:N8Y9 Y?V?GW##CNI9 M:":A[3I,1T"DB(8&BR)T/9:W"#HWJ[;-3B1E\)A<#J%=;9X,BB1VIJCY[7!% ML#J#P! X'QD"E;G!GOD??H;<:TE.RI?K,= P(BXJ1HH<[$'[#W72[@'=P0I M=V0T,"OGV-V60%I#&WDX!B\M%7XR?8&NDSG7GGBLJ3YCRW)'!)R\=FW"^"8O M8,)\U7SZIL>)P_(GE:]4>SXV MIE><9_ O;/+]"DH9""9RS=O?^ 2240X-.Z? ,31).I,U73ZU-(G^2OPJ_]P M=4>#3YEU8UK>1MD7;S=GEVV)(\!WTR.Y==M[2\RODJ\F*3<[ M[!?[[#K5<*F-J>TYR@FS-U$7&J:3>!4@*4S=!M=>5R<,/3\@E$;CI$>\,. U M"^NH".H*-2.93=3WKW"M4.A1S2HT9KJZY7(#3K^MBE=Q=@0S VOBH(!@HA\# M9W!.F,XHB1N>;X:NN1#&*&( GC-[>#FVPV*$=%G]7!R:(2\S+FRWPD7S7 MF.M?X0!I.@I/;%O$+[N!-4;3$$K5>7X?;I*D5:0W5CR;&V?/70KL1C!D:2:F M(>R?;>IPQV09?S)8OQ2JJ?GWPG!D-*^3\*G&@G6BV:UV+%FN4F)GXBL;P>C@ MEH84?+",A0XJ;#9;4;IZ\(;P:>0,Q:?H)NK1R ,5"49-OIRE"U9P7@[$&85( M12<3V\C;!VPBO_&YU(?)G$U='2PI&4EDJ/CAU&%SE#R+G&70+GF M;ENR9_KFO7AW ABTAY<#:;SW/TD/V5=\##+(GI0WKH'3LUM$/!DDQE[E!$:-9C>9'*RTL!^1 MC>Y57]C+@ZJY>QS-82L#<:Z\JF,. RB(U-GH=';6PO(0\)Q'[C\06F;U=4I) ME$6J%I!O-1Y,"Q23[5&C,]P9$&_M&6PBQE^9;7]4QC[T">:%O:TTON4D22#S M6ANQ536E\A'V;Y?QDI1$.KI6$EOCXONM81LN]A]<76J=;E3M>D7 MXQ^:,?6.9Q1I!*/80%'X[>RRVQ@-=M84)M\2I$OGIH".'^*"4CL;4BWEGP&D M8C@\):79MDL;A;MH%%P'.ML*=-*TE[S>9:\^3E2!?8HA6 MQI0N%0Q'G6&_L4)N4:#5VMU]!C[)]9-O>U1*T1V+.Q9 %#?\=@.BIHPVXV7; M_4>@[TJ*JKX''/5A*Z._[+ZTWP,'.210OTVZK70;K?X^,\!;QU]/@*+7Z'X' M0/<;U>A^-;I?2LG;%X):-QA7H508.+74MZGY9F35L87K"X.#6L_/"/[A"*P% M[UQ-UA'QD20?MS]D]FU[J^N=N$\VN@P0SSAHG:6>!X>18C3% TGBZ)0W6@Z% M9YQ3$;9_'DDT7LIUL"K'&:H+):5*TD.S:G'N\) VO,,D!EO;)6* M+,>PLS[KCB2$:06$V3L7[X8P?3EA!%8L,AH_I\Z/X&4IVU3&#C84.'9+@KWQ M9$4.7ATVFR7C52_Y?BCT[J@P70\P&SC30(R+_\YJ^S(0$ ]1P#3_!W1T*'ZM*?P$X&!\4US'F$: M2>Y#$TRQ(#^PC7^)Q!\GA\U"1[UM1#83Q[9M.B*E6IZU#_ *Y(G"%C\@.">O MVU$6KH691<(*X?!OB;7!2SG%V32@>0JMCT]>J,?:G;J:^.%I>D*XM,B6F6^>(Y\;+APOE MX05/,'_"M!:>YA^+ZRP>F0>L\VGLLPX/C^ 3>O*S]BKX4+0M FH'N@ ' 2P% M4H#7D2ZV$9X"7\I>%KJYQ$9)=(;W!ULX'M0!K+9EPB6('*,&\&&B%8CGM44U M.SW$14!:PIOA3T#G67A"KB/Z^D;#.SJ\+6XBOTB,E<@!0NS[*RB>)\$\OF%M M#1JA5&3X(#PH,.X7 BN!5N&^&@)9^$R''4:?4$,A;M72)ZK'>\@]?!DYY TL M'7\NK!>BWA#2GY?[-'Q6^DI Q;X_HG/L/5[#F^B:=A"CH5R<)9SZEH!%V%\N5%),WI MMDOBW"6"7@+@1O!1H41S2K*.M+ UO;LYX5R(S#8,!60D@F(B9^?CBJ>B,J9 M--V5HQM+LQ0A\D!.8XOIO)N-&=48>]/:>VI@CH6'C-UZ2N$K4T&\$U 1K>'^ M^I@/+Q0^BHKV,-\$%3C(/P6Y)AV)H9A/\$25%ZV#[7GAH,'8, %<+()78H2@ M;\YFV@0B ET%OU9UP-_G>&0P>'<&S,U3AHC@X<$-J6*+$NRC3@YV[-41\"E/ M'GR,/I<O/E M,5!M67OL$?<(5AP*DBC&KQY,JD#VMS^[Q8#6>RN;OY*<&)(V@CZE>!.&4,.+ M4(#1XOW5.!'?J"P(,Z_8&O*9A?SB@*G3:B^1]!E61LLP+5':_5.,8LP'<>^- M@;[$M%3+,S;M0822YS:;?)RZ%OHUD1TBSS+RS8^3D9^X9> 9(@$!Z@%ABWC' MGB-RI( "%2I9>57UH'&/4.#$<#ZO>?E\Y!E,RZ3(EKP[0ARE0];91"9-4LT^#;,';H MOJG); _&DYK;()S<1.,S/09LN-UX4L)N-Q1>88A?T'LIMQCX&$'?;1[[B]ML MOO1>$I+6O)&[RF38EA53R+STU# S*C0B\+GVIO)',($;QL;&E,)^+\CG@RX2 M);6:/6F<%/.%J*448O<+[9)O6UI*/G!1#8^/T 2<:S_/Y]H4EOOC9-B!(:VX MHB4J^O"J2_'#,[$IY48^&_AK/0O%U 7G(66#3GL#-O"4Z)]BN,0(6*-5R!5I M9I8]II=<=#JY2B[V,X5V1@HI6H[CBP\_*G%NSLY=7EB&AC)<2C9;G4\IM/2R MO<%UESZJ!.YQ)K>S[S8;XS3"]5'QQ,AZM2>M8IS1VP)G['Z&?7FSDS3&$84D MOK'FI;XOZI3RP6!+,%,,:B_%W(1BQ+1B[5S;[_ U$G\Z)UA5=? U#4P==E H369U*P]$="]#3<:!2'RE^4XK0Y]OG MVD#H-P&E;C5:G>1F\O'!RAZ+T:YA9?=BJ.4=S[%ZX0J8JLOJ$=JJE.@%OO-G(0@B/W"':U2-%)!]Z,UVB=,_7' %QYNI\J>8QO2^]OOWKZTOQOE MZPN-A1J.ATZK2A 5%"I$U^"/2K8VI>JW>"&(,?T:$$*^F]1OU[M)N]M-ZHS6 MV$W:R19*H*IV](*,8H=VO^2S!Z<)*Q^I+&I5B<5^77A_Y,-WV_8^5]0J__:$ M_R9W%W>VPRA-F:4O7'[W^-#RO._=87*!SN]%<<4XL(DA([##=_ M: 1RS#)[Q+NJA!ZEY;Z>\)ZL"+N#/;X7W1L-]=C(_'L^]FDY0$?L4]%NKOH4ZSE-0 M*6I& GJ]D8G[9AJ3C:Q(]ZE.4 LZAW" MH?VAQ F;^NQ=F13'NEGT0;<^>U?O#QTE9\MJ_,U224Z5[ZNYU%71D M&AO3*Q,;F3]CTU1F8[L-W;1=*WEBOT842&B0=YHD,LZ)-P.+3O'.M MR1R]BMN@C]>JJ6WZVG+TY/!G'NY@%NI;IGH]YFV"5_>N?C;-*6<'FUFOVH1A M^P7>N/!)-*"-=I#")J*Q/F?A=F7P1-NE]JT6 M[_K@#02_ I\0]R=R ;0/,L#"_O)H$7"\W[@#FW-CJB7XBG=)3-R1J_^WN"M@ MMATT )##5'"JOZC_XNU[J0^(9GO=;ZA7F@^-'%L ?^TUXQ4^,VE57Q:F01?@ MHL :4Y,.TZ7&-U-WP@^U5[+Y4^),'(C-BZ'---ZTM:**;VW]\(4+,K]=(L;1 M;@FD VRN E#,D"VYF@CK$>SDA-^JU%$)1\@X+UI,@'\+/80WOJF6!1, 6R,: M)2[]IDJ\'V!D6;S.-AP,R%JHEK-,:2?#?B[(O@8]K+'<,!@F"(-K_##,-T-Y M8A/L0*AHV)/@U=1?83 37=5>Q&1P4$^,=YM0G[$/K\.O#6&8-X!D#F]799B. MLF0.[YJ,-\$(3>J('J7FG/=?YM?9[M._V(3:MN-WXO5 ?K6;YP-7T_9C"'% ML>4UUWTAH=:HD56,9H'JKZ*D;M*'*J %6C#1&DFC'FL64-NT1(\I:MLI; _\ M0JS+7HE/4/%->*IJ0NC[P4)Y5^H:*%+L0S77P+#A$GN/I]:)%K6G(4.*=LR1 M@]+C$F,C- UY 08*#J ZH8T [)L!MDES<(TY-W^&%0?)80K\H!F@J$VPE0G! MX+]ISIRFB2/DC""ZK<$E"U/TA,?[GI;P!&&LPTTQXSPD&K;KJNU01V[;F&RRN%95&D8T$WP(W8@(.B70=$.U0<1R: M'?RMJ(@W$ M5A#1#P8MILLI 6RB:M.HX_7$P*E"?>;WUYMAU]9P$T([2:ZPLPCSI':SJGZA MC(G%8 UU8$O-\358J ,KOC24N^.ZB3!U3/&R\,-1WHA+.'OY;6NKJ*?B'L57 M]@P,>>?S?U6#J00+B$@>4:BU:>MQO0B5J!MA !K)H9/J@B$['J.3;4!%)J: BA9&"0Z1RYVAAN]Q MD0:0#)\^GVJX?\#1IAS2>5P7X,-@.=5G#BPQHSD$W4J#B_SPK.Z/=+C^2*VZ M/U*Y^R/M*3_XX)B3'^AM@ *[!@UME-0F4MI],9E*M.F-N)Z3$/,O?.:W M<5@\9$G)M@YE12'2K=T[9N6@P9UJW5H$CS7]$P.4X*XMKIAL.UJZ:7>(,3'>KICEZ[N:>X2WK@,Z MB@*/8L/L-QNC?IZ%0MJGS"E??]9#4CW?^:B>2[5%&\9"A,8P M<414Y$G!8+C53T=HEP_@I>*&KN:]3KL<*YENCU9%MZ=0MD*XN,@PG$S*.&$( M,=N* ;>C\TR[!7I6PU2$8;B8AIA,+!<3&1 <:/!\W#YU%%6QA,^4(F*Q1BD8 M.+2&YTW0;=WPKY_9D\/7"C.EGY;?#>W?+OL,L8"E+?!YM%T97'$[N[/ 2],6 MJLY;)=S.'IBAF=8#FT!@,?UJJL:C"835EX'+P:<^CHHNW_#\RP>MO,*H#IZ& MW]%+,^X**8D[=Y6.^"SH=@\O B.*X;7Z')C1\W9.3=$^NTPV9'K7P)ZR/*-J M*%C!@A\C/+>O*5(77N2'&JF9>Y-6@.==R&ZW]O:X4_F;\HE91[2<+@KZO0/N_;TDJGT* M'8PR@KQ]$'A['OMPT%^+!S,BQ0I-')SF3E\R\1R6BM@KY 8GV(_V-- Q"O9W MP@XWU8D$[Y&GELR7%R"Y\+&<5..7$:/NS_B%W.7 UP)/JZ@%[&;:/^Y1I#ND MZ'%BK!)HB<#WQ/WA/ 5SHWX^0[0%$L=)ZVO.Z*V%:N6Z%Q+UZ=?*@8BG37^0 MS\Z4?OK) W[^]*?K.RUA,3_2V/=3'?ORV%?HET^2.,4N%*9(LD8BCNVOE*-/ MV]+4^TC+AB.5F0MA",3ZDSES@$Y@$90GU:9,DJ.=3S7=%10T'3;AVR:\>$82 MX&BVK,C,?#/ WLRU!2\W$_5\2N828HW2RPN;:MP&A&VS"&9Y[.I99YX'\8?& M]W&PU,*U>"4:EB"8C-=T@)L)BN+9U54+GBVN#5D@RV_CF0B<4E10N@\J29/( MPX$@ 4)LD"=3(N6\+^"Z7)%KLH;_EG@]=^&$HF'35C'N&R6;R0>E6\*]FGCO MX$Z7E(RC9K/*9.0)[H(T; T;?9FS%61D>);6KQ5Y ,;-I-$3:7U T:FX2FF_-U&X[*$J9ZR;1>&GGVKKH M2;$YTF/""KJE7MX;ROZKAXAFZ5E=2@Q,]=JZ. M@MUMT+X)^GN:S0?$Z^/QZ 0CW^X]5U^37[WYD+WTON9?3G_]@$XDO 5>\YRU M,S9J#M,2$[0SYO^Z2O0_R[>SW"=; [?86CZ T(;O$J/'-]R*L>[MW5-/.;18P$7U5,#\\6.6\2*V(+V>9F^!!*4F:E1E)KXU M('@4F!HHCUKR_;Q2TC7L@9.YVXR4JW;^\%2ZX;M/C10-Q8L(_7,EOH[SSA1& MC[7R8L-\RJ)%\2T]>0IN2 M+.!U/A,_'%BM^.6(2*7DWMV&/\.+;#-01P#5CP!NBT8 K5X= 90C FC)RZ\K MH+!*'@'(&RB5DJZG%@'(@83J"&![$4!ROWFZ1@10H:3$(2( *MTJ& *TRY:8 M.+X0H)V58"@9^QXV!,A9.@ ^,Q:"IU!;5DTLK;8NO.\=6Y,RE0^L=!U3-7)8 MB00!""'R96B/3I6)O5&1P9I:@WP<&V&??!\'Z$U$_PW!O;V(]!Q"OG/MY_E< MFT+@^!%(W#V[-,S?_HX7Y5K(T 9U*G+@H>/@-(=K8@QB6' M,/1...(:8M&AEDX@U*6N!=50,3QV0K4#XB1*["$(&$;UNV!(T%9/N9MKF(CR M,E4)G1'/)9D"JQ6+#. 5C+W0&2?\]857=LT85F\Q42GF^\7!H0&.]N4[SD+D MP910C#\#5]MGG=A82278CN42H%X4=VJF6;9#L%@3(M2S9=JVAY%C!P U&>F$ M)^:\(?8=7B8CHB.?3S 7E]#&5 %!]1J!OB+BJI.Y!PJ$5Q(B$?Q?(R0Q,7:D M(3R5L.."V6:9]KQIBSSV^LY]TK5)EM5.6FM.8H0Q^B*X]W86LMHIY<9Y%5T3 MJXTE*FYUL?6HG5IK'J7,JO"*!N[%&5QA_U-SYL(VI$ZU./6\=Q6JS>Y<2 Y? M"&K%*JV56\[MGM:18$8BIM2+KWH26&Y*+ J3RD4(=C.N"!:Z.N&I1!6U"DS% M!MT)*L 7ID]PQ8_SA\G3&&;K"S)'TQ%I!P<\A=CX3J/RP4_!!;_XOHGTIE-'^%=N4ZG M>B0<&U,>:(?JSN(/+W@R1W9H@4KT&T BH!$38U9>3=1@A$&8>9YXU,Y*6^2F M%;GS?_KOW!VYGU>E?2" 7WA&M@%B(M7B.YLHO.UY%JZP40FY:(5H3 M'D+$8\LE(=2%!".!R/0:8BFO4'L%D3I9N8"UA2]\QKL$Q,+V"4E3]H[7N;\' M:B$.5R21NSHG)BZ:JLM(Z?T"X0*FGEY,]WJX%Q75ZXFP#)S#P [P8P;N D: M_AG+<2$F3/SD^XHOFJ@08/"#38KH$& MRPTT>."S7ZB"IYA."Z4N1<#(M8P?Z!)6M#8#R>8AD1_ Q;6*B!'G)MC?-P$/ M'(HG#5 4M@W1#5=TOJ<;CYJS(,G ,T544QP5:"Z#0=0LD%+C<_!WI#]=W?@; M$GZ%OHE[YQR:3HS:WUO'D0O/F/;4(2Z4T4JXOQRIU@X/)A98\]-0]!&H9;9$ M[:K!O/G]'OX\1[://YTJHPR!;XMA;"+/[+U?1_A8^$.\2+5^^(?1!'T)/5Q? MHJ;V$]?\K5XO"*ZT([$\HCM;4Q%R "4]W&_N^/BA0^)T1"BN)L!:'ZX[)3[L MY /%6!7!A6.^>S\1XOEIA6*X7E8K#FZ 31&Z052C ;=/HF&9E$WIE)&,=,1] M*>?V1.^%D,<1.BLH& A"K9=(,LIB'"-9W+ KQX'_(<*ACI4=0*+BH4D8>

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